Document:

Exhibit 4.9

 Exhibit 4.9 

CONFIDENTIAL TREATMENT REQUESTED 

EXECUTION VERSION 
 1 March 2015 

NOVARTIS AG 
 and 

GLAXOSMITHKLINE PLC 
 DEED OF
AMENDMENT AND RESTATEMENT 
 relating to the 

SHARE AND BUSINESS SALE AGREEMENT 

relating to the Vaccines Group, 

dated 22 April 2014 (as amended) 

 This Deed (the “Deed”) is made on 1 March 2015 between: 

 

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the “Seller”); and 

 

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (the “Purchaser”),

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	The Seller and the Purchaser entered into the Share and Business Sale Agreement relating to the Vaccines Group on 22 April 2014 (the “SAPA”). 

 

	(B)	The SAPA was subsequently amended and restated on 29 May 2014, and further amended on 9 October 2014 (the “Original Agreement”). 

 

	(C)	The Seller and the Purchaser now wish to further amend and restate the Original Agreement, in the form of the Amended Agreement (as defined below). 

It is agreed as follows: 
 DEFINITIONS AND
INTERPRETATION 
 In this Deed, unless the context otherwise requires, the provisions of this clause 1 apply. 

Incorporation of defined terms 
 Unless
otherwise stated, terms defined in the Original Agreement shall have the same meaning in this Deed. 
 Definitions 

“Amended Agreement” means the Original Agreement, as amended and restated in the form set out in the Schedule to this Deed;
and 
 “Signing Date” means 22 April 2014. 

Interpretation clauses 
 The principles of
interpretation set out in Clause 1 of the Original Agreement shall have effect as if set out in this Deed, save that references to “this Agreement” shall be construed as references to “this Deed”. 

References to this Deed include the Schedule. 

 AMENDMENT 

In accordance with Clauses 16.4.3 and 16.5.1 of the Original Agreement, the parties agree that the Original Agreement shall be amended and
restated as set out in the Schedule to this Deed. 
 The amendment and restatement of the Original Agreement pursuant to clause 2.1 shall
take effect from the Signing Date, as if the Amended Agreement had been entered into on the Signing Date. 
 Upon this Deed being entered
into, the Amended Agreement shall supersede the Original Agreement in its entirety. 
 MISCELLANEOUS 

Each party represents and warrants that it has full power and authority to enter into this Deed and to perform its obligations under it. 

The provisions of Clauses 14, 17.2 to 17.5 and 17.11 to 17.15 of the Amended Agreement shall apply to this Deed as if set out in full in this
Deed and as if references in those Clauses to “this Agreement” are references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

 In witness whereof this Deed has been delivered on the date first stated above. 

 

					
	Executed as a DEED by	 	)	 	
	GLAXOSMITHKLINE PLC acting by	 	)	 	
	its duly appointed attorney	 	)	 	/s/ Edgar B. Cale
		 	)	 	(Signature of attorney)
		 	)	 	
	In the presence of:	 		 	
			
	Witness’ signature:	 		 	/s/ Richard Hilton
			
	Name (print):	 		 	Richard Hilton
			
	Occupation:	 		 	Solicitor
			
	Address:	 		 	1 Bunhill Row, EC1Y 8YY

 In witness whereof this Deed has been delivered on the date first stated above. 

 

							
	Executed as a DEED by	 	)	 		 	
		 	)	 		 	
	Roy Papatheodorou As Attorney and	 	)	 		 	/s/ Roy Papatheodorou
		 	)	 		 	
	Bernard Cornuejols As Attorney	 	)	 		 	
		 	)	 		 	/s/ Bernard Cornuejols
	on behalf of NOVARTIS AG	 	)	 		 	

 SCHEDULE 

Amended Agreement 

 EXECUTION VERSION 

Dated 22 April 2014 
 as amended
and restated on 29 May 2014, amended on 9 October 2014 and further 
 amended and restated on 1 March 2015 

NOVARTIS AG 
 and 

GLAXOSMITHKLINE PLC 
 SHARE AND
BUSINESS SALE AGREEMENT 
 relating to the Vaccines Group 
  

 
 

 
 Linklaters LLP 
 One Silk
Street 
 London EC2Y 8HQ 
 United Kingdom 

Telephone (+44 20) 7456 2000 
 Facsimile (+44 20) 7456 2222 

Ref L-220595 

 Table of Contents 

 

							
	Contents	  	 	Page	  
			
	1	  	Interpretation	  	 	4	  
			
	2	  	Sale and Purchase of the Vaccines Group	  	 	38	  
			
	3	  	Consideration	  	 	45	  
			
	4	  	Conditions	  	 	47	  
			
	5	  	Pre-Closing	  	 	53	  
			
	6	  	Closing	  	 	56	  
			
	7	  	Post-Closing Adjustments	  	 	60	  
			
	8	  	Post-Closing Obligations	  	 	62	  
			
	9	  	Transitional Trademark Use	  	 	74	  
			
	10	  	Warranties	  	 	78	  
			
	11	  	Limitation of Liability	  	 	79	  
			
	12	  	Claims	  	 	83	  
			
	13	  	Restrictive Covenants	  	 	84	  
			
	14	  	Confidentiality	  	 	86	  
			
	15	  	Insurance	  	 	88	  
			
	16	  	France Business and Netherlands Business	  	 	89	  
			
	17	  	Other Provisions	  	 	91	  
			
	Schedule 1	  	Details of the Share Sellers, Shares etc. (Clause 2.1)	  	 	104	  
			
	Schedule 2	  	Companies, Subsidiaries and Minority Interest Entities	  	 	105	  
			
	Schedule 3	  	The Properties Part 1 (Company Real Property)	  	 	110	  
			
	Schedule 3	  	The Properties Part 2 (Transferred Real Property)	  	 	111	  
			
	Schedule 3	  	The Properties Part 3 Terms relating to the Company Real Property	  	 	116	  

  
 1 

							
			
	Schedule 3	  	The Properties Part 4 Terms relating to the Transferred Real Property	  	 	120	  
			
	Schedule 4	  	Vaccines Group Intellectual Property Rights and Vaccines Group Intellectual Property Contracts (Clause 2.3)	  	 	132	  
			
	Schedule 5	  	Excluded Employees (Clause 1.1)	  	 	133	  
			
	Schedule 6	  	International Assignees (Clause 1.1)	  	 	134	  
			
	Schedule 7	  	Permitted Encumbrances (Clause 1.1)	  	 	135	  
			
	Schedule 8	  	Product Approvals and Product Applications Part 1 Terms relating to the Product Approvals and Product Applications	  	 	136	  
			
	Schedule 8	  	Product Approvals and Product Applications Part 2 Transfer of Marketing Authorisations	  	 	138	  
			
	Schedule 8	  	Product Approvals and Product Applications Part 3 List of Products, Products Under Registration and Pipeline Products	  	 	146	  
			
	Schedule 8	  	Product Approvals and Product Applications Part 4 Tenders	  	 	147	  
			
	Schedule 9	  	Certificate (Clause 1.1)	  	 	148	  
			
	Schedule 10	  	Shared Business Contracts, Mixed Contracts and Transferred Contracts	  	 	149	  
			
	Schedule 11	  	Employees (Clause 2.4.1)	  	 	157	  
			
	Schedule 12	  	Employee Benefits (Clause 2.4.2)	  	 	176	  
			
	Schedule 13	  	Allocation of Purchase Price (Clauses 3.3 and 7.6)	  	 	187	  
			
	Schedule 14	  	VAT (Clause 3.4)	  	 	188	  
			
	Schedule 15	  	Closing Obligations (Clause 6)	  	 	190	  
			
	Schedule 16	  	Post Closing Adjustments (Clause 7)	  	 	192	  
			
	Schedule 17	  	Milestone and Royalty Payments	  	 	199	  
			
	Schedule 18	  	Warranties given under Clause 10.1	  	 	206	  
			
	Schedule 19	  	Warranties given by the Purchaser under Clause 10.3	  	 	224	  
			
	Schedule 20	  	Pre-Closing Obligations (Clause 5.2)	  	 	225	  

  
 2 

							
			
	 Schedule 21
	  	Key Employees (Clause 1.1)	  	 	231	  
			
	 Schedule 22
	  	Ongoing Clinical Trials (Clause 1.1)	  	 	232	  
			
	 Schedule 23
	  	Statement of Net Assets (Clause 1.1)	  	 	233	  
			
	 Schedule 24
	  	Regulatory Approvals	  	 	240	  
			
	 Schedule 25
	  	Delayed Jurisdictions	  	 	241	  
			
	 Schedule 26
	  	[***]	  	 	259	  
			
	 Schedule 27
	  	Vaccines Group Information Technology	  	 	261	  
			
	 Schedule 28
	  	Global TDSA Jurisdictions	  	 	286	  
			
	 Schedule 29
	  	Surviving Affiliate Contracts	  	 	287	  
			
	 Schedule 30
	  	[***]	  	 	288	  
			
	 Schedule 31
	  	Anti-bribery and corruption	  	 	289	  

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 3 

 Share and Business Sale Agreement 

This Agreement is made on 22 April 2014, amended and restated on 29 May 2014, amended on 9 October 2014 and further amended and restated on
1 March 2015 
 between: 
  

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the “Seller”); and

  

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road Brentford, Middlesex, TW8 9GS, United Kingdom (the “Purchaser”),

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	the Seller and certain of the Seller’s Affiliates, including the Vaccines Group Companies (as defined below), are engaged in the Business; 

 

	(B)	as of the date of this Agreement, the Seller and certain of the Seller’s Affiliates directly or indirectly own shares and other equity interests in the Vaccines Group Companies; 

 

	(C)	the Seller has agreed to sell (or procure the sale of) the Vaccines Group (as defined below) and to assume the obligations imposed on the Seller under this Agreement; 

 

	(D)	the Purchaser has agreed to purchase (or procure the purchase of) the Vaccines Group and to assume the obligations imposed on the Purchaser under this Agreement; 

 

	(E)	the Seller and certain of the Seller’s Affiliates are also engaged in the Influenza Business, and shall retain the Influenza Business following the date hereof (such Influenza Business not to be the subject of the
transactions between the Seller and the Purchaser contemplated by this Agreement). The Seller may carry out a Re-organisation (as defined below) on or prior to Closing to facilitate separation of the business from the Influenza Business; and

  

	(F)	in connection with the transactions contemplated by this Agreement, the Purchaser and the Seller, or certain of their respective Affiliates, have entered into or will enter into the Ancillary Agreements.

 It is agreed as follows: 
  

	1	Interpretation 

 In this Agreement, unless the context otherwise requires, the provisions
in this Clause 1 apply: 
  

	1.1	Definitions 

 “2013 DCOGS” means the highlighted sections of the COGS
analysis in the Agreed Terms; 
 “2013 Gross Profit” means US$274 million (being the difference between net sales (excluding
other revenue) of US$935 million and cost of goods sold of US$661 million); 
 “2013 Income Statement” means the 2013 income
statement of the Vaccines Group and the Influenza Business in the Agreed Terms; 

  
 4 

 “Abandoned Patents” means any Patent Exclusively Related to the Business
abandoned by a member of the Seller’s Group before Closing from which a Vaccines Patent can claim priority, or from the priority chain of which a right to priority can be claimed in respect of a Vaccines Patent; 

“Accounts” means, for each Vaccines Group Company, the audited financial statements of that Vaccines Group Company, prepared
in accordance with legislation as in force and applicable to that Vaccines Group Company for the accounting reference period ended on the Accounts Date, comprising the balance sheet, the profit and loss account and the notes to the accounts; 

“Accounts Date” means in respect of: 
  

	 	(i)	Chiron Behring Vaccines Private Limited, 31 March 2013; and 

  

	 	(ii)	each other Vaccines Group Company, 31 December 2012; 

 “Action” means the
taking of any steps by any Governmental Entity to seek a Judgment which would have the effect of preventing the consummation of the transactions contemplated by this Agreement by the Purchaser; 

“Affiliate” means: 
  

	 	(i)	with respect to any person (other than a party to this Agreement), any other person that Controls, is Controlled by or is under common Control with such person; or 

 

	 	(ii)	with respect to a party to this Agreement, any other person that is Controlled by such party, 

provided that any Delayed Vaccines Group Company shall not constitute an “Affiliate” of the Purchaser unless, and until, the relevant
Delayed Closing Date in respect of such Delayed Vaccines Group Company, and “Affiliates” shall be interpreted accordingly; 

“Affiliate Contract” means a Contract between or among any member of the Seller’s Group (other than the Vaccines Group
Companies) on the one hand, and any Vaccines Group Company on the other hand, but excluding: 
  

	 	(i)	any Ancillary Agreement; 

  

	 	(ii)	any Affiliate Quality Agreement; 

  

	 	(iii)	any Mixed Affiliate Quality Agreement; and 

  

	 	(iv)	those Contracts listed in Schedule 29; 

 “Affiliate Quality Agreement” means
any quality agreement in respect of GMP, quality and safety matters relating to the Products in respect of the Vaccines Business between or among one or more members of the Seller’s Group, other than any such agreement exclusively between or
among Vaccines Group Companies; 
 “Agreed Terms” means, in relation to a document, such document in the terms agreed
between the Seller and the Purchaser and signed for identification purposes by the Seller’s Lawyers and the Purchaser’s Lawyers, with such alterations as may be agreed in writing between the Seller and the Purchaser from time to time; 

“Agreement” means this share and business sale agreement; 

“Allocation” has the meaning given to it in paragraph 1 of Schedule 13; 

  
 5 

 “Allowance” means any amount payable or repayable to customers in respect of a
contractual allowance or discount due on the sales of products; 
 “Ancillary Agreement Liabilities” means the Liabilities
of any member of the Seller’s Group to any member of the Purchaser’s Group and, the Liabilities of any member of the Purchaser’s Group to any member of the Seller’s Group, in each case arising under any Ancillary Agreement; 

“Ancillary Agreements” means the Implementation Agreement, the Local Transfer Documents, the Disclosure Letter, the Tax
Indemnity, the France Offer Letter, the France SPA, the Netherlands Offer Letter, the Netherlands APA, the Transitional Services Agreement, the Transitional Distribution Services Agreement, the Influenza Business Agreements, the Influenza Business
Global Quality Agreement, the Influenza Business Pharmacovigilance Agreement, the Vaccines Business Manufacturing and Supply Agreements, the Vaccines Business Pharmacovigilance Agreement, the Purchaser Intellectual Property Licence Agreement, the
Intellectual Property Assignment Agreements, the Claims Management Agreement and the Secondment Agreement; 
 “Anti-Bribery
Law” means any Applicable Law that relates to bribery or corruption, including the US Foreign Corrupt Practices Act of 1977 and the UK Bribery Act 2010, in each case as amended, re-enacted or replaced from time to time; 

“Applicable Law” means any supra-national, federal, national, state, municipal or local statute, law, ordinance, regulation,
rule, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including common law), or any other order of, or agreement issued, promulgated or
entered into by, any Governmental Entity or any rule or requirement of any national securities exchange, including all Healthcare Laws, and GCP, GLP, and GMP, each as may be amended from time to time; 

“Appointment Notice” has the meaning given to it in paragraph 1.3 of Schedule 16; 

“Associated Person” means, in relation to the Seller’s Group, a person (including any director, officer, employee, agent
or other intermediary) who performs services for or on behalf of any member of the Seller’s Group or who holds shares of capital stock, partnership interests, limited liability company membership interests and units, shares, interest and other
participations in any member of the Seller’s Group (in each case when performing such services or acting in such capacity); 

“Assumed Liabilities” means all Liabilities relating to the Vaccines Group Businesses (including, for the avoidance of doubt,
any Delayed Vaccines Group Businesses) other than: (i) the Excluded Liabilities; (ii) any Relevant Pension and Employment Liability; (iii) any Liabilities in respect of Tax (other than Tax which has been provided for or reflected in the Closing
Statement and Tax which has been assumed by the Purchaser’s Group under an express provision of this Agreement); (iv) any Ancillary Agreement Liabilities; and (v) any Liabilities relating to the Abandoned Patents; 

“Base Working Capital” means, in respect of the Vaccines Group Companies and Vaccines Group Businesses, the amount shown in
paragraph 4 of Part 2 of Schedule 16; 
 “Benefit Plans” means the US Benefit Plans and the Non-US Benefit Plans; 

  
 6 

 “Beta Interferon Patent Rights” means the Patents listed in Part 3 of Schedule 4
(the “Beta Interferon Patents”) together with the rights of Novartis Vaccines and Diagnostics, Inc. under the Merck 2012 Licence; 

“Business” means the research, development, manufacture, sales, marketing and commercialisation of Vaccines for human use by
the Seller’s Group as recorded and reported by the Seller’s Group from time to time under the “Vaccines and Diagnostics” segment as described in and consistent with the Novartis 2013 Annual Report and, with respect only to the
Vaccines Institute for Global Health, through the Novartis Institutes for BioMedical Research, and including the fill-finish process undertaken at the Rosia Site and, to the extent relevant, the Siena Site, but excluding: 

 

	 	(i)	the Influenza Business; 

  

	 	(ii)	the Diagnostics Business; and 

  

	 	(iii)	any Non-strategic Assets if and to the extent disposed of or transferred otherwise than to the Purchaser or a member of the Purchaser’s Group in accordance with this Agreement; 

“Business Day” means a day which is not a Saturday, a Sunday or a public holiday in the canton of Basel-Stadt (Switzerland) or
London; 
 “Business Information” means: (i) Commercial Information; (ii) Medical Information; and (iii) any other
information Predominantly Related to the Business; 
 “Business Sellers” means the members of the Seller’s Group (other
than the Vaccines Group Companies) that own assets of or otherwise conduct any of the Vaccines Group Business; 
 “Call for New
Tender” means any calls for a tender (including any tender for a basket of products), whether a new tender or the renewal of an existing tender, which includes the Products and which is published after Closing of which the Seller and/or any
of the Seller’s Affiliates become aware and which relates in whole or in part to the sale of Products; 
 “Cash
Balances” means cash in hand or credited to any account with a financial institution and securities which are readily convertible into cash; 

“Cash Pooling Arrangements” means the cash pooling arrangements of members of the Seller’s Group in which the Vaccines
Group Companies participate; 
 “Cell-based Influenza Business” means: 

 

	 	(i)	the business conducted by the Seller’s Group from time to time of research, development, manufacture, sales, distribution, marketing and commercialisation of: 

 

	 	(a)	influenza Vaccines using cell-based technologies, including such business conducted at the Holly Springs Site; 

  

	 	(b)	adjuvants conducted at the Holly Springs Site; and 

  

	 	(c)	other Vaccines products to the extent that such business is conducted or contemplated to be conducted by the Seller’s Group at the Holly Springs Site in accordance with its obligations to, or as requested by, the
US government or regulatory authorities; and 

  
 7 

	 	(ii)	technical development, manufacturing and supply of Enoxaparin, Copaxone or any other pharmaceutical or biological products (other than Vaccines) at the Holly Springs Site, including, but not limited to, pursuant to
agreements or arrangements with Sandoz Inc. or its Affiliates; 

 “Certificate” means a certificate signed by
a director, officer or an authorised signatory of the Seller in the form set out in Schedule 9, to be provided to the Purchaser immediately prior to Closing; 

“CFIUS” means the Committee on Foreign Investment in the United States; 

“CFIUS Approval” means written notice from CFIUS that any review or investigation of the Transaction under Section 721 of the
Defense Production Act of 1950, as amended (50 U.S.C. App. Section 2170), has been concluded and there are no unresolved national security concerns with respect to the Transaction or the President shall have determined not to take action with
respect to the Transaction; 
 “Chinese JV Partner” means Mr. Ding Xiaohang (

), a resident of [***], whose residential address is [***] and whose identity card number is [***], being the joint venture partner of the Tianyuan JV; 

“Claims Management Agreement” means the agreement between the Seller and the Purchaser, to be negotiated in good faith between
the parties and entered into at Closing, in respect of the management of claims or investigations by or against third parties (including by any Governmental Entity) which constitute or may constitute an Assumed Liability or an Excluded Liability;

 “Clinical Trials/Data Liability” means any Liability arising out of, relating to or resulting from any breach of
Applicable Law in connection with the conduct of, or reporting or data in relation to, clinical studies or trials (including post-approval studies) in relation to the Vaccines Group; 

“Closing” means the completion of the sale of the Shares and the Vaccines Group Businesses pursuant to this Agreement, and
Closing shall be deemed to have taken place notwithstanding that some of the Shares only or other parts of the Vaccines Group Businesses have not transferred to the Purchaser pursuant to Schedule 25, in each case which the provisions of Schedule 25
shall then apply in respect thereof; 
 “Closing Date” means the date on which Closing takes place; 

“Closing Statement” means the statement setting out the Working Capital, the Working Capital Adjustment, the Vaccines Group
Companies’ Cash Balances, the Intra-Group Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables and the Tax Adjustment, to be prepared by the Seller and agreed or determined in accordance with Clause 7 and
Schedule 16; 
 “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985 of the United States, as amended,
section 4980B of the Code, Title I Part 6 of ERISA, and any similar US state group health plan continuation law, together with its implementing regulations; 

“Code” means the U.S. Internal Revenue Code of 1986, as amended, together with its implementing regulations; 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

 8 

 “Commercial Information” means information that is, as of the Closing Date, or,
in respect of any Delayed Business, the Delayed Closing Date as applicable, owned by the Seller and/or its Affiliates and relates predominantly to the Commercialisation of any Products; 

“Commercial Practices Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable
Law in connection with the Commercialisation of any product; 
 “Commercialise” means to promote, market, distribute and/or
sell a Product and “Commercialising” and “Commercialisation” shall be construed accordingly; 

“Companies” means the companies, details of which are set out in paragraph 1 of Schedule 2, and “Company”
means any one of them; 
 “Company Lease” has the meaning given to it in paragraph 1.1 of Part 3 of Schedule 3; 

“Company Leased Real Properties” has the meaning given to it in paragraph 1.1 of Part 3 of Schedule 3; 

“Company Owned Real Properties” has the meaning given to it in paragraph 1.1 of Part 3 of Schedule 3; 

“Company Real Properties” means the Company Owned Real Properties and the Company Leased Real Properties, and “Company
Real Property” means any one of them; 
 “Composite” has the meaning given to it in Clause 9.3.2(iv); 

“Consumer Contribution Agreement” means the contribution agreement dated 22 April 2014, as amended from time to time,
between Leo Constellation Limited, the Purchaser and the Seller, relating to the establishment of a joint venture between the Purchaser and the Seller; 

“Contract” means any binding contract, agreement, instrument, lease, licence or commitment, excluding: (i) any lease or other
related or similar agreements, undertakings and arrangements with respect to the leasing or ownership of the Properties (to which the provisions set out in Schedule 3 shall apply); and (ii) any contract with any Employee; 

“Contracts Liabilities” means Liabilities relating to the: (i) Transferred Contracts; (ii) Transferred Intellectual Property
Contracts; and (iii) all other contracts or parts thereof transferred, assigned, novated or assumed by the Purchaser pursuant to this Agreement or to which a Vaccines Group Company is or was a party or under which a Vaccines Group Company has any
Liability, and a “Contracts Liability” shall mean any one of them; 
 “Control” means the power to direct
the management and policies of a person (directly or indirectly), whether through ownership of voting securities, by Contract or otherwise (and the term “Controlled” shall be interpreted accordingly); 

“Co-Owned Vaccines Group Intellectual Property Right” means any Vaccines Group Intellectual Property Right that is owned in
part by a third party; 
 “Copyright” means any works of authorship, copyrights, database rights, mask work rights and
registrations and applications therefor; 
 [***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 9 

 “Decision” means the issuing of any decision by a competition, antitrust,
foreign investment, national, local, supranational or supervisory or other government, governmental, quasi-governmental, trade, or regulatory body, agency, branch, subdivision, department, commission, official or authority, including any Tax
Authority and any governmental department and any court or other tribunal, that would have the effect of prohibiting the acquisition of the Vaccines Group by the Purchaser; 

“Deferred Employee” means any person to whom the Seller, any Vaccines Group Company or any other member of the Seller’s
Group has made an offer of employment for a role in the Business (as carried on by the Vaccines Group) in compliance with Clause 5 and whose employment in the Business (as carried on by the Vaccines Group) will take effect on a date following the
Closing Date, save that no person shall become a Deferred Employee unless and until the Seller has provided to the Purchaser a copy of the offer letter setting out the agreed principal terms of employment and/or employment agreement (if executed)
applicable to such person; 
 “Delayed Businesses” has the meaning given in Schedule 25; 

“Delayed Closing” has the meaning given to it in Schedule 25; 

“Delayed Closing Date” has the meaning given in Schedule 25; 

“Delayed Contract” has the meaning given to it in Schedule 10; 

“Delayed Contract Transfer Date” has the meaning given to it in Schedule 10; 

“Delayed Local Payment Amount” has the meaning given to it in Clause 6.6; 

“Delayed Vaccines Group Business” has the meaning given in Schedule 25; 

“Delayed Vaccines Group Company” has the meaning given in Schedule 25; 

“Designated Purchaser” means an entity within the Purchaser’s Group acquiring part of the Business; 

“Diagnostics Business” means the human blood and blood products diagnostics business (and certain related activities) sold by
Novartis Vaccines and Diagnostics Inc. and its Affiliates to G-C Diagnostics Corp. pursuant to a share and asset purchase agreement dated 10 November 2013; 

“Diagnostics GESA” means the Global Employee Services Agreement and Amendment No. 3 to Share and Asset Purchase Agreement
dated as of 9 January 2014 by and between Novartis Vaccines and Diagnostics, Inc., Novartis Corporation, G-C Diagnostics Corp., and Grifols, S.A.; 

“Disclosure Letter” means the letter dated 22 April 2014 from the Seller to the Purchaser disclosing information constituting
exceptions to the Seller’s Warranties; 
 “Distribution Contract” has the meaning given to it in Schedule 10; 

“Distribution Transfer Date” has the meaning given to it in the Transitional Distribution Services Agreement; 

“Draft Closing Statement” has the meaning given to it in Clause 7.1.1; 

“Effective Time” means 11.59 p.m. (local time in the relevant location) on the Closing Date or, if the Closing Date is not the
last day of a month but the first Business Day of a month, 11.59 p.m. on the last day of the immediately preceding month; 

  
 10 

 “Egg-based Influenza Business” means the business conducted by the Seller’s
Group from time to time of research, development, manufacture, sales, distribution, marketing and commercialisation of influenza Vaccines and other products using egg-based technologies and related adjuvant technologies; 

“Employee Adjustment Payment” has the meaning given to it in Clause 3.1.1(ii); 

“Employee Benefit Indemnification Amount” has the meaning given to it in paragraph 3 of Schedule 12; 

“Employee Benefits” has the meaning given to it in Schedule 12; 

“Employees” means the Vaccines Business Employees and the Vaccines Group Company Employees, and “Employee”
means any one of them; 
 “Encumbrance” means any claim, charge, mortgage, lien, option, equitable right, power of sale,
pledge, hypothecation, usufruct, retention of title, right of pre-emption, right of first refusal or other security interest of any kind or an agreement, arrangement or obligation to create any of the foregoing, and for the avoidance of doubt, shall
exclude any licences of or claims of infringement relating to, Intellectual Property Rights; 
 “Environmental Laws” means
any and all Applicable Law regulating or imposing Liability or standards of conduct concerning pollution or protection of the environment (including surface water, groundwater or soil); 

“Environmental Liabilities” means any Liability arising out of, relating to or resulting from any Environmental Law or
environmental, health or safety matter or condition, including natural resources, but excluding any Product Liability; 

“Environmental Permit” means any permit, licence, consent or authorisation required by Environmental Laws issued by any
relevant competent authority and used in relation to the operation or conduct of Manufacturing at each Property, and “Environmental Permit” shall be construed accordingly; 

“ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, as amended, together with its
implementing regulations; 
 “Estimated Employee Benefit Adjustment” means the amount by which the Seller’s reasonable
estimate (in so far as practicable), made in good faith after consulting with the Purchaser, of 95 per cent. of the anticipated aggregate of the Employee Benefit Indemnification Amounts exceeds US$60,000,000, to be notified by the Seller to the
Purchaser pursuant to Clause 6.4; 
 “Estimated Intra-Group Non-Trade Payables” means the Seller’s reasonable estimate
of the Intra-Group Non-Trade Payables, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated
Intra-Group Non-Trade Receivables” means the Seller’s reasonable estimate of the Intra-Group Non-Trade Receivables, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Tax Adjustment” means the Seller’s reasonable estimate of the Tax Adjustment, to be notified by the Seller to
the Purchaser pursuant to Clause 6.4; 

  
 11 

 “Estimated Third Party Indebtedness” means the Seller’s reasonable estimate
of the Third Party Indebtedness, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated Vaccines
Group Companies’ Cash Balances” means the Seller’s reasonable estimate of the aggregate of the Vaccines Group Companies’ Cash Balances, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Working Capital” means the Seller’s reasonable estimate of the Working Capital, to be notified by the Seller
to the Purchaser pursuant to Clause 6.4; 
 “Estimated Working Capital Adjustment” means the amount by which the Estimated
Working Capital is greater or less than the Base Working Capital, any such excess amount being treated as a positive number and any shortfall being treated as a negative number; 

“Excluded Assets” means the property, rights and assets referred to in Clause 2.3.2 or Schedule 5; 

“Excluded Contracts” means, collectively, each Contract which is not Predominantly Related to the Business; 

“Excluded Employees” means the employees of any member of the Seller’s Group (including the Vaccines Group Companies) (i)
who are referred to in Schedule 5, and (ii) any Vaccines Group Company Employees who do not work wholly or substantially in the Business (as carried on by the Vaccines Group), save for those employees referred to in paragraph 2.1.2 of Schedule 11;

 “Excluded Liabilities” means (in each case excluding any Ancillary Agreement Liability and any Liabilities relating to
Abandoned Patents): 
  

	 	(i)	all Liabilities: 

  

	 	(a)	relating to the Vaccines Group Businesses (including, for the avoidance of doubt, any Delayed Vaccines Group Businesses) other than to the extent taken into account in the Closing Statement; 

 

	 	(b)	of the Vaccines Group Companies (including, for the avoidance of doubt, any Delayed Vaccines Group Companies) other than to the extent taken into account in the Closing Statement and other than Liabilities in respect of
Tax, 

 in either case, to the extent that they have arisen or arise (whether before or after the applicable Liability Cut-off
Time for that Liability) as a result of, or otherwise relate to, an act, omission, fact, matter, circumstance or event undertaken, occurring, in existence or arising before the applicable Liability Cut-off Time, and in each case, other than (a) any
Relevant Pension and Employment Liability and (b) any Liabilities in respect of Tax provided for or reflected in the Closing Statement; and 
  

	 	(ii)	all Liabilities relating to the Seller’s Group Retained Business and the Excluded Assets; and 

  

	 	(iii)	any Seller Allowance Rebate and Royalty Amount; 

 “Exclusively Related to the
Business” means exclusively related to, or exclusively used or held for use exclusively, in connection with the Business; 

  
 12 

 “FCA” means the Financial Conduct Authority; 

“FCC Vaccines” means bulk influenza Vaccines produced using cell-based technologies; 

“FDA” means the United States Food and Drug Administration (or its successor); 

“Final Allocation Schedule” has the meaning given to it in paragraph 4 of Schedule 13; 

“Final Payment Date” means five Business Days after the date on which the process described in Part 1 of Schedule 16 for the
preparation of the Closing Statement is complete; 
 “France Assumed Liabilities” means the Assumed Liabilities to the
extent they relate to the France Business; 
 “France Business” means that part of the Vaccines Group, comprising:

  

	 	(i)	Novartis Vaccines and Diagnostics S.A.S. and the part of the Business conducted by Novartis Vaccines and Diagnostics S.A.S.; 

  

	 	(ii)	the France Assumed Liabilities; 

  

	 	(iii)	the France Employees; and 

  

	 	(iv)	any other assets that are exclusively related to the France Business; 

 “France
Closing” has the meaning given to it in the France SPA; 
 “France Employees” means the Employees employed by
Novartis Vaccines and Diagnostics S.A.S.; 
 “France Offer Letter” means the letter from the Purchaser to the Seller in
respect of the binding offer from the Purchaser to acquire the France Business dated on or around the date hereof; 
 “France Put
Option Exercise” has the meaning given to it in the France Offer Letter; 
 “France SPA” has the meaning given to
it in the France Offer Letter; 
 “FSMA” means the Financial Services and Markets Act 2000; 

“Full Disclosure” means disclosure by the Seller to the Purchaser of the material terms, including financial terms, of the
Relevant Part of a Shared Business Contract; 
 “Full Title Guarantee” means on the basis that the covenants implied under
Part 1 of the Law of Property (Miscellaneous Provisions) Act 1994 where a disposition is expressed to be made with full title guarantee are deemed to be given by the Seller (on behalf of the relevant Share Seller or Business Seller) on Closing; 

“German Influenza Operations” means the operations for the manufacture of FCC Vaccines and MF59® adjuvant located at the Marburg Site; 
 “Good Clinical Practices” or
“GCP” means the then-current standards, practices and procedures promulgated or endorsed by (i) the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical
practices for trials on medicinal products in the European Union; (ii) the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements
imposed by the FDA; and (iii) the equivalent Applicable Law in any relevant country; 

  
 13 

 “Good Laboratory Practices” or “GLP” means the then-current
standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices as well as “The rules governing medicinal products in
the European Union,” Volume 3, Scientific guidelines for medicinal products for human use (ex - OECD principles of GLP); (ii) the then-current standards, practices and procedures promulgated or endorsed by the FDA as defined in 21 C.F.R. Part
58; and (iii) the equivalent Applicable Law in any relevant country; 
 “Good Manufacturing Practices” or
“GMP” means the then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 91/356/EEC, as amended by Directive 2003/94/EC and 91/412/EEC respectively, as well as “The
rules governing medicinal products in the European Union,” Volume 4, Guidelines for good manufacturing practices for medicinal products for human and veterinary use; (ii) the FDA and the provisions of 21 C.F.R. Parts 210 and 211; (iii) the
principles detailed in the ICH Q7A guidelines; and (iv) all Applicable Law with respect to each of (i) through (iii); 

“Governmental Entity” means any supra-national, federal, national, state, county, local, municipal or other governmental,
regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities exchange or automated quotation service including, any governmental
regulatory authority or agency responsible for the grant approval, clearance, qualification, licensing or permitting of any aspect of the research, development, manufacture, marketing distribution or sale of the Products including the FDA, the
European Medicines Agency, or any successor agency thereto; 
 “Governmental Liability” means any Liability arising out of,
relating to or resulting from any claim, demand, action, suit, proceedings or investigation by a Governmental Entity (other than a Tax Authority) brought or undertaken in connection with products sold or developed by, or operations or practices of,
the Vaccines Group prior to Closing; 
 “Gross Negligence” has the meaning given to it in paragraph 3.16 of Schedule 25;

 “GSK Break Fee” has the meaning given to it in the Implementation Agreement; 

“Hazardous Substance” means any gasoline or petroleum products, polychlorinated biphenyls, urea-formaldehyde insulation,
hazardous wastes, toxic substances, asbestos, pollutants, or contaminants defined as such in or regulated under any applicable Environmental Law; 

“Headline Price” has the meaning given to it in Clause 3.1.1(i); 

“Healthcare Laws” means the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)); the Anti-Inducement Law (42 U.S.C.
§ 1320a-7a (a)(5)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)); the Exclusion Laws (42 U.S.C. § 1320a-7); the Medicare statute (Title XVIII of the
Social Security Act), including Social Security Act §§ 1860D-1 to 1860D-43 (relating to Medicare Part D and the Medicare Part D Coverage Gap Program); the Medicaid statute (Title XIX of the Social Security Act); the Physician Payment
Sunshine Act (42 U.S.C. § 1320a-7h) and any analogous state laws; the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, and any other similar law, including the price reporting requirements and the requirements relating to the processing of any applicable 

  
 14 

 rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid
Drug Rebate Program (42 U.S.C. § 1396r-8), any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the Veterans Health Care Act (38 U.S.C.
§ 8126), regulatory requirements applicable to sales on the Federal Supply Schedule or under any state pharmaceutical assistance program or United States Department of Veterans Affairs agreement, all legal requirements relating to the billing
or submission of claims, collection of accounts receivable, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing, by the Seller’s Group and any successor government
programs, and all foreign equivalents of the foregoing; 
 “Holly Springs Site” means properties located in Holly Springs,
North Carolina, United States of America at which the Influenza Business undertakes Manufacturing activities; 
 “HSR Act”
means the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, together with its implementing regulations; 

“IFRS” means International Financial Reporting Standards, comprising the accounting standards and interpretations issued,
adopted and/or approved by the International Accounting Standards Board; 
 “Illustrative Working Capital Statement” has the
meaning given to it in Part 2 of Schedule 16; 
 “Implementation Agreement” means the implementation agreement dated 22
April 2014 between the Seller and the Purchaser relating to, amongst other things, the implementation of the Transaction; 

“In-Market Inventory” means all inventory of Products for Commercialisation that, at any particular time: (i) is beneficially
owned by a member of the Seller’s Group; and (ii) is in finished packed form and released for Commercialisation; and (iii) is located: (a) in (or in transit to) the relevant Market; or (b) in (or in transit to) a multi-market warehouse owned or
operated by a member of the Seller’s Group or by a third party; or (c)at a Property pending despatch following release by the relevant qualified person to the relevant market or multi-market warehouse; 

“Indebtedness” means all loans and other financing liabilities and obligations in the nature of borrowed moneys and overdrafts
and moneys borrowed, but excluding trade debt and liabilities arising in the ordinary course of business; 
 “Influenza
Business” means the Cell-based Influenza Business, the Egg-based Influenza Business and the German Influenza Operations, taken together; 

“Influenza Business Agreements” means: 
  

	 	(i)	Influenza Business Manufacturing and Supply Agreement; 

  

	 	(ii)	Influenza Business Manufacturing, Supply and Distribution Agreement; 

  

	 	(iii)	Influenza Business Transitional Services Agreement; 

  

	 	(iv)	Marburg Support Services Agreement; 

  

	 	(v)	Influenza Business Global Quality Agreement; 

  

	 	(vi)	Influenza Business Pharmacovigilance Agreement; and 

  
 15 

	 	(vii)	any local services agreements to be entered into pursuant to the agreements referred to in paragraphs (i) and (iii) above, 

each as amended or restated from time to time; 

“Influenza Business Global Quality Agreement” means the agreement to be entered into between the Seller and the Purchaser on
Closing, pursuant to which the quality agreements applicable to the Influenza Business Manufacturing and Supply Agreement, Influenza Business Manufacturing, Supply and Distribution Agreement and Influenza Business Transitional Services Agreement are
identified; 
 “Influenza Business Manufacturing and Supply Agreement” means the manufacturing and supply agreement in
respect of the Influenza Business dated 23 October 2014 between the Seller and the Purchaser; 
 “Influenza Business
Manufacturing, Supply and Distribution Agreement” means the manufacturing, supply and distribution agreement in respect of the Influenza Business dated 23 October 2014 between the Seller and the Purchaser; 

“Influenza Business Pharmacovigilance Agreement” means the pharmacovigilance agreement between the Seller or a member
of the Seller’s Group and the Purchaser or a member of the Purchaser’s Group, to be entered into at Closing, in respect of pharmacovigilance and regulatory matters relating to certain Influenza Business products; 

“Influenza Business Transitional Services Agreement” means the transitional services agreement in respect of the
Influenza Business dated 23 October 2014 between the Seller and the Purchaser; 
 “Information Technology” means computer,
hardware, software and network; 
 “Intellectual Property Assignment Agreements” means the assignments between the Seller
and/or one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the transfer of certain Intellectual Property Rights in each of the
relevant jurisdictions; 
 “Intellectual Property Rights” means all: (i) Patents; (ii) Know-How; (iii) Trademarks; (iv)
internet domain names; (v) Copyrights; (vi) rights in designs; (vii) database rights; and (viii) all rights or forms of protection, anywhere in the world, having equivalent or similar effect to the rights referred to in paragraphs (i) to (vii)
above, in each case whether registered or unregistered and including applications for registration of any such thing; 

“International Assignees” means the employees of any member of the Seller’s Group (including the Vaccines Group
Companies) who are referred to in Schedule 6; 
 “Intra-Group Non-Trade Payables” means all outstanding loans or other
financing liabilities or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by a Vaccines Group Company to a member of the Seller’s Group (other than a Vaccines Group Company)
as at the Effective Time as derived from the Closing Statement, but excluding: (i) Intra-Group Trading Balances; and (ii) any item which falls to be included in calculating the Vaccines Group Companies’ Cash Balances or the Third Party
Indebtedness; 
 “Intra-Group Non-Trade Receivables” means all outstanding loans or other financing liabilities or
obligations (including, for the avoidance of doubt, interest accrued, dividends 

  
 16 

 
declared or payable but not paid) owed by a member of the Seller’s Group (other than a Vaccines Group Company) to a Vaccines Group Company as at the Effective Time as derived from the
Closing Statement, but excluding: (i) Intra-Group Trading Balances; and (ii) any item which falls to be included in calculating the Vaccines Group Companies’ Cash Balances or the Third Party Indebtedness; 

“Intra-Group Trading Balances” means all trade accounts and notes receivable or payable arising in the ordinary course between
any two members of the Seller’s Group, in each case to the extent related to the Vaccines Group, to which lines “BS01_630 Payables Other BU’s”, “BS01_140 Receivables Other BU’s”, “BS01_620 Payables Own
BU” and “BS01_130 Receivables Own BU” of the Statement of Net Assets apply, together with any unpaid financing charges accrued thereon; 

“IP Liability” means any Liability arising out of, relating to or resulting from any actual or alleged infringement,
misappropriation or other violation of Intellectual Property Rights of third parties; 
 “Judgment” means any order, writ,
judgment, injunction, decree, stipulation, determination, decision or award entered by or with any Governmental Entity of competent jurisdiction; 

“Key Personnel” means the Employees listed in Schedule 21; 

“Key Sites” means the Marburg Site, the Rosia Site and the Siena Site; 

“Know-How” means all existing and available technical information, know-how and data, including inventions (whether patentable
or not), discoveries, trade secrets, specifications, instructions, processes and formulae, including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, preclinical and clinical
data; 
 “Lease” has the meaning given to it in paragraph 1.1 of Part 4 of Schedule 3; 

“Liabilities” means all liabilities, claims, damages, proceedings, demands, orders, suits, costs, losses and expenses of every
description, whether deriving from contract, common law, statute or otherwise, whether present or future, actual or contingent, ascertained or unascertained or disputed and whether owed or incurred severally or jointly or as principal or surety;

 “Liability Cut-off Time” means (i) Closing in respect of any Liability that is a Clinical Trials/Data Liability,
Commercial Practices Liability, Environmental Liability, Governmental Liability, IP Liability, Manufacturing Liability or Product Liability; (ii) Delayed Closing in respect of any Liability that relates to a Non-Controlled Delayed Business and is a
Clinical Trials/Data Liability, Commercial Practices Liability, Environmental Liability, Governmental Liability, IP Liability, Manufacturing Liability or Product Liability (but, in respect of any such Environmental Liability, IP Liability or Product
Liability that arises as a result of, or otherwise relates to, any act, omission, fact, matter or circumstance or event undertaken, occurring, in existence or arising between Closing and Delayed Closing, only to the extent that such Liability arises
due to the wilful default or Gross Negligence of the relevant Seller or any of its Associated Persons); or (iii) the Effective Time in respect of any other Liability; 

“LIBOR” means the London interbank offered rate, being the interest rate offered in the London inter-bank market for three
month US dollar deposits as displayed on pages 

  
 17 

 
LIBOR01 or LIBOR02 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the Closing Date; 

“Licensed Intellectual Property Contract” means any Vaccines Group Intellectual Property Contract constituting or containing a
licence of Intellectual Property Rights in respect of the Business or Products; 
 “Listing Rules” means the listing rules
made by the FCA under section 73A of FSMA; 
 “Local Payment Amount” has the meaning given to it in Clause 6.5; 

“Local Transfer Document” has the meaning given to it in Clause 2.6.1; 

“Long Stop Date” has the meaning given to it in Clause 4.3; 

“Long Stop Expiry Date” has the meaning given to it in Clause 9.1.6; 

“Losses” means all losses, liabilities, costs (including legal costs and experts’ and consultants’ fees), charges,
expenses, actions, proceedings, claims and demands; 
 “MA Costs” has the meaning given to it in paragraph 4 of Part 2 of
Schedule 8; 
 “MA Documentation” has the meaning given to it in paragraph 1.4 of Part 2 of Schedule 8; 

“Manufacture”, “Manufacturing” or “Manufactured” means the planning, purchasing of materials
for, production, processing, compounding, storage, filling, packaging, labelling, leafleting, warehousing, quality control testing, waste disposal, quality release, sample retention and stability testing of products; 

“Manufacturing Inventory” means any packed inventory of Products and/or products for Commercialisation that is: (i) in
finished form (save for any secondary packaging undertaken outside of a Property); (ii) beneficially owned by any member of the Seller’s Group; (iii) held at a Property; and (iv) not yet released by the qualified person at a Property; and
excluding in each case, for the avoidance of doubt, any In-Market Inventory and Manufacturing Stocks; 
 “Manufacturing
Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable Law in connection with the manufacturing of products; 

“Manufacturing Licences” means any certificates, permits, licences, consents and approvals issued by any Governmental Entity,
used in the operation or conduct of Manufacturing at each Property, and “Manufacturing Licence” shall be construed accordingly; 

“Manufacturing Stocks” means, as at Closing, all stocks of raw materials, active pharmaceutical ingredients, ingredients,
adjuvants, drug substances, intermediates, packaging materials, components, devices and other production and pre-production consumables and work-in-progress that are beneficially owned by any member of the Seller’s Group for use in the
Manufacture of Products or Pipeline Products and held at a Property; 
 “Marburg Site” means the Properties located in
Marburg (Germany) at which the Vaccines Group undertakes Manufacturing activities; 

  
 18 

 “Marburg Support Services Agreement” means the Marburg support services
agreement in respect of the Influenza Business dated 23 October 2014 between the Seller and the Purchaser; 
 “Marketing
Authorisation Data” means the existing and available dossiers containing the relevant Know-How used by the Seller and/or its Affiliates to obtain and maintain the Marketing Authorisations; 

“Marketing Authorisation Holder” means the holder of the relevant Marketing Authorisation; 

“Marketing Authorisation Re-registration” has the meaning given to it in paragraph 1.1.2 of Part 2 of Schedule 8; 

“Marketing Authorisation Re-Registration Date” means the date on which the relevant Governmental Entity approves, or is deemed
to approve, the relevant Marketing Authorisation Re-registration; 
 “Marketing Authorisation Transfer” has the meaning
given to it in paragraph 1.1.1 of Part 2 of Schedule 8; 
 “Marketing Authorisation Transfer Date” means the date on which
the relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Transfer; 
 “Marketing
Authorisation Transferee” means the member of the Purchaser’s Group or, where no member of the Purchaser’s Group satisfies the requirements under Applicable Law to be transferred the relevant Marketing Authorisation, such Third
Party as is nominated by the Purchaser, in either case to whom the relevant Marketing Authorisation is to be transferred; 

“Marketing Authorisations” means the marketing authorisations issued or applications for marketing authorisations with respect
to the Products and all supplements, amendments and revisions thereto; 
 “Markets” means the markets in which the Products
are marketed and sold under the relevant Marketing Authorisation, and “Market” shall be construed accordingly; 

“Material Adverse Effect” means any matter, change, event or circumstance arising or discovered on or after the date of this
Agreement and prior to Closing (including a breach of the Seller’s obligations under Clause 5 or Clause 10.1) (a “Relevant Matter”) that, individually or in the aggregate with other Relevant Matters, if known to the Purchaser
prior to the date of this Agreement, could reasonably have expected to have resulted in the Purchaser offering to acquire the Vaccines Group on the terms of this Agreement at a discount to the Headline Price of 30 per cent. or more and, in
determining such reduction, regard shall be had to the actual basis on which the Purchaser determined the Headline Price. A Relevant Matter shall not constitute or count towards a “Material Adverse Effect” to the extent resulting or
arising from: 
  

	 	(i)	any change that is generally applicable to, or generally affects, the industries or markets in which the Vaccines Group operates (including changes arising as a result of usual seasonal variations) or arises from or
relates to changes in Applicable Law or accounting rules or changes in any authoritative interpretation of any Applicable Law by any Governmental Entity; 

  
 19 

	 	(ii)	any change in financial, securities or currency markets or general economic or political conditions or changes in prevailing interest rates or exchange rates; 

 

	 	(iii)	the execution of this Agreement, the public announcement thereof or the pendency or consummation of the transactions contemplated hereby (including any cancellations of or delays in customer orders or other decreases in
customer demand, any reduction in revenues and any disruption in supplier, distributor, customer or similar relationships); or 

  

	 	(iv)	the taking of any action expressly required by this Agreement or by any Ancillary Agreement or otherwise taken with the advance written consent of the Purchaser, 

except, in relation to either paragraph (i) or paragraph (ii) above, if that change adversely affects the Vaccines Group in a disproportionate
manner relative to other comparable businesses operating in the same industry and geographic markets as the Vaccines Group (in which case it may constitute or count towards a “Material Adverse Effect”); 

“Material Employee Jurisdictions” means China, Germany, India, Italy, the United Kingdom and the United States of America;

 “Medical Information” means information relating to clinical and technical matters, such as therapeutic uses for the
approved indications, drug-disease information, and other product characteristics Predominantly Related to the Business which is available to or used by the Seller and/or its Affiliates as of the Closing Date, or, in respect of any Delayed Business,
the Delayed Closing Date, as applicable; 
 “MenA Fill Finish Manufacturing and Supply Agreement” means the manufacturing
and supply agreement, and the quality agreement relating thereto, to be entered into between the Seller or a member of the Seller’s Group and the Purchaser or a member of the Purchaser’s Group on Closing, pursuant to which Novartis Pharma
Stein AG will manufacture and supply certain products to the Vaccines Business in connection with Meningococcal serogroup A vaccines; 

“MenACWY Fill Finish Clinical Supply Agreement” means the clinical supply agreement, and the quality agreement relating
thereto, to be entered into between the Seller or a member of the Seller’s Group and the Purchaser or a member of the Purchaser’s Group on Closing, pursuant to which Novartis Pharma Stein AG will manufacture and supply certain products to
the Vaccines Business in connection with clinical trials of quadrivalent Meningococcal vaccines; 
 “MenB Manufacturing and Supply
Agreement” means the manufacturing and supply agreement, and the quality agreement relating thereto, to be entered into on or before Closing between Sandoz GmbH and Novartis Vaccines and Diagnostics S.r.l. with the written consent of the
Purchaser, pursuant to which Sandoz GmbH will manufacture and supply certain products to the Vaccines Business in connection with Meningococcal serogroup B vaccines; 

“Merck 2012 Licence” means the Settlement and Licence Agreement between Novartis Vaccines and Diagnostics Inc. and Merck KGaA
and Ares Trading SA dated 14 November 2012; 
 “Milestone Payments” has the meaning given to it in paragraph 10 of Schedule
17; 
 “Minority Interest Entities” means the entities, details of which are set out in paragraph 3 of Schedule 2, and
“Minority Interest Entity” means any one of them; 

  
 20 

 “Mixed Affiliate Quality Agreement” means any Affiliate Quality Agreement which
relates both: 
  

	 	(i)	to the Business or any part of the Business to be transferred to the Purchaser at Closing; and 

  

	 	(ii)	to any part of the Seller’s Group Retained Business, any product other than the Products, or any Excluded Asset; 

“Mixed Contract” means any Contract which relates both: 

 

	 	(i)	to the Business or any part of the Business to be transferred to the Purchaser at Closing; and 

  

	 	(ii)	to any part of the Seller’s Group Retained Business, any product other than the Products, or any Excluded Asset, 

and which is either a Transferred Contract or a Contract to which a Vaccines Group Company is party; 

“Mixed Contracts Separation” has the meaning given to it in Schedule 10; 

“MOFCOM” means the Ministry of Commerce in the PRC or its local counterparts; 

“Moratorium Date” has the meaning given to it in Schedule 10; 

“Multi-Basket Tender” means any Tender other than a Products-Only Tender; 

“NDRC” means the National Development and Reform Commission in the PRC or its local counterparts; 

“Netherlands APA” has the meaning given to it in the Netherlands Offer Letter; 

“Netherlands Assumed Liabilities” means the Assumed Liabilities to the extent they relate to the Netherlands Business; 

“Netherlands Business” means that part of the Vaccines Group, comprising: 

 

	 	(i)	the Vaccines Group Businesses that relate predominantly to the part of the Business conducted in the Netherlands; 

  

	 	(ii)	the Netherlands Assumed Liabilities; 

  

	 	(iii)	the Netherlands Employees; and 

  

	 	(iv)	any other assets that are exclusively related to the Netherlands Business; 

“Netherlands Closing” has the meaning given to it in the Netherlands APA; 

“Netherlands Employees” means the Employees employed in the Netherlands; 

“Netherlands Offer Letter” means the letter from the Purchaser to the Seller in respect of the binding offer from the
Purchaser to acquire the Netherlands Business dated on or around the date hereof; 
 “Netherlands Put Option Exercise” has
the meaning given to it in the Netherlands Offer Letter; 
 “Non-Controlled Delayed Business” has the meaning given to it in
Schedule 25; 

  
 21 

 “Non-strategic Assets” means the assets of the Vaccines Group exclusively
related to the Products Encepur and Ixiaro and any Liabilities relating to those Products; 
 “Non-Transferring Tender”
means: 
  

	 	(i)	any Products-Only Tender which is subject to public procurement law and regulation in the relevant Market and cannot be transferred under Applicable Law; and 

 

	 	(ii)	any Multi-Basket Tender; 

 “Non-US Benefit Plans” has the meaning given to it
in paragraph 16.3.1 of Schedule 18; 
 “Notice” has the meaning given to it in Clause 17.11.1; 

“Novartis 2013 Annual Report” means the 2013 annual report of Novartis AG, including the consolidated financial statements of
the Seller’s Group for the financial year ending on 31 December 2013; 
 “Novartis Branded Inventory” has the meaning
given to it in Clause 9.1.1(iii); 
 “Novartis Branded Literature” has the meaning given to it in Clause 9.1.1(v); 

“Novartis Branded Products” has the meaning given to it in Clause 9.1.1(iv); 

“Novartis Branded Websites” has the meaning given to it in Clause 9.1.1(ii); 

“Novartis Break Fee” has the meaning given in the Implementation Agreement; 

“NTT Multi-Basket Tender” has the meaning given to it in Schedule 10; 

“NTT Products-Only Tender” has the meaning given to it in Schedule 10; 

“Ongoing Clinical Trials” means the ongoing clinical studies sponsored or supported by the Seller’s Group (including
post-approval studies) or otherwise recommended by a Governmental Entity, and regulatory commitments in respect of the Products and the Pipeline Products, listed in Schedule 22 and “Ongoing Clinical Trial” shall mean any one of them; 

“Out-Licensing Programme” means the out-licensing and enforcement of Intellectual Property Rights that are not used in or
developed for the Business and generally relate to base technology useful in drug discovery and/or manufacturing processes, including any contracts or Intellectual Property Rights related thereto but excluding the Beta Interferon Patent Rights; 

“Out-Licensing Programme Intellectual Property Rights” means the Intellectual Property Rights used in relation to the
Out-Licensing Programme; 
 “Out of Scope Patent” means any Patent of the Seller’s Group at the Closing Date, but
excluding (i) the Transferred Intellectual Property Rights; (ii) any Patents licensed under the Purchaser Intellectual Property Licence Agreement; (iii) Out-Licensing Programme Intellectual Property Rights; and (iii) any Patents in any Non-strategic
Assets; 
 “Owned Information Technology” means: 
  

	 	(i)	in the case of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd, all of the Information Technology owned by it; 

  
 22 

	 	(ii)	in the case of Novartis Vaccines and Diagnostics GmbH, the Site Specific Information Technology that is located in the datacentres at the building “H1” located at Emil-von-Behring-Straße 76, 35041
Marburg, Germany and the building “N310” located at Emil-von-Behring-Straße 200, 35041 Marburg, Germany; 

  

	 	(iii)	in the case of Chiron Behring Vaccines Private Limited, the Site Specific Information Technology that is located in the datacentre at Plot Nos. 3501/A, 3502 & 3503/A, Post Box No. 94, GIDC Estate, Ankleshwar –
393 002. Dist: Bharuch, Gujarat, India (First Floor of admin building); and 

  

	 	(iv)	in the case of Novartis Vaccines and Diagnostics S.r.l, the Site Specific Information Technology that is located in the datacentre at Building 15, Via Fiorentina,1, 53100 Siena Italy and Building 53, Località
Bellaria Rosia, 53018 Sovicille (Si) Italy, 

 including the Information Technology set out in Part 2 of Schedule 27; 

“Owned Intellectual Property Contracts” means the Contracts Exclusively Related to the Business which relate to Intellectual
Property Rights and that are held by the Vaccines Group Companies, including any such Contracts set out in Part 2 of Schedule 4; 

“Owned Intellectual Property Rights” means the Intellectual Property Rights of any Vaccines Group Company to the extent
Exclusively Related to the Business, including the Intellectual Property Rights of any Vaccines Group Company set out in Part 1 of Schedule 4; 

“Patent Term Extensions” means any and all extensions of a term of a Patent granted under the Patent laws or regulations of
any country, the European Union (including any supplementary protection certificate), or any other Governmental Entity; 

“Patents” means patents, design patents, patent applications, and any reissues, re-examinations, divisionals, continuations,
continuations-in-part, provisionals, and extensions thereof or any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating to any of the foregoing); 

“PA Transfer Date” means, in relation to a Product or Product Application, the date upon which the relevant Governmental
Entity approves and notifies the Product Approval or Product Application (as applicable) naming the Purchaser or the relevant Affiliate of the Purchaser (or designee thereof) as the holder of such Product Approval or Product Application in the
relevant country or territory covered by that Product Approval or Product Application; 
 “Payables and Receivables Plan”
has the meaning given to it in Clause 8.6; 
 “Payment” has the meaning given to it in Clause 1.9; 

“Permit” has the meaning given to it in paragraph 9.2 of Schedule 18; 

“Permitted Encumbrance” means: 
  

	 	(i)	Encumbrances imposed by Applicable Law; 

  

	 	(ii)	Encumbrances imposed in the ordinary course of business which are not yet due and payable or which are being contested in good faith; 

 

	 	(iii)	Encumbrances which are listed in Schedule 7; 

  
 23 

	 	(iv)	pledges or deposits to secure obligations under Applicable Law relating to workers’ compensation, unemployment insurance or to secure public or statutory obligations; and 

 

	 	(v)	liens, title retention arrangements or deposits to secure the performance of bids, trade contracts (other than for borrowed money), conditional sales contracts, leases, statutory obligations, surety and appeal bonds,
performance bonds and other obligations of a like nature incurred in the ordinary course of the Business; 

 “Personal
Property” means all tangible personal property legally and beneficially owned by the Seller’s Group which is Predominantly Related to the Business and is located at a Property at Closing; 

[***] 
 [***] 

“Pipeline Product” means: 
  

	 	(i)	each product in development by the Business set out under the heading “Pipeline Products” in Part 3 of Schedule 8; and 

  

	 	(ii)	any other product in development Exclusively Related to the Business; 

 “Pipeline
Product Approvals” means the approvals in relation to the Pipeline Products; 
 “PRC” means the People’s
Republic of China which, for the purpose of this Agreement, shall exclude the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan; 

“PRC Transfer Documents” means the Local Transfer Agreement in respect of the transfer of the Tianyuan Shares from the
relevant Share Seller to the Purchaser, the amended joint venture contract and amended articles of association of Tianyuan JV, each to be submitted to the NDRC and MOFCOM in connection with the approval of (i) each of those documents and (ii) the
sale and transfer of the Tianyuan Shares from the relevant Share Seller to the Purchaser; 
 “Predominantly Related to the
Business” means exclusively or predominantly related to, or used or held for use exclusively or predominantly, in connection with the Business; 

“Proceedings” means any legal actions, proceedings, suits, litigations, prosecutions, investigations, enquiries, mediations or
arbitrations; 
 “Product Applications” means all applications for Product Approval filed with respect to Products Under
Registration, with each individual application being a “Product Application”; 
 “Product Approvals”
means all permits, licences, certificates, clearances, registrations or other authorisations or consents issued by any Governmental Entity to the Seller or one of its Affiliates with respect to the Products or the use, research, development,
marketing, distribution or sale thereof, including the Marketing Authorisations; 
 “Product Filings” means all filings,
written representations, declarations, listings, registrations, reports or submissions with or to any Governmental Entity, including adverse event reports and all submitted data relating to each Product; 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 24 

 “Product Liabilities” means any Liability arising out of, relating to or
resulting from actual or alleged harm, injury, damage or death to persons in connection with the use of any product (including in any clinical trial or study); 

“Product Packaging” means (i) the primary packaging in which the Novartis Branded Products and Novartis Branded Inventory are
packaged (e.g., blister packs, bottles with labels); (ii) the secondary packaging in which Novartis Branded Products and Novartis Branded Inventory are packaged (e.g., boxes containing blister packs or bottles); and (iii) any leaflets contained
inside the secondary packaging; 
 “Product Partners” means any third parties which pursuant to a Contract with the Seller
or any Affiliate of the Seller co-develop, co-promote, co-market, or otherwise have a licence or other right to research, develop, manufacture, promote, distribute, market, or sell any Product, including all manufacturers and suppliers of any such
Product; 
 “Products” means: 
  

	 	(i)	the products set out under the heading “Products” in Part 3 of Schedule 8; and 

  

	 	(ii)	any other products Exclusively Related to the Business; 

 “Products-Only
Tender” means any Tender that relates solely to the Products; 
 “Products Under Registration” means: 

 

	 	(i)	the products set out under the heading “Products Under Registration” in Part 3 of Schedule 8, which are pending Product Approval as of the date hereof; and 

 

	 	(ii)	any other products under registration Exclusively Related to the Business; 

“Properties” means the Company Real Properties and the Transferred Real Properties and “Property” means any
one of them; 
 “Proprietary Information” means all confidential and proprietary information of the Seller or its Affiliates
that is Predominantly Related to the Business, including confidential Medical Information, confidential Know How and confidential Commercial Information; 

“Purchase Price” has the meaning given to it in Clause 3.1.1; 

“Purchase Price Bank Account” means the account notified by the Seller to the Purchaser no later than two Business Days prior
to the Closing Date; 
 “Purchaser Articles of Association” means the articles of association of the Purchaser in force and
effect from time to time; 
 “Purchaser Intellectual Property Licence Agreement” means the agreement between the Seller
and/or one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the grant of licences from the Seller to the Purchaser of certain
Intellectual Property Rights; 
 “Purchaser’s Disagreement Notice” has the meaning given to it in paragraph 1.3 of
Schedule 16; 
 “Purchaser’s Group” means the Purchaser and its Affiliates from time to time; 

“Purchaser’s Lawyers” means Slaughter and May of One Bunhill Row, London EC1Y 8YY, United Kingdom; 

  
 25 

 “Purchaser Shareholder Meeting” has the meaning given to it in Clause 4.1.6;

 “Purchaser Shareholder Resolution” has the meaning given to it in Clause 4.1.6; 

“Purchaser Shareholders” means the holders of ordinary shares in the capital of the Purchaser from time to time; 

“Rebate” means any amount payable or repayable to customers or Governmental Entities in respect of a contractual rebate or
other rebate including under applicable Healthcare Laws (or under similar laws or regulations) due on sales of products; 

“Registered Intellectual Property Rights” means Intellectual Property Rights that are registered, issued, filed, or applied
for under the authority of any Governmental Entity; 
 “Registered Transferred Intellectual Property Rights” means all
Transferred Intellectual Property Rights that are Registered Intellectual Property Rights; 
 “Registered Vaccines Group Intellectual
Property Rights” means all Vaccines Group Intellectual Property Rights that are Registered Intellectual Property Rights; 

“Registration” has the meaning given to it in Clause 9.3.2(ii); 

“Regulation” has the meaning given to it in Clause 4.1.1; 

“Relevant Employees” means the Relevant Vaccines Business Employees and the Relevant Vaccines Group Company Employees and
“Relevant Employee” means any one of them; 
 “Relevant Employers” means the Business Sellers and such
other members of the Seller’s Group who employ the Relevant Vaccines Business Employees; 
 “Relevant Matter” has the
meaning given to it in the definition of Material Adverse Effect; 
 “Relevant Part” means: 

 

	 	(i)	with respect to any Shared Business Contracts or Mixed Affiliate Quality Agreement, the relevant part of such Shared Business Contract or Mixed Affiliate Quality Agreement (as the case may be) which relates exclusively
to the Vaccines Group; and 

  

	 	(ii)	with respect to any Mixed Contract, the relevant part of such Mixed Contract which relates exclusively to the Seller’s Group Retained Business, any product other than the Products or any Excluded Asset;

 “Relevant Parties” has the meaning given to it in paragraph 1.1.1 of Schedule 17; 

“Relevant Pension and Employment Liability” means (i) any Liabilities assumed by the Purchaser or a member of the
Purchaser’s Group as contemplated by Schedule 11; and (ii) any Transferred Employee Benefit Liabilities (as defined in Schedule 12) which the Purchaser agrees to assume in accordance with Schedule 12; 

“Relevant Period” means the period of two years prior to the date of this Agreement; 

“Relevant Persons” has the meaning given to it in Clause 8.2.2; 

[***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 26 

 “Relevant Vaccines Business Employees” means the Vaccines Business Employees
immediately prior to the Closing Date and “Relevant Vaccines Business Employee” means any one of them; 
 “Relevant
Vaccines Group Company Employees” means the Vaccines Group Company Employees immediately prior to the Closing Date (excluding any who do not work wholly or substantially in the Business (as carried on by the Vaccines Group)) and
“Relevant Vaccines Group Company Employee” means any one of them; 
 “Relevant Working Day” means a normal
working day in the relevant jurisdiction and excludes a Saturday or Sunday or public holiday in the relevant jurisdiction; 

“Reorganisation” has the meaning given to it in Clause 2.3.5; 

“Reporting Accountants” means the London office of Ernst & Young or, if that firm is unable or unwilling to act in any
matter referred to them under this Agreement, the London office of Deloitte or, if that firm is also unable or unwilling to act in any matter referred to them under this Agreement, an internationally recognised and independent firm of accountants
who does not act as auditor to the Seller or the Purchaser, to be agreed by the Seller and the Purchaser within seven days of a notice by one to the other requiring such agreement or, failing such agreement, to be nominated on the application of
either of them by or on behalf of the Institute of Chartered Accountants of England and Wales; 
 “Representatives” means,
in relation to any party, any of its and/or any other member of the Purchaser’s Group’s or Seller’s Group’s directors, officers, employees, agents, representatives, bankers, auditors, accountants, financial advisers, legal
advisers and any other professional advisers; 
 “Required Item” has the meaning given to it in paragraph 2 of Schedule 13;

 “Required Notifications” has the meaning given to it in Clause 4.2.1; 

“Restricted Vaccines Group Employee” means any Transferred Employee who is at or above grade GG5 or GJFA3 (or, in either case,
the Purchaser’s equivalent from time to time); 
 “Retained Information Technology” means all Information Technology of
the Vaccines Group, excluding the Transferred Information Technology and the Owned Information Technology; 
 “Retained
Inventory” has the meaning given to it in Clause 2.7.1; 
 “Rosia Site” means the Properties located in Rosia
(Italy) at which the Vaccines Group undertakes Manufacturing activities; 
 “Royalty” means any royalty payable in respect
of sales of Products; 
 “Royalty Payments” has the meaning given to it in paragraph 10 of Schedule 17; 

“Sanctions Laws” has the meaning given to it in paragraph 9.5 of Schedule 18; 

“Secondment Agreement” means the secondment agreement made between Novartis Vaccines and Diagnostics, Inc., Novartis Pharma AG
and GlaxoSmithKline LLC dated on or about the Closing Date relating to the secondment of [***]; 
 “Seller Allowance Rebate and
Royalty Amount” means any Allowance, Rebate or Royalty payable after the Effective Time by the Purchaser or any member of the 

 

	***	 Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted
from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 27 

 
Purchaser’s Group (including any Delayed Vaccines Group Company), to the extent it relates to the sales of any products made prior to the Effective Time; 

“Seller Marks” means any of the marks (including in either or both logo and local script form) “Novartis”,
“Sandoz”, “Alcon” and “Ciba Vision” used alone or in combination with other words or marks; 
 “Seller
Restricted Marks” means any of the marks (including in either or both logo and local script form) “Novartis”, “Sandoz”, “Alcon” and “Ciba Vision”; 

“Seller Partner” means any counterparty to a development, contract research, commercialisation, manufacturing, distribution,
sales, marketing, supply, consulting or other collaboration Contract with the Seller or any Affiliate of the Seller; 

“Seller’s Disagreement Notice” has the meaning given to it in paragraph 1.4 of Schedule 16; 

“Seller’s Group” means the Seller and its Affiliates from time to time; 

“Seller’s Group Insurance Policies” means all insurance policies (whether under policies maintained with third party
insurers or any member of the Seller’s Group), other than Vaccines Group Insurance Policies, maintained by the Seller or any member of the Seller’s Group in relation to the Vaccines Group or under which, immediately prior to Closing, any
Vaccines Group Company or the Seller or member of the Seller’s Group in relation to the Vaccines Group Businesses is entitled to any benefit, and “Seller’s Group Insurance Policy” means any one of them; 

“Seller’s Group Retained Business” means, from time to time, all businesses of the Seller’s Group, including, the
Influenza Business, but excluding the Business; 
 “Seller’s Knowledge” has the meaning given to it in Clause 10.1.4;

 “Seller’s Lawyers” means Linklaters LLP of One Silk Street, London EC2Y 8HQ, United Kingdom; 

“Seller’s Warranties” means the warranties given by the Seller pursuant to Clause 9 and Schedule 18, and
“Seller’s Warranty” means any one of them; 
 “Separation” has the meaning given to it in paragraph
3.4 of Schedule 10; 
 “Service Provider” means an Associated Person who is a legal person; 

“Share Seller” means, in relation to each of the Companies and Minority Interest Entities referred to in column (2) of
Schedule 1, the company whose name is set out opposite that Company or Minority Interest Entity in column (1); 
 “Shared Business
Contracts” means any Contract which: 
  

	 	(i)	is not a Transferred Contract; and 

  

	 	(ii)	relates both: 

  

	 	(A)	to the Business or any part of the Business to be transferred to the Purchaser at Closing; and 

  

	 	(B)	to any part of the Seller’s Group Retained Business, any product other than the Products, or any Excluded Asset, 

  
 28 

 and to which a member of the Seller’s Group (excluding any Vaccines Group Company) is a
party or in respect of which a member of the Seller’s Group (excluding any Vaccines Group Company) has any right, liability or obligation at Closing (including the Multi-Basket Tenders), and “Shared Business Contract” shall
mean any of them; 
 “Shared Employees” means employees of any member of the Seller’s Group who work wholly or
substantially in the Business (as carried on by the Vaccines Group) pursuant to service level agreements with the Vaccines Group Companies and other members of the Seller’s Group but excluding, for the avoidance of any doubt, any Vaccines Group
Company Employee and any employees included on the list of employees provided pursuant to paragraph 15.2 of Schedule 18; 

“Shares” means the shares in the capital of the Companies and the Minority Interest Entities specified in Schedule 1; 

“Siena Site” means the Properties located in Siena (Italy) at which the Vaccines Group undertakes Manufacturing activities;

 “Site Specific Information Technology” means Information Technology that is owned by a member of the Seller’s Group
and located at a Property which is used for research and development or Manufacturing activities conducted at that Property or the removal of which would compromise the research and development or manufacturing activities or the integrity of the
local network and Information Technology operations at such Property, but shall exclude any devices or application based infrastructure; 

“Specified Excluded Businesses” means the businesses and activities of: (i) Roche Holding AG which, for the avoidance of
doubt, is not an Affiliate and (ii) Novartis Institutes for BioMedical Research (and other activities of a similar type to those currently conducted by Novartis Institutes for BioMedical Research); 

“Statement of Net Assets” means the statement of net assets as at the Statement of Net Assets Date, as set out in Part 2 of
Schedule 23; 
 “Statement of Net Assets Date” means 31 December 2013; 

“Statement of Net Assets Rules” means the rules in accordance with which the Statement of Net Assets was prepared, as set out
in Part 2 of Schedule 23; 
 “Subsidiaries” means the companies listed in paragraph 2 of Schedule 2 and
“Subsidiary” means any one of them; 
 “Target Asset Agreements” has the meaning given to it in the
Implementation Agreement; 
 “Taxation” or “Tax” means all supra-national, federal, state, county, local,
municipal, foreign and other taxes, assessments, duties or similar charges of any kind whatsoever (other than deferred tax), including all corporate franchise, income, gross receipts, sales, use, ad valorem, receipts, value added, profits, licence,
withholding, payroll, employment, excise, premium, property, net worth, capital gains, transfer, stamp, documentary, social security, alternative minimum, occupation, recapture and other taxes regardless as to whether any such taxes, assessments,
duties or similar charges are chargeable directly or primarily against or attributable directly or primarily to a Vaccines Group Company or any other person, and including all interest, penalties and additions imposed with respect to such amounts by
any Tax Authority or with respect to any failure to file any Tax Return; 
 “Tax Adjustment” means the amount by which: 

  
 29 

	 	(a)	the aggregate amount of the income taxes and sales taxes payable by the Vaccines Group Companies, as at the Effective Time and as derived from the Closing Statement; 

exceeds or is less than 
  

	 	(b)	the aggregate amount of the current income tax and sales tax receivables of the Vaccines Group Companies as at the Effective Time as derived from the Closing Statement, 

and any such excess amount shall be treated as a positive number and any shortfall shall be treated as a negative amount; 

“Tax Authority” has the meaning ascribed to it in the Tax Indemnity; 

“Tax Consolidation” has the meaning ascribed to it in the Tax Indemnity; 

“Tax Group” has the meaning ascribed to it in the Tax Indemnity; 

“Tax Indemnity” means the deed of covenant against taxation, in the Agreed Terms, to be entered into on the Closing Date
between the Seller and the Purchaser; 
 “Tax Return” has the meaning ascribed to it in the Tax Indemnity; 

“Tax Warranties” means the Seller’s Warranties set out in paragraph 13 of Schedule 18; 

“Tender” means any Contract or arrangement to which a member of the Seller’s Group is a party (itself or through an
agent) with a third party, entered into following a call for a tender by the relevant third party, for the supply by the Seller’s Group of products including the Products in a Market and pursuant to which Products may be sold after Closing;

 “Third Party” has the meaning given to it in Clause 17.4.2; 

“Third Party Claim” has the meaning given to it in Clause 12.4; 

“Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from third parties
for (i) the assignment or transfer to a member of the Purchaser’s Group of any of the Transferred Contracts, Transferred Intellectual Property Contracts or Shared Business Contracts or Co-Owned Vaccines Group Intellectual Property Rights or
Transferred Plant and Equipment or Mixed Contracts (ii) the Mixed Contracts Separation of the Mixed Contracts and (iii) Separation, as the case may be, and “Third Party Consent” means any one of them; 

“Third Party Indebtedness” means the aggregate amount as at the Effective Time of all outstanding Indebtedness owed by the
Vaccines Group Companies to any third party less any Indebtedness owed by any third party to any Vaccines Group Company as derived from the Closing Statement (but excluding any item included in respect of any Vaccines Group Companies’ Cash
Balances or Intra-Group Non-Trade Payables), and, for the purposes of this definition, third party shall exclude any member of the Seller’s Group; 

“Threshold Amount” means, in the case of Ixiaro, US$ 50 million, and in the case of Encepur, US$ 200 million; 

“Tianyuan JV” means Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., whose particulars are specified in Paragraph 1 of Schedule
2; 
 [***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 30 

 “Tianyuan Shares” means the 85 per cent. of the equity interests in Tianyuan JV
which are specified in Schedule 1; 
 [***] 

“Time-Limited Excluded Liability” means an Excluded Liability which is: 

 

	 	(i)	a Contracts Liability; 

  

	 	(ii)	an Environmental Liability; 

  

	 	(iii)	a Manufacturing Liability; or 

  

	 	(iv)	a Commercial Practices Liability; 

 “Trademarks” means trademarks, service
marks, trade names, certification marks, service names, industrial designs, brand names, brand marks, trade dress rights, identifying symbols, logos, emblems, and signs or insignia and all goodwill of the business in relation to which any of the
foregoing are used (but no other or greater goodwill); 
 “Transaction” has the meaning given to it in Clause 4.1.1; 

“Transfer Regulations” means the relevant national measure by which the employment of a Relevant Vaccines Business Employee
automatically transfers to the Purchaser or a relevant member of the Purchaser’s Group; 
 “Transferred Accounts
Payable” means all trade accounts and notes payable arising in the ordinary course of the Seller’s Group (other than any Vaccines Group Company) to the extent related to the Business, and outstanding at the Effective Time, together
with any unpaid financing charges accrued thereon; 
 “Transferred Accounts Receivable” means all trade accounts and notes
receivable arising in the ordinary course of the Seller’s Group (other than any Vaccines Group Company) to the extent related to the Business, and outstanding at the Effective Time, together with any unpaid financing charges accrued thereon;

 “Transferred Affiliate Quality Agreement” means: 

 

	 	(i)	any Affiliate Quality Agreement that is not a Mixed Affiliate Quality Agreement; and 

  

	 	(ii)	the Relevant Part of any Mixed Affiliate Quality Agreement; 

 “Transferred Books and
Records” means all books, ledgers, files, reports, plans, records, manuals and other materials (in any form or medium) to the extent of, or maintained predominantly for, the Business by the Seller’s Group (excluding the Vaccines Group
Companies) (other than emails), but excluding: 
  

	 	(i)	any such items to the extent that: (A) they are related to any Excluded Assets or Excluded Liabilities, (B) they are related to any corporate, Tax, human resources or stockholder matters of the Seller or its Affiliates
(other than the Vaccines Group Companies), (C) any Applicable Law prohibits their transfer, (D) any transfer thereof otherwise would subject the Seller or any of its Affiliates to any material liability or (E) they are retained by the Seller in
accordance with Clause 8.15; 

  

	 	(ii)	any laboratory notebooks to the extent containing research and development information unrelated to the Business; and 

  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 31 

	 	(iii)	any books and records (including but not limited to the content of any personnel files) kept by the Seller’s Group relating to the employment of the Transferred Employees with the Seller’s Group;

 “Transferred Contracts” means: 
  

	 	(i)	the Contracts, other than Transferred Intellectual Property Contracts, that are Predominantly Related to the Business between a member of the Seller’s Group (excluding the Vaccines Group Companies), on the one
hand, and any third party, on the other hand (other than this Agreement and any Ancillary Agreement), including, without limitation, Products-Only Tenders, but excluding any Excluded Contract; 

 

	 	(ii)	any Transferred Affiliate Quality Agreement; and 

  

	 	(iii)	subject to the Purchaser making an election under paragraph 1.3 of Schedule 10, the Relevant Part of the Shared Business Contracts; 

“Transferred Employees” means (i) the Vaccines Business Employees to whom the Purchaser (or a member of the Purchaser’s
Group) offers employment and who accept such employment and become employed by the Purchaser (or a member of the Purchaser’s Group) in accordance with Schedule 11; (ii) any Relevant Vaccines Business Employees who transfer to the Purchaser (or
a member of the Purchaser’s Group) by operation of the Transfer Regulations and do not object to such transfer (to the extent permitted by the Transfer Regulations) in accordance with Schedule 11; and (iii) the Relevant Vaccines Group Company
Employees, and “Transferred Vaccines Business Employees” means the employees in (i) and (ii), “Transferred Vaccines Group Company Employees” means the employees in (iii) and “Transferred Employee”,
“Transferred Vaccines Business Employee” and “Transferred Vaccines Group Company Employee” respectively means any one of them; 

“Transferred Information Technology” means: 
  

	 	(i)	in the case of Shanghai Novartis Trading Limited, the Site Specific Information Technology; and 

  

	 	(ii)	in the case of Novartis Korea Ltd, the Site Specific Information Technology that is located in the datacentre at 17fl. Yonsei Bldg., Tongil-ro 10, Joong-gu, Seoul 100-753, 

including the Information Technology set out in Part 1 of Schedule 27; 

“Transferred Intellectual Property Contracts” means Contracts Exclusively Related to the Business which relate to Intellectual
Property Rights (but excluding the rights under any such Contracts that are held by the Vaccines Group Companies), including any such Contracts set out in Part 2 of Schedule 4 and the Merck 2012 Licence; 

“Transferred Intellectual Property Rights” means the Intellectual Property Rights of any member of the Seller’s Group
(other than a Vaccines Group Company) Exclusively Related to the Business, including the Intellectual Property Rights of any member of the Seller’s Group (other than a Vaccines Group Company) set out in Parts 1 and 3 of Schedule 4; 

“Transferred Inventory” means all inventories (including Manufacturing Inventory and Manufacturing Stocks and In-Market
Inventory), wherever located, including all raw materials, work in progress, finished Products and packaging and labelling material in 

  
 32 

 
respect of the Products and otherwise Predominantly Related to the Business (but excluding any such items held by the Vaccines Group Companies) whether held at any location or facility of a
member of the Seller’s Group or in transit to a member of the Seller’s Group, in each case as of the Effective Time; 

“Transferred Leased Real Properties” has the meaning given to it in paragraph 1.1 of Part 4 of Schedule 3; 

“Transferred Owned Real Properties” has the meaning given to it in paragraph 1.1 of Part 4 of Schedule 3; 

“Transferred Plant and Equipment” means: 
  

	 	(i)	the Transferred Information Technology; and 

  

	 	(ii)	all plant, furniture, furnishings, vehicles, equipment, tools and other tangible Personal Property (other than Transferred Inventory or Transferred Information Technology) of the Seller’s Group that are
Predominantly Related to the Business (but excluding any such items owned by the Vaccines Group Companies); 

“Transferred Real Properties” means: 
  

	 	(i)	the Transferred Owned Real Properties; 

  

	 	(ii)	the Transferred Leased Real Properties; and 

  

	 	(iii)	all other freehold, leasehold or other immovable property Predominantly Related to the Business, other than any freehold, leasehold or other immovable property within the definition of “Excluded Assets”,

 and “Transferred Real Property” means any one of them; 

“Transitional Distribution Services Agreement” means the transitional distribution services agreement to be entered into
between the Seller and the Purchaser at Closing, the quality agreement thereto and each local agreement entered pursuant to such transitional distribution services agreement on terms consistent with the Agreed Terms; 

“Transitional Services Agreement” means the transitional services agreement to be entered into between the Seller and the
Purchaser at Closing (and each local agreement entered pursuant to such transitional services agreement) on terms consistent with the heads of terms in the Agreed Terms, pursuant to which: (i) the Seller will provide or procure the provision of
certain transitional services to the Purchaser; and (ii) the Purchaser will provide or procure the provision of certain transitional services to the Influenza Business; 

“Transitional Trademark Licence” has the meaning given to it in Clause 9.1.1; 

“US Benefit Plans” means all United States “employee benefit plans” (within the meaning of section 3(3) of ERISA),
severance, change in control or employment, vacation, incentive, bonus, stock option, stock purchase, or restricted stock plans, programmes, agreements or policies benefiting the Vaccines Business Employees; 

“Vaccines” means a preparation comprising (i) an antigen, (ii) an epitope of an antigen, or (iii) a polynucleotide encoding an
antigen derived directly or indirectly from, or mimicking, an agent (including, but not limited to, a compound, a toxin, a microbe including a pathogen or component thereof), wherein such preparation may further comprise a composition capable of
modulating an immune response, including preparations intended to improve a human’s immune response to a microbe that has been linked to cancer, 

  
 33 

 
wherein said preparation is intended for purposes of inducing an immune response in a human, including, but not limited to, a functional immune response or immunological memory to the particular
or related antigen or agent, thereby causing or improving an immune response to a challenge by the particular or related agent. “Vaccines” shall not include preparations intended to improve a human’s immune response to or to treat
other non-infectious conditions, whether or not related to pathogens, such as certain autoimmune diseases, Alzheimer’s disease and certain cancers, or non-antigen preparations comprising immune system components intended to function analogous
to corresponding native components within the patient, such as antibodies or white blood cells (both unmodified or modified to better treat disease); 

“Vaccines Business Employees” means the employees of any member of the Seller’s Group who work wholly or substantially in
the Business (as carried on by the Vaccines Group) from time to time including, for the avoidance of any doubt, the International Assignees other than the Vaccines Group Company Employees, the Excluded Employees and the Shared Employees and provided
that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement” and “Vaccines Business Employee” means any one of them; 

“Vaccines Business Manufacturing and Supply Agreements” means the MenA Fill Finish Manufacturing and Supply Agreement, the
MenACWY Fill Finish Clinical Supply Agreement and the MenB Manufacturing and Supply Agreement; 
 “Vaccines Business
Pharmacovigilance Agreement” means the pharmacovigilance agreement between the Seller or a member of the Seller’s Group and the Purchaser or a member of the Purchaser’s Group, to be entered into at Closing, in respect of
pharmacovigilance and regulatory matters relating to certain Vaccines Business products; 
 “Vaccines Group” means the
Vaccines Group Companies and the Vaccines Group Businesses, taken as a whole; 
 “Vaccines Group Businesses” means
the businesses of the Business (but excluding the businesses of the Business carried on by the Vaccines Group Companies) as set out in Clause 2.3.1, but subject always to Clause 2.3.2, and “Vaccines Group Business” means any one of
them; 
 “Vaccines Group Companies” means the Companies and the Subsidiaries, and “Vaccines Group Company”
means any one of them; 
 “Vaccines Group Companies’ Cash Balances” means the aggregate amount of the Cash Balances
held by or on behalf of the Vaccines Group Companies (excluding 50 per cent. of the Cash Balances held by Chiron Behring Vaccines Private Limited and Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. above US$1,000,000) at the Effective Time; 

“Vaccines Group Company Employees” means the employees from time to time of any of the Vaccines Group Companies other than the
Excluded Employees, and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement”, and “Vaccines Group Company
Employee” means any one of them; 
 “Vaccines Group Goodwill” means all goodwill of the Vaccines Group Businesses,
but excluding any Trademark goodwill; 

  
 34 

 “Vaccines Group Information Technology” means the Transferred Information
Technology and the Owned Information Technology; 
 “Vaccines Group Insurance Policies” means all insurance policies held
exclusively by and for the benefit of the Vaccines Group Companies and “Vaccines Group Insurance Policy” means any one of them; 

“Vaccines Group Intellectual Property Contracts” means the Transferred Intellectual Property Contracts and the Owned
Intellectual Property Contracts; 
 “Vaccines Group Intellectual Property Rights” means the Transferred Intellectual
Property Rights and the Owned Intellectual Property Rights; 
 “Vaccines Patent” means any Vaccines Group Intellectual
Property Right which is a Patent; 
 “Variation” has the meaning given to it in Clause 9.3.2(iii); 

“VAT” means within the European Union such Taxation as may be levied in accordance with (but subject to derogations from)
Council Directive 2006/112/EC and outside the European Union any Taxation levied by reference to added value or sales; 
 “WARN
Act” means the Worker Adjustment and Retraining Notification Act of 1988 of the United States; 
 “Working Capital”
means the aggregate amount of the working capital of the Vaccines Group Companies and Vaccines Group Businesses set out in the Closing Statement (which shall not include any amount in respect of Tax), at the Effective Time, as derived from the
Closing Statement; and 
 “Working Capital Adjustment” means the amount by which the Working Capital exceeds or is less than
the Base Working Capital, any such excess being treated as a positive amount and any such shortfall being treated as a negative amount. 
  

	1.2	Shares 

 References to shares shall include, where relevant, quotas. 

 

	1.3	Singular, plural, gender 

 References to one gender include all genders and references to
the singular include the plural and vice versa. 
  

	1.4	References to persons and companies 

 References to: 

 

	 	1.4.1	a person include any individual, company, partnership or unincorporated association (whether or not having separate legal personality); and 

 

	 	1.4.2	a company include any company, corporation or any body corporate, wherever incorporated. 

  

	1.5	Schedules etc. 

 References to this Agreement shall include any Recitals and Schedules to
it and references to Clauses and Schedules are to Clauses of, and Schedules to, this Agreement. References to paragraphs and Parts are to paragraphs and Parts of the Schedules. 

  
 35 

	1.6	Reference to documents 

 References to any document (including this Agreement), or to a
provision in a document, shall be construed as a reference to such document or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.7	References to enactments 

 Except as otherwise expressly provided in this Agreement, any
express reference to an enactment (which includes any legislation in any jurisdiction) includes references (i) to that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement; (ii)
any enactment which that enactment re-enacts (with or without modification); and (iii) any subordinate legislation (including regulations) made before or after the date of this Agreement under that enactment as amended, consolidated or re-enacted as
described in paragraph (i) or (ii) above, except to the extent that any of the matters referred to in paragraphs (i) to (iii) above occurs after the date of this Agreement and increases or alters the liability of the Seller or Purchaser under this
Agreement. 
  

	1.8	Information 

 References to books, records or other information mean books, records or
other information in any form including paper, electronically stored data, magnetic media, film and microfilm. 
  

	1.9	References to “indemnify” 

 Unless specified to the contrary, references to
“indemnify” and “indemnifying” any person against any circumstance include indemnifying and holding that person harmless on an after-Tax basis and: 
  

	 	1.9.1	references to the Purchaser indemnifying each member of the Seller’s Group shall constitute undertakings by the Purchaser to the Seller for itself and on behalf of each other member of the Seller’s
Group; 

  

	 	1.9.2	references to the Seller indemnifying each member of the Purchaser’s Group shall constitute undertakings by the Seller to the Purchaser for itself and on behalf of each other member of the Purchaser’s
Group; 

  

	 	1.9.3	to the extent that the obligation to indemnify relates to any Shares (including any Vaccines Group Companies) or other assets or liabilities transferred by a Share Seller or Business Seller (as the case may be)
to a member of the Purchaser’s Group pursuant to this Agreement, references to the Seller indemnifying the Purchaser and references to the Seller indemnifying the Purchaser or any member of the Purchaser’s Group shall constitute
undertakings by the Seller, to indemnify or procure the indemnification of the relevant purchaser of the Shares transferred or to be transferred by that Share Seller or the relevant purchaser of the assets or liabilities transferred or to be
transferred by that Business Seller (as the case may be), and references to the Purchaser indemnifying the Seller and references to the Purchaser indemnifying the Seller and each member of the Seller’s Group shall constitute undertakings by the
Purchaser to indemnify or procure the indemnification of the relevant member of the Seller’s Group; and 

  
 36 

	 	1.9.4	where under the terms of this Agreement one party is liable to indemnify or reimburse another party in respect of any costs, charges or expenses, the payment shall include an amount equal to any VAT thereon not
otherwise recoverable by the other party or any member of any group or consolidation of which it forms part for VAT purposes, subject to that party using reasonable endeavours to recover or to procure recovery of such amount of VAT as may be
practicable. 

 For the purposes of this Clause 1.9, indemnifying and holding harmless a person on an “after-Tax
basis” means that the amount payable pursuant to the indemnity (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

 

	 	(i)	any Tax required to be deducted or withheld from the Payment and any additional amounts required to be paid by the payer of the Payment in consequence of such withholding; 

 

	 	(ii)	the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other relief which would otherwise have been available to reduce the Tax liabilities of any member of the
Seller’s Group, have become) payable by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group, as the case may be) as a result of the Payments being subject to Tax in the hands of that person; and

  

	 	(iii)	the amount and timing of any Tax benefit which is obtained by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group, as the case may be) to the extent that such Tax benefit
is attributable to the matter giving rise to the indemnity payment or to the receipt of the Payment, 

 which amount and timing
is to be determined by the auditors of the recipient at the shared expense of both relevant parties and is to be certified as such to the party making the Payment, the recipient of the Payment is in no better and no worse after Tax position as that
in which it would have been if the matter giving rise to the indemnity payment had not occurred, provided that if either party to this Agreement shall have assigned or novated the benefit of this Agreement in whole or in part or shall, after the
date of this Agreement, have changed its Tax residence or the permanent establishment to which the rights under this Agreement are allocated then no Payment to that party shall be increased by reason of the operation of paragraphs (i) to (iii) above
to any greater extent than would have been the case had no such assignment, novation or change taken place. 
  

	1.10	References to wholly or substantially in the Business (as carried on by the Vaccines Group) 

References to “wholly or substantially in the Business (as carried on by the Vaccines Group)” in relation to any employee employed by
a member of the Seller’s Group means that such employee spends more than 70 per cent. of their time working in the Business (as carried on by the Vaccines Group) at the relevant time. 

 

	1.11	Legal terms 

 References to any English legal term shall, in respect of any jurisdiction
other than England and Wales, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction. 

  
 37 

	1.12	Non-limiting effect of words 

 The words “including”, “include”,
“in particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them. 
  

	1.13	Currency conversion 

  

	 	1.13.1	Subject to Clause 1.13.2, any amount to be converted from one currency into another currency for the purposes of this Agreement shall be converted into an equivalent amount at the Conversion Rate prevailing at
the Relevant Date. For the purposes of this Clause 1.13: 

 “Conversion Rate” means the spot reference rate
for a transaction between the two currencies in question as quoted by the European Central Bank on the Business Day immediately preceding the Relevant Date or, if no such rate is quoted on that date, on the preceding date on which such rates are
quoted; 
 “Relevant Date” means, save as otherwise provided in this Agreement, the date on which a payment or an
assessment is to be made, save that, for the following purposes, the date shall mean: 
  

	 	(i)	for the purposes of Clause 5, the date of this Agreement; 

  

	 	(ii)	for the purposes of Clause 7 and Schedules 16 and 23, the Closing Date; or 

  

	 	(iii)	for the purposes of Clause 11, the date of this Agreement; and 

  

	 	(iv)	for the purposes of the monetary amounts set out in Schedule 18, the date of this Agreement. 

  

	 	1.13.2	The conversion of an amount from one currency into another as may be required in connection with the matters contemplated in Schedule 17 shall be carried out in accordance with the accounting policies and
practices of the Purchaser’s Group in operation from time to time. 

  

	2	Sale and Purchase of the Vaccines Group 

  

	2.1	Sale and Purchase of the Vaccines Group 

 On and subject to the terms of this Agreement
and the Local Transfer Documents: 
  

	 	2.1.1	the Seller shall procure that the Share Sellers and Business Sellers shall sell, 

 and

  

	 	2.1.2	the Purchaser shall purchase or shall procure the purchase by one or more other members of the Purchaser’s Group of, 

the Vaccines Group as a going concern. 
  

	2.2	Sale of the Shares 

  

	 	2.2.1	The Seller shall procure that the Share Sellers shall sell the Shares, which shall be sold with Full Title Guarantee free from Encumbrances and together with all rights and advantages attaching to them as at
Closing (including the right to receive all dividends or distributions declared, made or paid on or after the Effective Time). 

  
 38 

	 	2.2.2	The Seller shall procure that, on or prior to Closing, any and all rights of pre-emption over the Shares and the Shares or equity interests in any subsidiaries are waived irrevocably by the persons entitled
thereto. 

  

	2.3	Sale of the Vaccines Group Businesses 

  

	 	2.3.1	The Seller shall sell, or shall procure that the Business Sellers shall sell, the assets comprising the Vaccines Group Businesses, under this Agreement or, where relevant, the Local Transfer Documents with Full
Title Guarantee (save in respect of the Transferred Intellectual Property Rights and the Abandoned Patent Applications) and free from Encumbrances other than Permitted Encumbrances (save for the Transferred Real Properties, which shall be sold free
from Encumbrances other than as provided in paragraph 1.9 of Schedule 3), such assets being: 

  

	 	(i)	the Transferred Real Properties; 

  

	 	(ii)	the Transferred Plant and Equipment; 

  

	 	(iii)	the Transferred Inventory; 

  

	 	(iv)	the Transferred Accounts Receivable; 

  

	 	(v)	the Transferred Books and Records; 

  

	 	(vi)	subject to and in accordance with Schedule 10, the Transferred Intellectual Property Rights; 

  

	 	(vii)	subject to and in accordance with Schedule 10, the Transferred Intellectual Property Contracts; 

  

	 	(viii)	subject to and in accordance with Schedule 10, the Transferred Contracts; 

  

	 	(ix)	subject to and in accordance with Schedule 8, all Product Approvals and all Product Applications and all other permits, licences, certificates, registrations, marketing or other authorisations or consents issued by a
Governmental Entity Predominantly Related to the Business and not held by the Vaccines Group Companies; 

  

	 	(x)	subject to and in accordance with Schedule 8, all Marketing Authorisation Data not held by the Vaccines Group Companies; 

  

	 	(xi)	all Business Information not held at Closing by the Vaccines Group Companies; 

  

	 	(xii)	all rights of the Purchaser, its Affiliates and the Vaccines Group Companies as contemplated by Schedule 11 and Schedule 12; 

  

	 	(xiii)	the Abandoned Patents; 

  

	 	(xiv)	the Vaccines Group Goodwill; and 

  

	 	(xv)	all other property, rights and assets owned or held by the Seller’s Group (other than the Vaccines Group Companies) and Predominantly Related to the Business at Closing (other than any property, rights and assets
of the Vaccines Group expressly excluded from the sale under this Agreement). 

  
 39 

	 	2.3.2	There shall be excluded from the sale of the Vaccines Group under this Agreement and the Local Transfer Documents the following: 

 

	 	(i)	the Seller’s Group Retained Business, including the Influenza Business; 

  

	 	(ii)	the Non-strategic Assets to the extent not transferred to the Purchaser or a member of the Purchaser’s Group at Closing; 

  

	 	(iii)	the Out-Licensing Programme; 

  

	 	(iv)	any Intellectual Property Right that is not a Vaccines Group Intellectual Property Right (subject to the Purchaser Intellectual Property Licence Agreement and any Contract relating to Intellectual Property Rights that
is not a Vaccines Group Intellectual Property Contract or the Relevant Part of a Shared Business Contract); 

  

	 	(v)	the Retained Information Technology; 

  

	 	(vi)	the Seller Marks; 

  

	 	(vii)	any product and any permits, licences, certificates, registrations, marketing or other authorisations or consents issued by any Governmental Entity in respect of any products, or any applications therefor, other than
(a) the Products, Product Approvals, Products Under Registration and Pipeline Product Approvals; and (b) Permits Predominantly Related to the Business; 

  

	 	(viii)	all cash, marketable securities and negotiable instruments, and all other cash equivalents, of the Seller’s Group (other than the Vaccines Group Companies); 

 

	 	(ix)	all real property and any leases therefor and interests therein, other than the Properties; 

  

	 	(x)	the land and buildings of the Seller’s Group at 4560 Horton Street, Emeryville CA, United States of America; 

  

	 	(xi)	the land and buildings of the Seller’s Group at Jaboatão dos Guararapes, State of Pernambuco (Brazil), together with all buildings, fixtures, and improvements erected thereon, and any other assets, rights
and Contracts related thereto; 

  

	 	(xii)	the company seal, minute books, charter documents, stock or equity record books and such other books and records pertaining to the Seller or its Affiliates (other than the Vaccines Group Companies and the Transferred
Books and Records), as well as any other records or material relating to the Seller or its Affiliates (other than Vaccines Group Companies) generally and not involving or related to the Vaccines Group; 

 

	 	(xiii)	any right of the Seller or its Affiliates to be indemnified in respect of Assumed Liabilities; 

  

	 	(xiv)	all Tax assets (including Tax refunds and prepayments), other than Tax Assets of any Vaccines Group Company); 

  

	 	(xv)	 all Tax Returns of the Seller’s Group (other than the Vaccines Group Companies) and all Tax Returns relating to Tax Groups of which persons

  
 40 

	 	
other than Vaccines Group Companies are members and, in each case, all books and records (including working papers) related thereto; 

 

	 	(xvi)	any rights in respect of any insurance policies of the Seller’s Group as provided in Clause 15; 

  

	 	(xvii)	all artwork, paintings, drawings, sculptures, prints, photographs, lithographs and other artistic works of the Seller’s Group that are not embodiments of Vaccines Group Intellectual Property Rights;

  

	 	(xviii)	any rights of the Seller’s Group (other than the Vaccines Group Companies) under any Intra-Group Non-Trade Payables or Intra-Group Non-Trade Receivables (excluding Transferred Accounts Receivable);

  

	 	(xix)	any rights of the Seller or its Affiliates (other than the Vaccines Group Companies) contemplated by Schedule 11 and Schedule 12; 

  

	 	(xx)	any equity interest in any person other than a Vaccines Group Company or a Minority Interest Entity; 

  

	 	(xxi)	the Excluded Contracts; 

  

	 	(xxii)	all rights of the Seller’s Group under this Agreement and the Ancillary Agreements; 

  

	 	(xxiii)	the Purchase Price Bank Account; 

  

	 	(xxiv)	the Manufacturing, production and research activity carried on by the Seller’s Group at the Holly Springs Site; and 

  

	 	(xxv)	the Diagnostics GESA. 

  

	 	2.3.3	The Seller agrees to procure the transfer (to the extent it is able so to do) and the Purchaser agrees to accept (or procure the acceptance by another member of the Purchaser’s Group of) the transfer of, and
to assume, pay, satisfy, discharge, perform or fulfil (or procure that another member of the Purchaser’s Group will assume, pay, satisfy, discharge, perform or fulfil) the Assumed Liabilities with effect from Closing. 

 

	 	2.3.4	Clause 2.3.3 shall not apply to, and the Purchaser shall not be obliged to accept (or procure the acceptance by another member of the Purchaser’s Group of), the transfer of or to assume, pay, satisfy,
discharge, perform or fulfil, or procure that another member of the Purchaser’s Group will assume, pay, satisfy, discharge, perform or fulfil: 

  

	 	(i)	any Excluded Liability; or 

  

	 	(ii)	any Liability to the extent it relates to an Excluded Asset. 

  

	 	2.3.5	Without prejudice to Clauses 2.1, 2.2, 2.3.1 to 2.3.4, 2.4 and 2.5 on or prior to Closing, the Seller may: 

  

	 	(i)	assign or otherwise transfer assets, liabilities and (only where in compliance with Clause 5 (other than Clause 5.2.2)) employees between members of the Seller’s Group as may be reasonably required to facilitate
separation of (A) the Business from the Influenza Business and (B) the Business from the Retained Information Technology; and 

  
 41 

	 	(ii)	otherwise, carry out or procure one or more reorganisations of the Seller’s Group (including assigning or otherwise transferring assets and liabilities between members of the Seller’s Group but excluding
assigning or otherwise transferring assets or liabilities to Vaccines Group Companies) as may reasonably be required to facilitate the Transaction, 

each, a “Reorganisation”. 
  

	 	2.3.6	In respect of any Reorganisation: 

  

	 	(i)	the Seller shall notify the Purchaser of any proposed Reorganisation, the steps proposed to be implemented and such other information as the Purchaser may reasonably request regarding the proposed Reorganisation in
advance of it being implemented; 

  

	 	(ii)	the Seller shall, in good faith, consult with, and take into account the reasonable views of, and any reasonable requests made by, the Purchaser in relation to any Reorganisation before it is implemented, including any
proposals to reduce or avoid Liability or cost being suffered or incurred by any member of the Purchaser’s Group or any Vaccines Group Company; 

  

	 	(iii)	subject to the following sub-clause (iv) of this Clause 2.3.6, all fees, costs and expenses of implementing any Reorganisation (or any part thereof) shall be borne by the Seller’s Group; and 

 

	 	(iv)	all out-of-pocket fees, costs and expenses which (x) are incurred by either party, whether before or after Closing, (y) specifically relate to the separation of the German Influenza Operations from the Vaccines Group,
and (z) are incurred in respect of works council consultations (including court fees, notary fees and works council legal fees) or physical separation at the Marburg Site (including IT systems workarounds, costs of new access cards and construction
works), but excluding the parties’ own legal fees, shall, to the extent that such fees, costs and expenses arise solely as a result of such works council consultations or physical separation, be split equally between the Seller and the
Purchaser. For the avoidance of doubt, this Clause 2.3.6(iv) shall not affect the cost allocation of wider measures necessary to effect the separation of the Business from the Influenza Business. 

 

	 	2.3.7	In respect of the separation of the Influenza Business from the Vaccines Group, the parties shall work together in good faith to facilitate such separation. 

 

	 	2.3.8	The Seller undertakes to the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group and each Vaccines Group Company) that, with effect from Closing, the Seller will indemnify on
demand and hold harmless the relevant member of the Purchaser’s Group (including each Vaccines Group Company) against and in respect of any and all Liabilities arising in connection with any Reorganisation (or part thereof) undertaken by the
Seller, other than: 

  

	 	(i)	such Liabilities where the allocation has been, or is, otherwise agreed between the parties; 

  

	 	(ii)	any Liabilities of any Vaccines Group Company in respect of Tax (which shall be dealt with under the Tax Indemnity); and 

  
 42 

	 	(iii)	any Liabilities in connection with this Agreement or any document entered into as provided by this Agreement (including the provisions of Clause 8.14) or any Ancillary Agreement. 

 

	2.4	Employees and Employee Benefits 

  

	 	2.4.1	The provisions of Schedule 11 shall apply in respect of the Employees. 

  

	 	2.4.2	The provisions of Schedule 12 shall apply in respect of Employee Benefits. 

  

	2.5	Properties 

 The provisions of Schedule 3 shall apply in respect of the Properties. 

 

	2.6	Local Transfer Documents 

  

	 	2.6.1	On Closing or at such other time as agreed between the parties, the Seller shall procure that the Share Sellers and Business Sellers execute, and the Purchaser shall execute (or procure the execution by one or
more other members of the Purchaser’s Group of), such agreements, transfers, conveyances and other documents, as may be required pursuant to the relevant local law and otherwise as may be agreed between the Seller and the Purchaser to implement
the transfer of (i) the Shares and (ii) the Vaccines Group Businesses, in each case on Closing, subject to the provisions of Schedule 25 (the “Local Transfer Documents” and each, a “Local Transfer Document”). The
parties do not intend this Agreement to transfer title to any of the Shares, title to which shall be transferred by the applicable Local Transfer Document. 

  

	 	2.6.2	To the extent that the provisions of a Local Transfer Document are inconsistent with or (except to the extent they implement a transfer in accordance with this Agreement) additional to the provisions of this
Agreement: 

  

	 	(i)	the provisions of this Agreement shall prevail; and 

  

	 	(ii)	so far as permissible under the laws of the relevant jurisdiction, the Seller and the Purchaser shall procure that the provisions of the relevant Local Transfer Document are adjusted, to the extent necessary to give
effect to the provisions of this Agreement or, to the extent this is not permissible, the Seller shall indemnify the Purchaser against all Liabilities suffered by the Purchaser or its Affiliates or, as the case may be, the Purchaser shall indemnify
the Seller against all Liabilities suffered by the Seller or its Affiliates, in either case through or arising from the inconsistency between the Local Transfer Document and this Agreement or the additional provisions (except to the extent they
implement a transfer in accordance with this Agreement). 

  

	 	2.6.3	If there is an adjustment to the Purchase Price under Clause 7.3 which relates to a part of the Vaccines Group which is the subject of a Local Transfer Document, then, if required to implement the adjustment and
so far as permissible under Applicable Law, the Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group will), and the Seller shall procure that its relevant Affiliate shall, enter into a supplemental agreement
reflecting such adjustment and the allocation of such adjustment. 

  
 43 

	 	2.6.4	The Seller shall not, and shall procure that none of its Affiliates shall bring any claim against the Purchaser or any member of the Purchaser’s Group (including any Vaccines Group Company) in respect of or
based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Shares or Vaccines Group Businesses as contemplated by this Agreement. To the extent that the Seller or a member of the Seller’s Group does
bring a claim in breach of this Clause, the Seller shall indemnify the Purchaser and each member of the Purchaser’s Group (including any Vaccines Group Company) against all Liabilities which the Purchaser or that member of the Purchaser’s
Group (including any Vaccines Group Company) may suffer through or arising from the bringing of such a claim. 

  

	 	2.6.5	The Purchaser shall not, and shall procure that none of its Affiliates shall, bring any claim against the Seller or any member of the Seller’s Group in respect of or based upon the Local Transfer Documents
save to the extent necessary to implement any transfer of the Shares or Vaccines Group Businesses as contemplated by this Agreement. To the extent that the Purchaser or a member of the Purchaser’s Group does bring a claim in breach of this
Clause, the Purchaser shall indemnify the Seller and each member of the Seller’s Group against all Liabilities which the Seller or any member of the Seller’s Group may suffer through or arising from the bringing of such a claim.

  

	2.7	Inventory 

  

	 	2.7.1	The parties agree that neither this Agreement nor the applicable Local Transfer Agreement shall transfer legal title to any Transferred Inventory held by the relevant Vaccines Group Business in the jurisdictions
set out in Schedule 28 (the “Retained Inventory”) on Closing. 

  

	 	2.7.2	Legal title to In-Market Inventory shall be transferred to the relevant member of the Purchaser’s Group in accordance with Article XVII of the Transitional Distribution Services Agreement. 

 

	 	2.7.3	In respect of the relevant Vaccines Group Business in each jurisdiction set out in Schedule 28, the Seller shall, by no later than 5 Business Days after the date on which the relevant member of the Seller’s
Group receives payment under Article XVII of the Transitional Distribution Services Agreement for In-Market Inventory in respect of the relevant Vaccines Group Business, pay to the Purchaser (in accordance with Clause 17.6) an amount equal to
the value of the Retained Inventory in respect of the relevant Vaccines Group Business as recorded in the Closing Statement. 

  

	 	2.7.4	If, following Closing, any Manufacturing Inventory or Manufacturing Stock is found to have formed part of the Retained Inventory, the Seller shall procure that such Manufacturing Inventory and/or Manufacturing
Stock is transferred from the relevant member of the Seller’s Group to the member of the Purchaser’s Group nominated by the Purchaser as soon as practicable following Closing at no cost to the Purchaser. 

  
 44 

	 	2.7.5	Clause 3.5 shall apply to payments or other contributions under this Clause 2.7 as if such payments or other contributions were made or procured in respect of an indemnity under this Agreement. 

 

	3	Consideration 

  

	3.1	Amount 

  

	 	3.1.1	The Seller and the Purchaser agree, for themselves and on behalf of the members of the Seller’s Group and the Purchaser’s Group (as the case may be), that the aggregate consideration for the purchase of
the Vaccines Group under this Agreement and the Local Transfer Documents (the “Purchase Price”) shall be an amount in US dollars equal to the sum of: 

 

	 	(i)	US$5,255,000,000 (the “Headline Price”); 

 minus 

 

	 	(ii)	US$9,500,000 (the “Employee Adjustment Payment”); 

 plus 

 

	 	(iii)	the Vaccines Group Companies’ Cash Balances and the Intra-Group Non-Trade Receivables; 

minus 
  

	 	(iv)	the Third Party Indebtedness; 

 minus 

 

	 	(v)	the Intra-Group Non-Trade Payables; 

 minus 

 

	 	(vi)	any Employee Benefit Indemnification Amount paid in accordance with Schedule 12; 

 minus 

 

	 	(vii)	the Tax Adjustment; 

 plus 

 

	 	(viii)	the Working Capital Adjustment; 

 plus 

 

	 	(ix)	the Milestone Payments and the Royalty Payments. 

  

	 	3.1.2	For the avoidance of doubt, the aggregate consideration provided for under Clause 3.1.1 includes the consideration payable in respect of the Delayed Businesses. 

 

	3.2	Payment of Purchase Price 

 The Purchase Price shall be satisfied: 

 

	 	3.2.1	other than in the case of the Milestone Payments and the Royalty Payments: 

  
 45 

	 	(i)	by the Purchaser making a cash payment for itself and on behalf of the members of the Purchaser’s Group in accordance with Clauses 6.3 and 7.6; and 

 

	 	(ii)	by the Designated Purchasers making payments in accordance with Clauses 6.5 and 6.6 (at the procurement of the Purchaser); and 

  

	 	3.2.2	in the case of the Milestone Payments and the Royalty Payments, pursuant to and in accordance with Schedule 17. 

  

	3.3	Allocation of Purchase Price 

 The Purchase Price shall be allocated in accordance with
Schedule 13. 
  

	3.4	VAT 

  

	 	3.4.1	The provisions of Schedule 14 shall apply in respect of VAT. 

  

	 	3.4.2	The Seller and the Purchaser agree that the consideration given under this Agreement in respect of the sale of the Vaccines Group Businesses and the Shares is exclusive of any VAT. To the extent that VAT is
chargeable in respect of that sale or any part thereof, the Purchaser shall, against delivery of a valid VAT invoice (or equivalent, if any), in addition to any other amount expressed in this Agreement to be payable by the Purchaser, pay or procure
the payment to the Seller (on behalf of the relevant Business Seller or Share Seller as applicable) any amount of any VAT so chargeable for which the Seller (or the relevant Share Seller or Business Seller, as the case may be) is liable to account,
in accordance with Schedule 14. 

  

	3.5	Treatment of Payments 

  

	 	3.5.1	If any payment is made or procured (i) by the Seller or a member of the Seller’s Group to the Purchaser or the relevant member of the Purchaser’s Group, or (ii) by a Purchaser or a member of the
Purchaser’s Group to the Seller or the relevant member of the Seller’s Group, in either case in respect of any claim under or for any breach of this Agreement or pursuant to an indemnity (or equivalent covenant to pay) under this
Agreement, the payment shall be treated, so far as possible, as an adjustment of the consideration paid by the relevant member of the Purchaser’s Group for the Shares or the particular part of the Vaccines Group to which the payment and/or
claim relates under this Agreement and the consideration shall be deemed to be increased or reduced (as applicable) by the amount of such payment, provided that this Clause 3.5.1 shall not require any amount to be treated as an amount in respect of
the Purchase Price for the purposes of Clause 17.10 if it would not otherwise have been so treated 

  

	 	3.5.2	If: 

  

	 	(i)	the payment and/or claim relates to the shares in more than one Vaccines Group Company or to more than one category of Vaccines Group Business, it shall be allocated in a manner which reflects the impact of the matter
to which the payment and/or claim relates, failing which it shall be allocated rateably to the shares in the Vaccines Group Companies or Vaccines Group Businesses concerned by reference to the proportions in which the consideration is allocated in
accordance with Schedule 13; or 

  
 46 

	 	(ii)	the payment and/or claim relates to no particular shares in any Vaccines Group Company or no particular category of Vaccines Group Business, it shall be allocated rateably to all the Shares and all the Vaccines Group
Businesses by reference to the proportions in which the consideration is allocated in accordance with Schedule 13, 

 and in
each case the consideration shall be deemed to have been reduced by the amount of such payment. 
  

	3.6	Non-strategic Assets 

  

	 	3.6.1	If, prior to Closing, any member of the Seller’s Group completes the disposal of a Non-strategic Asset to a third party in accordance with Clause 5.2.1, the Seller shall pay to the Purchaser at Closing the
greater of: 

  

	 	(i)	the relevant Threshold Amount; or 

  

	 	(ii)	an amount equal to the consideration (less any Taxes, costs and expenses incurred by any member of the Seller’s Group in connection with such disposal) received for the relevant Non-strategic Asset.

 Any payment obligation of the Seller arising pursuant to this Clause 3.6.1 shall be set-off against the Purchaser’s
payment obligation pursuant to Clause 6.3.1. 
  

	 	3.6.2	If, following Closing, any member of the Seller’s Group receives consideration for the disposal of a Non-strategic Asset, the Seller shall pay to the Purchaser, within five Business Days of the date of
receipt of the consideration, the greater of: 

  

	 	(i)	the Threshold Amount; or 

  

	 	(ii)	an amount equal to the consideration (less any Taxes, costs and expenses incurred by any member of the Seller’s Group in connection with such disposal) received for the relevant Non-strategic Asset.

  

	4	Conditions 

  

	4.1	Conditions Precedent 

 The sale and purchase of the Vaccines Group is conditional upon
satisfaction or, where applicable, waiver of the following conditions, or their satisfaction subject only to Closing: 
  

	 	4.1.1	to the extent that the proposed acquisition of all or any of the Shares or Vaccines Group Businesses (the “Transaction”) either constitutes (or is deemed to constitute under Article 4(5) or
Article 5(2)) a concentration with a Community dimension within the meaning of Council Regulation (EC) 139/2004 (as amended) (the “Regulation”) or is to be examined by the European Commission as a result of a decision under Article
22(3) of the Regulation: 

  

	 	(i)	the European Commission taking a decision (or being deemed to have taken a decision) under Article 6(1)(b) or, if the Commission has initiated proceedings pursuant to Article 6(1)(c), under Article 8(1) or 8(2) of the
Regulation declaring the Transaction compatible with the common market; or 

  

	 	(ii)	 the European Commission taking a decision (or being deemed to have taken a decision) to refer the whole or part of the Transaction to the

  
 47 

	 	
competent authorities of one or more Member States under Articles 4(4) or 9(3) of the Regulation; and 

  

	 	(a)	each such authority taking a decision with equivalent effect to Clause 4.1.1(i) with respect to those parts of the Transaction referred to it; and 

 

	 	(b)	the European Commission taking any of the decisions under Clause 4.1.1(i) with respect to any part of the Transaction retained by it. 

 

	 	4.1.2	any waiting period (and any extension thereof) under the HSR Act applicable to the Transaction having expired; 

  

	 	4.1.3	to the extent required or otherwise agreed between the parties as appropriate to permit the parties to consummate the Transaction in the jurisdictions listed in Schedule 24, any additional clearances, approvals,
waivers, no-action letters and consents having been obtained and any additional waiting periods having expired under applicable antitrust, merger control or foreign investment rules set forth in Schedule 24; 

 

	 	4.1.4	receipt of CFIUS Approval if CFIUS has initiated a review of the transactions contemplated by this Agreement, whether pursuant to Clause 4.2.3 or otherwise; 

 

	 	4.1.5	no Governmental Entity having enacted, issued, promulgated, enforced or entered any Applicable Law or Judgment (whether temporary, preliminary or permanent) that is in effect at the Closing Date and that has the
effect of making the transactions contemplated by this Agreement illegal or otherwise restraining or prohibiting the consummation of such transactions; 

  

	 	4.1.6	the passing at a duly convened and held general meeting of the Purchaser Shareholders of an ordinary resolution validly approving the Target Asset Agreements (as defined in the Implementation Agreement) and any
sale and purchase under the Put Option Agreement (as defined in the Implementation Agreement) in accordance with the Purchaser Articles of Association, the Listing Rules and all other Applicable Law (such resolution being the “Purchaser
Shareholder Resolution” and such meeting being the “Purchaser Shareholder Meeting”); 

  

	 	4.1.7	the Seller not delivering a Novartis AG Board Certificate (as defined in the Implementation Agreement), in accordance with clause 3 of the Implementation Agreement, prior to the conclusion of the vote on the
Purchaser Shareholder Resolution at the Purchaser Shareholder Meeting; 

  

	 	4.1.8	none of the Key Sites (each taken as a whole) being, or being reasonably likely to be, from or after Closing: 

  

	 	(i)	incapable of operation in whole or part by the Purchaser’s Group without a member of the Purchaser’s Group being in breach of any Applicable Law or any other material duty or obligation; or 

 

	 	(ii)	 otherwise incapable of operation in whole or part by virtue of some other event, matter, or circumstance,

  
 48 

	 	but only where the circumstances giving rise to the inability of the Purchaser’s Group to operate a Key Site would, or would be reasonably likely to (whether alone or together with any other such circumstances),
result in: 

  

	 	(a)	a Key Site being prohibited from, or otherwise being substantially incapable of, operation for a period of at least three consecutive or non-consecutive months in the 12 month period immediately following the Closing
Date; and 

  

	 	(b)	the manufacturing output of that Key Site in the 12 month period following the Closing Date falling by 30 per cent. or more as compared to the manufacturing output at that Key Site in the 12 month period ending on the
corresponding date in the immediately preceding year; and 

  

	 	4.1.9	the obtaining in form and substance satisfactory to the Purchaser of any consent, amendment, waiver or approval that the Purchaser, acting reasonably and in good faith, notifies to the Seller prior to 21 May 2014
that it wishes to obtain or be obtained for its benefit prior to Closing in relation to the [***]; and 

  

	 	4.1.10	each of the other Target Asset Agreements having become unconditional in accordance with its terms (save for any condition in those agreements relating to this Agreement or the other of those agreements having
become unconditional). 

  

	4.2	Responsibility for Satisfaction 

  

	 	4.2.1	The Purchaser and the Seller shall prepare and file the notifications necessary for the fulfilment of the conditions in Clauses 4.1.1 to 4.1.3 (the “Required Notifications”) as soon as reasonably
practicable (with notifications under the HSR Act to be filed by 29 May 2014). Notwithstanding anything to the contrary contained in this Agreement, the Purchaser shall have primary responsibility for obtaining all consents, approvals or actions of
any Governmental Entity which are required in connection with the Required Notifications. 

  

	 	4.2.2	The Purchaser shall be responsible for payment of all filing and other fees and expenses in connection with the Required Notifications and the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3.

  

	 	4.2.3	CFIUS: 

  

	 	(i)	The Seller and the Purchaser shall consult, cooperate and keep each other reasonably informed regarding communications with, and requests for additional information from, CFIUS with respect to the Transaction. The
Seller and the Purchaser shall use their respective reasonable best efforts to provide promptly all information that is pursuant to a request by CFIUS. 

  

	 	(ii)	Within 60 calendar days after the execution of this Agreement, any party wishing to submit a formal joint voluntary notice to CFIUS pursuant to 31 C.F.R. Section 800.401, et. seq. (“CFIUS Filing”) shall
provide the other party with written notice of its intent to make a CFIUS Filing (“Election Date”). Prior to making its election to submit a CFIUS Filing, the party wishing to make a CFIUS Filing shall consult in good faith with
senior executives of the other party. If neither the Seller nor the Purchaser 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

 49 

	 	
provides notice to submit a formal joint voluntary notice to CFIUS, a CFIUS Filing will not be made unless requested by CFIUS. 

 

	 	(iii)	If either the Seller or the Purchaser elects to make a CFIUS Filing following the procedures and consultations in Clause 4.2.3(i) or if CFIUS requires a filing, then: 

 

	 	(a)	the Seller and the Purchaser shall use their respective reasonable best efforts to submit a draft CFIUS Filing no later than 15 Business Days following the Election Date, and a final CFIUS Filing the earlier of (1) five
business days after submitting the draft CFIUS filing or (2) five calendar days after the receipt of any comments from CFIUS staff regarding the draft CFIUS Filing; 

 

	 	(b)	the Seller and the Purchaser will provide each other with the reasonable opportunity to review and comment on any information provided to CFIUS to the extent permitted by Applicable Law, with the exception of personal
identifier information required under Section 800.402(c)(6)(vi)(B) of the CFIUS regulations, 31 C.F.R.. Competitively sensitive information, or information not related to the transactions contemplated by this Agreement, may be restricted to each
party’s external counsel to the extent reasonably considered necessary or advisable by the providing party; 

  

	 	(c)	the Seller and the Purchaser shall each have an opportunity to approve and mutually agree on the joint contents of the CFIUS Filing and shall be jointly responsible for the accuracy of such contents. The Seller and
the Purchaser respectively, shall each be responsible for the accuracy of contents of the CFIUS Filing that exclusively relate to itself, its business, and any subsidiaries, parents or other related parties; and 

 

	 	(d)	The Seller and the Purchaser shall use their respective reasonable best efforts to obtain CFIUS Approval as promptly as practicable and shall consult with each other on strategic matters related to obtaining such CFIUS
Approval, provided that the Purchaser shall have no obligation to agree to any mitigation or other restrictive provision that could reasonably be considered to have a substantial impact on either the Business or the Purchaser. 

 

	 	4.2.4	The party responsible for satisfaction of each condition pursuant to this Clause 4.2 shall give notice to the other party of the satisfaction of the relevant condition within one Business Day of becoming aware of
the same. 

  

	 	4.2.5	 The parties shall cooperate with each other in connection with the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3. The parties will
consult and cooperate reasonably with one another, consider in good faith the views of one another, and provide to the other party in advance any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or
their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree to: (a) give each other reasonable advance notice of all meetings with any Governmental Entity; (b) give each other an opportunity to participate
in each of such meetings; (c) to the extent practicable, give each other reasonable advance 

  
 50 

	 	
notice of all substantive oral communications with any Governmental Entity; (d) if any Governmental Entity initiates a substantive oral communication, promptly notify the other party of the
substance of such communication; (e) provide each other with a reasonable advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals) with a
Governmental Entity; (f) provide each other with copies of all written communications to or from any Governmental Entity; and (g) not advance arguments in connection with any regulatory review or litigation proceeding related to this Agreement
(other than litigation between the parties) over the objection of the other party that would reasonably be likely to have a significant adverse impact on that other party, provided however, that neither party shall be required to comply with
paragraph (b) above to the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in which case, the disclosure may be made on
an outside counsel basis). 

  

	 	4.2.6	The Purchaser shall, and shall cause its Affiliates to use reasonable endeavours to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not
later than the Longstop Date). Notwithstanding any other provision of this Agreement to the contrary, the Purchaser shall and, shall cause its Affiliates to use best endeavours to propose, negotiate, offer to commit and effect (and if such offer is
accepted, commit to and effect), by consent decree, undertaking, hold separate order, or otherwise, the sale, divestiture, licence or disposition of its Nimenrix and Mencevax products on a global basis (excluding existing manufacturing capabilities)
as may be required or desirable in order to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than the Longstop Date) and to avoid the commencement of any Action or the
issuing of any Decision to prohibit the acquisition or any other transaction contemplated by this Agreement or, if such Action is already commenced, to avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining order
or other order in any Action so as to enable the Closing to occur as soon as reasonably possible (and, in any event, not later than the Longstop Date): 

  

	 	4.2.7	The Seller shall, and shall cause the Vaccines Group to use reasonable endeavours to cooperate with the Purchaser in connection with procuring the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon
as reasonably possible (and, in any event, not later than the Longstop Date), including providing to the Purchaser such information with respect to the Vaccines Group as the Purchaser may reasonably require in connection with satisfaction of its
obligations under this Clause. 

  

	 	4.2.8	The Purchaser and Seller shall cooperate to confirm, within 21 Business Days from signing of this Agreement, any additional merger notification requirements reasonably required or advisable in respect of the
Transaction in jurisdictions beyond those listed in Schedule 24, and shall cooperate with each other, within the meaning of Clause 4.2.6, in achieving any additional clearances, approvals and consents or waiting period expirations in such
jurisdictions. For the avoidance of doubt, Closing shall not be conditional upon such additional clearances, approvals and consents or waiting period expirations. 

  
 51 

	 	4.2.9	The Purchaser and Seller shall cooperate, in the manner contemplated in Clause 4.2.6, and use reasonable endeavours to ensure that no Governmental Entity shall enact, issue, promulgate, enforce or enter any
Applicable Law or Judgment as contemplated under Clause 4.1.5. In the event that any Governmental Entity enacts, issues, promulgates, enforces or enters any Applicable Law or Judgment as contemplated under Clause 4.1.5, the Seller and the Purchaser
shall cooperate and use reasonable endeavours to put in place arrangements that would allow the Transaction to complete to the greatest possible extent in compliance with the relevant Applicable Law or Judgment. 

 

	 	4.2.10	Without prejudice to the provisions of Schedule 3, each of the Seller and the Purchaser shall, and shall procure that each of its respective Affiliates shall, cooperate with each other in relation to the
satisfaction of the condition set out in Clause 4.1.8, and shall use its reasonable endeavours to ensure that the condition set out in Clause 4.1.8 is satisfied at Closing. 

 

	 	4.2.11	The Seller shall use best efforts to obtain the consents, amendments, waivers and approvals referred to in Clause 4.1.9 prior to the Closing Date. The cost of obtaining such consents, amendments, waivers and
approvals shall be borne by the Seller, including any payment or other incentive that may (whether required to be offered or not) be offered to [***] and/or [***] or any of their respective Affiliates in order to obtain such consents, amendments,
waivers and approvals. The Purchaser shall, and shall cause its Affiliates to cooperate with the Seller in connection with obtaining the consents, amendments, waivers and approvals referred to in Clause 4.1.9 and use its reasonable endeavours to
ensure that such conditions are satisfied at Closing, including providing to the Seller such information as the Seller may reasonably require in connection with the satisfaction of its obligations under this Clause 4.2.11. 

 

	4.3	Non-Satisfaction by the Long Stop Date 

  

	 	4.3.1	The Purchaser may at any time waive in whole or in part (and conditionally or unconditionally) the conditions set out in Clause 4.1.8 or 4.1.9 by notice in writing to the Seller. 

 

	 	4.3.2	If the conditions in Clause 4.1 are not satisfied (or waived in accordance with Clause 4.3.1) as of 22 October 2015 (the “Long Stop Date”), the Purchaser or the Seller may, in its sole
discretion, terminate this Agreement (other than Clauses 1, 14 and 17.2 to 17.14) and no party shall have any claim against the other under it, save for any claim arising from breach of any obligation contained in such Clauses or Clause 4.2. Neither
the Seller nor the Purchaser may terminate this Agreement after satisfaction or waiver of the conditions in Clause 4.1, except in accordance with this Agreement. 

 

	4.4	Termination 

  

	 	4.4.1	This Agreement may be terminated at any time prior to Closing: 

  

	 	(i)	by written consent of the Seller and the Purchaser; 

  

	 	(ii)	by either the Seller or the Purchaser by notice to the other party in the event that any Judgment restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement shall have become final
and 

  

	***	 Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted
from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 52 

	 	
non-appealable, provided that the party seeking to terminate this Agreement pursuant to this Clause 4.4 has complied with the terms of the Implementation Agreement and this Agreement in
connection with having such Judgment vacated or denied; or 

  

	 	(iii)	by the Purchaser by notice to the Seller if: 

  

	 	(a)	a Material Adverse Effect occurs prior to Closing (which shall include any breach or breaches of Clause 10.1 which alone or together constitute a Material Adverse Effect); or 

 

	 	(b)	the Seller fails to provide a Certificate immediately prior to Closing; or 

  

	 	(iv)	in accordance with the terms of the Implementation Agreement. 

  

	 	4.4.2	This Agreement shall terminate automatically at any time prior to Closing in the event that: 

  

	 	(i)	any other Target Asset Agreement terminates or is terminated in accordance with its terms; or 

  

	 	(ii)	the Novartis Break Fee and/or the GSK Break Fee becomes payable under clause 5.1 or clause 5.8 of the Implementation Agreement, respectively. 

 

	 	4.4.3	Save as provided in this Clause 4, neither party shall be entitled to terminate or rescind this Agreement (whether before or after Closing). If this Agreement is terminated pursuant to this Clause 4.4, this
Agreement shall be of no further force and effect and there shall be no further liability under this Agreement or any of the Ancillary Agreements on the part of any party, except that Clauses 1, 14 and 17.2 to 17.14, in each case, to the extent
applicable, shall survive any termination. 

  

	 	4.4.4	Nothing in this Clause 4.4 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement prior to termination of this Agreement.

  

	5	Pre-Closing 

  

	5.1	The Seller’s Obligations in Relation to the Business 

  

	 	5.1.1	The Seller undertakes to procure that between the date of this Agreement and Closing, it and the relevant members of the Seller’s Group shall, so far as permitted by Applicable Law, carry on the Business as
carried on by the Vaccines Group as a going concern in the ordinary course as carried on immediately prior to the date of this Agreement save in so far as agreed in writing by the Purchaser (such consent not to be unreasonably withheld or delayed).

  

	 	5.1.2	Without prejudice to the generality of Clause 5.1.1 and subject to Clause 5.2, the Seller undertakes to procure that, with respect to the Business as carried on by the Vaccines Group, between the date of this
Agreement and Closing, no member of the Seller’s Group shall, except as may be required to comply with this Agreement, without the prior written consent of the Purchaser (such consent not to be unreasonably withheld or delayed), take any of the
actions listed in Part 1 of Schedule 20. 

  
 53 

	 	5.1.3	Without prejudice to the generality of Clause 5.1.1, the Seller shall, in each case with respect to the Business as carried on by the Vaccines Group only: (i) undertake to procure the satisfaction of its
obligations listed in paragraph 1, Part 2 of Schedule 20; and (ii) procure that the Vaccines Group shall, between the date of this Agreement and Closing, comply with the requirements of paragraph 2, Part 2 of Schedule 20. 

 

	5.2	Exceptions to Seller’s Obligations in Relation to the Conduct of Business 

 Clause
5.1 shall not operate so as to prevent or restrict: 
  

	 	5.2.1	the disposal or transfer by one or more members of the Seller’s Group of any or all of the Non-strategic Assets; 

  

	 	5.2.2	any matter undertaken by any member of the Seller’s Group to facilitate or implement a Reorganisation in accordance with Clause 2.3.5; 

 

	 	5.2.3	any matter undertaken by any member of the Vaccines Group that is set out in Part 3 of Schedule 20; 

  

	 	5.2.4	any action to the extent it is required to be undertaken to comply with Applicable Law; or 

  

	 	5.2.5	any matter reasonably undertaken by any member of the Seller’s Group in an emergency or disaster situation with the intention of minimising any adverse effect of such situation in relation to the Vaccines
Group and where any delay arising by virtue of having to give notice to the Purchaser and await consent would materially prejudice the Vaccines Group, 

provided that the Seller shall notify the Purchaser as soon as reasonably practicable of any action taken or proposed to be taken as described
in Clause 5.2.4, shall provide to the Purchaser all such information as the Purchaser may reasonably request and shall use reasonable endeavours to consult with the Purchaser in respect of any such action. 

 

	5.3	The Seller’s obligations in relation to insurance 

 Without prejudice to the
generality of this Clause 5, between the date of this Agreement and Closing or, in respect of Delayed Businesses, the relevant Delayed Closing Date, the Seller shall or shall procure that the relevant members of the Seller’s Group shall
maintain in force all Vaccines Group Insurance Policies and all Seller’s Group Insurance Policies for the benefit of the Vaccines Group Businesses and Vaccines Group Companies. 

 

	5.4	The Seller’s obligations in relation to cash, Intra-Group Non-Trade Payables and Receivables and Third Party Indebtedness 

Prior to Closing, the Seller shall seek to minimise the amounts which would, but for this Clause 5.4, otherwise fall to be treated as: 

 

	 	(i)	Intra-Group Non-Trade Payables; 

  

	 	(ii)	Intra-Group Non-Trade Receivables; 

  

	 	(iii)	Vaccines Group Companies Cash Balances; and 

  

	 	(iv)	Third Party Indebtedness, 

  
 54 

 in each case to the extent reasonably possible, taking into account the consequences of any such
reduction for the Seller’s Group. 
  

	5.5	Other Seller’s Obligations Prior to Closing 

 Without prejudice to the generality of
this Clause 5, prior to Closing the Seller shall, and shall procure that the relevant Vaccines Group Companies, the Seller and the Seller’s Affiliates shall allow the Purchaser and its respective agents, upon reasonable notice, reasonable
access to, and to take copies of, the books, records and documents of or relating in whole or in part to the Vaccines Group, provided that the obligations of the Seller under this Clause shall not extend to allowing access to information which is
(i) reasonably regarded as confidential to the activities of the Seller and the Seller’s Group otherwise than in relation to the Vaccines Group or (ii) commercially sensitive; or (iii) other information of the Vaccines Group if such information
cannot be shared with the Purchaser prior to Closing in compliance with Applicable Law (though the Seller shall seek to share such information with the Purchaser to the extent and in such a manner as would comply with Applicable Law). 

 

	5.6	Affiliate Contracts 

  

	 	5.6.1	Other than as provided in the Ancillary Agreements and subject to Clause 8.7 and Clause 8.9, the Seller and the Purchaser shall procure that: 

 

	 	(i)	the Cash Pooling Arrangements; and 

  

	 	(ii)	each Affiliate Contract in force immediately prior to Closing, 

 shall terminate prior to
Closing and each counterparty thereto shall, effective as of Closing, settle all outstanding financial obligations arising out of such Affiliate Contracts and unconditionally release and irrevocably discharge each other party thereto from (i) any
and all further obligations to perform or any further performance of the various covenants, undertakings, warranties and other obligations contained in such Affiliate Contract and (ii) any and all claims and Liabilities whatsoever arising out of, in
any way connected with, as a result of or in respect of such Affiliate Contract. 
  

	 	5.6.2	As soon as practicable following the date of this Agreement, and in any event within one month of the date of this Agreement, the Seller shall provide a copy of each Affiliate Contract that is material to the
Vaccines Group and is in writing to the Purchaser. Within two months of the date of this Agreement, the Purchaser shall notify the Seller of the services provided under the Affiliate Contracts from the Seller’s Group which the Purchaser
reasonably requires in order to operate the business of the Vaccines Group as it is carried on at the date of this Agreement to continue to receive on the same terms as contained in the relevant Affiliate Contract for a maximum period of 6 months
following Closing provided that such services are not addressed by the Ancillary Agreements. 

  

	5.7	Tax Groups 

  

	 	5.7.1	 The Seller shall take all reasonable steps to procure that any Tax Consolidation existing between any member of the Seller’s Group Company
and any Vaccines Group Company be terminated on or before Closing, so far as permitted by Applicable Law, or otherwise on the earliest date on which such termination is permitted under Applicable Law, and the Seller and the Purchaser shall take such

  
 55 

	 	
action as is necessary to procure or effect this, including timely submitting any necessary Tax documents. 

  

	 	5.7.2	Pending the taking effect of the action referred to in Clause 5.7.1, and for so long thereafter as may be necessary, the Purchaser shall (subject to the provisions of the Tax Indemnity) procure that such
information is provided to the Seller as may reasonably be required to enable any relevant member of the Seller’s Group to make all Tax Returns and other filings required of it in respect of the Tax Consolidation. 

 

	 	5.7.3	The Seller and the Purchaser shall cooperate in good faith to take, and procure that each member of the Seller’s Group and the Purchaser’s Group takes, all reasonable procedural or administrative steps
(including the making of elections and filings with relevant Tax Authorities) which are reasonably necessary to procure the minimisation of the extent to which Tax liabilities of members of the Seller’s Group (other than Vaccines Group
Companies) can be assessed on members of the Purchaser’s Group or on Vaccines Group Companies. 

  

	 	5.7.4	The Seller shall take all reasonable steps to procure that Chiron Panacea Vaccines Limited is finally liquidated and ceases to exist before Closing. 

 

	6	Closing 

  

	6.1	Date and Place 

 Save where otherwise provided in this Agreement (including Schedule 25),
Closing shall take place simultaneously with closing under the other Target Asset Agreements at the offices of Freshfields Bruckhaus Deringer, 65 Fleet Street, London EC4Y 1HS (other than in respect of any Local Transfer Documents agreed between the
parties to be executed in another jurisdiction) on the last Business Day of the month in which fulfilment or waiver of the last of the condition(s) set out in Clause 4.1 to be fulfilled or waived takes place, except that: 

 

	 	6.1.1	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the following month; and 

 

	 	6.1.2	where less than five Business Days remain between such fulfilment or waiver and the last Business Day of the month, Closing shall take place: 

 

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the month following the month referred to in Clause 6.1.2(i); or 

 

	 	(iii)	at such other location, time or date as may be agreed between the Purchaser and the Seller in writing. 

provided that: 
  

	 	(a)	Closing shall not take place and shall not be effective in any circumstances unless closing also takes place under and in accordance with the terms of the other Target Asset Agreements at the same time; and

  

	 	(b)	 in determining the date on which the last of the conditions set out in Clause 4.1 is fulfilled or waived, the date shall be the date on which the
last 

  
 56 

	 	
of the conditions set out in Clauses 4.1.1, 4.1.2, 4.1.3, 4.1.4, 4.1.6, 4.1.7 and 4.1.9 is fulfilled or waived unless any of the conditions set out in Clauses 4.1.5 and 4.1.8 is not
fulfilled or waived on that date, in which case the date shall then be the first following date on which all of the conditions set out in Clauses 4.1.5 and 4.1.8 are fulfilled or waived. 

 

	6.2	Closing Events 

  

	 	6.2.1	On Closing, the parties shall comply with their respective obligations specified in Schedule 15. The Seller may waive some or all of the obligations of the Purchaser as set out in Schedule 15 and the Purchaser
may waive some or all of the obligations of the Seller as set out in Schedule 15. 

  

	 	6.2.2	The parties acknowledge that the transfer of Product Approvals and Product Applications in respect of Vaccines Group Businesses to the Purchaser or other members of the Purchaser’s Group may be subject to
the approval of applicable Governmental Entities, and that, notwithstanding anything in this Agreement to the contrary, each Product Approval and Product Application in respect of Vaccines Group Businesses shall continue to be held by the relevant
member of the Seller’s Group from the Closing Date until the relevant PA Transfer Date. 

  

	 	6.2.3	The parties shall perform their respective obligations with respect to: 

  

	 	(i)	the transfer of the Product Approvals, Product Applications and Pipeline Product Approvals as set out in Schedule 8; 

  

	 	(ii)	the transfer of Contracts (other than Product Approvals, Product Applications and Pipeline Product Approvals) and the Transferred Intellectual Property Contracts as set out in Schedule 10 and the treatment of Shared
Business Contracts; 

  

	 	(iii)	to the extent the Purchaser has elected to have the Relevant Part of a Shared Business Contract transferred to it, the separation of each Shared Business Contract as set out in Schedule 10; and 

 

	 	(iv)	the Delayed Businesses as set out in Schedule 25. 

  

	6.3	Payment on Closing 

  

	 	6.3.1	On Closing the Purchaser shall pay (for itself and on behalf of each relevant member of the Purchaser’s Group in accordance with Clause 17.6) an amount in cleared funds, to the Purchase Price Bank Account,
which is equal to the sum of: 

  

	 	(i)	the Headline Price; 

 minus 

 

	 	(ii)	the Employee Adjustment Payment; 

 plus 

 

	 	(iii)	the Estimated Vaccines Group Companies’ Cash Balances and the Estimated Intra-Group Non-Trade Receivables; 

minus 
  

	 	(iv)	the Estimated Third Party Indebtedness; 

  
 57 

 minus 
  

	 	(v)	the Estimated Intra-Group Non-Trade Payables; 

 minus 

 

	 	(vi)	any Estimated Employee Benefit Adjustment; 

 minus 

 

	 	(vii)	the Estimated Tax Adjustment; 

 plus 

 

	 	(viii)	the Estimated Working Capital Adjustment. 

  

	 	6.3.2	The amounts payable in accordance with Clause 6.3.1 shall, in each case, include all such amounts payable in respect of the Delayed Businesses. 

 

	6.4	Notifications to determine payments on Closing 

  

	 	6.4.1	Five Business Days prior to Closing, the Seller shall notify the Purchaser of: 

  

	 	(i)	the Estimated Vaccines Group Companies’ Cash Balances; 

  

	 	(ii)	the Estimated Third Party Indebtedness; 

  

	 	(iii)	the Estimated Intra-Group Non-Trade Receivables; 

  

	 	(iv)	the Estimated Intra-Group Non-Trade Payables; 

  

	 	(v)	any Estimated Employee Benefit Adjustment; 

  

	 	(vi)	the Estimated Tax Adjustment; 

  

	 	(vii)	the Estimated Working Capital; and 

  

	 	(viii)	the Estimated Working Capital Adjustment, 

 and shall at the same time provide to the Purchaser
reasonable supporting calculations and information to enable the Purchaser to review the basis on which the estimates have been prepared. 
  

	 	6.4.2	The Seller’s notification pursuant to Clause 6.4.1 shall specify the relevant debtor and creditor for each Estimated Intra-Group Payable and Estimated Intra-Group Receivable. 

 

	 	6.4.3	The Seller shall notify the Purchaser prior to Closing of the estimate for each Employee Benefit Indemnification Amount used in the calculation of the Estimated Employee Benefit Adjustment on a country-by-country
(or, where necessary, plan-by-plan) basis. 

  

	 	6.4.4	Immediately following Closing: 

  

	 	(i)	the Purchaser shall procure that each Vaccines Group Company repays to the relevant member of the Seller’s Group the amount of any Estimated Intra-Group Non-Trade Payables and shall acknowledge on behalf of each
Group Company the payment of the Estimated Intra-Group Non-Trade Receivables in accordance with Clause 6.4.4(ii); and 

  
 58 

	 	(ii)	the Seller shall procure that each relevant member of the Seller’s Group repays to the relevant Vaccines Group Company the amount of any Estimated Intra-Group Non-Trade Receivables and shall acknowledge on behalf
of each relevant member of the Seller’s Group the payment of the Estimated Intra-Group Non-Trade Payables in accordance with Clause 6.4.4(i). 

  

	 	6.4.5	The repayments made pursuant to Clause 6.4.3 shall be adjusted in accordance with Clauses 7.3 and 7.4 when the Closing Statement becomes final and binding in accordance with Clause 7.2.1. 

 

	6.5	Local Payments 

 The Purchaser shall procure that each relevant Designated Purchaser set
out in column 2 of the table in Part A of Schedule 26 shall, subject to the terms of the relevant Local Transfer Agreement (and, for the avoidance of doubt, in partial satisfaction of the Purchase Price) pay to the relevant Share Seller or Business
Seller set out in column 3 the amount set out against its name in column 4 (each a “Local Payment Amount”) converted into the relevant currency set out in the relevant Local Transfer Document as at the Closing Date, on: 

 

	 	6.5.1	the date falling 7 days after the Closing Date; or 

  

	 	6.5.2	if this is not possible, the date falling 14 days after the Closing Date; or 

  

	 	6.5.3	if this is not possible, the date falling 21 days after the Closing Date, or 

  

	 	6.5.4	if this is not possible, the date falling 28 days after the Closing Date, or 

 provided
that, in any event, all such payments shall be made by no later than the date falling 28 days after the Closing Date. 
  

	6.6	Delayed Local Payments 

 In respect of each Delayed Business, the Purchaser shall procure
that each relevant Designated Purchaser set out in column 2 of the table in Part B of Schedule 26 shall, subject to the terms of the relevant Local Transfer Agreement (and, for the avoidance of doubt, in partial satisfaction of the Purchase
Price), pay to the relevant Share Seller or Business Seller set out in column 3 the amount set out against its name in column 4 in respect of that Delayed Business (each a “Delayed Local Payment Amount”) converted into the relevant
currency set out in the relevant Local Transfer Document as at the relevant Delayed Closing Date, as soon as reasonably practicable following the relevant Delayed Closing Date and, in any event, within 10 Business Days following the relevant Delayed
Closing Date, in accordance with the terms of the relevant Local Transfer Document. 
  

	6.7	Repayment of Local Payments and Delayed Local Payments 

 Where a Local Payment Amount or
Delayed Local Payment Amount is received by a member of the Seller’s Group pursuant to Clause 6.5 or Clause 6.6, the Seller shall (on behalf of the relevant Share Seller or Business Seller, in accordance with Clause 17.6) pay to the Purchaser
in US Dollars an amount equal to such Local Payment Amount or Delayed Local Payment Amount by way of repayment of all or part (as the case may be) of the amount paid by the Purchaser on behalf of the Designated Purchaser that paid the relevant Local
Payment Amount or Delayed Local Payment Amount, so as to ensure that 

  
 59 

 
the total amount received by members of the Seller’s Group under Clauses 2.7, 6.3, 6.5 and 6.6 does not exceed the amount of the Purchase Price. 

 

	6.8	[***] 

  

	6.9	Breach of Closing Obligations 

 If any party fails to comply with any material obligation
in Clauses 6.2, 6.3 or 6.4, or Schedule 15 in relation to Closing, the Purchaser, in the case of non-compliance by the Seller, or the Seller, in the case of non-compliance by the Purchaser, shall be entitled (in addition to and without prejudice to
all other rights or remedies available) by written notice to the Seller or the Purchaser fix a new date for Closing which, except as agreed by the parties, shall be the last day of the month next ending or, if that day is not a Business Day,
the first Business Day falling after that day, in which case the provisions of Schedule 15 shall apply to Closing as so deferred, but provided such deferral may only occur once. In all circumstances Closing shall only occur simultaneously with
closing under the other Target Asset Agreements. 
  

	7	Post-Closing Adjustments 

  

	7.1	Closing Statements 

  

	 	7.1.1	The Seller shall procure that as soon as practicable following Closing there shall be drawn up a draft of the Closing Statement (the “Draft Closing Statement”) in accordance with Schedule 16 in
relation to the Vaccines Group Companies and Vaccines Group Businesses, on a combined basis. 

  

	 	7.1.2	The Closing Statement shall be drawn up as at the Effective Time and shall in each case include the Delayed Businesses which, for the purposes of this Clause 7, shall be deemed to have transferred to the
Purchaser with effect from the Effective Time. 

  

	7.2	Determination of Closing Statement 

  

	 	7.2.1	The Draft Closing Statement as agreed or determined pursuant to paragraph 1 of Part 1 of Schedule 16: 

  

	 	(i)	shall constitute the Closing Statement for the purposes of this Agreement; and 

  

	 	(ii)	shall be final and binding on the parties. 

  

	 	7.2.2	The Working Capital, the Vaccines Group Companies’ Cash Balances, the Third Party Indebtedness, the Intra-Group Non-Trade Receivables, the Intra-Group Non-Trade Payables and the Tax Adjustment shall be
derived from the Closing Statement. 

  

	7.3	Adjustments to Purchase Price 

  

	 	7.3.1	Vaccines Group Companies’ Cash Balances: 

  

	 	(i)	if the Vaccines Group Companies’ Cash Balances are less than the Estimated Vaccines Group Companies’ Cash Balances, the Seller shall repay to the Purchaser an amount equal to the deficiency; or

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 60 

	 	(ii)	if the Vaccines Group Companies’ Cash Balances are greater than the Estimated Vaccines Group Companies’ Cash Balances, the Purchaser shall pay to the Seller an additional amount equal to the excess.

  

	 	7.3.2	Intra-Group Non-Trade Receivables: 

  

	 	(i)	if the Intra-Group Non-Trade Receivables are less than the Estimated Intra-Group Non-Trade Receivables, the Seller shall repay to the Purchaser an amount equal to the deficiency; or 

 

	 	(ii)	if the Intra-Group Non-Trade Receivables are greater than the Estimated Intra-Group Non-Trade Receivables, the Purchaser shall pay to the Seller an additional amount equal to the excess. 

 

	 	7.3.3	Third Party Indebtedness: 

  

	 	(i)	if the Third Party Indebtedness is greater in magnitude than the Estimated Third Party Indebtedness, the Seller shall repay to the Purchaser an amount equal to the excess; or 

 

	 	(ii)	if the Third Party Indebtedness is less in magnitude than the Estimated Third Party Indebtedness, the Purchaser shall pay to the Seller an additional amount equal to the deficiency. 

 

	 	7.3.4	Intra-Group Non-Trade Payables: 

  

	 	(i)	if the Intra-Group Non-Trade Payables are greater in magnitude than the Estimated Intra-Group Non-Trade Payables, the Seller shall repay to the Purchaser an amount equal to the excess; or 

 

	 	(ii)	if the Intra-Group Non-Trade Payables are less in magnitude than the Estimated Intra-Group Non-Trade Payables, the Purchaser shall pay to the Seller an additional amount equal to the deficiency. 

 

	 	7.3.5	Tax Adjustment: 

  

	 	(i)	if the Tax Adjustment is greater than the Estimated Tax Adjustment, the Seller shall repay to the Purchaser an amount equal to the difference; or 

 

	 	(ii)	if the Tax Adjustment is less than the Estimated Tax Adjustment, the Purchaser shall pay to the Seller an additional amount equal to the difference. 

 

	 	7.3.6	Working Capital: 

  

	 	(i)	if the Working Capital Adjustment is less than the Estimated Working Capital Adjustment, the Seller shall repay to the Purchaser an amount equal to the deficiency; or 

 

	 	(ii)	if the Working Capital Adjustment exceeds the Estimated Working Capital Adjustment, the Purchaser shall pay to the Seller an additional amount equal to the excess. 

 

	7.4	Adjustments to repayment of Intra-Group Non-Trade Payables and Intra-Group Non-Trade Receivables 

Following the determination of the Closing Statement pursuant to Clause 7.2 and paragraph 1 of Part 1 of Schedule 16, if the amount of any
Intra-Group Non-Trade Payable 

  
 61 

 
and/or any Intra-Group Non-Trade Receivable contained in the Closing Statement is greater or less than the amount of the corresponding Estimated Intra-Group Non-Trade Payable or Estimated
Intra-Group Non-Trade Receivable, then the Seller and the Purchaser shall procure that such adjustments to the repayments pursuant to Clause 6.4.3 are made as are necessary to ensure that (taking into account such adjustments) the actual amount of
each Intra-Group Non-Trade Payable and each Intra-Group Non-Trade Receivable has been repaid by each Group Company to the relevant member of the Seller’s Group or by the relevant member of the Seller’s Group to the relevant Group Company,
as the case may be. 
  

	7.5	Interest 

 Any payment to be made in accordance with Clause 7.3 shall include interest
thereon calculated from the Effective Time to the date of payment at a rate per annum of LIBOR. 
  

	7.6	Payment 

  

	 	7.6.1	Any payments pursuant to Clause 7.3 or 7.4, and any interest payable pursuant to Clause 7.5, shall be made on or before the Final Payment Date. 

 

	 	7.6.2	Where any payment is required to be made pursuant to Clause 7.3 or Clause 7.5 (in relation to a payment pursuant to Clause 7.3) the payment made on account of the Purchase Price shall be reduced or increased
accordingly. 

  

	 	7.6.3	Where any payment is required to be made pursuant to Schedule 12, the payment made shall be deemed to be a reduction to the Purchase Price. 

 

	8	Post-Closing Obligations 

  

	8.1	Indemnities 

  

	 	8.1.1	Indemnity by the Purchaser against Assumed Liabilities 

 The Purchaser hereby undertakes
to the Seller (for itself and on behalf of each other member of the Seller’s Group (excluding any Delayed Vaccines Group Companies) and their respective directors, officers, employees and agents) that, with effect from Closing, the Purchaser
will indemnify on demand and hold harmless each member of the Seller’s Group (excluding any Delayed Vaccines Group Companies) and their respective directors, officers, employees and agents against and in respect of any and all Assumed
Liabilities. 
  

	 	8.1.2	Indemnities by Seller 

 Subject to Clause 8.1.3, the Seller hereby undertakes to the
Purchaser (for itself and on behalf of each other member of the Purchaser’s Group (including any Delayed Vaccines Group Companies) and their respective directors, officers, employees and agents) that, with effect from Closing, the Seller will
indemnify on demand and hold harmless each member of the Purchaser’s Group (including any Delayed Vaccines Group Companies) and their respective directors, officers, employees and agents against and in respect of any and all: 

 

	 	(i)	Excluded Liabilities; and 

  

	 	(ii)	 Liabilities, including legal fees, to the extent they have arisen or arise (whether before or after Closing) as a result of or otherwise relate to any

  
 62 

	 	
act, omission, fact, matter, circumstance or event undertaken, occurring or in existence or arising before Closing so far as related to: (A) any breach of any anti-bribery warranty, including
without limitation those set forth in paragraphs 9.1 through 9.6 of Schedule 18, not being true and correct when made; (B) any government inquiries or investigations involving the Seller or its Affiliates or associated persons; (C) save to the
extent in existence as at the date of this Agreement, any limitation, restriction or other reduction in drug registrations, licenses, listings or marketing approvals, government pricing or reimbursement rates relating to the Products including
specifically the value of lost future profits as a result of any such limitation, restriction or reduction; or (D) any other claim, litigation, investigation or proceeding to the extent related to any of the foregoing (A) to (C), including but not
limited to costs of investigation and defence and legal fees. 

  

	 	8.1.3	Limitations on Indemnities 

 Subject to Clause 8.1.4, the Seller shall not be liable
under Clause 8.1.2 in respect of: 
  

	 	(i)	any Time-Limited Excluded Liability unless a notice of claim in respect of the matter giving rise to such Liability is given by the Purchaser to the Seller within ten years of Closing, provided that this sub-Clause (i)
shall not apply in respect of any claim by the Purchaser which relates to: 

  

	 	(a)	a Product Liability; 

  

	 	(b)	a Governmental Liability; 

  

	 	(c)	a Clinical Trials/Data Liability; 

  

	 	(d)	an IP Liability; or 

  

	 	(e)	an Excluded Asset; 

  

	 	(ii)	any claim if and to the extent that the relevant Liability is included in the Closing Statement; or 

  

	 	(iii)	any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the Liability (disregarding the provisions of this Clause 8.1.3(iii))) in respect of any such claim or series
of claims does not exceed US$10 million, provided that, for the avoidance of doubt, where the Liability in respect of any such claim or series of claims exceeds US$10 million, the Liability of the Seller shall be for the whole amount of such
claim(s) and not just the excess. 

  

	 	8.1.4	Disapplication of limitations 

 None of the limitations contained in Clause 8.1.3 shall
apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the consequence of, or which is delayed as a result of, fraud by any member of the Seller’s Group or any
director, officer or employee of any member of the Seller’s Group. 

  
 63 

	8.2	Conduct of Claims 

  

	 	8.2.1	Assumed Liabilities 

  

	 	(i)	If the Seller becomes aware after Closing of any claim by a third party which constitutes or may constitute an Assumed Liability, the Seller shall as soon as reasonably practicable: 

 

	 	(a)	give written notice thereof to the Purchaser, setting out such information as is available to the Seller as is reasonably necessary to enable the Purchaser to assess the merits of the potential claim; 

 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Purchaser with periodic updates on the status of the claim upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the prior written agreement of the
Purchaser (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Seller shall, and shall procure that each Share Seller and Business Seller shall, take such action as the Purchaser may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim
which constitutes or may constitute an Assumed Liability subject to the Seller and each Share Seller and Business Seller being indemnified and secured to their reasonable satisfaction by the Purchaser against all Liabilities which may thereby be
incurred. In connection therewith, the Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours all relevant books of account, records and correspondence
relating to the Vaccines Group Businesses which have been retained by the Seller’s Group (and shall permit the Purchaser to take copies thereof at its expense) for the purposes of enabling the Purchaser to ascertain or extract any information
relevant to the claim. 

  

	 	8.2.2	Liabilities Indemnified by the Seller 

  

	 	(i)	If the Purchaser becomes aware after Closing of any claim by a third party which constitutes or may constitute a Liability falling within Clause 8.1.2 or relates to a Liability or any investigations related thereto,
regardless of whether the Purchaser believes that such claim would be made against a member of the Purchaser’s Group or a member of the Seller’s Group, the Purchaser shall as soon as reasonably practicable: 

 

	 	(a)	give written notice thereof to the Seller, setting out such information as is available to the Purchaser as is reasonably necessary to enable the Seller to assess the merits of the potential claim; 

 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Seller with periodic updates on the status upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the prior written agreement of the Seller (such agreement
not to be unreasonably withheld or delayed). 

  
 64 

	 	(ii)	The Purchaser shall take such action as the Seller may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim which constitutes or may constitute a Liability falling within Clause
8.1.2 subject to the Purchaser being indemnified and secured to its reasonable satisfaction by the Seller against all Liabilities which may thereby be incurred by it or any member of the Purchaser’s Group (including for this purpose any Delayed
Vaccines Group Company). 

  

	 	(iii)	In addition, where any such claim or investigation involves a Governmental Entity, the Purchaser shall, subject to Applicable Law, the requirements of the Relevant Governmental Entity and the Seller providing an
appropriate confidentiality undertaking in favour of the Purchaser’s Group, provide to the Seller, at least five Business Days in advance (or, where not possible, as soon as reasonably possible), any analyses, appearances, presentations,
memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree, subject to the Applicable Law, and the requirements of the relevant Governmental
Entity, and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group, to: 

  

	 	(a)	give the Seller reasonable advance notice of all meetings with any Governmental Entity; 

  

	 	(b)	give the Seller an opportunity to participate in each of such meetings; 

  

	 	(c)	to the extent practicable, give the Seller reasonable advance notice of all substantive oral communications with any Governmental Entity; 

 

	 	(d)	if any Governmental Entity initiates a substantive oral communication, promptly notify the Seller of the substance of such communication; 

 

	 	(e)	provide the Seller with a reasonable advance opportunity to review and comment upon all substantive written communications (including any substantive correspondence, analyses, presentations, memoranda, briefs,
arguments, opinions and proposals) that the Purchaser or its agents intend to make or submit to a Governmental Entity in connection with such claim; 

  

	 	(f)	provide the Seller with copies of all substantive written communications to or from any Governmental Entity; and 

  

	 	(g)	not advance arguments with the Governmental Entity without prior agreement of the Seller that would reasonably be likely to have a significant adverse impact on the Seller, provided however, that the Purchaser shall not
be required to comply with paragraph (b) above to the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in which case,
the disclosure may be made on an outside counsel basis). 

  

	 	(iv)	 Other than in respect of any claim to the extent it relates to an IP Liability, a Commercial Practices Liability or a Governmental Liability (other
than in 

  
 65 

	 	
respect of any Liability arising solely by virtue of a breach of any Contract with any Governmental Entity which breach does not also constitute a breach of Applicable Law), the Seller shall be
entitled at its own expense and in its absolute discretion, by notice in writing to the Purchaser, to take such action as it shall deem necessary to avoid, dispute, deny, defend, resist, appeal, compromise or contest any such claim (including making
counterclaims or other claims against third parties) in the name of and on behalf of the Purchaser or other member of the Purchaser’s Group concerned and to have the conduct of any related proceedings, negotiations or appeals. In taking action
on behalf of any member of the Purchaser’s Group as permitted by this Clause 8.2, the Seller shall, in good faith, take into account and have due regard to any reputational matters or issues arising out of the claim for any member of the
Purchaser’s Group or any of their respective directors, officers, employees or agents which are brought to its attention by the Purchaser or a member of the Purchaser’s Group. 

 

	 	(v)	Without limitation to the Seller’s rights pursuant to Clause 8.12, the Purchaser shall make or procure to be made available to the Seller or its duly authorised agents on reasonable notice during normal business
hours full and free access to all relevant books of account, records and correspondence relating to the Vaccines Group which are in the possession or control of the Purchaser or any member of the Purchaser’s Group (and shall permit the Seller
to take copies thereof) for the purposes of enabling the Seller to ascertain or extract any information relevant to the claim. 

  

	 	(vi)	The Purchaser shall, and shall procure that each other member of the Purchaser’s Group shall, on reasonable notice from the Seller, give such assistance to the Seller as it may reasonably require in relation to the
claim including providing the Seller or any member of the Seller’s Group and its representative and advisers with access to and assistance from directors, officers, managers, employees, advisers, agents or consultants of the Purchaser and/or of
each other member of the Purchaser’s Group (collectively, the “Relevant Persons”) and the Purchaser will use its reasonable endeavours to procure that such Relevant Persons comply with any reasonable requests from the Seller
and generally co-operates with and assists the Seller and other members of the Seller’s Group. 

  

	 	(vii)	When seeking assistance under Clauses 8.2.2(v) and (vi), the Seller, or any other relevant member of the Seller’s Group, shall use reasonable endeavours to minimise interference with the Purchaser and the
Purchaser’s Group’s conduct of the relevant business or the performance by the Relevant Persons of their employment duties. 

  

	8.3	Release of Guarantees 

  

	 	8.3.1	 The Purchaser shall use reasonable endeavours to procure as soon as reasonably practicable after Closing, the release of the Seller or any
member of the Seller’s Group from any securities, guarantees or indemnities given by or binding upon the Seller or any member of the Seller’s Group in respect of the Assumed Liabilities or in connection with a liability of any of the
Vaccines Group Companies (other than an Excluded Liability). Pending such release, the Purchaser shall indemnify the 

  
 66 

	 	
Seller and any member of the Seller’s Group against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such Assumed
Liabilities or such liability of the Vaccines Group Companies (other than an Excluded Liability). 

  

	 	8.3.2	The Seller shall use reasonable endeavours to procure by Closing or, to the extent not done by Closing, as soon as reasonably practicable after Closing, the release of the Vaccines Group Companies from any
securities, guarantees or indemnities given by or binding upon the Vaccines Group Companies in respect of any liability of the Seller or any member of the Seller’s Group. Pending such release, the Seller shall indemnify the Vaccines Group
Companies against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such liability of the Seller which arises after Closing. 

 

	8.4	Transferred Accounts Payable 

 If at any time after Closing, the Seller or any of its
Affiliates (but, in relation to any Delayed Business, only with effect from the relevant Delayed Closing Date) pays any monies in respect of any Transferred Accounts Payable, then the Purchaser shall pay or procure payment to the Seller (for the
relevant Business Seller), as soon as reasonably practicable the amount paid, plus any Taxation suffered or incurred by the Seller’s Group which would not have arisen but for the payment and receipt of such monies. 

 

	8.5	Transferred Accounts Receivable 

 If at any time after Closing, a Business Seller
receives any monies in respect of any Transferred Accounts Receivable, then the Business Seller shall pay or procure payment to the Purchaser, as soon as reasonably practicable the amount recovered, less any Taxation suffered or incurred by the
Seller’s Group which would not have arisen but for the receipt and payment of such monies. 
  

	8.6	Payables and Receivables Plan 

  

	 	8.6.1	Without prejudice to the provisions of Clauses 8.4 and 8.5, the parties shall cooperate in good faith to agree, as soon as reasonably practicable after the Closing Date and in any event within one month of the
Closing Date, a written plan in respect of each Market detailing: (i) the process for the collection of Transferred Accounts Receivables by the Seller (or its Affiliates) and the process and periodic timing of payment of monies received in respect
of Transferred Accounts Receivable to the Purchaser; and (ii) the process for the settlement of Transferred Accounts Payable by the Seller (or its Affiliates) and the payment of monies by the Purchaser to the Seller in respect thereof (together, the
“Payables and Receivables Plan”). In agreeing the Payables and Receivables Plan, the parties shall take into account the comments of the parties’ respective accounting and tax teams. 

 

	 	8.6.2	If the parties fail to agree the Payables and Receivables Plan by the date specified in Clause 8.6.1, the matter shall be referred to and discussed by the Purchaser’s and the Seller’s chief financial
officers who shall aim to resolve the matter within 10 Business Days. 

  
 67 

	8.7	Intra-Group Trading Balances 

 Any Intra-Group Trading Balances shall be settled after
Closing in the ordinary course of business and, in any event, within 60 days of Closing. 
  

	8.8	Transfer of Marketing Authorisations 

  

	 	8.8.1	The transfer of the Marketing Authorisations following Closing shall take place in accordance with Part 2 of Schedule 8 and the terms of the Transitional Distribution Services Agreement. 

 

	 	8.8.2	Between the Closing Date and the Marketing Authorisation Transfer Date, the Seller agrees to assist the Purchaser in accordance with Part 4 of Schedule 8 in respect of any tenders relating to the Products.

  

	8.9	Wrong Pockets Obligations 

  

	 	8.9.1	Except as provided in Schedules 3, 8, 10, 11, 12 and 25, if any property, right or asset forming part of the Vaccines Group (other than any property, right or asset expressly excluded from the sale under this
Agreement) has not been transferred to the Purchaser or to another member of the Purchaser’s Group and should have transferred pursuant to the terms of this Agreement, the Seller shall procure that such property, right or asset (and any related
liability which is an Assumed Liability) is transferred to the Purchaser, or to such other member of the Purchaser’s Group as the Purchaser may nominate reasonably acceptable to the Seller, as soon as practicable and at no cost to the
Purchaser. 

  

	 	8.9.2	If, following Closing or, in respect of any Delayed Business, the relevant Delayed Closing, any property, right or asset not forming part of the Vaccines Group including, for the avoidance of doubt, any trade
accounts and notes receivable or payable arising in the ordinary course between a member of the Seller’s Retained Group and a Vaccines Group Company, in each case to the extent related to the Influenza Business (other than any property, right
or asset expressly included in the sale under this Agreement) is found to have been transferred to the Purchaser (or another member of the Purchaser’s Group) and should not have transferred pursuant to the terms of this Agreement, the Purchaser
shall procure that such property, right or asset is transferred to the transferor or another member of the Seller’s Group nominated by the Seller reasonably acceptable to the Purchaser as soon as practicable and at no cost to the Seller.

  

	8.10	Information Technology 

  

	 	8.10.1	 If, within six months from Closing or, in respect of any Delayed Business, the Delayed Closing Date, the Purchaser identifies any Site Specific
Information Technology, the Purchaser shall notify the Seller in writing and the Seller shall procure that such Information Technology is transferred to the Purchaser or a company nominated by the Purchaser for nominal consideration as soon as
practicable after receipt of the Purchaser’s notification provided that any such Site Specific Information Technology shall be transferred by the Seller on an “as-is” basis and the Seller shall have no liability for not wiping or
relocating such assets prior to such transfer and, to the extent that any third party consent is required for the transfer of such software, the Seller shall only be obliged to use reasonable endeavours to obtain such third party consent and the
cost of any fee demanded 

  
 68 

	 	
by the third party as consideration for giving such consent shall be borne by the Purchaser. 

  

	 	8.10.2	If and to the extent that the Purchaser no longer requires a member of the Seller’s Group to perform its obligations under the Transitional Services Agreement (or any part thereof) as a result of the
transfer of Site Specific Information Technology to the Purchaser pursuant to Clause 8.10.1: 

  

	 	(i)	no member of the Seller’s Group shall be in breach of the Transitional Services Agreement or otherwise liable to the Purchaser as a result of such failure to perform and no member of the Purchaser’s Group
shall have any claim in respect of such failure; and 

  

	 	(ii)	no member of the Purchaser’s Group shall be in breach of the payment obligations of the Transitional Services Agreement or otherwise liable to the Seller in respect of those obligations which are no longer required
to be performed, and no member of the Seller’s Group shall have any claim in respect of the Purchaser’s failure to pay for the performance of such obligations. 

 

	8.11	Covenant not to sue 

  

	 	8.11.1	The Seller hereby undertakes not to enforce, at any time after Closing, any Out of Scope Patent against the Purchaser’s Group in relation to the Purchaser’s Group carrying on the Business as at the date
of Closing. 

  

	 	8.11.2	The Purchaser hereby undertakes not to enforce, at any time after Closing, any Vaccines Patent against the Seller’s Group in relation to the Seller’s Group carrying on the Seller’s Group Retained
Business as at the date of Closing. 

  

	8.12	The Purchaser’s Continuing Obligations 

  

	 	8.12.1	The Purchaser shall procure that as soon as practicable after Closing or, in respect of any Delayed Vaccines Group Company, the relevant Delayed Closing, each of the Vaccines Group Companies shall change its name
so that it does not contain any of the Seller Restricted Marks or any name which is likely to be confused with the same and shall provide the Seller with appropriate evidence of such change of name. 

 

	 	8.12.2	Except as provided in the Ancillary Agreements, the Purchaser shall not, and shall procure that no member of the Purchaser’s Group shall, after Closing or, in respect of any Delayed Vaccines Group Company,
the relevant Delayed Closing, use the Seller Restricted Marks or any confusingly similar name or mark, any extensions thereof or developments thereto in any business which competes with the Seller’s business, or any other business of the Seller
or any member of the Seller’s Group in which the Seller Restricted Marks are used for a minimum period of five (5) years following Closing and thereafter for so long as any member of the Seller’s Group continues to retain an interest in
the relevant Seller Restricted Marks. 

  

	 	8.12.3	The Purchaser shall, and shall procure that the relevant Vaccines Group Companies shall: 

  

	 	(i)	 retain for a period of one (1) year from Closing, and not dispose of or destroy in that period, any emails of the Vaccines Group to the extent they

  
 69 

	 	
are created prior to Closing and shall, and shall procure that the relevant Vaccines Group Companies shall, if reasonably requested by the Seller, allow the Seller reasonable access in that
period to such emails (including the right to take copies at the Seller’s expense); and 

  

	 	(ii)	retain for a period of 10 years from Closing (and, upon notice from the Seller between 9 and 10 years from Closing, for a further period of 5 years), and not dispose of or destroy during that period, the other books,
records and documents (except, in each case, emails) of the Vaccines Group to the extent they relate to the period prior to Closing and shall, and shall procure that the relevant Vaccines Group Companies shall, if reasonably requested by the Seller,
allow the Seller reasonable access during that period to such books, records and documents (including the right to take copies at the Seller’s expense) and to the employees of the Vaccines Group or former employees of the Vaccines Group who are
employees of any member of the Purchaser’s Group. 

  

	 	8.12.4	During the 90 days following the Closing Date, the Purchaser shall provide and cause to be provided to the Seller the information reasonably required to enable the Seller to prepare and audit the standard monthly
reporting forms of the Seller’s Group, to the extent that such financial reporting relates to the Vaccines Group, in respect of the period prior to the Closing and in respect of the calendar month in which the Closing occurs. The Purchaser
shall provide such financial reporting in respect of the calendar month in which Closing occurs to the Seller within six Business Days of the last day of the relevant month. 

 

	8.13	The Seller’s Continuing Obligations 

 The Seller shall retain and not dispose of or
destroy and make or procure to be made available to the Purchaser or their duly authorised agents and/or professional advisers on reasonable notice during normal business hours: 

 

	 	8.13.1	in each case for a period of one (1) year from Closing (or from the relevant Delayed Closing Date in respect of emails relating to a Delayed Business), all emails relating to the Vaccines Group which have not
been transferred to the Purchaser under this Agreement (and shall permit the Purchaser to take copies thereof); 

  

	 	8.13.2	in each case for a period of 10 years from Closing (and, upon notice from the Purchaser between 9 and 10 years from Closing, for a further period of 5 years), all relevant books, accounts, other records and
correspondence (except, in each case, emails) relating to the Vaccines Group which have not been, or to the extent they have not been, transferred to the Purchaser under this Agreement (and shall permit the Purchaser to take copies thereof), save as
otherwise agreed by the parties in relation to any books and records (including but not limited to the content of any personnel files) relating to the employment of the Transferred Employees; 

 

	 	8.13.3	 in each case for a period of 10 years from Closing (and, upon notice from the Purchaser between 9 and 10 years from Closing, for a further
period of 5 years), reasonable access to employees of the Seller’s Group who have knowledge relating to any of the Products (including any inventor of the Products) for the purposes of the defence, prosecution or enforcement of any Vaccines
Group Intellectual Property Rights, any actual or potential regulatory or safety 

  
 70 

	 	
investigation involving any of the Products, or as required by Applicable Law or a Governmental Entity, provided that the Purchaser shall promptly reimburse the Seller in relation to the
provision of such access for (i) out of pocket expenses reasonably incurred by the Seller; and (ii) for the time of that employee of the Seller’s Group if it exceeds 25 man hours in aggregate per annum; and 

 

	 	8.13.4	in each case for a period of 3 years from Closing, the Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours
reasonable access to any employees of the Seller’s Group who have knowledge relating to the Vaccines Group (including, for the avoidance of doubt and without limitation, any background information relating to the legal position of the Vaccines
Group and the Products), to the extent that such employees are retained by the Seller after Closing, to answer any questions other than those covered by Clause 8.13.3 that the Purchaser may reasonably ask in relation to the Vaccines Group, provided
that: 

  

	 	(i)	the Purchaser shall promptly reimburse the Seller in relation to the provision of such access for the time of that employee of the Seller’s Group to the extent it exceeds 25 man hours in aggregate per annum;

  

	 	(ii)	the Seller shall have no obligations under this Clause 8.13.4 where such access to employees of the Seller’s Group is prohibited under Applicable Law; 

 

	 	(iii)	the Purchaser shall have no access rights under this Clause 8.13.4 to employees of the Seller’s Group to the extent such access is prohibited by applicable anti-trust rules or any undertakings, contractual
arrangements, or guidelines entered into or provided, with the aim of reasonably ensuring compliance with applicable anti-trust rules; and 

  

	 	(iv)	without prejudice to any indemnity provided by the Seller to the Purchaser under this Agreement, no member of the Seller’s Group shall have any Liability to any member of the Purchaser’s Group in connection
with the provision of any information by employees of the Seller’s Group pursuant to this Clause 8.13.4. 

  

	8.14	Influenza Business 

  

	 	8.14.1	General 

  

	 	(i)	Without prejudice to Clauses 2.1, 2.2, 2.3.1 to 2.3.4, 3 and 4, the parties shall, acting reasonably and as soon as practicable, enter into such arrangements as are required to enable the Influenza Business (or parts
thereof) retained by the Seller, purchased by the Purchaser, or purchased by one or more third party purchasers (as applicable) to continue to operate the Influenza Business (or parts thereof) on substantially the same basis as it was operated by
the Seller immediately prior to the date of this Agreement. 

  

	 	(ii)	Each party shall take all reasonable steps to cooperate with the other party to ensure that each relevant technology transfer takes place as soon as practicable. 

  
 71 

	 	(iii)	The Purchaser acknowledges that the Seller shall, at its option, be entitled to: 

  

	 	(a)	assign or novate the burden and benefit of the Influenza Business Manufacturing and Supply Agreement and any of the arrangements referred to in Clause 8.14.1(i) to any purchaser(s) of the Influenza Business (or parts
thereof) without the consent of the Purchaser; or 

  

	 	(b)	require the Purchaser to enter into separate agreements with any purchaser(s) of the Influenza Business (or parts thereof) on the same terms as the Influenza Business Manufacturing and Supply Agreement and any of the
arrangements referred to in Clause 8.14.1(i). 

  

	 	8.14.2	Influenza Business Manufacturing and Supply Agreement 

 If the Influenza Business
Manufacturing and Supply Agreement has not been entered into on the earlier of: (i) Closing; or (ii) the closing of any sale to the purchaser(s) of the Influenza Business (or parts thereof), the provisions of the heads of terms in relation to the
Influenza Business Manufacturing and Supply Agreement in the Agreed Terms shall be binding on the Seller and Purchaser until the earlier of: (i) the date on which the Influenza Business Manufacturing and Supply Agreement is entered into; and (ii)
the date specified in the heads of terms. 
  

	 	8.14.3	Confidential information 

 In connection with the services to be provided pursuant to
this Clause 8.14, where required by Applicable Law, the Seller and the Purchaser shall establish appropriate safe guards to maintain, and protect from improper disclosure, confidential information arising from the provision of such services. 

 

	 	8.14.4	Influenza defects indemnity 

 Notwithstanding the terms of any Influenza Business
Agreement and except in respect of any loss of profit suffered by an indemnified person (other than any loss of profit included in the charges paid or payable under the Influenza Business Agreements), the Seller hereby undertakes to the Purchaser
(for itself and on behalf of each other member of the Purchaser’s Group (including the Delayed Vaccines Group Companies)) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member of the Purchaser’s
Group (including the Delayed Vaccines Group Companies) and their respective directors, officers, employees and agents (each an “indemnified person”) against and in respect of any and all Losses suffered by an indemnified person and arising
as a result of the failure or alleged failure by an indemnified person to perform or discharge all or part of its obligations under any provision of any Influenza Business Agreement or any other agreement required to be entered into by the Purchaser
or any member of the Purchaser’s Group pursuant to Clause 8.14.1(i): 
  

	 	(i)	to the extent that such Losses arise as a result of or otherwise relate to any act, omission, fact, matter, circumstance or event undertaken or occurring, in existence or arising in relation to the Vaccines Business or
the Influenza Business prior to Closing (“Inherited Defect”); and 

  
 72 

	 	(ii)	to the extent that such Losses arise as a result of or otherwise relate to any failure by the Seller to transfer, or procure the transfer of, or provide to, or procure the provision to, the Purchaser or any member of
the Purchaser’s Group such assets, rights or information of or relating to the Influenza Business or the Vaccines Business (including any contracts, licences, authorisations and permits) as are reasonably required by the Purchaser’s Group
(including the Delayed Vaccines Group Companies) to fulfil such obligations as at Closing. 

  

	 	8.14.5	The Purchaser shall notify the Seller as soon as reasonably practicable after becoming aware of: 

  

	 	(i)	any such Inherited Defect; or 

  

	 	(ii)	any claim it may wish to make under Clause 8.14.4, 

 and the conduct of any claim notified to
the Seller pursuant to (ii) above shall be dealt with pursuant to Clause 8.2.2 as if references in that Clause to “a Liability falling within Clause 8.1.2” were references to any liability to be indemnified under Clause 8.14.4. 

 

	 	8.14.6	The Purchaser shall take reasonable steps to mitigate any liability arising in respect of any Inherited Defects, including 

  

	 	(i)	taking reasonable steps in accordance with cGMP to identify and remediate any Inherited Defects; and 

  

	 	(ii)	by implementing reasonable corrective actions to prevent such failure in the performance of its obligations under the Influenza Business Agreements from recurring. 

 

	8.15	Retention of books and records 

 To the extent and for so long as required by, or to the
extent and for so long as required in order to perform any obligations under, any Ancillary Agreement or Applicable Law, or where otherwise agreed between the parties, the Seller shall be entitled to retain the original or a copy of any book,
ledger, file, report, plan record, manual or other material (in any form or medium) which would otherwise transfer to the Purchaser under this Agreement, provided that: 
  

	 	8.15.1	any copy or original retained is treated as strictly confidential in accordance with Clause 14.2; 

  

	 	8.15.2	in the case of retained originals, a copy of such book, ledger, file, report, plan, record, manual or other material is provided to the Purchaser; 

 

	 	8.15.3	upon reasonable notice by the Purchaser, the Seller shall provide access to such retained book, ledger, file, report, plan, record, manual or other material in accordance with Clause 8.13.2; and

  

	 	8.15.4	upon expiry of the relevant obligation under the applicable Ancillary Agreement the Seller is entitled to retain a copy of any such book, ledger, file, report, plan, record, manual or other material to comply
with Applicable Law but shall transfer the original to the Purchaser. 

  
 73 

	8.16	Abandoned Patents 

 Notwithstanding anything to the contrary contained in this Agreement
or any of the Ancillary Agreements, no representations are made and no warranties are given (in each case, whether express or implied) by the Seller (or any member of the Seller’s Group) in relation to the Abandoned Patents (or transfer of the
same) by the Seller (or a member of the Seller’s Group) to the Purchaser (or a member of the Purchaser’s Group). 
  

	8.17	[***] 

  

	8.18	Anti-bribery and corruption 

 The provisions of Schedule 31 shall apply in respect of the
parties’ compliance with anti-bribery and corruption laws. 
  

	9	Transitional Trademark Use 

  

	9.1	Grant of Transitional Trademark Licence 

  

	 	9.1.1	Subject to the terms set out in this Clause 9, the Seller hereby grants, and shall procure that each member of the Seller’s Group shall grant (as applicable), to the Purchaser, from Closing a non-exclusive,
worldwide, royalty-free, non-assignable, licence without the right to sub-license (save with the prior written consent of the Seller which shall not be unreasonably withheld or delayed, or as otherwise permitted under Clause 9.1.7) to use the Seller
Marks: 

  

	 	(i)	subject to Clause 9.1.3, on signage of the Properties, solely in the manner and to the extent such signage bears any Seller Marks as at the Closing Date, which licence shall, unless terminated earlier under Clause 9.6,
continue in force on a country by country basis for the longer of: (i) 6 months from the Closing Date; or (ii) for such period following the Closing Date as is required by Applicable Laws, provided that in either case the Purchaser shall,
and shall procure that its sub-licensees shall, use all reasonable endeavours to cease such use of such Seller Marks as soon as reasonably practicable following the Closing Date; 

 

	 	(ii)	subject to Clause 9.1.3, on any websites (or related digital assets) which exclusively relate to any Product or Pipeline Product solely in the manner and to the extent such websites (or related digital assets) bear any
Seller Marks as at the Closing Date, which licence shall, unless terminated earlier under Clause 9.6, continue in force on a country by country basis for the longer of: (i) 6 months from the Marketing Authorisation Transfer Date or Marketing
Authorisation Re-registration Date, as applicable, in accordance with Schedule 8; or (ii) for such period following the Closing Date as is required by Applicable Laws, provided that in either case the Purchaser shall, and shall procure that its
sub-licensees shall, use all reasonable endeavours to cease such use of such Seller Marks as soon as reasonably practicable following the Closing Date (“Novartis Branded Websites”); 

 

	 	(iii)	on any Transferred Inventory, solely in the manner and to the extent that the Transferred Inventory bears any Seller Marks as at the Closing Date or as is otherwise required by Applicable Laws (“Novartis Branded
Inventory”); 

  

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

 74 

	 	(iv)	on any products intended to be sold by the Business as the result of the Vaccines Business Manufacturing and Supply Agreements or the Transitional Distribution Services Agreement solely in the manner and to the extent
that those products bear any Seller Marks as at the Closing Date or as is otherwise required by Applicable Laws (“Novartis Branded Products”); and 

 

	 	(v)	on any stationery, sales literature, patient information leaflets or similar documentation used in the Business, solely in the manner and to the extent such materials: (i) bear any Seller Marks as at the Closing Date;
and (ii) relate to the Novartis Branded Inventory or Novartis Branded Products (“Novartis Branded Literature”), 

(the “Transitional Trademark Licence”). 
  

	 	9.1.2	Subject to Clauses 9.1.3, 9.1.4, 9.1.5 and 9.1.6, in each case in respect of Clauses 9.1.1(iii) to 9.1.1(v), such licence shall, unless terminated earlier under Clause 9.6, continue in force, on a country by
country basis, in relation to each item of Novartis Branded Inventory or Novartis Branded Product (or any Novartis Branded Literature related to the same), as applicable, from the Closing Date for the longer of: 

 

	 	(i)	the period required by the Vaccines Business Manufacturing and Supply Agreements or the Transitional Distribution Services Agreement, where applicable; 

 

	 	(ii)	the period until the Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date, as applicable, in accordance with Schedule 8; or 

 

	 	(iii)	such period as is required by Applicable Laws, 

  

	 	9.1.3	Subject always to Clause 9.1.6, the parties shall co-operate in the consideration of an extension of any licences granted under this Clause 9.1 in the event that it is reasonably necessary for any such licences
to continue beyond the period contemplated in Clause 9.1, and the Seller shall not unreasonably withhold its agreement to any such extension. 

  

	 	9.1.4	The Purchaser shall, and shall procure that its sub-licensees shall: 

  

	 	(i)	use all reasonable endeavours to cease such use of the Seller Marks as soon as reasonably practicable following the Closing Date; and 

 

	 	(ii)	use the Seller Marks in accordance with Applicable Laws only. 

  

	 	9.1.5	Neither the Purchaser nor its sub-licensees shall have any rights under the licences granted in Clauses 9.1.1(iii) to 9.1.1(v) to use any of the Seller Marks in relation to any Novartis Branded Inventory or
Novartis Branded Products whose “sell-by date” or shelf life, as applicable, has passed or expired. 

  

	 	9.1.6	The licences granted under Clauses 9.1.1(ii) to 9.1.1(v) shall expire after 24 months of the Closing Date (the “Long Stop Expiry Date”). 

 

	 	9.1.7	The Purchaser shall be entitled to sub-license its rights under the Transitional Trademark Licence to: 

  
 75 

	 	(i)	any member of the Purchaser’s Group without the prior written consent of the Seller, provided that any act of the sub-licensee which would, if committed by the Purchaser be a breach of any of the terms applying to
the Transitional Trademark Licence, shall be treated as an equivalent breach by the Purchaser of the terms of the Transitional Trademark Licence; and 

  

	 	(ii)	third party sub-contractors working with the Purchaser in relation to the Manufacture or Commercialisation of the Novartis Branded Inventory, Novartis Branded Products or Novartis Branded Literature, provided that:

  

	 	(a)	any act of the sub-licensee which would, if committed by the Purchaser be a breach of any of the terms applying to the Transitional Trademark Licence, shall be treated as an equivalent breach by the Purchaser of the
terms of the Transitional Trademark Licence; and 

  

	 	(b)	if the Seller or the Purchaser determines that any sub-licensee under Clause 9.1.7(ii) is using any Seller Marks outside the scope of a permitted sub-licence under this Clause 9.1, the Purchaser promptly will cause the
sub-licensee to cease such unpermitted use and will notify such sub-licensee that it is in material breach of its sub-licence agreement. If the breach continues unremedied for a period of fifteen (15) calendar days after the Purchaser provides
notice to such sub-licensee describing the nature of the breach, the Purchaser will, upon the Seller’s request, terminate the applicable sub-licence and will cooperate with the Seller to enforce the Seller’s rights against such former
sub-licensee as the Seller directs. 

  

	9.2	Reservation of Rights 

 The Seller reserves all rights in and to the Seller Marks. The
Purchaser acknowledges and agrees that as between the Seller (or the relevant member of the Seller’s Group) and the Purchaser, the Seller (or the relevant member of the Seller’s Group) is the sole and exclusive owner of all right, title
and interest in and to the Seller Marks, including all goodwill of the business connected with the use of, or symbolised by, the Seller Marks. All goodwill generated from the use of the Seller Marks by the Purchaser or its sub-licensees shall inure
solely to the benefit of the Seller (or the relevant member of the Seller’s Group). Nothing in this Clause 9 grants the Purchaser or its sub-licensees any ownership or other proprietary interest in any Seller Marks. 

 

	9.3	Restrictions on Use 

  

	 	9.3.1	The Purchaser shall have no right pursuant to this Clause 9 to use or permit any other person to use, any of the Seller Marks as part of a corporate or trading name or to hold itself out or otherwise represent
itself to be a member of, or to be associated or connected with, any member or business venture of the Seller’s Group, or permit any other person to do that same. 

 

	 	9.3.2	Without limiting the generality of Clause 9.2 of this Agreement, the Purchaser will not, nor attempt to, nor permit, enable, or request any other person to: 

 

	 	(i)	 use any Seller Marks in any manner, or engage in any other act or omission, that would impair the right of the Seller (or the relevant member

  
 76 

	 	
of the Seller’s Group) in and to the Seller Marks, including any act or omission that would invalidate or cause the cancellation or abandonment of any Seller Marks; 

 

	 	(ii)	file, acquire or otherwise obtain any registration for or application to register any Trademark or domain name, or acquire, create or otherwise obtain any social media account that consists of, incorporates, uses, or is
confusingly similar to any Seller Marks; whether with any Governmental Entity, internet domain name registrar, social media platform or otherwise (each, a “Registration”); 

 

	 	(iii)	adopt or use any variation, derivation or acronym of the Seller Marks or any word, symbol or Trademark that is confusingly similar to the Seller Marks (each, a “Variation”); 

 

	 	(iv)	use any Seller Marks with any other word, symbol or Trademark (other than a Trademark assigned or otherwise expressly transferred to the Purchaser pursuant to this Agreement) so as to form a composite Trademark (each, a
“Composite”); 

  

	 	(v)	represent to any other person that it, any sub-licensee, or any other person (other than the Seller (or the relevant member of the Seller’s Group) or its or their successors in interest to the Seller Marks) has or
will have any ownership interest in any Seller Marks; or 

  

	 	(vi)	grant or attempt to grant a security interest in or lien on, record any security interest or lien against, or otherwise encumber, any Seller Marks. 

 

	9.4	Transfer of Rights 

 If the Purchaser or any of its sub-licensees has or acquires any
rights in or to the Seller Marks, or any Registrations, Composites or Variations, the Purchaser hereby irrevocably assigns, and will cause its sub-licensees to assign irrevocably, all such rights to the Seller. At the request of the Seller, the
Purchaser will, and will procure that its sub-licensees will, execute any document, and perform any act reasonably necessary to obtain, or confirm the Seller’s or its designee’s exclusive ownership interest in and to the Seller Marks and
Registrations, in each applicable jurisdiction, including executing and delivering applications, oaths, declarations, affidavits, waivers, assignments and other documents. 
  

	9.5	Quality Control 

  

	 	9.5.1	The Purchaser will use, and cause its sub-licensees to use, the Seller Marks under the terms of this Clause 9 solely in a manner consistent with the operation of the Business immediately prior to the Closing
Date. 

  

	 	9.5.2	The Purchaser will comply, and will cause its sub-licensees to comply, with any specifications, standards and directions that the Seller may provide in writing from time to time relating to the use of the Seller
Marks under this Clause 9. 

  

	 	9.5.3	 Concerning any Novartis Branded Products and Novartis Branded Inventory manufactured by the Seller or its Affiliates, or by any third party in
privity of contract with the Seller or its Affiliates, the Purchaser will not tamper, modify or otherwise take any action, and will procure that its sub-licensees will not tamper, modify or

  
 77 

	 	
otherwise take any action, to affect the quality of such Novartis Branded Products and Novartis Branded Inventory. 

 

	 	9.5.4	Concerning any Novartis Branded Products and Novartis Branded Inventory manufactured by the Purchaser or its sub-licensees, or by any third party in privity of contract with the Purchaser or its sub-licensees,
the Purchaser will ensure that such Novartis Branded Products and Novartis Branded Inventory at all times meet or exceed (i) the quality and manufacturing standards of similar products in the Novartis Branded Products and Novartis Branded
Inventory’ industry; (ii) the Good Manufacturing Practices applicable to such Novartis Branded Products and Novartis Branded Inventory, as updated from time to time; (iii) any other standards imposed by the applicable Governmental Entities; and
(iv) any specifications and quality provisions set forth in any agreement entered into by the parties in connection with this Agreement. The Purchaser will notify the Seller in the event that any Product does not meet such standards.

  

	 	9.5.5	Except where Product Packaging or Novartis Branded Literature originate with the Seller or the Seller’s Affiliates, the Purchaser will, to the extent physically practicable, include, and will procure that
its sub-licensees will include, on all Product Packaging, Novartis Branded Literature and Novartis Branded Websites that bear the Seller Marks: (i) a statement that the Seller Marks used thereon is a Trademark of the Seller and used under license
(or any similar statement required by the Seller concerning the status of the Seller Marks), and (ii) the symbols “®”, “TM” or other notice required by the applicable Governmental Entity in proximity to each prominent use
of the Seller Marks, all in line with the current practices applied by the Seller or its Affiliates prior to the Closing Date. 

  

	9.6	Termination of the Transitional Trademark Licence 

  

	 	9.6.1	The Seller may terminate the Transitional Trademark Licence and the rights granted to the Purchaser under the same at any time by providing notice of termination to the Purchaser if: 

 

	 	(i)	the Purchaser commits a material breach of this Clause 9 and the material breach continues un-remedied for two months after the Seller provides notice to the Purchaser describing the nature of the material breach; or

  

	 	(ii)	the Purchaser contests, challenges or otherwise makes any claim or takes any action adverse to the Seller’s (or the relevant member of the Seller’s Group) ownership of or interest in, or the validity of, the
Seller Marks, including in any proceeding before any Governmental Entity. 

  

	10	Warranties 

  

	10.1	The Seller’s Warranties 

  

	 	10.1.1	Subject to Clause 10.2, the Seller warrants (on behalf of the relevant Business Sellers or Share Sellers as applicable) to the Purchaser and each member of the Purchaser’s Group to which Shares or other
assets are transferred pursuant to this Agreement or any Local Transfer Document, that the statements set out in Schedule 18 are true and accurate as of the date of this Agreement. 

  
 78 

	 	10.1.2	Each of the Seller’s Warranties shall be separate and independent and shall not be limited by reference to any other paragraph of Schedule 18 or by anything in this Agreement or any Local Transfer Document
or in the Tax Indemnity. 

  

	 	10.1.3	The Seller does not give or make any warranty as to the accuracy of the forecasts, estimates, projections, statements of intent or statements of opinion provided to the Purchaser or any of its directors,
officers, employees, agents or advisers on or prior to the date of this Agreement. 

  

	 	10.1.4	Any Seller’s Warranty qualified by the expression “so far as the Seller is aware” or to the “Seller’s Knowledge” or any similar expression shall, unless
otherwise stated, be deemed to refer to the knowledge of the following persons: [***], [***], [***], [***], [***], [***], [***], [***], [***] and [***], such persons having made due and reasonable enquiry. 

 

	 	10.1.5	The Seller’s Warranties shall be deemed to be repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the
date of this Agreement were references to the Closing Date. Without prejudice to the provisions of Clause 11, the Seller shall have no liability for any breach of any Seller’s Warranty where such Seller’s Warranty was true as at the date
of this Agreement unless the fact, event or circumstances giving rise to the breach constitutes a Material Adverse Effect. The Seller shall have no liability under this Clause 10.1.5 if the Purchaser has exercised its termination right in accordance
with Clause 4.4.1(iv). 

  

	 	10.1.6	Save insofar as they are specifically referred to in paragraphs 4.4 and 4.5 of Schedule 18, none of the Seller’s Warranties shall apply to any of the Beta Interferon Patent Rights. 

 

	10.2	Seller’s Disclosures 

  

	 	10.2.1	The Seller’s Warranties are subject to all matters which are fairly disclosed in this Agreement or in the Disclosure Letter. 

 

	 	10.2.2	References in the Disclosure Letter to paragraph numbers shall be to the paragraphs in Schedule 18 to which the disclosure is most likely to relate. Such references are given for convenience only and, shall not
limit the effect of any of the disclosures, all of which are made against the Seller’s Warranties as a whole. 

  

	10.3	The Purchaser’s Warranties 

 The Purchaser warrants to the Seller that the
statements set out in Schedule 19 are true and accurate as of the date of this Agreement. 
  

	11	Limitation of Liability 

  

	11.1	Application 

  

	 	11.1.1	In respect of the Tax Indemnity, the provisions of this Clause 11 shall operate to limit the liability of the Seller only in so far as any provision in this Clause 11 is expressed to be applicable to the Tax Indemnity,
and the provisions of the Tax Indemnity shall further operate to limit the liability of the Seller in respect of any claims thereunder. 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 79 

	 	11.1.2	References to the Seller’s Warranties in Clauses 11.2 to 11.5 and 11.7 to 11.9 shall not include the Tax Warranties and the provisions of clause 3 of the Tax Indemnity shall operate to limit the liability of
the Seller and to govern the claims procedure in respect of any claim under the Tax Warranties in respect of a liability for Tax as if such claim had been a claim in respect of a Tax Liability (as defined in the Tax Indemnity) under the Tax
Indemnity. 

  

	11.2	Time Limitation for Claims 

 The Seller shall not be liable under this Agreement or any
Local Transfer Document for breach of any Seller’s Warranty or under the Tax Indemnity in respect of any claim unless a notice of the claim is given by the Purchaser to the Seller specifying the matters set out in Clause 12.2: 

 

	 	11.2.1	in the case of a claim under paragraph 1, 2.1, 2.2.1, 2.2.3 or 2.3 of Schedule 18, within the applicable statutory limitation period; 

 

	 	11.2.2	in the case of any claim under paragraphs 4.1 to 4.11 of Schedule 18, within 6 years of Closing; 

  

	 	11.2.3	in respect of claims under the Tax Warranties or the Tax Indemnity, before the date falling six months after the expiry of the period specified by statute during which an assessment of the relevant liability to
Tax may be issued by the relevant Tax Authority; and 

  

	 	11.2.4	in the case of any other claim, within two years of Closing. 

  

	11.3	Minimum Claims 

  

	 	11.3.1	The Seller shall not be liable under: 

  

	 	(i)	this Agreement or any Local Transfer Document for breach of any Seller’s Warranty in respect of any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the
liability agreed or determined (disregarding the provisions of this Clause 11.3) in respect of any such claim or series of claims does not exceed 0.1 per cent. of the Headline Price; or 

 

	 	(ii)	this Agreement for breach of any Tax Warranty or under the Tax Indemnity in respect of any individual claim (or series of claims arising from similar or identical facts or circumstances) where the liability agreed or
determined (disregarding the provisions of this Clause 11.3) in respect of any such claim or series of claims does not exceed US$1 million; 

  

	 	11.3.2	Where the liability agreed or determined in respect of any such claim or series of claims exceeds (in the case of claims falling within Clause 11.3.1(i)) 0.1 per cent. of the Headline Price or, in the case of
claims falling within Clause 11.3.1(ii))) US$1 million, the liability of the Seller shall be for the whole amount of such claim(s) and not just the excess. 

 

	11.4	Aggregate Minimum Claims 

  

	 	11.4.1	 The Seller shall not be liable under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty in respect of any
claim unless the aggregate amount of all claims for which the Seller would otherwise be liable under 

  
 80 

	 	
this Agreement or any Local Transfer Document for breach of any Seller’s Warranty (disregarding the provisions of this Clause 11.4) exceeds one per cent. of the Headline Price.

  

	 	11.4.2	Where the liability agreed or determined in respect of all claims exceeds one per cent. of the Headline Price, the Seller shall be liable for the aggregate amount of all claims as agreed or determined and not
just the excess. 

  

	 	11.4.3	For the avoidance of doubt, the Purchaser may give notice of any single claim in accordance with and for the purposes of Clause 11.2, irrespective of whether, at the time the notice is given, the amount set out
in Clause 11.4.2 has been exceeded. 

  

	11.5	Maximum Liability 

 The aggregate liability of the Seller in respect of: 

 

	 	11.5.1	any breaches of the Seller’s Warranties (other than the Seller’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3, 2.3 or 4.1 to 4.10 of Schedule 18) shall not exceed an amount equal to 30 per
cent. of the Headline Price; 

  

	 	11.5.2	any breaches of the Seller’s Warranties contained in paragraphs 4.1 to 4.10 of Schedule 18 shall not exceed an amount equal to 60 per cent. of the Headline Price; and 

 

	 	11.5.3	any breaches of the Seller’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3, or 2.3 of Schedule 18 shall not exceed the Headline Price. 

 

	11.6	Contingent Liabilities 

 The Seller shall not be liable under this Agreement or any Local
Transfer Document for breach of any Seller’s Warranties in respect of which the liability is contingent, unless and until such contingent liability becomes an actual liability and is due and payable (but the Purchaser has the right under Clause
12.1 to give notice of such claim before such time). For the avoidance of doubt, the fact that the liability may not have become an actual liability by the relevant date provided in Clause 11.2 shall not exonerate the Seller in respect of any claim
properly notified before that date. 
  

	11.7	Provisions 

 The Seller shall not be liable under this Agreement or any Local Transfer
Document, in either case, in respect of any claim for breach of any Seller’s Warranty, if and to the extent that any allowance, provision or reserve has been properly made in the Closing Statement or Statement of Net Assets for the matter
giving rise to the claim and the Seller can demonstrate that the allowance, provision or reserve so made was in respect of such matter. 
  

	11.8	Matters Arising Subsequent to this Agreement 

 Subject to Clause 8.1.2, the Seller shall
not be liable under this Agreement or any Local Transfer Document in either case in respect of any claim for breach of any Seller’s Warranty in respect of any matter, act, omission or circumstance (or any combination thereof), to the extent
that the same would not have occurred but for: 

  
 81 

	 	11.8.1	Agreed matters 

 any matter or thing done or omitted to be done by the Seller or any
member of the Seller’s Group before Closing pursuant to and in compliance with this Agreement or any Local Transfer Document or otherwise at the request in writing of the Purchaser; or 

 

	 	11.8.2	Changes in legislation 

 the passing of, or any change in, after the Closing Date, any
Applicable Law or administrative practice of any government, governmental department, agency or regulatory body having the force of the law including (without prejudice to the generality of the foregoing) any increase in the rates of Taxation or any
imposition of Taxation or any withdrawal of relief from Taxation not in force at the Closing Date. 
  

	11.9	Insurance 

 Without prejudice to Clause 15, the Seller’s Liability under this
Agreement for breach of any Seller’s Warranty shall be reduced by an amount equal to any loss or damage to which such claim related which has actually been recovered under a policy of insurance held by the Purchaser or a Vaccines Group Company
(after deducting any reasonable costs incurred in making such recovery including the amount of any excess or deductible). 
  

	11.10	Purchaser’s Right to Recover 

 If the Seller has paid an amount in discharge of any
claim under this Agreement for breach of any Seller’s Warranty and subsequently the Purchaser recovers (whether by payment, discount, credit, relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the
Purchaser (in whole or in part) in respect of the loss or liability which is the subject matter of the claim, the Purchaser shall pay to the Seller as soon as practicable after receipt an amount equal to (i) the sum recovered from the third party
less any costs and expenses incurred in obtaining such recovery and any Tax on any amounts recovered (or Tax that would have been payable on such amounts but for the availability of any Tax relief), or if less (ii) the amount previously paid by the
Seller to the Purchaser. Any payment made by the Purchaser to the Seller under this Clause shall be made or procured by way of further adjustment of the consideration paid by the Purchaser and the provisions of Clause 3.3 shall apply mutatis
mutandis. 
  

	11.11	No Double Recovery and no Double Counting 

 A party shall be entitled to make more than
one claim under this Agreement arising out of the same subject matter, fact, event or circumstance but shall not be entitled to recover under this Agreement or any Local Transfer Document or the Tax Indemnity or otherwise more than once in respect
of the same Losses suffered or amount for which the party is otherwise entitled to claim (or part of such Losses or amount), regardless of whether more than one claim arises in respect of it. No amount (including any relief) (or part of any amount)
shall be taken into account, set off or credited more than once under this Agreement or any Local Transfer Document or the Tax Indemnity or otherwise, with the intent that there will be no double counting under this Agreement or any Local Transfer
Document and the Tax Indemnity or otherwise. 

  
 82 

	11.12	Fraud 

 None of the limitations contained in this Clause 11 shall apply to any claim to
the extent that such claim arises or is increased as the consequence of, or which is delayed as a result of, fraud by any director or officer of any member of the Seller’s Group. 

 

	12	Claims 

  

	12.1	Notification of Potential Claims 

 Without prejudice to the obligations of the Purchaser
under Clause 12.2, if the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against the Seller under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty other than a Tax
Warranty (ignoring for these purposes the application of Clause 12.2 or 12.3), the Purchaser shall as soon as reasonably practicable give a notice in writing to the Seller of such facts, matters or circumstances as are then available regarding the
potential claim. Failure to give notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty, except that the failure
shall be taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced, as a result of such failure. 

 

	12.2	Notification of Claims under this Agreement 

 Notices of claims under this Agreement or
any Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) shall be given by the Purchaser to the Seller within the time limits specified in Clause 11.2 and shall specify information (giving reasonable detail)
in relation to the basis of the claim and setting out the Purchaser’s estimate of the amount of Losses which are, or are to be, the subject of the claim. 
  

	12.3	Commencement of Proceedings 

 Any claim notified pursuant to Clause 12.2 shall (if it has
not been previously satisfied, settled or withdrawn) be deemed to be irrevocably withdrawn 9 months after the relevant time limit set out in Clause 11.2 unless, at the relevant time, legal proceedings in respect of the relevant claim have been
commenced by being both issued and served except: 
  

	 	12.3.1	where the claim relates to a contingent liability, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served with 9
months of it having become an actual liability; or 

  

	 	12.3.2	where the claim is a claim for breach of a Seller’s Warranty of which notice is given for the purposes of Clause 11.2 at a time when the amount set out in Clause 11.4.2 has not been exceeded, in which case
it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 9 months of the date of any subsequent notification to the Seller pursuant to Clause 12.1 of one or more
claims which result(s) in the total amount claimed in all claims notified to the Seller pursuant to Clause 11.2 exceeding the amount set out in Clause 11.4.2 for the first time. 

  
 83 

	12.4	Conduct of Third Party Claims 

  

	 	12.4.1	If the matter or circumstance that may give rise to a claim against the Seller under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) is a result
of or in connection with a claim by a third party (a “Third Party Claim”) then: 

  

	 	(i)	the Purchaser shall as soon as reasonably practicable give written notice thereof to the Seller and thereafter shall provide the Seller with periodic updates upon reasonable request and shall consult with the Seller so
far as reasonably practicable in relation to the conduct of the Third Party Claim and shall take reasonable account of the views of the Seller in relation to the Third Party Claim; 

 

	 	(ii)	the Third Party Claim shall not be admitted, compromised, disposed of or settled without the written consent of the Seller (such consent not to be unreasonably withheld or delayed); and 

 

	 	(iii)	subject to the Seller indemnifying the Purchaser or other member of the Purchaser’s Group (including any Delayed Vaccines Group Company) concerned against all reasonable costs and expenses (including legal and
professional costs and expenses) that may be incurred thereby, the Purchaser shall, or the Purchaser shall procure that any other members of the Purchaser’s Group shall, take such action as the Seller may reasonably request to avoid, dispute,
deny, defend, resist, appeal, compromise or contest the Third Party Claim, provided that this Clause 12.4.1(iii) shall not apply where the claim by the third party relates to matters or circumstances referred to in paragraph 4 or 9 of Schedule 18
and the Purchaser shall then have the right to conduct the claim at its discretion (subject to Clauses 12.4.1(i) and 12.4.1(ii)), 

provided that failure to give notice in accordance with Clause 12.4.1(i) shall not affect the rights of the Purchaser to make a relevant claim
under this Agreement for breach of any Seller’s Warranty, except that the failure shall be taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or
is not reduced, as a result of such failure. 
  

	 	12.4.2	Notwithstanding the provisions of this Clause 12.4, if a Third Party Claim may give rise to a claim against the Seller under Clause 8.1.2, the conduct of any such Third Party Claim shall be dealt with pursuant to
Clause 8.2.2 and Clause 12.4.1 shall not apply. 

  

	13	Restrictive Covenants 

  

	13.1	Non-compete 

 The Seller will not, and undertakes to procure that each member of the
Seller’s Group will not, for the period from Closing until three years after the Closing Date: 
  

	 	13.1.1	 be engaged (directly or indirectly) in any business which competes with the Business as it is carried on at the Closing Date (the
“Restricted Business”), provided that commercial transactions outside the Restricted Business with a client, customer, supplier, licensor or distributor that is not a member of the Seller’s

  
 84 

	 	
Group shall not be deemed to indirectly violate this Clause 13.1.1 by reason of such person being engaged in the Restricted Business or taking any other action prohibited hereunder; or

  

	 	13.1.2	solicit the custom of any person to whom goods or services have been sold by any member of the Vaccines Group in the course of its business during the two years before the Closing Date, in each case only to the
extent that such solicitation is in competition with the Business of the Vaccines Group as it is carried on at the Closing Date. 

  

	13.2	Exceptions to the non-compete 

  

	 	13.2.1	The restrictions in Clause 13.1 shall not apply to: 

  

	 	(i)	any Delayed Business in the period between Closing and the relevant Delayed Closing Date; 

  

	 	(ii)	the Specified Excluded Businesses; 

  

	 	(iii)	the Influenza Business; 

  

	 	(iv)	any activities of any nature undertaken or developed by the Seller’s Group (other than the Vaccines Group) in relation to oncology; 

 

	 	(v)	any activities of any nature (or any assets related thereto) contributed by the Seller’s Group pursuant to the Consumer Contribution Agreement; 

 

	 	(vi)	any supply agreements between the Seller’s Group (other than the Vaccines Group) and the Business, the Influenza Business or Leo Constellation Limited (or its Affiliates); 

 

	 	(vii)	any person at such time as it is no longer a member of the Seller’s Group, and any person that purchases assets, operations, subsidiaries or businesses from the Seller’s Group if such Person is not a member of
the Seller’s Group after such transaction is consummated; 

  

	 	(viii)	any Affiliate of Seller in which a person who is not a member of the Seller’s Group holds equity interests and with respect to whom a member of the Seller’s Group has existing contractual or legal obligations
limiting its discretion to impose non-competition obligations; 

  

	 	(ix)	the holding of shares in a company or other entity for investment purposes provided the Seller does not exercise, directly or indirectly, Control over that company or entity; 

 

	 	(x)	any business activity that would otherwise violate Clause 13.1 that is acquired in connection with an acquisition so long as the relevant member of the Seller’s Group divests all or substantially all of the
business activity that would otherwise violate Clause 13.1 or otherwise terminates or disposes of such business activity, product line or assets of such acquired business that would otherwise violate Clause 13.1 within nine months after the
consummation of the relevant acquisition, or such longer period as may reasonably be necessary to comply with Applicable Law (provided that in those circumstances the Seller shall procure that the Restricted Business is disposed of as soon as
reasonably practicable); 

  
 85 

	 	(xi)	passive investments by a pension or employee benefit plan or trust for present or former employees; 

  

	 	(xii)	financial investments by the Novartis Venture Funds; 

  

	 	(xiii)	investments by the Novartis Foundation for Sustainable Development, or a similar non-profit-based organization; 

  

	 	(xiv)	performance of any obligation of the Seller’s Group under the Ancillary Agreements, as amended from time to time in accordance with its their terms; or 

 

	 	(xv)	provision of data or other content to or in connection with business conducted by any person, in each case as required by Applicable Law. 

 

	13.3	Non-solicit 

 The Seller will not, and undertakes to procure that each member of the
Seller’s Group will not, for a period of two years after the Closing Date, solicit or induce any Restricted Vaccines Group Employee to become employed or engaged whether as employee, consultant or otherwise by any member of the Seller’s
Group. 
  

	13.4	Exceptions to the non-solicit 

 The restrictions in Clause 13.3 may be relaxed or
additional exceptions allowed by written approval of the Purchaser’s Division Head of HR and shall in any event not apply to the solicitation, inducement or recruitment of any person: 

 

	 	13.4.1	through the placing of advertisements of posts available to the public generally; 

  

	 	13.4.2	through an employment agency, provided that no member of the Seller’s Group encourages or advises such agency to approach any such person; 

 

	 	13.4.3	who is no longer employed by the Purchaser’s Group; or 

  

	 	13.4.4	who is under formal notice of termination from his employer, provided that this exception only applies if the employment or engagement by the member of the Seller’s Group is offered with a start date which
is no earlier than the day after the last scheduled date of the person’s employment with the Purchaser’s Group. 

  

	13.5	Reasonableness of Restrictions 

 Each undertaking contained in this Clause 13 shall be
construed as a separate undertaking and if one or more of the undertakings is held to be against the public interest or unlawful or in any way an unreasonable restraint of trade, the remaining undertakings shall continue to bind the Seller. 

 

	14	Confidentiality 

  

	14.1	Announcements 

 No announcement, communication or circular concerning the existence or
the subject matter of this Agreement shall be made or issued by or on behalf of any member of the Seller’s Group or the Purchaser’s Group without the prior written approval of the Seller and the Purchaser (such consent not to be
unreasonably withheld or delayed). This shall not affect any announcement, communication or circular required by law or any governmental 

  
 86 

 
or regulatory body or the rules of any stock exchange on which the shares of any party (or its holding company) are listed but the party with an obligation to make an announcement or
communication or issue a circular (or whose holding company has such an obligation) shall consult with the other parties (or shall procure that its holding company consults with the other parties) insofar as is reasonably practicable before
complying with such an obligation. 
  

	14.2	Confidentiality 

  

	 	14.2.1	Subject to Clause 14.1 and Clause 14.2.2, each of the parties shall treat as strictly confidential and not disclose or use any information received or obtained as a result of entering into this Agreement, the
Ancillary Agreements or any agreement entered into pursuant to this Agreement which relates to: 

  

	 	(i)	the existence and provisions of this Agreement, the Ancillary Agreements and of any other agreement entered into pursuant to this Agreement; 

 

	 	(ii)	the negotiations relating to this Agreement, the Ancillary Agreements and any such other agreement; 

  

	 	(iii)	(in the case of the Seller) any information relating to the Vaccines Group Companies and Vaccines Group Businesses following Closing and any other information relating to the business, financial or other affairs
(including future plans and targets) of the Purchaser’s Group, provided that nothing in this Clause 14.2.1(iii) shall prohibit the use or disclosure by the Seller for or to the Influenza Business or any purchaser(s) of the Influenza Business
(or parts thereof) of any information (as redacted to the extent required to comply with Applicable Law) to the extent it is exclusively related to the Influenza Business or reasonably necessary for the commercialization of the Influenza Business
(including, but not limited to, any books, records and documents related to the SAM platform technology or other shared vaccines platforms, information or technologies); or 

 

	 	(iv)	(in the case of the Purchaser) any information relating to the business, financial or other affairs (including future plans and targets) of the Seller’s Group including, prior to Closing, the Vaccines Group
Companies and Vaccines Group Businesses. 

  

	 	14.2.2	Clause 14.2.1 shall not prohibit disclosure or use of any information if and to the extent: 

  

	 	(i)	the disclosure or use is required by law, any governmental or regulatory body or any stock exchange on which the shares of any party (or its holding company) are listed; 

 

	 	(ii)	the disclosure or use is required to vest the full benefit of this Agreement or the Ancillary Agreements in any party; 

  

	 	(iii)	the disclosure or use is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement, the Ancillary Agreements or any other agreement entered into under or pursuant to this Agreement
or to enable a determination to be made by the Reporting Accountants under this Agreement; 

  
 87 

	 	(iv)	the disclosure is made to a Tax Authority in connection with the Tax affairs of the disclosing party; 

  

	 	(v)	the disclosure is made to a ratings agency on a confidential basis in connection with the affairs of the disclosing party; 

  

	 	(vi)	the disclosure is made by the Purchaser to any of its Representatives, any member of the Purchaser’s Group and/or any of their respective Representatives, or by the Seller to any of its Representatives, any member
of the Seller’s Group and/or any of their respective Representatives, in each case on a “need-to-know” basis and provided they have a duty (contractual or otherwise) to keep such information confidential; 

 

	 	(vii)	the information was lawfully in the possession of that party without any obligation of secrecy prior to its being received or held, in either case as evidenced by written records; 

 

	 	(viii)	the information is or becomes publicly available (other than by breach of this Agreement); 

  

	 	(ix)	the other party has given prior written approval to the disclosure or use; or 

  

	 	(x)	the information is independently developed, 

 provided that prior to disclosure or use of any
information pursuant to Clause 14.2.2(i), (ii) or (iii), the party concerned shall, where not prohibited by law, promptly notify the other parties of such requirement with a view to providing the other parties with the opportunity to contest
such disclosure or use or otherwise to agree the timing and content of such disclosure or use. 
  

	15	Insurance 

  

	15.1	No cover under Seller’s Group Insurance Policies from Closing 

 The Purchaser
acknowledges and agrees that following Closing: 
  

	 	15.1.1	neither the Purchaser nor any Vaccines Group Company (but, in relation to any Delayed Business, only with effect from the relevant Delayed Closing Date) shall have or be entitled to the benefit of any
Seller’s Group Insurance Policy in respect of any event, act or omission that takes place after Closing and it shall be the sole responsibility of the Purchaser to ensure that adequate insurances are put in place for those Vaccines Group
Companies (but, in relation to any Delayed Business, only with effect from the relevant Delayed Closing Date) and Vaccines Group Businesses (but, in relation to any Delayed Business, only with effect from the relevant Delayed Closing Date) with
effect from Closing; 

  

	 	15.1.2	except in respect of any Delayed Vaccines Group Company or Delayed Vaccines Group Business until the relevant Delayed Closing Date, neither the Seller nor any member of the Seller’s Group shall be required
to maintain any Seller’s Group Insurance Policy for the benefit of the Vaccines Group; 

  

	 	15.1.3	 no Vaccines Group Company shall make or shall be entitled to make or notify a claim under any Seller’s Group Insurance Policy in respect
of any event, act or 

  
 88 

	 	
omission that occurred prior to the Closing Date or, in respect of a Delayed Vaccines Group Company, prior to the relevant Delayed Closing Date. 

 

	15.2	Existing claims under Seller’s Group Insurance Policies 

 With respect to any claim
made before the Closing Date under any Seller’s Group Insurance Policy by or on behalf of any Vaccines Group Company or in respect of any Vaccines Group Business, or to any claim made before the relevant Delayed Closing Date under any
Seller’s Group Insurance Policy by or on behalf of any Delayed Vaccines Group Company or in respect of any Delayed Vaccines Group Business, to the extent that: 
  

	 	15.2.1	neither the Purchaser nor the Vaccines Group Companies have been indemnified by the Seller prior to the Closing Date in respect of the matter in respect of which the claim was made; or 

 

	 	15.2.2	the Liability in respect of which the claim was made has not been properly provided for in the Closing Statement and reduced the Working Capital accordingly, 

the Seller shall use reasonable endeavours after Closing to recover all monies due from insurers and shall pay any monies received (after
taking into account any deductible under the Seller’s Group Insurance Policies and less any Taxation suffered on the proceeds and any reasonable out of pocket expenses suffered or incurred by the Seller or any member of the Seller’s Group
in connection with the claim) to the Purchaser or, at the Purchaser’s written direction, the relevant Vaccines Group Company as soon as practicable after receipt. 
  

	16	France Business and Netherlands Business 

  

	16.1	France Business 

 Notwithstanding any other provision of this Agreement, this Agreement
shall not constitute a binding agreement to sell or purchase the France Business, provided that: 
  

	 	16.1.1	in the event that the France Put Option Exercise occurs before Closing, this Clause 16.1 (other than this Clause 16.1.1) shall terminate and shall cease to have effect, and the sale of the France Business shall
be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

  

	 	16.1.2	in the event that the France Put Option Exercise does not occur before Closing: 

  

	 	(i)	the provisions of Clauses 2 and 6 (the “Disapplied Provisions”) shall not apply to the France Business; 

  

	 	(ii)	prior to the France Closing, the provisions of Clause 13 and Schedules 11 and 12 (the “Suspended Provisions”) shall not apply to the France Business; and 

 

	 	(iii)	in respect of the Disapplied Provisions and, prior to the France Closing, the Suspended Provisions only: 

  

	 	(a)	the term “Business” shall be deemed to exclude the France Business; 

  
 89 

	 	(b)	the term “Companies” shall be deemed to exclude Novartis Vaccines and Diagnostics S.A.S.; 

  

	 	(c)	the term “Assumed Liabilities” shall be deemed to exclude the France Assumed Liabilities; and 

  

	 	(d)	the term “Employees” shall be deemed to exclude the France Employees; 

  

	 	16.1.3	with effect from the France Closing, the Suspended Provisions shall apply to the France Business mutatis mutandis save that in respect of the Suspended Provisions only (A) the term “Closing”
shall be deemed to refer to the France Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the France Closing; and 

  

	 	16.1.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any of the Ancillary Agreements as are required in order to give effect to the principles set forth in this Clause 16.1 for
the purposes of complying with the information and consultation requirements in respect of the Comité d’enterprise de Novartis Vaccines and Diagnostics SAS (being the relevant works council in respect of the France Business); and

  

	 	16.1.5	the provisions of Clause 11 shall apply to the France Business as if the remaining provisions of this Clause 16.1 did not have any force or effect. 

 

	16.2	Netherlands Business 

 Notwithstanding any other provision of this Agreement, this
Agreement shall not constitute a binding agreement to sell or purchase the Netherlands Business, provided that: 
  

	 	16.2.1	in the event that the Netherlands Put Option Exercise occurs before Closing, this Clause 16.2 (other than this Clause 16.2.1) shall terminate and shall cease to have effect, and the sale of the Netherlands
Business shall be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

  

	 	16.2.2	in the event that the Netherlands Put Option Exercise does not occur before Closing: 

  

	 	(i)	the Disapplied Provisions shall not apply to the Netherlands Business; 

  

	 	(ii)	prior to the Netherlands Closing, the Suspended Provisions shall not apply to the Netherlands Business; and 

  

	 	(iii)	in respect of the Disapplied Provisions and, prior to the Netherlands Closing, the Suspended Provisions only: 

  

	 	(a)	the term “Business” shall be deemed to exclude the Netherlands Business; 

  

	 	(b)	the term “Vaccines Group Businesses” shall be deemed to exclude the Netherlands Business; 

  

	 	(c)	the term “Assumed Liabilities” shall be deemed to exclude the Netherlands Assumed Liabilities; and 

  
 90 

	 	(d)	the term “Employees” shall be deemed to exclude the Netherlands Employees; 

  

	 	16.2.3	with effect from the Netherlands Closing, the Suspended Provisions shall apply to the Netherlands Business mutatis mutandis save that in respect of the Suspended Provisions only (A) the term
“Closing” shall be deemed to refer to the Netherlands Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the Netherlands Closing; and 

 

	 	16.2.4	the parties shall negotiate in good faith to agree any amendments to the Ancillary Agreements as are required in order to give effect to the principles set forth in this Clause 16.2 for the purposes of complying
with the information and consultation requirements in respect of Onderdeelcommissie NV (being the relevant works council in respect of the Netherlands Business); and 

 

	 	16.2.5	the provisions of Clause 11 shall apply to the Netherlands Business as if the remaining provisions of this Clause 16.2 did not have any force or effect. 

 

	17	Other Provisions 

  

	17.1	Further Assurances and IP Recordals 

  

	 	17.1.1	Without prejudice to any restriction or limitation on the extent of any party’s obligations under this Agreement, each of the parties shall from time to time, so far as each is reasonably able, do or procure
the doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the party concerned as they may reasonably consider necessary to transfer the Vaccines Group to the Purchaser or otherwise
to give the other party the full benefit of this Agreement. 

  

	 	17.1.2	Subject to Clause 17.1.3, the parties shall negotiate in good faith to agree definitive and legally binding documentation in respect of each of the Ancillary Agreements for which heads of terms are in the Agreed
Terms on the date of this Agreement, and shall duly execute and deliver such definitive and legally binding documentation in respect of the Ancillary Agreements at Closing. 

 

	 	17.1.3	In the event that the parties are unable to agree definitive and legally binding documentation in respect of an Ancillary Agreement referred to in Clause 17.1.2 by Closing, the parties shall be subject to and
shall adhere to the heads of terms in the Agreed Terms for that Ancillary Agreement, which terms shall be legally binding on the parties. Following Closing, the parties shall continue to negotiate in good faith to agree definitive and legally
binding documentation in respect of each of the Ancillary Agreements which remains to be agreed and, once definitive and legally binding documentation has been agreed, such documentation shall supersede the heads of terms in the Agreed Terms.

  

	 	17.1.4	For the purposes of Clauses 17.1.4 to 17.1.9, the terms “Assignor” and “Assignee” shall have the meanings given to them in the Intellectual Property Assignment Agreement. 

 

	 	17.1.5	 The Purchaser and its Affiliates shall be responsible for preparing and filing any documentation necessary for the recordal with any relevant
intellectual property office of the transfer of ownership of all of the Registered Transferred Intellectual Property Rights from the Assignor to the Assignee under the Intellectual Property

  
 91 

	 	
Assignment Agreement. The Purchaser (or such of its Affiliates as it nominates) shall be responsible for all out-of-pocket filing fees and other costs and expenses associated with those
recordals. 

  

	 	17.1.6	Subject to Clause 17.1.8 and Clauses 17.1.11 to 17.1.16, the Seller shall procure that each relevant member of the Seller’s Group shall, at the request and cost of any member of the Purchaser’s Group,
execute and deliver any further documents that may be reasonably necessary to secure the vesting in the Assignee under the Intellectual Property Assignment Agreement of all the Registered Transferred Intellectual Property Rights. 

 

	 	17.1.7	Subject to Clauses 17.1.11 to 17.1.16, the Seller shall procure that each relevant member of the Seller’s Group shall, at the request and cost of any member of the Purchaser’s Group, (i) request that
the applicable registrar for each of the Assigned Domain Names (as defined in the Intellectual Property Assignment Agreement), and any other domain name registration authorities that exercise authority over the Assigned Domain Names, facilitate the
transfer of the Assigned Domain Names from the relevant Assignor to the Assignee; and (ii) execute all such documentation and take all such further acts as are reasonably necessary to effect such transfer. Within ten (10) Business Days of a date to
be agreed by the parties, the Seller shall procure that each relevant member of the Seller’s Group shall (a) unlock the Assigned Domain Names; and (b) provide the Assignee with authorisation codes for any Assigned Domain Names that have
authorisation codes. 

  

	 	17.1.8	To the extent that any transfers of Registered Vaccines Group Intellectual Property Rights to an Assignor or a Vaccines Group Company have not been recorded prior to the Closing Date (including any transfers of
such Registered Vaccines Group Intellectual Property Rights prior to the transfer of the same to the Assignor or a Vaccines Group Company), and to the extent that such separate recordal is necessary to effect: 

 

	 	(i)	the recordal referred to in Clause 17.1.5; or 

  

	 	(ii)	the recordal of any transfer of Owned Intellectual Property Rights that constitute Registered Intellectual Property Rights to a Vaccines Group Company (or its predecessor in title), 

the Purchaser and its Affiliates shall be responsible for preparing and filing any documentation necessary for the recordal with any relevant
intellectual property office of the transfer of ownership to such Assignor or Vaccines Group Company (as applicable). Subject to Clauses 17.1.11 to 17.1.16, the Seller shall or shall procure that such Assignor shall provide to the Purchaser or a
relevant Affiliate of the Purchaser any documentation or information that is reasonably necessary to record such transfer in the name of the Assignor or Vaccines Group Company (as applicable) as soon as reasonably possible after receipt of a request
for the same from the Purchaser or one of its Affiliates for the purposes of such recordal. The Seller (or such of its Affiliates as it nominates) shall be responsible for all out-of-pocket filing fees and other costs and expenses associated with
the recordal of any such transfer to the Assignor or to the Vaccines Group Company (as applicable). 

  
 92 

 Abandoned Patent Applications 

 

	 	17.1.9	Subject to Clauses 17.1.10 to 17.1.16, in respect of any Abandoned Patents, the Seller shall, on reasonable request from the Purchaser’s Group for assistance from any member of the Seller’s Group, use
reasonable endeavours to execute a document confirming the transfer of such rights as any member of the Seller’s Group has (if any) in such Abandoned Patent, to the extent not prohibited under Applicable Law in the relevant country of any such
Abandoned Patent, to the Assignee under each Intellectual Property Assignment, provided that: 

  

	 	(i)	if the Seller provides such assistance the Purchaser shall promptly reimburse the Seller for its reasonable costs; and 

  

	 	(ii)	a request from the Purchaser’s Group for assistance will be deemed to be not reasonable if: 

  

	 	(a)	the Assignee or any other member of the Purchaser’s Group is able to prove common ownership of (i) the Abandoned Patent and (ii) the relevant Patent(s) that constitute Vaccines Patent(s) to the satisfaction of any
relevant intellectual property office, court or tribunal without such assistance from any member of the Seller’s Group (provided further that in no event shall the Purchaser’s Group be required to narrow the scope of protection of the
claims of a Patent that constitutes a Vaccine Patent in order to avoid its request being unreasonable); 

  

	 	(b)	any member of the Seller’s Group is asked to take any steps to achieve an outcome that is the same or equivalent to an outcome the Assignee or any other member of the Purchaser’s Group could achieve without
such assistance from any member of the Seller’s Group (provided that the Seller’s Group shall not be required to narrow a Patent that constitutes a Vaccine Patent in order to avoid its request being unreasonable); or 

 

	 	(c)	it requires any member of the Seller’s Group to state that an Abandoned Patent was abandoned inadvertently or unavoidably when this was not the case. 

Sanctions - Restrictions 
  

	 	17.1.10	For the purposes of Clauses 17.1.10 to 17.1.16 only, the terms below shall have the following meanings: 

“Assignor” means an assignor under the Intellectual Property Assignment Agreement or any relevant member of the Seller’s
Group’s (other than a Vaccines Group Company); 
 “Assignee” means an assignee under the Intellectual Property
Assignment Agreement or a Vaccines Group Company; and 
 “Further Assurance Obligations” means any obligation to be
performed by an Assignor under Clauses 17.1.1 to 17.1.9; 
  

	 	17.1.11	 The parties agree that to the extent that Vaccines Group Intellectual Property Rights which are the subject of a transfer pursuant to the
Intellectual Property 

  
 93 

	 	
Assignment Agreement are registered (or are the subject of an application to register) in Iran, Iraq, Democratic People’s Republic of Korea or Syria, the Assignor’s Further Assurance
Obligations shall be modified as set out in Clauses 17.1.12 to 17.1.16 below. 

  

	 	17.1.12	If an Assignor is prevented from complying with its Further Assurance Obligations, with the effect that the recordal of assignment of legal title from the Assignor to the Assignee under the Intellectual Property
Assignment Agreement (or to effect a transfer which is the subject of Clause 17.1.8) cannot be completed for any Vaccines Group Intellectual Property Rights by reason of: 

 

	 	(i)	Applicable Law; 

  

	 	(ii)	other factors beyond the reasonable control of the Assignor; or 

  

	 	(iii)	application of the Assignor’s: 

  

	 	(a)	internal sanctions and export control policy (or equivalent); or 

  

	 	(b)	anti-bribery and corruption policy, 

 in each case in force from time to time, provided that
such policy applies to all Affiliates of the Assignor and the policy is applied in the same way it would apply if the Assignee were an Affiliate of the Assignor, 

each such Vaccines Group Intellectual Property Right (being an “Affected Right” and each of (i) to (iii) being a
“Restriction” and in the plural the “Restrictions”), Clauses 17.1.13 to 17.1.16 shall apply. 
  

	 	17.1.13	The relevant Assignor shall notify the Assignee as soon as reasonably practicable after Closing of: 

  

	 	(i)	each Affected Right and the country in which it is registered (or is the subject of an application to register); and 

  

	 	(ii)	the relevant Restriction. 

  

	 	17.1.14	As soon as reasonably practicable and, in any event within three months after the date that Assignor notifies the Assignee of an Affected Right under Clause 17.1.13 above the parties shall discuss in good
faith the means by which the Assignee may be able to achieve protection in the relevant country which is equivalent or similar to the protection provided by the Affected Right. Such means may include, without limitation: 

 

	 	(i)	the Assignee filing a new trade mark application and the Assignor providing to the Assignee the consent of the Assignor to the new application to endeavour to overcome any objection raised by the relevant intellectual
property registry on relative grounds based on the Affected Right; or 

  

	 	(ii)	the Assignor filing a WIPO trade mark application in the name of the Assignor, which shall be assigned by the Assignor to the Assignee on grant of registration or earlier if possible. The reasonable costs incurred
by the Assignor in filing and prosecuting that registration to grant to be met by the Assignee; or 

  

	 	(iii)	the Assignor withdrawing or cancelling any Affected Right subject to the written consent of the Assignee. 

  
 94 

 The parties will agree such means as are possible in light of the limitations imposed by the
Restrictions and both parties will use reasonable efforts to achieve the agreed means. Neither party shall be obliged to take any action agreed pursuant to this Clause 17.1.14 to the extent that such party is prevented from doing so by a
Restriction. 
 The reasonable costs incurred by either party in fulfilling any such actions shall be met by the Assignee. 

 

	 	17.1.15	The relevant Assignor undertakes (at the cost of the Assignee), during the current registration period up to the next renewal date of the Affected Right: 

 

	 	(i)	to take any action to comply with its Further Assurance Obligations to the extent it is able to do so given the Restrictions; 

  

	 	(ii)	to comply with its Further Assurance Obligations as soon as reasonably practicable if and to the extent that such obligations are no longer prevented by the Restrictions; and 

 

	 	(iii)	not to take any other action in connection with an Affected Right without the consent of the Assignee. 

  

	 	17.1.16	The parties acknowledge that in relation to Vaccines Group Intellectual Property Rights that are Trademarks, there is nothing in this Agreement to preclude the Assignee from taking action to revoke or cancel an
Affected Right and the Assignor hereby undertakes not to defend any such action. 

  

	17.2	Whole Agreement 

  

	 	17.2.1	This Agreement and the Ancillary Agreements contain the whole agreement between the parties relating to the subject matter of this Agreement at the date hereof to the exclusion of any terms implied by law which
may be excluded by contract and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Agreement. 

  

	 	17.2.2	The Purchaser acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated into it. 

 

	 	17.2.3	Each of the parties agrees and acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection with this Agreement shall be for breach of the
terms of this Agreement and each of the parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking. 

 

	 	17.2.4	In Clauses 17.2.1 to 17.2.3, “this Agreement” includes the Ancillary Agreements and all other documents entered into pursuant to this Agreement. 

 

	 	17.2.5	Nothing in this Clause 17.2 excludes or limits any liability for fraud. 

  

	17.3	No Assignment 

 No party may without the prior written consent of the other parties,
assign, grant any security interest over, hold on trust or otherwise transfer the benefit of the whole or any part of this Agreement. 

  
 95 

	17.4	Third Party Rights 

  

	 	17.4.1	Subject to Clause 17.4.2, the parties to this Agreement do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act 1999, by any person who is not
a party to this Agreement. 

  

	 	17.4.2	Certain provisions of this Agreement confer benefits on the Affiliates of the Purchaser and the Affiliates of the Seller (each such Affiliate being, for the purposes of this Clause 17.4, a “Third
Party”) and, subject to Clause 17.4.3, are intended to be enforceable by each Third Party by virtue of the Contracts (Rights of Third Parties) Act 1999. 

  

	 	17.4.3	Notwithstanding Clause 17.4.2, this Agreement may be varied in any way and at any time without the consent of any Third Party. 

 

	17.5	Variation or waiver 

  

	 	17.5.1	No variation of this Agreement shall be effective unless in writing and signed by or on behalf of each of the parties. 

  

	 	17.5.2	No failure or delay by a party in exercising any right or remedy provided by Applicable Law or under this Agreement or any Ancillary Agreement shall impair such right or remedy or operate or be construed as a
waiver or variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any other remedy. 

 

	17.6	Method of Payment and set off 

  

	 	17.6.1	Except as set out in Clause 17.6.2, payments (including payments pursuant to an indemnity, compensation or reimbursement provision) made or expressed to be made by the Purchaser and the Seller pursuant to this
Agreement or any claim for breach of this Agreement shall, insofar as the payment or claim relates to or affects any Shares (including the underlying Vaccines Group Companies transferred (directly or indirectly) by reason of the transfer of those
Shares), assets or liabilities, transferred pursuant to this Agreement and the Local Transfer Documents, be made or received (as the case may be) by: 

  

	 	(i)	the Seller, for itself or as agent on behalf of the relevant Share Seller or the Business Seller (each in respect of the Shares and/or assets and liabilities to be transferred by it pursuant to this Agreement and the
Local Transfer Documents); and 

  

	 	(ii)	the Purchaser, for itself or as agent on behalf of the relevant members of the Purchaser’s Group (each in respect of Shares and/or the assets and liabilities to be transferred by it pursuant to this Agreement and
the Local Transfer Documents). 

  

	 	17.6.2	The repayment of the Estimated Intra-Group Non-Trade Receivables and the Estimated Intra-Group Non-Trade Payables pursuant to Clause 6.4.3 and any adjustments to such repayment pursuant to Clause 7.4 shall be
settled by payments between the Seller, on behalf of the relevant members of the Seller’s Group, and the Purchaser, on behalf of the relevant Group Companies. 

  
 96 

	 	17.6.3	Any payments pursuant to this Agreement shall be made in full, without any set-off, counterclaim, restriction or condition and without any deduction or withholding (save as may be required by law or as otherwise
agreed), except that payments due between the Seller and the Purchaser: 

  

	 	(i)	in relation to repayments of the Estimated Intra-Group Non-Trade Payables and Estimated Intra-Group Non-Trade Receivables pursuant to Clause 6.4.3; or 

 

	 	(ii)	in relation to adjustments to those repayments pursuant to Clause 7.4, 

 respectively, shall be
discharged to the fullest extent possible by way of set-off against each other. 
  

	 	17.6.4	Any payments pursuant to this Agreement shall be effected by crediting for same day value the account specified by the Seller or the Purchaser (as the case may be) on behalf of the party entitled to the payment
(reasonably in advance and in sufficient detail to enable payment by telegraphic or other electronic means to be effected) on or before the due date for payment. 

  

	 	17.6.5	Payment of a sum in accordance with this Clause 17.6 shall constitute a payment in full of the sum payable and shall be a good discharge to the payer (and those on whose behalf such payment is made) of the
payer’s obligation to make such payment and the payer (and those on whose behalf such payment is made) shall not be obliged to see to the application of the payment as between those on whose behalf the payment is received. 

 

	17.7	Costs 

  

	 	17.7.1	Subject to Clauses 17.1 and 17.8, the Seller shall bear all costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this Agreement, the Local Transfer
Documents, the Tax Indemnity and the sale of the Vaccines Group. 

  

	 	17.7.2	Subject to Clause 17.1, the Purchaser shall bear all such costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this Agreement, the Local Transfer
Documents, the Tax Indemnity and the purchase of the Vaccines Group. 

  

	17.8	Notarial Fees, Registration, Stamp and Transfer Taxes and Duties 

  

	 	17.8.1	Subject to Clauses 2.3.5, 2.3.6, 17.1 and 17.8.2, the Purchaser or the relevant member of the Purchaser’s Group: 

  

	 	(i)	shall bear the cost half of all notarial fees and all registration, stamp and transfer taxes and duties or their equivalents (which fees, taxes, duties or equivalents shall not include, for the avoidance of doubt, the
$0.75 per antigen excise tax imposed by 26 United States Code section 4131 on the sale of certain vaccines products) in all jurisdictions where such fees, taxes and duties are payable as a result of the transactions contemplated by this Agreement
the other half of such cost to be borne by the Seller; 

  

	 	(ii)	shall be responsible for arranging the payment of all such fees, taxes and duties, including fulfilling any administrative or reporting obligation imposed by the jurisdiction in question in connection with such payment;
and 

  
 97 

	 	(iii)	shall indemnify the Sellers or any other member of the Seller’s Group against any Losses suffered by that Seller or member of the Seller’s Group as a result of the Purchaser failing to comply with its
obligations under this Clause 17.8. 

  

	 	17.8.2	The Purchaser and the Seller shall make or procure the making of such payments to each other (and to each other’s Affiliates) as are necessary to ensure the sharing of cost provided for under Clause 17.8.1.

  

	17.9	Interest 

 If any party defaults in the payment when due of any sum payable under this
Agreement, the Local Transfer Documents or the Tax Indemnity the liability of that party shall be increased to include interest on such sum from the date when such payment is due until the date of actual payment (as well after as before judgment) at
a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 
  

	17.10	Grossing-up 

  

	 	17.10.1	All sums payable under this Agreement, the Local Transfer Documents and the Tax Indemnity shall be paid free and clear of all deductions, withholdings, set-offs or counterclaims whatsoever save only as may be
permitted by Clause 17.6.3 or required by law. Subject to Clauses 17.10.3 to 17.10.7 if any deductions or withholdings are required by law the party making the payment shall (except in the case of (i) any interest payable under Clause 7.5 or 17.9
(ii) or any amount payable under Schedule 17 which would not have been the subject of a deduction or withholding had it been paid to a company resident in Switzerland for the purposes of the double taxation treaty between Belgium and Switzerland
which was beneficially entitled to the payments and was not party to a conduit arrangement in respect of them) be obliged to pay to the other party such sum as will after such deduction or withholding has been made leave the other party with the
same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding, provided that if either party to this Agreement shall have assigned or novated the benefit in whole or in part of this
Agreement or shall, after the date of this Agreement, have changed its tax residence or the permanent establishment to which the rights under this Agreement are allocated then the liability of the other party under this Clause 17.10.1 shall be
limited to that (if any) which it would have been had no such assignment, novation or change taken place. 

  

	 	17.10.2	If either party is or becomes aware of any facts making it reasonably likely that the Purchaser, or any relevant member of the Purchaser’s Group, will be required to deduct or withhold any amount in respect
of the Purchase Price (excluding any amount payable under Schedule 17) (a “Relevant Tax Deduction”), then that party shall, as soon as reasonably practicable, give notice to the other party (including details of the relevant facts
and, so far as possible, details of the rate and basis of such withholding) provided that for purposes of this Clause 17.10.2, the Seller may assume that the Purchase Price will be paid by (and for) a company resident for Tax purposes only in
Belgium. 

  

	 	17.10.3	 The Seller and the Purchaser shall, and shall procure that the members of their respective groups shall (at the Seller’s cost), co-operate
with each other in good 

  
 98 

	 	
faith and use all reasonable efforts to reduce or mitigate any Relevant Tax Deduction (or its amount) and/or to enable the Seller or the relevant Share Seller or Business Seller to obtain any
available credit or refund in respect of such Relevant Tax Deduction, including, without limitation, making any available claim under an applicable double taxation treaty. 

 

	 	17.10.4	Without prejudice to the generality of Clause 17.10.3, the Seller and the Purchaser shall co-operate in good faith to establish or agree the amount or basis of calculation of any Relevant Tax Deduction prior to
Closing (and in this regard the Purchaser shall consider reasonably any relevant information or evidence provided or obtained by the Seller) including, if requested by the Seller and at the Seller’s expense, by seeking to obtain a ruling or
confirmation from a relevant Tax Authority, or obtaining an opinion from reputable local tax counsel or a firm of accountants of international standing satisfactory to the Purchaser (acting reasonably) and instructed jointly by the Seller and the
Purchaser. 

  

	 	17.10.5	The Purchaser shall, or shall procure that the relevant member of the Purchaser’s Group shall, make any Relevant Tax Deduction in the minimum amount required by Applicable Law, provided that:

  

	 	(i)	if a double taxation treaty between the jurisdiction under the laws of which the Relevant Tax Deduction is required and the jurisdiction of residence of the Seller or the relevant Share Seller or Business Seller is in
force, the Purchaser shall (and shall procure that any relevant member of the Purchaser’s Group shall) make any Relevant Tax Deduction in an amount not exceeding the rate specified in such double taxation treaty (which may be nil), provided
that the Seller has provided the Purchaser with such evidence as is required under Applicable Law to establish the entitlement of the Seller (or relevant Share Seller or Business Seller) to the benefit of the applicable treaty; and

  

	 	(ii)	if an opinion from reputable local counsel or a firm of accountants of international standing has been obtained at the request of the Seller as envisaged by Clause 17.10.4, the Purchaser shall (and shall procure that
any relevant member of the Purchaser Group shall) make such Relevant Tax Deduction in an amount or on a basis which is consistent with that opinion (which may result in no withholding or deduction), provided that the Seller has indemnified the
Purchaser and any relevant member of the Purchaser’s Group, to the Purchaser’s reasonable satisfaction, against any Liabilities arising (including any interest and penalties) should such opinion be wholly or partly incorrect.

  

	 	17.10.6	The Purchaser shall promptly provide the Seller with evidence reasonably satisfactory to the Seller that a Relevant Tax Deduction has been made and an appropriate amount paid to the relevant Tax Authority.

  

	 	17.10.7	If any Relevant Tax Deduction is required an additional sum shall be payable in accordance with Clause 17.10.1 only if and to the extent that such deduction or withholding would not have been required had the
Purchaser and each member of the Purchaser’s Group making such payment or to which such payment relates been resident for Tax purposes only in Belgium. 

  
 99 

	17.11	Notices 

  

	 	17.11.1	Any notice or other communication in connection with this Agreement (each, a “Notice”) shall be: 

  

	 	(i)	in writing in English; and 

  

	 	(ii)	delivered by hand, fax, or by courier using an internationally recognised courier company. 

  

	 	17.11.2	A Notice to the Seller shall be sent to such party at the following address, or such other person or address as the Seller may notify to the Purchaser from time to time: 

Novartis AG 
 Postfach 

CH-4002 Basel 
 Switzerland 

Fax: +41 613244300 
 Attention:
Head of M&A Legal, Novartis International AG 
 with a copy to the Seller’s Lawyers, marked for the urgent attention of James
Inglis (delivery of such copy shall not in itself constitute valid notice). 
  

	 	17.11.3	A Notice to the Purchaser shall be sent to such party at the following address, or such other person or address as the Purchaser may notify to the Seller from time to time: 

GlaxoSmithKline plc 
 980 Great
West Road 
 Brentford 

Middlesex TW8 9GS 
 United
Kingdom 
 Fax: +44 (0)208 0476904 

Attention: The Company Secretary 

with a copy to the Purchaser’s Lawyers, marked for the urgent attention of Simon Nicholls (delivery of such copy shall not in itself
constitute valid notice). 
  

	 	17.11.4	A Notice shall be effective upon receipt and shall be deemed to have been received: 

  

	 	(i)	at the time of delivery, if delivered by hand or courier; 

  

	 	(ii)	at the time of transmission in legible form, if delivered by fax. 

  

	17.12	Invalidity or Conflict 

  

	 	17.12.1	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision
is legal, valid and enforceable and gives effect to the commercial intention of the parties. 

  
 100 

	 	17.12.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 17.12.1, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable,
be deemed not to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject to any deletion or modification made under Clause 17.12.1, not be affected. 

 

	 	17.12.3	If there is any conflict between the terms of this Agreement and any of the Ancillary Agreements this Agreement shall prevail (as between the parties between this Agreement and as between any member of the Seller
Group and any member of the Purchaser Group) unless (i) such Ancillary Agreement expressly states that it overrides this Agreement in the relevant respect and (ii) the Seller and the Purchaser are either also parties to that Ancillary Agreement or
otherwise expressly agree in writing that such Ancillary Agreement shall override this Agreement in that respect. 

  

	 	17.12.4	For the avoidance of doubt, nothing in this Agreement is intended to limit the Liabilities of any party under any Ancillary Agreement (other than, to the extent expressly stated, the Tax Indemnity).

  

	17.13	Counterparts 

 This Agreement may be entered into in any number of counterparts, all of
which taken together shall constitute one and the same instrument. Any party may enter into this Agreement by executing any such counterpart. Delivery of a counterpart of this Agreement by email attachment shall be an effective mode of delivery.

  

	17.14	Governing Law and Submission to Jurisdiction 

  

	 	17.14.1	This Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and any non-contractual obligations arising out of or in connection with the Agreement and such documents
shall be governed by and construed in accordance with English law. 

  

	 	17.14.2	Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement and the documents
to be entered into pursuant to it, save as expressly referred to therein, and that accordingly any proceedings arising out of or in connection with this Agreement and the documents to be entered into pursuant to it shall be brought in such courts.
Each of the parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been brought in an inconvenient forum.

  

	17.15	Appointment of Process Agent 

  

	 	17.15.1	The Seller hereby irrevocably appoints Hackwood Secretaries Limited of One Silk Street, London EC2Y 8HQ as its agent to accept service of process in England and Wales in any legal action or proceedings arising
out of this Agreement, service upon whom shall be deemed completed whether or not forwarded to or received by the Seller. 

  

	 	17.15.2	The Seller agrees to inform the Purchaser in writing of any change of address of such process agent within 28 days of such change. 

  
 101 

	 	17.15.3	If such process agent ceases to be able to act as such or to have an address in England and Wales, the Seller irrevocably agrees to appoint a new process agent in England and Wales and to deliver to the Purchaser
within 14 days a copy of a written acceptance of appointment by the process agent. 

  

	 	17.15.4	Nothing in this Agreement shall affect the right to serve process in any other manner permitted by law. 

This Agreement has been entered into on the date stated at the beginning. 

  
 102 

					
	  
 SIGNED by
	 	 }
	  	
	  
 AND
	 	  	
	  
 for and on behalf of

NOVARTIS AG:
	 	 }
	  	
	  
 SIGNED by

 
 for and on behalf of

GLAXOSMITHKLINE PLC:
	 	 }
	  	

  
 103 

 Schedule 1 

Details of the Share Sellers, Shares etc. 

(Clause 2.1) 
  

					
	(1)	  	(2)	  	(3)
	 Name

of Share Seller
	  	 Name of

Company/Minority Interest

Entity
	  	Shares
			
	Novartis Deutschland GmbH	  	Novartis Vaccines and Diagnostics GmbH	  	2 shares (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics S.A.S	  	93,750 shares (100%)
			
	Novartis Farmaceutica S.A	  	Novartis Vaccines and Diagnostics S.L	  	150,100 shares (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics AG	  	1,600 shares (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics S.r.l.	  	1 quota of entire share capital (as defined under Italian law) (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics Pty Ltd	  	1,024,921 shares (100%)
			
	 (A) Novartis Pharma AG
 (B) Novartis Vaccines
and Diagnostics Inc.
	  	Chiron Behring Vaccines Private Limited	  	 (A) 4,900,000 shares (49%)
 (B) 5,100,000 shares
(51%)
 TOTAL: 10,000,000 shares

			
	Novartis Overseas Investments AG	  	Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd	  	85%
			
	Novartis Pharma AG	  	Novartis Vaccines Institute for Global Health S.r.l.	  	1 quota of entire share capital (as defined under Italian law) (100%)
			
	(A) Novartis Pharma AG	  	Valneva SE	  	(A) 3,788,048 (6.63%)
			
	(B) Novartis Vaccines and Diagnostics Inc.	  		  	(B) 1,560,000 (2.73%)

  
 104 

 Schedule 2 

Companies, Subsidiaries and Minority Interest Entities 
  

	1	Particulars of the Companies 

  

					
	Name of Company:	  	Novartis Vaccines and Diagnostics GmbH
		
	Registered Number:	  	HRB 5629
		
	Registered Office:	  	Emil-von-Behring-Str. 76, 35041 Marburg, Germany
		
	Date and place of incorporation:	  	
		
	Issued share capital:	  	EUR 5,000,000.00 divided into 2 shares of 1 EUR and EUR 4,999,999 each
			
	Shareholders and shares held:	  	Novartis Deutschland GmbH	  	2 (100%)
		
	Name of Company:	  	Novartis Vaccines and Diagnostics SAS
		
	Registered Number:	  	423 697 168
		
	Registered Office:	  	10, rue Chevreul, 92150 Suresnes, France
		
	Date and place of incorporation:	  	22 July 1999, Nanterre
		
	Issued share capital:	  	EUR 1,500,000 divided into 93,750 shares of EUR 16 each
			
	Shareholders and shares held:	  	Novartis Pharma AG	  	93,750
 (100%)

		
	Name of Company:	  	Novartis Vaccines and Diagnostics S.L.
		
	 Registered Number:
	  	B58564808
		
	 Registered Office:
	  	Gran Vía de les Corts Catalanes, 764. 08013 Barcelona, Spain
		
	 Date and place of incorporation:
	  	19 September 1988, Barcelona
		
	 Issued share capital:
	  	EUR 675,450 divided into 150,100 shares of EUR 4.50 each
			
	 Shareholders and shares held:
	  	Novartis Farmaceutica S.A	  	150,100
 (100%)

  
 105 

					
	 Name of Company:
	  	Novartis Vaccines and Diagnostics AG
		
	Registered Number:	  	CHE-103.264.079
		
	Registered Office:	  	Basel, Switzerland
		
	Date and place of incorporation:	  	28 September 1953, Avenches
		
	Issued share capital:	  	CHF 800,000.00 divided into 1,600 shares of CHF 500 each
			
	Shareholders and shares held:	  	Novartis Pharma AG	  	1,600 shares
 (100%)

		
	 Name of Company:
	  	Novartis Vaccines and Diagnostics S.r.l.
		
	Registered Number:	  	01392770465
		
	Registered Office:	  	Via Fiorentina 1, 53100, Siena, Italy
		
	Date and place of incorporation:	  	18 September 1990, Barga (LU)
		
	Issued share capital:	  	EUR 41,610,809.00 comprising 1 quota of entire share capital
			
	Shareholders and shares held:	  	Novartis Pharma AG	  	1 (100%)
		
	 Name of Company:
	  	Novartis Vaccines and Diagnostics Pty Limited
		
	ABN / ACN:	  	ABN 60 089 509 544; ACN 089 509 544
		
	Registered Office:	  	54 Waterloo Road, North Ryde NSW 2113, Australia
		
	Date and place of incorporation:	  	10 September 1999, Victoria
		
	Issued share capital:	  	ASD 1,024,921 divided into 1,024,921 shares of ASD 1 each
			
	Shareholders and shares held:	  	Novartis Pharma AG	  	1,024,921
 (100%)

		
	 Name of Company:
	  	Chiron Behring Vaccines Private Limited
		
	Registered Number:	  	U24230MH1997PTC111122
		
	Registered Office:	  	501 Shree Amba Shanti Chambers, Kurla Road, Andheri, Mumbai 400059, India
		
	Date and place of incorporation:	  	7 October 1997, Mumbai

  
 106 

					
	 Name of Company:
	  	Chiron Behring Vaccines Private Limited
		
	Issued share capital:	  	INR 100,000,000 divided into 10,000,000 shares of INR 10 each
			
	Shareholders and shares held:	  	Novartis Pharma AG	  	4,900,000
 (49%)

	  	  
 Novartis Vaccines and Diagnostics Inc.
	  	  
 5,100,000

(51%)

		
	Name of Company:	  	 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
 

		
	Registered Number:	  	330000000015616
		
	Registered/Principal Office:	  	No.56 Tian He Road, Yuhang Economic Development Zone, Hangzhou, Zhejiang Province, PRC.
		
	Date and place of incorporation:	  	
		
	Registered capital:	  	RMB 46,800,000
		
	Paid-in capital:	  	RMB 46,800,000
		
	 Total investment amount:
	  	 RMB 117,000,000

			
	 Shareholder and shares held:
	  	 Novartis Overseas Investments AG
	  	85%
		
	Name of Company:	  	Novartis Vaccines Institute for Global Health S.r.l.
		
	Registered Number:	  	01204770521
		
	Registered/Principal Office:	  	Via Fiorentina 1, 53100, Siena, Italy
		
	Date and place of incorporation:	  	2 February 2007, Siena, Italy
		
	Issued share capital:	  	EUR 500,000.00 comprising 1 quota of entire share capital
			
	Shareholder and shares held:	  	Novartis Pharma AG	  	1 (100%)

  

	2	Particulars of the Subsidiaries 

  

			
	Name of Subsidiary:	  	Novartis Vaccines Vertriebs GmbH
		
	Registered Number:	  	HRB 193621

  
 107 

					
	Name of Subsidiary:	  	Novartis Vaccines Vertriebs GmbH
		
	Registered Office:	  	Rudolf-Diesel-Ring 27, 83607 Holzkirchen, Germany
		
	Date and place of incorporation:	  	
		
	Issued share capital:	  	EUR 26,000.00 divided into 2 shares of EUR 25,600 and EUR 400 each
			
	Shareholders and shares held:	  	Novartis Vaccines and Diagnostics GmbH	  	2 (100%)

  

	3	Particulars of the Minority Interest Entities 

  

					
	Name of Company:	  	Valneva SE
		
	Registered Number:	  	422 497 560 RCS Lyon
		
	Registered Office:	  	70 Rue Saint Jean de Dieu, 69007 Lyon, France
		
	Date and place of incorporation:	  	Initially incorporated on 26 January 2011, Commercial Court (greffe du Tribunal de Commerce) of Roussay, France
		  	Incorporated with the Commercial Court (greffe du Tribunal de Commerce) of Lyon, France since change of registered office on 28 May 2013.
		
	Issued share capital:	  	€8,390,317.14, divided into 54,746,333 ordinary shares of €0.15 each and 17,836,719 preferred shares with a nominal value of €0.01 each
			
	Shareholders and shares held:	  	Novartis Vaccines & Diagostics Inc.	  	1,560,000
	  	Novartis Pharma AG	  	3,788,048
		
	Name of Company:	  	Chiron Panacea Vaccines Private Limited
		
	Registered Number:	  	U24230MH2004PTC147790
		
	Registered Office:	  	 7th Floor, A Wing, Sagar Tech Plaza

Sakinaka, Mumbai 400072, Maharashtra, India

		
	Date and place of incorporation:	  	13 July 2004, Mumbai, India

  
 108 

					
	Name of Company:	  	Chiron Panacea Vaccines Private Limited
		
	Issued share capital:	  	INR 45,918,200 (4,591,820 shares of INR 10 each)
			
	Shareholders and shares held:	  	Novartis Vaccines & Diagnostic S.r.l.	  	2,295,910
 (50%)

  
 109 

 Schedule 3 

The Properties 
 Part 1

 (Company Real Property) 
 [***]

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 110 

 Schedule 3 

The Properties 
 Part 2

 (Transferred Real Property) 

[***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 111 

 Part B 

Transferred Leased Real Property 
  

					
	1	  	BUSINESS SELLER:	  	Shanghai Novartis Trading Ltd.
			
	1.1	  	Property Description:	  	Units 01-02 (inclusive), 6th Floor, China World Office 1, Beijing, PRC
			
		  	Date and parties to Lease:	  	Lease starting from 1 January 2014
			
		  		  	 (1)             China World Trade
Centre Co., Ltd
  

(2)             Shanghai Novartis Trading
Ltd

			
	1.2	  	Property Description:	  	Unit. 1, Floor 22, No, 139, Central Ke Hua Road, Wu Hou District, Si Chuan Province, PRC
			
		  	Date and parties to Lease:	  	Effective from 16 April 2013
			
		  		  	 (1)             Fu Qiang

 

(2)             Shanghai Novartis Trading
Ltd.

			
	1.3	  	Property Description:	  	Unit 2203, South Securities Plaza, East Ti Yu Road, Tian He District, Guang Zhou, Guang Dong Province, PRC
			
		  	Date and parties to Lease:	  	Effective from 9 May 2013
			
		  		  	 (1)             Shi Hua

 

(2)             Shanghai Novartis Trading
Ltd.

			
	1.4	  	Property Description:	  	Unit 18 F, Bai Ma Plaza, Mi Du Qiao Road, Gong Shu District, Hangzhou, Zhe Jiang Province, PRC
			
		  	Date and parties to Lease:	  	Lease starting from 1 May 2014
			
		  		  	 (1)             Ni Yu Dan and Zhou
Ai Xian
  

(2)             Shanghai Novartis Trading
Ltd.

			
	1.5	  	Property Description:	  	C1310, Wan Da Plaza, Jing Si Road, Jinan, Shan Dong Province, PRC
			
		  	Date and parties to Lease:	  	Effective from 23 April 2013
			
		  		  	 (1)             Liu Wenbo

 

(2)             Shanghai Novartis Trading
Ltd.

  
 112 

					
	1.6	  	Property Description:	  	Units 01-02 (inclusive), 26th Floor, International Plaza, No. 1788 West Nan Jing Road, Shanghai, PRC
			
		  	Date and parties to Lease:	  	Effective from 17 October 2013
			
		  		  	 (1)             Shanghai Century
Jing An Real Estate Development Co., Ltd
  

(2)             Shanghai Novartis Trading
Ltd.

			
	2	  	BUSINESS SELLER:	  	Novartis Vaccines and Diagnostics, Inc.
			
	2.1	  	Property Description:	  	Approximately 109,835 rentable feet in the buildings located at 45 Sidney Street and 75 Sidney Street, Cambridge, Massachusetts (plus 137 parking passes), US
			
		  	Date and parties to Lease:	  	27 August 2007
			
		  		  	 (1)             FC 45/75 Sidney,
Inc.
  

(2)             Novartis Vaccines and Diagnostics,
Inc.

			
	2.2	  	Property Description:	  	24,833 rentable square feet, representing the entire second floor, and approximately 7,257 rentable square feet on the third floor of the building located at 350 Massachusetts Avenue, Cambridge Massachusetts (plus 48 parking
passes for the 55 Franklin Street Garage), US
			
		  	Date and parties to Lease:	  	19 March 2007
			
		  		  	 (1)             University Park
Phase II Limited Partnership
  

(2)             Novartis Vaccines and Diagnostics,
Inc.

			
	2.3	  	Property Description:	  	Residential Apartment at 100 Landsdowne Street, Apartment 1608, Cambridge, MA 02139
			
		  	Date and parties to Lease:	  	12 October 2013
			
		  		  	 (1)             Forest City
Residential Management, Inc.
  

(2)             Novartis Vaccines and Diagnostics,
Inc.

			
	2.4	  	Property Description:	  	 40,884 rentable square feet in building located at 7030 Kit Creek Road, Research Triangle Park, North Carolina, US

 
 Real Estate ID Number: 0206337, Wake County Tax Office

  
 113 

					
		  	Date and parties to Lease:	  	1 August 2013
			
		  		  	 (1)             ARE-7030 Kit Creek,
LLC
  

(2)             Novartis Vaccines and Diagnostics,
Inc.

			
	3	  	 BUSINESS SELLER:
	  	 Novartis Pharma B.V.

			
	3.1	  	Property Description:	  	Real property located on Hullenbergweg 81-135 (1011 CL), in Amsterdam, the Netherlands consisting of the ground floor (499 square meters), first floor (651 sq m), second floor (710 sq m), third floor (812 sq m) and fourth floor (147
sq) in building A and 43 parking spaces.
			
		  	Date and parties to Lease:	  	23 September 2004
			
		  		  	 (1)             Dutch Property
Company Rembrandt 6 B.V. as successor of IFH

                   
geschlossener Immobilienfonds für Holland GmbH & Co KG as original

                   
landlord in 2007.
  

(2)             Versatel Nederland B.V. as original
tenant.
  

(3)             Novartis Pharma B.V. as successor of
Chiron B.V. as original subtenant.

			
	4	  	 BUSINESS SELLER:
	  	 Novartis Healthcare Private Limited

Novartis Vaccines & Diagnostics BU

			
	4.1	  	 Property Description:
	  	Fourth Floor, Shree Amba Shanti Chambers, Andheri - Kurla Road, Opp. Hotel Leela, andheri (East), Mumbai – - 400 059, India
			
		  	Date and parties to Agreement:	  	26 September 2012 as renewed from time to time
			
		  		  	 (1)             Dhaval Atul
Barot.
  

(2)             Novartis Healthcare Private
Limited.
  

(3)             Novartis Vaccines & Diagnostics
BU.

			
	4.2	  	 Property Description:
	  	Fifth Floor, Shree Amba Shanti Chambers, Andheri - Kurla Road, Opp. Hotel Leela, andheri (East), Mumbai - 400 059, India
			
		  	Date and parties to Agreement:	  	16 May 2012
			
		  		  	 (1)             Rekha Atul
Barot
  

(2)             Novartis Healthcare Private
Limited
  

(3)             Novartis Vaccines & Diagnostics
BU

  
 114 

					
	5	  	 BUSINESS SELLER:
	  	 Novartis Healthcare Philippines, Inc.

			
	5.1	  	Property Description:	  	Fifth Floor of the Republic Glass Building, 196 Salcedo St., Legaspi Village, Makati City, consisting of an aggregate area of 618 sqm.
			
		  	Date and parties to Lease:	  	Initial lease dated 10 January 2012 as renewed on 18 December 2014
			
		  		  	 (1)             Metropolitan
Management Corporation
  

(2)             Novartis Healthcare Philippines,
Inc.

			
	5.2	  	Property Description:	  	Two parking spaces at the Republic Glass Building Republic Glass Building, 196 Salcedo St., Legaspi Village, Makati City,
			
		  	Date and parties to Lease:	  	Initial lease dated 12 November 2013 and further renewed on 18 December 2014
			
		  		  	 (1)             Metropolitan
Management Corporation
  

(2)             Novartis Healthcare Philippines,
Inc.

			
	6	  	 BUSINESS SELLER:
	  	 Novartis Poland sp. z o.o.

			
	6.1	  	Property Description:	  	ul. Rzymowskiego 34, PL-02-697, Warsaw, Poland
			
		  	Date and parties to Lease:	  	29 October 2013
			
		  		  	 (1)             BTA Office Building
Sp. z o.o.
  

(2)             Novartis Poland sp. z
o.o.

			
	7	  	 BUSINESS SELLER:
	  	 Novartis s.r.o.

			
	7.1	  	Property Description:	  	A building located at Domažlická 1161/5, 130 00 Prague 3, Czech Republic, located on plot of land No. 1995, in the real estate registration area of Žižkov.
			
		  	Date and parties to Lease:	  	7 May 2009
			
		  		  	 (1)             Rocco a.s.

 

(2)             Novartis s.r.o.

  
 115 

 Schedule 3 

The Properties 
 Part 3

 Terms relating to the Company Real Property 
  

	1	General Provisions relating to the Company Real Property 

  

	1.1	Interpretation 

 The following further definitions apply in this Part 3 of Schedule 3:

 “Company Landlord” means the person for the time being entitled to the reversion immediately expectant on the termination
of the term granted by a Company Lease; 
 “Company Leased Real Properties” means the leasehold properties identified in
Part B of Part 1 of this Schedule 3, and “Company Leased Real Property” means any one of them; 
 “Company
Leases” means the leases, licence documents or tenancy agreements under which the Company Leased Real Properties are held, including all documents supplemental to them, and “Company Lease” means any one of them; 

“Company Owned Real Properties” means the owned properties as identified in Part A of Part 1 of this Schedule 3 together with
all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Clause 2.3.2), and “Company Owned Real Property” means any one of them; 

“Company Real Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a
Company Third Party Consent has been lawfully refused or cannot be obtained and/or that the Purchaser may not acquire (directly or indirectly, acting through a subsidiary) the relevant Company Real Property; 

“Company Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from any
Company Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory, governmental, state, provincial or municipal
bodies or authorities which are required under a Company Lease or otherwise in relation to any change of control, shareholders or directors of the Vaccines Group Companies, and “Company Third Party Consent” means any one of them;

 “German Carve-out Leases” means the leases of the Company Leased Real Properties referred to at paragraphs 3.2 and 3.3 of
Part B of Part 1 of Schedule 3 and any other lease(s) of the Company Leased Real Properties at the Marburg Site where the premises demised by such lease(s) are occupied by both the Business and the German Influenza Operations; 

“German Influenza Lease(s)” has the meaning set out in paragraph 2.1 of this Part 3 of Schedule 3; and 

“German Vaccines Lease(s)” has the meaning set out in paragraph 2.1 of this Part 3 of Schedule 3. 

  
 116 

	1.2	Company Third Party Consents 

 1.2.1 This paragraph 1.2.1 of Part 3 of Schedule 3
applies to those Company Real Properties in relation to which a Company Third Party Consent is required and if such Company Third Party Consent remains to be obtained as at the Closing Date this paragraph 1.2.1 of Part 3 of Schedule 3 shall continue
to apply until the relevant Company Third Party Consent shall have been obtained or until the Company Real Property Longstop Date. If any Company Third Party Consents are required: 

 

	 	(i)	the Seller shall make an application for, and shall use all reasonable endeavours to obtain each Company Third Party Consent as soon as reasonably practicable following the date of this Agreement and shall at all times
keep the Purchaser informed of progress in obtaining such Company Third Party Consents; 

  

	 	(ii)	the Purchaser shall supply such information and references as may reasonably be required by a Company Landlord, any superior landlord or other relevant third party in connection with a Company Third Party Consent;

  

	 	(iii)	the Purchaser shall be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Company Landlord, any superior landlord or other relevant person
(including any Tax or disbursements in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Company Landlord, any superior landlord or any other relevant person) properly incurred in connection with any
application for Company Third Party Consents, whether or not such Company Third Party Consents are given; and 

  

	 	(iv)	in respect of the period after Closing only, the Purchaser shall enter into such covenants for the payment of the rent under the Company Lease and for the observance and performance of the covenants and conditions
contained in the Company Lease as may reasonably be required by the Company Landlord, any superior landlord or other relevant third party. 

  

	1.2.2	Each party shall give written notice to the other party as soon as reasonably practicable after obtaining any Company Third Party Consents which shall be accompanied by a copy of such consent. 

 

	1.2.3	Save as set out in paragraph 1.2.1(iii) of this Part 3 of Schedule 3, the Seller shall pay any moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required
by a Company Landlord, superior landlord or other relevant third party in connection with the obtaining of the Company Third Party Consents, provided that the Purchaser shall indemnify and keep indemnified the Seller in an amount equal to:

  

	 	(i)	any moneys required to be paid by the Seller pursuant to this paragraph; and 

  

	 	(ii)	 any Liabilities under any guarantees or other security given or procured by the Seller pursuant to this paragraph and arising out of, or in connection
with, an act or omission on the part of the Purchaser or (following Closing) the relevant Vaccines Group Company, 

  
 117 

	 	and where the Company Landlord, superior landlord or other relevant third party lawfully requires any guarantees or other security to be given by the person who is acquiring a membership interest in respect of the
relevant Vaccines Group Company, the Purchaser shall provide or procure the giving of any such guarantees or security. 

Company Third Party Consent not obtained 
  

	 	1.2.4	If a Company Third Party Consent has been refused or otherwise not obtained within twelve months following the Closing Date, the Seller and the Purchaser may (acting reasonably) agree that an application is to be
made to a court of competent jurisdiction that the relevant Company Third Party Consent has been unreasonably withheld or delayed. 

  

	 	1.2.5	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.2.4 of this Part 3 of Schedule 3: 

 

	 	(i)	the proceedings shall be brought by, and prosecuted at the expense of, the Purchaser; 

  

	 	(ii)	the Seller shall provide all such assistance in connection with such proceedings as the Purchaser (acting reasonably) may require in the interests of obtaining the Company Third Party Consent; and 

 

	 	(iii)	provided that the Seller has complied with its obligation under paragraph 1.2.1(i) of this Part 3 of Schedule 3, the Purchaser shall indemnify and keep indemnified the Seller for any costs and expenses properly incurred
in connection with any such assistance provided by the Seller. 

  

	 	1.2.6	If a Company Third Party Consent has not been obtained by the Company Real Property Longstop Date then the Seller and the Purchaser shall each bear fifty per cent. of any Losses of the Seller and the Purchaser
arising out of or in connection with the failure to obtain such Company Third Party Consent. 

  

	2	Specific provisions relating to the Marburg Site 

  

	2.1	The Seller agrees to procure that Novartis Vaccines and Diagnostics GmbH shall use reasonable efforts to procure the contemporaneous surrender of the German Carve-out Leases and the grant of replacement leases,
certain of which shall relate to those parts of the premises demised by the German Carve-out Leases which are used by the Business (the “German Vaccines Lease(s)”), and certain other of which shall relate to the balance of the
premises demised by the German Carve-out Leases (the “German Influenza Lease(s)”). 

  

	2.2	If Novartis Vaccines and Diagnostics GmbH is able to procure the surrender of the German Carve-out Leases and the grant of the German Vaccines Lease(s) and the German Influenza Lease(s) prior to Closing, it is
acknowledged that: 

  

	 	2.2.1	the German Influenza Lease(s) shall be entered into by, or assigned prior to Closing to, an entity in the Seller’s Group Retained Business; 

 

	 	2.2.2	the German Influenza Lease(s) shall not constitute lease(s) of Company Leased Real Property; and 

  

	 	2.2.3	 the demise of the relevant Company Leased Real Property set out in Part B of Part 1 of this Schedule 3 shall be deemed amended to exclude the
premises demised 

  
 118 

	 	
by the German Carve-out Leases and the German Influenza Lease(s) and to include reference to the premises demised by the German Vaccines Lease(s). 

 

	2.3	If Novartis Vaccines and Diagnostics GmbH is not able to procure the surrender of the German Carve-out Leases and the grant of the German Vaccines Lease(s) and the German Influenza Lease(s) prior to Closing, the
Seller and the Purchaser shall use reasonable efforts to give practical effect to the above-described separation following Closing, and shall consider (without limitation): 

 

	 	2.3.1	continued negotiations with the relevant Company Landlords to achieve a separation of each German Carve-out Lease into a German Vaccines Lease and a German Influenza Lease, the latter of which shall be entered
into by, or immediately assigned to, an entity in the Seller’s Group Retained Business; or 

  

	 	2.3.2	if a separation pursuant to paragraph 2.3.1 of this Part 3 of Schedule 3 is not achievable, a sub-lease of those parts of the premises demised by the German Carve-out Leases which are used by the German Influenza
Operations to an entity in the Seller’s Group Retained Business. 

  

	2.4	The Seller agrees to procure that Novartis Vaccines and Diagnostics GmbH shall not agree to any terms of any German Vaccines Lease(s) which are not substantially similar to the equivalent terms of the relevant
underlying German Carve-out Lease without the consent of the Purchaser (not to be unreasonably withheld or delayed), and shall not agree to any terms of any German Influenza Lease(s) which are not substantially similar to the equivalent terms of the
relevant underlying German Carve-out Lease without the consent of the Seller (not to be unreasonably withheld or delayed). 

  

	2.5	In connection with the implementation of the arrangements set out in this paragraph 2 of Part 3 of Schedule 3, the parties agree to work together prior to Closing (or, where paragraph 2.3 of this Part 3 of
Schedule 3 applies, after Closing) to agree the provision of any site engineering services reasonably required by the other in order to operate those premises demised by the German Vaccines Lease(s) or the German Influenza Lease(s), as applicable,
in substantially the same manner as operated immediately prior to Closing. Such services may include, but are not limited to, supply of water, gas and electricity, the operation of clean utility systems (water for injection, clean steam, clean
gases, etc.), facility services contract management and administration, preventive and corrective maintenance, and shutdown coordination. 

  
 119 

 Schedule 3 

The Properties 
 Part 4

 Terms relating to the Transferred Real Property 
  

	1	General Provisions Relating to the Transferred Real Property 

  

	1.1	Interpretation 

 The following further definitions apply in this Part 4 of Schedule 3:

 “Landlord” means the person for the time being entitled to the reversion immediately expectant on the termination of the
term granted by a Lease; 
 “Leases” means the leases, licences or tenancy agreements under which the Transferred Leased
Real Properties are held by the relevant member of the Seller’s Group, including all documents supplemental to them, and “Lease” means any one of them; 

“Letting Document” means any lease, licence or tenancy agreement to which a Transferred Real Property is subject; 

“Licence” means a right in favour of the Purchaser and all persons authorised by it to occupy the Licensed Premises during the
Licence Period pursuant to this Part 4 of Schedule 3; 
 “Licence Fee” means the payments to be made by the Purchaser to the
Seller’s Group pursuant to paragraph 1.4.4 of this Part 4 of Schedule 3; 
 “Licence Period” means a period, which may
be different for each of the Licensed Premises, commencing on the Closing Date and ending on the earliest of the following dates: 
  

	 	(i)	the date on which this Agreement is terminated by whatever means whether in whole or in relation to the relevant Licensed Premises; 

  

	 	(ii)	the date immediately preceding the date on which the term of the relevant Lease ends by whatever means; 

  

	 	(iii)	the date of Property Transfer Completion in relation to the relevant Transferred Real Property; and 

  

	 	(iv)	the Property Longstop Date; 

 “Licensed Premises” means any of the Transferred
Real Properties for which all relevant Property Third Party Consents have not been obtained prior to, or at, the Closing Date; 

“Property Agreed Terms” means a transfer in the terms agreed between the relevant Business Seller, the Purchaser and any
relevant third party or determined pursuant to paragraph 1.3.2 of this Part 4 of Schedule 3 and signed for identification by or on behalf of the Business Sellers and by or on behalf of the Purchaser from time to time before or after the date of this
Agreement, with such alterations as may be agreed from time to time in writing between the relevant Business Seller, the Purchaser and any relevant third party; 

“Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a Property Third
Party Consent has been lawfully refused; 

  
 120 

 “Property Third Party Consents” means all consents, licences, approvals,
permits, authorisations or waivers required from any Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory,
governmental, state, provincial or municipal bodies or authorities for or in connection with the transfer of a Transferred Real Property by the Business Sellers to the Purchaser and includes (where the context so admits) Sublease Consents; 

“Property Transfer Completion” means the completion of the transfer of a Transferred Real Property under this Agreement, where
such completion does not take place on the Closing Date because any relevant Property Third Party Consents have not been obtained on or prior to such date; 

“Property Transfer Completion Date” means the date of Property Transfer Completion in accordance with paragraph 1.7 of this
Part 4 of Schedule 3; 
 “Registered Title” means the registered title relating to a Transferred Real Property; 

“Sublease Consent” has the meaning given to it in paragraph 1.11.2 of this Part 4 of Schedule 3; 

“transfer”, for the purposes of this Part 4 of Schedule 3 only, means in respect of a Transferred Leased Real Property, the
transfer or assignment of the relevant Lease or Leases, and in the case of a Transferred Owned Real Property the transfer thereof, and “a transfer” means and includes any instruments, deeds or agreements effecting such
transfer; 
 “Transferred Leased Real Properties” means the leasehold properties held by a Business Seller and identified in
Part B of Part 2 of this Schedule 3 and “Transferred Leased Real Property” means any one of them; and 

“Transferred Owned Real Properties” means the owned properties identified in Part A of Part 2 of this Schedule 3 together with
all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Clause 2.3.2), and “Transferred Owned Real Property” means any one of them. 

 

	1.2	Each of the Transferred Real Properties and/or the Leases thereof shall be transferred subject to the terms set out in this Part 4 of Schedule 3 and all other applicable terms of this Agreement.

  

	1.3	Pre-Closing 

  

	 	1.3.1	Prior to Closing, the Business Sellers and the Purchaser shall agree (acting reasonably) the form of all documents on Property Agreed Terms necessary for the transfer of each of the Transferred Real Properties
pursuant to the terms set out in this Part 4 of Schedule 3 and all other applicable terms of this Agreement. 

  

	 	1.3.2	Any dispute arising out of or connected with paragraph 1.3.1 of this Part 4 of Schedule 3 which is not resolved by agreement between the parties within nine months of such dispute arising shall be referred for
and resolved by expert determination as follows: 

  

	 	(i)	either the relevant Business Seller or the Purchaser may initiate an expert reference under this provision by proposing to the other party the appointment of an expert (the “Expert”); 

  
 121 

	 	(ii)	the Expert shall either be the nearest equivalent to a chartered surveyor in the relevant jurisdiction or (in relation to legal issues) a single QC (or equivalent), in each case with no less than 15 years’
post-qualification experience in commercial real estate in the relevant jurisdiction chosen by agreement between the relevant Business Seller and the Purchaser or, failing agreement within 14 days of the initiation of the reference, by the President
for the time being of the relevant professional body to which the Expert belongs (the “President”) on the application of either the relevant Business Seller or the Purchaser; 

 

	 	(iii)	the relevant Business Seller and the Purchaser shall request that the Expert determines the referred dispute within 10 days of receiving the reference; 

 

	 	(iv)	if the Expert has been appointed but is unable or unwilling to complete the reference, another Expert shall be appointed by agreement between the relevant Business Seller and the Purchaser or, failing agreement within 7
days of the parties being notified that the Expert is unable or unwilling to complete the reference, by the President on the application of either party; 

  

	 	(v)	the Expert shall act as an expert and not as an arbitrator; 

  

	 	(vi)	the relevant Business Seller and the Purchaser shall have the right to make representations and submissions to the Expert, but there will be no formal hearing; 

 

	 	(vii)	the relevant Business Seller and the Purchaser shall make all relevant documents and information within their control available to the Expert; 

 

	 	(viii)	the costs of the Expert shall be borne equally by the relevant Business Seller and the Purchaser; and 

  

	 	(ix)	the decision of the Expert shall, in the absence of fraud or manifest error, be final and binding on the parties. 

  

	 	1.3.3	This paragraph 1.3.3 of Part 4 of Schedule 3 applies to those Transferred Real Properties in relation to which a Property Third Party Consent is required and if such Property Third Party Consent remains to be
obtained as at the Closing Date this paragraph 1.3.3 of Part 4 of Schedule 3 shall continue to apply until the relevant Property Third Party Consent shall have been obtained or until the Property Longstop Date. If any Property Third Party Consents
are required: 

  

	 	(i)	the Seller or relevant Business Seller shall make an application for, and shall use all reasonable endeavours to obtain each Property Third Party Consent as soon as reasonably practicable following the date of this
Agreement for the transfer of the Transferred Real Property and shall, at all times, keep the Purchaser informed of progress in obtaining such Property Third Party Consents; 

 

	 	(ii)	the Purchaser shall: 

  

	 	(a)	supply such information and references as may reasonably be required by a Landlord, any superior landlord or other relevant third party in connection with a Property Third Party Consent; 

  
 122 

	 	(b)	in respect of the period after Closing only, enter into such covenants for the payment of the rent in respect of the Transferred Leased Real Properties and for the observance and performance of the covenants and
conditions on the part of the lessee contained in any Lease as may reasonably be required by the Landlord, any superior landlord or other relevant third party; 

  

	 	(c)	if reasonably required by the Landlord, any superior landlord or other relevant third party, provide a rent deposit or procure that a surety acceptable to such person guarantees the Purchaser’s obligations under
the Lease following the transfer of the relevant Transferred Leased Real Property; and 

  

	 	(d)	be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Landlord, any superior landlord or other relevant person (including any Tax or disbursements
in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Landlord, any superior landlord or any other relevant person) properly in connection with any application for Property Third Party Consents, whether or
not such Property Third Party Consents are given. 

  

	 	1.3.4	Each party shall give written notice to the other party as soon as reasonably practicable after obtaining any Property Third Party Consents which shall be accompanied by a copy of such consent. 

 

	 	1.3.5	Subject to the Purchaser complying with its obligations under paragraphs 1.3.3(ii)(b) to (d) of this Part 4 of Schedule 3, the Seller shall pay, or shall procure that a member of the Seller’s Group pays, any
moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required by a Landlord, superior landlord or other relevant third party in connection with the obtaining of the Property Third Party
Consents, provided that the Purchaser shall indemnify and keep indemnified the Seller in an amount equal to: 

  

	 	(i)	any moneys required to be paid or procured to be paid by the Seller pursuant to this paragraph; and 

  

	 	(ii)	any Liabilities under any guarantees or other security given or procured by the Seller pursuant to this paragraph and arising out of, or in connection with, an act or omission on the part of the Purchaser.

  

	1.4	Licence 

  

	 	1.4.1	In the event that any Property Third Party Consents are not obtained on or before the Closing Date, notwithstanding the terms of the Leases, the Seller shall procure that the relevant Business Seller allows the
Purchaser to occupy the Licensed Premises for the Licence Period relating to the relevant Licensed Premises on the terms set out in this paragraph 1.4 of Part 4 of Schedule 3. 

 

	 	1.4.2	The Purchaser acknowledges that the grant of each Licence may amount to a breach of the terms of the relevant Lease. 

  

	 	1.4.3	The Licence of each Licensed Premises is granted: 

  
 123 

	 	(i)	subject to all of the matters to which the relevant Leases relating to the Transferred Leased Real Property are subject; 

  

	 	(ii)	subject to the matters referred to in the Registered Title and the Letting Documents; 

  

	 	(iii)	out of whatever right, title and interest that the relevant Business Seller has in the Licensed Premises and/or under the Leases; 

  

	 	(iv)	in such state of repair and condition as the Licensed Premises may be in as at the date on which the relevant Licence is granted; and 

 

	 	(v)	without making any statement or representation that the relevant Business Seller is entitled to grant it. 

  

	 	1.4.4	From Closing and pending Property Transfer Completion, the Purchaser shall pay to the relevant Business Seller a “Licence Fee” equivalent to: 

 

	 	(i)	all rents and other charges (including VAT due thereon under the relevant Lease where payable at the date of this Agreement by the relevant Business Seller) payable in respect of the Licensed Premises; and

  

	 	(ii)	all outgoings (including VAT due thereon under the relevant Lease) (including, but not limited to, rates, service charges, management charges, levies, air-conditioning charges, insurance, heating, electricity, gas,
telecommunications and other services and the cost of complying with fire and other statutory regulations) payable by the relevant Business Seller in respect of the Licensed Premises or charged upon the owner or occupier of the Licensed Premises,

 such payments to be made not less than 10 Business Days before any such sum falls due subject to the relevant Business
Seller giving the Purchaser not less than 10 Business Days’ prior written notice to that effect. To the extent that there has been a prepayment at the Closing Date of the amounts in paragraphs 1.4.4(i) and (ii) of this Part 4 of Schedule 3 by
the Seller’s Group which is not otherwise accounted for in the Closing Statement, the Purchaser shall pay to the relevant member of the Seller’s Group within 10 Business Days of written demand an amount equal to the amount of such
prepayment in respect of any period after the Closing Date. 
  

	 	1.4.5	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only: 

  

	 	(i)	keep the Licensed Premises in no worse a state of repair than they are in at the Closing Date, fair wear and tear excepted; 

  

	 	(ii)	observe and perform the covenants and conditions on the part of the lessee in the relevant Lease under which the relevant Business Seller holds the Licensed Premises (other than in relation to the payment of rent and
other charges paid to the relevant Business Seller as part of the Licence Fee and subject to paragraph 1.4.5(i) of this Part 4 of Schedule 3); and 

  

	 	(iii)	 use the Licensed Premises only in accordance with the terms of the Lease of the relevant Licensed Premises and in compliance with the law and

  
 124 

	 	
regulations where the relevant Licensed Premises is located (save for any such law or regulation that prohibits the use of the Licensed Premises without a Property Third Party Consent having
been obtained). 

  

	 	1.4.6	The Purchaser and each Business Seller agree that: 

  

	 	(i)	the Licence is personal to the Purchaser and may only be exercised by the Purchaser and those authorised by it; 

  

	 	(ii)	(subject to paragraph 1.4.5 of this Part 4 of Schedule 3) the Purchaser and all persons authorised by it are permitted to have the unrestricted use and occupation of the Licensed Premises; and 

 

	 	(iii)	no relationship of landlord and tenant is created as a result of the Licence. 

  

	 	1.4.7	If a Landlord or any other relevant third party commences proceedings, raises any lawful objection or takes any other action in connection with the Purchaser’s occupation or use of any of the Licensed
Premises pending the obtaining of the relevant Property Third Party Consents, the Purchaser and the relevant Business Seller shall meet and negotiate in good faith in order to determine which steps should be taken in respect of the relevant
Transferred Real Property. 

  

	 	1.4.8	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only, indemnify and keep indemnified each member of the Seller’s Group from and against any Licence Fee and any Losses
arising from the Licence and/or as a result of the occupation of the Licensed Premises by the Purchaser. 

  

	 	1.4.9	The Purchaser and the Business Sellers shall each inform the other forthwith of any notice received by it in relation to any of the Licensed Premises from the Landlord or any other third party. 

 

	1.5	Determination of Licence 

  

	 	1.5.1	The Licence in relation to any one or more of the Licensed Premises shall determine: 

  

	 	(i)	immediately if the Property Longstop Date occurs; or 

  

	 	(ii)	by the relevant Business Seller giving at least three months’ prior written notice to the Purchaser if the Purchaser fails to make the payment of the Licence Fee for a period of one month or is otherwise in
material breach of the provisions of the Licence for a continuous period of one month following written notification by the relevant Business Seller to the Purchaser of the same, and in either case the Purchaser has failed to remedy the relevant
failure to pay or to remedy the breach prior to the expiry of the three month notice period (or, if the breach is not capable of remedy within such three month period, the Purchaser has failed to commence to remedy the breach within that period and
thereafter failed diligently to continue with such remedy); or 

  

	 	(iii)	 if the relevant Landlord in relation to a Transferred Leased Real Property prosecutes forfeiture proceedings (or the nearest local law
equivalent) as a result of the occupation by the Purchaser of the Licensed Premises then the parties shall either: 

  
 125 

	 	agree that the Licence shall determine on a date to be agreed between the parties (acting reasonably); or 

in the absence of such agreement, either party may require a QC (or equivalent) with no less than 15 years’ post-qualification experience
in commercial real estate in the relevant jurisdiction to be appointed (such appointment to be by agreement between the Seller and the Purchaser or, failing agreement, within 14 days, by the President (as defined in paragraph 1.3.2(ii) of this Part
4 of Schedule 3)). Should the QC determine that there is more than a 50% chance of the proceedings in question resulting in the Lease in question being forfeited (or equivalent), then the Licence shall determine on a date to be agreed between the
parties (acting reasonably) in order to afford the Seller the opportunity to apply for relief from forfeiture or otherwise challenge the proceedings in question on the basis that any breach resulting from the grant of the Licence has been
cured, 
 provided that this paragraph 1.5.1(iii) shall at all times operate without prejudice to paragraphs 1.4.7, 1.5.1(i) and 1.12. 

 

	 	1.5.2	If, for whatever reason, the Licence Period comes to an end in relation to any of the Licensed Premises then: 

  

	 	(i)	the Licence insofar as it relates to the relevant Licensed Premises shall be severable from the remainder of this Agreement and this Agreement shall otherwise remain in full force and effect; 

 

	 	(ii)	the Purchaser shall not be entitled to any refund, abatement or reduction of the Purchase Price but shall be entitled to a refund in respect of any Licence Fee prior to the termination of the Licence for the Licensed
Premises and which relates to the period following termination of the Licence; 

  

	 	(iii)	it shall not prejudice or affect any claim by any relevant Business Seller in respect of any prior breach of this Agreement by the Purchaser in respect of that Licensed Premises; and 

 

	 	(iv)	unless the Licence Period comes to an end due to Property Transfer Completion in respect of the relevant Licensed Premises taking place, the Purchaser shall: 

vacate the Licensed Premises forthwith; 

remove from the Licensed Premises all items belonging to it; 

leave the Licensed Premises in a clean and tidy condition; and 

at the request of the relevant Business Seller, reinstate the Licensed Premises or any part or parts thereof to at least as good a state of
repair or condition as at Closing, fair wear and tear excepted. 
  

	1.6	Closing 

  

	 	1.6.1	The transfer of the Transferred Real Property shall only take place on Closing to the extent that all necessary Property Third Party Consents in respect of the relevant transfer have been obtained prior to the
Closing Date. 

  
 126 

	 	1.6.2	Without prejudice to Clause 4.1.8, the Purchase Price shall be paid on the Closing Date in accordance with this Agreement even if any necessary Property Third Party Consents have not then been obtained and not
all the Transferred Real Property is transferred on the Closing Date. 

  

	 	1.6.3	Completion of the transfer of the Transferred Real Property shall take place at such place (or places) as the parties may agree. 

 

	1.7	Property Transfer Completion 

 Property Transfer Completion in respect of a Transferred
Real Property shall take place on the date falling 15 Business Days following the grant of all relevant Property Third Party Consents for such Transferred Real Property or on such other date as the parties shall agree acting reasonably (but not
before the Closing Date). 
  

	1.8	General Transfer Provisions 

  

	 	1.8.1	The Seller shall procure that the relevant members of the Seller’s Group shall transfer the Transferred Real Property to the Purchaser subject to the terms set out in this Part 4 of Schedule 3 and all other
applicable terms of this Agreement on the Closing Date or (if later) Property Transfer Completion. 

  

	 	1.8.2	The Transferred Real Property is sold subject to the Letting Documents (if any) but otherwise with vacant possession together with all buildings, structures, fixed plant, fixed machinery and fixed equipment
thereon except as excluded in Clause 2.3.2. 

  

	 	1.8.3	The transfer of each Transferred Real Property shall contain covenants with the relevant Business Seller by the Purchaser to comply with: 

 

	 	(i)	the obligations arising from the matters mentioned in the Registered Title; and 

  

	 	(ii)	obligations on the part of the landlord arising under the Letting Documents (if any), 

 insofar
as the relevant Business Seller may remain liable directly or indirectly for them after the Closing Date or Property Transfer Completion (as the case may be) and to indemnify the relevant member of the Seller’s Group against any non-compliance
and a further covenant by the Purchaser to indemnify the relevant Business Seller against any liability arising under an authorised guarantee agreement (or equivalent) entered into by the relevant member of the Seller’s Group. 

 

	 	1.8.4	The transfer of each Transferred Real Property shall be on the nearest equivalent terms that exist under local (national) law to a transfer of real property in England and Wales made with full title guarantee
save that where it is a Transferred Leased Real Property the covenant set out in Section 4(2)(b) of the Law of Property (Miscellaneous Provisions) Act 1994 shall not extend to the imposition on the transferor of liability for any subsisting breach
of obligation relating to the physical state of the Transferred Leased Real Property. 

  

	 	1.8.5	On the Closing Date or Property Transfer Completion (as the case may be) in respect of each of the Transferred Real Properties: 

  
 127 

	 	(i)	the Seller shall procure that the relevant Business Seller delivers to the Purchaser a duly executed transfer in respect of the relevant Transferred Real Property on Property Agreed Terms; and 

 

	 	(ii)	the Purchaser shall deliver to the Seller a duly executed transfer in respect of the relevant Transferred Real Property on Property Agreed Terms. 

 

	 	1.8.6	The Purchaser shall, at its own cost and expense, procure that all transfers are duly stamped, filed or registered at the relevant registries on a timely basis and within the statutory period (if any) and the
relevant Business Seller shall promptly assist the Purchaser with any requisitions or enquiries raised in relation thereto. 

  

	1.9	Subjections 

 Notwithstanding anything contained in this Agreement: 

 

	 	1.9.1	Each of the Transferred Real Properties is transferred subject to and (where appropriate) with the benefit of the following matters (to the extent applicable under the laws of the relevant jurisdiction):

  

	 	(i)	any unregistered interest which overrides first registration under Schedule 1 of the Land Registration Act 2002 (the “2002 Act”) and any interest which fall within Section 11(4)(c) of the 2002 Act and
any unregistered interests which override registered dispositions under Schedule 3 of the 2002 Act or their local jurisdiction equivalent (if any); 

  

	 	(ii)	such unregistered interests as may affect that Transferred Real Property to the extent and for so long as they are preserved by the transitional provisions of Schedule 12 of the 2002 Act or its local jurisdiction
equivalent (if any); 

  

	 	(iii)	all matters contained or referred to in the Letting Documents; 

  

	 	(iv)	all matters contained or referred to in the Property, Proprietorship and Charges registers (or equivalent entries and registers) of the Registered Title relating to that Transferred Real Property (except fixed and
floating charges securing money or liabilities); 

  

	 	(v)	all exceptions, reservations, rights, easements, quasi-easements, wayleaves, rent charges, covenants, conditions, declarations, leases, tenancies (including statutory tenancies), licences and agreements affecting the
same; 

  

	 	(vi)	(in the case of a leasehold property) the rents, covenants and conditions reserved by or contained in the Lease under which the same is respectively held; 

 

	 	(vii)	all local land charges (whether or not registered before the date of this Agreement) and all matters capable of registration as local land charges (whether or not actually registered) or their local jurisdiction
equivalent (if any); 

  

	 	(viii)	all notices served and orders, demands, proposals, or requirements made by any local or other public or competent authority; 

  
 128 

	 	(ix)	all actual or proposed orders, directions, plans, notices, instruments, charges, restrictions, conditions, agreements or other matters arising under any statute relating to town and country planning and any laws and
regulations intended to control or regulate the construction, demolition, alteration or change of use of land or buildings or to preserve or protect the environment; and 

 

	 	(x)	matters which are fairly disclosed by the Disclosure Letter. 

  

	 	1.9.2	The Purchaser is deemed to acquire with full knowledge of the matters referred to in paragraph 1.9.1 of this Part 4 of Schedule 3. 

 

	 	1.9.3	The Business Sellers shall procure that any and all financial charges affecting the Transferred Real Properties will be discharged on or before the date on which such Transferred Real Property is to be
transferred to the Purchaser, and shall provide to the Purchaser such evidence as the Purchaser may reasonably require in order to satisfy itself that such discharge has been effected and to remove any notices or entries in respect of such charges
from any relevant register. 

  

	 	1.9.4	The Business Sellers do not give any warranty as to the use or area of any of the Transferred Real Properties and shall not be required to define the boundaries of any of the Transferred Real Properties. The
transfer of the Transferred Real Properties shall not be annulled, nor shall any compensation be allowed or payable, in respect of any error in respect of any such matters. 

 

	 	1.9.5	On the date on which the transfer of each Transferred Real Property is completed, the Seller shall deliver, to the Purchaser (or such other third party as the Purchaser may reasonably direct) all of the original
documents in the possession of the Business Sellers or relevant member of the Seller’s Group in respect of each of the Transferred Real Properties. 

  

	 	1.9.6	The Purchaser shall not raise any requisition on matters arising after the date of this Agreement, except where the subject matter of the requisition is registered at the Land Registry (or equivalent local
registry) after the date of this Agreement and does not relate to any matter referred to in paragraph 1.9.1 of this Part 4 of Schedule 3. 

  

	 	1.9.7	To the extent that deposit guarantees have been given by the Seller’s Group in respect of any Transferred Real Property and/or insofar as the Seller’s Group retains any residual or ongoing liabilities
or obligations (including performance guarantees) in connection with the Transferred Real Property, the Purchaser shall use all reasonable endeavours procure that the Seller’s Group is released from all deposit guarantees and all other residual
or ongoing liabilities or obligations and, insofar as the counterparties thereto shall properly and lawfully refuse to give any such release, the Purchaser shall indemnify and keep indemnified the Seller (or the relevant member of the Seller’s
Group) in an amount equal to any Liabilities under any such residual or ongoing liabilities or obligations arising out of, or in connection with, an act or omission on the part of the Purchaser. 

 

	1.10	Insurance 

 The Business Sellers shall maintain their existing insurance (if any) on the
Transferred Real Properties and shall cancel such insurance with effect from the Closing Date or, if 

  
 129 

 
later, the date of Property Transfer Completion (as the case may be) unless agreed otherwise with the Purchaser. 
  

	1.11	Grant of Sublease 

 If a Business Seller is unable to obtain a Property Third Party
Consent from a Landlord for the transfer of a Transferred Leased Real Property the provisions of this paragraph 1.11 of Part 4 of Schedule 3 shall apply: 
  

	 	1.11.1	where a Lease permits a sublease to be granted without the requirement for any Property Third Party Consent from the Landlord, the relevant Business Seller shall grant to the Purchaser a sublease of the
Transferred Leased Real Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Real Property with such changes as are appropriate and agreed between the relevant Business Seller and the Purchaser acting
reasonably and the term of the sublease shall be the term of such Lease less one day; and 

  

	 	1.11.2	where the Transferred Leased Real Property is held by the relevant Business Seller from a Landlord on terms which require the consent of the Landlord to: 

 

	 	(i)	the grant of a sublease; or 

  

	 	(ii)	the terms on which a sublease is granted, 

 the Seller or the relevant Business Seller shall
use all reasonable endeavours to obtain such consent (“Sublease Consent”) from such Landlord. Where the relevant Business Seller is able to obtain the appropriate Sublease Consent (or, where applicable, the court of competent
jurisdiction referred to in paragraph 1.12.1 of this Part 4 of Schedule 3 declares that the Sublease Consent has been unreasonably withheld or delayed), the relevant Business Seller shall grant to the Purchaser a sublease of the Transferred Leased
Real Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Real Property with such changes as are appropriate and agreed between the relevant Business Seller and the Purchaser acting reasonably and the term
of the sublease shall be the term of such Lease less one day. 
  

	1.12	Property Third Party Consent not obtained 

  

	 	1.12.1	If a Property Third Party Consent (and, where applicable, a Sublease Consent) has been refused or otherwise not obtained within twelve months following the Closing Date, the Seller and the Purchaser may (acting
reasonably) agree that an application is to be made to a court of competent jurisdiction that the relevant Property Third Party Consent has been unreasonably withheld or delayed. 

 

	 	1.12.2	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.12.1 of this Part 4 of Schedule 3: 

 

	 	(i)	the proceedings shall be brought and prosecuted by the Seller; and 

  

	 	(ii)	the Purchaser shall provide all such assistance in connection with such proceedings as the Seller (acting reasonably) may require in the interests of obtaining the Property Third Party Consent; and 

 

	 	(iii)	 provided that the Seller has complied with its obligations under paragraphs 1.3.3(i) and 1.11.2 of this Part 4 of Schedule 3, the Purchaser shall
indemnify and keep indemnified the Seller for any costs and expenses 

  
 130 

	 	
properly incurred by the Seller in bringing and prosecuting proceedings under this paragraph. 

  

	 	1.12.3	If a Property Third Party Consent has not been obtained by the Property Longstop Date then the Seller and the Purchaser shall each bear fifty per cent. of any Losses of the Seller and the Purchaser arising out of
or in connection with the failure to obtain such Property Third Party Consent. 

  

	1.13	Obligations on the Business Sellers 

 In this Part 4 of Schedule 3, any reference to an
obligation on the part of the Business Sellers (or any of them, as the case may be) shall be read as if it were an obligation on the part of the Seller to procure performance of such obligation by the Business Seller or Business Sellers in question.

  

	1.14	Amsterdam Lease 

  

	 	1.14.1	The Seller shall keep the Purchaser fully informed of any discussions or negotiations with the Landlord in respect of the lease of premises at Hullenbergweg 81-135 (1011 CL), Amsterdam, The Netherlands (the
“Amsterdam Lease”), or any notices received by the Seller (or any member of the Seller’s Group) from the Landlord in respect of the Amsterdam Lease relating to the determination thereof or the yielding up of the premises demised
thereunder. 

  

	 	1.14.2	The Seller shall not, and shall procure that no member of the Seller’s Group shall, act independently of the Purchaser in relation to any discussions or negotiations relating to the extension or renewal of
the Amsterdam Lease, and shall not enter into any document or deed extending or renewing the term of the Amsterdam Lease without the prior written approval of the Purchaser (not to be unreasonably delayed). 

 

	 	1.14.3	The Seller shall, and shall procure that any relevant member of the Seller’s Group shall, take such action as the Purchaser may reasonably request in connection with the Amsterdam Lease, including taking
steps to extend or renew the same. 

  

	 	1.14.4	The Purchaser shall indemnify and keep indemnified the Seller against all costs properly incurred by the Seller (or any member of the Seller’s Group) arising out of or in connection with paragraph 1.14.3 of
this Part 4 of Schedule 3. 

  

	 	1.14.5	If the Amsterdam Lease is extended or renewed, the leasehold property as extended or renewed shall be a “Transferred Real Property” for the purposes of this Agreement and the provisions of this Part 4
of Schedule 3 shall apply to such lease as extended or renewed. 

  
 131 

 Schedule 4 

Vaccines Group Intellectual Property Rights and Vaccines Group Intellectual 

Property Contracts 

(Clause 2.3) 
 Part 1 

Vaccines Group Intellectual Property Rights 
 Part 2

 Vaccines Group Intellectual Property Contracts 

Part 3 
 Beta Interferon Patents 

  
 132 

 Schedule 5 

Excluded Employees 

(Clause 1.1) 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 133 

 Schedule 6 

International Assignees 

(Clause 1.1) 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 134 

 Schedule 7 

Permitted Encumbrances 

(Clause 1.1) 
  

	1.	Co-owned Vaccines Group Intellectual Property Rights. 

  
 135 

 Schedule 8 

Product Approvals and Product Applications 

Part 1 
 Terms relating to
the Product Approvals and Product Applications 
  

	1	General Provisions 

  

	1.1	The Purchaser shall do all things necessary to effect the transfer of each Product Approval and Product Application, including complying with requirements and requests of Governmental Entities with respect to the
transfer of each Product Approval and Product Application. 

  

	1.2	The Marketing Authorisations shall be transferred in accordance with Part 2 of this Schedule 8. 

  

	2	Product Applications 

  

	2.1	The Purchaser shall file or cause to be filed applications for the transfer of each Product Application in each country or territory in which such transfer is required to be submitted as soon as possible after
the Closing Date. 

  

	2.2	Pending the transfer of each Product Application each Seller shall, and shall cause the relevant members of its Group to: 

  

	 	2.2.1	upon reasonable request from the Purchaser and at the Purchaser’s expense, reasonably cooperate and coordinate with the Purchaser in relation to the transfer of the Product Applications, including by
providing the Purchaser with regulatory documentation concerning the Products owned or controlled by that Seller or any of its Affiliates; 

  

	 	2.2.2	perform such acts and services as may be requested by the Purchaser that are reasonably necessary or required by any Governmental Entity to maintain or renew any Product Application or are reasonably necessary
for the Purchaser to pursue the regulatory approval for any Product Application, including conducting any studies, including clinical and stability studies, concerning the Products; and 

 

	 	2.2.3	notify the Purchaser as soon as is reasonably practicable of any written communication received by such Seller or any member of its Group with respect to any Product Application and shall consult with the
Purchaser with respect to such communication and take into account the Purchaser’s views as to the form and content of any communication with any Governmental Entity concerning such Product Application. 

 

	3	Fees and expenses 

 From and after the Closing Date, the Purchaser shall promptly
reimburse the relevant members of the Seller’s Group for all maintenance and renewal fees and similar fees paid, and all out of pocket expenses reasonably incurred in connection with the satisfaction of any commitments or obligations by such
member of the Seller’s Group with respect to each Product Approval and each Product Application. 
  

	4	Notification 

 As soon as a Seller or the Purchaser or any of their respective Affiliates
receives notification, if any, of impending approval or approval of the transfer of a Product 

  
 136 

 
Application from a Governmental Entity, the notified party or the party whose Affiliate was notified shall inform the other party of the expected date of appointment or transfer and actual date
of appointment or transfer of that Product Application. 
  

	5	Responsibility for transfer 

 Notwithstanding any other provision of this Agreement, no
Seller nor any of its Affiliates shall have any Liability to the Purchaser in the event that the transfer of any Product Application alone results in any further obligations, commitments or Liabilities in relation to such Product Application. 

  
 137 

 Schedule 8 

Product Approvals and Product Applications 

Part 2 
 Transfer of
Marketing Authorisations 
  

	1	Marketing Authorisation Transfer and Marketing Authorisation Re-registration 

  

	1.1	The Seller and the Purchaser hereby agree they will each use, and will procure that their respective Affiliates will use, all reasonable endeavours to ensure that, as soon as reasonably practicable after the
Closing Date: 

  

	 	1.1.1	subject to paragraphs 1.1.2 and 1.1.3, each Marketing Authorisation shall be transferred in accordance with Applicable Law by the Marketing Authorisation Holder to the Marketing Authorisation Transferee
(“Marketing Authorisation Transfer”); and 

  

	 	1.1.2	where Applicable Law does not permit Marketing Authorisation Transfer, a new marketing authorisation shall be registered in the name of the Marketing Authorisation Transferee to replace the existing Marketing
Authorisation (“Marketing Authorisation Re-registration”) and the Seller shall procure that the relevant Marketing Authorisation Holder takes all necessary steps to withdraw, abandon, cancel or allow to lapse the superseded
Marketing Authorisation as soon as practicable after the Marketing Authorisation Re-registration Date; and 

  

	 	1.1.3	good faith discussions are held between the Seller and the Purchaser (or their respective Affiliates) to determine whether a structure may be implemented such that the Marketing Authorisation Transfers in Brazil
may be effected without the need for a Marketing Authorisation Re-registration, such as by means of a spin-off structure under Applicable Law. 

  

	1.2	The parties agree that the transfer of any Marketing Authorisation from the Marketing Authorisation Holder to the Marketing Authorisation Transferee in respect of any Delayed Businesses shall not complete until
on or after the relevant Delayed Closing Date. 

  

	1.3	Any Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) shall each be effected on a Market-by-Market basis (such that there shall not be any staggered Marketing
Authorisation Transfer or Marketing Authorisation Re-registration (as the case may be) on a Product-by-Product basis in any Market), unless otherwise agreed between the Seller and the Purchaser. 

 

	1.4	With effect from the Closing Date until the Marketing Authorisation Transfer Date or the Marketing Authorisation Re-registration Date (as applicable), the Seller shall procure that each Marketing Authorisation
Holder shall hold the Marketing Authorisation(s) in its name but for the account, risk and benefit of the relevant Marketing Authorisation Transferee. 

Submission of MA Documentation 
  

	1.5	 Without prejudice to paragraph 1.5, the Purchaser shall be responsible for preparing and submitting, or for procuring that there is prepared and
submitted (in any such case at the Purchaser’s cost and expense), all notices, applications, submissions, reports and any other instruments, documents, correspondence or filings necessary to complete Marketing Authorisation Transfer or
Marketing Authorisation Re-registration (as applicable) (the “MA 

  
 138 

	 	
Documentation”). The MA Documentation shall be prepared in accordance with Applicable Law as soon as reasonably practicable. 

 

	1.6	At the Seller’s election, the Purchaser shall procure that advanced drafts of the MA Documentation are submitted to the Seller so as to allow the Seller and/or the Marketing Authorisation Holder a reasonable
opportunity to provide comments on such MA Documentation before it is submitted to the relevant Governmental Entity. The Purchaser shall incorporate all comments on such drafts as may reasonably be made by the Seller and/or the Marketing
Authorisation Holder PROVIDED THAT the Purchaser shall not be obliged to incorporate any comments if the Purchaser considers, acting reasonably that to do so would materially delay Marketing Authorisation Transfer or Marketing Authorisation
Re-registration (as applicable). 

  

	1.7	Where under Applicable Law the MA Documentation is required to be submitted to the relevant Governmental Entity: 

  

	 	1.7.1	by the Marketing Authorisation Holder, the Purchaser shall procure that the finalised MA Documentation is provided to the Seller after such MA Documentation is finalised in accordance with paragraph 1.5 above and
the Seller shall, in turn, procure that the Marketing Authorisation Holder submits such MA Documentation to the relevant Governmental Entity (the timing and date of such submission to be agreed with the Purchaser) and the Seller shall promptly
thereafter advise the Purchaser of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Purchaser; and 

  

	 	1.7.2	by the Marketing Authorisation Transferee, the Purchaser shall procure that the relevant Marketing Authorisation Transferee submits the finalised MA Documentation to the relevant Governmental Entity as soon as
reasonably after such MA Documentation is finalised in accordance with paragraph 1.5 above and the Purchaser shall promptly thereafter advise the Seller of such submission and provide a copy of the relevant MA Documentation (in the form submitted)
to the Seller. 

  

	1.8	From the Closing Date, the Seller shall procure that the relevant Marketing Authorisation Holder shall, as soon as reasonably practicable, sign any notices, applications, submissions, reports and other
instruments, documents, correspondence or filings presented to it by the Purchaser or the relevant Marketing Authorisation Transferee that are necessary to effect Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as
applicable). The Marketing Authorisation Holder shall: 

  

	 	1.8.1	provide notice of its consent to a Marketing Authorisation Transfer or Marketing Authorisation Re-registration if required by any Governmental Entity; and 

 

	 	1.8.2	provide to the Purchaser or the relevant Marketing Authorisation Transferee any information or other data or technical or other information in its possession that relates to the relevant Marketing Authorisation
and that is required by a relevant Governmental Entity or otherwise reasonably required by the Purchaser or the relevant Marketing Authorisation Transferee to assist the Purchaser or the relevant Marketing Authorisation Transferee to effect the
relevant Marketing Authorisation Transfer or Marketing Authorisation Re-registration; 

  

	 	1.8.3	 in the event of any request for information or any query from any relevant Governmental Entity in respect of Marketing Authorisation Transfer
or the 

  
 139 

	 	
Marketing Authorisation Re-registration (as applicable), the relevant party receiving such request or query shall provide copies of any such request or query to the Seller or, as the case may be,
to the Purchaser. The Purchaser shall be responsible for preparing, or shall be responsible for procuring that there is prepared, (at the Purchaser’s cost and expense) any response to such a request or query with the intention that such request
or query shall be dealt with as promptly and efficiently as possible. In advance of finalising any such response, the Purchaser shall procure that the relevant response is submitted to the Seller so as to allow the Seller and/or the relevant
Marketing Authorisation Holder a reasonable opportunity to provide comments on such response before it is submitted to the Governmental Entity. The Purchaser shall procure that relevant Marketing Authorisation Transferee (i) shall submit the
response to the relevant Governmental Entity as soon as reasonably practicable after the same has been finalised in accordance with this paragraph 1.7.3 and (ii) shall provide a copy of the relevant response (in the form submitted) to the Seller.

  

	2	Obligations Pending Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

  

	2.1	Unless otherwise required by Applicable Law or a relevant Governmental Entity (or unless otherwise agreed in writing by the Seller and the Purchaser), from the Closing Date until the applicable Marketing
Authorisation Transfer Date or Marketing Authorisation Re-registration Date: 

  

	 	2.1.1	the Seller shall: 

  

	 	(i)	maintain in force (or procure that there is maintained in force) each Marketing Authorisation, and shall not voluntarily amend, cancel or surrender any Marketing Authorisation unless requested to do so in writing by the
Purchaser or required to do so by any Applicable Law or any Governmental Entity; 

  

	 	(ii)	with the Purchaser’s consent (not to be unreasonably withheld or delayed) progress (or procure that there is progressed) any registrations, variations or renewals to Marketing Authorisations initiated by the Seller
(or any other member of the Seller’s Group) prior to the Closing Date or withdraw them upon the request of the Purchaser; 

  

	 	(iii)	procure that each Marketing Authorisation Holder shall comply with the terms of any Marketing Authorisation and shall notify the Purchaser as soon as reasonably practicable of the details of any variations or renewals
initiated following the Closing Date; 

  

	 	(iv)	inform the Purchaser of any impending renewals of Marketing Authorisations as at the Closing Date and the parties shall discuss in good faith to what extent any such renewal will be pursued or withdrawn (it being
agreed that the Purchaser shall have the final decision in any such matter); 

  

	 	(v)	not without the consent of the Purchaser, initiate any additional variations or amendments to the Marketing Authorisations, except to the extent required by any Governmental Entity or where failure to do so would
breach Applicable Law; and 

  
 140 

	 	(vi)	consider in good faith any request by the Purchaser to apply for a new marketing authorisation in respect of a Product PROVIDED THAT if the Seller agrees to submit such application, any costs or expenses incurred by the
Seller in making such application shall be for the Purchaser’s account and shall constitute MA Costs; 

  

	 	2.1.2	without prejudice to the generality of the foregoing paragraph 2.1.1(iii), the Purchaser acknowledges and agrees that each Marketing Authorisation Holder shall be entitled to do (or to procure that there is done)
any or all of the following (and the Purchaser acknowledges that, where the relevant Marketing Authorisation Holder so chooses and unless otherwise agreed, responsibility for each of the following activities shall rest with the relevant Marketing
Authorisation Holder): 

  

	 	(i)	pharmacovigilance activities related to the Marketing Authorisations, which activities shall be conducted in accordance with Applicable Law, the Vaccines Business Pharmacovigilance Agreement, and the standards, policies
and procedures of the Seller’s Group from time to time in force; and 

  

	 	(ii)	conducting any and all communications with a Governmental Entity in respect of a Marketing Authorisation (including, without limitation to the generality of the foregoing, attending any meetings with relevant
Governmental Entities and filing and submitting all reports and other documents which it reasonably considers necessary to be submitted in order to comply with Applicable Law or its obligations under this Agreement), PROVIDED THAT responsibility for
(a) the costs of preparation of any such documents, reports and/or filings shall be borne by the Purchaser (or the relevant Marketing Authorisation Transferee) to the extent such costs are reasonably necessary, and (b) the submission of MA
Documentation shall be the responsibility of the Purchaser in accordance with paragraph 1.4 above, PROVIDED THAT the Seller shall ensure that the Purchaser is kept fully and promptly informed of any such communications or submissions in advance, to
the extent reasonably practicable; and 

  

	 	2.1.3	the Seller shall procure that each Marketing Authorisation Holder shall act in accordance with the reasonable instructions of the Purchaser or the Marketing Authorisation Transferee in respect of each Marketing
Authorisation in respect of which such Marketing Authorisation Holder is the holder, PROVIDED THAT no Marketing Authorisation Holder shall be obliged to comply with such instructions to the extent the same: (i) infringe the terms of the relevant
Marketing Authorisation(s); or (iii) are otherwise inconsistent with the provisions of the Vaccines Business Pharmacovigilance Agreement relating to the Seller; 

  

	 	2.1.4	the Purchaser shall only request artwork changes to the extent such changes are required in order to comply with Applicable Law; 

 

	 	2.1.5	 the Purchaser shall submit to the Seller (or shall procure that there is submitted) written details (in such form and with such supporting
materials as the Seller may reasonably request) of any new, amended or proposed advertising and promotional activity or training materials in respect of any Product Commercialised pursuant to any Marketing Authorisation (including (without
limitation) any material reasonably 

  
 141 

	 	
requested by the Seller in order to validate new and/or amended promotional or training materials), and the Purchaser acknowledges and agrees that no such advertising, promotional or training
activity shall be implemented, undertaken or otherwise commenced without the prior written consent of the Seller (for itself and on behalf of the relevant Marketing Authorisation Holder), such consent not to be unreasonably withheld. The Purchaser
further agrees and acknowledges that, if it so chooses, the Seller shall be entitled to assume responsibility for obtaining (or procuring that there is obtained) the consent(s) and approval(s) of any relevant Governmental Entity required for such
new, amended or proposed advertising and promotional activity or training activity; and 

  

	 	2.1.6	to the extent permitted by the terms of the relevant Marketing Authorisation, the Purchaser or any other member of the Purchaser’s Group shall Commercialise the Product(s) which are the subject of such
Marketing Authorisation (notwithstanding that such Marketing Authorisation is held in the name of the relevant Marketing Authorisation Holder and, for the avoidance of doubt, the proceeds of any such Commercialisation shall be for the benefit of the
Purchaser’s Group) and the Purchaser shall: 

  

	 	(i)	indemnify each member of the Seller’s Group against any and all actions, claims, demands, investigations, judgments, proceedings, liabilities, loss, damages, payments, costs and expenses arising in relation to the
Commercialisation of the Products by the Purchaser or any other member of the Purchaser’s Group under this paragraph (i); and 

  

	 	(ii)	procure that such Product(s) are Commercialised in compliance with the terms of the relevant Marketing Authorisation and/or the requirements of the relevant Governmental Entity. 

 

	2.2	Unless otherwise required by Applicable Law or a relevant Governmental Entity, from the Closing Date until the applicable Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date,
where any Market Authorisation Holder is required by Applicable Law to consult with a Governmental Entity in order to negotiate the discounts, rebates or other pricing mechanisms (including reimbursement) (the “Pricing”) applicable
to the Commercialisation of the Products in the relevant Market (a “Pricing Negotiation”): 

  

	 	2.2.1	the Seller shall (or shall procure that the Marketing Authorisation Holder shall) notify the Purchaser as soon as reasonably practicable after the Marketing Authorisation Holder becomes aware of any opportunity
or requirement to enter into a Pricing Negotiation; 

  

	 	2.2.2	the Purchaser shall be responsible for preparing or procuring that there is prepared (at the Purchaser’s cost) all notices, submissions and reports, and any other documents or correspondence necessary for
the purposes of the Pricing Negotiation (the “Pricing Negotiation Documentation”); 

  

	 	2.2.3	the Seller shall (or shall procure that the Marketing Authorisation Holder shall) co-operate with the Purchaser and provide the Purchaser with such data and information as the Purchaser may reasonably request for
the purposes of preparing the Pricing Negotiation Documentation; 

  

	 	2.2.4	 the Purchaser shall procure that the Pricing Negotiation Documentation is provided to the Seller and/or Marketing Authorisation Holder prior to
the intended date of 

  
 142 

	 	
submission to the relevant Governmental Entity with such advance notice as is reasonably sufficient for the Seller and/or the Marketing Authorisation Holder to determine whether any of the
information or any proposal included in the Pricing Negotiation Documentation would constitute or result in a breach of Applicable Law by the Marketing Authorisation Holder or any other member of the Seller’s Group; 

 

	 	2.2.5	if the Seller and/or the Marketing Authorisation Holder believes (acting reasonably) that any of the information or any proposal included in the Pricing Negotiation Documentation prepared by the Purchaser (or a
member of the Purchaser’s Group) would constitute or result in a breach of Applicable Law by the Marketing Authorisation Holder, then it shall submit to the Purchaser (or relevant member of the Purchaser’s Group) within 10 Business Days of
the date of receipt of the Pricing Negotiation Documentation from the Purchaser pursuant to paragraph 2.2.4, a written legal opinion specifying why any of the information or any proposal included in the Pricing Negotiation Documentation would
constitute or result in a breach of Applicable Law. Following receipt of the legal opinion by the Purchaser (or relevant member of the Purchaser’s Group), the parties shall consult with each other, in good faith, in order to agree amendments to
the Pricing Negotiation Documentation that are reasonably required in order to ensure compliance with Applicable Law and the Seller (or the relevant Marketing Authorisation Holder) shall submit the revised Pricing Negotiation Documentation to the
relevant Governmental Entity as soon as possible thereafter; 

  

	 	2.2.6	if the Seller and/or Marketing Authorisation Holder believes (acting reasonably) that neither the information nor any proposal included in the Pricing Negotiation Documentation would constitute or result in a
breach of Applicable Law by the Marketing Authorisation Holder or any other member of the Seller’s Group, then the relevant member of the Purchaser’s Group shall submit such Pricing Negotiation Documentation directly to the Governmental
Entity unless prohibited by Applicable Law or by the Governmental Entity, in which case, the Seller shall procure that the Marketing Authorisation Holder makes the submission to the Governmental Entity as soon as reasonably practicable after it is
received from the Purchaser (or relevant member of the Purchaser’s Group); 

  

	 	2.2.7	the Purchaser (or a member of the Purchaser’s Group) shall be entitled to correspond with and attend all meetings with the Governmental Entity in relation to the Pricing Negotiation and, to the extent that
the Marketing Authorisation Holder is required to be present at any such meetings under Applicable Law or by the Governmental Entity, the Seller shall procure that the Marketing Authorisation Holder shall jointly attend any such meetings with the
relevant member of the Purchaser’s Group; 

  

	 	2.2.8	the Purchaser (or a member of the Purchaser’s Group) shall be entitled to conduct the Pricing Negotiation unless prohibited under Applicable Law or by the Governmental Entity, in which case, the Seller shall
procure that the Marketing Authorisation Holder shall conduct the Pricing Negotiation and in any event enter into any related agreement with the Governmental Entity in accordance with the reasonable instructions of the Purchaser (or a member of the
Purchaser’s Group); and 

  

	 	2.2.9	 the Seller undertakes (and shall procure that the Marketing Authorisation Holder undertakes) to ensure that the Pricing Negotiation
Documentation and any 

  
 143 

	 	
information received in connection with or as part of the Pricing Negotiation: (i) is kept confidential and is only disclosed to employees of the Seller’s Group on a need to know and
confidential basis; and (ii) is used by the Seller, the Marketing Authorisation Holder and/or employees of the Seller’s Group for the sole purpose of making a determination under sub-paragraph 2.2.4 above. 

 

	2.3	Subject to paragraph 2.4 below, the parties agree that nothing in paragraph 2.2 above shall preclude the Seller and/or Marketing Authorisation Holder from: (i) preparing and submitting to any Governmental Entity
any notices, submissions and reports, and any other documents or correspondence, (ii) attending meetings with any Governmental Entity, (iii) making representations to any Governmental Entity, and (iv) taking any and all steps as the Seller and/or
Marketing Authorisation Holder shall consider necessary or desirable, in each case in relation to the negotiation of Pricing applicable to the products that form part of the Seller’s Group Retained Business (and, for the avoidance of doubt,
excluding the Products). 

  

	2.4	Where Applicable Law does not permit the Purchaser to participate in a Pricing Negotiation as contemplated by paragraph 2.2 above or the Seller’s interest in respect of the outcome of a Pricing Negotiation
conflicts or is reasonably likely to conflict with the interests of the Purchaser in the outcome of the Pricing Negotiation, the Seller shall (or shall procure that the relevant Marketing Authorisation Holder shall): 

 

	 	2.4.1	notify the Purchaser of such conflict of interest as soon as reasonably practicable after becoming aware of it; and 

  

	 	2.4.2	afford the Purchaser to the fullest extent permissible under Applicable Law, the rights it has under paragraph 2.2 above. 

Following notification of a conflict of interest the parties shall, to the extent permitted by Applicable Law, consult together to agree the
approach to be taken by the Seller (or the relevant Marketing Authorisation Holder) to minimise the impact of the conflict of interest on the Purchaser’s interests and if the Parties cannot agree on the approach to be taken, the matter shall be
escalated at the Purchaser’s request to chief financial officers or their nominees of each party for resolution. 
  

	3	New and Pending Marketing Authorisations in Respect of the Products 

  

	3.1	If, at any time prior to Closing, any member of the Seller’s Group is granted or otherwise comes to hold any marketing authorisation which relates exclusively to one or more Products (a “New
Marketing Authorisation”) then: 

  

	 	3.1.1	the Seller undertakes to the Purchaser to notify the Purchaser as soon as reasonably practicable following the date on which the relevant member of the Seller’s Group is granted, or becomes entitled to, the
New Marketing Authorisation; and 

  

	 	3.1.2	the provisions of paragraphs 1 and 2 above shall apply to that new Marketing Authorisation. 

  

	3.2	Where a member of the Seller’s Group has submitted to any Governmental Entity any application relating to the grant of a new marketing authorisation in respect of the Vaccines Group which is pending or in
process as at the date of this Agreement (a “Pending Marketing Authorisation”): 

  
 144 

	 	3.2.1	the Seller shall continue to be responsible for preparation and submission of all documents required to register such Pending Marketing Authorisation but, following Closing, it shall do so at the Purchaser’s
cost and shall pass responsibility for such Pending Marketing Authorisation to the Purchaser (or such member of the Purchaser’s Group as the Purchaser may nominate) as soon reasonably possible after Closing, subject to Applicable Law;

  

	 	3.2.2	from the Closing Date, the provisions of paragraph 1 shall apply mutatis mutandis to any registration process for any Pending Marketing Approval. 

 

	4	MA Costs 

 From the Closing Date, the Purchaser shall be responsible for all necessary
costs of preparation and submission of MA Documentation and, save as expressly provided in this Agreement, any other necessary costs incurred by the Seller or a member of the Seller’s Group in connection with the maintenance and any variations,
amendments and renewals of the Marketing Authorisations relating to the Products or for any matter requested by the Purchaser pursuant to this Part 2 of Schedule 8 and for all fees and costs reasonably incurred by the relevant member of the
Seller’s Group in complying with its obligations in respect of a Marketing Authorisation Transfer or Marketing Authorisation Re-registration (“MA Costs”). 

 

	5	Obligations following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

  

	5.1	On and from the relevant Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date (as applicable), the Purchaser shall procure that each Marketing Authorisation Transferee shall
assume and be solely responsible for: 

  

	 	5.1.1	all obligations as the holder of such Marketing Authorisation including (subject to the terms of the Vaccines Business Pharmacovigilance Agreement) pharmacovigilance activities related to such Marketing
Authorisation; 

  

	 	5.1.2	all activities and actions required by Applicable Law in connection with such Marketing Authorisation; and 

  

	 	5.1.3	any and all outstanding commitments and obligations to the relevant Governmental Entities with respect to the relevant Marketing Authorisation, save for any such commitments or obligations arising from a breach
of this Agreement by the Seller. 

  

	5.2	In the event that, following Marketing Authorisation Transfer or Marketing Authorisation Re-registration in respect of any Product, the Seller wishes to apply for a marketing authorisation in respect of a
retained product, the Purchaser shall (and shall procure that the relevant Marketing Authorisation Transferee shall) co-operate with and provide all reasonable assistance to the Seller (or the relevant member of the Seller’s Group) at the
Seller’s costs as may be reasonably required for the purposes of applying for such new marketing authorisation, including (without limitation) providing the Seller (or the relevant member of the Seller’s Group) and/or any Governmental
Entity with such access to Marketing Authorisation Data or such other data or technical or other information as is reasonably requested by the relevant Governmental Entity or is otherwise reasonably required by the Seller or the relevant member of
the Seller’s Group. 

  
 145 

 Schedule 8 

Product Approvals and Product Applications 

Part 3 
 List of Products,
Products Under Registration and Pipeline Products 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the
Securities and Exchange Commission. 

  
 146 

 Schedule 8 

Product Approvals and Product Applications 

Part 4 
 Tenders 

 

	1.	    Call for New Tender 

 From Closing until the Marketing Authorisation Transfer
Date in any Market, the Seller shall, and shall procure that each member of the Seller’s Group and the relevant Marketing Authorisation Holder shall, to the extent permitted by Applicable Law: 

 

	(a)	inform the Purchaser in writing of any Call for New Tender as soon as reasonably practicable following receipt; and 

  

	(b)	co-operate with and provide reasonable assistance to the Purchaser (or the relevant member of the Purchaser’s Group) for the purposes of responding to the Call for New Tender or otherwise applying for a new tender;
and 

  

	(c)	where Applicable Law requires such responses or applications to be made by the Marketing Authorisation Holder, the Seller shall procure that the Marketing Authorisation Holder submits such responses or applications on
behalf of the Purchaser PROVIDED THAT the Purchaser shall indemnify the Seller and/or the relevant Marketing Authorisation Holder (as the case may be) for any and all costs, expenses and liabilities suffered or reasonably incurred by the Seller
and/or the Marketing Authorisation Holder in complying with or as a result of the provisions of this paragraph. 

  

	2.	    Ongoing calls for tender 

 If, prior to Closing, the Seller or any member of the
Seller’s Group (other than a Vaccines Group Company) has submitted a bid in any Market in response to any call for a tender (whether a new tender or the renewal of an existing tender) which includes the Products (the “Bid”),
then, following Closing: 
  

	(a)	to the extent that the Purchaser (or any member of the Purchaser’s Group) is prohibited from progressing the Bid in place of the relevant member of the Seller’s Group under Applicable Law, the Seller shall (or
shall procure that the relevant member of the Seller’s Group shall) take all steps as may be reasonably required in order to progress the Bid, including responding to all questions raised by the relevant third party and the Purchaser shall
provide all assistance (including access to the Purchaser’s employees) reasonably requested by the Seller to enable it to progress the Bid; and 

  

	(b)	if the Bid is successful, then either: 

  

	 	(i)	if permitted by Applicable Law and the relevant third party consents, the Purchaser (or any member of the Purchaser’s Group as the Purchaser shall nominate) shall enter into any contracts or other arrangements as
are required to give effect to the tender with the relevant third party and no member of the Seller’s Group shall be obliged to enter into any such contracts or arrangements; or 

 

	 	(ii)	if paragraph 2(b)(i) does not apply, the Seller (or any member of the Seller’s Group as the Seller shall nominate) shall enter into any contracts or other arrangements as are required to give effect to the tender
with the relevant third party and the tender shall be deemed to be a Transferred Contract, Shared Business Contract and/or a Non-Transferring Tender (as the case may be) and the provisions of Schedule 10 shall apply accordingly. 

  
 147 

 Schedule 9 

Certificate 
 (Clause 1.1)

 To: GlaxoSmithKline plc 
 [Date] 

Certificate 
 This Certificate is issued in accordance
with clause 4.4.1(iii)(b) and paragraph 1.1.4 of Schedule 15 of the sale and purchase agreement between Novartis AG and GlaxoSmithKline plc dated 22 April 2014, as amended (the “Agreement”). Unless otherwise defined, capitalised
words used in this Certificate shall have the meanings given to them in the Agreement. 
 We confirm that: 

1. no Material Adverse Effect has occurred between the date of the Agreement and the date of this Certificate; 

2. having made due and careful enquiry, we are not aware of any breach or breaches of Clause 9.1 which alone or together give rise to a Material Adverse
Effect; and 
 [either] 
 3. having made
due and careful enquiry, we are not aware of any breach or breaches of the Seller’s Warranties that would have occurred and that would, alone or together, have given rise to a Material Adverse Effect had the Seller’s Warranties been
repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. 

[or] 
 3. having made due and careful
enquiry, we are aware of the following material breaches of the Seller’s Warranties that would, alone or together, be material and have occurred had the Seller’s Warranties been repeated immediately before Closing by reference to the
facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. 

[description of material breaches.] 
  

 
 For an on behalf of Novartis AG 

  
 148 

 Schedule 10 

Shared Business Contracts, Mixed Contracts and Transferred Contracts 

 

	1	Delayed transfer of certain Transferred Contracts and Shared Business Contracts 

 Subject
to paragraph 5.6, any Transferred Contract, Transferred Intellectual Property Contract, or Shared Business Contract relating to a Delayed Business (“Delayed Business Contracts”) shall not be transferred to the relevant member of the
Purchaser’s Group until the relevant Delayed Closing Date and references in this Schedule 10 to “Closing”, “Closing Date” or “Effective Time” shall be deemed to be to “Delayed Closing Date” insofar
as they relate to such Delayed Business Contracts, except paragraphs 2, 3.1 and 5.1. 
  

	2	Disclosure 

 From Closing the Purchaser shall have the right to full disclosure of all
Transferred Contracts and Full Disclosure of the Relevant Part of the Shared Business Contracts (other than the Relevant Part of any Mixed Contracts) and the Seller shall use reasonable efforts to facilitate such disclosure as soon as reasonably
practicable. 
  

	3	Separation of Shared Business Contracts 

  

	3.1	Prior to Closing, the Seller and the Purchaser shall discuss and agree in good faith a process to identify all material Shared Business Contracts. 

 

	3.2	The Seller shall use its reasonable efforts to maintain relationships under the Shared Business Contracts and continue to operate the Shared Business Contracts, including without limitation fulfilling all its
obligations under the Shared Business Contracts (excluding the Relevant Parts), in the same manner as it has for the twelve months prior to the date of this Agreement. 

 

	3.3	The Purchaser may, by notice to the Seller at any time prior to the date falling 90 days after the Closing Date or, if the Seller has not provided Full Disclosure of the Relevant Part of a Shared Business
Contract on or prior to Closing, the date falling 90 days after the date on which Full Disclosure of the Relevant Part of the relevant Shared Business Contract is made (the “Relevant Election Date”), elect to take the rights and
obligations of the Relevant Part of any Shared Business Contract. 

  

	3.4	If the Purchaser makes an election under paragraph 3.3 above, the Seller and the Purchaser shall use their respective reasonable endeavours to procure that an arrangement is entered into with the relevant
counterparty to each Shared Business Contract, the effect of which shall be that, with effect from the date of the relevant arrangement, the benefit and burden of the Relevant Part is severed from such Shared Business Contract and an agreement or
arrangement equivalent to such Shared Business Contract is entered into between the relevant counterparty and a member of the Purchaser’s Group (or the Relevant Part of the Shared Business Contract is sub-licensed to such Purchaser) (a
“Separation”). For the avoidance of doubt, no part of any such Shared Business Contract shall be severed and transferred to the Purchaser in so far as it relates to the Seller’s Group Retained Business, any product other than
the Products or any Excluded Asset. 

  
 149 

	3.5	If no election is made by the Purchaser under paragraph 3.3 above by the Relevant Election Date, the provisions of paragraphs 6.2 of this Schedule shall apply in respect of the Relevant Part of such Shared
Business Contract until the earlier of 9 months from the Relevant Election Date and the date on which the Purchaser notifies the Seller that an alternative arrangement has been put in place. 

 

	3.6	For the avoidance of doubt, (i) paragraphs 3.3, 3.4 and 3.5 shall not apply in respect of any Shared Business Contract which terminates before the Relevant Election Date and (ii) paragraph 5.6 shall not apply in
respect of Shared Business Contracts or Mixed Contracts. 

  

	4	Separation of Mixed Contracts 

  

	4.1	Prior to Closing, the Seller and the Purchaser shall discuss and agree in good faith a process to identify all material Mixed Contracts. 

 

	4.2	From Closing, the Purchaser shall use all reasonable efforts to maintain relationships under the Mixed Contracts and continue to operate the Mixed Contracts, including without limitation fulfilling all its
obligations under the Mixed Contracts (excluding the Relevant Parts), substantially in the same manner in which they had been operated for the twelve months prior to the date of this Agreement. 

 

	4.3	The Seller and the Purchaser shall use their respective reasonable endeavours to procure that an arrangement is entered into with the relevant counterparty to each Mixed Contract (save for those Mixed Contracts
which the Seller and Purchaser otherwise agree and subject to such Mixed Contracts not containing any competitively sensitive information of the Influenza Business), the effect of which shall be that, with effect from the date of the relevant
arrangement, the benefit and burden of the Relevant Part is severed from such Mixed Contract and an agreement or arrangement equivalent to such Mixed Contract is entered into between the relevant counterparty and a member of the Seller’s Group
(or the Relevant Part of the Mixed Contract is sub-licensed to such Seller) (a “Mixed Contracts Separation”). 

  

	4.4	The Seller and the Purchaser shall, and shall procure that each other member of its Group shall, take all reasonable steps to install appropriate firewalls and other proportionate safeguards against the sharing
of competitively sensitive information of the Influenza Business with those employees of the Purchaser’s Group engaged in the business of influenza vaccines. To the extent it is necessary to redact any Mixed Contracts pending a Mixed Contracts
Separation, the Seller shall pay the costs of such redaction exercise. 

  

	5	Obligation to obtain Third Party Consents 

  

	5.1	Subject to paragraph 3, in relation to any Transferred Contract (excluding, for the purposes of this Schedule 10, any Product Approval or Product Application) or Transferred Intellectual Property Contract or
Co-Owned Vaccines Group Intellectual Property Right or Transferred Plant and Equipment which is not assignable or sub-licensable without a Third Party Consent or a Separation of a Shared Business Contract or a Mixed Contracts Separation of a Mixed
Contract which is not separable without a Third Party Consent, this Agreement shall not be construed as an assignment, an attempted assignment, a sub-licensing or an attempted sub-licensing and the Seller and the Purchaser shall each use their
respective reasonable endeavours both before and after Closing to obtain all necessary Third Party Consents as soon as possible and shall keep the other informed of progress in obtaining such Third Party Consents. The Seller shall deliver to the
Purchaser, on Closing or, if later, as soon as possible after receipt, any Third Party Consent. 

  
 150 

	5.2	In connection with the obtaining of any Third Party Consent referred to in paragraph 5.1, the Purchaser shall supply to the Seller such information as may be reasonably requested by the Seller or any
relevant third party. 

  

	5.3	Save as otherwise provided in this Agreement and save where related to the Mixed Contracts Separation of a Mixed Contract, the cost of any fee demanded by the third party as consideration for giving the Third
Party Consent shall be borne by the Purchaser, provided that: 

  

	 	5.3.1	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

  

	 	5.3.2	no party shall be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent.  

 

	5.4	Save as otherwise provided in this Agreement, the cost of any fee demanded by the third party as consideration for consenting to a Mixed Contracts Separation of a Mixed Contract and all administrative and all
reasonable fully burdened internal costs of the Purchaser’s Group (including any Delayed Vaccines Group Company) shall be borne by the Seller, provided that the cost of any fee demanded by the third party is agreed in advance by the Seller
(such agreement not to be unreasonably withheld or delayed). 

  

	5.5	The parties agree that the provisions of any document entered into in connection with a Third Party Consent (including by way of novation) shall be without prejudice to the provisions of Clauses 8.1, 8.2 and 14
of this Agreement. 

  

	5.6	Without prejudice to the obligation in paragraph 5.1 for the Seller and the Purchaser to use their respective reasonable endeavours to obtain Third Party Consents as soon as possible, the transfer to the
Purchaser (or any member of the Purchaser’s Group or its third party nominee) of any Transferred Contract shall not occur on Closing or, if later, the date on which the relevant Third Party Consent is obtained (a “Delayed
Contract”), in the following circumstances: 

  

	 	5.6.1	if the Seller or the relevant Business Seller and a member of the Purchaser’s Group agree in writing in respect of a specific Market that the Delayed Contract shall transfer at a later agreed date (a
“Delayed Contract Transfer Date”), in which case such Delayed Contract shall transfer on the Delayed Contract Transfer Date; or 

  

	 	5.6.2	if a Delayed Contract Transfer Date has not been agreed under sub-paragraph 5.6.1 and such Delayed Contract relates to an Ongoing Clinical Trial (a “Clinical Trial Agreement”), the Clinical
Trial Agreement shall not transfer before 1 May 2015 and shall transfer after that date but only to the extent permitted by Applicable Law; or 

  

	 	5.6.3	if a Delayed Contract Transfer Date has not been agreed under sub-paragraph 5.6.1 and such Delayed Contract is required to facilitate the provision of services by the Seller’s Group under the
Transitional Distribution Services Agreement in any Market (a “Distribution Contract”), such Delayed Contract shall transfer in accordance with paragraph 5.7. 

The parties agree that the provisions of this paragraph 5.6 shall not apply where a Contract is required under Applicable Law to transfer at a
date that is earlier than the dates set out in sub paragraphs 5.6.1 to 5.6.3 and paragraph 5.7. 

  
 151 

	5.7	The parties agree that no Distribution Contracts shall transfer to the Purchaser (or a member of the Purchaser’s Group) before the date falling 90 days after the Closing Date (the “Moratorium
Date”) (unless such Distribution Contract relates to distribution services provided in the USA). Following the Moratorium Date (or after the Closing Date if the Distribution Contract relates to distribution services in the USA), the
Distribution Contracts shall transfer to the Purchaser (or a member of the Purchaser’s Group) as soon as possible after any relevant Third Party Consent is obtained unless either party notifies the other by the date which is 15 Business Days
prior to the Moratorium Date that it believes (acting reasonably) that the transfer of the relevant Distribution Contract prior to the Planned Distribution Transfer Date will result in one or more Identified Risks, in which case, the relevant
Distribution Contract shall not transfer to the Purchaser (or a member of the Purchaser’s Group) until the relevant Distribution Transfer Date unless any and all of the Identified Risks have been resolved to the reasonable satisfaction of the
party that may be adversely affected by the relevant Identified Risks before such date. 

  

	5.8	From the Effective Time until the transfer of any Delayed Contract is effected in accordance with sub-paragraphs 5.6 or 5.7, the provisions of paragraph 6 of this Schedule shall apply to such Delayed Contracts.
Nothing in this paragraph 5.8 shall preclude the Purchaser or any member of the Purchaser’s Group from informing the counterparty to any Delayed Contract of the transfer of the Business to it or from engaging with such counterparty with respect
to any matter relating to such Delayed Contract. 

  

	5.9	The provisions of paragraphs 3.3 to 3.5 (inclusive), paragraphs 5.1 to 5.8 (inclusive) and the entirety of paragraph 5 of this Schedule 10 shall not apply to Non-Transferring Tenders. The parties agree that each
Non-Transferring Tender shall remain with the relevant member of the Seller’s Group that is the contracting party to the Non-Transferring Tender as at the date of this Agreement and no Third Party Consents shall be sought in respect of any
Non-Transferring Tenders. 

  

	6	Obligations until Third Party Consents are obtained/where Third Party Consents are refused and with respect to Non-Transferring Tenders 

 

	6.1	Subject to paragraph 5.2 and paragraph 5.3 and the Seller’s obligations under the Transitional Distribution Services Agreement, the Purchaser shall assume, carry out, perform and discharge the Seller’s
and the Business Seller’s obligations arising under the Transferred Contracts (excluding the Relevant Part of any Mixed Contracts), Transferred Intellectual Property Contracts, Co-Owned Vaccines Group Intellectual Property Rights, Transferred
Plant and Equipment, and the Relevant Part of the Shared Business Contracts as from the Effective Time but only to the extent such obligations do not constitute Excluded Liabilities. 

 

	6.2	In respect of any Transferred Contract (excluding the Relevant Part of any Mixed Contract), Transferred Intellectual Property Contract, Transferred Plant and Equipment, Relevant Part of Shared Business Contract
(other than a Non-Transferring Tender) or Co-Owned Vaccines Group Intellectual Property Right, from the Effective Time until the relevant Third Party Consent has been obtained as contemplated by paragraph 5.1 or where the Third Party Consent has
been refused and in respect of the Non-Transferring Tenders: 

  

	 	6.2.1	 the relevant Business Seller shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where
holding on trust is not possible under local law or otherwise impracticable, the relevant Business Seller and the 

  
 152 

	 	
Purchaser shall make such other arrangements between themselves to provide to the Purchaser the benefits of the Contract (other than amounts corresponding to any Tax Liability by the relevant
Business Seller in respect of amounts due under or in respect of the Transferred Contract (excluding the Relevant Part of any Mixed Contracts), Transferred Intellectual Property Contract, Relevant Part of Shared Business Contract, Transferred Plant
and Equipment or Co-Owned Vaccines Group Intellectual Property Right or any Non-Transferring Tender) including the enforcement at the cost and for the account of the Purchaser of all rights of the relevant Business Seller against any other party
thereto; 

  

	 	6.2.2	to the extent that the Purchaser (or the relevant member of the Purchaser’s Group) is lawfully able to do so and subject to the Seller’s obligations under the Transitional Distribution Services
Agreement, the Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) perform the relevant Business Seller’s obligations under the Contract (but only to the extent such obligations do not constitute
Excluded Liabilities) as agent or sub-contractor and shall indemnify the Seller and the relevant Business Seller if the Purchaser or the relevant member of the Purchaser’s Group fails to do so; 

 

	 	6.2.3	to the extent that the Purchaser (or a member of the Purchaser’s Group) is not lawfully able to perform such obligations, the Seller shall procure that the relevant Business Seller shall, (subject to being
indemnified by the Purchaser for any Losses the Seller or the relevant Business Seller may incur in connection therewith) do all such things as the Purchaser (or the relevant member of the Purchaser’s Group may direct or reasonably require to
enable due performance of the Contract; 

  

	 	6.2.4	the Seller shall (or shall procure that the relevant Business Seller shall) act in accordance with any reasonable instructions or directions provided to it by the Purchaser (or a relevant member of the
Purchaser’s Group) in relation to the management and operation of any Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of any Shared Business Contract (excluding, for the avoidance of doubt, any part of any
Shared Business Contract which relates exclusively to the Seller Group’s Retained Business), and the Purchaser shall indemnify the relevant Business Seller for any Losses that the Business Seller may incur in connection therewith, provided that
should the Seller (or relevant Business Seller) believe (acting reasonably) that compliance with any instruction or direction given by the Purchaser (or a member of the Purchaser’s Group) pursuant to this sub-paragraph 6.2.4 will result in a
breach of Applicable Law (including a breach of the terms of the relevant Contract), (i) the Seller (or relevant member of the Seller’s Group), shall inform the Purchaser (or the member of the Purchaser’s Group which gave the instruction)
and shall not be required to implement such instruction or direction; and (ii) the parties shall discuss the concerns of the relevant member of the Seller’s Group in good faith, to determine whether an agreement can be reached such that the
relevant instruction or direction can be implemented by the Seller (or the relevant Business Seller); 

  

	 	6.2.5	 without prejudice to the provisions of paragraph 6.2.2 and subject to Applicable Law, the Seller shall provide (or procure that the relevant
Business Seller shall provide) the Purchaser (or the relevant member of the Purchaser’s Group) (with access to such documents, facilities, information and assistance as the Purchaser

  
 153 

	 	
(or the relevant member of the Purchaser’s Group) may reasonably require with respect to any Transferred Contract, the Transferred Intellectual Property Contract, the Co-Owned Transferred
Product Intellectual Property Right, and the Relevant Part of the Shared Business Contract which is subject to the provisions of this paragraph 6; and 

  

	 	6.2.6	in respect of any Contract for the sale of any Product or Products and any Non-Transferring Tender, the amount of any profit arising from sales pursuant to any such Contract shall be calculated and remitted to
the Purchaser in accordance with the relevant provisions of the Transitional Distribution Services Agreement. 

  

	6.3	The Seller shall (or shall procure that the relevant Business Seller shall) retain, carry out, perform and discharge the Seller’s and the Business Seller’s obligations under the Relevant Part of the
Mixed Contracts which are Transferred Contracts, and subject to paragraph 6.4, the Seller shall assume, carry out, perform and discharge the Purchaser’s Group and the Vaccines Group Companies’ obligations arising under the Relevant Part of
the Mixed Contracts held by a Vaccines Group Company as from Closing. 

  

	6.4	In respect of the Relevant Part of each Mixed Contract held by a Vaccines Group Company from Closing until the relevant Mixed Contracts Separation: 

 

	 	6.4.1	the relevant Vaccines Group Company shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where holding on trust is not possible under local law or otherwise
impracticable, the Seller and the Purchaser shall make such other arrangements between themselves to provide to the Seller the benefits of the Contract (other than amounts corresponding to any Tax Liability by the relevant Vaccines Group Company in
respect of amounts due under or in respect of the Relevant Part of such Mixed Contract) including the enforcement at the cost and for the account of the Seller of all rights of the relevant Vaccines Group Company against any other party thereto;

  

	 	6.4.2	to the extent that the Seller (or the relevant member of the Seller’s Group) is lawfully able to do so, the Seller shall perform (or procure that a member of the Seller’s Group performs) the relevant
obligations of the relevant Vaccines Group Company under the Contract as agent or sub-contractor and shall indemnify the Purchaser and relevant Vaccines Group Company if the Seller fails to do so; and 

 

	 	6.4.3	 to the extent that the Seller (or a member of the Seller’s Group) is not lawfully able to perform, or procure performance of, such
obligations, the Purchaser shall procure that the relevant Vaccines Group Company shall, (subject to being indemnified by the Seller for any Losses the relevant Vaccines Group Company may incur in connection therewith) act in accordance with any
reasonable instructions or directions provided to it by the Seller (or a relevant member of the Seller’s Group) in relation to the management and operation of any Relevant Part of any Mixed Contract, and the Seller shall indemnify the
Purchaser and the relevant member of the Purchaser’s Group in respect thereof, provided that should the Purchaser or the relevant member of the Purchaser’s Group believe that compliance with any instruction or direction given by the Seller
(or a member of the Seller’s Group) pursuant to this sub-paragraph 6.4.3 will result in a breach of Applicable Law (including a breach of the terms of the relevant Contract), the Purchaser (or relevant member of the Purchaser’s Group),
shall inform the Seller 

  
 154 

	 	
(or the member of the Seller’s Group which gave the instruction and shall not be required to implement such instruction or direction. 

 

	7	Failure to Obtain Third Party Consents 

  

	7.1	If a Third Party Consent is refused or otherwise not obtained on terms reasonably acceptable to the Purchaser within 18 months of Closing, or in the case of a Separation or a Mixed Contracts Separation, 18 months
of the Relevant Election Date or Closing (respectively): 

  

	 	7.1.1	the Seller shall be entitled to procure the termination of the Transferred Contract, Transferred Plant and Equipment, Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract
and the obligations of the parties under this Agreement in relation to such Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract shall cease forthwith; 

 

	 	7.1.2	the Seller may request termination of the Relevant Part of the Mixed Contract and the obligations of the parties under this Agreement in relation to such Relevant Part of the Mixed Contract shall cease forthwith;

  

	 	7.1.3	references in this Agreement to the Transferred Contracts, Transferred Intellectual Property Contracts, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract and the Vaccines Group
Businesses (other than in this paragraph 7) shall be construed as excluding such Transferred Contract, Transferred Intellectual Property Contract, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract; and

  

	 	7.1.4	the Seller and the Purchaser shall use all reasonable efforts to put in place alternative arrangements so as to give the Purchaser or the Seller (as the case may be) equivalent benefits or rights as would have
been enjoyed under the terminated Transferred Contract, Transferred Intellectual Property Contract, Relevant Part of the Shared Business Contract, Co-Owned Vaccines Group Intellectual Property Right or Relevant Part of the Mixed Contract.

  

	7.2	Notwithstanding the above, the Purchaser and the Seller may agree at any time after Closing not to seek the Separation of a Shared Business Contract or the Mixed Contracts Separation of a Mixed Contract (to the
extent only that the Seller and the Purchaser agree that such Mixed Contract does not contain any competitively sensitive information). 

  

	8	Non-Transferring Tenders 

  

	8.1	Subject to the termination of any Non-Transferring Tender (or any Relevant Part thereof) pursuant to paragraphs 8.2 and 8.3 below, the provisions of paragraph 6.2 of this Schedule 10 shall continue to apply in
respect of a Non-Transferring Tender for the term of the relevant Non-Transferring Tender. 

  

	8.2	The Purchaser may serve written notice on the Seller requesting it at its absolute discretion to (i) terminate (or to procure the termination of) any Non-Transferring Tender which is a Products-Only Tender (an
“NTT Products-Only Tender”) or (ii) amend or to procure the amendment of any Non-Transferring Tender which is a Multi-Basket Tender (a “NTT Multi-Basket Tender”) such that the Relevant Part thereof shall be
terminated. 

  
 155 

	8.3	Upon receipt of such notice, the Seller shall as soon as reasonably practicable thereafter (i) take such steps as are reasonably necessary to terminate the relevant NTT Products-Only Tender and (ii) use its
reasonable endeavours to procure an amendment of the relevant NTT Multi-Basket Tender. Where the Purchaser serves such a request: 

  

	 	8.3.1	any and all actions, claims, demands, proceedings, judgments, liabilities, loss, damages, payments, costs and expenses arising in connection with such termination or amendment (including in respect of any early
termination or similar fee or payment and all liabilities costs, expenses and payments suffered or reasonably incurred by the Business Seller in procuring such termination or amendment (as applicable)) shall be for the account of the Purchaser and
the Purchaser shall indemnify the relevant Business Seller in respect thereof; and 

  

	 	8.3.2	the Purchaser shall be solely responsible for putting in place its own arrangements in respect of the matters the subject of such terminated NTT Products-Only Tender or amended NTT Multi-Basket Tender (as the
case may be) and no member of the Seller’s Group shall have any responsibility for putting in place any such arrangements. 

  

	8.4	For the avoidance of doubt, if any NTT Products-Only Tender is terminated (or, in the case of a NTT Multi-Basket Tender, amended such that the Relevant Part thereof is terminated) by the relevant Business Seller
pursuant to paragraph 8.2 then no member of the Seller’s Group shall be liable to make any payment to the Purchaser or any other member of the Purchaser’s Group in respect of any consideration payable or allocation made under this or any
other Ancillary Agreement. 

 For the purposes of this Schedule, the following terms shall have the following meanings: 

“Separation Plan” has the meaning given to it under the Transitional Distribution Services Agreement; 

“Identified Risk” means a specifically identified adverse operational, legal or tax impact affecting either the Seller’s Group or the
Purchaser’s Group (including an impact on the ability of the Seller’s Group to perform its obligations under the Transitional Distribution Services Agreement) which would arise or which would increase (by more than a de minimis amount)
solely by reason of the relevant Distribution Contract transferring to the Purchaser (or the relevant member of the Purchaser’s Group) on a date prior to the Planned Distribution Transfer Date; and 

“Planned Distribution Transfer Date” means the Distribution Transfer Date for the applicable Market as set out in the Separation Plan. 

  
 156 

 Schedule 11 

Employees 
 (Clause 2.4.1)

  

	1	Information and consultation 

  

	1.1	At such time as the parties agree to be appropriate following the public announcement of the matters contemplated by this Agreement, the Seller and the Purchaser or the relevant member of the Purchaser’s
Group shall jointly communicate to the Employees an agreed notice which shall, other than to the extent the parties agree otherwise: 

  

	 	1.1.1	inform the Employees that following Closing those Employees who continue to be employed in the Business (as carried on by the Vaccines Group) would be employed by the Purchaser or relevant member of the
Purchaser’s Group; and 

  

	 	1.1.2	comply with the requirements of any applicable national law. 

 For the avoidance of doubt
the parties may agree to issue such notice to different Employees or categories of Employees at different times and in different forms. 
  

	1.2	Notwithstanding the operation of paragraph 1.1 above, the Seller and the Purchaser agree to comply with any more onerous notice requirements imposed by local laws. 

 

	1.3	The Purchaser (on its own behalf and on behalf of any relevant member of the Purchaser’s Group) shall provide the Seller (for itself and any relevant member of the Seller’s Group) with such information
and assistance at such times as the Seller may reasonably request or as may be reasonably necessary for the Seller or any other member of the Seller’s Group to comply with any formal or informal requirement to inform or consult with the
Employees, a relevant trade union, a relevant works council, or any other employee representatives in connection with the matters contemplated by this Agreement (which formal or informal requirements the Seller hereby undertakes to comply or procure
compliance with). Where reasonably necessary to ensure compliance with any formal or informal requirements or obligations to inform or consult with Employees, a relevant trade union, a relevant works council or any other employee representatives in
connection with the matters contemplated by this Agreement, the Seller (for itself and for each member of the Seller’s Group) and the Purchaser (for itself and for each member of the Purchaser’s Group) agree that the Purchaser or relevant
member of the Purchaser’s Group shall cooperate with and participate in any information, negotiation and/or consultation process as reasonably required by the Seller. 

 

	1.4	As soon as practicable following the date of this Agreement, the Purchaser agrees to provide on a timely basis such information, in writing, in respect of its existing terms and conditions of employment as may
reasonably be required by the Seller so as to facilitate the Seller’s information and consultation exercise with its Employees in respect of the matters set out in this Agreement. 

 

	2	Vaccines Business Employees 

  

	2.1	General 

  

	 	2.1.1	 The Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) fulfil all its duties and obligations under
Applicable Law in relation to the Vaccines Business Employees. Where the provisions of local law do not provide for an automatic transfer of the employment of the Vaccines Business

  
 157 

	 	
Employees to the Purchaser or a relevant member of the Purchaser’s Group with effect from (and including) the Closing Date, then paragraph 2.2 below shall apply. Where the provisions of
local law do provide for an automatic transfer of employment of the Relevant Vaccines Business Employees to the Purchaser or the relevant member of the Purchaser’s Group with effect from (and including) the Closing Date, then paragraph 2.3
below shall apply. 

  

	 	2.1.2	Notwithstanding that the employees referred to in the document attached to the email from [***] of Linklaters LLP and received by [***] of Slaughter and May on 25 February 2015 at 15:30 (GMT) may not in fact be
working wholly or substantially in the Business (as carried on by the Vaccines Group), the parties hereby acknowledge and agree to treat them as if they are so working for the purposes of this Agreement. 

 

	 	2.1.3	The parties acknowledge and agree that: 

  

	 	(i)	any Deferred Employee shall be treated for all purposes under this Agreement as if such Deferred Employee were a Vaccines Business Employee or a Vaccines Group Company Employee (as appropriate); and 

 

	 	(ii)	the Purchaser’s obligations under this Schedule 11 shall apply in respect of each Deferred Employee in the same way as they do to each Vaccines Business Employee or Vaccines Group Company Employee (as appropriate);
and 

  

	 	(iii)	if any Deferred Employee accepts an offer of employment made by the Purchaser under paragraph 2.2.1 below or becomes an employee of a Vaccines Group Company after the Closing Date, such Deferred Employee shall further
be treated for all purposes under this Agreement as a Transferred Employee. 

  

	 	2.1.4	For the avoidance of doubt, this paragraph 2 shall not apply to any Excluded Employee, who will remain employed by the Seller or the relevant member of the Seller’s Group. 

 

	 	2.1.5	The parties agree that no provisions in this paragraph 2 shall require the Purchaser or another member of the Purchaser’s Group (including any Vaccines Group Company) to employ a Relevant Employee on and
from the Closing Date until such time as such employee has the right (including, for the avoidance of any doubt, under any grace period) or is otherwise permitted under Applicable Law to accept an offer to work for the Purchaser or relevant member
of the Purchaser’s Group and to commence working for the Purchaser or relevant member of the Purchaser’s Group. Any such employee will only be a “Transferred Employee” for the purposes of this Agreement from the time (the
“Transfer Date”) he becomes an employee of a member of the Purchaser’s Group, and any provisions relating to Transferred Employees in this Agreement shall only apply to any such employee with effect on and from the Transfer
Date and with the following amendments: 

  

	 	(i)	references to the “Closing Date” and the “Effective Time” in paragraphs 4.1, 4.3.1, 4.3.2 and 4.4 shall be replaced with references to the “Transfer Date”; 

 

	 	(ii)	references to an “Employee” in paragraphs 4.2.1, 4.2.2 and 4.3.5 shall be extended to refer to such Transferred Employee, and to the extent required 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 158 

	 	
in respect of such Transferred Employee references to the “Closing Date” and the “Effective Time” shall be replaced with references to the “Transfer Date;

  

	 	(iii)	the reference to “basic salary” in paragraph 5.1.1 shall mean the basic salary that applied to such Transferred Employee immediately prior to the Transfer Date; 

 

	 	(iv)	references to the “Closing Date” and the “Effective Time” in paragraph 6.2 shall be replaced with references to the “Transfer Date”; 

 

	 	(v)	for the purposes of paragraphs 11.2 and 11.8 references to “Closing” and the “Closing Date” shall be construed as references to the Transfer Date; and 

 

	 	(vi)	such other amendments as the parties may agree, each acting in good faith. 

  

	2.2	Where no automatic transfer of employment 

  

	 	2.2.1	In such timescale as the parties may agree in order to comply with any Applicable Law, but in any event at least 15 days prior to the Closing Date, unless agreed otherwise by the parties (such agreement not to be
unreasonably withheld by any party), the Purchaser or relevant member of the Purchaser’s Group shall make an offer to each Vaccines Business Employee employed by the Seller or a member of the Seller’s Group to employ him or her under a new
contract of employment to commence with effect from (and including) the Closing Date provided that such employee continues to be a Vaccines Business Employee until the Closing Date. Save as otherwise agreed with the Seller (such agreement not to be
unreasonably withheld), the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that Vaccines Business Employee immediately prior to the Closing Date. The Purchaser shall
keep the Seller updated throughout the offer process on when offers are made and accepted or rejected. 

  

	 	2.2.2	If the Vaccines Business Employee wishes to accept the offer of employment from the Purchaser or the relevant member of the Purchaser’s Group, then the Seller shall (or shall procure that the relevant member
of the Seller’s Group shall), insofar as it is permitted by Applicable Law, waive the requirement on the Vaccines Business Employee concerned to give any period of notice of termination of his or her employment under the terms of his or her
employment so as to allow the Vaccines Business Employee to commence employment with the Purchaser or relevant member of the Purchaser’s Group with effect from (and including) the Closing Date. 

 

	 	2.2.3	 The parties agree that where a Relevant Employee (a “Leave Employee”) in the United States is absent on short term disability
(including, without limitation, maternity) leave or military leave which will end on or after the Closing Date, and would otherwise have been made an offer of employment to commence with effect from (and including) the Closing Date by the Purchaser
or relevant member of the Purchaser’s Group, such an offer shall be made, but employment pursuant to such offer shall commence only with effect from (and including) the date on which the Leave Employee returns to work at the end of such period
of short term disability (including, without limitation, maternity) or military leave, provided always that the 

  
 159 

	 	
date of such return to work is no more than six months after the date on which such short term leave began. Any such employee will only be a “Transferred Employee” for the purposes of
this Agreement from the time (the “Transfer Date”) he becomes an employee of a member of the Purchaser’s Group, and any provisions relating to Transferred Employees in this Agreement shall only apply to any such employee with
effect on and from the Transfer Date and with the following amendments: 

  

	 	(i)	references to the “Closing Date” and the “Effective Time” in paragraphs 4.1, 4.3.1, 4.3.2 and 4.4 shall be replaced with references to the “Transfer Date”; 

 

	 	(ii)	references to an “Employee” in paragraphs 4.2.1, 4.2.2 and 4.3.5 shall be extended to refer to such Transferred Employee, and to the extent required in respect of such Transferred Employee references to the
“Closing Date” and the “Effective Time” shall be replaced with references to the “Transfer Date”; 

  

	 	(iii)	the reference to “basic salary” in paragraph 5.1.1 shall mean the basic salary that applied to such Transferred Employee immediately prior to the Transfer Date; 

 

	 	(iv)	references to the “Closing Date” and the “Effective Time” in paragraph 6.2 shall be replaced with references to the “Transfer Date”; 

 

	 	(v)	for the purposes of paragraphs 11.2 and 11.8 references to “Closing” and the “Closing Date” shall be construed as references to the “Transfer Date”; and 

 

	 	(vi)	such other amendments as the parties may agree, each acting in good faith. 

  

	 	2.2.4	If any Leave Employee has not returned to work by the date falling six months after the date on which such short term leave began then such Leave Employee shall be treated for all purposes under this Agreement as
an Excluded Employee. 

  

	 	2.2.5	If in relation to any Relevant Employee, the day prior to the Closing Date occurs on a day which is not a Relevant Working Day in the jurisdiction in which that Employee is employed, the parties may agree (such
agreement not to be unreasonably withheld by any party), that such Relevant Employees (the “Working Day Relevant Employees”) shall remain employees of the Seller or a member of the Seller’s Group until the first Relevant
Working Day on or after the Closing Date (the “Working Day Employee Termination Date”). If so agreed, the parties agree that the transfer of employment of the Working Day Relevant Employees to the Purchaser or one of its Affiliates
shall take effect on and from the day following the Working Day Employee Termination Date which applies to the relevant Working Day Relevant Employee. The Purchaser acknowledges that it will be responsible for the total amount actually paid by the
Seller or its Affiliate for compensation and benefits, including any withholding taxes and payroll taxes paid by the Seller’s Group, to or in respect of the Working Day Relevant Employees in relation to their ordinary course of employment for
the period on and from the Effective Time to (and including) the Working Day Employee Termination Date which applies to the relevant Working Day Relevant Employee. 

  
 160 

	2.3	Where automatic transfer of employment 

 If the Transfer Regulations do not or are found
not to or are alleged not to apply to any person who is a Relevant Vaccines Business Employee and to whom paragraph 2.2 does not apply, the Purchaser agrees that following Closing: 

 

	 	2.3.1	in consultation with the Seller, the Purchaser or relevant member of the Purchaser’s Group shall within 10 Business Days of being so requested by the Seller (as long as the request is made no later than 3
months after Closing) (or if the Purchaser so chooses), make such Relevant Vaccines Business Employee an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, a date agreed between the parties
and such employee; and 

  

	 	2.3.2	save as otherwise agreed with the Seller (such agreement not to be unreasonably withheld) the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were
provided to that Relevant Vaccines Business Employee immediately prior to the Closing Date. 

  

	3	Wrong-pocket arrangements for persons other than Relevant Employees 

  

	3.1	If the contract of employment of any person other than a Relevant Employee is found or alleged to have effect upon Closing as if originally made with the Purchaser or another member of the Purchaser’s Group
(including any Vaccines Group Company) as a consequence of this Agreement, or if any Vaccines Group Company employs any person who at Closing does not work wholly or substantially in the Business (as carried on by the Vaccines Group), or if any
Vaccines Group Company employs or becomes liable to employ on or after the Closing Date any person other than a Relevant Employee as a consequence of such person exercising a right of objection against the transfer of his employment relationship
(including without limitation pursuant to Section 613a para. 6 German Civil Code (BGB)) which results in his continuing employment relationship with that Vaccines Group Company or otherwise exercising a right to be re-hired by that Vaccines Group
Company and provided in either case that the right arose in connection with Closing or matters arising prior to Closing, the Seller agrees that following Closing: 

 

	 	3.1.1	in consultation with the Purchaser, the Seller or relevant member of the Seller’s Group may within 10 Business Days of being so requested by the Purchaser (as long as the request is made no later than 3
months after Closing or, in the case of an objection or a right to be re-hired referred to above, no later than 3 months after that person exercises a right of objection or a right to be re-hired) (or if the Seller so chooses), make to that person
an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, the termination referred to below; and 

  

	 	3.1.2	the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that person immediately prior to the Closing Date. 

 

	3.2	 After the expiry of the 10 Business Days referred to at paragraph 3.1 above, and provided that the relevant member of the Purchaser’s
Group takes such steps as are legally possible to terminate the employment of the person concerned as soon as reasonably practicable after becoming aware of the finding, allegation, objection or re-hire referred to at paragraph 3.1 above (either by
giving notice or transferring the person by agreement to 

  
 161 

	 	
be concluded between the relevant member of the Purchaser’s Group, the person concerned and the relevant member of the Seller’s Group), the Seller shall be responsible for and shall
indemnify and keep indemnified the Purchaser (for itself and as trustee for any relevant member of the Purchaser’s Group) against all Losses from time to time made, suffered or incurred by the Purchaser (or any other member of the
Purchaser’s Group) as a result of: 

  

	 	3.2.1	the actual or alleged transfer to (or continued employment with or right to be employed by) a member of the Purchaser’s Group and (regardless of whether there has been such a transfer) any employment
liabilities relating to such person; 

  

	 	3.2.2	employing such person on and from the Closing Date until such termination (up to the time reasonably expected to have achieved such termination in accordance with the terms of the contract of employment and
Applicable Law) but subject to a maximum period of 6 months unless prevented by the terms of the contract of employment or Applicable Law; and 

  

	 	3.2.3	such termination. 

  

	3.3	The parties agree to co-operate in good faith to minimise the Losses which are subject to the indemnity referred to in paragraph 3.2 above. 

 

	3.4	Save as set out in paragraph 3.5 below, the provisions of this paragraph 3 shall not apply in relation to any of the people listed in Schedule 5 under the heading “Marburg 35”. 

 

	3.5	As soon as any 18 people listed in Schedule 5 under the heading “Marburg 35” have exercised a right of objection or a right to be re-hired referred to at paragraph 3.1 above, then the provisions of this
paragraph 3 shall apply in relation to the remaining 17 people listed under the heading “Marburg 35”. 

  

	4	Employment liabilities 

  

	4.1	All wages, salaries, employer’s liabilities in respect of associated Taxes and other periodic outgoings in respect of the Transferred Employees which relate to a period: 

 

	 	4.1.1	on and after the Effective Time shall be borne or discharged by the Purchaser or relevant member of the Purchaser’s Group; and 

 

	 	4.1.2	before the Effective Time shall be borne or discharged by the Seller or relevant member of the Seller’s Group. 

  

	4.2	Subject to paragraph 4.1, the Seller shall (for itself and for each member of the Seller’s Group) indemnify and keep indemnified the Purchaser (for itself and as trustee for each other member of the
Purchaser’s Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 12) in respect of: 

  

	 	4.2.1	the employment of any Employee at any time prior to the Effective Time (excluding any Transferred Employee Benefit Liabilities (as defined in Schedule 12) which the Purchaser agrees to assume in accordance with
Schedule 12); 

  

	 	4.2.2	 any termination of the employment of any Employees prior to the Effective Time and any termination of the employment of any Employees on and
after the Effective Time but prior to the Closing Date which are not otherwise covered by paragraph 4.3.2 including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination and similar obligations
(excluding any liability arising directly as a result of any breach of the commitments 

  
 162 

	 	
set out in paragraph 5 or 6 below by the Purchaser or a member of the Purchaser’s Group and any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to
any Employee before the Closing Date as a result of which that Employee treats his employment as having been terminated prior to the Closing Date); 

  

	 	4.2.3	any amount which becomes payable to any Employee or benefit to which any Employee becomes entitled by reason of this Agreement or the matters it contemplates, including any change of control or other payment or
benefit (and including any enhancement of severance terms on a subsequent termination of employment but excluding any Losses relating to any share-based incentive schemes, as to which see paragraph 11 below); 

 

	 	4.2.4	any failure by the Seller or any other member of the Seller’s Group to comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this
Agreement (other than as a result of any failure set out in paragraph 4.3.3 below); and 

  

	 	4.2.5	any breach by the Seller or any other member of the Seller’s Group of paragraph 4.1.2 above or paragraph 4.4, 4.5 or 10 below. 

 

	4.3	The Purchaser shall (for itself and for each member of the Purchaser’s Group) indemnify and keep indemnified the Seller (for itself and as trustee for each other member of the Seller’s Group) against
all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 12) in respect of: 

  

	 	4.3.1	the employment of any of the Transferred Employees on and after the Effective Time (including, without limitation, any changes to terms and conditions of employment by the Purchaser or any other member of the
Purchaser’s Group); 

  

	 	4.3.2	any termination of the employment of any Transferred Employees on and after the Effective Time and any termination of the employment of any Employees by a member of the Seller’s Group on and after the
Effective Time but prior to the Closing Date who would, but for such termination of employment by a member of the Seller’s Group, have been Transferred Employees (save in each case where such termination is in order to facilitate the transfer
of any Relevant Employees pursuant to paragraph 2 of this Schedule 11 or is otherwise in connection with any rejection or objection to such transfer in circumstances where paragraph 4.3.5 does not apply) including, but not limited to, all claims
relating to severance, termination pay, pay in lieu of notice of termination and similar obligations except as contemplated under paragraph 3.2 above; 

  

	 	4.3.3	any failure by the Purchaser or any other member of the Purchaser’s Group to provide information and reasonable assistance to the Seller to enable the Seller or any other member of the Seller’s Group to
comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Agreement; 

  

	 	4.3.4	any breach by the Purchaser or any other member of the Purchaser’s Group of paragraph 4.1.1 above or paragraph 4.4 or 4.5 below; and 

 

	 	4.3.5	 any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before the Closing Date as a
result of which that 

  
 163 

	 	
Employee treats his employment as having been terminated prior to the Closing Date. 

  

	4.4	Any amount payable to or in respect of any Transferred Employee on or after the Closing Date (including without limitation amounts paid under paragraph 4.5 below) which (ignoring vesting conditions and any amount
payable in respect of Employee Benefits or otherwise in accordance with Schedule 12) is referable to the period prior to the Effective Time is payable by the Seller (for itself or on behalf of the relevant Share Seller or Business Seller).
Responsibility for amounts payable which are only partly referable to the period prior to the Effective Time (again ignoring vesting conditions) is to be shared between the Seller (for itself or on behalf of the relevant Share Seller or Business
Seller) and the Purchaser (for itself or on behalf of the relevant member of the Purchaser’s Group) such that the Seller bears S per cent. of the cost and the Purchaser bears P per cent., where S is the percentage of the period by reference to
which the amount was earned which fell before the Effective Time and P is the percentage of that period which falls on and after the Effective Time. Save for the payments described in paragraph 4.5 below, the Purchaser shall, or shall procure that
such other member of the Purchaser’s Group shall, pay such amounts when due to the relevant Transferred Employees on or after the Closing Date and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in
respect of such amounts. The Seller covenants to reimburse the Purchaser in respect of any such amount (or S per cent. of it where relevant), including any Tax payable or accountable for by the employer in respect of such amount, within 30 days of
receiving notification that it has been paid to the extent such amounts are not reflected in the Closing Statement. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made.

  

	4.5	Following the Closing Date: 

  

	 	4.5.1	the Seller shall, or shall procure that a member of the Seller’s Group shall, pay a pro-rated cash bonus for the current bonus year as at the Effective Time and any unpaid cash bonus for the bonus year which
ended before the Effective Time to each Transferred Employee who participated in such annual cash bonus plan within 90 days following the Closing Date. For the avoidance of doubt, this paragraph 4.5.1 shall apply whether or not a member of the
Seller’s Group provides post-Closing payroll services to a Vaccines Group Company; and 

  

	 	4.5.2	where the Seller is able to determine performance, any such bonus payment made to such eligible employees will be based on the Seller’s determination of performance to the Effective Time and (where
applicable) pro-rated to the Effective Time; or 

  

	 	4.5.3	where the Seller is unable to determine performance (either business or individual), for example, because the Effective Time occurs near the start of the bonus year, the Seller shall calculate any such bonus
payment based on a deemed achievement of performance conditions at target level pro-rated to the Effective Time; and 

  

	 	4.5.4	as soon as reasonably practicable after the Closing Date, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, provide such information as the Seller requires in order
for the Seller to calculate the Tax payable or accountable for by the employer in respect of such bonus payments; and 

  
 164 

	 	4.5.5	if and to the extent permitted by Applicable Law, the Seller shall, or shall procure that such other member of the Seller’s Group shall, deduct and/or account for any Tax payable or accountable for by the
employer in respect of such bonus payments; or 

  

	 	4.5.6	if and to the extent paragraph 4.5.5 above is not permitted by Applicable Law, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, pay and/or account for any Tax
payable or accountable for by the employer in respect of such bonus payments and the Seller shall reimburse the Purchaser in respect of such amounts so paid and/or accounted for; and 

 

	 	4.5.7	where any amount in respect of payments made by the Seller or any other member of the Seller’s Group pursuant to this paragraph 4.5 is reflected in the Closing Statement, the Purchaser shall reimburse the
Seller in respect of the amount so reflected. For the avoidance of doubt, no reimbursement by the Purchaser shall be due in respect of any such payment to the extent it is not reflected in the Closing Statement. 

 

	4.6	If any loan made by a member of the Seller’s Group to a Transferred Employee (an “Employee Loan”) remains outstanding at the Closing Date, then the parties shall co-operate in good faith to
procure an outcome such that: 

  

	 	4.6.1	the Employee Loan shall be discharged in full within a reasonable period after the Closing Date and the relevant member of the Seller’s Group shall receive all outstanding amounts of principal and interest
under the Employee Loan (either from the relevant Transferring Employee or from a member of the Purchaser’s Group); and 

  

	 	4.6.2	a loan in the same amount and on the same terms as to interest and repayment as the outstanding portion of the Employee Loan shall be made available by the Purchaser to the relevant Transferred Employee.

  

	5	Protection of terms and conditions and termination rights post-Closing 

  

	5.1	Without prejudice to paragraph 5.4 below, the Purchaser shall procure that for a period of 24 months following the Closing Date: 

 

	 	5.1.1	each Transferred Employee will (for so long as such Transferred Employee continues in the same role with any member of the Purchaser’s Group save that the Purchaser shall not seek to demote any Transferred
Employee to avoid the application of this provision) continue to receive at least the same basic salary; and 

  

	 	5.1.2	each Transferred Employee will continue to receive contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) which the Purchaser reasonably
considers to be substantially comparable, taken as a whole, to the contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) of such Transferred Employee immediately prior to the
Closing Date; and 

  

	 	5.1.3	 no Transferred Employee will suffer a change to his overall employment terms (whether contractual or otherwise) and including, without
limitation, any related to length of service (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans), which, when taken as a whole viewed

  
 165 

	 	
in the round (including to the extent relevant alongside any other changes being made at the same time to that Transferred Employee’s employment terms), would in the Purchaser’s
reasonable opinion acting in good faith, be regarded as materially detrimental. 

  

	5.2	The Purchaser confirms that, following the Closing Date and for so long as the Transferred Employees continue in the employment of any member of the Purchaser’s Group, the Transferred Employees will be
eligible to participate in those share-based incentive schemes or other long-term incentive plans that are operated by the Purchaser or relevant members of the Purchaser’s Group from time to time for employees of equivalent status, subject
always to the rules of such share-based incentive schemes or long-term incentive plans and any qualifying conditions. 

  

	5.3	The Seller shall provide or shall cause to be provided to any member of the Purchaser’s Group such information reasonably requested in writing by any member of the Purchaser’s Group to enable the
Purchaser to comply with its obligations in paragraph 5.1 above. 

  

	5.4	If the employment of any Transferred Employee is terminated by reason of redundancy within 24 months following the Closing Date, the Purchaser shall procure that there shall be provided to such Transferred
Employee benefits which are equivalent to those provided under such redundancy and severance policies and benefits (whether contractual or otherwise and giving due credit to the Transferred Employees for any additional service or earnings from the
Closing Date onwards) (but excluding Employee Benefits) as were applicable in respect of the particular Transferred Employee immediately prior to the Closing Date, to the extent that such policies and benefits are notified in writing to the
Purchaser prior to the Closing Date. If, at any time during the 24 month period immediately following the Closing Date, the Purchaser places any Transferred Employee into a redundancy selection process, the Purchaser undertakes that, in determining
such selection, it will or will procure that the relevant member of the Purchaser’s Group will take no account of the costs of dismissal of any person within the relevant selection pool (including such Transferred Employee). For the avoidance
of doubt, redundancy payments of the type described in this paragraph 5.4 (whether paid within 24 months of Closing or later) are not intended to be covered by the apportionment mechanism at paragraph 4.4 above. 

 

	5.5	For the avoidance of doubt, the provisions of this paragraph 5 are without prejudice to the operation of any rule of law in relation to the terms and conditions of employment of the Transferred Employees.

  

	6	Benefits arrangements/service continuity 

  

	6.1	Each Transferred Employee shall have their service with the Seller’s Group and their respective predecessors recognised under any employee benefit plans or arrangements of the Purchaser’s Group for all
purposes of eligibility, vesting and accrual of benefits to the extent past service was recognised for such Transferred Employee under a comparable plan or arrangement immediately prior to the Closing Date. Notwithstanding the foregoing, nothing in
this paragraph 6.1 shall be construed to require recognition of service for the purposes of calculation of Employee Benefits or that would result in: 

  

	 	6.1.1	any additional liability being assumed by the Purchaser’s Group in respect of Employee Benefits other than subject to and in accordance with the provisions of Schedule 12; 

  
 166 

	 	6.1.2	duplication of benefit; 

  

	 	6.1.3	recognition of service for any purposes under any plan or arrangement for which participation, service and/or benefits accrual is frozen or any post-retirement medical plan; or 

 

	 	6.1.4	recognition of service under a newly established plan or arrangement for which prior service is not taken into account for employees of the Purchaser’s Group generally. 

 

	6.2	Without limiting the foregoing, with respect to the Transferred Employees, the Purchaser shall, or shall cause such other member of the Purchaser’s Group to, be responsible for all paid time off benefits,
including vacation pay, sick pay, banked leave, flexitime and other payments for time off of normal work hours accrued by the Transferred Employees up to the Closing Date, provided that, if the value of such matters (excluding normal accrued but
untaken annual leave for the year current as at the Closing Date) would exceed US$7.5 million if accrued for in a balance sheet in accordance with IFRS prior to the Effective Time, then the Seller shall compensate the Purchaser for such matters
accrued prior to the Effective Time (again excluding normal accrued but untaken annual leave for the year current as at the Closing Date) by paying the Purchaser an amount equal to that value, less any amount actually accrued and transferred to the
Purchaser for such matters. 

  

	6.3	With respect to any welfare plan maintained by the Purchaser or any other member of the Purchaser’s Group in which Transferred Employees are eligible to participate after the Closing Date, the Purchaser
shall: 

  

	 	6.3.1	waive all limitations as to pre-existing conditions, exclusions, evidence of insurability provisions, waiting periods with respect to such participation and coverage requirements or similar provisions under a
Purchaser’s benefit plans that are welfare plans (as defined in section 3(1) of ERISA or any equivalent Applicable Law) applicable to such employees to the extent such conditions, exclusions and waiting periods or other provisions were
satisfied or did not apply to such employees under welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing Date; and 

 

	 	6.3.2	provide each Transferred Employee with credit for any co-payments and deductibles paid prior to the Closing Date in satisfying any analogous deductible or out-of-pocket requirements to the extent applicable under
any such plan in the year in which Closing occurs, to the extent credited under the welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing Date. 

 

	7	US Transferred Employees 

 With effect on and from the Closing Date, the Purchaser shall,
or shall procure that such other members of the Purchaser’s Group shall, assume the responsibility and obligation to provide COBRA continuation coverage to all Transferred Employees who are employed in the United States and/or covered by US
Benefit Plans and whose employment is terminated after the Closing Date and their eligible dependents. 
  

	8	Shared Employees 

 After the date of this Agreement, the Seller shall identify any Shared
Employees who work wholly or substantially in the Business (as carried on by the Vaccines Group) but who are not Vaccines Group Company Employees or Vaccines Business Employees. In 

  
 167 

 
consultation with the Purchaser, the Seller will procure that a Vaccines Group Company will offer employment to any such employee before the Closing Date, to take effect from immediately before
the Closing Date (provided that such employee continues to work wholly or substantially in the Business (as carried on by the Vaccines Group) until the Closing Date) or, where that is not reasonably practicable or there is no Vaccines Group Company
in the country in which the employee works, the Purchaser shall treat such employee as if he or she were a Vaccines Business Employee (provided that such employee continues to work wholly or substantially in the Business (as carried on by the
Vaccines Group) until the Closing Date) and the provisions of this Schedule 11 will apply to him or her and further provided, however, that these arrangements will apply to no more than 10 full time equivalent employees. 

 

	9	International Assignees 

 Where Applicable Law does not provide for the automatic
transfer of employment of any International Assignee and/or the other terms governing their international assignment, the Purchaser shall assume and agree to be bound by the individual contract of employment and such other terms governing their
international assignment including any tax equalisation agreement entered into between an International Assignee and a member of the Seller’s Group provided that such employee becomes a Transferred Employee and the Seller has disclosed to the
Purchaser the template international assignment terms of the Seller’s Group prior to the Closing Date. 
  

	10	Liability for retention arrangements 

 The Seller or any other member of the
Seller’s Group has or will put in place certain retention arrangements (in the form of cash) to retain key employees in connection with the matters contemplated by this Agreement. To the extent that details of such retention arrangements are
disclosed to the Purchaser prior to the Closing Date, and in respect of arrangements put in place after the date of this Agreement, with the agreement of the Purchaser, the Purchaser shall, or shall procure that such other member of the
Purchaser’s Group shall, make the cash retention payments when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in respect of such cash
payments. The Seller covenants to reimburse the Purchaser in respect of any cash retention payments, whether or not disclosed (including any Tax payable or accountable for by the employer in respect of such payments), which are put in place prior to
the Closing Date. The Seller acknowledges that the Purchaser may ask the Seller to put in place more generous retention arrangements than those proposed by the Seller (including, where practicable, putting in place retention arrangements which last
for a period of at least six months following Closing) and will not unreasonably withhold consent to such arrangements provided that any incremental cost of such arrangements over and above the cost of the Seller’s own proposals will be for the
Purchaser’s account. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 
  

	11	Share-based incentive schemes 

  

	11.1	This paragraph 11 applies notwithstanding any other provision of this Agreement. 

  
 168 

	11.2	Subject to paragraph 11.11, the Seller undertakes to use its best endeavours to ensure that share-based awards held by Transferred Employees pursuant to a share-based incentive scheme operated by the Seller or
another member of the Seller’s Group (“Relevant Awards”) shall be treated in a manner consistent with the “good leaver treatment” in the share-based incentive schemes operated by the Purchaser, to the extent possible
under the relevant plan rules and any Applicable Law. Where Relevant Awards are subject to performance (or other) conditions and it is not possible to determine whether or not such conditions have been met at the applicable early vesting date (or
within a reasonable period thereafter), the Seller and Purchaser agree that performance shall be deemed “on target”. 

For the avoidance of doubt: 
  

	 	(a)	where necessary and subject to (b), the Seller shall rely on the exercise of existing discretions in the relevant plan rules and (provided the approval of the Seller’s shareholders is not required) shall be
expected to amend the relevant plan rules to achieve the “good leaver treatment”; 

  

	 	(b)	the Seller (or relevant member of the Seller’s Group) shall not take any action which would require shareholder approval or which could trigger any significant legal, Tax or operational issues for the relevant
Transferred Employee (including the loss of any Tax-favourable treatment), the Seller’s Group or the Purchaser’s Group. 

For the purposes of this paragraph 11.2, the “good leaver treatment” shall be that: 

 

	 	(c)	Relevant Awards shall not lapse or be forfeited as a result of Closing except to the extent that they do not vest in accordance with (D) and/or (E) below; 

 

	 	(d)	Relevant Awards shall vest early as a result of Closing and shall be time pro-rated to take account of the reduced period of time, as a proportion of the original vesting period, that the relevant Transferred Employee
worked within the Seller’s Group (calculated on the basis of the number of years of service as at the Closing Date, where part years of service are rounded up); and 

 

	 	(e)	Relevant Awards that vest after the Closing Date shall remain subject to any relevant performance (or other) conditions, adjusted as necessary to take account of Closing and measured up to the applicable early vesting
date. 

 For the purposes of this paragraph 11.2, “on target” performance shall not be construed as permitting
share-based awards to vest in full. 
  

	11.3	The Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with the Relevant Awards, including any Tax.
The Purchaser agrees to use its best endeavours to seek any applicable Tax relief in respect of the Relevant Awards and to indemnify the Seller in respect of any Tax relief obtained, provided always that the Seller provides the Purchaser with any
information that the Purchaser may reasonably request in this respect in a timely manner. 

  

	11.4	 Subject to paragraph 11.5, the Seller undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the Relevant Awards and
to provide, in a timely manner, details of the Relevant Awards that so vest or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and pay any Tax for which the Purchaser’s

  
 169 

	 	
Group is liable in respect of the Relevant Awards to the relevant Tax Authority within any applicable timescale. 

 

	11.5	To the extent permitted under the relevant plan rules and any Applicable Law, the Seller undertakes to sell such number of the shares underlying the Relevant Awards as may be necessary for the sale proceeds to
satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any applicable timescale, provided always that the Purchaser provides the
Seller with any information that the Seller may reasonably request in this respect in a timely manner. 

  

	11.6	The Seller undertakes to procure that each relevant member of the Seller’s Group will pay any Tax for which such member is liable in respect of the Relevant Awards to the relevant Tax Authority within any
applicable timescale. 

  

	11.7	The Seller undertakes to procure the completion of any relevant Tax Return in respect of the Relevant Awards and to procure the submission of any such Tax Return to the relevant Tax Authority within any
applicable timescale. 

  

	11.8	This paragraph shall apply where Relevant Awards lapse or are forfeited (or will lapse or be forfeited) either in whole or in part as a result of Closing. As soon as practicable following Closing with the
intention being, where possible, to grant within 30 days of the Closing Date or the first date after the Closing Date when dealing restrictions do not apply (and, in any event, by the later of 90 days from the Closing Date and 90 days from the first
date after the Closing Date when the granting of share-based awards is not prevented by dealing restrictions) subject in both cases to the relevant plan rules and any Applicable Law, the Purchaser (or member of the Purchaser’s Group) shall
grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the portion of their Relevant Awards which lapsed or was forfeited
(or will lapse or be forfeited) as a result of Closing (valued as at the Closing Date), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Compensation Award”). To the extent that (i) it
could reasonably have been expected that any related matching share award and/or free share award would have been granted to a Transferred Employee following Closing in connection with any Relevant Award which lapsed or was forfeited (or will lapse
or be forfeited) as a result of Closing (each a “Relevant Matching Award”), and (ii) such Relevant Matching Award has not been granted (or will not be granted) as a result of Closing, on or around the date on which such
Relevant Matching Award would, in the ordinary course of business, have been made by the Seller (or member of the Seller’s Group), the Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a
share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of such Relevant Matching Award (valued as at the date of grant of the related Matching Award, defined below),
where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Matching Award”), subject to the relevant plan rules and any Applicable Law. 

Such Compensation Awards and Matching Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by the
Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Seller’s Group pursuant to which the related Relevant Award had been granted (or related Relevant
Matching Award would have been granted) but will vest 

  
 170 

 
according to a vesting schedule substantially similar to the vesting schedule that would have otherwise applied to the related Relevant Award or related Relevant Matching Award if Closing had not
occurred. In such cases: 
  

	 	(a)	the Purchaser undertakes to seek any applicable Tax relief in respect of the Compensation Awards and Matching Awards and to indemnify the Seller in respect of 50 per cent of any Tax relief obtained, provided always that
the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

  

	 	(b)	where a Compensation Award or Matching Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act
2003 (or, as applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive this obligation in respect of certain
Compensation Awards or certain Matching Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph (B) shall not apply in respect of such Compensation Awards or Matching Awards; and

  

	 	(c)	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for 50 per cent. of any Liabilities borne by the Purchaser’s Group in connection with such Compensation Awards and
Matching Awards, including any Tax, provided that: 

  

	 	(i)	the Seller shall not indemnify the Purchaser (or relevant member of the Purchaser’s Group) to the extent that the Purchaser (or member of the Purchaser’s Group) compensates Transferred Employees for any loss
(or expected loss) of Tax-favourable treatment in respect of Relevant Awards or for any Liabilities to Tax as contemplated in paragraph 11.9 below; 

  

	 	(ii)	the Seller only agrees to indemnify the Purchaser (or member of the Purchaser’s Group) to a maximum of 50 per cent of the total of (i) the value of the portion of such Relevant Awards that lapsed or was forfeited
(or will lapse or be forfeited) as a result of Closing, (ii) the value of the Relevant Matching Awards, and (iii) any related Liabilities, including any Tax; and 

  

	 	(iii)	for the avoidance of doubt, the Seller shall not indemnify the Purchaser (or member of the Purchaser’s Group) for any lapse or forfeiture (or expected lapse or forfeiture) due to a failure to meet any applicable
performance (or other) conditions. 

 For these purposes, the compensation in respect of the portion of a Relevant Award which
lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall not exceed the difference between (i) the value of the Relevant Award which could reasonably have been expected to vest on the normal vesting date but for Closing
(subject, where applicable, to performance (or other) conditions), and (ii) the value of the Relevant Award which actually vested (or will vest) as a result of Closing. 

For the purposes of this paragraph 11.8: 
  

	 	(a)	 the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall be valued on the basis of
the average price of 

  
 171 

	 	
an ordinary share in the capital of the Seller over the five trading days immediately prior to Closing; 

  

	 	(b)	the value of a Compensation Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the date of grant;

  

	 	(c)	the value of a Relevant Matching Award shall be valued on the basis of the average price of an ordinary share in the capital of the Seller over the five trading days immediately prior to the date of grant of the related
Matching Award; 

  

	 	(d)	the value of a Matching Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the date of grant; and

  

	 	(e)	any currency conversion shall be made in accordance with Clause 1.13.1 of this Agreement. 

  

	11.9	To the extent that any payment to a Transferred Employee (whether by the Seller’s Group or by the Purchaser’s Group) would trigger Liabilities to Tax under section 280G of the United States Internal
Revenue Code (“Section 280G”), the relevant Transferred Employee shall be allowed to choose whether to accept the full payment (and pay any relevant Section 280G Tax) or to receive such lower payment as may be necessary in order to
fall below the Section 280G threshold for Tax. To the extent that any similar Tax would arise pursuant to any Applicable Law in another jurisdiction, this paragraph 11.9 shall apply mutatis mutandis. 

 

	11.10	This paragraph shall apply where: (i) a Transferred Employee would, in the ordinary course of business, have been granted a share-based award pursuant to a share-based incentive scheme operated by the Seller or
another member of the Seller’s Group on the basis of performance criteria linked to the Seller’s Group’s 2014 financial year (which may, for the avoidance of doubt, be business and/or individual performance criteria and assessment)
(each a “2014 Performance Award”), and (ii) Closing occurs prior to the grant of such 2014 Performance Award. As soon as practicable following Closing (and, in any event, by the later of 30 days from the Closing Date and 30 days
from the date when the value of each 2014 Performance Award has been determined), the Seller shall notify the Purchaser in writing of the value of each 2014 Performance Award and under which share-based incentive plan operated by the Seller’s
Group the related 2014 Performance Award would have been granted. As soon as practicable following the receipt of such notice (and, in any event, by the later of 30 days from the receipt of such notice and 30 days from the first date following the
receipt of such notice when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any Applicable Law), the Purchaser (or member of the Purchaser’s Group) shall grant
each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the 2014 Performance Award which would have been granted but for the
occurrence of Closing. Such 2014 Performance Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to the
share-based incentive plan operated by the Seller’s Group pursuant to which the related 2014 Performance Award would have been granted. In such cases: 

  
 172 

	 	(a)	the Purchaser undertakes to seek any applicable Tax relief in respect of the 2014 Performance Awards and to indemnify the Seller in respect of any Tax relief obtained, provided always that the Seller provides the
Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

  

	 	(b)	where a 2014 Performance Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as
applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive this obligation in respect of certain 2014 Performance
Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph (b) shall not apply in respect of such 2014 Performance Awards; and 

 

	 	(c)	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with such 2014 Performance Awards, including any Tax.

 The grant of a 2014 Performance Award to a Transferred Employee shall be taken into account by the Purchaser when
determining the extent to which that Transferred Employee shall participate in incentive arrangements (other than any Compensation Award or Matching Award) operated by the Purchaser’s Group following Closing. 

For the purposes of this paragraph 11.10: 
  

	 	(d)	the value of a 2014 Performance Award to be granted shall: (i) be determined by the Seller acting reasonably and in good faith, (ii) be consistent with past practice and with the level of similar awards granted to
employees remaining in service within the Seller’s Group, (iii) take into account the relevant business and/or individual performance criteria linked to the Seller’s Group’s 2014 financial year, and (iv) if Closing occurs before 31
December 2014, be time pro-rated to take account of the reduced period of time, as a proportion of the Seller’s Group’s 2014 financial year, that the relevant Transferred Employee worked within the Seller’s Group (calculated on the
basis of the number of complete months of service as at the Closing Date); 

  

	 	(e)	the number of shares to be placed under a 2014 Performance Award shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the
date of grant; and 

  

	 	(f)	any currency conversion shall be made in accordance with Clause 1.13.1 of this Agreement. 

  

	11.11	This paragraph shall apply if any member of the Seller’s Group’s corporate executive team (or similar body) is a Transferred Employee (each a “CET Member”). The treatment of share-based
awards held by CET members shall be determined by the remuneration committee of the board of directors of the Seller (acting reasonably and in good faith and following informal consultation with the Purchaser), subject to the rules of any relevant
share-based incentive scheme and any Applicable Law, and the provisions of paragraphs 11.8 and 11.10 shall apply. 

  
 173 

	12	Delayed Employees 

  

	12.1	In this Schedule: 

 “Controlled Business Instruction” has the meaning
given to it in Schedule 25; 
 “Delayed Business Employees” means (i) the Relevant Vaccines Business Employees who
immediately prior to the Closing Date work in any of the Delayed Vaccines Group Businesses, and (ii) any employees of any member of the Seller’s Group who are appointed to their position (whether by internal or external hire) on or after the
Closing Date in accordance with a Controlled Business Instruction or Seller Involvement Instruction to work wholly or substantially in the Business (as carried on by the Vaccines Group) (other than the Delayed Company Employees), and in each case
for so long as they are not assigned to work other than wholly or substantially in the Business (as carried on by the Vaccines Group); 

“Delayed Closing Date” has the meaning given to it in Schedule 25; 

“Delayed Company Employees” means (i) the Relevant Vaccines Company Employees who immediately prior to the Closing Date
are employees of any of the Delayed Vaccines Group Companies, and (ii) any employees of any of the Delayed Vaccines Group Companies who are appointed to their position (whether by internal or external hire) on or after the Closing Date to work
wholly or substantially in the Business (as carried on by the Vaccines Group) in accordance with a Controlled Business Instruction or Seller Involvement Instruction, and in each case for so long as they are not assigned to work other than wholly or
substantially in the Business (as carried on by the Vaccines Group); 
 “Delayed Employees” means the Delayed Business
Employees and the Delayed Company Employees; 
 “Delayed Vaccines Group Business” has the meaning given to it in Schedule
25; 
 “Delayed Vaccines Group Company” has the meaning given to it in Schedule 25; and 

“Seller Involvement Instruction” has the meaning given to it in Schedule 25. 

 

	12.2	The parties intend and agree that: 

  

	 	12.2.1	the employment of the Delayed Employees shall not be transferred by the Seller or another member of the Seller’s Group to a member of the Purchaser’s Group on and from the Closing Date but shall
transfer on and from the Delayed Closing Date which relates to the Delayed Vaccines Group Company or Delayed Vaccines Group Business associated with that Delayed Employee; 

 

	 	12.2.2	 notwithstanding the intention at paragraph 12.2.1 above, if the contract of employment of any Delayed Employee is found or alleged to have
effect at any time prior to the Delayed Closing Date as if originally made with the Purchaser or another member of the Purchaser’s Group (including any Vaccines Group Company) as a consequence of this Agreement, paragraph 3 shall not apply in
relation to that Delayed Employee and as a result the parties shall in good faith seek to agree as soon as reasonably practicable how best to deal with such unintended transfer or allegation of transfer having regard to the reason why the
individual’s transfer to the Purchaser or another member of the Purchaser’s Group (including any Vaccines Group Company) was delayed but provided that, if the parties are unable to reach such agreement within a reasonable period and if it
is 

  
 174 

	 	
agreed that such Delayed Employee’s contract of employment has so transferred, then such Delayed Employee shall be treated from the time he actually became so employed as a “Transferred
Employee” (and no longer a Delayed Employee) for the purposes of this Agreement; 

  

	 	12.2.3	no provisions in paragraph 2 shall require the Purchaser or another member of the Purchaser’s Group (including any Vaccines Group Company) to employ, or make an offer to employ, a Delayed Employee, on and
from the Closing Date; 

  

	 	12.2.4	paragraph 2.2 shall be amended to the extent required so that it applies to Delayed Business Employees and, in respect of such Delayed Business Employees, references to the “Closing Date” shall be
replaced with references to the “Delayed Closing Date which relates to the Delayed Vaccines Group Business associated with that Delayed Employee”; 

  

	 	12.2.5	paragraph 2.3 shall be amended to the extent required so that it applies to Delayed Business Employees and, in respect of such Delayed Business Employees, references to the “Closing Date” or
“Closing” shall be replaced with references to the “Delayed Closing Date which relates to the Delayed Vaccines Group Business associated with that Delayed Employee”; and 

 

	 	12.2.6	paragraph 3 shall be amended to the extent required so that it applies on each Delayed Closing Date in respect of any person who is not at that time a Delayed Business Employee or Delayed Company Employee and any
references to the “Closing Date” or “Closing” shall be replaced with references to that “Delayed Closing Date”. 

  

	12.3	Notwithstanding the provisions of paragraph 12.2 above, the parties agree that each Delayed Employee shall, with effect from and including the Closing Date, be treated for economic purposes as if he is employed
by a member of the Purchaser’s Group, and as a consequence will be deemed to be a “Transferred Employee” (meaning that the Purchaser will be economically responsible for all costs and liabilities relating to his employment on and from
the Effective Time or termination of his employment on and from the Effective Time) provided that such treatment shall not result, in relation to any Delayed Employee, in any member of the Purchaser’s Group being liable for any costs and
liabilities under this Schedule to the extent that any such costs and liabilities arise from (i) any failure by the relevant member of the Seller’s Group prior to a Delayed Employee’s Delayed Closing Date, without good reason, to comply
with any Controlled Business Instruction or Seller Involvement Instruction in relation to that Delayed Employee; or (ii) any claim by a Delayed Employee as a result of any breach of contract or Applicable Law by the relevant member of the
Seller’s Group (other than in express compliance with any Controlled Business Instruction or Seller Involvement Instruction or as otherwise expressly agreed in writing by the Purchaser) in respect of such Delayed Employee. Any amount payable
pursuant to this paragraph 12.3 shall be paid in accordance with Part 4 of Schedule 25, For the avoidance of doubt, no provision of this paragraph 12.3 shall entitle the Seller or any member of the Seller’s Group to recover any amount in
respect of any Delayed Employee if that would entitle that Seller or member of the Seller’s Group to recover more than once in respect of the same amount under this Agreement or any Ancillary Agreement. 

 

	12.4	For the purposes of paragraphs 11.2 and 11.8 above, references to “Closing” and the “Closing Date” shall be construed as references to the relevant Closing, Closing Date or Delayed Closing
Date which applies to each of the relevant Transferred Employees. 

  
 175 

 Schedule 12 

Employee Benefits 

(Clause 2.4.2) 
 In this Schedule 12: 

“Delayed Business Employees” has the meaning given to it in Schedule 11; 

“Delayed Company Employees” has the meaning given to it in Schedule 11; 

“Delayed Employees” has the meaning given to it in Schedule 11; 

“Employee Benefits” means benefits to or in respect of any current or former employee, including without limitation, any pension, early
retirement, disability, death benefit, long service awards, termination indemnity (such as Italian TFR) or post-retirement medical benefits or deferred compensation linked to retirement, disability or death benefits or old age part-time benefits
(such as German ATZ) and jubilee payments; 
 “Employee Benefit Liabilities” means liabilities and obligations (whether funded or unfunded)
in respect of any employee benefit promise, scheme, plan, fund, program, policy, practice or other individual or collective arrangement providing Employee Benefits; 

“Purchaser Funding Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the Purchaser’s Group
provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), and there is a local obligation or
practice prior to the date of this Agreement to pre-fund or externally fund those similar or comparable benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the
case in relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those similar or comparable benefits immediately prior to the date of this Agreement (so, taking the
example of UK defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully funded on
that basis at any relevant time); 
 “Purchaser IFRS Assumptions” means, in relation to any Transferred Employee Benefits, where a member
of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), the
method and assumptions used most recently prior to the date of this Agreement to value those similar or comparable benefits by the Purchaser’s Group (or any relevant member thereof) for IFRS accounting purposes; 

“Seller Funding Assumptions” means, in relation to any Transferred Employee Benefits, if there is a local obligation or practice prior to the
date of this Agreement to pre-fund or externally fund those Transferred Employee Benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the case in relation to UK
HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those Transferred Employee Benefits immediately prior to the date of this Agreement (so, taking the example of UK defined benefit
obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully funded on that basis at any relevant time);

  
 176 

 “Seller IFRS Assumptions” means, in relation to any Transferred Employee Benefits, the method
and assumptions used by the Seller’s Group (or the most relevant member thereof) most recently prior to the date of this Agreement to value those Transferred Employee Benefits for IFRS accounting purposes; 

“Swiss Actuary” means an actuary: (a) who can reasonably be viewed: (i) as independent of both the Purchaser and the Seller; and (ii) as
familiar with Swiss pension issues; and (b) whom the Purchaser and Seller have agreed should be jointly appointed by them for the purposes of determining the Swiss Assumptions or who in default of such agreement has been appointed by the Swiss
Association of Actuaries or other industry body of actuaries in Switzerland as agreed by the Seller and the Purchaser; 
 “Swiss Assets”
means cash with a value equal to the aggregate of: 
  

	(i)	the value of the vested benefits, as at the Effective Time, held by the Swiss Pension Providers on behalf of each Transferred Employee in Switzerland; 

multiplied by 
  

	(ii)	the applicable coverage ratio as determined by the board of trustees of the Swiss Pension Providers in accordance with Article 44 BVV2 (Swiss Ordinance on Occupational Retirement, Survivors’ and Disability Pension
Plans) under the partial liquidation regulations of each of Novartis Pensionskasse 1, Novartis Pensionskasse 2 and Kaderkasse Novartis on the assumption that the Swiss Assets were to transfer to the Purchaser’s replacement pension vehicle at
the Effective Time; 

 “Swiss Assumptions” means, in relation to any Transferred Employee Benefits in Switzerland, the Seller
IFRS Assumptions adjusted: 
  

	(a)	by replacing any assumed “cash balance” annuity conversion rate in the Seller IFRS Assumptions with a conversion rate which the Swiss Actuary certifies to the Purchaser and the Seller as representing a
reasonable estimate of the likely effective overall blended conversion rate which will apply in relation to the Transferred Employee Benefits in question, having regard to the changes to the rate which can (having regard to longevity projections,
legal and governance constraints around Swiss pension structures and such other matters as the Swiss Actuary considers relevant) in the Swiss Actuary’s opinion reasonably be expected to occur during the expected service lives of the Transferred
Employees to whom the Transferred Employee Benefits relate, and weighting the impact of those changes by reference to the ages of the relevant employees (and so the extent to which the changes will in fact operate to reduce the effective liability
on the Purchaser); and 

  

	(b)	by removing any reserve for death or disability benefits to the extent that the Swiss Actuary certifies to the Purchaser and the Seller that it constitutes a reserve for liabilities to and in respect of the relevant
Transferred Employees which could reasonably be externally insured by the Purchaser without introducing a new ongoing cost on the Purchaser which was not reflected in the Accounts; 

“Swiss EB Liabilities” means those of the Transferred Employee Benefit Liabilities that are attributable to the Transferred Employees in
Switzerland; 
 “Swiss Employee Benefits” means the benefits to which the Swiss EB Liabilities relate; 

“Swiss Pension Providers” means the provider(s) of Swiss Employee Benefits; 

  
 177 

 “Swiss Post-Closing Employers” means the Vaccines Group Companies, and any relevant members of
the Purchaser’s Group which employ the Transferred Employees in Switzerland on and from Closing; 
 “Temporary Participation Plan”
means any plan or arrangement (whether funded or unfunded) for the provision of Employee Benefits in which Transferred Employees participate prior to Closing and continue (for any reason, whether by special arrangement as is the case for the Swiss
Post-Closing Employers or because they are Delayed Business Employees or Delayed Company Employees, or otherwise) to participate for a temporary period after Closing; and 

“Temporary Participation Cessation Date” means, in relation to any Temporary Participation Plan, the date on which Transferred Employees
cease to participate in the relevant plan or arrangement. 
 For the purposes of each of the Purchaser Funding Assumptions, the Purchaser IFRS Assumptions,
the Seller Funding Assumptions, the Seller IFRS Assumptions and the Swiss Assumptions, any economic and financial assumptions which are based (whether expressly or implicitly) on yields, rates or indices shall be updated for the purposes of such
definitions to take account of those yields, rates or indices as at the Effective Time (or the latest practicable time prior to the Effective Time). 
  

	1	Except to the extent otherwise requested by the Seller and expressly agreed by the Purchaser before Closing (such Purchaser agreement not to be unreasonably withheld to the extent that it is not reasonably
possible for the Seller or its Affiliates to retain the relevant Employee Benefit Liabilities – for example, where a Vaccines Group Company operates its own standalone arrangement, liability for which cannot lawfully be assumed by another
member of the Seller’s Group, or where liability unavoidably transfers by operation of law under European Council Directive 2001/23/EC or its local implementing legislation), any Employee Benefit Liabilities in respect of service in the
Vaccines Group or with any member of the Seller’s Group (including any Vaccines Group Company) or in any plan or arrangement in which any member of the Seller’s Group (including any Vaccines Group Company) participates or has participated:

  

	 	(a)	(in the case of a Transferred Employee) prior to Closing; or 

  

	 	(b)	(in the case of any other person) at any time, 

 (together, “Pre-Closing EB
Liabilities”) will stay with or be assumed by the Seller or its Affiliates (excluding any Vaccines Group Company) and the Seller shall fully indemnify the Purchaser and its Affiliates and/or any Vaccines Group Company) against any such
Employee Benefit Liabilities and against any liabilities and obligations to or in respect of any plan or arrangement for the provision of Employee Benefits in which any member of the Seller’s Group (including any Vaccines Group Company)
participates or participated prior to Closing. For the avoidance of doubt, the Purchaser’s agreement under this paragraph 1 may, if the Purchaser so determines, relate only to certain specified categories or tranches of Pre-Closing EB
Liabilities under a particular benefit programme (in other words, it does not need to be “all or nothing”), in which case it is only those specified Pre-Closing EB Liabilities which are excluded from the scope of the Purchaser’s
indemnity entitlement hereunder. 
  

	2	 Where and to the extent that the Purchaser agrees under paragraph 1 that any Pre-Closing EB Liabilities may transfer to or remain with the
Purchaser and/or its Affiliates and/or any Vaccines Group Company (such Pre-Closing EB Liabilities being the 

  
 178 

	 	
“Transferred Employee Benefit Liabilities” and the benefits to which they relate being the “Transferred Employee Benefits”), the Purchaser will be compensated in
respect of such Transferred Employee Benefit Liabilities as set out in the rest of this Schedule 12. Subject to being so compensated but without prejudice to paragraphs 9 and 11, the Purchaser shall, or shall procure that its relevant Affiliate
shall, assume, with a full discharge for the Seller and its Affiliates, the Transferred Employee Benefit Liabilities. The Purchaser acknowledges its agreement to the principle that the post-retirement medical healthcare plan to which it admits US
Transferred Employees who immediately before Closing were members of such a plan will take account of periods of employment with the Seller’s Group to the extent previously recognised under the equivalent Seller’s Group plan for the
purposes of determining eligibility, contributions, and vesting; again, therefore, subject to appropriate identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule
12, they will become Transferred Employee Benefit Liabilities. 

  

	2A	This paragraph 2A applies where there are Transferred Employee Benefits in a Temporary Participation Plan. In such a case, notwithstanding that the Transferred Employee Benefit Liabilities may (subject to the
Purchaser’s agreement as per 1 above) include liabilities in respect of service after the Effective Time, the Transferred Employee Benefit Liabilities which are included in the calculation of the Employee Benefit Indemnification Amount as per
paragraph 3 below shall (unless the Seller and the Purchaser agree otherwise in any particular case) comprise only those liabilities attributable to service before the Effective Time. Conversely, although the Transferred Employee Benefit Liabilities
will not for the purposes of paragraph 1 and 2 above include liabilities in respect of Transferred Employees or other individuals who leave employment or crystallise benefits before the Temporary Participation Cessation Date in relation to the
relevant Temporary Participation Plan (unless the Seller and the Purchaser agree otherwise in any particular case and without prejudice to the Purchaser or its Affiliates’ obligation to comply with any requirements in relation to such
individuals before they leave employment or crystallise benefits), the parties agree that the calculation of the Employee Benefit Indemnification Amount under paragraph 3 below in relation to any Temporary Participation Plan shall be carried out on
the basis of a conclusive presumption (regardless of any actual knowledge to the contrary) that: 

  

	 	2A.1	any individual who is a Delayed Employee on the day after the Closing Date is or will become a Transferred Employee, and 

  

	 	2A.2	no Contingent Individual will leave employment or crystallise benefits before the relevant Temporary Participation Cessation Date. For these purposes a “Contingent Individual” is a Transferred
Employee or other individual who on the day after the Closing Date has not left employment or crystallised benefits and in respect of whom liabilities: (a) would become Transferred Employee Benefit Liabilities if he does not leave employment or
crystallise benefits before the relevant Temporary Participation Cessation Date; but (b) would not otherwise become Transferred Employee Benefit Liabilities. 

United Kingdom 
 For the
avoidance of doubt, it is also agreed that no UK defined benefit pension liabilities are to be Transferred Employee Benefit Liabilities. 

  
 179 

	3	The value of the Transferred Employee Benefit Liabilities shall be determined on employee census data and plan provision as at the Effective Time (and making the conclusive presumptions at 2A.1 and 2A.2 above)
on: 

  

	3.1	in relation to any Transferred Employee Benefits in Switzerland, the Swiss Assumptions; and 

  

	3.2	in relation to any other Transferred Employee Benefits, the Seller IFRS Assumptions, PROVIDED that if any of the following values is available and is greater than the value derived using the Seller IFRS
Assumptions then that value will be used instead (and if more than one of these values is available then the one which would place the greatest value on the relevant Transferred Employee Benefit Liabilities will be used): 

 

	 	3.2.1	if a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in
the terms of entitlement of accrual etc), the value which is midway between the value based on the Seller IFRS Assumptions and the Purchaser IFRS Assumptions; 

  

	 	3.2.2	if there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding target which is determined by reference to a method and
assumptions other than IFRS, the value derived using the Seller Funding Assumptions; and 

  

	 	3.2.3	if there is both: (i) a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding target which is determined by reference to a
method and assumptions other than IFRS; and (ii) a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of
differences in the terms of entitlement of accrual etc), the value which is midway between the value based on the Seller Funding Assumptions and the Purchaser Funding Assumptions. 

Where there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or other
vehicle established for the purposes of meeting such Transferred Employee Benefit Liabilities, and the actuary chosen by the Seller and the actuary chosen by the Purchaser agree under paragraph 4 (or it is otherwise determined under paragraph 5)
that, having regard to all relevant matters as they subsisted immediately after Closing, it would be reasonable to expect all or part of such assets to be or remain available to the Purchaser or its Affiliates to meet the cost of such Transferred
Employee Benefit Liabilities (whether by transfer out to another vehicle or because a Vaccines Group Company is expected to remain affiliated to the vehicle on more than a merely temporary basis), then the value as at the Effective Time of the
assets which, ignoring matters arising after Closing, the actuaries would expect to be made or remain so available (the “Available Assets”) (including for the avoidance of doubt, in the case of Switzerland, the Swiss Assets to the
extent that they are so agreed or determined) as agreed under paragraph 4 or determined under paragraph 5 will be deducted from the value of the Transferred Employee Benefit Liabilities, and the remaining value of the Transferred Employee Benefit
Liabilities (if any) is the “Employee Benefit Indemnification Amount”. The determination of the Employee Benefit Indemnification Amounts shall be carried out on a country-by-country basis and, where necessary, on a plan-by-plan
basis. 

  
 180 

 If the Employee Benefit Indemnification Amount for any country (or plan, where applicable) is
greater than 95% of the estimate of the Employee Benefit Indemnification Amount for that country (or plan) set out in the Seller’s notification pursuant to Clause 6.4.3 (or, where no such estimate was made, greater than zero), then the Seller
shall pay or procure payment, by way of a reduction in the Purchase Price attributable to the relevant Shares or the particular part of the Vaccines Group to which the payment relates, an amount equal to the difference (or, where no such estimate
was made, the full Employee Benefit Indemnification Amount for that country (or plan)) to the Purchaser, or at the request of the Purchaser to an Affiliate of the Purchaser, as compensation for the Transferred Employee Benefit Liabilities. If the
Employee Benefit Indemnification Amount for any country (or plan, where applicable) is less than 95% of the estimate of the Employee Benefit Indemnification Amount for that country (or plan) set out in the Seller’s notification pursuant to
Clause 6.4.3 (if any), the Purchaser shall pay an amount equal to the difference to the Seller. 
  

	4	The Seller and its Affiliates shall, within 45 days after Closing, provide its actuary, the Swiss Actuary (if relevant) and the actuary chosen by the Purchaser with all relevant plan, asset, assumptions and
employee census information needed to calculate the Employee Benefit Indemnification Amounts in respect of any Transferred Employees or Delayed Employees to the extent not otherwise within the control of the Purchaser or its Affiliates (including
any Vaccines Group Company). The actuary chosen by the Seller shall provide the actuary chosen by the Purchaser with its calculation of the Employee Benefit Indemnification Amounts (including, but not limited to, any supporting documentation on
which it relied as well as the methodologies it employed in calculating the Employee Benefit Indemnification Amounts), on a plan-by-plan basis, within 90 days following Closing. The actuary chosen by the Purchaser shall review the calculation of the
Employee Benefit Indemnification Amounts of the Seller’s actuary within 120 days following Closing. The Employee Benefit Indemnification Amounts shall be determined, on a plan-by-plan basis, by mutual agreement between the parties within 180
days following the Closing Date. 

  

	5	If the parties cannot agree on any Employee Benefit Indemnification Amount within the 180-day period referred to in paragraph 4, the parties shall appoint within 5 days an independent actuary acceptable to both
parties, or such actuary shall be selected by the President of the Institute and Faculty of Actuaries in the UK if they cannot agree, and the independent actuary thus appointed shall review their calculations and, within 75 days after appointment,
render a final and binding decision on the amount of that Employee Benefit Indemnification Amount, and, in making such decision, shall be limited to adopting the position taken by either one of the parties. The cost of any independent actuary shall
be borne jointly by the parties. 

  

	6	In connection with the procedures referred to in this Schedule 12, the parties shall provide each other and the actuaries referred to in this Schedule 12 with access to the relevant business records and other
relevant documents and information as may reasonably be requested. All documents, records and information provided for the purposes of this Schedule 12 must be accurate and complete in all material respects. 

 

	7	 Each payment in respect of an Employee Benefit Indemnification Amount shall be made by the Seller (by way of a reduction in the Purchase Price
attributable to the relevant Shares or the particular part of the Vaccines Group to which the payment relates) within 14 days following its final determination. The Seller may make an accelerated or advance payment at its own discretion (which,
for the avoidance of doubt, includes in relation to each 

  
 181 

	 	
Employee Benefit Indemnification Amount so much (if any) of the Estimated Employee Benefit Adjustment as the Seller notified pursuant to Clause 6.4 was intended to relate to that Employee Benefit
Indemnification Amount). Each Employee Benefit Indemnification Amount shall include interest calculated from the Effective Time to (and including) the date of payment at a rate per annum of LIBOR (but where amounts are prepaid or paid in stages
or treated as paid via inclusion in the Estimated Employee Benefit Adjustment then the interest will cease to accrue on so much of the Employee Benefit Indemnification Amount as has been paid). Such interest shall accrue from day to day. Any such
payment shall be made in US dollars (and any underlying values shall be expressed in US dollars) and any currency other than US dollars shall be converted into US dollars at the exchange rates determined in accordance with Clause 1.13 of this
Agreement on the Closing Date. 

  

	8	To the extent (if any) that there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or other vehicle established for the purposes of meeting
such Transferred Employee Benefit Liabilities, the Purchaser will, if requested by the Seller before Closing (or the relevant Temporary Participation Cessation Date) and unless it is not reasonably practicable to do so, establish or nominate a trust
or other vehicle which is capable of receiving a transfer of assets from the pre-Closing trust or other vehicle to the extent that such assets relate to the Transferred Employee Benefit Liabilities. 

 

	9	If, within one year of Closing, the Seller or the Purchaser notifies the other that the membership or other benefit data (the “Data”) used for calculating any Employee Benefit Indemnification
Amount may be inaccurate, other than by reason of an Excluded Matter, then a “Data Dispute” has arisen and the following provisions shall apply: 

  

	9.1	On such notification, the Seller shall procure that its actuary and the Purchaser shall procure that its actuary consult each other with a view to agreeing whether the Data is inaccurate and if so, what the
accurate Data should be. If the Seller’s actuary and the Purchaser’s actuary agree that the Data is inaccurate, they will jointly certify this to be the case and advise on what the accurate Data should be. The notification is deemed to
have occurred on the date of the certification. 

  

	9.2	If the Seller’s actuary and the Purchaser’s actuary fail to agree whether the Data is inaccurate within 60 days of the notification by one party to the other that the Data may be inaccurate, paragraph 5
shall apply mutatis mutandis. The notification is deemed to have occurred when the independent actuary advises that the Data is inaccurate and what the accurate Data should be. 

 

	9.3	On the occurrence of the Data Dispute, the Seller and the Purchaser shall respectively procure that a valuation of the relevant Employee Benefit Indemnification Amount is carried out in accordance with paragraphs
3 and 4 (mutatis mutandis) but on the basis of the accurate Data as agreed under paragraph 9.1 or determined under paragraph 9.2. 

  

	9.4	If as a consequence of paragraph 9.3, the Seller has paid to the Purchaser an amount which on the basis of the further valuation is not payable, such amount (the “Overpayment”) shall be repaid
within 21 days of the amount of the Overpayment being agreed or determined. Any such payment shall bear interest calculated from (and including) the date the Overpayment was made to (and including) the date the payment is made in full in accordance
with this paragraph 9.4 at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  
 182 

	9.5	If as a consequence of paragraph 9.3, the Seller has not paid to the Purchaser an amount which on the basis of the further valuation is payable, such amount (the “Outstanding Amount”) shall be
paid within 21 days of the amount of the Outstanding Amount being agreed or determined. Any such payment shall bear interest calculated from (and including) the Closing Date to (and including) the date the payment is made in full in accordance with
this paragraph 9.5 at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

 For the purposes of this
paragraph 9, the “Excluded Matters” are: 
  

	 	(i)	assets which were assumed to be Available Assets ultimately turning out not to be available to the Purchaser or its Affiliates to meet the cost of the Transferred Employee Benefit Liabilities to which they related, and

  

	 	(ii)	liabilities in respect of individuals being assumed to be Transferred Employee Benefit Liabilities but turning out not to be because the individuals leave service or crystallise benefits before the date liabilities are
transferred. 

  

	10	Except as otherwise agreed by the Seller, the Purchaser shall where a trust or other vehicle has been established under paragraph 8, procure that all of the assets transferred as envisaged by paragraph 8 are paid
into such trust or other vehicle. If, after such payment or transfer, or after payment of an Employee Benefit Indemnification Amount or after making an Estimated Employee Benefit Adjustment, the Purchaser and/or its Affiliates achieves a reduction
in its liability to any Tax in respect of or in connection with the payment or transfer, the Purchaser shall pay to Seller (for itself or on behalf of the relevant Share Seller or Business Seller as applicable), within 30 days after the Purchaser
would otherwise have been liable to pay the saved Tax, a sum equal to the amount of that Tax reduction by way of an increase in the Purchase Price in respect of the relevant Shares or the particular part of the Vaccines Group. This paragraph 10
applies for a period of four years following the later of the date on which a transfer of assets is made, or payment of any Employee Benefit Indemnification Amount or Estimated Employee Benefit Adjustment is made to the Purchaser. 

 

	11	The Seller covenants with the Purchaser to pay to the Purchaser an amount equal to any cost, claim or liability incurred by any member of the Purchaser’s Group which it is or becomes liable to make on or at
any time after Closing by reason of any change or purported change made to the terms of any Transferred Employee Benefits prior to Closing proving to be or have been legally ineffective or by reason of such terms and/or benefits failing to comply
with any mandatory legal requirements (excluding any obligation to equalise guaranteed minimum pensions in the United Kingdom). The Seller shall not be liable under this paragraph 11 in respect of any individual claim (or a series of claims arising
from similar or identical facts or circumstances) unless the liability in respect of such claim or series of claims exceeds US$100,000. If the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against the
Seller under this paragraph 11, the Purchaser shall as soon as reasonably practicable give notice in writing to the Seller of such facts, matters or circumstances as are then available regarding the potential claim. Failure to give such notice
within such period shall not affect the rights of the Purchaser to make a relevant claim under this paragraph 11, except that the Seller shall not be liable for any increase in the amount of such claim arising from such failure. The latest date on
which the Purchaser may give notice of a claim under this paragraph 11 is the fourth anniversary of the Closing Date. 

  
 183 

	12	Notwithstanding any general provision to the contrary in Schedule 11 and subject to being compensated in accordance with this Schedule 12, the Purchaser shall admit Transferred Employees in the United States who
participated in a post-retirement medical plan immediately prior to Closing to its own post-retirement medical plan. Subject to being compensated in accordance with this Schedule 12, periods of employment with the Seller’s Group (including,
without limitation, any current or former Affiliate of the Seller, to the extent previously recognised under the applicable benefit plan arrangement provided by the Seller’s Group), shall be taken into account for the purposes of determining,
as applicable, the eligibility for participation, contributions, and vesting for any employee under such post-retirement medical plan. 

  

	13	Notwithstanding any general provision to the contrary in Schedule 11, the US Transferred Employees shall, as of the Closing Date, become eligible to participate in a US tax-qualified defined contribution plan to
the extent such plan is sponsored by the Purchaser or a relevant member of the Purchaser’s Group. The Purchaser agrees that it will use commercially reasonable efforts to cause such plan to accept rollovers of the account balances of the US
Transferred Employees (including participant loan promissory notes) from the relevant employer’s tax-qualified retirement plans; provided that (i) the Purchaser will not be required to accept any such rollovers that might result in material
liability to the Purchaser or may otherwise cause the relevant plan to cease to qualify under Section 401(a) of the Code and (ii) the Purchaser will not be required to amend any plan to permit participant loans. 

 

	14	The parties agree that where any Transferred Employee has accrued defined contribution benefits prior to Closing in a Seller’s Group arrangement then: 

 

	14.1	the Seller shall use commercially reasonable efforts to procure the vesting of those benefits (if they would otherwise lapse as a result of Closing); 

 

	14.2	the parties shall, provided this will not impose unreasonable administrative burdens on the Purchaser’s Group, co-operate in good faith to procure a transfer of the account balances of such Transferred
Employee from the Seller’s Group arrangement to a Purchaser’s Group arrangement; and 

  

	14.3	for the avoidance of doubt, the Purchaser will comply with the provisions of paragraph 6.1 of Schedule 11. 

Switzerland: temporary period of participation 
  

	15	The Seller and Purchaser shall use all reasonable endeavours to procure that, with effect from Closing, the Swiss Post-Closing Employers shall be admitted to participate in the relevant plans operated by the
Swiss Pension Providers, to enable the Swiss Post-Closing Employers to continue to provide Swiss Employee Benefits to, and in respect of, the Transferred Employees in Switzerland for the period from Closing up to 31 December 2015 or such earlier
date as the Swiss Pension Providers may permit under their temporary affiliation agreements with the Swiss Post-Closing Employers. 

  

	16	The Purchaser shall use all reasonable endeavours to procure that the Swiss Post-Closing Employers shall each enter into a temporary affiliation agreement with the board of trustees of the Swiss Pension Providers
on such terms as the Seller and the Purchaser may have agreed prior to Closing. 

  
 184 

	17	The Seller and the Purchaser agree that, if, during the period on and from the Effective Time up to and including the Temporary Participation Cessation Date in relation to the plans operated by the Swiss Pension
Providers, there is underperformance in the investment returns achieved in respect of the assets held by the Swiss Pension Providers in respect of the Transferred Employees in Switzerland who are cash balance members (so that the assets are not
sufficient to provide the mandatory 1.5% p.a interest rate accrual), then there may be payment due from the Swiss Post-Closing Employers to the Swiss Pension Providers in accordance with the terms of the relevant affiliation agreement. If such a
payment is demanded by the Swiss Pension Providers, then the Seller undertakes to pay to the Purchaser 50% of the amount demanded from the Purchaser or any Affiliate (including without limitation a Swiss Post-Closing Employer) to the Swiss Pension
Providers within 14 days of being notified of such demand. The Purchaser shall, as soon as reasonably practicable, pay (or procure that its Affiliate pays) any such amount received from the Seller to the Swiss Pension Providers, to the extent
that the amount is still owed to the Swiss Pension Providers by the Purchaser or its Affiliate. 

 Other jurisdictions:
temporary periods of participation 
  

	18	The Seller and Purchaser may agree that an employing entity in the Purchaser’s Group shall be admitted to participate, for a temporary period with effect from Closing, in one or more Employee Benefit plans
operated by a member of the Seller’s Group, or in which a member of the Seller’s Group participates. 

  

	19	In such event, the Seller and Purchaser shall use all reasonable endeavours to enter into an agreement with the provider or board of trustees of the relevant Employee Benefit plan on such terms as the provider or
board of trustees may reasonably require. 

 Specific assurance in relation to plans operated by Swiss Pension
Providers 
  

	20	The Seller warrants to the Purchaser that, assuming the Temporary Participation Cessation Date is on or before 31 December 2015, the regulations governing the plans operated by the Swiss Pension Providers
would oblige the Swiss Pension Providers to transfer to the replacement pension arrangement put in place for the Transferred Employees, in addition to amounts calculated as at Closing in respect of benefits accrued to that date, the contributions
paid after the Effective Time in respect of the retirement accounts of the Transferred Employee by the employees or their employers. For the avoidance of doubt, the Seller gives no warranty as to whether the Swiss Pension Providers will comply with
this obligation. 

 Jubilee payments 
  

	21	For the purposes of calculating the amount of jubilee payments and long service awards falling within the definition of “Transferred Employee Benefit Liabilities” the following principles shall apply:

  

	21.1	in relation to Vaccines Group Company Employees, liabilities to make jubilee payments and grant long service awards will be treated as falling within Transferred Employee Benefit Liabilities and shall be
calculated on the basis of the value of such liabilities determined in accordance with the preceding provisions of this Schedule; 

  

	21.2	in relation to Vaccines Business Employees in respect of whom each of the following applies: 

  
 185 

	 	21.2.1	liabilities to make jubilee payments or grant long service awards transfer to a member of the Purchaser’s Group by operation of law; and 

 

	 	21.2.2	the relevant member of the Purchaser’s Group replicates or will replicate the benefits which applied while they were employees of the Seller’s Group, 

liabilities to make jubilee payments or grant long service awards will be treated as falling within the Transferred Employee Benefit
Liabilities and shall be calculated on the basis of the benefit scales which applied while the Vaccines Business Employees were employees of the Seller’s Group; 
  

	21.3	in relation to Vaccines Business Employees for whom either: 

  

	 	21.3.1	liabilities to make jubilee payments or grant long service awards do not transfer by operation of law but the relevant member of the Purchaser’s Group provides or will provide replacement benefits which
replicate the benefits provided by the Seller’s Group); or 

  

	 	21.3.2	the relevant member of the Purchaser’s Group provides or will provide replacement jubilee or long service benefits but does not or will not replicate the benefits which applied while they were employees of
the Seller’s Group, 

 liabilities to make jubilee payments or grant long service awards will be treated as falling within
the Transferred Employee Benefit Liabilities and shall be calculated on the basis of the benefit scales which applied while the Vaccines Business Employees were employees of the Seller’s Group or, if less, the value of the actual benefit to be
provided by the relevant members of the Purchaser’s Group. 
  

	21.4	for the avoidance of doubt, no amount will be included within “Transferred Employee Benefit Liabilities” in respect of jubilee payments or long service awards in relation to Vaccines Business
Employees for whom liabilities to make such payments or grant such awards do not transfer by operation of law and no replacement benefits are provided by any member of the Purchaser’s Group; 

 

	21.5	the Purchaser and the Seller will negotiate in good faith with a view to agreeing an appropriate and simple method in each jurisdiction for valuing jubilee payments and long service awards which are not
disproportionate to the amounts of such payments but which is suitably even-handed as between the parties. Any such agreement will override the foregoing provisions of this paragraph 21 to the extent there is any inconsistency. 

  
 186 

 Schedule 13 

Allocation of Purchase Price 

(Clauses 3.3 and 7.6) 
  

	1	The Seller and the Purchaser agree that the Purchase Price (and any adjustments thereto) and the Assumed Liabilities shall be allocated for Tax purposes among the Shares and the Vaccines Group Businesses in
accordance with Applicable Law (the “Allocation”). 

  

	1	Prior to the Closing Date and subject always to paragraph 1, the Seller and the Purchaser shall negotiate in good faith to reach an agreement as to the Allocation of the Purchase Price and the Assumed Liabilities
including by ascribing a value to that part of the Vaccines Group comprising the Products Encepur and Ixiaro (which, if disposed of by the Seller’s Group prior to the Closing Date shall be the amount payable by the Seller to the Purchaser
pursuant to Clause 3.6.1) to the Shares, and to any Vaccines Group Businesses that are subject to transfer Taxes or VAT, or where a valuation of a particular Vaccines Group Business prior to Closing is otherwise required by Applicable Law (each a
“Required Item”). 

  

	2	Failing agreement between the parties on the Allocation in respect of any Required Item in accordance with this Schedule 13, the Allocation shall be determined by the Reporting Accountants on the application of
the Seller or the Purchaser. Paragraphs 1.6 to 1.12 of Part 1 of Schedule 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 2. 

 

	3	The Seller and the Purchaser shall negotiate in good faith to further allocate the Purchase Price and Assumed Liabilities among the Vaccines Group Businesses for which an allocation was not agreed prior to
Closing within 90 calendar days after the Closing Date. If the Seller and the Purchaser reach written agreement within such 90 day period, the Allocation, as so amended, shall become binding upon the Seller and the Purchaser as the “Final
Allocation Schedule”. 

  

	4	The Seller and the Purchaser shall, and shall procure that each of their Affiliates will, file all Tax Returns in a manner consistent with the Final Allocation Schedule, unless otherwise required by Applicable
Law, and shall take no position inconsistent with the Final Allocation Schedule in any proceedings before any Governmental Entity or otherwise. 

  

	5	If the Seller and the Purchaser are unable to agree to an Allocation pursuant to paragraph 4, the matter shall be determined by the Reporting Accountants on the application of the Seller or the Purchaser.
Paragraphs 1.6 to 1.12 of Part 1 of Schedule 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 5. 

  
 187 

 Schedule 14 

VAT 
 (Clause 3.4)

  

	1	VAT: Records 

  

	1.1	The Seller may, on or before the date of Closing, obtain a direction from the relevant Tax Authority for the retention and preservation by it of any VAT records relating to its period of ownership of the relevant
part of the Vaccines Group and, where any such direction is obtained, the Seller shall: 

  

	 	1.1.1	preserve the records to which that direction relates in such a manner and for such period as may be required by the direction or by Applicable Law; and 

 

	 	1.1.2	allow the Purchaser, upon the Purchaser giving reasonable notice, reasonable access to and copies of such records where reasonably required by the Purchaser for its Tax purposes. 

 

	1.2	If no such direction as is referred to in paragraph 1.1 above is obtained or before the date of Closing and any documents in the possession or control of a member of the Seller’s Group are required by law to
be preserved by the Purchaser, the Seller shall, as soon as reasonably practicable after Closing, deliver such documents to the Purchaser. 

  

	2	VAT: Going Concern - EU Member States 

  

	2.1	The Seller and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into a written
agreement) to secure that, to the extent reasonably possible, the sale of all or any part of the Vaccines Group Businesses, so far as carried on in the European Union, is treated as neither a supply of goods nor a supply of services for the purposes
of the laws governing VAT in each relevant member state. 

  

	2.2	Each Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Vaccines Group Businesses, so far as carried on in the relevant member
state, should be treated as neither a supply of goods nor a supply of services for the purposes of the laws governing VAT in that member state and to account for VAT (and accordingly to seek an additional payment from the Purchaser under Clause
3.4.2) in accordance with that ruling. The Seller shall not be obliged to challenge (or to procure that any relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If the Purchaser wishes to challenge, or to
require the relevant Business Seller to challenge, any such ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from or in connection with, that challenge
and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. 

  

	2.3	Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the Seller shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Vaccines
Group Businesses and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination. 

  
 188 

	3	VAT: Going Concern - non-EU Jurisdictions 

  

	3.1	To the extent that any state outside the European Union provides for relief or exemption from VAT on the transfer of a business or a company or treats such a transaction as being non-taxable for VAT purposes, the
Seller and the Purchaser shall, use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into a written agreement) to secure such relief, exemption
or treatment, to the extent reasonably possible, as regards the sale of all or part of the Vaccines Group Businesses (insofar as the business of the Vaccines Group is carried on in the relevant state) under this Agreement. 

 

	3.2	The relevant Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Vaccines Group Businesses, so far as the business of the Vaccines
Group is carried on in the relevant state, is eligible for a relief or exemption or is otherwise eligible to be treated as non-taxable for the purposes of the laws governing VAT in that state and to account for VAT and accordingly seek an additional
payment from the Purchaser under Clause 3.4.2) in accordance with that ruling. The Seller shall not be obliged to challenge (or to procure then the relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If the
Purchaser wishes to challenge, or to require the relevant Business Purchaser to challenge, any ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from or
in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the Seller
shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Vaccines Group Businesses and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination.

  

	4	VAT: Time, Manner and Currency of Payment 

  

	4.1	Any amounts which the Purchaser is obliged to pay to the Seller under this Agreement in respect of VAT shall be paid by the Purchaser, on its own account or on behalf of another member of the Purchaser’s
Group, to the Seller or to such member of the Seller’s Group as the Seller may direct. Such amounts shall be paid in the currency in which the VAT in question must be accounted for to the relevant Tax Authority. 

 

	4.2	Subject to any provision or express agreement to the contrary (including the terms of any Ancillary Agreements or other agreements entered into between members of the Seller’s Group and members of the
Purchaser’s Group in respect of the provision of transitional services dealing with payments of amounts in respect of VAT arising in connection with the supply of goods or services to members of the Purchaser’s Group at Closing), any
amounts in respect of VAT payable in any jurisdiction in respect of the transfer at Closing of any of the Vaccines Group Businesses or Shares shall be paid in accordance with paragraph 4.1 above at Closing against production of a valid VAT invoice
(or equivalent, if any). 

  

	4.3	Notwithstanding any other provision of this Agreement, the Purchaser shall not be liable to account to the Seller or any member of the Seller’s Group for or in respect of penalties or interest arising solely
from the failure of the Seller or any other member of the Seller’s Group to account promptly for VAT to the relevant Tax Authority following the Seller having been placed in the appropriate amount of funds for that purpose by the Purchaser.

  
 189 

 Schedule 15 

Closing Obligations 

(Clause 6) 
  

	1	General Obligations 

  

	1.1	The Seller’s Obligations 

 On Closing, the Seller shall deliver or make available to
the Purchaser the following: 
  

	 	1.1.1	the Ancillary Agreements (other than the France SPA and the Netherlands APA and, if they have not been agreed, the Transitional Services Agreement, the Transitional Distribution Services Agreement and the
Influenza Business Manufacturing and Supply Agreement) duly executed by the relevant members of the Seller’s Group; 

  

	 	1.1.2	a valid power of attorney or such other evidence reasonably satisfactory to the Purchaser that the Seller, and each of its relevant Affiliates, are authorised to execute this Agreement, the Ancillary Agreements
and the Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Schedule 15), in each case to the extent that they are parties thereto; 

 

	 	1.1.3	the Certificate duly executed by the Seller; 

  

	 	1.1.4	the statutory books of the Vaccines Group Companies (which shall be written up to but not including the Closing Date), the certificate of incorporation (and certificate of incorporation on change of name) and
common seal (if any) of each Vaccines Group Company and share certificates (or other documents of title) in respect of all the issued share capital of each Vaccines Group Company; 

 

	 	1.1.5	In addition, the Seller shall, if requested by the Purchaser by notice in writing not less than five Business Days prior to the Closing Date: 

 

	 	(i)	procure any then present directors and officers (if any) of each Vaccines Group Company that are not Transferred Employees resign their offices to take effect at the Closing Date as such and to relinquish any rights
which they may have under any contract of employment with any Vaccines Group Company or under any statutory provisions (including any right to damages or compensation for breach of contract, loss of office, redundancy or unfair dismissal or on any
other account whatsoever) and to confirm that no agreement or arrangement is outstanding under which any Vaccines Group Company has or could have any obligation to any of them including in respect of remuneration or expenses; 

 

	 	(ii)	procure the present auditors of each Vaccines Group Company to resign their office as such, such resignations to take effect as at the Closing Date; and 

 

	 	(iii)	procure board meetings of the relevant Vaccines Group Companies are held, or written resolutions of the board are passed, at or by which: 

it shall be resolved that each of the transfers relating to the Shares shall, so far as possible, be approved for registration and 

  
 190 

 any person nominated by the Purchaser shall be appointed director, such appointments to take
effect on the Closing Date. 
  

	1.2	The Purchaser’s Obligations 

 On Closing, the Purchaser shall deliver or make
available to the Seller the following: 
  

	 	1.2.1	the Ancillary Agreements (other than the France SPA and the Netherlands APA and, if they have not been agreed, the Transitional Services Agreement, the Transitional Distribution Services Agreement and the
Influenza Business Manufacturing and Supply Agreement) duly executed by the relevant members of the Purchaser’s Group; 

  

	 	1.2.2	evidence reasonably satisfactory to the Seller that the Purchaser, and each of its relevant Affiliates, are authorised to execute this Agreement, the Ancillary Agreements and the Local Transfer Documents
(including, where relevant, any notarial deeds referred to in this Schedule 15), in each case to the extent that they are parties thereto. 

  

	2	Transfer of the Shares and Vaccines Group Businesses 

  

	2.1	General Transfer Obligations 

 On Closing or such other date as agreed between the
parties, the Seller shall procure that the Share Sellers and Business Sellers shall, and the Purchaser shall, execute and/or deliver and/or make available Local Transfer Documents and take such steps as are required to transfer the Shares and
Vaccines Group Businesses in accordance with this Agreement. 
  

	2.2	Specific Transfer Obligations 

 For the purposes of compliance with paragraph 2.1, the
Seller and the Purchaser shall, between the date of this Agreement and Closing, negotiate in good faith any and all Local Transfer Documents and other such steps as are required to transfer the Shares and Vaccines Group Businesses in accordance with
this Agreement. 

  
 191 

 Schedule 16 

Post Closing Adjustments 

(Clause 7) 
 Part 1

 Preparation of Closing Statement 
  

	1	Preparation 

  

	1.1	No later than 60 days following Closing, the Seller shall deliver to the Purchaser the Draft Closing Statement. Prior to such delivery, the Seller shall so far as is practicable consult with the Purchaser with a
view to reducing the potential areas of disagreement. 

  

	1.2	In order to enable the Seller to prepare the Draft Closing Statement, the Purchaser shall keep up-to-date and, subject to reasonable notice, make available to the Seller’s representatives and to the
Seller’s accountants all books and records relating to the Vaccines Group during normal office hours and co-operate with them with regard to the preparation, review and agreement or determination of the Draft Closing Statement. The Purchaser
agrees to make available the services of the employees of the Vaccines Group to assist the Seller in the preparation, review and agreement or determination of the Draft Closing Statement. 

 

	 	In order to allow the Purchaser to review the Draft Closing Statement, the Seller shall, subject to reasonable notice, make available to the Purchaser’s representatives and to the Purchaser’s accountants all
books and records relating to the Vaccines Group during normal office hours and co-operate with them with regard to their review of the Draft Closing Statement. The Seller agrees to make available the services of the employees of the Seller and its
Affiliates to assist the Purchaser in its review of the Draft Closing Statement. 

  

	1.3	If the Purchaser does not within 60 days of presentation to it of the Draft Closing Statement give notice to the Seller that it disagrees with the Draft Closing Statement or any item thereof, such notice stating
the reasons for the disagreement in reasonable detail and specifying the adjustments which, in the Purchaser’s opinion should be made to the Draft Closing Statement (the “Purchaser’s Disagreement Notice”),
the Draft Closing Statement shall be final and binding on the parties for all purposes. If the Purchaser gives a valid Purchaser’s Disagreement Notice within such 60 days, the Seller and the Purchaser shall attempt in good faith to reach
agreement in respect of the Draft Closing Statement and, if they are unable to do so within 30 days of such notification, the Seller or the Purchaser may by notice to the other require that the Draft Closing Statement be referred to the Reporting
Accountants (an “Appointment Notice”). 

  

	1.4	Within 30 days of the giving of an Appointment Notice, the Seller may by notice to the Purchaser indicate that, in the light of the fact that the Purchaser has not accepted the Draft Closing Statement in its
entirety, it wishes the Reporting Accountants to consider matters relating to the Draft Closing Statement in addition to those specified in the Purchaser’s Disagreement Notice, provided that such matters as are related to the matters specified
in the Purchaser’s Disagreement Notice and that the notice states in reasonable detail the reasons why and in what respects the Seller believes that the Draft Closing Statement should be altered in respect of such matters (the
“Seller’s Disagreement Notice”). 

  
 192 

	1.5	The Reporting Accountants shall be engaged jointly by the Seller and the Purchaser on the terms set out in this paragraph 1 and otherwise on such terms as shall be agreed; provided that neither the Seller nor the
Purchaser shall unreasonably (having regard, inter alia, to the provisions of this paragraph 1) refuse its agreement to terms proposed by the Reporting Accountants or by the other party. If the terms of engagement of the Reporting Accountants have
not been settled within 45 days of their identity having been determined (or such longer period as the Seller and the Purchaser may agree) then, unless the Seller or the Purchaser is unreasonably refusing its agreement to those terms, those
accountants shall be deemed never to have become the Reporting Accountants and new Reporting Accountants shall be selected in accordance with the provisions of this Agreement. 

 

	1.6	Except to the extent that the Seller and the Purchaser agree otherwise, the Reporting Accountants shall determine their own procedure but: 

 

	 	1.6.1	apart from procedural matters and as otherwise set out in this Agreement shall determine only: 

  

	 	(i)	whether any of the arguments for an alteration to the Draft Closing Statement put forward in the Purchaser’s Disagreement Notice or the Seller’s Disagreement Notice is correct in whole or in part; and

  

	 	(ii)	if so, what alterations should be made to the Draft Closing Statement in order to correct the relevant inaccuracy in it; 

  

	 	1.6.2	shall apply the accounting principles, policies, procedures, practices and estimation techniques as set out in Part 2 of this Schedule; 

 

	 	1.6.3	shall make their determination pursuant to paragraph 1.6.1 as soon as is reasonably practicable; 

  

	 	1.6.4	the procedure of the Reporting Accountants shall: 

  

	 	(i)	give the Seller and Purchaser a reasonable opportunity to make written and oral representations to them; 

  

	 	(ii)	require that each party supply the other with a copy of any written representations at the same time as they are made to the Reporting Accountants; 

 

	 	(iii)	permit each party to be present while oral submissions are being made by the other party; and 

  

	 	(iv)	for the avoidance of doubt, the Reporting Accountants shall not be entitled to determine the scope of their own jurisdiction. 

  

	1.7	The Reporting Accountants shall send the Seller and the Purchaser a copy of their determination pursuant to paragraph 1.6.1 within one month of their appointment. Such determination: 

 

	 	1.7.1	shall be made available to the Seller and the Purchaser in writing; and 

  

	 	1.7.2	unless otherwise agreed by the Seller and the Purchaser, shall include reasons for each relevant determination. 

  

	1.8	 The Reporting Accountants shall act as experts and not as arbitrators and their determination of any matter falling within their jurisdiction
shall be final and binding on the Seller and the Purchaser save in the event of manifest error (when the relevant part of their 

  
 193 

	 	
determination shall be void and the matter shall be remitted to the Reporting Accountants for correction). In particular, their determination shall be deemed to be incorporated into the Draft
Closing Statement. 

  

	1.9	The expenses (including amounts in respect of VAT) of the Reporting Accountants shall be borne as they shall direct at the time they make any determination under paragraph 1.6.1(i) or, failing such direction,
equally between the Purchaser and the Seller. 

  

	1.10	The Seller and the Purchaser shall co-operate with the Reporting Accountants and comply with their reasonable requests made in connection with the carrying out of their duties under this Agreement. In particular,
the Purchaser shall keep up-to-date and, subject to reasonable notice, make available to the Seller’s representatives, the Seller’s accountants and the Reporting Accountants all books and records relating to the Vaccines Group during
normal office hours as the Seller or the Reporting Accountants may reasonably request during the period from the appointment of the Reporting Accountants down to the making of the relevant determination. 

 

	1.11	Nothing in this Schedule 16 shall entitle a party or the Reporting Accountants access to any information or document which is protected by legal professional or litigation privilege, provided that neither the
Seller nor the Purchaser shall be entitled to refuse to supply such part or parts of documents as contain only the facts on which the relevant claim or argument is based. 

 

	1.12	Each party and the Reporting Accountants shall, and shall procure that its accountants and other advisers shall, keep all information and documents provided to them pursuant to this paragraph 1 confidential and
shall not use the same for any purpose, except for disclosure or use in connection with the preparation of the Draft Closing Statement, the proceedings of the Reporting Accountants or another matter arising out of this Agreement. 

  
 194 

 Part 2 

Closing Statement Principles 
 This Part 2
of Schedule 16 comprises the specific rules, principles, policies and practices, without limitation, for preparing the Closing Statement. 
 The Closing
Statement sets out the Working Capital, the Working Capital Adjustment, the Vaccines Group Companies’ Cash Balances, the Intra-Group Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables and the Tax Adjustment,
in each case as prepared in accordance with the specific rules, principles, policies and practices set forth in this Part 2 of Schedule 16. The Closing Statement shall be prepared in the form of the Illustrative Closing Statement in Part 3 of this
Schedule 16 which also sets forth, for illustrative purposes only, a computation of each of the components of the Closing Statement as of the close of business on 31 December 2013. 

For the avoidance of doubt, the Closing Statement as referred to in this Part 2 of Schedule 16 shall inclusively apply to each of the Draft Closing Statement
and the Closing Statement. 
  

	1	Closing Statement Rules 

  

	1.1	The Closing Statement shall be prepared as follows: 

  

	 	1.1.1	in accordance with the specific accounting treatments set out in paragraph 2 of this Part 2 of Schedule 16; and, subject thereto 

 

	 	1.1.2	adopting the same accounting principles, methods, procedures and practices utilized in preparing the Statement of Net Assets, as detailed in the Statement of Net Asset Rules, applied on a consistent basis using
consistent estimation methodologies and judgments and with consistent classifications as were used to prepare the Statement of Net Assets; and subject thereto 

  

	 	1.1.3	in accordance with IFRS. 

  

	1.2	For the avoidance of doubt, paragraph 1.1.1 shall take precedence over paragraphs 1.1.2 and 1.1.3, and paragraph 1.1.2 shall take precedence over paragraph 1.1.3. 

 

	2	Specific requirements 

  

	2.1	Cut-off 

 The Closing Statement (including the Draft Closing Statement) shall not take
into account any additional events and any additional information that becomes available after the Statement time up to the date that such Closing Statement is prepared. 
  

	2.2	Change of Ownership 

 The Closing Statement shall not be adjusted for any charges,
provisions, reserves or write-offs in respect of any costs, liabilities or charges that may be incurred by the Vaccines Group prior to or after the Closing as a consequence of the change of ownership of the Vaccines Group or any changes in the
management strategy, direction or priority or possible closure of any part of the Vaccines Group by the Purchaser after Closing, whether or not resulting from the change in ownership. 

  
 195 

	2.3	Deferred Tax 

 The Closing Statement (including the Draft Closing Statement) shall not
take into account or provide for deferred Tax. 
  

	2.4	Other Taxes 

 The Closing Statement (including the Draft Closing Statement) shall take
account of or provide for all income taxes and sales taxes, to which lines BS14_120 Taxes other than income taxes (Liability account) and BS13_108 Value added tax receivable apply. 

 

	3	Illustrative Working Capital Statement 

  

	3.1	Part 4 of this Schedule 16 sets forth, for illustrative purposes only a computation of the Working Capital as of the close of business on 31 December 2013 (the “Illustrative Working Capital Statement”).

  

	4	Base Working Capital 

  

	4.1	Base Working Capital is US$575 million to US$700 million and references in this Agreement to amounts being in excess of, greater than or less than Base Working Capital shall mean less than US$575 million and
greater than or in excess of US$700 million. 

  

	4.2	In relation to the France Business and the Netherlands Business, if one or both businesses is not transferred to the Purchaser under the terms of this Agreement at Closing, the Working Capital relating to such
business (or businesses) shall not be included in the determination of the Working Capital at the Effective Time. If one or both of the France Business or the Netherlands Business are transferred to the Purchaser after Closing, then a further
adjustment shall be made to the Closing Statement on the assumption that the France Business and/or the Netherlands Business were included in the Closing Statement taking the relevant items for the relevant business as of the date they are
transferred to the Purchaser. Any adjustment arising as a result of including the France Business or the Netherlands Business in the Closing Statement after the date of this Agreement shall be agreed and paid on the same basis as the Closing
Statement was agreed and paid in respect thereof made. 

  
 196 

 Part 3 

Illustrative Closing Statement 
 [***] 

 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 197 

 Part 4 

Illustrative Working Capital Statement 

All amounts in USD thousands 
  

					
	 	  	Vaccines Group (excl. Influenza business)
Illustrative Net Working Capital as
per December 
31, 2013	 
	 BS01_110 Total inventories
	  	 	400,663	  
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	335,387	  
	 BS01_130 Receivables own BU
	  	 	22,683	  
	 BS01_140 Receivables other BU’s
	  	 	20,419	  
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	(176,115	) 
	 BS01_620 Payables own BU
	  	 	(18,295	) 
	 BS01_630 Payables other BU’s
	  	 	(40,675	) 
		  	  
	  
	 
	 Illustrative Net Working Capital
	  	 	544,067	  
		  	  
	  
	 

  
 198 

 Schedule 17 

Milestone and Royalty Payments 
  

	1	Milestone Payments 

  

	1.1	MenABCWY Single Milestone Payment 

  

	 	1.1.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “MenABCWY Milestone
Payment”) upon issuance to the Purchaser or any of its Affiliates or their respective authorised sub-licensees or assignees (the “Relevant Parties”) on or before 31 December 2018 of a letter of approval of a Biologics
License Application or supplemental Biologics License Application (a “BLA”) issued by the FDA for any meningococcal vaccine (groups A, B, C, W-135 and Y) whether adjuvanted, combined or otherwise (the “MenABCWY
Product”) for use in, at a minimum, Adolescents. 

  

	 	1.1.2	The Purchaser shall not be obliged to make the MenABCWY Milestone Payment more than once under this paragraph 1.1 and its maximum aggregate liability under this paragraph 1.1 shall not exceed the amount of the
MenABCWY Milestone Payment. 

  

	1.2	Bexsero Single Milestone Payment 

  

	 	1.2.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “Bexsero Milestone
Payment”) following the first Calendar Year during which Net Sales of Bexsero worldwide excluding the US in excess of [***] are achieved. 

  

	 	1.2.2	The Purchaser shall not be obliged to make the Bexsero Milestone Payment more than once under this paragraph 1.2 and its maximum aggregate liability under this paragraph 1.2 shall not exceed the amount of the
Bexsero Milestone Payment. 

  

	1.3	ACIP Category A Single Milestone Payment 

  

	 	1.3.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “ACIP Category A Milestone
Payment”) upon any positive Category A recommendation by the Advisory Committee on Immunization Practices to the U.S. Centers for Disease Control and Prevention (or its successor) (“ACIP”), before 31 December 2019,
regardless of the population, sub-population, age group or risk-factor-based group to which the recommendation pertains, with respect to either (i) the MenABCWY Product; or (ii) Bexsero (whichever is earlier, and provided such milestone is paid only
once). 

  

	 	1.3.2	The Purchaser shall not be obliged to make the ACIP Category A Milestone Payment more than once under this paragraph 1.3 and its maximum aggregate liability under this paragraph 1.3 shall not exceed the amount of
the ACIP Category A Milestone Payment. 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 199 

	1.4	GBS Single Milestone Payment 

  

	 	1.4.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “GBS Milestone
Payment”) upon any positive Category A or Category B recommendation by ACIP, regardless of the population, sub-population, age group or riskfactor-based group to which the recommendation pertains, with respect to any Group B streptococcus
vaccine, whether adjuvanted, combined or otherwise (the “GBS Product”). 

  

	 	1.4.2	The Purchaser shall not be obliged to make the GBS Milestone Payment more than once under this paragraph 1.4 and its maximum aggregate liability under this paragraph 1.4 shall not exceed the amount of the GBS
Milestone Payment. 

  

	2	Notification and Settlement of Milestone Payments 

  

	2.1	As promptly as practicable, but in any event within five days, the Purchaser shall notify the Seller in writing of any Milestone Payment becoming due. 

 

	2.2	The Purchaser shall pay each Milestone Payment within 30 days of achievement of the relevant Milestone. 

  

	2.3	All Milestone Payments due from the Purchaser to the Seller shall be made to the Seller or to an entity designated by the Seller by wire transfer of immediately available funds in US dollars to the credit of such
bank account or accounts as may be designated by the Seller from time to time. 

  

	3	Royalty Payments 

  

	3.1	GBS Worldwide Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or
cause to be paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of the GBS Product and any adjuvanted or combined versions thereof, in the world in each Calendar Year, at the rate of
10% of such Net Sales in the world (the “GBS Royalty Payments”). 
  

	3.2	MenABCWY US Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or
cause to be paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of the MenABCWY Product and any adjuvanted or combined versions thereof, in the US in each Calendar Year, at the rate
of 10% of such Net Sales in the US (the “MenABCWY US Royalty Payments”). 
  

	3.3	US Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or cause to be
paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of Bexsero and any adjuvanted or combined versions (excluding, for the avoidance of doubt, MenABCWY) thereof, in the US in each
Calendar Year, at the rate of 10% of such Net Sales in the US (the “Bexsero US Royalty Payments”). 

  
 200 

	3.4	Bexsero Ex-US Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or
cause to be paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of Bexsero and any adjuvanted or combined versions (excluding, for the avoidance of doubt, MenABCWY) thereof, in the
world (excluding the US) in each Calendar Year, at the rate of 10% of such Net Sales in the world (excluding the US) in excess of [***] in such Calendar Year (the “Bexsero Ex-US Royalty Payments”). 

 

	3.5	Combinations 

 If the GBS Product, the MenABCWY Product or Bexsero is sold as part of the
combination (each a “Combination Product”) then, for the purposes of paragraph 3.1, 3.2, 3.3 or 3.4 (as applicable), the figure of Net Sales of the relevant Combination Product shall be calculated by multiplying the total amount of
Net Sales of that Combination product by the fraction A/(A+B), where A is the invoice price of the GBS Product, the MenABCWY Product or Bexsero (as applicable) sold separately and B is the invoice price of the other active ingredients and/or active
antigens and/or adjuvants in the Combination Product. 
  

	4	Settlement of Royalty Payments 

  

	4.1	Each Royalty Payment shall be an independent obligation of the Purchaser (not linked to any Royalty Payment in respect of another Applicable Product or Calendar Year) and shall continue to be due and payable
indefinitely in accordance with the terms of this Agreement. 

  

	4.2	Each Royalty Payment shall be payable on a Calendar Quarter basis in accordance with paragraph 5. 

  

	4.3	In respect of any period between the Closing Date and the start of the next Calendar Quarter (the “Stub Period”), the amount of any Royalty Payments due in respect of the Stub Period shall be
adjusted on a pro rata basis to reflect the number of days in the Stub Period as a proportion of the number of days in the Calendar Quarter in which Closing occurs. 

 

	5	Reporting of Royalty Payments 

  

	5.1	Within 10 Business Days of the end of: 

  

	 	5.1.1	each Calendar Quarter, the Purchaser shall provide to the Seller a Sales & Royalties Report; and 

  

	 	5.1.2	each Calendar Year, the Purchaser shall provide to the Seller an Annual Reconciliation Report. 

  

	5.2	The Seller shall submit an invoice to the Purchaser in a form agreed by the Seller and the Purchaser from time to time with respect to any Royalty Payment and/or Estimated Quarterly Bexsero Ex-US Royalty Payment
shown as due in a Sales & Royalties Report. 

  

	5.3	The Purchaser shall pay each Royalty Payment and/or Estimated Quarterly Bexsero Ex-US Royalty Payment due within 30 days of receipt of an invoice in respect of the same pursuant to paragraph 5.2.

  

	5.4	All Royalty Payments due from the Purchaser to the Seller shall be made to the Seller or to an entity designated by the Seller by wire transfer of immediately available funds in US 

 

	***	 Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted
from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 201 

	 	
dollars to the credit of such bank account or accounts as may be designated by the Seller from time to time. 

 

	6	Reconciliation of Bexsero Ex-US Royalty Payments 

  

	6.1	Following agreement or determination of the amount of the Bexsero Ex-US Royalty Payment due in respect of each Calendar Year (a “Final Bexsero Ex-US Royalty Payment”) either as set out in any
Annual Reconciliation Report or as subsequently agreed or determined in accordance with paragraphs 7 and 8: 

  

	 	6.1.1	if the Paid Bexsero Ex-US Royalty Payment is greater than the Final Bexsero Ex-US Royalty Payment, the Seller shall repay to the Purchaser an amount equal to the excess; or 

 

	 	6.1.2	if the Paid Bexsero Ex-US Royalty Payment is less than the Final Bexsero Ex-US Royalty Payment, the Purchaser shall pay to the Seller an additional amount equal to the deficiency. 

 

	6.2	The Seller or the Purchaser (as applicable) shall pay any amount due under paragraph 6.1 within 30 days of the agreement or determination of the Final Bexsero Ex-US Royalty Payment due in respect of such Calendar
Year. 

  

	6.3	Any payment to be made in accordance with paragraph 6.2 shall include interest thereon calculated from the date on which the amount would have been due for payment (had the Estimated Bexsero Ex-US Royalty
Payments for the Calendar Year been equal to the Bexsero Ex-US Royalty Payment for such Calendar Year) to the date of payment at a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 

 

	7	Records and Audit 

  

	7.1	The Purchaser shall, and, so far as it is able to do so, shall cause the Relevant Parties to, keep in all material respects complete, true and accurate books and records in accordance with its Accounting
Standards in relation to this Agreement including in relation to Net Sales and Royalty Payments. The Purchaser shall, and, so far as it is able to do so, shall cause the Relevant Parties to, keep such books and records for at least five years
following the Calendar Year to which they pertain. 

  

	7.2	The Seller shall have the right, for a period of five years after receiving each Report, to audit such Report, whether by itself or through its Affiliates and/or to appoint an internationally-recognised
independent accounting firm to audit (whether the Seller, its Affiliates, or the accounting firm, the “Auditor”) such Report, and to inspect the relevant records of the Relevant Parties to verify such Report and the underlying
statements, records or books of accounts, as applicable. Where the Auditor is not the Seller, the Auditor shall have the right to disclose to the Seller and/or other Affiliates its conclusions regarding any payments owed hereunder to the Seller.

  

	7.3	The Purchaser shall, and shall cause the other Relevant Parties to, make their records available for inspection by the Auditor during regular business hours at such place or places where such records are
customarily kept upon receipt of reasonable advance notice from the Auditor to verify the accuracy of each Report and compliance with this Schedule 17. 

  
 202 

	7.4	The Seller shall bear the cost of any audit pursuant to this paragraph 7, as well as its own costs, fees and expenses associated with enforcing its rights with respect to any payments hereunder, except that, if
it is determined by the Auditor that the amounts set out in the Sales & Royalties Report for any Calendar Quarter are more than three per cent. below the amounts actually due pursuant to this Schedule 17, the reasonable costs, fees and expenses
charged or incurred by the Auditor shall be paid or reimbursed by the Purchaser. 

  

	7.5	In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by the Purchaser, the underpaid or overpaid amount, as applicable, shall be settled promptly by the Seller or
the Purchaser (as applicable). 

  

	8	Disputes 

 In the event of any dispute between the parties in respect of whether a
Milestone Payment or a Royalty Payment is due, or the amount of any such payment due, in accordance with this Schedule 17, the dispute shall be determined by the Reporting Accountants on the application of the Seller or the Purchaser. Paragraphs 1.6
to 1.12 of Part 1 of Schedule 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 8. 
  

	9	Covenants 

  

	9.1	The Purchaser agrees to procure that, following Closing, the Purchaser’s Group uses its commercially reasonable endeavours to satisfy each of the Milestones. 

 

	9.2	The Purchaser agrees that it will not, and it shall procure that no member of the Purchaser’s Group will, take any action or omit to take any action, in either case which is intended to frustrate the
achievement of any of the Milestones, or which is intended to reduce the amount of any Milestone Payment or Royalty Payment due pursuant to this Schedule 17. 

  

	10	Definitions 

 The following further definitions apply in this Schedule 17: 

“Accounting Standards” means, with respect to a Relevant Party, IFRS as generally and consistently applied by the Relevant
Party’s Group. The Purchaser shall promptly notify the Seller in writing in the event that it or its Group changes the Accounting Standards pursuant to which its records are maintained, it being understood that the Purchaser and its Group may
only use internationally recognised accounting principles; 
 “Adolescents” means individuals aged anywhere between 11 and
18 years old; 
 “Annual Reconciliation Report” means a written report or reports in a form to be agreed by the Seller and
the Purchaser from time to time showing a reconciliation of the amount of the Estimated Bexsero Ex-US Royalty Payment to the amount of the Bexsero Ex-US Royalty Payment due in respect of such Calendar Year; 

“Applicable Product(s)” means the GBS Product, the MenABCWY Product and Bexsero; 

“Calendar Quarter” means each of the four periods of 3 consecutive calendar months, starting on 1 January, 1 April, 1 July and
1 October; 

  
 203 

 “Calendar Year” means each period of 12 consecutive calendar months starting on
1 January and ending on 31 December; 
 “Estimated Bexsero Ex-US Royalty Payment” means the Purchaser’s reasonable
estimate of the Bexsero Ex-US Royalty Payment that will be payable pursuant to paragraph 3.4 in respect of the current Calendar Year; 

“Estimated Quarterly Bexsero Ex-US Royalty Payment” means one quarter of the Estimated Bexsero Ex-US Royalty Payment;

 “Milestone Payments” means the MenABCWY Milestone Payment, the Net Sales Milestone Payment, the ACIP Category A Milestone
Payment and the GBS Milestone Payment, and “Milestone Payment” means any one of them; 
 “Milestones” means
the facts, matters and circumstances giving rise to the requirement for the Purchaser to make the Milestone Payments; 
 “Net
Sales” means, in respect of an Applicable Product, the net sales by the Relevant Parties for the Applicable Product(s) sold to Third Parties other than sublicensees or assignees, as determined in accordance with Accounting Standards
consistently applied by the Purchaser. The deductions booked by the Relevant Parties to calculate the recorded net sales from gross sales shall include the following: 
  

	 	(i)	normal trade, quantity and cash discounts; 

  

	 	(ii)	sales taxes, value added taxes and other taxes directly linked to the sale of Products to the extent included in the gross amount invoiced; 

 

	 	(iii)	amounts repaid or credited by reasons of defects, rejections, recalls or returns; 

  

	 	(iv)	rebates, commissions and chargebacks to customers and Third Parties; 

  

	 	(v)	any amounts recorded in gross revenue associated with goods provided to customers for free, with the exception of samples; 

  

	 	(vi)	amounts provided or credited to customers through coupons, other discount programs and co-pay assistance programs; 

  

	 	(vii)	delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates; and 

  

	 	(viii)	fees for service payments to customers for any non-separate services (including compensation for maintaining agreed inventory levels and providing information), 

and with respect to the calculation of Net Sales: 
  

	 	(a)	Net Sales only include the value charged or invoiced on the first sale to a Third Party and sales between or among Respective Parties shall be disregarded for purposes of calculating Net Sales; 

 

	 	(b)	if a Product is delivered to the Third Party before being invoiced (or is not invoiced), Net Sales will be calculated at the time all the revenue recognition criteria under Accounting Standards are met; and

  

	 	(c)	distributors shall not be considered as sublicensees/assignees; 

 “Paid Bexsero Ex-US
Royalty Payment” means the aggregate of all Estimated Quarterly Bexsero Ex-US Royalty Payments paid by the Purchaser in each Calendar Year; 

  
 204 

 “Report” means any Annual Reconciliation Report or Sales & Royalties Report;

 “Royalty Payments” means the GBS Royalty Payments, the MenABCWY US Royalty Payments, the Bexsero US Royalty Payments and
the Bexsero Ex-US Royalty Payments, and “Royalty Payment” means any one of them; 
 “Sales & Royalties
Report” means a written report or reports in a form to be agreed by the Seller and the Purchaser from time to time showing, on an Applicable Product-by-Applicable Product basis: 

 

	 	(i)	each of (a) gross sales; (b) Net Sales; and (c) Royalty Payments (other than the Bexsero Ex-US Royalty Payments) payable, for each such Applicable Product in respect of the relevant Calendar Quarter; 

 

	 	(ii)	the Purchaser’s reasonable estimate of gross sales and Net Sales of the Bexsero Product in the world (excluding the US) in the current Calendar Year; 

 

	 	(iii)	the Estimated Quarterly Bexsero Ex-US Royalty Payment; and 

  

	 	(iv)	the information in paragraphs (i) to (iii) for (a) the equivalent Calendar Quarter in the prior Calendar Year; and (b) the cumulative totals for the current Calendar Year; 

“Third Party” means any person other than a party or an Affiliate of a party; and 

“US” means the United States of America, its territories and possessions, any state of the United States and the District of
Columbia; and “possessions” include Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands. 

  
 205 

 Schedule 18 

Warranties given under Clause 10.1 
  

	1	Authority and Capacity 

  

	1.1	Incorporation 

 The Seller and each Share Seller and Business Seller is validly existing
and is a company duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Seller and each Share Seller and Business Seller has the legal right and full power and authority to enter into and perform this Agreement, any Ancillary Agreement to which it is a party and any other
documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Seller and each Share Seller and Business Seller in accordance with their respective terms.

  

	 	1.2.3	Except as referred to in this Agreement, the Seller: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

  

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case
in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Seller, each Share Seller and each Business Seller of their respective obligations under them, will not:

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the Seller’s Group; 

 

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Seller’s Group is party or by which the relevant member of the Seller’s Group is bound where
such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Seller’s Group is bound and where such breach is material to their ability to
perform their obligations under such documents. 

  

	1.3	Authorisation 

 The Seller and each Share Seller and Business Seller has taken, or will
have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant to or in connection with
this Agreement or any Ancillary Agreement. 

  
 206 

	2	Vaccines Group 

  

	2.1	Organisation and Standing of the Vaccines Group Companies 

  

	 	2.1.1	Schedule 2 sets out a complete and accurate list of each of the Vaccines Group Companies, together with its jurisdiction of organisation, its authorised and outstanding capital stock or other equity interests,
all of which equity interests are held by the Seller or an Affiliate of the Seller unless otherwise stated in Schedule 2. 

  

	 	2.1.2	Each Vaccines Group Company is duly incorporated, validly existing and in good standing, under the laws of its jurisdiction of organisation and has all necessary corporate power under its constitutional documents
to conduct its portion of the Business as at the date of this Agreement. 

  

	2.2	The Shares 

  

	 	2.2.1	Either the Seller or one of its Affiliates is the legal and beneficial owner of the Shares. 

  

	 	2.2.2	There is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance or equity on, over or affecting the Shares or the shares, capital stock or other equity interests in
the Subsidiaries or any of them and there is no agreement or commitment to give or create any. 

  

	 	2.2.3	All of the Shares and all of the shares, capital stock or other equity interests in the Subsidiaries have been duly authorised and validly issued and are fully paid and non-assessable. There are no options,
warrants, rights, convertible, exercisable or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which any of the
Vaccines Group Companies is a party or by which it is bound obligating any of the Vaccines Group Companies to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any
security convertible into, or exercisable or exchangeable for, any capital stock of, or other equity interest in, such Vaccines Group Company. 

  

	 	2.2.4	There are no outstanding Contracts to which any of the Vaccines Group Companies is a party or is otherwise bound to repurchase, redeem or otherwise acquire any shares, capital stock or other equity interest of
such Vaccines Group Company. 

  

	 	2.2.5	None of the Shares, and the shares, capital stock and other equity interests in the Subsidiaries and Minority Interest Entities is subject to and was not issued in violation of any purchase option, call option,
right of first refusal, pre-emptive right, subscription right or similar right or any provision of Applicable Law or the constitutional documents of the Vaccines Group Companies. 

 

	2.3	The Assets 

 Save in relation to the Transferred Intellectual Property Rights, either the
Seller or another member of the Seller’s Group has good and valid title to the assets listed in Clause 2.3.1 free and clear of all Encumbrances other than Permitted Encumbrances. 

  
 207 

	2.4	Accounts 

 The Accounts of each Vaccines Group Company: 

 

	 	2.4.1	were prepared in accordance with accounting practices generally accepted in the jurisdiction of incorporation of the relevant Vaccines Group Company at the time they were audited; and 

 

	 	2.4.2	show in accordance with applicable legal requirements: 

  

	 	(i)	the assets and liabilities of the relevant Vaccines Group Company at the Accounts Date; and 

  

	 	(ii)	of the profits or losses of the relevant Vaccines Group Company for the accounting period ended on the Accounts Date. 

  

	2.5	Income Statements 

  

	 	2.5.1	The 2013 Income Statement: 

  

	 	(i)	is based on information properly extracted from the Seller’s Group accounting records without adjustment; and 

  

	 	(ii)	presents fairly in all material respects the results of operations of the Vaccines and Diagnostics division of the Seller’s Group as reported in the “Vaccines and Diagnostics” segment in the Novartis 2013
Annual Report for the period from and including 1 January 2013 up to and including 31 December 2013 excluding the Diagnostics Business but including the Influenza Business and the Out-Licensing Programme. 

 

	2.6	Statement of Net Assets 

  

	 	2.6.1	Schedule 23 sets out the Statement of Net Assets. 

  

	 	2.6.2	The Statement of Net Assets was prepared, in all material respects, in accordance with the Statement of Net Assets Rules, and on that basis fairly presents, in all material respects, the financial position of the
Vaccines Group as of the date thereof, subject to year-end audit adjustments and the absence of footnote discussions and similar presentation items therein. 

  

	2.7	Changes Since 31 December 2013 

 Except as a result of the execution and delivery of this
Agreement and, other than as contemplated by Clause 2.3.5 or Clause 5, from 31 December 2013 to the date of this Agreement: 
  

	 	2.7.1	the Business of the Vaccines Group has been conducted in all material respects in the ordinary and usual course; 

  

	 	2.7.2	the Vaccines Group has not entered into any material contract or commitment outside the ordinary course of business as conducted prior to 31 December 2013; and 

 

	 	2.7.3	to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference in the definition of “Material Adverse
Effect” to the date of this Agreement were to 31 December 2013). 

  
 208 

	2.8	Third Party Indebtedness and financial instruments 

 None of the Vaccines Group
Companies: (i) has any Third Party Indebtedness exceeding $1 million (other than short-term bank borrowings in the ordinary course of business) or (ii) is a party to any financial instruments (including any swaps or derivatives) 

 

	2.9	Gross Profit and DCOGS 

  

	 	2.9.1	So far as the Seller is aware, based on management allocations and adjustments, and having regard to the purpose for which it was prepared, the 2013 Gross Profit does not materially misstate the gross profit of
the Vaccines Group for the period from and including 1 January 2013 up to and including 31 December 2013. 

  

	 	2.9.2	So far as the Seller is aware, the 2013 DCOGS: 

  

	 	(i)	is derived from information extracted from the Seller’s Group reporting systems with reasonable care and attention; and 

  

	 	(ii)	having regard to the purpose for which the 2013 DCOGS was prepared, does not materially misstate the direct cost of goods of each of the Products identified in the 2013 DCOGS for the period from and including 1 January
2013 up to and including 31 December 2013. 

  

	3	Real Property and Key Sites 

  

	3.1	Company Real Properties 

  

	 	3.1.1	The Company Real Properties are the only material freehold, leasehold or other immovable property in any part of the world owned, used or occupied by the Vaccines Group Companies or in respect of which any
Vaccines Group Company has any estate, or any material interest, right or liability. 

  

	 	3.1.2	Each of the Company Real Properties is used and occupied for the purpose of the business of a member of a Vaccines Group Company. 

 

	 	3.1.3	A member of the Seller’s Group is solely legally and beneficially entitled to such Company Real Property. 

  

	 	3.1.4	No person has or will have any right to possession, occupation or use of such Company Real Property in a manner that has or will have a material adverse effect on the use of, or operations at, such Company Real
Property. 

  

	 	3.1.5	There are no mortgages or charges affecting any of the Company Real Properties other than those registered in the relevant Land Register. 

 

	 	3.1.6	There are no material outstanding disputes, actions, claims or demands in respect of any Company Real Property, nor has the Seller or any member of the Seller’s Group received any notice threatening the
same. 

  

	 	3.1.7	In respect of each Company Leased Real Property, all material covenants and conditions contained in the Company Lease have been observed and performed to date. 

 

	3.2	Transferred Real Properties 

  

	 	3.2.1	 The Transferred Real Properties are the only material freehold, leasehold or other immovable property in any part of the world owned or
occupied by the Vaccines 

  
 209 

	 	
Group Businesses or in respect of which any Vaccines Group Business has any estate, or any material interest, right or liability. 

 

	 	3.2.2	Each of the Transferred Real Properties is used and occupied for the purpose of the business of the Vaccines Group Business. 

  

	 	3.2.3	A member of the Seller’s Group is solely legally and beneficially entitled to such Transferred Real Property. 

  

	 	3.2.4	No person has or will have any right to possession, occupation or use of such Transferred Real Property in a manner that has or will have a material adverse effect on the use of, or operations at, such
Transferred Real Property. 

  

	 	3.2.5	There are no mortgages or charges affecting any of the Transferred Real Properties other than those registered in the relevant Land Register. 

 

	 	3.2.6	There are no material outstanding disputes, actions, claims or demands in respect of any Transferred Real Property, nor has the Seller or any member of the Seller’s Group received any notice threatening the
same. 

  

	 	3.2.7	In respect of each Transferred Leased Real Property, all material covenants and conditions contained in the Lease have been observed and performed to date. 

 

	3.3	Key Sites 

  

	 	3.3.1	The Key Sites are the only properties used or occupied by the Seller’s Group for the purpose of Manufacturing in respect of the Business. 

 

	 	3.3.2	No consents, licences, approvals, permits, authorisations or waivers are required from any Landlord, superior landlord or other third party to transfer any Key Site to the Purchaser (or any other member of the
Purchaser’s Group) indirectly (through the transfer of the Vaccines Group Companies). 

  

	 	3.3.3	There is no circumstance which would entitle any third party to exercise a right of power of entry or to take possession which would materially adversely restrict the continued possession, enjoyment or existing
use of each Key Site and there are no material restrictive conditions of servitude or public easements attaching to each Key Site. 

  

	 	3.3.4	No member of the Seller’s Group has had any notice from any competent authority to make any alteration, repair or addition to any Key Site, including with regards to the disposal of effluent or the state of
buildings or the number of legally required parking spaces which is presently outstanding. 

  

	4	Intellectual Property and Information Technology 

  

	4.1	Schedule 4 sets out, as of the date of this Agreement, complete and accurate details of Registered Vaccines Group Intellectual Property Rights, including for each such item, as applicable, (i) the identity of the
record owner, (ii) the registration or application number, and (iii) the jurisdiction of issuance or registration. 

  

	4.2	 In relation to Products or Pipeline Products which are material to the Business, all documents and instruments necessary to maintain and
preserve any extension of patent terms including Patent Term Extensions and patent term adjustments in relation to: the (i) Registered Vaccines Group Intellectual Property Rights; and (ii) any Registered Intellectual Property Rights licensed under
any Vaccines Group Intellectual Property Contracts for 

  
 210 

	 	
which the Seller controls the prosecution and maintenance; and in each case, where such applications have a reasonable prospect of success, have been validly executed, delivered and filed in a
timely manner with the appropriate Governmental Entity. 

  

	4.3	Each of the Patents: (i) included within the Registered Vaccines Group Intellectual Property Rights for the Products or Pipeline Products which are material to the Business; and (ii) to the Seller’s
Knowledge, included within the Registered Intellectual Property Rights licensed under the Vaccines Group Intellectual Property Contracts for Products or Pipeline Products material to the Business, in each case, correctly identifies by name each
inventor thereof as determined in accordance with the Applicable Law of each jurisdiction in which such Patent issued and/or is pending. 

  

	4.4	To the Seller’s Knowledge, the Patents forming part of (i) the Registered Vaccines Group Intellectual Property Rights, and (ii) the Registered Intellectual Property Rights licensed under the Vaccines Group
Intellectual Property Contracts in each case for the Products or Pipeline Products which are material to the Business are subsisting, valid and enforceable and have not lapsed or been abandoned. 

 

	4.5	All renewal, application and other registry fees required for the maintenance, prosecution and enforcement of the Registered Vaccines Group Intellectual Property Rights relating to Products or Pipeline Products
that are material to the Business have been paid. 

  

	4.6	Schedule 4 sets out, a complete and accurate list of each material Vaccines Group Intellectual Property Contract. Neither the Seller nor any of its Affiliates has given, or received, written notice to terminate
any material Vaccines Group Intellectual Property Contract or the Merck 2012 Licence, and neither the Seller nor any Affiliate of the Seller is in default of any material Vaccines Group Intellectual Property Contract or the Merck 2012 Licence. To
the Seller’s Knowledge, no third party is in default under any material Vaccines Group Intellectual Property Contract or the Merck 2012 Licence. 

  

	4.7	The Seller and its Affiliates between them own all Registered Vaccines Group Intellectual Property Rights and the Beta Interferon Patent Rights free of all Encumbrances except Permitted Encumbrances. The Seller
and its Affiliates have taken reasonable steps to protect the confidentiality of Proprietary Information and Know-How relating to the Products. 

  

	4.8	To the Seller’s Knowledge: (i) the conduct of the Business as currently conducted does not infringe or misappropriate the Intellectual Property Rights of any third party; and (ii) there is no material
judicial, administrative or arbitral action, suit, hearing, inquiry, investigation or other proceeding (public or private) before any Governmental Entity pending against the Seller or any of its Affiliates in which it is alleged that the conduct of
the Business as currently conducted by the Seller and its Affiliates infringes or misappropriates any Intellectual Property Rights of any third party. Neither the Seller nor any of its Affiliates has received any written notice of such infringement
or misappropriation. 

  

	4.9	To the Seller’s Knowledge, no third party is infringing or misappropriating any Vaccines Group Intellectual Property Rights or Proprietary Information and neither the Seller nor its Affiliates have made any
such claims against any such persons, nor, to the Seller’s knowledge is there any basis for such a claim. 

  

	4.10	 The Vaccines Group Intellectual Property Rights, the Intellectual Property Rights licensed under the Vaccines Group Intellectual Property
Contracts, and the Intellectual Property Rights licensed under the Purchaser Intellectual Property Licence Agreement constitute all 

  
 211 

	 	
the material Intellectual Property Rights used in the conduct of the Business as currently conducted by the Seller and its Affiliates on a worldwide basis; provided however, that the foregoing is
not a representation of non-infringement, non-misappropriation, or any other non-violation of Intellectual Property Rights of any third party, which representation is solely set out in paragraph 4.8 above. 

 

	4.11	No entity within the Seller’s Group (excluding the Vaccines Group Companies) which is not an Assignor (as that term is defined in the Intellectual Property Assignment Agreement) under the Intellectual
Property Assignment Agreement holds any right, title or interest in or to the Vaccines Group Intellectual Property Rights, with the exception of any right, title or interest that is held under any agreement or other arrangement (whether written or
unwritten) which will terminate immediately after (i) the date upon which the Vaccines Group Intellectual Property Rights that are registered in, or held exclusively for use in relation to, Ukraine transfer to a member of the Purchaser’s Group
pursuant to the terms of the Intellectual Property Assignment Agreement; or (ii) Closing in respect of all other Vaccines Group Intellectual Property Rights. 

  

	4.12	The Business has not, in the 12 months prior to the date of this Agreement, experienced any material disruption in its operations as a result of any failure of its Information Technology. 

 

	5	Contracts 

  

	5.1	No Vaccines Group Company or Business Seller is a party to or subject to any Contract, transaction, arrangement, understanding or obligation (other than in relation to any Property, lease or contract of
employment, Information Technology or Intellectual Property Right) which is material to the business of the Vaccines Group and which: 

  

	 	5.1.1	is not in the ordinary course of business or is unduly onerous; 

  

	 	5.1.2	is not on an arm’s length basis; 

  

	 	5.1.3	has an unexpired term or likely duration of 10 years or more; 

  

	 	5.1.4	restricts its freedom to carry on its business in any part of the world in such manner as it thinks fit; 

  

	 	5.1.5	involves an aggregate outstanding expenditure by it of more than US$50 million, exclusive of VAT; 

  

	 	5.1.6	can be terminated in the event of a change of underlying ownership or control of a Vaccines Group Company; or 

  

	 	5.1.7	involves the supply of goods and services, the aggregate sales value of which (exclusive of VAT) will be more than 5 per cent of turnover of the Vaccines Group (exclusive of VAT) for the preceding financial year.

  

	5.2	Save in relation to any Vaccines Group Intellectual Property Contract, no Vaccines Group Company is in material default under any material Contract to which it is party and no third party is in material default
under any material Contract to which a Vaccines Group Company is party and, to the Seller’s knowledge, there are no circumstances in either case likely to give rise to such a material default. 

 

	5.3	 Save in relation to any Vaccines Group Intellectual Property Contract, no Business Seller is in material default under any material Contract to
which it is party and no third party is in material default under any material Contract to which a Business Seller is party and, to the 

  
 212 

	 	
Seller’s knowledge, there are no circumstances in either case likely to give rise to such a material default. 

 

	6	Joint Ventures etc. 

 No Vaccines Group Company or Business Seller is, or has agreed to
become, a member of any joint venture, consortium, partnership or other unincorporated association (other than a recognised trade association in relation to which the Vaccines Group Company or Business Seller has no liability or obligation except
for the payment of annual subscription or membership fees). 
  

	7	Agreements with Connected Parties 

  

	7.1	There are no existing contracts or arrangements material to the business of the Vaccines Group between, on the one hand, any Business Seller or Vaccines Group Company and, on the other hand, the Seller, any
Relevant Seller other than on normal commercial terms in the ordinary course of business. 

  

	7.2	No Affiliate Contract is required to run the Business and the termination of any Affiliate Contract will not, when taken together with the rights and services under the Ancillary Agreements and for the respective
terms thereof, have a material effect on the Business. 

  

	7.3	The Vaccines Group Companies do not currently carry on any Seller’s Group Retained Business (other than the Influenza Business). 

 

	8	Sufficiency of Vaccines Group 

  

	8.1	Each of the assets listed in Clause 2.3.1 is owned both legally and beneficially by the Seller or its Affiliates and each of those assets capable of possession is, save where in the possession of third parties in
the ordinary course of business, in the possession of the Seller or its Affiliates. 

  

	8.2	Save for Permitted Encumbrances, no option, right to acquire, mortgage, charge, pledge, line or other form of security or Encumbrance (excluding licences of Intellectual Property or Know-How) or equity on, over
or affecting the whole or any part of the assets listed in Clause 2.3.1 is outstanding and, save in relation to Permitted Encumbrances, there is no agreement or commitment entered into by any member of the Seller’s Group to give or create any
and no claim has been made against any member of the Seller’s Group by any person entitled to any. 

  

	8.3	The Vaccines Group Businesses, assets of the Vaccines Group Companies and the assets of the Minority Interest Entities, when taken together with the rights and services under the Ancillary Agreements and for the
respective terms thereof: 

  

	 	(i)	comprise all of the assets required to carry out the Business of the Vaccines Group in substantially the same manner as it has been during the twelve months prior to the date of this Agreement; and 

 

	 	(ii)	are sufficient in all material respects to carry out the Business of the Vaccines Group after the Closing substantially as conducted by the Seller and its Affiliates as of the date of this Agreement, 

provided however, that the foregoing is not a warranty of non-infringement, non-misappropriation or any other non-violation of Intellectual
Property Rights of any third party, which warranty is solely set out in paragraph 4.8. 

  
 213 

	8.4	The Vaccines Group Businesses, assets of the Vaccines Group Companies and the assets of the Minority Interest Entities, when taken together with the rights and services under the Ancillary Agreements and for the
respective terms thereof, are sufficient in all material respects to carry out the Purchaser’s obligations under the Influenza Business Transitional Services Agreement and under any other arrangements the Purchaser is required to enter into
pursuant to Clause 8.14.1(i), substantially as conducted by the Seller and its Affiliates as of 22 April 2014, provided however, that the foregoing is not a warranty of non-infringement, non-misappropriation or any other non-violation of
Intellectual Property Rights of any third party, which warranty is solely set out in paragraph 4.8. 

  

	9	Compliance with Laws, Permits and Anti-Bribery 

  

	9.1	None of the Seller or its Affiliates is in breach of any Applicable Law where such breach is reasonably likely to be material to the Vaccines Group. 

 

	9.2	Neither the Seller nor any of its Affiliates has received any written notice from any Governmental Entity that it is not in compliance (or any warning letter that it may not be in compliance) with any Applicable
Law or is not in possession of any permits, licences, certificates or other authorisations or consents of a Governmental Entity in each case as is necessary for the conduct of the Business of the Vaccines Group in all material respects as presently
conducted (each a “Permit” and, collectively, the “Permits”), except where such non-compliance or non-possession does not remain outstanding or uncured as of Closing or would not reasonably be expected to have a
material effect on the Business. 

  

	9.3	With respect to the Vaccines Group, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the Seller’s Knowledge, no Seller
Partner has, directly or indirectly: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or to influence official action; (ii) made or offered to make any unlawful
payment to any foreign or domestic government official or employee, or agent, political party or any official of such party, or political candidate from corporate funds; (iii) made or offered to make any bribe, rebate, payoff, influence payment,
money laundering, kickback or other unlawful payment; or (iv) violated or is in violation of any provision of any applicable Anti-Bribery Law; and with respect to the Vaccines Group, the Seller and its relevant Affiliates have instituted and
maintain policies and procedures reasonably designed to ensure compliance with applicable Anti-Bribery Law. 

  

	9.4	With respect to the Vaccines Group, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the Seller’s Knowledge, no Seller Partner: (i) is
currently the subject of, nor has it been since 1 January 2009, the subject of, any action alleging a violation, or possible violation, of any Anti-Bribery Law, or been since 1 January 2009, the recipient of a subpoena, letter of investigation or
other document alleging a violation, or possible violation, of any Anti-Bribery Law, or (ii) has, since 1 January 2009, improperly or inaccurately recorded in any books and records (A) any payments, cash, contributions, gifts, hospitalities or
entertainment to a foreign or domestic government official, employee of an enterprise owned or controlled in whole or in part by any foreign government, official of a foreign or domestic political party or campaign, or a foreign or domestic
candidate for political office; or (B) other expenses related to political activity or lobbying. 

  

	9.5	 With respect to the Vaccines Group, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors
or officers, and, to the Seller’s Knowledge, 

  
 214 

	 	
none of their respective employees has received notice that any such person is or has been alleged to be in violation of any sanctions administered by the Office of Foreign Assets Control of the
U.S. Department of the Treasury or by the U.S. Department of State or equivalent measures of the United Kingdom, European Union, or the United Nations (the “Sanctions Law”). With respect to the Vaccines Group, neither the Seller nor
any of its Affiliates, nor any of their respective directors or officers, and, to the Seller’s Knowledge, none of their respective employees has conducted any of their business activities whatsoever with, or for the benefit of, a government,
national or legal entity to the extent such actions would violate any Sanctions Law. None of the execution, delivery and performance of this Agreement and the direct or indirect use of proceeds from any transaction contemplated hereby or the
fulfilment of the terms hereof will result in a violation by any person of any Sanctions Law. 

  

	9.6	Each member of the Seller’s Group, in connection with the Products, the Product Approvals, the Product Applications, the Transferred Contracts and the Transferred Intellectual Property Contracts requires its
Service Providers to act in accordance with the requirements of applicable Anti-Bribery Law and uses all reasonable endeavours to procure that they do so. Each such Service Provider has in place policies, systems, controls and procedures designed to
prevent, and which are reasonably expected to continue to prevent, it and its Associated Persons from violating applicable Anti-Bribery Law. 

  

	10	Product Approvals 

  

	10.1	The Seller or one of its Affiliates is the registered holder of each of the Product Approvals. All material Product Approvals held by Seller or its Affiliates are in full force and effect. No material
deficiencies have been asserted by any applicable Government Entity with respect to any Product Approval or Product Filing, nor, to the Seller’s knowledge, are there any facts or circumstances that would be likely to lead to such assertions
being made. 

  

	10.2	Each Product was and is being researched, developed, manufactured, marketed or sold in all material respects in accordance with the specifications and standards contained in the relevant Product Approval and the
related Marketing Authorisation Data and in accordance with Applicable Law. 

  

	10.3	Neither the Seller or any of its Affiliates has received any written notice that any Governmental Entity with jurisdiction over the Products has commenced or will commence any action: (i) to withdraw the approval
of any Product or otherwise revoke or materially amend any Product Approval or Marketing Authorisation Data; or (ii) enjoin production, marketing or sale of any Product and, to the Seller’s knowledge, no such action has been threatened.

  

	10.4	All application and renewal fees due and payable with respect to all material Product Approvals have been paid. 

  

	10.5	All preclinical and clinical investigations with respect to the Products are being and have been conducted in compliance with Applicable Law in all material respects. The Seller and its Affiliates have not, and
to the Seller’s Knowledge, none of its Product Partners or any other third party under any Licensed Intellectual Property Contract has received since 1 January 2009, any written notices or other correspondence from any Governmental Entity with
respect to any on-going clinical or pre-clinical studies or tests of any Product requiring the termination, suspension or material modification of such studies or tests. 

  
 215 

	10.6	None of the Seller or its Affiliates or, to the Seller’s Knowledge, any Product Partner or any other third parties pursuant to any Licensed Intellectual Property Contract, has any knowledge of any adverse
event, arising since the date three years prior to the date of this Agreement, reportable with respect to the safety or efficacy of any Product which is expected to be material. 

 

	11	Product Recall 

  

	11.1	No Product (or any component thereof) has been recalled, suspended, withdrawn, seized, discontinued or the subject of a refusal to file, clinical hold, deficiency or similar action letter (including any
correspondence questioning data integrity) as a result of any action by any Governmental Entity, by the Seller or any of its Affiliates; nor are any such actions pending or under consideration (or any facts, conditions, or circumstance known) by the
Seller or any of its Affiliates, or, to the Seller’s Knowledge, by any Governmental Entity. There is not, to the Seller’s Knowledge, pending or threatened litigation anywhere in the world seeking the recall, withdrawal, suspension, seizure
or discontinuance of any of the Products. 

  

	12	Product Liability 

 The Products sold by the Business during the Relevant Period have
complied in all material respects with all applicable product specifications and have been Manufactured in all material respects in accordance with applicable requirements of then current GMP and any Applicable Law, except for any such
non-compliance that has not had, and would not reasonably be expected to have, a materially adverse impact on the relevant Product. 
  

	13	Taxes 

  

	13.1	Each Vaccines Group Company and each Tax Group to which it belongs has, and every member of the Seller’s Group with an interest in the Vaccines Group has in respect of the Vaccines Group, duly, and within
any appropriate time limits, filed all Tax Returns required to be filed and has maintained all records required to be maintained for tax purposes in relation to the assets comprised in the Vaccines Group; all such information was and remains
complete and accurate in all material respects and all such Tax Returns were complete and accurate in all material respects and were made on the proper basis. 

  

	13.2	There are no Tax liens on any asset comprised in the Vaccines Group Businesses (other than Permitted Encumbrances). 

  

	13.3	No Vaccines Group Company and no Tax Group to which a Vaccines Group Company belongs is currently under audit or examination by a Tax Authority that could result in the assessment of a material amount of Tax and
neither the Seller nor any Vaccines Group Company (nor any Tax Group to which a Vaccines Group Company belongs) has received notice from a Tax Authority of any dispute or disagreement outstanding or contemplated at the date of this Agreement with
any Tax Authority regarding liability or potential liability to any Tax recoverable from any Vaccines Group Company or regarding the availability of any relief from Tax to any Vaccines Group Company and, so far as the Seller is aware, there are no
circumstances which make it likely that any such dispute or disagreement will commence. 

  

	13.4	 The Disclosure Letter lists every written agreement that a Vaccines Group Company has entered into, in each case, which is currently in force,
to have its Tax affairs dealt with on a consolidated basis and for any Tax sharing arrangement (including without limitation any arrangement under which Tax losses or Tax reliefs are surrendered or agreed to be

  
 216 

	 	
surrendered or claimed) in respect of the profits, gains or losses of that Vaccines Group Company with any company not being another Vaccines Group Company. 

 

	13.5	No Vaccines Group Company, and no Tax Group to which a Vaccines Group Company belongs, has received or requested any extension of time to file a Tax Return that remains unfiled or has granted or requested a
waiver or extension of a limitation on any period for audit and examination or assessment and collection of Tax for any taxable period as to which Tax could be assessed. 

 

	13.6	No member of the Seller’s Group with an interest in the Vaccines Group has received notice from a Tax Authority of, and so far as the Seller is aware, there is not any dispute or disagreement outstanding at
the date of this Agreement with any Tax Authority regarding the proper method of computing the profits of the Vaccines Group (or any part of it) for Tax purposes or the proper treatment for VAT purposes of any supplies of goods or services made (or
treated as made) in the course of the Vaccines Group and, so far as the Seller is aware, there are no circumstances which make it likely that any such dispute or disagreement will commence. 

 

	13.7	So far as the Seller is aware, no Vaccines Group Company benefits from any preferential Tax regime, granted by law or by special authorisation issued by any Tax Authority or by any other authority, which would in
whole or in part be withdrawn as a result of the signature of this Agreement. 

  

	13.8	So far as the Seller is aware, no Tax Authority has within the past three years operated or agreed to operate any special arrangement (being an arrangement which is not based on relevant legislation or any
published practice) in relation to any assets comprised in the Vaccines Group. 

  

	13.9	In respect of all documents which establish or are necessary to establish the title of the relevant member of the Seller’s Group to each material asset comprised in the Vaccines Group, or by virtue of which
the relevant member of the Seller’s Group has any right in respect of each such asset, all applicable stamp duties, transfer taxes, registration charges or similar duties or charges have been duly paid. 

 

	13.10	So far as the Seller is aware, other than any payments which are of a nature or type (such as expenditure on business entertainment or marketing) which are not deductible for Tax purposes by reason of a general
restriction on deductibility applicable to payments of that nature or type under the laws of the jurisdiction in which the relevant Vaccines Group Company is resident for Tax purposes or carries on its business, no Vaccines Group Company is under
any obligation to make any future payment which will not be deductible for Tax purposes in an amount which, if the payment were deductible for Tax purposes, would reduce the Tax liability of the relevant Vaccines Group Company by an amount exceeding
US$5 million. 

  

	13.11	The country of incorporation which is given in Schedule 2 for each Vaccines Group Company is also the Tax residence of each Vaccines Group Company, and is the only country whose Tax Authorities seek to charge Tax
on the worldwide profits or gains of that Vaccines Group Company and no Vaccines Group Company has, within the past three years, carried on the Business of the Vaccines Group through a permanent establishment in any other country. 

  
 217 

	14	Environmental Matters 

  

	14.1	To the Seller’s Knowledge, each Business Seller (with respect to its conduct of the Business and any Transferred Real Property) and Vaccines Group Company is in compliance in all material respects with all
Environmental Laws. 

  

	14.2	To the Seller’s Knowledge, each Vaccines Group Company and each Business Seller (with respect to its conduct of the Business and any Transferred Real Property) possesses all material Permits required under
applicable Environmental Laws necessary to conduct its portion of the Business. 

  

	14.3	To the Seller’s Knowledge, no Vaccines Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) has received any written notice alleging a
material violation of any Environmental Laws, other than matters that have been resolved in all material respects. 

  

	14.4	To the Seller’s Knowledge, no Vaccines Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) has received any written notice or claim alleging
that it is or may be liable to any person in any material respect under any applicable Environmental Law as a result of a release or threatened release of any Hazardous Substance at any Transferred Real Property, other than matters that have been
resolved in all material respects. 

  

	14.5	To the Seller’s Knowledge, no Vaccines Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) is a party to any pending proceedings relating to
any Environmental Laws, other than proceedings that would not reasonably be expected to have a Material Adverse Effect. 

  

	15	Employees 

  

	15.1	The Employees are all employed by a Vaccines Group Company or a Business Seller and work wholly or substantially in the Business (as carried on by the Vaccines Group). 

 

	15.2	The Disclosure Letter contains a true, complete and correct list of the following information in respect of each Vaccines Business Employee and each Vaccines Group Company Employee as of 17 April 2014 (organised
by country and, in relation to any Vaccines Group Company, by legal employer): (A) employee identification details; (B) date of birth; (C) employment status (part-time or full-time); (D) employment start date; (E) base salary; (F) target annual
incentive for 2014 (and actual bonus for 2013); and (G) target long-term incentive for 2014 (and actual long-term incentive for 2013). 

  

	15.3	In each of the Material Employee Jurisdictions except as would not be reasonably expected to have a Material Adverse Effect: 

  

	 	15.3.1	as of the date of this Agreement there is not, and in the two years prior to the date of this Agreement there has not been, nor to the Seller’s Knowledge is there pending or threatened, any labour strike,
dispute, work stoppage or lockout by any group of either Vaccines Business Employees or Vaccines Group Company Employees; 

  

	 	15.3.2	 no trade union or works council is recognised in any way for bargaining, information or consultation purposes in relation to any of the
Vaccines Business Employees or Vaccines Group Company Employees and no collective bargaining negotiations, whether voluntary or mandatory, are currently taking place with respect to any of the Vaccines Business Employees or Vaccines Group Company

  
 218 

	 	
Employees and, as of the date of this Agreement, no Vaccines Group Company or Business Seller is a party to any agreement (whether legally binding or not) with any trade union or works council
affecting any Vaccines Business Employee or Vaccines Group Company Employee and there is no existing dispute with any such representative body (or, to the Seller’s Knowledge, pending or threatened) in relation to the Business (as carried on by
the Vaccines Group); 

  

	 	15.3.3	there is no material litigation, claim or other dispute existing, nor to the Seller’s Knowledge, pending or threatened by or in respect of any Employees (or any former employees of the Vaccines Group
Companies) in respect of their employment or any matter arising from their employment; and 

  

	 	15.3.4	no Vaccines Group Company or Business Seller has, within the 2 years prior to the date of this Agreement, closed any plant or facility, effectuated any layoffs of employees or implemented any early retirement,
separation or similar programme in each case in violation of the WARN Act, nor has any Vaccines Group Company or Business Seller announced any such action or programme for the future. 

 

	15.4	No Key Personnel has given notice terminating his or her contract of employment, nor is under notice of dismissal. 

  

	15.5	To the Seller’s Knowledge, and subject to the next sentence, no Vaccines Group Company Employee will, as a result of the entering into of this Agreement or Closing, be entitled to receive any payment or
benefit which he would not otherwise be entitled to receive (including, without limitation, an enhanced severance package on a subsequent termination) or be entitled to treat either such event as amounting to a breach of his terms and conditions of
employment or to treat himself as redundant or dismissed or released from any obligation. This warranty shall not apply to any retention arrangements (in the form of cash or shares) put in place by the Seller or any member of the Seller’s Group
to retain key employees in connection with the matters contemplated by this Agreement as described in paragraphs 10 and 11 of Schedule 11, or any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to
paragraph 11 of Schedule 11. 

  

	15.6	Since the Statement of Net Assets Date, no material change has been made, announced or proposed to the emoluments or other terms of employment of any Employee, and no such change, and no negotiation or request
for such a change, is due or expected within 12 months from the date of this Agreement, and the employing company is under no obligation to make such a change (with or without retrospective operation) other than any arrangement relating to the
share-based incentive schemes of the Seller’s Group pursuant to paragraph 11 of Schedule 11. 

  

	15.7	All the employees needed to carry on the Business (as carried on by the Vaccines Group) at the date of this Agreement at the Key Sites are employed by a Vaccines Group Company and, to the Seller’s Knowledge
(other than insofar as would not reasonably be expected to have a Material Adverse Effect) have not resigned and are not expected to resign their employment as a result of this Agreement or the transactions it contemplates. 

 

	16	Employee Benefits 

  

	16.1	 The Disclosure Letter contains a true, complete and correct list of all bonus, staff incentives (including any share-based incentive schemes),
redundancy or other benefits payable on termination of employment (whether voluntary or involuntary but excluding 

  
 219 

	 	
arrangements required in accordance with Applicable Law), ill-health, Employee Benefits or other benefits which are the material benefits available to the Vaccines Business Employees and the
Vaccines Group Company Employees in the Material Employee Jurisdictions. To the Seller’s Knowledge, other than any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 11 of Schedule 11, no
Vaccines Group Company or Business Seller has made any promises or commitments to make available any additional benefits to the Vaccines Business Employees and the Vaccines Group Company Employees in the Material Employee Jurisdictions, or to modify
or change in any material way any existing benefits in the Material Employee Jurisdictions, or to continue or maintain the level of any existing benefits generally for any period, which in each case could reasonably be expected to have a Material
Adverse Effect. 

  

	16.2	The Disclosure Letter contains true and complete copies of all documents of any written benefit schemes, plans or arrangements referred to in paragraph 16.1 above applicable to either Vaccines Business Employees
or Vaccines Group Company Employees in the Material Employee Jurisdictions containing material terms (including governing documents, and for benefit plans that are not share-based incentive schemes, related trust agreements or other funding
documents) and a true, complete and correct summary of the material terms of any unwritten benefit schemes, plans or arrangements referred to in paragraph 16.1 above. 

 

	16.3	Benefit Plans 

  

	 	16.3.1	 In the Material Employee Jurisdictions all benefit and compensation schemes, plans, funds, contracts, policies, agreements or arrangements
(other than the US Benefit Plans and any schemes, plans, funds, contracts, policies, agreements or arrangements operated by any Governmental Entity) (A) operated by or on behalf of a Vaccines Group Company or Business Seller, with respect to
Vaccines Group Company Employees or Vaccines Business Employees or current or former employees or directors of a Vaccines Group Company, (B) in respect of which any Vaccines Group Company or Business Seller, with respect to Vaccines Group Company
Employees or Vaccines Business Employees, the Seller or any member of the Seller’s Group contributes or has contributed or (C) in respect of which any Vaccines Group Company or Business Seller, with respect to Vaccines Group Company Employees
or Vaccines Business Employees, has any liability (whether actual or contingent), including, but not limited to, plans providing Employee Benefits or during periods of sickness or disablement, or any deferred or incentive compensation, welfare,
healthcare, medical, stock or stock-related award plans, including individual pension commitments, “jubilee” pension benefits and retirement and termination indemnity arrangements, and in relation to Switzerland, all plans, funds,
contracts, policies, agreements or arrangements providing pension or other benefits on retirement (such schemes, plans, funds, contracts, policies, agreements and arrangements hereinafter being referred to as “Non-US Benefit Plans”)
and the US Benefit Plans have been administered in accordance with their terms and are in compliance with Applicable Law, except for any failures to so administer or be in compliance that, individually and in the aggregate, would not reasonably be
expected to have a Material Adverse Effect. All required filings for all Benefit Plans have been made on time and with the appropriate Governmental Entity, except for any failures to timely file that, individually and in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. As of the date 

  
 220 

	 	
of this Agreement, there is no existing, pending or, to the Seller’s Knowledge, threatened material litigation, claim or other dispute relating to Benefit Plans. 

 

	 	16.3.2	The Vaccines Group Companies or Business Sellers, with respect to Vaccines Group Company Employees or Vaccines Business Employees in each Material Employee Jurisdiction, (A) are in material compliance with all
Applicable Law respecting employment, employment practices, terms and conditions of employment, occupational health, safety, wages and hours, (B) have withheld all amounts required by Applicable Law, collective bargaining agreements or the Benefit
Plans to be withheld from the wages, salaries or other payments to the Vaccines Group Company Employees or the Vaccines Business Employees and former employees of the Vaccines Group Companies, (C) in respect of the Vaccines Group Company Employees
or Vaccines Business Employees or former employees of the Vaccines Group Companies, are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any arrears, wages, Taxes, other than payments not yet due, or any
penalty for failure to comply with the foregoing and (D) are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any payment to any trust or other fund or to any Governmental Entity with respect to unemployment
compensation benefits, workers compensation, social security or other benefits for Vaccines Group Company Employees or Vaccines Business Employees or former employees of the Vaccines Group Companies, other than payments not yet due, except, in each
case, for any failures to comply, failures to withhold or liabilities that, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

 

	 	16.3.3	All material contributions that the Vaccines Group Companies or Business Sellers, with respect to Vaccines Business Employees or the Vaccines Group Company Employees in a Material Employee Jurisdiction and
Switzerland, are required to make to any Benefit Plan in respect of the period on or before the date of this Agreement have been fully and timely paid when due. 

  

	17	Litigation 

  

	17.1	No Vaccines Group Company or Business Seller is involved whether as claimant or defendant or other party in any claim or Proceeding (other than as claimant in the collection of debts arising in the ordinary
course of its business none of which exceeds US$5 million) which is material to the Business. 

  

	17.2	To the Seller’s Knowledge, no such claim or Proceeding of material importance is pending or threatened by or against any Vaccines Group Company or Business Seller. 

 

	18	Insolvency 

  

	18.1	No order has been made and no resolution has been passed for the winding up of any Share Seller or any Business Seller, or for the appointment of any administrator, receiver (including administrative receiver) or
liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Share Seller or any Business Seller. 

  

	18.2	 No petition has been presented or meeting convened for the purpose of considering a resolution or resolution circulated for the winding up of
any Share Seller or any Business Seller, or for the appointment of any administrator, receiver (including administrative 

  
 221 

	 	
receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Share Seller or any Business Seller. 

 

	18.3	Neither any Share Seller nor any Business Seller has stopped payment or suspended payment of its debts generally, is insolvent or deemed unable to pay its debts as they fall due. 

 

	19	Insurance 

 All material insurance policies relating to the Vaccines Group are in full
force and effect and, to the Seller’s Knowledge, no notice of cancellation, termination or default has been received with respect to any such insurance policy. All premiums due and payable on such policies covering periods up to Closing have
been paid in full or accrued. 
  

	20	Consents and Licences 

  

	20.1	All governmental and quasi-governmental licences, consents, permissions, waivers, exceptions and approvals required for carrying on the Business of the Vaccines Group, the absence of which, individually or in the
aggregate, would be material to the Vaccines Group, are in force and, to the Seller’s Knowledge, no written notice has been received by the Seller or any member of the Seller’s Group which indicates that any such licence, consent,
permission, waiver, exception or approval is likely to be revoked or which may confer a right of revocation. 

  

	21	Delinquent and Wrongful Acts 

  

	21.1	To the Seller’s Knowledge, no member of the Seller’s Group has, during the Relevant Period, committed any criminal or illegal act which relates to the Vaccines Group Companies or the Vaccines Group
Businesses. 

  

	21.2	No member of the Seller’s Group has, during the Relevant Period, received notification that any investigation or inquiry is being or has been conducted by any supranational, national or local authority or
governmental agency specifically related to the Vaccines Group, which is material in respect of the Vaccines Group. 

  

	22	Compliance 

  

	22.1	No member of the Seller’s Group has received in the Relevant Period any written notification or written claim (in each case, which remains outstanding) that it has conducted the Business of the Vaccines
Group with respect to the research, development, manufacturing, distribution and sale of the Products in a manner which does not in any respect comply with all Applicable Law, or which in any respect is defective or dangerous, where the pursuit of
any such notification or claim is, or would reasonably be expected to be, material in respect of the Vaccines Group. 

  

	22.2	So far as the Seller is aware, the Vaccines Group has, and has during the Relevant Period been, operated in all material respects in compliance with all Applicable Law or standards and to the Seller’s
Knowledge there are no circumstances that could involve or lead to a material violation of any material Applicable Law or standards. 

  

	23	Pipeline Products 

  

	23.1	 The Seller or one of its Affiliates is the registered holder of each of the Pipeline Product Approvals, and the benefit of each Pipeline
Product Approval can be transferred to the Purchaser (or another member of the Purchaser’s Group) regardless as to whether such 

  
 222 

	 	
transfer occurs directly (whether by way of transfer, reissuance or any other equivalent mechanism under Applicable Law of the relevant jurisdiction) or indirectly (through the transfer of the
Vaccines Group Companies). 

  

	23.2	All development activities in relation to the Pipeline Products have been conducted in the ordinary course and in accordance with all Applicable Law and standards and to the Seller’s Knowledge there are no
circumstances relating to the development of the Pipeline Products that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	23.3	No material regulatory, clinical or safety event has occurred in relation to the Pipeline Products and no member of the Seller’s Group has received any notification or claim from any person of any such event
(or the possibility of any such event). 

  

	24	Manufacturing Licences and Manufacture 

  

	24.1	All Manufacturing Licences which are material to the Vaccines Group, are in effect and are validly held by a member of the Seller’s Group and during the Relevant Period, to the Seller’s Knowledge, no
member of the Seller’s Group has received any written notice of any suit, action or proceeding regarding the revocation or modification of any such Manufacturing Licence. 

 

	24.2	No directive, order or notice has been given to the Seller or any member of the Seller’s Group by any relevant regulatory authority to update, modify, amend, vary, supplement or delete any process and/or
methodology relevant to the manufacture at the Sites of any Product currently manufactured at the Sites and, so far as the Seller is aware, no such directive, order or notice is pending. 

 

	25	No Industrial Action 

 To the Seller’s Knowledge, there is no industrial action
currently taking place, threatened or expected which is, or is expected to be, material to the Business. 
  

	26	Ongoing Clinical Trials 

 Schedule 22 contains a complete list of all Ongoing Clinical
Trails. 

  
 223 

 Schedule 19 

Warranties given by the Purchaser under Clause 10.3 
  

	1	Authority and Capacity 

  

	1.1	Incorporation 

 The Purchaser is validly existing and is a company duly incorporated and
registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Purchaser and each member of its Group has the legal right and full power and authority to enter into and perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be
executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Purchaser and each member of its Group in accordance with their respective terms.

  

	 	1.2.3	Except as referred to in this Agreement, the Purchaser: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

  

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case
in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Purchaser and each member of its Group of their respective obligations under them, will not:

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the Purchaser’s Group; 

 

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Purchaser’s Group is party or by which the relevant member of the Purchaser’s Group is bound
where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Purchaser’s Group is bound and where such breach is material to their ability to
perform their obligations under such documents. 

  

	1.3	Authorisation 

 The Purchaser has taken, or will have taken by Closing, all corporate
action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary
Agreement. 

  
 224 

 Schedule 20 

Pre-Closing Obligations 

(Clause 5.2) 
 Part 1

 Seller Restrictions 
 The actions
for the purposes of Clause 5.1.2 are: 
  

	1	amend or otherwise modify the constitutional documents of any Vaccines Group Company other than minor or administrative amendments or modifications which are not adverse to the Business or to the Purchaser of any
member of the Purchaser’s Group; 

  

	2	create, allot or issue, or grant an option or right to subscribe for or purchase, any share capital or other securities or loan capital of any Vaccines Group Company; 

 

	3	repay, redeem or repurchase any share capital, or other securities of any Vaccines Group Company; 

  

	4	make any acquisition or disposal which has a value in excess of US$10 million, exclusive of VAT; 

  

	5	grant any guarantee or indemnity for the obligations of any person which has a value in excess of US$5 million (other than in the ordinary course of trading); 

 

	6	dispose of, or agree to dispose of, any material asset or material stock at below market value other than in the ordinary course of business; 

 

	7	acquire or agree to acquire any share, shares or other interest in any company, partnership or other venture, other than an investment of 5 per cent or less of the total shares or interest in such company,
partnership or venture and provided the investment is not more than US$5 million; 

  

	8	enter into, extend, amend, give notice to terminate or vary in any material respect any lease of real property or change the existing use of such property which is material to the Vaccines Group;

  

	9	cease, compromise or settle any dispute including litigation, arbitration or administrative proceedings in relation to (or otherwise compromise or settle) any claim by Pfizer which relates to any form of
meningococcal vaccine (Group B) whether adjuvanted, combined or otherwise (or any similar product) of Pfizer or enter into any licensing arrangements with Pfizer in relation to such products or Intellectual Property Rights relevant to them;

  

	10	enter into any borrowing facility which has a value in excess of US$10 million; 

  

	11	enter into any off-balance sheet finance arrangements; 

  

	12	sell, lease, license, transfer or dispose of, or create any Encumbrance over, any material assets of the Vaccines Group other than (i) in the ordinary course of business (including any sale of inventory); or (ii)
any Permitted Encumbrance; 

  

	13	 (a) terminate, materially amend (or amend in any respect in relation to a Product or Pipeline Product which is material to the Business) or
grant any material waiver under (or any waiver in relation to a Product or Pipeline Product which is material to the Business) 

  
 225 

	 	
any Vaccines Group Intellectual Property Contract or the Merck 2012 Licence or (b) terminate any Transferred Contract other than in the ordinary course of business or terminate any Contract held
by the Vaccines Group Companies other than in the ordinary course of business; 

  

	14	fail to comply in all material respects with all Applicable Law, Product Approvals, Pipeline Product Approvals and Marketing Authorisations applicable to the operation of the Business; 

 

	15	assign, dispose of, license (save in respect of non-exclusive licences relating to the Seller’s research, development or Commercialisation of the Products) abandon any material Vaccines Group Intellectual
Property Rights (or any Vaccines Group Intellectual Property Rights in respect of a Product or Pipeline Product which is material to the Business), or cease to prosecute or otherwise dispose of, fail to maintain, defend or pursue applications for
any material Registered Vaccines Group Intellectual Property Rights (or any Registered Vaccines Group Intellectual Property Rights in respect of a Product or Pipeline Product which is material to the Business). Notwithstanding the foregoing, the
parties agree that the restrictions set out in this paragraph will not apply in respect of the Abandoned Patents abandoned prior to 22 April 2014; 

  

	16	save where requested in writing by the Purchaser or required by any applicable Governmental Entity, cancel, surrender or materially amend (or amend in any respect in relation to a Product or Pipeline Product
which is material to the Business) any applications, submissions or filings with respect to Registered Vaccines Group Intellectual Property Rights; 

  

	17	instigate, cease, compromise or settle any litigation or arbitration proceedings related to the Vaccines Group in relation to a claim for which the potential liability attaching thereto is in excess of US$5
million; 

  

	18	make any material amendment to any Marketing Authorisation, Manufacturing Licence or Environmental Permit, in each case except to the extent required by: (a) Applicable Law; (b) any Governmental Entity, or (c)
the standards, policies and procedures of the Seller’s Group as then in force; 

  

	19	enter into or amend in any material respect any Transferred Contract, or incur any commitment, which is not capable of being terminated without compensation at any time with twelve months’ notice or less or
which is not in the ordinary course of business, or which involves or may involve total annual expenditure in excess of US$10 million, exclusive of VAT; 

  

	20	enter into any contract which would materially restrict the freedom of the Vaccines Group to operate in any part of the world; 

 

	21	terminate (except for good cause) the employment of any Key Personnel; 

  

	22	 take any steps to increase or reduce the proportion of time spent working in the Business (as carried on by the Vaccines Group) by any employee
of any member of the Seller’s Group or to transfer the employment of any Employee to another member of the Seller’s Group or to employ or offer to employ or engage any new persons in the Business (as carried on by the Vaccines Group) other
than in the ordinary course of business consistent with past practice and subject to an aggregate increase of not more than 2.5 per cent. in total staff costs of the Business (as carried on by the Vaccines Group) per annum,

  
 226 

	 	
provided that this restriction shall not apply to the redeployment of any Vaccines Group Company Employee who is not wholly or substantially engaged in the Business (as carried on by the Vaccines
Group) before the Closing Date to employment with another member of the Seller’s Group; 

  

	23	make, or commit to make, any changes to the terms and conditions of employment (including pension fund commitments or any increase to remuneration) or to any employee benefit plan of any Employee, other than (a)
those required by Applicable Law or (b) pursuant to normal annual pay reviews in the ordinary course of business consistent with past practice and subject to an aggregate increase of not more than five per cent. in total staff costs of the Business
(as carried on by the Vaccines Group) per annum or (c) retention arrangements in the form of cash or shares to retain key employees in connection with the matters contemplated by this Agreement as described in paragraphs 10 and 11 of Schedule 11, or
(d) those changes to the share-based incentive schemes made for the purpose of complying with paragraph 11 of Schedule 11; 

  

	24	make any promises or commitment to any Employees or employee representative body concerning the matters contemplated by this Agreement or offer or otherwise give any assurances to any Employees as to the
possibility of continued employment with the Purchaser’s Group after Closing; 

  

	25	make any change or commitment to make any change to the terms of any redundancy policy or practice applying to the Employees (including amounts payable on redundancy); 

 

	26	enter into (where there is no existing agreement) or materially amend any collective bargaining agreement or other contract with a labour organisation, works council or employee organisation to create new or
additional obligations for any member of the Seller’s Group, in each case in relation to the Business (as carried on by the Vaccines Group); and 

  

	27	undertake any recall or withdrawal of any Product (other than in the ordinary course of business or to comply with Applicable Law). 

  
 227 

 Part 2 

Seller Obligations 
  

	1	Obligations Prior to be Satisfied prior to the Closing Date 

 At least five Business Days
prior to the Closing Date, the Seller shall provide the Purchaser with a list of any required actions that must be taken within three (3) months after Closing with respect to the payment of any registration, maintenance, or renewal fees or the
filing of any documents, applications or certificates in order to maintain any Registered Vaccines Group Intellectual Property Rights in full force and effect. Upon the Purchaser’s reasonable request, the Seller shall execute and deliver
assignment agreements and other transfer documentation, including, where applicable, duly executed assignments of such Registered Vaccines Group Intellectual Property Rights for recording with the applicable Governmental Entity, and to take such
further actions, in each case at the Purchaser’s reasonable cost and expense and as may be required, to give effect to the foregoing assignments. 
  

	2	Obligations from the Date of the Agreement to the Closing Date 

 The requirements for the
purposes of Clause 5.1.3 are: 
  

	2.1	so far as permitted by Applicable Law, the Seller shall procure that each member of the Seller’s Group informs the Purchaser promptly if the Seller becomes aware of, or has reasonable grounds for suspecting
any violation of Anti-Bribery Law which is reasonably likely to have an impact on the Vaccines Group, and 

  

	2.2	carry out capital expenditure in relation to any site operated by the Vaccines Group where the Products are manufactured in a manner materially consistent (and within a variance of 10 per cent. in aggregate) with
the Seller’s capital expenditure programme for the Business as at the date of this Agreement; 

  

	2.3	maintain and keep any Registered Vaccines Group Intellectual Property Rights and ensure that all filings and notifications required to be made in respect of the same are made in accordance with past practice;

  

	2.4	progress, in accordance with past practice any applications, submissions, filings or other correspondence relating to the grant of new Registered Vaccines Group Intellectual Property Rights; 

 

	2.5	progress, in accordance with past practice during the Relevant Period, any applications, submissions, filings or other correspondence initiated by such member of the Seller’s Group relating to the grant of
new Manufacturing Licences and Environmental Permits in respect of the Vaccines Group; 

  

	2.6	continue to promote, market and Commercialise the Products in accordance with past practice during the Relevant Period and do not materially accelerate or increase the quantity of Products distributed to the
relevant distributors and/or wholesalers, in each case except in respect of a bona fide increase in demand for the relevant Product by the relevant distributor and/or wholesaler which has not been stimulated in any way by discounts, rebates,
claw-backs or the like outside of the ordinary course of business or the grant of preferred terms offered by the Seller’s Group outside of the ordinary course; 

 

	2.7	not discontinue or cease to operate or materially reduce the resources applied to any part of the Business; 

  
 228 

	2.8	maintain the level of Manufacturing Stocks and Manufacturing Inventory held for use in the Business materially in accordance with the Seller’s Group’s operating policies as applied to the Vaccines Group
from time to time in force; 

  

	2.9	maintain the level of In-Market Inventory held for use in the Business materially in accordance with the Seller’s Group’s operating policies as applied to the Vaccines Group from time to time in force;

  

	2.10	use all reasonable endeavours to ensure that the manufacture of the Products by the Seller’s Group comply with Applicable Law; 

 

	2.11	use all reasonable endeavours to ensure that the Products sold by the Business comply with Applicable Law; 

  

	2.12	continue to conduct the Ongoing Clinical Trials in accordance with GCP and the Seller Group’s policies and procedures; and 

 

	2.13	notify the Purchaser in writing of any actual safety or quality issue in respect of any Product or the manufacture of any Product (as soon as reasonably practicable after becoming aware of the same) which issue
the relevant member of the Seller’s Group, acting reasonably and in good faith, considers material in the context of the manufacture or commercialisation of such Product. 

 

	2.14	so far as permitted by Applicable Law, report periodically to the Purchaser concerning the status of the Business, including delivering to the Purchaser as soon as reasonably practicable each month:

  

	 	2.14.1	an update on material commercial developments in relation to the Business and the Products during the previous month; 

  

	 	2.14.2	the gross profit for each Product in respect of the previous month; and 

  

	2.15	a report on the month-end in-trade inventory in respect of each Product for the previous month prepared in the ordinary course of business consistent with past practice, together with a comparison against the
comparable period of trading for the prior year; 

  

	2.16	use all reasonable endeavours to obtain a waiver in relation to the Transaction from the joint venture partner in Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd in respect of the joint venture partner’s rights
of first refusal; and 

  

	2.17	shall or shall procure that each member of the Seller’s Group continues to respond to any Calls For Tender in accordance with past practices in the relevant market. 

  
 229 

 Part 3 

Exceptions 
 Clause 5.1 shall not operate
so as to prevent or restrict the declaration, making or payment of any dividend or other distribution to shareholders. 

  
 230 

 Schedule 21 

Key Employees 
 (Clause
1.1) 
 [***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 231 

 Schedule 22 

Ongoing Clinical Trials 

(Clause 1.1) 
  

	1	[***] 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 232 

 Schedule 23 

Statement of Net Assets 

(Clause 1.1) 
 Part 1

 Statement of Net Assets Rules 

Part 1 of Schedule 23 comprises the Statement of Net Assets Rules. 

Part 2 of Schedule 23 sets forth, for illustrative purposes only, a computation of the Statement of Net Assets as of the close of business on 31 December 2013
(the “Statement of Net Assets”). 
  

	1	Preparation of the Statement of Net Assets 

  

	1.1	Period 

 The Statements of Net Assets is prepared as of the close of business on the
final day of the relevant calendar month. 
  

	1.2	Translation of Reporting Entity’s Statements of Net Assets 

 A reporting entity
reports in local currency. All reports are translated into US dollars by the Seller for reporting purposes. The Statement of Net Assets is translated with the period-end exchange rates which are the rates provided by Novartis Group Treasury and are
based on Bloomberg’s mid-morning CET exchange rates and are published in the Group Treasury section of the Novartis intranet. 
  

	1.3	Novartis Reporting System and Materiality: 

  

	 	1.3.1	Financial information is obtained from the Financial Consolidation & Reporting System of Novartis and the supporting general ledgers are prepared in accordance with Novartis’ Accounting Manual (the
“NAM”). The Financial Consolidation & Reporting System is the system of record for Novartis external reporting. References in the Statement of Net Assets included as part 2 of this Schedule 23 shown as “BS01 lines
010-671” relate to the groupings shown in Novartis’ monthly reporting form “BS01 – Balance sheet”. 

  

	 	1.3.2	 For the Seller’s reporting purposes, the financial reporting of a legal entity is separated into a divisional part, which includes
operating items and a corporate part, which mainly captures the amounts related to taxes, post-employment benefit obligations and most of the financial assets and liabilities. The Statement of Net Assets contains the business of the Vaccines
division (including the Influenza Business) as included in Novartis’ segment reporting (column C - “Vaccines Divisional Reported Statement of Net Assets”), and items of the corporate Statement of Net Assets for the Vaccines Group
Companies (Column D – “Vaccines Statement of Net Assets of the Corporate part of the Vaccines Group Companies” and items related to the Statement of Net Assets for the Novartis Vaccines Institute for Global Health (column E –
“Statement of Net Assets of the part of Novartis Vaccines Institute for Global Health”) as well as adjustments for certain items which are either excluded from or added to the transaction (columns F -“Excluded items”). A US$10
million threshold was applied. Column H shows the impact of the Influenza Business which is excluded from the transaction. For the purpose of the carve out of the Influenza Business allocations have been made

  
 233 

	 	
based on management’s best estimate of the contribution of the Influenza Business. For Receivables own BU (BS01_130) and Payables own BU (BS01_620) items related to the entity in Liverpool,
which will not transfer have been added back into the statement of net assets. For other entities amounts related to the Influenza Business have not been added back in as they are offsetting each other. Payables and Receivables to Other BU’s
related to the Influenza Business have been left in the statement of net assets as they are not expected to be material on a net basis. A materiality threshold of US$ 50million applies to the Influenza Business. 

 

	 	1.3.3	The Statement of Net Assets has been prepared as follows: 

  

	 	(i)	in accordance with the specific accounting treatments set out below; and, subject thereto, 

  

	 	(ii)	adopting the same accounting principles, methods, procedures and practices utilized in preparing the consolidated financial statements of Novartis AG as described in the Novartis Accounting Manual applied on a
consistent basis using consistent estimation methodologies and judgments and with consistent classifications and, subject thereto, 

  

	 	(iii)	in accordance with IFRS. 

  

	 	1.3.4	For the avoidance of doubt, paragraph 1.3.3(i) shall take precedence over paragraphs 1.3.3(ii) and 1.3.3(iii), and paragraph 1.3.3(ii) shall take precedence over paragraph 1.3.3(iii). 

 

	2	Specific Policies 

 The following supplement the description in the NAM for certain items
included in the Vaccines Group Statement of Net Assets: 
  

	2.1	Non-Current assets 

  

	 	2.1.1	Property, plant and equipment (BS01_010) 

 For the purpose of the Vaccines Divisional
Statement of Net Assets an amount of US$122 million is included for assets which are not dedicated to the Vaccines Group and will not transfer to the Purchaser (as reflected in Column F). These assets comprise all property, plant and equipment
located in Emeryville, California and in Pernambuco, Brazil. 
  

	 	2.1.2	Financial assets &– subsidiaries/JV (BS01_040) 

 This line reflects equity
investments that Vaccines Group Companies hold in other Vaccines Group Companies. These relationships have been eliminated in the Statement of Net Assets (as reflected in Column F). 

 

	 	2.1.3	Total financing and loans to subsidiaries/JV (BS01_050) 

 This line represents financing
owed by any member of the Seller’s Group to a Transferred Subsidiary. For the purpose of the Statement of Net Assets balances within the Vaccines Group have been excluded (as reflected in Column F). 

  
 234 

	2.2	Current Assets: 

  

	 	2.2.1	Trade receivables (BS01_120) 

 An amount of US$51 million of trade receivables is
excluded from this Statement of Net Assets (as reflected in Column F) as it relates to non-Vaccines business activity such as licence fee receivables related to HCV and HIV patents. 

 

	 	2.2.2	Receivables own BU (BS01_130) 

 Column C of the Statement of Net Assets represents
receivables against other entities within the Vaccines division, which are offset by an equivalent amount in the line Payables own BU. These amounts have been eliminated in Column F of the Statement of Net Assets. 

 

	 	2.2.3	Receivables own BU – Corporate and Institute for Global Health (BS01_130) 

 Columns
D and E of the Statement of Net Assets represent receivables against other members of the Seller’s Group as well as other Vaccines Group Companies. The receivables against other Vaccines Group Companies have been eliminated in Column F of the
Statement of Net Assets. 
  

	 	2.2.4	Receivables other BU’s (BS01_140) 

 Receivables recognized on this line are due
from members of the Seller’s Group operating in the Pharmaceuticals and Sandoz segments which are selling vaccines in markets where the Vaccines Group is not represented. The receivable of the Vaccines Institute for Global Health relates to a
Transferred Subsidiary and has therefore been eliminated. 
  

	 	2.2.5	Other current assets (BS01_160) 

 An amount of US$5 million is related to current assets
of the divested Diagnostics business, which did not transfer to the purchaser of the Diagnostics business. They are excluded from the Statement of Net Assets as they do not relate to the activities of the Vaccines Group (as reflected in Column F).
Furthermore, an amount of US$1 million is related to assets of the plant in Pernambuco, Brazil which will not be transferred and has therefore been excluded (as reflected in Column F) from the Statement of Net Assets. 

 

	 	2.2.6	Prepaid share-based payments (BS01_161) 

 An asset for prepaid share-based compensation
is recognized to reflect Novartis’ internal charge-out mechanism for its equity settled share-based compensation plans. For entities settling the charge for the shares at the beginning of the vesting period, it reflects the expense yet to be
recognized for the unvested part of a share-based compensation plan. This asset has been excluded (as reflected in Column F) and is not reflected in the Statement of Net Assets. 

 

	2.3	Long-term Liabilities: 

  

	 	2.3.1	Total financing and loans from subsidiaries/JV (BS01_520) 

 This line represents
financing received from any member of the Seller’s Group. For the purpose of the Statement of Net Assets, balances within the Vaccines Group have been excluded (as reflected in Column F). 

  
 235 

	 	2.3.2	Other non-current liabilities (BS01_540) 

 Column F excludes net liabilities for
post-employment benefits of US$90 million included in the corporate part of the Vaccines Group Companies as their treatment is addressed separately in Schedule 12. 
  

	2.4	Current Liabilities: 

  

	 	2.4.1	Trade payables (BS01_610) 

 An amount of US$11 million included in this line relates to
the construction of the plant in Pernambuco, Brazil which will not be transferred and has therefore been excluded (as reflected in Column F) from the Statement of Net Assets. 
  

	 	2.4.2	Payables own BU (BS01_620) 

 Column C of the Statement of Net Assets represents payables
against other entities within the Vaccines division, which are offset by an equivalent amount in the line Receivables own BU. These amounts have been eliminated in the Statement of Net Assets. 

 

	 	2.4.3	Payables own BU – Corporate (BS01_620) 

 Column D of the Statement of Net Assets
represents payables against other Vaccines Group Companies as well as payables against other members of the Seller’s Group. The corporate payables against Vaccines Group Companies have been eliminated in Column F of the Statement of Net Assets.

  

	 	2.4.4	Payables other BU’s (BS01_630) 

 Payables recognized on this line are due to
members of the Sellers’ Group, except for a payable recognized by the Vaccines Institute for Global Health, which is owed to a Vaccines Group Company and has therefore been eliminated. 

 

	 	2.4.5	Accrued and other current liabilities (BS01_670) 

 An amount of US$35 million is related
to short term liabilities of the divested Diagnostics business, which did not transfer to the purchaser of this Diagnostics business. They are excluded from the Statement of Net Assets (as reflected in Column F) as they do not relate to the
activities of the Vaccines Group. Furthermore, an amount of US$3 million relates to the construction of the plant in Pernambuco, Brazil, which will not be transferred and has therefore also been excluded (as reflected in Column F) from the Statement
of Net Assets. An amount of US$1 million relates to legal fees for litigation not related to the Vaccines Group. 
  

	 	2.4.6	Accrued share-based payments (BS01_671) 

 A liability for share-based compensation is
recognized to reflect Novartis’ internal charge-out mechanism for its equity-settled share-based compensation plans. For entities settling the charge for the shares after the vesting period, it reflects the expense recognized for the vested
part of a share based compensation plan. This liability has been excluded (as reflected in Column F) and is not reflected in the Statement of Net Assets. 

  
 236 

 Part 2 

Statement of Net Assets 
 All amounts in $
thousands 
  

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 	  	Vaccines
Dataroom
balance
sheet
Dec 31,
2013	 	  	Adjustments*	 	  	Vaccines
Divisional
Reported
Statement
of Net
Assets at
Dec 31,
2013	 	  	Vaccines
Statement
of Net
Assets of
the
Corporate
part of the
Vaccines
Group
Companies	 	  	Statement
of Net
Assets of
the part of
Novartis
Vaccines
Institute for
Global
Health	 	  	Excluded
items	 	  	Vaccines
Group
Statement
of Net
Assets
Dec 31,
2013	 	  	Influenza
business	 	  	Vaccines
Group
(excl.
Influenza
business)
Statement
of Net
Assets
Dec 31,
2013	 
	 BS01_010 Property, plant and equipment
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	729,492	  
	 BS01_020 Intangible assets
	  	 	[***]	  	  				  	 	[***]	  	  				  				  				  	 	[***]	  	  	 	[***]	  	  	 	1,853,635	  
	 BS01_034 Financial assets_ associated companies
	  	 	[***]	  	  				  	 	[***]	  	  				  				  				  	 	[***]	  	  	 	[***]	  	  	 	777	  
	 BS01_035 Financial assets - 3rd parties and loans to AC
	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  				  				  	 	[***]	  	  	 	[***]	  	  	 	17,981	  
	 BS01_040 Financial assets & subsidiaries//JV
	  				  				  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  				  	 	0	  
	 BS01_042 Deferred tax assets
	  				  				  				  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	78,951	  
	 BS01_044 Other non-current non-financial assets
	  	 	[***]	  	  				  	 	[***]	  	  				  				  				  	 	[***]	  	  				  	 	23,129	  
	 BS01_050 Total financing and loans to subsidiaries / JV
	  				  				  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	58,563	  
	 BS01_110 Total inventories
	  	 	[***]	  	  				  	 	[***]	  	  				  				  				  	 	[***]	  	  	 	[***]	  	  	 	400,663	  
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	[***]	  	  				  	 	[***]	  	  				  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	335,387	  
	 BS01_130 Receivables own BU
	  	 	[***]	  	  				  	 	[***]	  	  				  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	21,818	  
	 BS01_130 Receivables own BU – Corporate and Institute for Global Health
	  				  				  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	865	  

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 237 

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 BS01_140 Receivables other BU’s
	  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	20,419	  
	 BS01_160 Other current assets (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	70,207	  
	 BS01_161 Prepaid share-based payments
	  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	0	  
	 BS01_180 Cash & cash equivalents
	  				  				  				  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  	  				  	 	4,393	  
	 Total Assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	3,616,280	  
	 Bs01_511 Financial debt – long-term
	  				  				  				  	 	[***]	  	  				  				  	 	[***]	  	  				  	 	8	  
	 BS01_520 Total financing and loans from subsidiaries// JV
	  				  				  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	680,633	  
	 BS01_535 Deferred tax liabilities
	  				  				  				  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	92,072	  
	 BS01_540 Other non-current liabilities (3rd parties and AC)
	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	54,071	  
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	176,115	  
	 BS01_620 Payables own BU
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	15,056	  
	 BS01_620 Payables own BU – Corporate
	  				  				  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  				  	 	3,239	  
	 BS01_630 Payables other BU’s
	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	40,675	  
	 BS01_651 Financial debt – Short-term (3rd parties and AC)
	  				  				  				  	 	[***]	  	  				  				  	 	[***]	  	  	 	[***]	  	  	 	1,395	  
	 BS01_660 Income taxes payable
	  				  				  				  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	55,060	  
	 BS01_670 Accrued and other current liabilities (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	238,671	  
	 BS01_671 Accrued share-based payments
	  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	0	  

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 238 

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 Total Liabilities
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,356,995	  
	 Net Assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	2,259,285	  

  

	*	The difference for BS01_010 Property, plant and equipment relates to the plant built in Pernambuco Brazil, which had been excluded in the dataroom balance sheet. 

The difference for BS01_160 Other current assets is composed of other current assets related to the Diagnostics Business, but which have not been transferred
to Grifols; these were excluded in the dataroom balance sheet. 
 Line BS01_620 and Line BS01_630 have been combined into the line Intercompany payable in
the dataroom balance sheet and items related to Pernambuco have been excluded. 
 The difference for BS01_670 Accrued and other current liabilities is
composed of items related to the Diagnostics business, which have not been transferred to Grifols and were therefore excluded in the dataroom balance and items related to the Plant in Pernambuco, which have also been excluded in the dataroom balance
sheet. 
  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 239 

 Schedule 24 

Regulatory Approvals 
 The following table
provides the additional jurisdictions and applicable antitrust, merger control, or foreign investment rules referenced in Clause 4.1.3. 
 This list of
jurisdictions and statutes is not meant to be indicative of a known filing or approval requirement in these jurisdictions. To the extent that clearances, approvals, waivers, no action letters or consents are not required to be obtained or not
otherwise agreed by the parties to be appropriate, and waiting periods are not required to have expired in these jurisdictions, prior to Closing, such clearances, approvals, waivers, no action letters, consents, and waiting period expirations will
not be conditions precedent to Closing 
  

			
	Country	  	Statute Under Which Filing/Approval is Required
		
	Australia	  	The Competition and Consumer Act of 2010
		
	Brazil	  	Law No. 12,529 of November 30, 2011
		
	Canada	  	The Competition Act
		
	China	  	The Chinese Anti-Monopoly Law
		
	India	  	The Competition Act of 2002, as amended by The Competition (Amendment) Act of 2007
		
	Israel	  	The Restrictive Trade Practices Law, 5748-1988
		
	Japan	  	The Act on Prohibition of Private Monopolisation and Maintenance of Fair Trade No. 54 of 1947
		
	Mexico	  	The Federal Law on Economic Competition
		
	New Zealand	  	The Commerce Act of 1986
		
	Russia	  	Federal Law No. 135-FZ of July 16, 2006 on Protection of Competition
		
	South Africa	  	The Competition Act 89 of 1998
		
	South Korea	  	The Monopoly Regulation and Fair Trade Act
		
	Taiwan	  	The Fair Trade Law of 1991
		
	Turkey	  	The Law on Protection of Competition No. 4054 of 1994

  
 240 

 Schedule 25 

Delayed Jurisdictions 
  

	1	Definitions used in this Schedule 

  

	1.1	In this Schedule: 

 “Accounting Standards” means the most recent
edition of the International Financial Reporting Standards as published by the International Accounting Standards Board at the time that any amount is to be calculated by reference to these standards; 

“Audit Team” has the meaning given in paragraph 4.3 of this Schedule; 

“Controlled Business Instruction” has the meaning given in paragraph 3.4.1 of this Schedule; 

“Controlled Delayed Businesses” means the Delayed Businesses other than the Non-Controlled Delayed Businesses; 

“Delay Milestone” means the milestone set out next to the relevant Delayed Business in Appendices 1 and 2 to this Schedule;

 “Delayed Business Employees” has the meaning given to it in Schedule 11; 

“Delayed Business Representative” has the meaning given in paragraph 3.3 of this Schedule; 

“Delayed Businesses” means the Delayed Vaccines Group Companies and the Delayed Vaccines Group Businesses; 

“Delayed Closing” means, in respect of a Delayed Business, completion of the transfer of legal ownership of that Delayed
Business to the Purchaser in accordance with this Schedule; 
 “Delayed Closing Date” has the meaning given to it in
paragraph 1.4 of this Schedule; 
 “Delayed Employees” has the meaning given to it in Schedule 11; 

“Delayed Liabilities” means the liabilities listed in Appendix 3 to this Schedule; 

“Delayed Vaccines Group Business” means a Vaccines Group Business listed in Appendix 2 to this Schedule; 

“Delayed Vaccines Group Company” means a Vaccines Group Company listed in Appendix 1 to this Schedule; 

“Disputed Items” has the meaning given in paragraph 4.10 of this Schedule; 

“Dispute Notice” has the meaning given in paragraph 4.9 of this Schedule; 

“Draft Economic Benefit Statement” has the meaning given in paragraph 4.3 of this Schedule; 

“Economic Benefit Amount” has the meaning given to it in paragraph 4.12.2 of this Schedule; 

“Economic Benefit Expert” has the meaning given in paragraph 4.12.2 of this Schedule; 

“Economic Benefit Objective” has the meaning given to it in paragraph 4.4 of this Schedule; 

“Economic Benefit Statement” has the meaning given in paragraph 4.14.2 of this Schedule; 

  
 241 

 “Economic Benefit Payment” has the meaning given in paragraph 4.15.1 of this
Schedule; 
 [***] 

“Half-Yearly Accounting Period” means (i) the period commencing on 1 January in any year and ending on 30 June in
the same year and (ii) the period commencing on 1 July in any year and ending on 31 December in the same year; 

“Non-Controlled Delayed Business” means: 
  

	 	(i)	the Businesses conducted by Novartis (Bangladesh) Limited, Novartis (Thailand) Limited and Novartis Healthcare Private Limited; and 

  

	 	(ii)	Chiron Behring Vaccines Private Limited; and 

 “Protected Information” has the
meaning given in paragraph 4.7 of this Schedule; and 
 “Reverse Payment” the meaning given in paragraph 4.15.2 of this
Schedule; and 
 “Seller Involvement Instruction” has the meaning given in paragraph 3.10 of this Schedule. 

 

	1.2	The parties agree that legal ownership of the Delayed Businesses shall not be transferred by the Seller to the Purchaser at Closing but that the Delayed Businesses shall be operated by Seller and that the benefit
and burden of such Delayed Business shall be for the Purchaser with effect from the Effective Time on the terms set out in this Schedule. 

  

	1.3	The Seller and the Purchaser shall (and shall procure that their respective Affiliates shall) use all reasonable endeavours to procure the achievement of each Delay Milestone as soon as possible after the Closing
Date. 

  

	1.4	Delayed Closing in respect of a Delayed Business shall occur on the date which is the last Business Day of the month in which the relevant Delay Milestone has been achieved except that: 

 

	 	1.4.1	where the last day of such month is not a Business Day, the Delayed Closing shall instead take place on the first Business Day of the following month; and 

 

	 	1.4.2	where less than five (5) Business Days remain between achievement of the Delay Milestone and the last Business Day of the month, Delayed Closing shall take place: 

 

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, the Delayed Closing shall instead take place on the first Business Day of the month following the month referred to in paragraph 1.4.2(i); or 

 

	 	(iii)	on such other date as may be agreed between the Purchaser and the Seller, 

 such date (in each
case) being the “Delayed Closing Date”. 
  

	2	Obligations on Delayed Closing Date 

 The Sellers’ Obligations 

 

	2.1	On each Delayed Closing Date, the Seller shall deliver to the Purchaser the Ancillary Agreements relating to the Delayed Business (including, without limitation, the Local Transfer Documents) duly executed by the
relevant member(s) of the Seller’s Group. 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 242 

 The Purchaser’s Obligations 

 

	2.2	On each Delayed Closing Date, the Purchaser shall deliver to the Seller the Ancillary Agreements relating to the Delayed Business (including, without limitation, the Local Transfer Documents) duly executed by the
relevant member(s) of the Purchaser’s Group. 

  

	2.3	For the purposes of compliance with paragraphs 2.1 and 2.2 of this Schedule, the Seller and the Purchaser shall, between the date of this Agreement and the Delayed Closing Date, negotiate in good faith any and
all Ancillary Agreements relating to the Delayed Business (including, without limitation, the Local Transfer Documents) such that they are consistent with equivalent Ancillary Agreements executed at Closing, and shall take all such other steps as
are required to transfer the Delayed Businesses in accordance with this Agreement and the Ancillary Agreements. 

 Tax
Indemnity 
  

	2.4	References in paragraphs 2.1 to 2.3 above to Ancillary Agreements shall not include the Tax Indemnity, the execution and delivery of which shall be dealt with under Schedule 15. 

 

	2.5	This Schedule is without prejudice to the rights and obligations of the parties and their respective Groups under the Tax Indemnity. 

 

	2.6	The Purchaser shall use reasonable endeavours to procure that any Controlled Business Instructions are consistent with the rights and obligations of the parties and their respective Groups under the Tax
Indemnity. 

  

	2.7	Nothing done or procured (or omitted to be done or procured) by or on behalf of the Seller in accordance with the Seller’s rights under the Tax Indemnity shall constitute a breach by the Seller of its
obligations under paragraphs 3.4 and 3.10 of this Schedule. 

  

	3	Management and Control of Delayed Businesses 

 Management and control 

 

	3.1	To the maximum extent permissible by Applicable Law, and the terms of any Product Approvals and Product Applications, the parties intend that, pursuant to this Schedule, all management and control rights and
powers that the Seller (or any member of the Seller’s Group) has in relation to a Controlled Delayed Business shall transfer to the Purchaser with effect from Closing and, accordingly, that the Purchaser shall consolidate the Controlled Delayed
Businesses into its accounts with effect therefrom in accordance with its accounting policies as applied from the Closing Date. 

  

	3.2	As soon as reasonably practicable after Closing, the Purchaser shall notify the Seller of the names of its personnel permitted to provide Controlled Business Instructions (“Instructing
Personnel”) and the Seller shall be entitled to rely on and act in accordance with Controlled Business Instructions from Instructing Personnel without further verification. Instructions provided by or on behalf of the Purchaser shall not be
required to be in writing if they are provided by the Instructing Personnel. The Purchaser shall be free to change its Instructing Personnel from time to time by providing 10 Business Days’ written notice to the Seller’s Delayed Business
Representative. 

  

	3.3	In order to cooperate in managing the implementation of the provisions set out in this Schedule, the Seller and the Purchaser shall notify each other of the identity of a senior member of management (the
“Delayed Business Representative”) who shall be the primary point of contact in the event that there is any issue in connection with the operation of the provisions in this Schedule. The parties shall notify each other in writing of
the contact details for their respective Delayed Business Representatives from time to time. 

  
 243 

	3.4	From Closing until the relevant Delayed Closing Date, in respect of any Controlled Delayed Business, the Seller shall: 

  

	 	3.4.1	subject to paragraph 3.11 and to the maximum extent permitted by Applicable Law, and the terms of any relevant Product Approvals and Product Applications, act in accordance with any instructions provided to it by
any of the Instructing Personnel in relation to any aspect of the management and operation of that Controlled Delayed Business or any part of it, whether in relation to sales, marketing, distribution, manufacturing, research and development or any
other activities of that Controlled Delayed Business, the making (or otherwise) of expenditure, investments, employee matters (including the hiring or dismissal of any Delayed Employee), determining operating or financial policies of that Controlled
Delayed Business, or otherwise, including developing that Controlled Delayed Business into new areas and undertaking activities not previously undertaken in relation to that Controlled Delayed Business, and in each case with the effect that the
Purchaser shall have, to the maximum extent permissible by Applicable Law, and the terms of any relevant Product Approvals and Product Applications, the same powers in relation to the relevant Controlled Delayed Business as it would have following
the Delayed Closing Date of that Controlled Delayed Business (a “Controlled Business Instruction”); 

  

	 	3.4.2	comply with the provisions of Schedule 8 in relation to Product Approvals and Product Applications relating to the Controlled Delayed Business; 

 

	 	3.4.3	except to the extent otherwise instructed by the Purchaser’s Instructing Personnel in accordance with this paragraph 3.4 or as required by Schedule 8, ensure that the Controlled Delayed Business is carried
on in the ordinary course of business consistent with past practice in relation to that Controlled Delayed Business; and 

  

	 	3.4.4	ensure (but in respect of the Tianyuan JV, only to the maximum extent that it is able through the exercise of such interests, rights and powers that the Seller has in the Tianyuan JV), that any Delayed Vaccines
Group Company shall, between the Closing Date and the relevant Delayed Closing Date for that Delayed Vaccines Group Company: 

  

	 	(i)	make any distribution, dividend or any return of value to any member of the Seller’s Group (whether in cash or in kind) or any return of capital (whether by reduction of capital or redemption or purchase of shares)
other than dividends in the ordinary course of the business consistent with past practice; or 

  

	 	(ii)	take any action which results in a reduction in its dividend capacity (other than the incurrence of trading losses in the ordinary course of business); or 

 

	 	(iii)	make or incur any Liability to make any payment to, or enter into any transaction with, any member of the Seller’s Group other than with the consent of the Purchaser or in accordance with the provisions of this
Agreement or any of the Ancillary Agreements; or 

  

	 	(iv)	make or incur any Liability to make any payment to, or enter into any transaction other than (in any case) on arm’s length terms in the ordinary course of business or otherwise in accordance with the provisions of
this Agreement or any of the Ancillary Agreements; 

  
 244 

	 	(v)	permit any waiver, deferral or release by any Delayed Vaccines Group Company of any amount or obligation owed or due to such Delayed Vaccines Group Company; or 

 

	 	(vi)	permit any guarantee, indemnity or security to be provided by any Delayed Vaccines Group Company in respect of the obligations or liabilities of the Seller or any of its Affiliates, 

and provided that the Seller shall not be required, pursuant to any Controlled Business Instruction, to take any action (or omit to take any
action) in relation to any of its business (or the business of the Seller’s Group) that is not a Controlled Delayed Business. 
  

	3.5	The Seller shall indemnify on demand and hold harmless the Purchaser against and in respect of any and all Liabilities of the Purchaser’s Group and any Delayed Vaccines Group Company arising directly or
indirectly as a result of any breach of paragraph 3.4.4 above and, for the avoidance of doubt, any such liability shall not constitute an Assumed Liability for the purposes of this Agreement. 

 

	3.6	The provisions of Clause 5 and Schedule 20 shall not apply in respect of any Controlled Delayed Business following Closing and the provisions of Clause 13.1 shall not apply in respect of any Delayed Business
following Closing. 

  

	3.7	The Purchaser shall (or shall procure that its Affiliates shall) supply such assistance and access (including the supply of products, the supply of services and access to Transferred Books and Records and
Commercial Information, but excluding any access to Intellectual Property Rights except as referred to in paragraph 3.8 below) as shall be reasonably necessary to allow the Seller to operate each Controlled Delayed Business in accordance with this
Schedule. 

  

	3.8	The Purchaser shall (or shall procure that its Affiliates shall) grant the Seller from Closing a non-exclusive, fully paid up, royalty free and sub-licensable licence or sub-licence (as applicable) to use,
notwithstanding any other provision of this Agreement or any of the Ancillary Agreements, the Vaccines Group Intellectual Property Rights and Intellectual Property Rights licensed to the Purchaser (and its Affiliates) under any Ancillary Agreement
(except the Purchaser Intellectual Property Licence Agreement) for the sole purpose of operating each Delayed Business in accordance with the provisions of this Schedule 25. This licence shall continue on a country by country basis, in relation to
each Delayed Business, until the date on which that Delayed Business has been transferred by the Seller to the Purchaser in accordance with this Schedule. 

  

	3.9	Delayed Employees who are engaged in a Controlled Delayed Business shall report to the management of the Purchaser and shall be treated for such management and reporting purposes in the same way as any employee
of the Purchaser’s Group. Controlled Business Instructions may, accordingly, be given by the Instructing Personnel directly to any Delayed Employee engaged in a Controlled Delayed Business. 

 

	3.10	To the extent that the implementation of any Controlled Business Instruction requires an action or actions of a person employed by the Seller but who is not a Delayed Employee (whether because Applicable Law
prevents such Controlled Business Instruction from being given directly to a Delayed Employee or for any other reason) (a “Seller Involvement Instruction”), the Seller shall also provide the Controlled Business Instruction, in
writing (which may include email), to the Seller’s Delayed Business Representative specifying (i) that it is a Seller Involvement Instruction; (ii) the actions that are required to be taken by such person; and (iii) a reasonable time within
which such actions are required to be taken. 

  
 245 

	3.11	The Seller and the Purchaser acknowledge that the Delayed Employees shall continue to be bound by, and shall comply with, the employment policies and procedures (including terms and conditions and disciplinary
procedures) of the Seller’s Group that apply to employees of the Seller’s Group. 

  

	3.12	Subject to paragraph 3.11, the Seller and the Purchaser acknowledge that Delayed Employees shall continue to be bound by and shall comply with the policies of the Seller’s Group provided that:

  

	 	3.12.1	from the date on which the relevant Delayed Employees are given reasonable notice of the relevant restrictions and anti-bribery and corruption policies, Delayed Employees engaged the Delayed Business in China
shall be bound by and shall comply with any additional restrictions imposed on commercial practices and anti-bribery and corruption policies that the Purchaser’s Group implements and which apply to employees of the Purchaser’s Group in
China including (but not limited to) its policy related to payments to health care providers and such other policies as may be required by Applicable Law from time to time; 

 

	 	3.12.2	[***] 

  

	 	3.12.3	the Seller shall provide the Purchaser with copies of its operational and other policies that apply in relation to Controlled Delayed Businesses. In respect of such policies, the Purchaser may give notice to the
Seller that it wishes a particular policy of the Purchaser’s Group to apply in respect of a Controlled Delayed Business and/or the relevant Delayed Employees in place of the equivalent Seller’s policy. The Purchaser’s equivalent
policy shall apply to the relevant Delayed Employees from the date on which such Delayed Employees are given reasonable notice of the relevant policy. If the Seller’s and the Purchaser’s policies apply at the same time, if and to the
extent that there is any inconsistency or conflict between the two policies, the policy which requires behaviour that is likely to expose the parties to the smallest amount of legal, regulatory and/or compliance risk shall prevail.

  

	3.13	The Purchaser hereby undertakes to the Seller (for itself and on behalf of each other member of the Seller’s Group (excluding, for the avoidance of doubt, the Delayed Vaccines Group Companies) and their
respective directors, officers, employees and agents (excluding any Delayed Employees) (the “Delayed Indemnity Parties”) that, with effect from the Effective Time, the Purchaser will indemnify on demand and hold harmless each of the
Delayed Indemnity Parties against and in respect of any and all Liabilities, other than Liabilities in respect of Tax that are taken into account in calculating any Profit Payment resulting directly or indirectly from any Controlled Delayed Business
and/or from any Controlled Business Instruction to the extent that (i) such Liabilities are not Assumed Liabilities and (ii) the Controlled Delayed Indemnity Parties concerned would not have incurred such Liabilities if the Controlled Delayed
Business in question had been transferred to the relevant member of the Purchaser’s Group at Closing (“Incremental Delay Liabilities”), but in any case excluding any such Liabilities to the extent they arise from a breach by
the Seller under paragraph 3.16. 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 246 

	3.14	If the Seller is of the opinion that any Controlled Business Instruction may result in any Liability that would fall to be indemnified pursuant to paragraph 3.13 above, the Seller shall use its reasonable
endeavours to inform (and procure that the members of the Seller’s Group shall inform) the Purchaser of that opinion and the reasons for it as soon as reasonably practicable after reaching that opinion. The indemnity set out in paragraph 3.13
above shall not be affected or limited in any way by any failure of any member of the Seller’s Group to so inform the Purchaser. 

  

	3.15	The Purchaser shall not be entitled to make any claim for damages against the Seller in respect of a breach of paragraph 3.4 otherwise than pursuant to a claim brought under paragraph 3.16. 

 

	3.16	Each Seller shall procure that: 

  

	 	3.16.1	in respect of Controlled Business Instructions that are not Seller Involvement Instructions, neither it nor any of its Associated Persons shall act (or fail to act) fraudulently or with Gross Negligence in
connection with the implementation of any Controlled Business Instruction. “Gross Negligence” for these purposes means any act or failure to act by the Seller (or any of its Associated Persons that: (i) the Seller (or the relevant
Associated Person) knew may create a risk of material harm to the relevant Delayed Business; (ii) was intended to cause such harm, or was done in reckless disregard of, or in wanton indifference to, such risk of harm; and (iii) in all the
circumstances (having regard to both the probability and seriousness of such harm) was an unreasonable risk for the Seller (or the relevant Associated Person) to take; and 

 

	 	3.16.2	in respect of Seller Involvement Instructions, neither it nor any of its Associated Persons shall act (or fail to act) fraudulently or negligently or in wilful default in connection with the implementation of the
Seller Involvement Instruction and shall take no steps which are intended to have the effect of preventing this implementation of a Seller Involvement Instruction, 

provided that it shall not be a breach of this paragraph 3.16 (and shall accordingly not be acting with Gross Negligence or wilful default for
the purposes of this paragraph) to carry out any act, or fail to act, if to do so is: 
  

	 	3.16.3	required to implement a Controlled Business Instruction; 

  

	 	3.16.4	required to comply with any Applicable Law; 

  

	 	3.16.5	required to implement or comply with the terms of this Agreement or any Ancillary Agreement; or 

  

	 	3.16.6	taken to mitigate any other loss or damage to the Controlled Delayed Business which the Seller (or the relevant Associated Person) believes, acting reasonably and in good faith, could be material in the context
of that Controlled Delayed Business. 

 In any event, no claim shall be made by the Purchaser (and the Purchaser shall ensure
that no member of the Purchaser’s Group shall make any claim) for any breach of any other provisions of this Agreement (or the provisions of any Ancillary Agreement) by the Seller (or any member of the Seller’s Group) that occurs in order
to comply with any Controlled Business Instruction. 
  

	3.17	 Prior to the making of any claim under this Schedule 25 in respect of any matter, the parties shall use reasonable endeavours to escalate such
matter first for consideration to the Delayed 

  
 247 

	 	
Business Representatives and then to the Purchaser’s and the Seller’s chief financial officers, for the purpose of seeking to resolve such matter within a period of 30 days following
such escalation. 

  

	3.18	Subject in each case to Applicable Law, the Seller shall, in the period between Closing and the relevant Delayed Closing Date, promptly upon request by the Purchaser provide (or procure that any member of its
Group shall provide) the Purchaser and its representatives with access to: 

  

	 	3.18.1	any books and records of the Seller’s Group to the extent relating to any Controlled Delayed Business of the Seller; and 

 

	 	3.18.2	any personnel of the Seller for the purposes of any requests for information from such personnel in relation to the Controlled Delayed Business. 

For the avoidance of doubt, the parties shall take all steps necessary to ensure that no information is provided to the Purchaser or any person
on behalf of the Purchaser which relates to any business of the Seller or any member of the Seller’s Group other than the Controlled Delayed Business. 
  

	3.19	For the purposes of the Warranties deemed repeated by the Seller immediately before Closing pursuant to Clause 10.1.5, ownership of the Delayed Businesses shall be deemed to have transferred to the Purchaser at
Closing. 

  

	3.20	During the period between the Closing Date and the Delayed Closing Date, funding for Delayed Businesses shall continue to be provided by the Seller’s Group, save that in the event that any Delayed Business
requires funds (for the purposes of working capital, acquisitions, capital expenditure or otherwise) during such period, in excess of US$10 million and the Delayed Business does not have the required funding in place (including through any cash
pooling arrangements), then such funds shall promptly be provided by the Purchaser, on such terms as the Seller and the Purchaser shall agree, acting reasonably, having regard to, amongst other things, the Tax effects of such funding.

 Non-Controlled Delayed Businesses 
  

	3.21	From Closing until the relevant Delayed Closing Date: 

  

	 	3.21.1	the provisions of paragraph 3 of this Schedule shall not apply in respect of the Non-Controlled Delayed Businesses, with the exception of paragraphs 3.4.4, 3.5, 3.11, 3.18, 3.19 and 3.20 which shall apply if and
to the extent permitted by Applicable Law; 

  

	 	3.21.2	subject to paragraph 3.22, the provisions of paragraph 4 of this Schedule shall not apply in respect of the Non-Controlled Delayed Businesses; and 

 

	 	3.21.3	if and to the extent permitted by Applicable Law, the provisions of Clause 5 and Schedule 20 will continue to apply to the Non-Controlled Delayed Businesses and each Seller shall exercise such interests, rights
and powers that such Seller has in respect of that Non-Controlled Delayed Business to the maximum extent that it is able in order to procure that the Non-Controlled Business is operated in accordance with Clause 5 and Schedule 20. 

 

	3.22	With effect from the relevant Delayed Closing Date, the provisions of paragraph 4 of this Schedule shall apply in respect of the Non-Controlled Delayed Businesses, save that the first Half Yearly Accounting
Period shall be extended so that it commences at the Effective Time and ends on the relevant Delayed Closing Date. 

  
 248 

	3.23	From Closing until 31 March 2015, the Seller shall provide the Purchaser with such assistance and information to which it does not otherwise have access as it reasonably requests in order for it to be
able to calculate the necessary receivables to be recorded in respect of any payments that may be made under paragraph 3.23, including, such monthly profit and loss forecast information as already exists and is reasonably available to the Seller or
its Affiliates in relation to the Non-Controlled Delayed Businesses for the period up to the estimated relevant Delayed Closing Date. 

  

	4	Economic Benefit Transfer 

 Economic benefit 

 

	4.1	The Seller shall comply with the provisions of this Part 4, in relation to any Delayed Business (other than in relation to a Delayed Vaccines Group Company in respect of which only paragraph 4.2 of this Schedule
will apply), for each Half-Yearly Accounting Period in which such Delayed Business remains legally owned by it or any member of the Seller’s Group. The first Half-Yearly Accounting Period for which the provisions of this Part 4 shall be
extended so that it commences at the Effective Time and shall end on 31 December 2015. 

  

	4.2	Within 45 days of the relevant Delayed Closing Date for any Delayed Vaccines Group Company, the Seller shall provide the Purchaser with a cash flow statement (including opening and closing balances for cash and
cash equivalents, and payables and receivables that would have fallen within the definitions of Intra-Group Non-Trade Receivables and Intra-Group Non-Trade Payables) for such Delayed Vaccines Group Company for the period commencing at the Effective
Time and ending on the Delayed Closing Date prepared using the Accounting Standards. 

  

	4.3	Within one month following the end of each Half-Yearly Accounting Period, the Seller shall produce and provide to the internal audit team of the Purchaser (or, at the Purchaser’s discretion, the external
auditors) (the “Audit Team”) a draft statement setting out, for each Delayed Business that had not transferred to the Purchaser by the start of that Half-Yearly Accounting Period, the Economic Benefit Amount in respect of such
Delayed Business for such Half-Yearly Accounting Period (or, if applicable, such part of the Half-Yearly Accounting Period as falls prior to the Delayed Closing Date for such Delayed Business). Each such statement shall be a “Draft Economic
Benefit Statement”. 

  

	4.4	It is intended that the Economic Benefit Amount shown in each Economic Benefit Statement is the amount that is necessary to be paid to the Purchaser by the Seller or by the Seller to the Purchaser, in order to
put the Purchaser’s Group and the Seller’s Group in the same economic position as they would have been in, taking into account any arrangements that would have been in place in respect of the relevant Delayed Businesses pursuant
to any Ancillary Agreement, had such Delayed Businesses been transferred to the Purchaser at Closing before taking account, in each case, of any Tax effect for the Purchaser or the Seller in respect of such payment (the “Economic Benefit
Objective”). 

  

	4.5	In the period prior to 31 December 2015, the Seller and the Purchaser shall meet together to consider in good faith whether there are any adjustments required to the provisions of Part 5 of this
Schedule in order for the Economic Benefit Statements to achieve the Economic Benefit Objective and (acting reasonably and in good faith) seek to agree such adjustments. 

 

	4.6	 The portion of the Economic Benefit Amount set out in the Draft Economic Benefit Statement in relation to each Delayed Business shall be
calculated in the local currency for that Delayed Business but any Economic Benefit Payment shall be paid pursuant to paragraph 4.15 or 4.16 of this Schedule in pounds sterling, for which purpose each amount in a currency other than

  
 249 

	 	
pounds sterling shall be converted into pounds sterling at the spot reference rate for those currencies as quoted by the European Central Bank (or if there is no such rate, as quoted by the
nearest equivalent institution) on the Business Day immediately prior to the relevant payment date and the sum of such converted sterling amounts shall be the Economic Benefit Payment amount. The calculation of the Economic Benefit Amount set out in
an Economic Benefit Statement shall only be converted into pounds sterling in accordance with this paragraph 4.6 and aggregated after the Economic Benefit Statement has been agreed or determined in accordance with this Part 4. 

 

	4.7	The Seller shall, and shall procure that the members of the Seller’s Group (and, if applicable, its external accountants) shall, provide to the Audit Team, without charge, such access to their personnel,
books and records, calculations and working papers as the Audit Team may reasonably request in connection with its review of the Draft Economic Benefit Statement (and the parties acknowledge that local market information that is not contained on
central consolidation systems will only be requested where material in the context of the Draft Economic Benefit Statement as a whole), subject (where applicable) to the Purchaser providing such undertakings as the relevant external accountants may
reasonably request, and provided that the Seller hereby undertakes to the Purchaser that it shall procure that each member of its Audit Team shall (i) keep any such information which is commercially sensitive (the “Protected
Information”) confidential and shall only disclose such information to, and discuss such information with, other members of that Audit Team; (ii) be expressly prohibited from communicating (in any form) any Protected Information to any
other employee, agent, adviser or consultant of any member of the Purchaser’s Group; and (iii) be subject to the above requirements whilst employed or engaged by any member of the Purchaser’s Group in any capacity (whether or not as a
member of that Audit Team). The provisions of Clause 14 (Confidentiality) of this Agreement shall apply mutatis mutandis to such information including, for the avoidance of doubt, to allow (where permitted by that clause) disclosure of information
otherwise prohibited to be communicated to any agent, adviser or consultant of any party’s Group. 

  

	4.8	No amendments shall be made to any Draft Economic Benefit Statement except in accordance with the provisions of paragraph 4.9 below. 

 

	4.9	The Audit Team may dispute a Draft Economic Benefit Statement by notice in writing (in this Schedule, a “Dispute Notice”) delivered to the Seller by or on behalf of that Audit Team in accordance
with Clause 17.11 (Notices) of this Agreement within 3 weeks following receipt of the Draft Economic Benefit Statement. Any Dispute Notice shall specify (i) which items of the Draft Economic Benefit Statement are disputed; (ii) the reasons therefor,
making specific reference (where relevant and reasonably possible) to the parts of this Schedule which the Audit Team asserts have not been complied with in preparing the relevant statement; and (iii) to the extent practicable, any adjustments that
the Audit Team considers should be made to the Draft Economic Benefit Statement, and provided that a Dispute Notice may only be submitted if the aggregate impact of all disputed items comprised in that Economic Benefit Amount are greater than
£500,000. 

  

	4.10	Any Dispute Notice shall be accompanied by all relevant supporting documentation and working papers on which the Audit Team wishes to rely, it being acknowledged by the Purchaser that it shall procure that its
Audit Team shall provide further documentation to support its claims promptly on reasonable request by the Seller or, where relevant, the Economic Benefit Expert. Only those items or amounts specified in a Dispute Notice shall be treated as being in
dispute (the “Disputed Items”) and no amendment may be made by any party, or any Economic Benefit Expert, to any items or amounts which are not Disputed Items. 

  
 250 

	4.11	If the Audit Team does not serve a Dispute Notice under and within the time period set out in paragraph 4.9 of this Part 4, the Draft Economic Benefit Statement shall constitute the “Economic Benefit
Statement” for the Seller in respect of the relevant Half-Yearly Accounting Period to which that Economic Benefit Statement relates. 

  

	4.12	If the Audit Team does serve a Dispute Notice under and within the time period set out in paragraph 4.9 of this Part 4, the Seller shall use its reasonable endeavours to resolve the Disputed Items as soon as
reasonably practicable (with the Purchaser acting through its Audit Team) and either: 

  

	 	4.12.1	if the parties reach agreement on the Disputed Items within 10 Business Days of the service of the relevant Dispute Notice (or such longer period as they may agree in writing), the Draft Economic Benefit
Statement shall be amended to reflect such agreement and shall then constitute the “Economic Benefit Statement” in respect of the relevant Half-Yearly Accounting Period to which that Economic Benefit Statement relates; or

  

	 	4.12.2	if the parties do not reach agreement in accordance with paragraph 4.12.1 above, either party may refer the dispute to such individual at an independent firm of chartered accountants of international repute as
the parties may agree or, failing such agreement (including such firm and/or individual not accepting such appointment), within 2 Business Days of expiry of the period described in paragraph 4.12.1 above, to such independent firm of chartered
accountants of international repute in London as the President of the Institute of Chartered Accountants in England and Wales may, on the application of either party, nominate (the “Economic Benefit Expert”), on the basis that the
Economic Benefit Expert is to make a decision on the dispute and notify the parties of its decision within 3 weeks of receiving the reference or such longer reasonable period as the Economic Benefit Expert may determine. 

 

	4.13	The Purchaser shall bear the costs in relation to the preparation and certification of any Draft Economic Benefit Statement and in relation to the review of (and any dispute in relation to) any Draft Economic
Benefit Statement. 

  

	4.14	In any reference to the Economic Benefit Expert in accordance with paragraph 4.12 above: 

  

	 	4.14.1	the Economic Benefit Expert shall act as expert and not as arbitrator and shall be directed to determine any dispute in accordance with the Accounting Standards and Part 5 of this Schedule and (if necessary)
having regard to the Economic Benefit Objective; 

  

	 	4.14.2	the decision of the Economic Benefit Expert shall, in the absence of fraud or manifest error, be final and binding on the parties and the Draft Economic Benefit Statement shall be amended as necessary to reflect
the decision of the Economic Benefit Expert and, as amended, shall be the “Economic Benefit Statement” in respect of the relevant Half-Yearly Accounting Period to which that Economic Benefit Statement relates; 

 

	 	4.14.3	the costs of the Economic Benefit Expert shall be paid by the Purchaser; and 

  

	 	4.14.4	the parties shall respectively provide or procure the provision of the Economic Benefit Expert of all such information as the Economic Benefit Expert shall reasonably require including access to their respective
advisers and their respective books, records and personnel. 

  
 251 

	4.15	As soon as reasonably practicable and in any event within 5 Business Days following the agreement or determination of the Economic Benefit Statement in respect of any Half-Yearly Accounting Period:

  

	 	4.15.1	the Seller shall, if the Economic Benefit Amount set out in the Economic Benefit Statement is a positive number, pay the Purchaser, or procure the payment to the Purchaser of, an amount in cleared funds equal to
that Economic Benefit Amount, such payment being an “Economic Benefit Payment”. Clause 3.5 of this Agreement shall apply to any Economic Benefit Payment as if such payment were made pursuant to an indemnity under this Agreement; and

  

	 	4.15.2	the Purchaser shall, if the Economic Benefit Amount set out in the Economic Benefit Statement is a negative number, pay to the Seller, or procure the payment to the Seller of, an amount in cleared funds equal to
that Economic Benefit Amount expressed as a positive number, such payment being a “Reverse Payment”. 

  

	4.16	If: 

  

	 	4.16.1	the amount of an Economic Benefit Payment is, on an after-Tax basis (as defined in Clause 1.9 of this Agreement), less than the relevant Economic Benefit Amount, the amount due shall be increased so that the
amount of the payment on an after-Tax basis is equal to the relevant Economic Benefit Amount; or 

  

	 	4.16.2	the amount of a Reverse Payment is, on an after-Tax basis (as defined in Clause 1.9 of this Agreement), less than the absolute value of the relevant Economic Benefit Amount, the amount due shall be increased
so that the amount of the payment on an after-Tax basis is equal to such absolute value. 

  

	4.17	If the Purchaser reasonably believes that an Economic Benefit Payment made or procured by the Seller to the Purchaser in accordance with paragraph 4.15.1 will be subject to Tax in the hands of the
Purchaser or any member of the Purchaser’s Group: 

  

	 	4.17.1	the Purchaser shall as soon as reasonably practicable give the Seller written notice of such belief; and 

  

	 	4.17.2	following the giving of such notice, the Seller and the Purchaser shall, and shall procure that the members of their respective Groups will (at the Seller’s cost) co-operate with each other in good faith and
use all commercially reasonable efforts to reduce or mitigate the amount of any additional payment required to be made pursuant to paragraph 4.16 without prejudicing the interests of the Purchaser. 

 

	4.18	If the Seller reasonably believes that a Reverse Payment made or procured by the Purchaser to the Seller in accordance with paragraph 4.15.2 will be subject to Tax in the hands of the Seller or any
member of the Seller’s Group: 

  

	 	4.18.1	the Seller shall as soon as reasonably practicable give the Purchaser written notice of such belief; and 

  

	 	4.18.2	following the giving of such notice, the Seller and the Purchaser shall, and shall procure that the members of their respective Groups will (at the Purchaser’s cost) co-operate with each other in good faith
and use all commercially reasonable efforts to reduce or mitigate the amount of any additional payment required to be made pursuant to paragraph 4.16 without prejudicing the interests of the Seller. 

  
 252 

	5	Preparation of Economic Benefit Statements 

  

	5.1	For the purposes of this paragraph 5: 

  

					
	“Bad Debt”	 	has the meaning given in paragraph 5.2.9;
		
	“Customer”	 	means any person or entity that acquires and/or intends to acquire any of the Products or services provided by the Delayed Business (including any members of the Seller’s Group or the Purchaser’s
Group);
		
	“Employee Costs”	 	means the FTE costs incurred by the Seller’s Group in connection with the employment of the Delayed Employees of the relevant Delayed Business by the Seller’s Group, as provided in paragraph 12.3 of Schedule
11;
		
	“Landed Cost”	 	means, in respect of each Product, any costs incurred by the relevant Local Seller Entity in relation to that Product in respect of freight, insurance, duty, import and transportation costs;
		
	“Local Seller Entity”	 	means, in respect of a Delayed Business, the member of the Seller’s Group that owns and operates such Delayed Business;
		
	“Net Sales”	 	means net sales received from the sale and distribution of Products or the provision of services, in each case, by the relevant Local Seller Entity to any Customer plus any other revenue received in respect of the
Delayed Business, but excluding (for the avoidance of doubt) any amounts received by the Seller, any other member of Seller’s Group or any sub-contractor in respect of Sales Tax for which any member of the Seller’s Group is liable to
account to any Tax Authority. For these purposes, net sales shall be determined in accordance with Accounting Standards. The deductions booked by the Seller to calculate the recorded net sales from gross sales shall include the following:
			
		 	(a)        	  	normal trade, quantity and cash discounts;
			
		 	(b)	  	Sales Taxes and other taxes levied from Customers in relation to the sale of Products to the extent included in the gross amount invoiced;
			
		 	(c)	  	amounts repaid or credited by reasons of defects, rejections, recalls or returns, excluding amounts in respect of Sales Tax included in the amounts so repaid or credited, unless the Seller or a member of the Seller’s Group is
unable (having used reasonable diligent commercial endeavours) to recover such amounts in respect of Sales Tax by way of repayment or credit;
			
		 	(d)	  	rebates and chargebacks to Customers and Third Parties (including, without limitation, Medicare, Medicaid, Managed Healthcare and similar types of rebates), excluding amounts in respect of Sales Tax included in such rebates and
chargebacks, unless the Seller or a member of the Seller’s Group is unable (having used reasonable diligent commercial endeavours) to recover such amounts in respect of Sales Tax by way of repayment or
credit);

  
 253 

			
		  	 (e)            any amounts recorded in
gross sales associated with goods provided to customers for free, with the exception of samples;
  

(f)            amounts provided or credited to customers
through coupons, other discount programs and co-pay assistance programs;
  

(g)            delayed ship order credits, discounts or
payments related to the impact of price increases between purchase and shipping dates; and
  

(h)            fees for service payments to customers for
any non-separate services (including compensation for maintaining agreed inventory levels and providing information) and any associated Sales Tax to the extent the Seller (or a member of the Seller’s Group) is unable (having used reasonable
diligent commercial endeavours) to recover such amounts in respect of Sales Tax by way of repayment or credit,
  

and with respect to the calculation of Net Sales:
  

(i)            Net Sales shall only include the value
charged or invoiced on the first sale to a Customer;
  

(j)            if a Product is delivered to the Customer
before being invoiced (or is not invoiced), Net Sales will be calculated at the time all the revenue recognition criteria under Accounting Standards are met; and
  

(k)            revenue deduction adjustments which relate
to any event prior to Closing shall be excluded;

		
	“Product”	  	means any of the products Commercialised by the relevant Delayed Business, and “Products” shall be construed accordingly;
		
	“Sales Tax”	  	means any turnover, value-added, sales, use, goods and services or similar Tax (excluding, for the avoidance of doubt, any capital gains or similar Tax);
		
	“Third Party”	  	means any person other than (i) the Purchaser and members of the Purchaser’s Group and (ii) the Seller and members of the Seller’s Group;
		
	“Third Party Distributor”	  	means a Third Party distributor of the Seller’s Group;
		
	“Transfer Price”	  	 means:
  

(a)            in respect of each Product supplied to the
Local Seller Entity by a member of the Purchaser’s Group for distribution, any amount to be paid by the Seller (or its Affiliate) for the Product, as agreed between the Seller (or its Affiliate) and the Purchaser in writing from time to
time;
  

(b)            in respect of each Product provided to the
Local Seller Entity by a Local Purchaser Entity for distribution, any amount paid by the Local Seller Entity for the Product, as agreed between the Seller (or its Affiliate) and the Purchaser in writing from time to time; and

 

(c)            in respect of each Product provided to the
Local Seller Entity by a Third Party supplier for distribution, any amount paid by the Local Seller Entity for the Product to such Third Party; and

  
 254 

			
	“Working Hours”	  	means 9 a.m. to 5 p.m. on a Business Day at the relevant working location.

  

	5.2	The “Economic Benefit Amount” of a Delayed Business in respect of a given period shall be calculated as: 

  

	 	5.2.1	the Net Sales of the relevant Delayed Business in that period; 

  

	 	5.2.2	minus the Transfer Price (exclusive of Sales Taxes) paid in respect of the Products covered by those Net Sales; 

  

	 	5.2.3	minus the Landed Cost (exclusive of Sales Taxes) of the Products covered by those Net Sales; 

  

	 	5.2.4	minus the Employee Costs (exclusive of Sales Taxes); 

  

	 	5.2.5	minus any other costs (exclusive of Sales Taxes) incurred by the relevant Local Seller Entity in relation to the relevant Delayed Business other than the Employee Costs, Landed Costs and any costs of acquiring
Products for sale (including, but not limited to, the Transfer Price); 

  

	 	5.2.6	minus, where the relevant Local Seller Entity carried out any action that would, after Delayed Closing, be provided to the Delayed Business under a Transitional Services Agreement, the amount payable for such
services (exclusive of Sales Taxes) at the rates that will apply under such Transitional Services Agreement; 

  

	 	5.2.7	plus any foreign exchange gains and minus any foreign exchange losses arising in relation to the accounts receivable and accounts payable of the Delayed Business; 

 

	 	5.2.8	minus a sales and distribution charge of 2 per cent (2%) of Net Sales in the period (excluding any Sales Tax thereon); 

  

	 	5.2.9	minus any undisputed sum (exclusive of Sales Taxes) payable by any Third Party to the relevant Local Seller Entity in relation to any Products sold on or after the Closing Date which has not been paid by the
earlier of sixty (60) days of the due date for such payment and the Delayed Closing Date for the relevant Delayed Business (“Bad Debt”); and 

  

	 	5.2.10	plus any Bad Debt (exclusive of Sales Taxes) deducted pursuant to paragraph 5.2.9 in any prior period to the extent that such Bad Debt is recovered in the relevant period; 

 

	 	5.2.11	minus the amount of: 

  

	 	(i)	any expense of the relevant Local Seller Entity or a member of the relevant Local Seller Entity’s Sales Tax group in connection with or as a result of the Delayed Business which consists of an amount in respect of
Sales Tax in respect of the period for which neither the relevant Local Seller Entity nor a member of the relevant Local Seller Entity’s Sales Tax group is entitled to credit or repayment; and 

 

	 	(ii)	any Sales Tax in respect of the period for which the relevant Local Seller Entity or the relevant Local Seller Entity’s Sales Tax group is liable to account to any Tax Authority in connection with or as a result of
the Delayed Business; 

 save, in each case, to the extent otherwise deducted or excluded in the calculation of the Economic
Benefit Amount; 

  
 255 

	 	5.2.12	minus an amount equal to the product of (i) the amount resulting from the calculation at paragraphs 5.2.1 to 5.2.11 above, and (ii) the statutory local Tax rate applicable in respect of profits of the relevant
Delayed Business, expressed as a percentage (the “Headline Tax Rate”), as at the last day of the relevant period, 

provided that, if and to the extent that any costs incurred by a Local Seller Entity are subject to reimbursement under any indemnity or
equivalent covenant to pay in this Agreement or in an Ancillary Agreement are included in any Economic Benefit Statement, such costs shall not also be recoverable under such indemnity or covenant to pay. 

 

	5.3	The Economic Benefit Statement for a Delayed Vaccines Group Business will detail the following: 

  

	 	5.3.1	Net Sales (which will be reported in accordance with the Seller’s Group’s group reporting system) for the relevant Half-Year by brand, which shall show: 

 

	 	(i)	gross sales; 

  

	 	(ii)	returns and allowances; 

  

	 	(iii)	on-invoice discounts; 

  

	 	(iv)	off-invoice discounts; 

  

	 	(v)	any other deduction; and 

  

	 	(vi)	Net Sales; and 

  

	 	5.3.2	each line item forming part of the calculation of the Economic Benefit Amount in accordance with paragraph 5.2 above (and including, in respect of costs, the itemisation of those costs as between categories of
costs), 

 and the Seller will provide the Draft Economic Benefit Statement together with such supporting information as is
reasonably required to enable the Purchaser to review the Economic Benefit Statement, and prior to 31 December 2015, the Seller and the Purchaser shall meet together to agree the scope of such supporting information. 

  
 256 

 Appendix 1 

Delayed Vaccines Group Companies 
  

					
	 Jurisdiction
	  	 Delayed Vaccines

Group Company
	  	 Delay Milestone

			
	China	  	Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd	  	The receipt by the parties of all necessary approvals, consents and filings from or with the NDRC and MOFCOM, in each case in respect of the sale and transfer of the Tianyuan Shares and the PRC Transfer Documents.
			
	India	  	Chiron Behring Vaccines Private Limited	  	The receipt by the parties of all necessary approvals, consents and filings from or with the Indian Foreign Investment Promotion Board (“FIPB”) in respect of the sale and transfer of 100 per cent. of the shares in
Chiron Behring Vaccines Private Limited and the related Commencement Certificate being issued by the FIPB.

  
 257 

 Appendix 2 

Delayed Vaccines Group Businesses 
  

					
	 Jurisdiction
	  	 Delayed Vaccines

Group Business
	  	 Delay Milestone

			
	Bangladesh	  	Novartis (Bangladesh) Limited	  	The passing of a resolution of the shareholders of Novartis (Bangladesh) Limited validly approving the transfer of the Bangladesh Business to the Purchaser and the entry into of the Bangladesh Transfer Documents.
			
	India	  	Novartis Healthcare Private Limited	  	The receipt by the parties of all necessary approvals, consents and filings from or with the Indian Foreign Investment Promotion Board in respect of the sale and transfer of the India Business and the India Transfer
Documents.
			
	Thailand	  	Novartis (Thailand) Limited	  	The receipt by the relevant members of the Seller’s Group of a Foreign Business Licence in respect of transitional services and/or transitional distribution services to be provided to the Purchaser in Thailand.

 In this Appendix 2: 

“Bangladesh Business” means the assets and liabilities transferring from Novartis (Bangladesh) Limited to the Purchaser in accordance with
this Agreement and the relevant Local Transfer Agreement; 
 “Bangladesh Transfer Documents” means Local Transfer Agreement in respect of
the transfer of the Bangladesh Business to the Purchaser; 
 “Foreign Business Licence” means a foreign business certificate or a foreign
business licence from the Thailand Ministry of Commerce to provide transitional services and/or transitional distribution services in Thailand; 

“India Business” means the assets and liabilities transferring from Novartis Healthcare Private Limited to the Purchaser in accordance with
this Agreement and the relevant Local Transfer Agreement; and 
 “India Transfer Documents” means Local Transfer Agreement in respect of the
transfer of the India Business to the Purchaser. 

  
 258 

 Schedule 26 

Local Payments 
 Part A: Local payments

  

							
	 (1)

Jurisdiction
	  	 (2)

Designated Purchaser
	  	 (3)

Share Seller or
 Business
Seller
	  	 (4)

Local Payment

Amount

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 259 

 Part B: Local payments post-Closing 

 

							
	 (1)

Delayed

Jurisdiction
	  	 (2)

Designated Purchaser(s)
	  	 (3)

Share Seller(s) or
 Business
Seller
	  	 (4)

Local Payment

Amount

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 260 

 Schedule 27 

Vaccines Group Information Technology 

Part 1: 
 Transferred
Information Technology 
 Shanghai Novartis Trading Ltd 
  

							
	 No.
	  	 Asset
	  	 SNo
	  	 Asset description

	1.	  	Z130-67	  	CISCO SWITCH 3560	  	Cisco Switch 3560
	2.	  	Z130-69	  	PRINTER HP 2015DN	  	HP printer HP P2015D
	3.	  	Z130-220	  		  	

	4.	  	Z130-222	  		  	

	5.	  	Z130-223	  		  	

	6.	  	Z161-112	  	EMP-1710	  	

	7.	  	Z161-118	  	CANON L140 FAX	  	

	8.	  	Z161-346	  		  	

	9.	  	Z130-399	  		  	

	10.	  	Z130-482	  	V1HM679	  	Monitor V1HM679
	11.	  	Z130-483	  	V1HM677	  	Monitor V1HM677

 Novartis Korea Ltd 
  

							
	 No.
	  	Asset	  	 SNo
	  	 Asset description

	1.	  	13102612	  	0	  	HP Laserjet Enterprise 500 Color M551dn Printer
	2.	  	16100530	  	0	  	Roto-Shake Genie Shaker, 230V-Vaccines BU
	3.	  	16100531	  	0	  	Particles Size Analyzer machine ( Vaccines BU)
	4.	  	16100544	  	0	  	Details

 Part 2 : 

Owned Information Technology 
 Zhe Jiang
Tianyuan Bio-Pharmaceuticals Co., Ltd 
  

							
	 No.
	  	Asset	  	 SNo
	  	 Asset description

	1.	  	1401020066	  	

	  	Lenovo Desktop
	2.	  	1401020087	  	E5200/1G/DVD	  	Desktop
	3.	  	1401020089	  		  	Computer
	4.	  	1401020090	  		  	Computer
	5.	  	1401020094	  		  	Computer
	6.	  	1401020095	  	HP 1215	  	Color Laser Printer
	7.	  	1401020100	  		  	Computer
	8.	  	1401020106	  		  	Computer
	9.	  	1401020109	  	E8400	  	Computer
	10.	  	1401020110	  		  	Desktop
	11.	  	1401020111	  	

	  	Desktop
	12.	  	1401020112	  	

	  	Desktop
	13.	  	1401020113	  	T410 2537E85	  	Laptop
	14.	  	1401020115	  	

	  	Desktop
	15.	  	1401020116	  	T410 2537E85	  	Laptop
	16.	  	1401020117	  	T420 T4102537E85	  	Laptop

  
 261 

							
	17.	  	1401020121	  	T410	  	Computer
	18.	  	1401020122	  	M58P 6137E64	  	Desktop
	19.	  	1401020123	  	M58P 6137E64	  	Desktop
	20.	  	1401020124	  	M58P 6137E64	  	Desktop
	21.	  	1401020125	  	M58P 6137E64	  	Desktop
	22.	  	1401020126	  	M58P 6137E64	  	Desktop
	23.	  	1401020127	  	M58P 6137E64	  	Desktop
	24.	  	1401020128	  	M58P 6137E64	  	Desktop
	25.	  	1401020129	  	M58P 6137E64	  	Desktop
	26.	  	1401020130	  	58P 6137E64	  	Desktop
	27.	  	1401020131	  	M58P 6137E64	  	Desktop
	28.	  	1401020132	  	M58P 6137E64	  	Desktop
	29.	  	1401020133	  	M58P 6137E64	  	Desktop
	30.	  	1401020134	  	T410 2537E85	  	Laptop
	31.	  	1401020135	  	T410 2537E85	  	Laptop
	32.	  	1401020136	  	T410 2537E85	  	Laptop
	33.	  	1401020137	  	T410 2537E85	  	Laptop
	34.	  	1401020138	  	T410 2537E85	  	Laptop
	35.	  	1401020140	  	T410 2537E85	  	Laptop
	36.	  	1401020141	  	

	  	Computer
	37.	  	1401020142	  	HP1213	  	Printer
	38.	  	1401020143	  	16906DN	  	Printer
	39.	  	1401020144	  	1606D	  	Printer
	40.	  	1401020186	  	

	  	Laptop
	41.	  	1401020187	  	

	  	Laptop
	42.	  	1401020188	  	

	  	Laptop
	43.	  	1401020189	  	

	  	Copy machine
	44.	  	1401020190	  	HP 5035X	  	Copy machine
	45.	  	1401020191	  	HP 1606DN	  	Laser printer
	46.	  	1401020193	  	

	  	Laptop
	47.	  	1401020194	  	

	  	Laptop
	48.	  	1401020195	  	ASA5510-SEC-BUN-K9	  	Firewall
	49.	  	1401020196	  	M1536DNF	  	multi-function printer
	50.	  	1401020197	  	M1536DNF	  	multi-function printer
	51.	  	1401020198	  	

	  	Laptop
	52.	  	1401020200	  	

	  	Laptop
	53.	  	1401020203	  	

	  	Desktop
	54.	  	1401020204	  	

	  	Desktop
	55.	  	1401020205	  	

	  	Desktop
	56.	  	1401020206	  	

	  	Desktop
	57.	  	1401020207	  	

	  	Laptop
	58.	  	1401020208	  	

	  	Laptop
	59.	  	1401020209	  	

	  	Laptop
	60.	  	1401020210	  	

	  	Laptop
	61.	  	1401020212	  	

	  	Laptop
	62.	  	1401020213	  	HP E5620	  	Server
	63.	  	1401020214	  	

	  	Desktop
	64.	  	1401020216	  	

	  	Laptop

  
 262 

							
	65.	  	1401020217	  	

	  	Laptop
	66.	  	1401020218	  	SBXN-100-1	  	Firewall
	67.	  	1401020219	  	

	  	docking station
	68.	  	1401020220	  	WS-C2960G-8TC-L	  	Check Point
	69.	  	1401020221	  	M6100T	  	Desktop
	70.	  	1401020222	  	M6100T	  	Desktop
	71.	  	1401020223	  	

	  	Desktop
	72.	  	1401020224	  	

	  	Laptop
	73.	  	1401020225	  		  	Bar code printer
	74.	  	1401020226	  	M58P	  	Desktop
	75.	  	1401020227	  	M58P	  	Desktop
	76.	  	1401020228	  	M58P	  	Desktop
	77.	  	1401020229	  	M58P	  	Desktop
	78.	  	1401020230	  	M58P	  	Desktop
	79.	  	1401020231	  	M58P	  	Desktop
	80.	  	1401020232	  	M58P	  	Desktop
	81.	  	1401020233	  	M58P	  	Desktop
	82.	  	1401020234	  	M58P	  	Desktop
	83.	  	1401020235	  	M58P	  	Desktop
	84.	  	1401020236	  	M58P	  	Desktop
	85.	  	1401020237	  	M58P	  	Desktop
	86.	  	1401020238	  	M58P	  	Desktop
	87.	  	1401020239	  	M58P	  	Desktop
	88.	  	1401020240	  	M58P	  	Desktop
	89.	  	1401020241	  	M58P	  	Desktop
	90.	  	1401020242	  	M58P	  	Desktop
	91.	  	1401020243	  	M58P	  	Desktop
	92.	  	1401020244	  	M58P	  	Desktop
	93.	  	1401020245	  	M58P	  	Desktop
	94.	  	1401020246	  	M58P	  	Desktop
	95.	  	1401020247	  	M58P	  	Desktop
	96.	  	1401020248	  	M58P	  	Desktop
	97.	  	1401020249	  	M6100T M58P	  	Desktop
	98.	  	1401020250	  	M58P	  	Desktop
	99.	  	1401020251	  	T410 T420 4236GF7	  	Laptop
	100.	  	1401020252	  	

	  	Laptop
	101.	  	1401020253	  	

	  	Laptop
	102.	  	1401020254	  	

	  	Laptop
	103.	  	1401020255	  	

	  	Laptop
	104.	  	1401020256	  	

	  	Laptop
	105.	  	1401020257	  	

	  	Laptop
	106.	  	1401020258	  	

	  	Laptop
	107.	  	1401020259	  	

	  	Laptop
	108.	  	1401020260	  	

	  	Laptop
	109.	  	1401020261	  	

	  	Laptop
	110.	  	1401020262	  	

	  	Laptop
	111.	  	1401020263	  	

	  	Laptop
	112.	  	1401020264	  	

	  	Laptop

  
 263 

							
	113.	  	1401020265	  	

	  	Laptop
	114.	  	1401020	  	

	  	Laptop
	115.	  	1401020267	  	X220 T410 2537E85	  	Laptop
	116.	  	1401020268	  	

	  	Laptop
	117.	  	1401020270	  	WS-C2960-48TT-L	  	Cisco Switcher
	118.	  	1401020271	  	HP 1606DN	  	Printer
	119.	  	1401020272	  	HP 1606DN	  	Printer
	120.	  	1401020273	  	TEC B-SA4TP	  	Printer
	121.	  	1401020275	  	HP M1213NF HP M1213NF	  	Printer
	122.	  	1401020276	  	M6100T	  	Desktop
	123.	  	1401020277	  	M6100T	  	Desktop
	124.	  	1401020278	  	M6100T	  	Desktop
	125.	  	1401020279	  	M6100T	  	Desktop
	126.	  	1401020280	  	M6100T	  	Desktop
	127.	  	1401020281	  	HP E5620	  	Server
	128.	  	1401020282	  	HP E5620	  	Server
	129.	  	1401020283	  	HP E5620	  	Server
	130.	  	1401020284	  	HP-E5620	  	Server
	131.	  	1401020285	  	HP-E5620	  	Server
	132.	  	1401020287	  	

	  	Laptop
	133.	  	1401020289	  	

	  	Laptop
	134.	  	1401020290	  	M6100T	  	Desktop
	135.	  	1401020291	  	

	  	Desktop
	136.	  	1401020292	  	M6100T	  	Desktop
	137.	  	1401020293	  	M6100T	  	Desktop
	138.	  	1401020294	  	M6100T	  	Desktop
	139.	  	1401020295	  	M6100T	  	Desktop
	140.	  	1401020296	  	M6100T	  	Desktop
	141.	  	1401020297	  	M6100T	  	Desktop
	142.	  	1401020298	  	M6100T	  	Desktop
	143.	  	1401020299	  	M6100T	  	Desktop
	144.	  	1401020300	  	M6100T	  	Desktop
	145.	  	1401020301	  		  	Blackberry
	146.	  	1401020302	  		  	Blackberry
	147.	  	1401020303	  	LS4278	  	Scanner
	148.	  	1401020304	  	LS4278	  	Scanner
	149.	  	1401020305	  	PT-2730	  	Label printer
	150.	  	1401020306	  	M6100T	  	Desktop
	151.	  	1401020307	  	M6100T	  	Desktop
	152.	  	1401020308	  	HP16060DN	  	Printer
	153.	  	1401020309	  	HP 1213	  	Printer
	154.	  	1401020310	  	HP CM1415	  	Printer
	155.	  	1401020312	  		  	Laptop
	156.	  	1401020313	  		  	Laptop
	157.	  	1401020314	  		  	Laptop
	158.	  	1401020315	  		  	Laptop
	159.	  	1401020316	  		  	Laptop
	160.	  	1401020317	  		  	Desktop

  
 264 

							
	161.	  	1401020318	  		  	Desktop
	162.	  	1401020319	  		  	Desktop
	163.	  	1401020320	  		  	Desktop
	164.	  	1401020321	  		  	Desktop
	165.	  	1401020322	  		  	Desktop
	166.	  	1401020323	  		  	Desktop
	167.	  	1401020324	  		  	Printer
	168.	  	1401020325	  		  	Desktop
	169.	  	1401020326	  		  	Desktop
	170.	  	1401020327	  		  	Desktop
	171.	  	1401020328	  		  	Desktop
	172.	  	1401020329	  		  	Desktop
	173.	  	1401020330	  		  	Desktop
	174.	  	1401020331	  		  	Laptop
	175.	  	1401020332	  		  	Laptop
	176.	  	1401020333	  		  	Laptop
	177.	  	1401020336	  	ZM600(203DPI)	  	Zebra Printer
	178.	  	1401020337	  	ZM600(203DPI)	  	Zebra Printer
	179.	  	1401020338	  	ZM600(203DPI)	  	Zebra Printer
	180.	  	1401020339	  	M6100T	  	Desktop M6100T
	181.	  	1401020340	  	M6100T	  	Desktop M6100T
	182.	  	1401020341	  	M6100T	  	Desktop M6100T
	183.	  	1401020342	  	M6100T	  	Desktop M6100T
	184.	  	1401020343	  	M6100T	  	Desktop M6100T
	185.	  	1401020345	  	HP4525DN	  	HP-4525DN
	186.	  	1401020346	  	HP 1606CN	  	HP Printer 1606DN
	187.	  	1401020348	  	HP1606DN	  	HP Printer 1606DN
	188.	  	1401020349	  	M6100T	  	Desktop M6100T
	189.	  	1401020350	  	HP1606DN	  	HP Printer 1606DN
	190.	  	1401020351	  	M6100T	  	Desktop M6100T
	191.	  	1401020354	  	USB-P25	  	Printer USB-P25
	192.	  	1401020355	  	USB-P25	  	Printer USB-P25
	193.	  	1401020356	  	USB-P25	  	Printer USB-P25
	194.	  	1401020357	  	USB-P25	  	Printer USB-P25
	195.	  	1401020358	  	USB-P25	  	Printer USB-P25
	196.	  	1401020359	  	RS-P26	  	Printer RS-P26
	197.	  	1401020360	  	RS-P26	  	Printer RS-P26
	198.	  	1401020361	  	RS-P26	  	Printer RS-P26
	199.	  	1401020362	  	M6100T	  	Desktop M6100T
	200.	  	1401020363	  	HPM1213NF	  	HP Printer
	201.	  	1401020364	  	HP CP1025	  	HP color printer
	202.	  	1401020365	  	PT-2730	  	Label printer
	203.	  	1401020366	  	PT-2730	  	Label printer
	204.	  	1401020367	  		  	Screen monitor X220
	205.	  	1401020368	  	HP M1213NF	  	HP printer
	206.	  	1401020370	  	X220	  	Laptop X220
	207.	  	1401020372	  	M6100T	  	Desktop M6100T
	208.	  	1401020373	  	7034 M6100T	  	Desktop M6100T

  
 265 

							
	209.	  	1401020374	  	M6100T	  	Desktop M6100T
	210.	  	1401020375	  	M6100T	  	Desktop M6100T
	211.	  	1401020376	  	HP M1213NF	  	HP printer
	212.	  	1401020377	  	HP M1213NF	  	HP printer
	213.	  	1401020378	  	photo ex3	  	Ink Jet printer
	214.	  	1401020379	  	HP M1415NF HP M1213NF	  	Color Printer
	215.	  	1401020380	  	HP M1213NF	  	HP printer
	216.	  	1401020381	  	LQ-690K	  	Dot printer
	217.	  	1401020383	  	T420	  	Laptop
	218.	  	1401020384	  	T420	  	Laptop
	219.	  	1401020387	  	M6100T	  	Lenovo Desktop
	220.	  	1401020388	  	M6100T	  	Lenovo Desktop
	221.	  	1401020389	  	M6100T	  	Lenovo Desktop
	222.	  	1401020390	  	M6100T	  	Lenovo Desktop
	223.	  	1401020391	  	M6100T	  	Lenovo Desktop
	224.	  	1401020393	  	X220	  	Laptop
	225.	  	1401020394	  	T420	  	Laptop
	226.	  	1401020395	  	T420	  	Laptop
	227.	  	1401020396	  	T420	  	Laptop
	228.	  	1401020397	  	T420	  	Laptop
	229.	  	1401020398	  	T420	  	Laptop
	230.	  	1401020400	  	T420	  	Laptop
	231.	  	1401020401	  	T420	  	Laptop
	232.	  	1401020402	  	T420	  	Laptop
	233.	  	1401020403	  	T420	  	Laptop
	234.	  	1401020404	  	T420	  	Laptop
	235.	  	1401020405	  	T420	  	Laptop
	236.	  	1401020406	  	T420	  	Laptop
	237.	  	1401020407	  	T420	  	Laptop
	238.	  	1401020408	  	T420	  	Laptop
	239.	  	1401020409	  	T420	  	Laptop
	240.	  	1401020410	  	T420	  	Laptop
	241.	  	1401020411	  	T420	  	Laptop
	242.	  	1401020413	  	T420	  	Laptop
	243.	  	1401020439	  	F558	  	Lenovo Desktop
	244.	  	1401020440	  	pt-2730	  	Label printer
	245.	  	1401020441	  	pt-2730	  	Label printer
	246.	  	1401020442	  	pt-2730	  	Label printer
	247.	  	1401020444	  	ZM600 (200DPI)	  	Zebra Bar Code printer
	248.	  	1401020445	  	ZM600 (200DPI)	  	Zebra Bar Code printer
	249.	  	1401020446	  	ZM600 (200DPI)	  	Zebra Bar Code printer
	250.	  	1401010008	  	WS-C3750X-24S-S SN:FDO1613Z00R	  	Cisco Switcher
	251.	  	1401010009	  	WS-C3750X-24S-S SN:FDO1613Z03W	  	Cisco Switcher
	252.	  	1401010010	  	WS-C3750X-12S-S SN:FDO1612Z1PJ	  	Cisco Switcher
	253.	  	1401010011	  	WS-C3750X-12S-S SN:FDO1612Z1PC	  	Cisco Switcher
	254.	  	1401010012	  	WS-C2960S-24TS-S SN:FOC1611Z1MP	  	Cisco Switcher
	255.	  	1401010013	  	WS-C2960S-24TS-S SN:FOC1611X2A6	  	Cisco Switcher
	256.	  	1401010014	  	WS-C2960S-24TS-S SN:FOC1611X29D	  	Cisco Switcher

  
 267 

							
	257.	  	1401010015	  	WS-C2960S-24TS-S SN:FOC1611X2A3	  	Cisco Switcher
	258.	  	1401010016	  	WS-C2960S-24TS-S SN:FOC1611Y180	  	Cisco Switcher
	259.	  	1401010017	  	WS-C2960S-48TS-S SN:FOC1612Y18G	  	Cisco Switcher
	260.	  	1401010018	  	WS-C2960S-48TS-S SN:FOC1612Y17Q	  	Cisco Switcher
	261.	  	1401010019	  	WS-C2960S-48TS-S SN:FOC1612Y18B	  	Cisco Switcher
	262.	  	1401010020	  	WS-C2960S-48LPS-L SN:FOC1611W0YP	  	Cisco Switcher
	263.	  	1401010021	  	WS-C2960S-48LPS-L SN:FOC1611W101	  	Cisco Switcher
	264.	  	1401010022	  	WS-C2960S-48LPS-L SN:FOC1611W0YH	  	Cisco Switcher
	265.	  	1401010023	  	AIR-CT5508-25-K9 SN:FCW1607L0FX	  	Cisco wireless internet equipment
	266.	  	1401020447	  	7034/PBHFEBP	  	Lenovo Desktop
	267.	  	1401020448	  	7034/PBHFEBN	  	Lenovo Desktop
	268.	  	1401020449	  	7034/PBCEPLV	  	Lenovo Desktop
	269.	  	1401020458	  	T420/P16Y541	  	Laptop T420
	270.	  	1401020459	  	T420/P16Y540	  	Laptop T420
	271.	  	1401020466	  	V8-AY819	  	Screen monitor 22”
	272.	  	1401020467	  	V8-AY819	  	Screen monitor 22”
	273.	  	1401020469	  	S24B240BL	  	Samsung screen monitor
	274.	  	1401020470	  	CM1415FN	  	HP Printer
	275.	  	1401020471	  	CM1415FN	  	HP Printer
	276.	  	1401020473	  	7034/PBNLNRN	  	Lenovo Desktop
	277.	  	1401020474	  	7034/PBNLNRL	  	Lenovo Desktop
	278.	  	1401020475	  	7034/PBNLPAK	  	Lenovo Desktop
	279.	  	1401020476	  	7034/PBNLNZP	  	Lenovo Desktop
	280.	  	1401020477	  	7034/PBNLPAL	  	Lenovo Desktop
	281.	  	1401020483	  	T430/PBYKKDF	  	Laptop T430
	282.	  	1401020484	  	T430/PBYKKDP	  	Laptop T430
	283.	  	1401020486	  	T430/PBYKKDZ	  	Laptop T430
	284.	  	1401020492	  	M92P/PBXNMTZ	  	Lenovo Desktop
	285.	  	1401020493	  	M92P/PBXNMVA	  	Lenovo Desktop
	286.	  	1401020494	  	CM1415fn	  	HP Printer
	287.	  	1401020496	  	HP1213	  	HP Printer
	288.	  	1401020497	  	HP1213	  	HP Printer
	289.	  	1401020498	  	HP1213	  	HP Printer
	290.	  	1401020499	  	

	  	HP Printer
	291.	  	1401020500	  	M276N	  	HP color printer
	292.	  	1401020502	  	PB86KBX	  	Lenovo Laptop T430
	293.	  	1401020503	  	PB644DH	  	Lenovo Desktop
	294.	  	1401020504	  	P886KBN	  	Lenovo Laptop T430
	295.	  	1401020505	  	LQ300K Epson/G89H714213	  	Dot printer
	296.	  	1401020506	  	HP1213	  	HP Printer
	297.	  	1401020507	  	HP1213	  	HP Printer
	298.	  	1401020508	  	HP1213	  	HP Printer
	299.	  	1401020509	  	HP1213	  	HP Printer
	300.	  	1401020520	  	TEC B-SA4TP	  	label printer
	301.	  	1401020521	  	LS4278	  	Scanner
	302.	  	1401020522	  	LS4278	  	Scanner
	303.	  	1401020523	  	PB1XT7Y	  	Laptop T430
	304.	  	1401020524	  	PB1XT7Z	  	Laptop T430

  
 268 

							
	305.	  	1401020525	  	PB2PY6H	  	Laptop T430
	306.	  	1401020529	  	R9YWE6K	  	Laptop X230
	307.	  	1401020530	  	R9YWE71	  	Laptop X230
	308.	  	1401020531	  	R9YWE89	  	Laptop X230
	309.	  	1401020532	  	PB5HHN7	  	Laptop T430
	310.	  	1401020533	  	PB5HHR0	  	Laptop T430
	311.	  	1401020534	  	PB5HHN9	  	Laptop T430
	312.	  	1401020535	  	PB5HHR2	  	Laptop T430
	313.	  	1401020536	  	PB5HHP7	  	Laptop T430
	314.	  	1401020538	  	

	  	Returned goods destruction monitor system
	315.	  	1401020539	  	S/N PK00LG5	  	Laptop X230
	316.	  	1401020540	  	S/N PK00LFG	  	Laptop X230
	317.	  	1401020541	  	S/N PK00LFP	  	Laptop X230
	318.	  	1401020542	  	S/N PK019WG	  	Laptop X230
	319.	  	1401020543	  	S/N PK00LG7	  	Laptop X230
	320.	  	1401020544	  	S/N PK019X8	  	Laptop X230
	321.	  	1401020545	  	S/N PK00LG3	  	Laptop X230
	322.	  	1401020546	  	TYPE 2325C58 S/N PK1GR28	  	Laptop X230
	323.	  	1401020547	  	LT2252PW	  	Screen monitor
	324.	  	1401010024	  		  	tape library
	325.	  	1401020548	  	IPhone 5S	  	iPhone
	326.	  	1401020549	  	IPhone 5S	  	iPhone
	327.	  	1401020550	  	IPhone 5S	  	iPhone
	328.	  	1401020551	  	IPhone 5S	  	iPhone
	329.	  	1401020552	  	

	  	Screen monitor
	330.	  	1401020553	  	

	  	Screen monitor
	331.	  	1401020554	  		  	Screen monitor X230
	332.	  	1401020555	  		  	Screen monitor X230
	333.	  	1401020556	  		  	Screen monitor X230
	334.	  	1401020557	  		  	Screen monitor X230
	335.	  	1401020558	  		  	Screen monitor X230
	336.	  	1401020559	  		  	iPhone 5S
	337.	  	1401020560	  		  	iPhone 5S
	338.	  	1401020561	  	PBPV14L/MTM3228-AB2	  	Lenovo Desktop
	339.	  	1401020562	  	PB00XCDZ / 20AWS0H11J	  	Laptop T440

 Novartis Vaccines and Diagnostics GmbH 
  

							
	 No.
	  	 Asset
	  	 SNo
	  	 Asset description

	1.	  	4691	  	0	  	APC Smart-USV 1000 VA Line-Interactive
	2.	  	4692	  	0	  	APC Smart-USV 1000 VA Line-Interactive
	3.	  	7071	  	0	  	Klimagerät für Serverraum
	4.	  	7072	  	0	  	Klimagerät für Serverraum
	5.	  	9940	  	0	  	APC USV (Unterbrechungsfreie Stromversorger)
	6.	  	9941	  	0	  	HP Console Switch 8 Port
	7.	  	10330	  	0	  	APC USV 3000VA mit 8-Port-Erweiterung
	8.	  	10331	  	0	  	APC USV 3000VA mit 8-Port-Erweiterung
	9.	  	11281	  	0	  	Klimaanlage f.Serverraum 602

  
 269 

							
	10.	  	12682	  	0	  	HP J 1474 A 8Port Konsolen Switch
	11.	  	13023	  	0	  	HP J 1474 A 8Port Konsolen Switch
	12.	  	13255	  	0	  	HP J1474A 8 Port Konsolen Switch
	13.	  	13508	  	0	  	Beamer LG XG324 m. Deckenhalterung / Konferenzraum
	14.	  	15836	  	0	  	Server / Netzwerkschrank, H1
	15.	  	15837	  	0	  	Server / Netzwerkschrank, H1
	16.	  	15838	  	0	  	Server / Netzwerkschrank, H1
	17.	  	15900	  	0	  	12 MS Windows Standard 2003 Server englisch Lizenz
	18.	  	16657	  	0	  	HP Console Switch Box 8-Port, CAT 5, H1, R. 209
	19.	  	17720	  	0	  	Mc Data Sphereon 4500 Fabric Switch
	20.	  	17721	  	0	  	Mc Data Sphereon 4500 Fabric Switch
	21.	  	17811	  	0	  	Netzwerk- / Server-Schrank, R. 213
	22.	  	17812	  	0	  	USV APC 3000 mit 8 Port Erweiterung, R. 213
	23.	  	17813	  	0	  	USV APC 3000 m. 8 Port Erweiterung, R. 213
	24.	  	18413	  	0	  	Server / Netzwerschrank, H1 R. 141.1
	25.	  	18958	  	0	  	USV APC Smart 3000VA
	26.	  	18969	  	0	  	HP Console Switch 336045-B21
	27.	  	18970	  	0	  	Mc Data Switch (Erweiterung)
	28.	  	20667	  	0	  	APC Environmental Managment System
	29.	  	20668	  	0	  	APC Environmental Managment System
	30.	  	20669	  	0	  	APC Environmental Managment System
	31.	  	21872	  	0	  	Shavlik NetChk Protect 50 Seats
	32.	  	22526	  	0	  	3 Datenschränke f.M7
	33.	  	24515	  	0	  	Rittal Netzwerkschrank, H1 Keller
	34.	  	24516	  	0	  	Rittal Netzwerkschrank, H1 Keller
	35.	  	25025	  	0	  	2 Datenschränke für H1 Rack
	36.	  	25059	  	0	  	Rack Console Belkin OmniView 17 Zoll
	37.	  	25060	  	0	  	Rack Console Belkin OmniView 17 Zoll
	38.	  	25937	  	0	  	Split-Klimagerät RKL 470 mobil
	39.	  	27022	  	0	  	Verkleidung Rechnerraum H1
	40.	  	27023	  	0	  	Netzwerkschrank Server Rittal TS8
	41.	  	27024	  	0	  	Netzwerkschrank Server Rittal TS8
	42.	  	27025	  	0	  	Netzwerkschrank Server Rittal TS8
	43.	  	29868	  	0	  	Mobiles Klimagerät Airwell Aelia 10 f. Serverraum
	44.	  	32087	  	0	  	Data Center Infrastructure
	45.	  	32088	  	0	  	Netzwerkerweiterung HP Engine Business Small Data
	46.	  	36311	  	0	  	Avocent KVM Konsole N310 DC
	47.	  	41214	  	0	  	Erweiterung Datenschrank
	48.	  	4258	  	0	  	HP-LASERJET 5 / Fr. Monika Oberlies
	49.	  	4319	  	0	  	HP Laser Jet 4 Plus
	50.	  	4436	  	0	  	HP Tintenstrahldrucker HP-C3540A
	51.	  	4633	  	0	  	HP-C3166A Laserjet 5 SI
	52.	  	4645	  	0	  	HP Laserjet 5
	53.	  	4646	  	0	  	HP Laserjet 5
	54.	  	4647	  	0	  	HP Laserjet 5
	55.	  	4649	  	0	  	HP Laserjet 5
	56.	  	4651	  	0	  	HP Laserjet 5
	57.	  	4652	  	0	  	HP Laserjet 5

  
 270 

							
	58.	  	4653	  	0	  	HP Laserjet 5
	59.	  	4689	  	0	  	HP Laserjet 5L
	60.	  	4698	  	0	  	HP LaserJet 5M PS
	61.	  	4713	  	0	  	HP Laserjet 5, Greinert/Schnabel
	62.	  	4913	  	0	  	HP Laserjet / R.Lemke
	63.	  	4994	  	0	  	HP LaserJet
	64.	  	5095	  	0	  	HP Laserjet 5
	65.	  	5267	  	0	  	HP Scanjet 6100
	66.	  	5270	  	0	  	HP Scanjet 6100 C
	67.	  	5271	  	0	  	HP Scanjet 6100 C
	68.	  	6071	  	0	  	HP Laserjet 6P, R. 536 Hr. v. Tesmar
	69.	  	8790	  	0	  	Laserscanner 5400 / Hr.Richter (LIMS-Projekt)
	70.	  	11387	  	0	  	HP Laser Jet 3P
	71.	  	12742	  	0	  	Mobiler Laserscanner F7400 / Hr. Merle
	72.	  	12838	  	0	  	HP Color LaserJet 8550N
	73.	  	14381	  	0	  	Beamer NEC LT157 (Datenprojektor)
	74.	  	15950	  	0	  	Softwareerstellung für Probenverteilung,
	75.	  	18176	  	0	  	Mobiler Laserscanner F7400, 8 MB
	76.	  	23485	  	0	  	HP AO Designjet C7770B R.715
	77.	  	40389	  	0	  	Design & Engineering Services 1
	78.	  	40392	  	0	  	Design & Engineering Services 2
	79.	  	40395	  	0	  	Design & Engineering Services 3
	80.	  	42094	  	0	  	Design & Engineering Services 4
	81.	  	42869	  	0	  	Design & Engineering Services 5
	82.	  	43044	  	0	  	Design & Engineering Services 6
	83.	  	43199	  	0	  	Design & Engineering Services 7
	84.	  	43882	  	0	  	Design & Engineering Services 8
	85.	  	44279	  	0	  	Design & Engineering Services 1
	86.	  	44282	  	0	  	Design & Engineering Services 2
	87.	  	44285	  	0	  	Design & Engineering Services 3
	88.	  	10328	  	0	  	HP Racksystem/E41 U mit Front-u.Hintertür
	89.	  	10329	  	0	  	HP Racksystem/E41 U mit Front-u.Hintertür
	90.	  	10332	  	0	  	HP Rackmount Kit für HP Flachbildschirm + Tastatur
	91.	  	11846	  	0	  	Server Switching Module Gigabit/Anbindung Forum
	92.	  	12846	  	0	  	Klimagerät für Fenstereinbau
	93.	  	13081	  	0	  	Cisco VPN 3005 Concentrator
	94.	  	14151	  	0	  	LAN Management 2.1
	95.	  	14333	  	0	  	Netzwerkkomponente bestehend aus: Catalyst 4506
	96.	  	14334	  	0	  	Netzwerkkomponente bestehend aus: Catalyst 4506
	97.	  	14335	  	0	  	Netzwerkkomponente bestehend aus: Catalyst 4506
	98.	  	14690	  	0	  	Redundant Power Suppla f.Cisco Catalyst
	99.	  	15077	  	0	  	PIX-Firewall 525UR+Zubehör
	100.	  	15127	  	0	  	PIX-Firewall Failover +Zubehör
	101.	  	15652	  	0	  	Pix 506 E-BUN-K9 (Fireball), R. 208
	102.	  	15653	  	0	  	Pix 506 E-BUN-K9, (Fireball; Netzwerkkomp.)
	103.	  	25938	  	0	  	Switch für WAN Anbindung
	104.	  	25939	  	0	  	Switch für WAN Anbindung
	105.	  	26976	  	0	  	Cicso 4400 WLC 4402

  
 271 

							
	106.	  	26977	  	0	  	LAN Edge Switch 2960-48TC
	107.	  	26978	  	0	  	LAN Edge Switch 2960-48TC
	108.	  	26979	  	0	  	LAN Edge Switch 2960-48TC
	109.	  	26980	  	0	  	LAN Edge Switch 2960-48TC
	110.	  	26981	  	0	  	LAN Edge Switch 2960-48TC
	111.	  	26982	  	0	  	LAN Edge Switch 2960-48TC
	112.	  	26983	  	0	  	LAN Edge Switch 2960-48TC
	113.	  	26984	  	0	  	LAN Edge Switch 2960-48TC
	114.	  	26985	  	0	  	LAN Edge Switch 2960-48TC
	115.	  	26986	  	0	  	LAN Edge Switch 2960-48TC
	116.	  	26987	  	0	  	LAN Edge Switch 2960-24TC
	117.	  	26989	  	0	  	LAN Edge Switch 2960-24TC
	118.	  	26990	  	0	  	LAN Edge Switch 2960-24TC
	119.	  	26991	  	0	  	LAN Edge Switch 2960-24TC
	120.	  	26992	  	0	  	LAN Edge Switch 2960-24TC
	121.	  	26993	  	0	  	LAN Edge Switch 2960-24TC
	122.	  	26994	  	0	  	LAN Edge Switch 2960-24TC
	123.	  	26995	  	0	  	LAN Edge Switch 2960-24TC
	124.	  	26996	  	0	  	LAN Edge Switch 2960-24TC
	125.	  	26997	  	0	  	LAN Edge Switch 2960-24TC
	126.	  	26998	  	0	  	LAN Edge Switch 2960-24TC
	127.	  	27031	  	0	  	Cisco WS-C2960G-48TC-L
	128.	  	30472	  	0	  	Cisco Catalyst 3750
	129.	  	30473	  	0	  	Cisco Catalyst 3750
	130.	  	30474	  	0	  	Cisco Catalyst 3750
	131.	  	30475	  	0	  	Cisco Catalyst 3750
	132.	  	30476	  	0	  	Cisco Catalyst 3750
	133.	  	30477	  	0	  	Cisco Catalyst 3750
	134.	  	30478	  	0	  	Cisco Catalyst 3750
	135.	  	30479	  	0	  	Cisco Catalyst 3750
	136.	  	30480	  	0	  	Cisco Catalyst 3750
	137.	  	30481	  	0	  	Cisco Catalyst 3750
	138.	  	32089	  	0	  	InNominate Firewall MGuard smart
	139.	  	37382	  	0	  	Video-Konferenzsystem Forum
	140.	  	37383	  	0	  	Video-Konferenzsystem H1
	141.	  	24946	  	0	  	Beamer IBM / LeNovo M500
	142.	  	44962	  	0	  	Firewall AIR CT55808-250-K9
	143.	  	39923	  	0	  	GWG-130030 2012 (150-1000E)
	144.	  	42773	  	0	  	Erweiterung Glasfasernetz N100,N200,N310
	145.	  	44446	  	0	  	Cooling System
	146.	  	44449	  	0	  	Server Racks
	147.	  	44452	  	0	  	Server Racks
	148.	  	44455	  	0	  	USV
	149.	  	44458	  	0	  	Network
	150.	  	44906	  	0	  	W-Lan Access Point
	151.	  	44940	  	0	  	Elektroverteilung Handheld Projekt
	152.	  	44950	  	0	  	Access Points Handheld Project
	153.	  	44960	  	0	  	Firewall ASA 5585-S10-K9

  
 272 

							
	154.	  	44961	  	0	  	Firewall ASA 5585-S10-K9
	155.	  	44963	  	0	  	Cisco Port Switch Handheld Projekt
	156.	  	44964	  	0	  	Cisco Port Switch Handheld Projekt
	157.	  	44965	  	0	  	Cisco Port Switch Handheld Projekt
	158.	  	44966	  	0	  	Cisco Port Switch Handheld Projekt
	159.	  	44967	  	0	  	Cisco Port Switch Handheld Projekt
	160.	  	44968	  	0	  	Cisco Port Switch Handheld Projekt
	161.	  	44969	  	0	  	Motorola MC75A0-HC Handheld
	162.	  	44970	  	0	  	Motorola MC75A0-HC Handheld
	163.	  	44971	  	0	  	Motorola MC75A0-HC Handheld
	164.	  	44972	  	0	  	Motorola MC75A0-HC Handheld
	165.	  	44973	  	0	  	Motorola MC75A0-HC Handheld
	166.	  	45046	  	0	  	Tablet PC Motion C5
	167.	  	45047	  	0	  	Tablet PC Motion C5
	168.	  	45048	  	0	  	Tablet PC Motion C5
	169.	  	45049	  	0	  	Tablet PC Motion C5
	170.	  	45050	  	0	  	Tablet PC Motion C5
	171.	  	45120	  	0	  	Zebra Drucker / Label Printer Handheld Projekt
	172.	  	45121	  	0	  	Zebra Drucker / Label Printer Handheld Projekt
	173.	  	45122	  	0	  	Zebra Drucker / Label Printer Handheld Projekt
	174.	  	45123	  	0	  	Zebra Drucker / Label Printer Handheld Projekt
	175.	  	45983	  	0	  	Network Environment
	176.	  	46430	  	0	  	HP compaq 6300 Mini Tower
	177.	  	46431	  	0	  	HP compaq 6300 Mini Tower
	178.	  	46432	  	0	  	HP compaq 6300 Mini Tower
	179.	  	46433	  	0	  	HP compaq 6300 Mini Tower
	180.	  	46434	  	0	  	HP compaq 6300 Mini Tower
	181.	  	46435	  	0	  	HP compaq 6300 Mini Tower
	182.	  	46436	  	0	  	HP compaq 6300 Mini Tower
	183.	  	46437	  	0	  	HP compaq 6300 Mini Tower
	184.	  	46438	  	0	  	HP compaq 6300 Mini Tower
	185.	  	46439	  	0	  	HP compaq 6300 Mini Tower
	186.	  	46440	  	0	  	HP compaq 6300 Mini Tower
	187.	  	46441	  	0	  	HP compaq 6300 Mini Tower
	188.	  	46442	  	0	  	HP compaq 6300 Mini Tower
	189.	  	46443	  	0	  	HP compaq 6300 Mini Tower
	190.	  	46444	  	0	  	HP compaq 6300 Mini Tower
	191.	  	46445	  	0	  	HP compaq 6300 Mini Tower
	192.	  	46446	  	0	  	HP compaq 6300 Mini Tower
	193.	  	46447	  	0	  	HP compaq 6300 Mini Tower
	194.	  	46448	  	0	  	HP compaq 6300 Mini Tower
	195.	  	46449	  	0	  	HP compaq 6300 Mini Tower
	196.	  	46450	  	0	  	HP compaq 6300 Mini Tower
	197.	  	46451	  	0	  	HP compaq 6300 Mini Tower
	198.	  	46452	  	0	  	HP compaq 6300 Mini Tower
	199.	  	46453	  	0	  	HP compaq 6300 Mini Tower
	200.	  	46454	  	0	  	HP compaq 6300 Mini Tower
	201.	  	46455	  	0	  	HP compaq 6300 Mini Tower

  
 273 

							
	202.	  	46456	  	0	  	HP compaq 6300 Mini Tower
	203.	  	46457	  	0	  	HP compaq 6300 Mini Tower
	204.	  	46458	  	0	  	HP compaq 6300 Mini Tower
	205.	  	46459	  	0	  	HP compaq 6300 Mini Tower
	206.	  	46460	  	0	  	HP compaq 6300 Mini Tower
	207.	  	46461	  	0	  	HP compaq 6300 Mini Tower
	208.	  	46462	  	0	  	HP compaq 6300 Mini Tower
	209.	  	46463	  	0	  	HP compaq 6300 Mini Tower
	210.	  	46464	  	0	  	HP compaq 6300 Mini Tower
	211.	  	17438	  	0	  	Telefonkonferenzanlage
	212.	  	19552	  	0	  	Microsoft Windows Server 2003 Enterprise
	213.	  	27313	  	0	  	Aktenvernichter 2503
	214.	  	30097	  	0	  	Networks
	215.	  	31050	  	0	  	Microsoft Roundtable 360 Grad Kamera
	216.	  	31051	  	0	  	Microsoft Roundtable 360 Grad Kamera
	217.	  	31538	  	0	  	Deckenbeamer Optima Ultra High Performance
	218.	  	31917	  	0	  	Barcodescanner Software
	219.	  	11412	  	0	  	DSB Supporter / Hr. Tesmar
	220.	  	20050	  	0	  	Polycom Soundstation2 f.R.516
	221.	  	25863	  	0	  	Beamer IBM LeNovo M50 Hr. v.Tesmar
	222.	  	39661	  	0	  	Cisco Switch 2960
	223.	  	26014	  	0	  	Symbol MC7090 Scanner
	224.	  	26420	  	0	  	Symbol MC7090 Scanner
	225.	  	38414	  	0	  	Datalogger Motorola MC75

 Chiron Behring Vaccines Private Limited 
  

							
	 No.
	  	 Asset
	  	 SNo
	  	 Asset description

	1.	  	2114	  	0	  	RAck Mount Eclosure - VALRACK make
	2.	  	2115	  	0	  	Router CISCO make 1750-2V with IP+Voice IOS SW
	3.	  	2116	  	0	  	WAN Comp.-CAB V.35 FC - Serial Cable DTE Male
	4.	  	2127	  	0	  	Fibre optic cabling for LAN Connection/Business Li
	5.	  	2128	  	2	  	FIREWALL Watchguard X500 MK MS Ex. Windows Server
	6.	  	2129	  	0	  	Fibre 6Core Cable/Patch Cord/GI Pipes for Lan/Busi
	7.	  	2130	  	0	  	IP Based VPN Connectivity with Huwaie Router/Lease
	8.	  	2130	  	1	  	E Port Voice Box Wellgate 3502 for Lease Line/Ank
	9.	  	2133	  	0	  	Firewall Cyberoam CR50iA UTM
	10.	  	2136	  	0	  	Passive LAN
	11.	  	2318	  	0	  	Data Networking System-LAN in Admin Buldg
	12.	  	2323	  	0	  	Data Networking System-LAN in Admin Buldg Extn
	13.	  	2328	  	0	  	D Link 802.119 Wireless Access Point DWL 3200AP
	14.	  	2571	  	0	  	Modem - 56 KBPS D-Link make
	15.	  	2573	  	0	  	Passive Comp.-AMP E-CAT 5 UTP Cable
	16.	  	2574	  	0	  	Passive Comp.-AMP - 24 Port Jack Panel
	17.	  	2575	  	0	  	Passive Comp.-AMP-Surface Mount Box & Info. Outlet
	18.	  	2576	  	0	  	Passive Comp.-AMP E-CAT -5 Mounting Chords 7 feet
	19.	  	2577	  	0	  	Modem ASM20 64KBPS with V.35 & G.703 Interfaces
	20.	  	2581	  	0	  	Domain Name Registration+10MB Space with on POP AC
	21.	  	2582	  	0	  	Active Components D Link mk/DEC-1024R 24Port/16Hub

  
 274 

							
	22.	  	2591	  	1	  	FIREWALL Watch Guard mk X500 MS Ex Windows Server
	23.	  	2591	  	4	  	Windows Backup Software VERITAS/Ex Windows Server
	24.	  	2514	  	0	  	Watch Guard firewall - HO
	25.	  	534	  	0	  	Computer/HP Brio/PIII 550MHZ/64MB/8.4GB/No 5-EggIn
	26.	  	534	  	1	  	SAMSUNG 15” TFT Monitor for Media Section Computer
	27.	  	535	  	0	  	Printer HP 810C/ No 5 - Egg Incubation
	28.	  	536	  	0	  	Printer Epson LQ-1070+ /No.6
	29.	  	537	  	0	  	Printer Epson Dot Matrix LX 300 80Column/No.6
	30.	  	538	  	0	  	HP Deskjet 5160 Inkjet Printer with USB Port/Inact
	31.	  	539	  	0	  	HP Deskjet 5160 Inkjet Printer with USB Port/Media
	32.	  	540	  	0	  	Printer Epson LX-300 80column DMP For CIP Syst/VP
	33.	  	541	  	0	  	Printer Epson LX-300 80column DMP For SIP System/
	34.	  	542	  	0	  	EPSON Dot Matrix Printer LX-300 for Media Autoclav
	35.	  	543	  	0	  	Computer IBM A50 Thinkcentre PIV/CD Writer/Digrajk
	36.	  	544	  	0	  	Computer IBM Thinkcentre A51 PIV/RPS
	37.	  	545	  	0	  	Laptop IBM Lenovo Notebook R52 PIV 40GB HDD/MYD
	38.	  	546	  	0	  	Labtop IBM Thinkpad R 52(1860-A42)/Nadkarni/Creati
	39.	  	547	  	0	  	Epson LX 300+ Printer & USB to Parallel Port/Virus
	40.	  	548	  	0	  	Printer Epson TMU 220 for pH Meter Eutech/Virus Pr
	41.	  	549	  	0	  	Printer Epson TMU 220 for pH Meter Eutech/Virus Pr
	42.	  	550	  	0	  	LAPTOP HP 520 Business Notbook with DVD RW
	43.	  	551	  	0	  	HP 520 Business Notebook
	44.	  	552	  	0	  	HP 520 Business Notebook
	45.	  	553	  	0	  	HP 520 Business Notebook-Snehal Patel
	46.	  	554	  	0	  	D-Link Access point for office in production area
	47.	  	555	  	0	  	Laptop - HP make - Salunke
	48.	  	556	  	0	  	Dell Desktop - Virus Office
	49.	  	557	  	0	  	Dell Desktop - Concentration.
	50.	  	558	  	0	  	Dell Desktop - Inashu
	51.	  	560	  	0	  	HP Laser Jet P1106 Printer-Concent
	52.	  	561	  	0	  	HP Laser Jet P1106 Printer-Enginrg
	53.	  	562	  	0	  	HP Laser Jet P1106 Printer-Vir.Prod
	54.	  	1341	  	1	  	SAMSUNG 15” TFT Monitor for Media Section Computer
	55.	  	2322	  	1	  	15” TFT Monitor for PC/NO.33/VPA
	56.	  	559	  	0	  	Old Inactivation SCADA-Softaware
	57.	  	846	  	0	  	UPS System 2.0KVA Tata Libert make 15minute backup
	58.	  	847	  	0	  	Computer/Compaq Despro SB/Cel566/64MB/10GB/No 21
	59.	  	848	  	0	  	Laptop/COMPAQ Armada M300/PII333/64MB/6.4GB/No 25
	60.	  	849	  	0	  	Computer -Siemens133MHZ/8MB RAM/2.1GB HDD/No.11
	61.	  	850	  	0	  	Printer Epson Dot Matrix LX 300 80Column/No.11
	62.	  	851	  	0	  	Tata Libert UPS Model PB3000 30Min Bkup For FD C
	63.	  	852	  	0	  	IBM Thinkcentre A30 PIV Computer For FD C/3yrs War
	64.	  	854	  	0	  	HP Deskjet Printer 5160 For FD C/Statart
	65.	  	855	  	0	  	Data Networking Cable D Link Cat 5 2Roll/Phase II
	66.	  	856	  	0	  	HP Inkjet Colour Printer For BMS For HVAC Phase II
	67.	  	858	  	0	  	Communication Devices for BMS For HVAC Phase II
	68.	  	859	  	0	  	Computer IBM Thinkcentre A51 PIV 15” TFT Modul/VAK
	69.	  	860	  	0	  	Computer IBM Thinkcentre A51 PIV/PDO

  
 275 

							
	70.	  	861	  	0	  	Computer IBM Thinkcentre A51 PIV/PDO
	71.	  	862	  	0	  	Epson Printer TM-U-220 for Mettler Balance/Filling
	72.	  	863	  	0	  	HP 520 Business Notebook - Prasad Oak
	73.	  	866	  	0	  	HP Laser jet P1020 Printer
	74.	  	853	  	0	  	MS Windows 2000 Professional Software for FD C
	75.	  	857	  	0	  	Graphical Visualisation Software of BMS/HVAC Ph-II
	76.	  	864	  	0	  	Prosess Visulisation software for freez dryer
	77.	  	864	  	1	  	Prosess Visulisation hardware for freez dryer
	78.	  	1044	  	0	  	Computer/HP Brio/Cel466/64MB/8.4GB/No 7
	79.	  	1045	  	0	  	Compaq IPAQ DeskPro PIII733/128MB/No.29
	80.	  	1046	  	0	  	Printer HP 670C /No.10
	81.	  	1047	  	0	  	Computer Compaq D220 & Intel PIV Processor/Packing
	82.	  	1047	  	1	  	15” TFT Monitor for PC For NDG
	83.	  	1048	  	0	  	EPSON Dot Matrix Printer LX-300 for Packing Automa
	84.	  	1049	  	0	  	Barcode/Label Printer Datamax W-8306 & Rewinder
	85.	  	1050	  	0	  	Laserjet colour Printer/HP/model 1020 for NDG/Pack
	86.	  	1051	  	0	  	Computer PIV IBM Think Centre Santosh Kaushal
	87.	  	1052	  	0	  	1 TB USB Hard Disk Drive
	88.	  	1053	  	0	  	Citizen Thermal Transfer Printer CLP 621
	89.	  	1054	  	0	  	2D Scanner packing
	90.	  	1055	  	0	  	Mini Laptop 10.1” Display Screen
	91.	  	1056	  	0	  	2D Barcode System for Pkg. Line
	92.	  	1056	  	1	  	Markem Imaje Printer - Packaging
	93.	  	1057	  	0	  	Dell Desktop - Vinod Patela
	94.	  	1058	  	0	  	Rack 14U with Accessories
	95.	  	1059	  	0	  	Server for 2D system (Window & Global)
	96.	  	1060	  	0	  	Deskjet Printer for packing section
	97.	  	1799	  	0	  	Printer HP DJ 670C/No.8
	98.	  	1800	  	0	  	UPS Supernova
	99.	  	1801	  	0	  	UPS SuperNova
	100.	  	1802	  	0	  	Printer HP 710C/No.20
	101.	  	1803	  	0	  	Printer HP 810C /No.3
	102.	  	1804	  	0	  	UPS Tata Libert make 2KVA
	103.	  	1805	  	0	  	Data Networking in New Bio-Analytics Building
	104.	  	1807	  	0	  	UPS Mod PB3000 Tata Libert 3KVA 1/2Hrs BKUP/Akshin
	105.	  	1808	  	0	  	UPS Mod PB3000 Tata Libert 3KVA 1/2Hrs BKUP/Akshin
	106.	  	1809	  	0	  	Computer Compaq DeskPro P4 1.6Ghz/128MB RAM/No.8
	107.	  	1810	  	0	  	HP Deskjet 5550 Printer /No.34
	108.	  	1811	  	0	  	Compaq DeskPro EVO 380mx PIV 1.8Ghz/128MBRAM/NO.34
	109.	  	1813	  	0	  	Port Print Server for Parellel Part Printer WEP Mk
	110.	  	1814	  	0	  	Computer PIV Compaq EVO D320m 1.9Ghz 40GB HDD/No37
	111.	  	1815	  	0	  	Computer Compaq PIV 1.9GHz K Chammy
	112.	  	1817	  	0	  	HP Deskjet 5160 Printer for MYD’s Office/Statart
	113.	  	1819	  	0	  	Computer IBM A50 Thinkcentre PIV & CD Writer/QC BM
	114.	  	1820	  	0	  	Computer IBM A50 Thinkcentre PIV & CD Writer/QC AH
	115.	  	1821	  	0	  	Computer IBM A50 Thinkcentre PIV & CD Writer/ELISA
	116.	  	1822	  	0	  	Computer IBM A50 Thinkcentre PIV & CD Writer/ELISA
	117.	  	1824	  	0	  	Computer IBM Thinkcentre A51 PIV & CD Writer/AJN

  
 276 

							
	118.	  	1825	  	0	  	Dotmatrix Printer/Epson Lx 300+ for QC/Creative
	119.	  	1826	  	0	  	DATAMAX E-4203 Label Barcode Printer for QC/Stalli
	120.	  	1827	  	0	  	LAN Cable D-Link Cat5 100mt/Switch/Cable Manager
	121.	  	1828	  	0	  	LAPTOP IBM ThinkPad R52 1860-A42 Kamlesh Thakkar
	122.	  	1829	  	0	  	LAPTOP IBM Thinkpad R52 Centrino P-M/Chaubal
	123.	  	1832	  	0	  	Computer HP Compaq DX2300 Desktop PIV/QC
	124.	  	1833	  	0	  	Printer HP K5300 Officejet Endotoxin Plate Read/QC
	125.	  	1834	  	0	  	Computer HP Compaq DX2280 w.o. Monitor
	126.	  	1835	  	0	  	HP K5300 Office Jet Printer - Particle Counter
	127.	  	1836	  	0	  	HP DX2480 Desktop & HP 1008 printer for GC
	128.	  	1837	  	0	  	CCTV Monitoring & Recording System for QC
	129.	  	1838	  	0	  	Desktop for UV microscope
	130.	  	1839	  	0	  	Dell Desk Top with 18.5" LCD Monitor for QC Lab-2
	131.	  	1806	  	0	  	Software Port ALL on CD-ROM for Particle Counter
	132.	  	1812	  	0	  	Adobe Acrobate Software Version 5.0 full/QC/No.28
	133.	  	1816	  	0	  	Software for PC Operation for Incubator for Analys
	134.	  	1818	  	0	  	PICASO Software for Calibration of Pipettes/Inproc
	135.	  	1823	  	0	  	Adobe ACROBAT Professional (Writer) Version 6.0
	136.	  	1830	  	0	  	CA PC MACLAN Software for BEP-III/Eliza Processer
	137.	  	1830	  	1	  	Microwin 2000 Software for BEP-III/Eliza Processer
	138.	  	1831	  	0	  	Endoscan-V Software for Endotoxin Measurement/QC
	139.	  	1840	  	0	  	Sample site Pharma software 21 CFR Liquid Particle
	140.	  	1841	  	0	  	Spectra Manager software 21 CFR UV spectrometer
	141.	  	2847	  	0	  	Tiamo SoftwareMetrohm
	142.	  	2010	  	0	  	Printer HP DeskJet 640C/No.42
	143.	  	2011	  	0	  	Laptop Compaq Presarion 2800 Raju Kuril
	144.	  	2012	  	0	  	Compter Compaq EVD P-IV With Internal CD Writer/42
	145.	  	2012	  	1	  	15" TFT Monitor for PC/NO.40/AKC
	146.	  	2013	  	0	  	Computer PIV IBM Netvista/128MB RAM/40GB/Dr Kulkar
	147.	  	2014	  	0	  	IBM Thinkcentre QAP PC P4 2.2GHz 40GB HDD/QA
	148.	  	2015	  	0	  	Laserjet Printer HP 1010 USB Interface for QA/Crea
	149.	  	2016	  	0	  	Computer Lenovo Thinkcentre PIV Intel Pentium/QA
	150.	  	2017	  	0	  	Printer HP LaserJet 1020 for QA/Creative
	151.	  	2018	  	0	  	Scanner Scanjet HP 4370/Creative Infotec/AKC
	152.	  	2019	  	0	  	HP Laserjet Printer 1160 For QA/Creative
	153.	  	2020	  	0	  	HP Scanjet 8350 Scanner for QA
	154.	  	2021	  	0	  	HP Compaq D290 Desktop System Pentium IV/QA
	155.	  	2022	  	0	  	HP 520 Business Notebook
	156.	  	2023	  	0	  	HP 520 Notebook for Ravi Patel
	157.	  	2024	  	0	  	Epson Printer 2 Nos
	158.	  	2025	  	0	  	HP Desktop CPU Amit Prajapati
	159.	  	2026	  	0	  	PC, Scanner & Hard Disc(500 GB) for QA
	160.	  	2027	  	0	  	Laptop - HP make - H.P.Jain
	161.	  	2028	  	0	  	Laptop - HP make - Prabhakar
	162.	  	2029	  	0	  	Laptop - HP make - Harishh
	163.	  	2031	  	0	  	Sartorius Data Printer
	164.	  	2038	  	0	  	Dell Desktop - Gauri
	165.	  	2030	  	0	  	Supply & Installation of Software for Artwork

  
 277 

							
	166.	  	2041	  	0	  	Auto CAD LT for 2012 software
	167.	  	1093	  	0	  	External CD Writer with USB Interface HP8230/No.29
	168.	  	1094	  	0	  	Digital Camera/Sony/VKS045 DSC-P9 Sr No. 908912
	169.	  	1096	  	0	  	IBM Think Pad T43/Creative Infotec/For GSD/ED’s of
	170.	  	1097	  	0	  	Printer HP Offucejet 6500 for Site Head Office
	171.	  	1341	  	2	  	Pen Drive (32MB) For PIII Computer of GSD
	172.	  	2013	  	1	  	17” TFT Monitor for PC/NO.40/MUD
	173.	  	1211	  	0	  	Software for Load Manager for Power Control Centre
	174.	  	1210	  	0	  	HP Deskjet 845C Printer for Waghmare/Statart/No.7
	175.	  	1212	  	0	  	Computer IBM A50 Thinkcentre PIV & CD Writer/S stn
	176.	  	1340	  	0	  	Printer Dot Matrix Printer/Wipro LX 800/No 19
	177.	  	1341	  	0	  	Compaq DeskPro EXM PIII 933/128MB/20GB/No.28
	178.	  	1342	  	0	  	Printer Model 1125C HP Deskjet/No.35
	179.	  	1343	  	0	  	Laptop Toshiba Satellite 2430 PIV 30GB HDD/No.35
	180.	  	1345	  	0	  	Computer PIV/Compaq EVO/40GB HDD/Statart/No.41
	181.	  	1346	  	0	  	EPSON Dot Matrix Printer LX-300 for Engg
	182.	  	1347	  	0	  	Computer Pentium III 10.2GB For BMS For HVAC Ph-II
	183.	  	1348	  	0	  	Computer IBM Thinkcentre A51 PIV 15" TFT Modul/JSK
	184.	  	1349	  	0	  	HP-DJ-670 COLOUR PRINTER
	185.	  	1350	  	0	  	LAPTOP HP 520 Business Notbook with DVD RW
	186.	  	1351	  	0	  	Computer HP Compaq DX2280 PIV w.o.Monitor/MSM
	187.	  	1352	  	0	  	HP Laserjet 1020 Printer for Engg Office
	188.	  	1353	  	0	  	HP 520 Business Notebook - S R Tathe
	189.	  	1354	  	0	  	HP 520 Motebook for Mr Awati
	190.	  	1355	  	0	  	Printer Laser Jet CP2025DN - Site Engg Office
	191.	  	1357	  	0	  	Laptop - HP make - Khambhati
	192.	  	1358	  	0	  	Laptop - HP make - Mansuri
	193.	  	1359	  	0	  	Dell Desktop - Autocad PC
	194.	  	1360	  	0	  	H P Laser Jet P1106 Printer-Media
	195.	  	2120	  	1	  	Laptop Leather Carry Case for JSK Laptop/Statart T
	196.	  	1344	  	0	  	Computerised Maintenace Management System TECCMMS
	197.	  	1344	  	1	  	CMMS System Source Code Purchase from Tectona
	198.	  	1356	  	0	  	Software for BMS system
	199.	  	1361	  	0	  	BMS Software - Siemens
	200.	  	1386	  	0	  	Dot Matrix Printer EPSON LQ 1150 For Accounts
	201.	  	1984	  	0	  	Computer/HP Brio/PIII 550/64MB/8.4GB/No 3
	202.	  	1985	  	0	  	Monitor/Samtron 15" SVGA Colour/No 14
	203.	  	1986	  	0	  	Printer Epson LQ-1070+ /No 1
	204.	  	1987	  	0	  	Dot Matrix Printer LX 800 DX For Purchase Dept
	205.	  	1990	  	0	  	Axis Camera system for warehouse- Software
	206.	  	1990	  	1	  	Axis Camera system for warehouse- Hardwaree
	207.	  	2052	  	0	  	HP Notebook - IQP
	208.	  	2099	  	0	  	LAPTOP HP 520 Business Notbook with DVD RW
	209.	  	2112	  	0	  	External Data 3 Com 56K Modem 3/No.32/Server
	210.	  	2120	  	0	  	Laptop/COMPAQ Armada M300/PII333/64MB/6.4GB/No 27
	211.	  	2126	  	0	  	Motorola Canopy Wireless Subscriber Module/Bandwid
	212.	  	2128	  	0	  	IBM MS Exchange Windows Server with Exchange & Cal
	213.	  	2128	  	1	  	Memory Upgrade X205/IBM MS Exchange Windows Server

  
 278 

							
	214.	  	2128	  	3	  	Windows Backup Software VERITAS/Ex Windows Server
	215.	  	2132	  	0	  	Back-Up Tape Drive for Sever - H/W
	216.	  	2132	  	1	  	Back-Up Tape Drive for Sever - H/W
	217.	  	2139	  	0	  	Printer - Q.C.
	218.	  	2140	  	0	  	Printer - Q.A.
	219.	  	2134	  	0	  	MS Project Software Prjct 2010 /Autocad 2011 LT So
	220.	  	2319	  	0	  	10 KVA UPS Model S-410 Tata Libert make/Akshini Sy
	221.	  	2320	  	0	  	Battery Exide make (for 1 Hour) 42AH 26Nos/Akshini
	222.	  	2321	  	0	  	Printer/HP Deskjet BJC 1000 Replacement of 640C/21
	223.	  	2322	  	0	  	Computer Compaq ENL PIII 800/64MB RAM/10GB/NO.33
	224.	  	2324	  	0	  	Computer PIV Compaq EVO D320m 1.9Ghz 40GB HDD/No36
	225.	  	2325	  	0	  	Printer HP Business Ink Jet BIJ1100D For HR Fuctio
	226.	  	2327	  	0	  	LCD Multimedia Projector SONY Mk Model VPL ES2/Vin
	227.	  	2329	  	0	  	HP 520 Business Notebook - Bhavesh Panchal
	228.	  	2332	  	0	  	Laptop - HP make - Madhuri
	229.	  	2336	  	0	  	Time track System & Access readers-Abacus
	230.	  	2337	  	0	  	Printer cum scaner for HR
	231.	  	2333	  	0	  	Attendance Systems for HR
	232.	  	2680	  	0	  	Printer Epson LQ-1070+ /No 1
	233.	  	2485	  	0	  	Visual X-PORT Software - Export documents
	234.	  	2508	  	0	  	Sukam 1140W Invertor 7014/00/ for conf Rm/Busi Lnk
	235.	  	2511	  	0	  	Hitachi Projector for HO
	236.	  	2588	  	0	  	2 KVA UPS/ APC Mk /Mod SU2200UXI/Server/ Bus LNK
	237.	  	2591	  	0	  	IBM MS Exchange Windows Server with Exchange & Cal
	238.	  	2592	  	0	  	IP Based VPN Connectivity with Huwaie Router/Lease
	239.	  	2704	  	0	  	UPS 500VA APC-APC with 15 Minutes Battery Backup
	240.	  	2704	  	1	  	UPS 500VA APC-APC with 15 Minutes Battery Backup
	241.	  	2704	  	2	  	UPS 500VA APC-APC with 15 Minutes Battery Backup
	242.	  	2667	  	0	  	Network Switch WS-C3750X-24T-S
	243.	  	2668	  	0	  	Network Switch WS-C3560CG-8TC-S
	244.	  	2669	  	0	  	Network Switch WS-C2960S-48TS-L
	245.	  	2670	  	0	  	Network Switch WS-C2960S-24TS-L
	246.	  	2671	  	0	  	Network Switch WS-C2960S-48TS-L
	247.	  	2672	  	0	  	Network Switch WS-C2960S-24TS-L
	248.	  	2673	  	0	  	Network Switch WS-C3750X-24S-E
	249.	  	2673	  	1	  	Network Switch WS-C3750X-24S-E
	250.	  	2674	  	0	  	WIFI AIR-CT2504-5-K9 50X-24T-S
	251.	  	2677	  	0	  	LAN Kit from BT for Security Gate LAN connection

 Novartis Vaccines and Diagnostics S.r.l. 
  

							
	 No.
	  	 Asset
	  	 SNo
	  	 Asset description

	1.	  	35862	  		  	N.1 CISCO 3750+N.2 GLC+PWR675 LOTTO8ED1
	2.	  	35863	  		  	N.1 CISCO 3750+N.2 GLC LOTTO1 ED.5
	3.	  	34900	  		  	TELEFONO VIVAVOCE (MICROSOFT ROUNDTABLE)
	4.	  	36456	  		  	TELEFONO VIVAVOCE (MICROSOFT ROUNDTABLE)
	5.	  	46012	  		  	IMPIANTI ELETTRICI COMPUTER ROOM
	6.	  	48727	  		  	IMPIANTO RILEVAMENTO E SPEGNIMENTO INCENDIO
	7.	  	25932	  		  	ARMADIO TD

  
 279 

							
	8.	  	35836	  		  	ARMADIO DI RETE (RACK) MAGAZZINO 17
	9.	  	35840	  		  	CABLAGGIO COLLEGAMENTO RETE MAG.17
	10.	  	35841	  		  	SWITCH ROSIA ED.17 LOTTO 4+ACCESSOR
	11.	  	25933	  		  	ARMADIO TD
	12.	  	25934	  		  	ARMADIO TD
	13.	  	35864	  		  	N.1 CISCO 3560+N.2 GLC LOTTO4ED20WIRELE
	14.	  	35865	  		  	N.1 CISCO 3750+N.2 GLC+PWR675 LOTTO3ED20
	15.	  	6923	  		  	GRUPPO DI CONTINUITA’ POT.3000VA PER SERVER ROSIA
	16.	  	17215	  		  	ARMADIO DI RETE RITTAL DK
	17.	  	17215	  		  	PATCHPANEL R&M 24 PORTE CATEGORIA 6
	18.	  	21236	  		  	SIST. STATICO DI CONTINUITA’ SERIE SINTHESIS TWIN
	19.	  	25935	  		  	ARMADIO TD
	20.	  	25936	  		  	ARMADIO TD
	21.	  	25937	  		  	ARMADIO TD
	22.	  	25945	  		  	7204VXR VPN BUNDLE NPE-225 I/O 2FE,VAM,
	23.	  	25945	  		  	CISCO 7200 REDUNDANT AC POWER SUPPLY
	24.	  	27944	  		  	CATALYST 3750 WS-C3750-48TS-S CON ACCESS.
	25.	  	27950	  		  	CABLAGGIO FIBRE OTTICHE
	26.	  	27951	  		  	CATALYST 2950, 48 10/100 WITH 2 GBIC
	27.	  	27952	  		  	CATALYST 3750-48 10/100 POE+4SFP
	28.	  	27953	  		  	CATALYST 3750-48 10/100 POE+4SFP
	29.	  	27954	  		  	675W REDUNDANT POWER SUPPLY
	30.	  	27955	  		  	RACK IBM PER ROSIA (ARMADIO)
	31.	  	27957	  		  	PROIETTORE M400 - ITALIA
	32.	  	35005	  		  	RACK HP UNIVERSAL 10642 G2+ACCESSORI
	33.	  	35834	  		  	SAN SWITCH IBM TOTALSTORAGE SAN16B-2+ACCESSORI
	34.	  	35835	  		  	SAN SWITCH IBM TOTALSTORAGE SAN16B-2+ACCESSORI
	35.	  	35842	  		  	CABLAGGIO COLLEGAMENTO RETE ED.22
	36.	  	35845	  		  	N.1 CISCO 3750+N.2 GLC+PWR675 LOTTO5ED22
	37.	  	35846	  		  	N.1 CISCO 3750+N.2 GLC+PWR675 LOTTO7ED22
	38.	  	35848	  		  	CORE SWITCH ROSIA ED.22 LOTTO 1+ACCESSOR
	39.	  	35871	  		  	WS-X6724+N.28 GLC-LH-SM LOTTO14
	40.	  	35873	  		  	CISCO 3750+N.2 GLC+PWR675 LOTTO3MENB
	41.	  	35874	  		  	CISCO 3750+N.2 GLC+PWR675 LOTTO3MENB
	42.	  	35875	  		  	CISCO AIR-AP1242AG-E-K9+ACCESSORI
	43.	  	35876	  		  	CISCO AIR-AP1242AG-E-K9+ACCESSORI
	44.	  	35877	  		  	CISCO AIR-AP1242AG-E-K9+ACCESSORI
	45.	  	35878	  		  	CISCO AIR-AP1242AG-E-K9+ACCESSORI
	46.	  	42751	  		  	FIBRA OTTICA EDIFICIO 22 ROSIA
	47.	  	48463	  		  	CLIMATIZZATORE DAIKIN FAQ100B-I/RZQSC
	48.	  	48746	  		  	IMPIANTO CONDIZIONAMENTO SALA SERVER GIS
	49.	  	52950	  		  	N.3 SWITCHES + INSTALLATION
	50.	  	25938	  		  	ARMADIO TD
	51.	  	35866	  		  	N.1 CISCO 3560+N.2 GLC+PWR675 LOTTO9ED35
	52.	  	35850	  		  	CABLAGGIO COLLEGAMENTO RETE MAG.17
	53.	  	27946	  		  	CATALYST 3750 WS-C3750-48TS-S CON ACCESS.
	54.	  	27947	  		  	CATALYST 3750 WS-C3750-48TS-S CON ACCESS.
	55.	  	27948	  		  	CATALYST 3750 WS-C3750-48TS-S CON ACCESS.

  
 280 

							
	56.	  	27949	  		  	REDUNDANT POWER SUPPLY PWR675-AC-RPS-N1
	57.	  	35839	  		  	ARMADIO DI RETE (RACK) ED.40 MENB
	58.	  	35853	  		  	CABLAGGIO COLLEGAMENTO RETE
	59.	  	27945	  		  	CATALYST 3750 WS-C3750-48TS-S CON ACCESS.
	60.	  	35358	  		  	ARMADIO IGNIFUGO LAMPERTZ DATA SAFE S13
	61.	  	35837	  		  	ARMADIO DI RETE (RACK) FILL FINISH PIANO UFFICI
	62.	  	35838	  		  	ARMADIO DI RETE (RACK) FILL FINISH PIANO TERRA
	63.	  	35843	  		  	CORE SWITCH ROSIA FILL-FINISH RACK 1
	64.	  	35844	  		  	CORE SWITCH ROSIA FILL-FINISH RACK 1
	65.	  	35851	  		  	CABLAGGIO COLLEGAMENTO RETE MAG.17
	66.	  	35868	  		  	N.1 CISCO 3750 + ACCESS. LOTTO 1 ED. 42
	67.	  	35869	  		  	N.1 CISCO 3750 + ACCESS. LOTTO 1 ED. 42
	68.	  	46274	  		  	CONSOLE GESTIONE REMOTA BRIDGE VIDEO
	69.	  	46515	  		  	SISTEMA VIDEOCONFERENZA HDX 9002 BLD.42
	70.	  	30129	  		  	PROIETTORE BENQ CP220
	71.	  	35852	  		  	CABLAGGIO COLLEGAMENTO RETE MAG.17
	72.	  	35856	  		  	N.1 CISCO 4506+ACCESS. NEW QC P0A-LOTTO1
	73.	  	35857	  		  	N.1 CISCO 4506+ACCESS. NEW QC P0B-LOTTO1
	74.	  	35858	  		  	N.1 CISCO XENPAK 10GB NEW QC-LOTTO6
	75.	  	35859	  		  	N.1 CISCO 3750+ACCESS. NEW QC P0-LOTTO3
	76.	  	35860	  		  	N.1 CISCO 3750+ACCESS. NEW QC P1-LOTTO4
	77.	  	35861	  		  	N.1 CISCO 3750+ACCESS. NEW QC P2-LOTTO5
	78.	  	35854	  		  	CABLAGGIO COLLEGAMENTO RETE
	79.	  	35849	  		  	CORE SWITCH ROSIA ED.22 LOTTO 2+ACCESSOR
	80.	  	35872	  		  	WS-X6724+N.28 GLC-LH-SM LOTTO14
	81.	  	47849	  		  	LAVORI CIVILI PER NUOVO IT DATA CENTER ROSIA
	82.	  	47849	  		  	LAVORI CIVILI PER NUOVO IT DATA CENTER ROSIA
	83.	  	50153	  		  	IMPIANTO CONTROLLO ACCESSI DATACENTER BDG.53
	84.	  	50830	  		  	RACK - ARMADIO DI RETE
	85.	  	50830	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	86.	  	50830	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	87.	  	50831	  		  	RACK - ARMADIO DI RETE
	88.	  	50831	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	89.	  	50831	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	90.	  	50832	  		  	RACK - ARMADIO DI RETE
	91.	  	50832	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	92.	  	50832	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	93.	  	50833	  		  	RACK - ARMADIO DI RETE
	94.	  	50833	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	95.	  	50833	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	96.	  	50834	  		  	RACK - ARMADIO DI RETE
	97.	  	50834	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	98.	  	50834	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	99.	  	50835	  		  	RACK - ARMADIO DI RETE
	100.	  	50835	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	101.	  	50835	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	102.	  	50836	  		  	RACK - ARMADIO DI RETE
	103.	  	50836	  		  	CABLAGGIO RACK - ARMADIO DI RETE

  
 281 

							
	104.	  	50836	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	105.	  	50837	  		  	RACK - ARMADIO DI RETE
	106.	  	50837	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	107.	  	50837	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	108.	  	50838	  		  	RACK - ARMADIO DI RETE
	109.	  	50838	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	110.	  	50838	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	111.	  	50839	  		  	RACK - ARMADIO DI RETE
	112.	  	50839	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	113.	  	50839	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	114.	  	50840	  		  	RACK - ARMADIO DI RETE
	115.	  	50840	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	116.	  	50840	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	117.	  	50841	  		  	RACK - ARMADIO DI RETE
	118.	  	50841	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	119.	  	50841	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	120.	  	50842	  		  	RACK - ARMADIO DI RETE
	121.	  	50842	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	122.	  	50842	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	123.	  	50843	  		  	RACK - ARMADIO DI RETE
	124.	  	50843	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	125.	  	50843	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	126.	  	50844	  		  	RACK - ARMADIO DI RETE
	127.	  	50844	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	128.	  	50844	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	129.	  	50845	  		  	RACK - ARMADIO DI RETE
	130.	  	50845	  		  	CABLAGGIO RACK - ARMADIO DI RETE
	131.	  	50845	  		  	CABLAGGI E CONNETTORIZZAZ.X INST.SAN
	132.	  	50846	  		  	IMPIANTO ELETTRICO, UPS-STS PER IT DATA CENTRE
	133.	  	50846	  		  	IMPIANTO ELETTRICO, UPS-STS PER IT DATA CENTRE
	134.	  	50847	  		  	IMP. RAFFREDDAMENTO E CLIMATIZZ. X IT DATA CENTRE
	135.	  	50847	  		  	IMP. RAFFREDDAMENTO E CLIMATIZZ. X IT DATA CENTRE
	136.	  	50848	  		  	IMPIANTO ANTINCENDIO PER IT DATA CENTRE
	137.	  	50848	  		  	IMPIANTO ANTINCENDIO PER IT DATA CENTRE
	138.	  	50849	  		  	TRASMISSIONE DATI DA IT DATA CTR A ALTRI EDIFICI
	139.	  	50849	  		  	TRASMISSIONE DATI DA IT DATA CTR A ALTRI EDIFICI
	140.	  	52737	  		  	CORE SWITCH
	141.	  	52738	  		  	RACK - ARMADIO DI RETE
	142.	  	55475	  		  	NETWORK
	143.	  	17221	  		  	SISTEMA DI CALL ACCOUNTING TABS + ACCESS.
	144.	  	29505	  		  	ACC. POINT 802.11G+ACC.LOTTO 2 ED. 1 SIENA
	145.	  	29506	  		  	ACC. POINT 802.11G+ACC.LOTTO 2 ED. 1 SIENA
	146.	  	29510	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA
	147.	  	29511	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA
	148.	  	29512	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA
	149.	  	29513	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA
	150.	  	29514	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA
	151.	  	29515	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA

  
 282 

							
	152.	  	29516	  		  	CISCOSTACK 3750-48 ED.1 ACC. LOTTO 3 SIENA
	153.	  	46508	  		  	PROIETTORE E SCHERMO SALA MONTALCINI BLD.1
	154.	  	46513	  		  	CONFERENCE HALL PROIETTORE BLD.35
	155.	  	49026	  		  	ARMADIO 42 UNITA’
	156.	  	19645	  		  	CATALYST 6009 LAYER 3
	157.	  	19645	  		  	WS-X6416-GBIC CATALYST 6000 16 PORT
	158.	  	19645	  		  	UPGR. CATALYST 6009 TO 6509 LOT. 9 SIENA
	159.	  	23834	  		  	FORNITURA AAPPARECCHIATURE DI RETE CISCO
	160.	  	25939	  		  	CATALYST 3550-12T 12 PORT 10/100/1000 TX
	161.	  	25943	  		  	CATALYST 6000 16-PORT 1000TXGE MOD.RJ-45
	162.	  	28629	  		  	CATALYST 3750 48 10/100 WS-C3750-48TS-S
	163.	  	28630	  		  	CATALYST 3750 48 10/100 WS-C3750-48TS-S
	164.	  	28631	  		  	CATALYST 3750 48 10/100 WS-C3750-48TS-S
	165.	  	29503	  		  	VPN3020 CHASSIS 3FE,SEP-E+VPN3020SW
	166.	  	29521	  		  	CISCOSTACK 3750-48 ED.28 +ACC.LOT. 5 SIENA
	167.	  	30752	  		  	ARMADIO IGNIFUGO LAMPERTZ SAFE S14
	168.	  	35011	  		  	N 2 CISCO 3750-48PS+ACCES. ED.7P0 LOTTO4
	169.	  	35847	  		  	SWITCH ROSIA FILL-FINISH RACK 3 E 4
	170.	  	35847	  		  	UPGRADE SWITCH ROSIA FILL-FINISH RACK 3 E 4
	171.	  	35867	  		  	N.1 CISCO 3560+N.2 GLC+PWR675LOTTO10ED35
	172.	  	36705	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	173.	  	36706	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	174.	  	36707	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	175.	  	36708	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	176.	  	27703	  		  	ARMADIO DI RETE ED. 5 SIENA
	177.	  	29517	  		  	CISCOSTACK 3750-48 ED.5+ACC. LOT.4 SIENA
	178.	  	29518	  		  	CISCOSTACK 3750-48 ED.5+ACC. LOT.4 SIENA
	179.	  	29508	  		  	ACC. POINT 802.11G+ACC.LOTTO 2 ED. 1 SIENA
	180.	  	35008	  		  	N 1 CISCO 3750-48TS+ACCES. ED. 6 LOTTO1
	181.	  	35019	  		  	RACK RETE ED. 6 SIENA
	182.	  	46173	  		  	HALO SYSTEM
	183.	  	46173	  		  	HALO SYSTEM
	184.	  	46173	  		  	UPGRADE HALO SYSTEM
	185.	  	46507	  		  	ARMADIO DI RETE PER HALO ROOM
	186.	  	26352	  		  	ETICHETTATRICE PORTATILE BROTHER PT-2480
	187.	  	29507	  		  	ACC. POINT 802.11G+ACC.LOTTO 2 ED. 1 SIENA
	188.	  	35009	  		  	N 3 CISCO 3750-48PS+ACCES. ED.7P2 LOTTO2
	189.	  	35010	  		  	N 3 CISCO 3750-48PS+ACCES. ED.7P1 LOTTO3
	190.	  	35020	  		  	RACK RET ED.7 P.T. SIENA
	191.	  	46516	  		  	SISTEMA VIDEOCONFERENZA HDX 9002 BLD.7
	192.	  	35012	  		  	N 2 CISCO 3750-48TS+ACCES. ED.8 LOTTO5
	193.	  	34626	  		  	SWITCH CISCO CATALYST 3750 CON ACCESSORI
	194.	  	35018	  		  	IMPIANTO DATI ED.10
	195.	  	6034	  		  	CONDIZIONATORE MITSUBISHI ELEC.MATR.7XI00010
	196.	  	6035	  		  	CONDIZIONATORE MITSUBISHI ELEC.MATR.7XI00010
	197.	  	17299	  		  	SISTEMA AUDIOCONFERENZA 3M
	198.	  	17332	  		  	SOFTWARE DI AGGIORNAMENTO
	199.	  	17593	  		  	STRUMENTO FLUKE NET TOOL IN LINE PER TEST RETE

  
 283 

							
	200.	  	19133	  		  	CONDIZIONATORE MONOSPLI A PARETE MS-07RV
	201.	  	19522	  		  	ARMADIO IN METALLO PER SERVER (RISCATTO NOLEGGIO)
	202.	  	19645	  		  	N.2 CATALYST 6500 128MB DRAM C-MEM-S1-128MB
	203.	  	22636	  		  	PROIETTORE BENQ SL 705X
	204.	  	22787	  		  	SCAFFALATURA IN METALLO 100X50 A 5 RIPIANI
	205.	  	22788	  		  	SCAFFALATURA IN METALLO MOD.L1L23
	206.	  	23835	  		  	ARMADIO RETE
	207.	  	25585	  		  	VIDEOPROIETTORE BENQ PB2220
	208.	  	25699	  		  	RACK RISCATTO LEASING
	209.	  	25700	  		  	RACK RISCATTO LEASING
	210.	  	25944	  		  	7204VXR VPN BUNDLE NPE-225 I/O 2FE,VAM,
	211.	  	25944	  		  	CISCO 7200 REDUNDANT AC POWER SUPPLY
	212.	  	25946	  		  	PORT FAST ETHERNET 100BASE TX PORT
	213.	  	25947	  		  	PORT FAST ETHERNET 100BASE TX PORT
	214.	  	28627	  		  	WS-C3750-24TS-S CATALYST 3750 24 PORTE
	215.	  	28628	  		  	WS-C3750-24TS-S CATALYST 3750 24 PORTE
	216.	  	28632	  		  	ACCESS POINT 802.11G CON ANTENNE 4941
	217.	  	28633	  		  	CISCO ROUTER 2821
	218.	  	28634	  		  	CISCO ROUTER 2821
	219.	  	28635	  		  	INST. FIBRA OTTICA TRA ED. 15 E ED. 23
	220.	  	29356	  		  	RACK IBM COMPLETO DI ACCESSORI
	221.	  	29438	  		  	DISTRUGGIDOCUMENTI SB85C
	222.	  	29439	  		  	POLYCOM SOUNDSTATION2 (CONFERENCE PHONE)
	223.	  	29533	  		  	4250 SENSOR
	224.	  	29533	  		  	UPGRADE SOFTWARE SONDE IDS 4250 E PIATTAFORMA VMS
	225.	  	29826	  		  	CISCO SWITCH WS-C3560G-24PS-S+CONNETTORE
	226.	  	29827	  		  	CISCO SWITCH WS-C3560G-24PS-S+CONNETTORE
	227.	  	30127	  		  	PROIETTORE BENQ CP220
	228.	  	31351	  		  	N. 2 SWITCH 19” KVM 4 PC PER GESTIONE ALLARMI
	229.	  	33404	  		  	PROIETTORE MULTIMEDIALE BENQ CP120
	230.	  	34750	  		  	PROIETTORE BENQ
	231.	  	35013	  		  	N 3 CISCO 3750-48PS+ACCES.ED.11IM LOTTO6
	232.	  	35014	  		  	N 2 CISCO 3750-48TS+ACCES.ED11CC LOTTO7
	233.	  	35823	  		  	CAT6500 48-PORT 10/100/1000 GE
	234.	  	35870	  		  	CISCO SUPERVISOR 720 FABRIC MSFC3 PFC3B
	235.	  	35879	  		  	INSTALL. 8 PUNTI RETE SALA MACCHINE + ACCESS POINT
	236.	  	35946	  		  	SCHEDA 4 PORTE 10GBPS CAT.65XX + ACCESSO
	237.	  	36300	  		  	TELEFONO POLYCOM VOICESTATION 300
	238.	  	36996	  		  	VALIGIA IMATION DATAGUARD PER NASTRI MAGNETICI
	239.	  	36997	  		  	VALIGIA IMATION DATAGUARD PER NASTRI MAGNETICI
	240.	  	36998	  		  	VALIGIA IMATION DATAGUARD PER NASTRI MAGNETICI
	241.	  	36999	  		  	VALIGIA IMATION DATAGUARD PER NASTRI MAGNETICI
	242.	  	37000	  		  	VALIGIA IMATION DATAGUARD PER NASTRI MAGNETICI
	243.	  	37001	  		  	VALIGIA IMATION DATAGUARD PER NASTRI MAGNETICI
	244.	  	44627	  		  	SISTEMA DI AUDIOCONFERENZA CONVERGE 590 CLEAR ONE
	245.	  	46796	  		  	TV TFT 32 POLLICI LCD
	246.	  	48976	  		  	DISPOSITIVO DI RETE CATALYST 3750E 48 PORTE
	247.	  	49227	  		  	KVM SWITCH + ACCESSORI

  
 284 

							
	248.	  	49228	  		  	KVM SWITCH + ACCESSORI
	249.	  	35015	  		  	N 2 CISCO 3750-48PS+ACCES.ED.13 LOTTO8
	250.	  	35021	  		  	RACK RETE ED. 13 SIENA
	251.	  	30128	  		  	PROIETTORE BENQ CP220
	252.	  	35016	  		  	N 1 CISCO 3750-48PS+ACCES.ED.15DP LOTTO9
	253.	  	43361	  		  	INSTALLAZIONE CABLAGGIO NUOVI LOCALI ED.15
	254.	  	29509	  		  	ACC. POINT 802.11G+ACC.LOTTO 2 ED. 1 SIENA
	255.	  	29519	  		  	CISCOSTACK 3750-48 ED.23+ACC. LOT.4 SIENA
	256.	  	29520	  		  	CISCOSTACK 3750-48 ED.23+ACC. LOT.4 SIENA
	257.	  	26554	  		  	NUOVO ARMADIO RETE ED. 28 P.1
	258.	  	29522	  		  	CISCOSTACK 3750-48 ED.28 +ACC.LOT. 5 SIENA
	259.	  	29523	  		  	CISCOSTACK 3750-48 ED.28 +ACC.LOT. 5 SIENA
	260.	  	29524	  		  	CISCOSTACK 3750-48 ED.28 +ACC.LOT. 5 SIENA
	261.	  	29525	  		  	CISCOSTACK 3750-48 ED.28 +ACC.LOT. 5 SIENA
	262.	  	29526	  		  	CISCOSTACK 3750-48 ED.28 +ACC.LOT. 5 SIENA
	263.	  	36710	  		  	SWITCH DI RETE CATALYST 3750 24 PORTE
	264.	  	35017	  		  	N 2 CISCO 3750-48TS+ACCES.ED.30 LOTTO10
	265.	  	46509	  		  	SISTEMA VIDEOCONFERENZA HDX 9002 BLD.31
	266.	  	46510	  		  	ARMADIO PER SISTEMA VIDEOCONFERENZA BLD.31
	267.	  	46511	  		  	SIST.VIDEOCONFER. HDX POLYC.XSALA POLTR.ROSSE B31
	268.	  	36709	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	269.	  	36712	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	270.	  	36713	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	271.	  	37135	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	272.	  	37136	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	273.	  	37137	  		  	SWITCH DI RETE CATALYST 3750 48 PORTE
	274.	  	46263	  		  	ARMADIO DI RETE ED.35
	275.	  	46264	  		  	ARMADIO DI RETE ED.35
	276.	  	46512	  		  	SIST.VIDEOCONFER. HDX POLYCOM BLD.35
	277.	  	46514	  		  	AUDIOCONFERENZA POLYCOM SOUND STATION BLD.35
	278.	  	53138	  		  	DISTRIBUTION SWITCH CENTRO RICERCHE
	279.	  	53834	  		  	EPSON VIDEOPROIETTORE PROFESSIONALE
	280.	  	53838	  		  	AMPLIAMENTO SISTEMA AUDITORIUM
	281.	  	36711	  		  	SWITCH DI RETE CATALYST 3750 24 PORTE
	282.	  	46517	  		  	SIST.VIDEOCONFER.HDX POLYCOM SALA SABIN VILLA GORI
	283.	  	46518	  		  	ARMADIO PER SISTEMA VIDEOCONFERENZA SALA SABIN
	284.	  	46519	  		  	SISTEMA AUDIOCONFERENZA SALA TORRETTA VILLA GORI
	285.	  	35855	  		  	N. 1 CISCO SWITCH 3750-48PS-S BLD 48
	286.	  	58634	  		  	LAN REFRESH SITO SIENA

  
 285 

 Schedule 28 

Global TDSA Jurisdictions 
 Argentina 

Australia 
 Bangladesh 

Belgium 
 Brazil 

Canada 
 Chile 

China 
 Ecuador 

Egypt 
 Greece 

Hong Kong 
 Hungary 

Indonesia 
 Malaysia 

Mexico 
 Morocco 

Pakistan 
 Philippines 

Portugal 
 Russia 

Singapore 
 Slovenia 

South Korea 
 Switzerland (Sandoz AG only) 

Taiwan 
 Turkey 

Venezuela 

  
 286 

 Schedule 29 

Surviving Affiliate Contracts 
  

	1	The quality agreement dated 19 June 2012 between Novartis Vaccines and Diagnostics Ltd. on the one hand and Novartis Vaccines and Diagnostics AG, Novartis Vaccines and Diagnostics GmbH and Novartis
Vaccines and Diagnostics S.r.l. on the other; 

  

	2	the quality agreement dated 28 February 2013 between Novartis Vaccines and Diagnostics, Inc. and Novartis Vaccines and Diagnostics GmbH; 

 

	3	the quality agreement dated 12 May 2013 between Novartis Vaccines and Diagnostics Ltd. and Novartis Vaccines and Diagnostics S.r.l.; 

 

	4	the quality agreement dated 12 August 2013 between Novartis Vaccines and Diagnostics Ltd. and Novartis Vaccines and Diagnostics S.r.l.; 

 

	5	the quality agreement dated 14 February 2014 between Novartis Vaccines and Diagnostics Ltd. and Novartis Vaccines and Diagnostics GmbH; 

 

	6	the quality agreement dated 16 May 2014 between Novartis Influenza Vaccines Marburg GmbH and Novartis Vaccines and Diagnostics S.r.l.; 

 

	7	the quality agreement dated 28 November 2014 between Novartis Vaccines and Diagnostics Ltd. on the one hand and Novartis Vaccines and Diagnostics S.r.l., Novartis Vaccines and Diagnostics GmbH and
Novartis Vaccines and Diagnostics AG on the other; 

  

	8	the quality agreement dated 12 December 2014 between Novartis Influenza Vaccines Marburg GmbH and Novartis Vaccines and Diagnostics GmbH; 

 

	9	the quality agreement dated 15 December 2014 between Novartis Influenza Vaccines Marburg GmbH and Novartis Vaccines and Diagnostics S.r.l.; 

 

	10	the quality agreement dated 20 February 2015 between Novartis Vaccines and Diagnostics Ltd. and Novartis Vaccines and Diagnostics GmbH; 

 

	11	the quality agreement dated 21 February 2015 between Novartis Vaccines and Diagnostics, Inc. and Novartis Vaccines and Diagnostics AG; 

 

	12	the quality agreement dated 22 February 2015 between Novartis Vaccines and Diagnostics Ltd. and Novartis Vaccines and Diagnostics AG; 

 

	13	the quality agreement dated 23 February 2015 between Novartis Vaccines and Diagnostics, Inc. and Novartis Vaccines and Diagnostics AG; and 

 

	14	the quality agreement dated 23 February 2015 between Novartis Vaccines and Diagnostics Ltd. and Novartis Vaccines and Diagnostics AG. 

  
 287 

 Schedule 30 

[***] 
 [***] 

 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
 288 

 Schedule 31 

Anti-bribery and corruption 
  

	1	Each of the Purchaser and the Seller requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which the Purchaser’s Group or the Seller’s Group
(as the case may be)(whether through a third party or otherwise) conducts business. 

  

	2	Each of the Purchaser and the Seller requires the members of the Purchaser’s Group or the Seller’s Group (as the case may be), their employees and any third party acting for or on behalf of the party,
its members or their employees to ensure that all dealings with third parties, both in the private and government sectors, are carried out in compliance with all Applicable Laws and with the required standards of integrity. Each party values
integrity and transparency and does not tolerate corrupt activities of any kind, whether committed by its employees, officers, or third-parties acting for or on its behalf. 

 

	3	In performing this Agreement or any of the Ancillary Agreements, each of the Purchaser and the Seller shall (and shall procure that each member of the Purchaser’s Group or the Seller’s Group (as the
case may be) shall): 

  

	3.1	comply with all Applicable Laws, including but not limited to applicable anti-corruption laws, of the territory in which the party or the relevant member of Purchaser’s Group or the Seller’s Group (as
the case may be) conducts business with the other party or the relevant member of the Seller’s Group or the Purchaser’s Group (as the case may be); 

  

	3.2	covenant that it has not, and covenants that it will not, in connection with the performance of this Agreement or any of the Ancillary Agreements, directly or indirectly, promise, authorise, ratify or offer to
make or make any Payments of Anything of Value to any individual (or at the request of any individual) including a Government Official for the improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an
improper advantage or to improperly assist the Seller’s Group or the Purchaser’s Group in obtaining or retaining business; and 

  

	3.3	covenant that it has not, and covenants and that it will not, in connection with the performance of this Agreement or any of the Ancillary Agreements, directly or indirectly, promise, authorise, ratify or offer
to make or make any Facilitating Payments to any individual (or at the request of any individual) including a Government Official. 

In this Schedule: 

“Anything of Value” includes cash or cash equivalents, gifts, services, employment offers, loans, travel expenses,
entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value; 

“Facilitating Payments” (otherwise known as “greasing payments”) means any payment to an individual to secure or
expedite the performance of a routine government action by government officials. 
 “Government Official” means: (i) any
officer or employee of a government or any department, agency or instrument of a government; (ii) any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (iii) any officer
or employee of a company or business owned in whole or part by a government; (iv) any officer or employee of a public international organisation such as the World Bank or United Nations; (v) any officer or employee of a political party or any person
acting in an official capacity on behalf of a political party; and/or (vi) any candidate for political office. 

  
 289 

 “Payments” includes any direct or indirect offers to pay, promises to pay,
authorisations of or payments of anything of value. 
 The terms defined in this Schedule should be construed broadly to give effect to the
letter and spirit of each party’s ethical standards. 

  
 290Exhibit 4.10

 Exhibit 4.10 
 CONFIDENTIAL TREATMENT REQUESTED 
 EXECUTION VERSION 

1 March 2015 

GLAXOSMITHKLINE PLC 
 and 
 NOVARTIS AG 

DEED OF AMENDMENT AND RESTATEMENT 
 relating to the 
 SALE AND PURCHASE AGREEMENT 

relating to the Seller’s oncology business, 
 dated 22 April 2014 (as amended) 
  
 

 

 This Deed (the “Deed”) is made on 1 March 2015 between: 

 

	(1)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS,
United Kingdom (the “Seller”); and 

  

	(2)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the
“Purchaser”), 

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	The Seller and the Purchaser entered into the sale and purchase agreement relating to the Seller’s oncology business on 22 April 2014 (the
“SAPA”). 

  

	(B)	The SAPA was subsequently amended and restated on 29 May 2014 and further amended and restated on 21 November 2014 (the “Original Agreement”).

  

	(B)	The Seller and the Purchaser now wish to further amend and restate the Original Agreement, in the form of the Amended Agreement (as defined below).

 It is agreed as follows: 
 DEFINITIONS AND INTERPRETATION 
 In this Deed, unless the context otherwise
requires, the provisions of this clause 1 apply. 
 Incorporation of defined terms 

Unless otherwise stated, terms defined in the Original Agreement shall have the same meaning in this Deed. 

Definitions 

“Amended Agreement” means the Original Agreement, as amended and restated in the form set out in the Schedule to this
Deed; and 
 “Signing Date” means 22 April 2014. 
 Interpretation clauses 
 The principles of interpretation set out in Clause
1 of the Original Agreement shall have effect as if set out in this Deed, save that references to “this Agreement” shall be construed as references to “this Deed”. 

References to this Deed include the Schedule. 

  
 Page 2

	AMENDMENT	

 In accordance with Clauses 16.4.3 and
16.5.1 of the Original Agreement, the parties agree that the Original Agreement shall be amended and restated as set out in the Schedule to this Deed. 
 The amendment and restatement of the Original Agreement pursuant to clause 2.1 shall take effect from the Signing Date, as if the Amended Agreement had been entered into on the Signing Date. 

Upon this Deed being entered into, the Amended Agreement shall supersede the Original Agreement in its entirety. 

MISCELLANEOUS 
 Each party represents and
warrants that it has full power and authority to enter into this Deed and to perform its obligations under it. 
 The provisions of Clauses 13,
16.2 to 16.5 and 16.11 to 16.15 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if references in those Clauses to “this Agreement” are references to this Deed and references to “party”
or “parties” are references to parties to this Deed. 

  
 Page 3

 In witness whereof this Deed has been delivered on the date first stated above. 

 

					
	Executed as a DEED by	  	)	  	
	GLAXOSMITHKLINE PLC acting by	  	)	  	
	its duly appointed attorney	  	)	  	/s/ Edgar B. Cale
		  	)	  	(Signature of attorney)
		  	)	  	

 In the presence of: 
  

			
	Witness’ signature:	  	/s/ Maria Ledeneva
		
	Name (print):	  	Maria Ledeneva
		
	Occupation:	  	Trainee Solicitor
		
	Address:	  	65 Fleet Street, London

  
 Page 4

 In witness whereof this Deed has been delivered on the date first stated above. 

 

					
	Executed as a DEED by	  	)	  	
		  	)	  	
	Jonathan Emery As Attorney and	  	)	  	/s/ Jonathan Emery
		  	)	  	
	Sunny Jongsaritwang As Attorney	  	)	  	
		  	)	  	/s/ Sunny Jongsaritwang
	on behalf of NOVARTIS AG	  	)	  	

  
 Page 5

 SCHEDULE 
 Amended Agreement 

 EXECUTION VERSION 
 Dated 22 April 2014 
 As amended and restated on 29 May 2014, and as
further amended and restated on 
 21 November 2014 and on 1 March 2015 

GLAXOSMITHKLINE PLC 
 and 
 NOVARTIS AG 

 

	
	         
	  

 SALE AND PURCHASE AGREEMENT 

in relation to the Oncology Business 

	
	         
	  

 CONTENTS 

 

			
	CLAUSE	 	PAGE

							
	 1.
	  	 Interpretation
	  	 	1	  
	 2.
	  	 Sale and Purchase of the Business
	  	 	32	  
	 3.
	  	 Amounts Payable
	  	 	37	  
	 4.
	  	 Conditions
	  	 	39	  
	 5.
	  	 Pre-Closing
	  	 	47	  
	 6.
	  	 Closing
	  	 	49	  
	 7.
	  	 Development Plans
	  	 	56	  
	 8.
	  	 Post-Closing Obligations
	  	 	57	  
	 9.
	  	 Warranties
	  	 	72	  
	 10.
	  	 Limitation of Liability
	  	 	73	  
	 11.
	  	 Claims
	  	 	76	  
	 12.
	  	 Restrictive Covenants
	  	 	78	  
	 13.
	  	 Confidentiality
	  	 	80	  
	 14.
	  	 Insurance
	  	 	81	  
	 15.
	  	 France Business and Netherlands Business
	  	 	82	  
	 16.
	  	Other Provisions	  	 	84	  
	 Schedule 1 Products
	  	 	92	  
	 Schedule 2 Certain Intellectual Property Rights Matters (Clause 2.3.1)
	  	 	103	  
	 Schedule 3 Excluded Assets and Excluded Contracts (Clause 2.3.2)
	  	 	105	  
	  Part 1 Excluded Assets
	  	 	105	  
	  Part 2 Excluded Contracts
	  	 	105	  
	 Schedule 4 Excluded Liabilities (Clause 2.3.4)
	  	 	106	  
	 Schedule 5 Permitted Encumbrances (Clause 1.1)
	  	 	107	  
	 Schedule 6 Product Approvals (Clause 6.2.2)
	  	 	108	  
	  Part 1 Terms relating to the Product Approvals
	  	 	108	  
	  Part 2 Marketing Authorisation Transfer Provisions
	  	 	109	  
	  Part 3 Tenders
	  	 	118	  
	 Schedule 7 Transferred Contracts, Transferred Intellectual Property Contracts, Co-Owned Transferred
Product
Intellectual Property Rights, and Shared Business Contracts (Clause 2.3.1)
	  	 	120	  
	 Schedule 8 Employees (Clause 2.4.1)
	  	 	129	  
	 Schedule 9 Employee Benefits (Clause 2.4.2)
	  	 	151	  
	 Schedule 10 Allocation (Clause 3.2)
	  	 	161	  
	 Schedule 11 VAT
	  	 	163	  
	 Schedule 12 Closing Obligations
	  	 	165	  
	 Schedule 13 Not Used
	  	 	167	  
	Schedule 14 Warranties given under Clause 9.1	  	 	168	  

							
	 Schedule 15 Warranties given by the Purchaser under Clause 9.3
	  	 	183	  
	 Schedule 16 Certificate (Clause 4.4)
	  	 	184	  
	 Schedule 17 Key Study Plans
	  	 	185	  
	 Schedule 18 Pre-Closing Product Reorganisation
	  	 	186	  
	  Part 1
	  	Description of the Pre-Closing Product Reorganisation	  	 	186	  
	  Part 2
	  	Seller undertakings	  	 	194	  
	  Part 3
	  	Co-operation between the parties; modifications	  	 	195	  
	  Part 4
	  	Definitions	  	 	196	  
	  Part 5
	  	Details of the Company	  	 	197	  
	 Schedule 19 Pre-Closing Obligations
	  	 	198	  
	  Part 1
	  	Seller’s Group Restrictions	  	 	198	  
	  Part 2
	  	Seller’s Group Obligations	  	 	200	  
	 Schedule 20 Key Personnel
	  	 	203	  
	 Schedule 21 Regulatory Approvals
	  	 	204	  
	 Schedule 22 Ongoing Collaboration
	  	 	205	  
	 Schedule 23 Seller Marks
	  	 	208	  
	 Schedule 24 Statement of Company Intra-Group Debt
	  	 	209	  
	 Schedule 25 Delayed Jurisdictions
	  	 	210	  
	 Schedule 26 Assets related to China
	  	 	221	  
	 Schedule 27 Transitional Trademark Licence
	  	 	222	  
	 Schedule 28 Local Payments
	  	 	226	  
	 Schedule 29 Excluded Employees
	  	 	227	  
	 Schedule 30 China Product Trademarks
	  	 	228	  
	 Schedule 31 Anti-bribery and corruption
	  	 	229	  
	 Schedule 32 Ukraine Business
	  	 	231	  

 Sale and Purchase Agreement 
 This Agreement is made on 22 April 2014, as amended and restated on 29 May 2014, and as further amended and restated on 21 November 2014 and on 1 March 2015. 

Between: 
  

	(1)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford TW8 9GS,
United Kingdom (the “Seller”); and 

  

	(2)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the
“Purchaser”), 

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	As of the date of this Agreement, the Seller and certain of the Seller’s Affiliates own or license certain assets and other rights relating to the Products and are
engaged in the Business; 

  

	(B)	The Seller has agreed, inter alia, to procure the sale of the Share and to sell or license (or cause the sale or licence of) certain assets and other rights
relating to the Products together with the Assumed Liabilities comprising the Business, and to assume the obligations imposed on the Seller under this Agreement; 

 

	(C)	The Purchaser has agreed, inter alia, to purchase or procure the purchase of the Share and to purchase or license certain assets and other rights relating to the
Products, together with the Assumed Liabilities comprising the Business, and to assume the obligations imposed on the Purchaser under this Agreement; 

  

	(D)	In connection with the transactions contemplated by this Agreement, the Purchaser and the Seller, or certain of their respective Affiliates, will enter into the
Ancillary Agreements; and 

  

	(E)	The Seller has notified the Purchaser of its intention to carry out the Pre-Closing Product Reorganisation and accordingly this Agreement has been amended to give
effect to it. 

 It is agreed as follows: 
  

	1.	Interpretation 

 In this
Agreement, unless the context otherwise requires, the provisions in this Clause 1 apply: 
  

	1.1	Definitions 

“Abandoned Patent(s)” means any Patent Exclusively Related to the Business abandoned by a member of the Seller’s
Group before Closing from which a Patent that constitutes a Business Product Intellectual Property Right can claim priority, or from the priority chain of which a right to priority can be claimed in respect of a Patent that constitutes a Business
Product Intellectual Property Right; 

  
 1 

 “Action” means the taking of any steps by any Governmental Entity to
seek a Judgment which would have the effect of preventing the consummation of the transactions contemplated by this Agreement by the Purchaser; 
 “Affiliate” means: 
  

	 	(i)	with respect to any person (other than a party to this Agreement), any other person that Controls, is Controlled by or is under common Control with such person; or

  

	 	(ii)	with respect to a party to this Agreement, any other person that is Controlled by such party, 

and “Affiliates” shall be interpreted accordingly; 

“Agreed Terms” means, in relation to a document, such document in the terms agreed between the Seller and the
Purchaser and signed for identification purposes by the Seller’s Lawyers and the Purchaser’s Lawyers, with such alterations as may be agreed in writing between the Seller and the Purchaser from time to time; 

“Agreed UK Restructuring Arrangement” means the pension augmentation (or cash in lieu of augmentation) policy applying on
redundancy to UK employees of the Seller’s Group who joined service prior to 1 April 2005 as disclosed to the Purchaser prior to the date of this Agreement via a document which was signed on 22 April 2014 by Eleanor Hart of Slaughter and May
and Andrew Murphy of Freshfields Bruckhaus Deringer LLP for identification purposes; 
 “Agreement” means
this sale and purchase agreement; 
 “Allocation Statement” means a statement prepared in accordance with
Schedule 10 allocating whole number percentages to each of the Products so that the aggregate of those percentages equals 100 per cent.; 
 “Allowance” means any amount payable or repayable to customers in respect of a contractual allowance or discount due on the sales of the Products or any other contractually permitted
deductions from revenue arising from sales of the Products; 
 “Ancillary Agreements” means the
Implementation Agreement, the Company Tax Indemnity, the Direct Indemnity, the Disclosure Letter, the Manufacturing and Supply Agreement, the Transitional Distribution Services Agreement, the France Offer Letter, the France SPA, the Netherlands
Offer Letter, the Netherlands APA, the Purchaser Tax Indemnity, the Transitional Services Agreement, the Ofatumumab Intellectual Property Licence Agreement, the Oncology Intellectual Property Licence Agreement, the Intellectual Property Assignment,
the Claims Management Agreement, the Quality Agreement, the Pharmacovigilance Agreement, and the Oncology Development and Clinical Supply Agreement; 
 “Ancillary Agreement Liabilities” means the Liabilities of any member of the Seller’s Group to any member of the Purchaser’s Group and the Liabilities of any member of the
Purchaser’s Group to any member of the Seller’s Group, in each case arising under any Ancillary Agreement; 

  
 2 

 “Anti-Bribery Law” means any Applicable Law that relates to bribery
or corruption, including the US Foreign Corrupt Practices Act of 1977 and the UK Bribery Act 2010, in each case as amended, re-enacted or replaced from time to time; 
 “Applicable Law” means any supra-national, federal, national, state, municipal or local statute, law, ordinance, regulation, rule, code, order (whether executive, legislative,
judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including common law), or any other order of, or agreement issued, promulgated or entered into by, any Governmental Entity or any rule
or requirement of any national securities exchange, including all Healthcare Laws, and GCP, GLP, and GMP, each as may be amended from time to time; 
 “Aspen Agreements” means: (i) the Amended and Restated Sale and Purchase Agreement dated 14 August 2012 and amended and restated on 30 November 2012, between Glaxo Group Limited and Aspen
Global Incorporated; and (ii) the Principal Manufacturing and Supply Agreement dated 14 August 2002, between GlaxoSmithKline Trading Services Limited and Aspen Global Incorporated; 

“Assets” means the property, rights and assets referred to in Clause 2.3.1, in each case excluding the Excluded
Assets; 
 “Associated Person” means, in relation to the Seller’s Group, a person (including any
director, officer, employee, agent or other intermediary) who performs services for or on behalf of any member of the Seller’s Group or who holds shares of capital stock, partnership interests, limited liability company membership interests and
units, shares, interest and other participations in any member of the Seller’s Group (in each case when performing such services or acting in such capacity); 
 “Assumed Liabilities” means the Liabilities of the Business (including, for the avoidance of doubt, any Delayed Business) other than: (i) the Excluded Liabilities; (ii) any Relevant
Pension and Employment Liability; (iii) any Liabilities in respect of Tax; (iv) any Ancillary Agreement Liabilities; (v) Liabilities in respect of the Ofatumumab Autoimmune Business; and (vi) any Liabilities relating to the Abandoned Patents;

 “Benefit Plans” means the US Benefit Plans and the Non-US Benefit Plans; 

“Business” means the business of the Seller’s Group (including the Company) of research and development (including
any studies or trials (whether or not undertaken with third parties)) relating to the Products and the Commercialisation of the Products but excluding (i) the Manufacturing of the Products and (ii) the Seller Pipeline; 

“Business Consideration” has the meaning set forth in Clause 3.1.1; 

“Business Day” means a day which is not a Saturday, a Sunday or a public holiday in the canton of Basel-Stadt
(Switzerland) or London; 
 “Business Goodwill” means the goodwill of the Business; 

“Business Product Intellectual Property Rights” means the Owned Product Intellectual Property Rights and the Transferred
Product Intellectual Property Rights and including, for the avoidance of doubt, the OBM Intellectual Property Rights; 

  
 3 

 “Business Sellers” means the members of the Seller’s Group that own
assets of or otherwise conduct any of the Business immediately prior to Closing, or for the purposes of the Seller’s Warranties, at the date of this Agreement; 
 “Cabilly Agreement” means the licence and settlement agreement dated 26 March 2012 between: 
  

	 	(i)	Genentech Inc.; 

  

	 	(ii)	City of Hope; 

  

	 	(iii)	Glaxo Group Limited; 

  

	 	(iv)	Lonza Biologics Inc.; and 

  

	 	(v)	Lonza Biologics plc; 

“Call for New Tender” means any calls for a tender (including any tender for a basket of products), whether a new tender
or the renewal of an existing tender, which includes the Products and which is published after Closing of which the Seller and/or any of the Seller’s Affiliates become aware and which relates in whole or in part to the sale of Products;

 “Certificate” means a certificate signed by a director, officer or an authorised signatory of the
Seller in the form set out in Schedule 16, to be provided to the Purchaser immediately prior to Closing; 

“CFIUS” means the Committee on Foreign Investment in the United States; 

“CFIUS Approval” means written notice from CFIUS that any review or investigation of the Transaction under Section 721 of
the Defense Production Act of 1950, as amended (50 U.S.C. App. Section 2170), has been concluded and there are no unresolved national security concerns with respect to the Transaction or the President of CFIUS shall have determined not to take
action with respect to the Transaction; 
 “CFIUS Filing” has the meaning set forth in Clause 4.2.3;

 “China” means the People’s Republic of China excluding Hong Kong Special Administrative Region, Macau
Special Administrative Region and Taiwan; 
 “China Contracts” means the [***] and all other Contracts
exclusively related to the Commercialisation of the China Products in China; 
 “China Marketing Authorisations”
means the Marketing Authorisations held by a Marketing Authorisation Holder in respect of China for the China Products and the Marketing Authorisation Data to the extent exclusively related to such Marketing Authorisations and a “China
Marketing Authorisation” means any one of them; 
 “China Products” means Tykerb, Hycamtin and Zofran,
and a “China Product” shall mean any one of them; 
 “Claims Management Agreement” means the
agreement between the Seller and the Purchaser, to be negotiated in good faith between the parties and entered into at 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 4 

 
Closing, in respect of the management of claims or investigations by or against third parties (including by any Governmental Entity) which constitute or may constitute an Assumed Liability or an
Excluded Liability; 
 “Clinical Employee Transfer Date” means 1 May 2015 or such later date as the parties may
agree; 
 “Clinical Employees” means the Relevant Employees (other than those Relevant Employees who are
employed in France or Italy) who immediately prior to the Closing Date work wholly or substantially in clinical development activities in relation to the Products or the Business, provided that such Relevant Employees shall only constitute Clinical
Employees for so long as they are assigned to provide services within the Transitional Services Agreement; 
 “Clinical
Trial Agreement” has the meaning given to it in paragraph 4.6.2 of Schedule 7; 
 “Clinical Trials/Data
Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable Law in connection with the conduct of, or reporting or data in relation to, clinical studies or trials (including post-approval studies)
in relation to the Products or the Business; 
 “Closing” means the completion of the sale of the Share
and the Business pursuant to this Agreement, and Closing shall be deemed to have taken place notwithstanding that some of the Business has not transferred to the Purchaser pursuant to Schedule 25 in which case the provisions of Schedule 25 shall
then apply in respect thereof; 
 “Closing Date” means the date on which Closing takes place; 

“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985 of the United States, as amended, section
4980B of the Code, Title I Part 6 of ERISA, and any similar US state group health plan continuation law, together with its implementing regulations; 
 “Code” means the U.S. Internal Revenue Code of 1986, as amended, together with its implementing regulations; 

“Commercial Information” means information that is, as of the Closing Date, or, in respect of any Delayed
Business, the Delayed Closing Date, as applicable, owned by the Seller and/or its Affiliates and relates exclusively to the Commercialisation of any Product; 
 “Commercial Practices Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable Law in connection with the Commercialisation of any products;

 “Commercialise” means to promote, market, distribute and/or sell a Product and
“Commercialising” and “Commercialisation” shall be construed accordingly; 

“Commercially Reasonable Litigation Efforts” mean, with respect to the efforts to be expended by the Purchaser in
relation to undertaking litigation in accordance with Schedule 26, those reasonable, diligent commercial efforts in respect to such 

  
 5 

 
litigation that a person with operations of a similar scale and standing in the pharmaceutical industry would normally use when conducting litigation for its own benefit under similar
circumstances; 
 “Company” has the meaning given to it in Schedule 18; 

“Company Intra-Group Debt” means all sums owed by the Company to GlaxoSmithKline Finance plc at the Closing Date
(immediately prior to Closing) as shall be notified by the Seller to the Purchaser in accordance with Clause 6.3.2; 

“Company Tax Indemnity” has the meaning given to it in Schedule 18; 

“Competing Product” has the meaning given to it in Clause 12.1; 

“Contract” means any binding contract, agreement, instrument, lease, licence or commitment, excluding any contract
with any Employee; 
 “Contracts Liabilities” means Liabilities relating to the: (i) Transferred
Contracts; (ii) Transferred Intellectual Property Contracts (but excluding until the OBM Transfer Date, any OBM Intellectual Property Contracts); and (iii) all other contracts or parts thereof transferred, assigned, novated or assumed by the
Purchaser pursuant to this Agreement, and a “Contracts Liability” shall mean any one of them; 

“Control” means the power to direct the management and policies of a person (directly or indirectly), whether
through ownership of voting securities, by Contract or otherwise (and the term “Controlled” shall be interpreted accordingly); 
 “Controlled Business Instruction” has the meaning given to it in sub-paragraph 3.4.1 of Schedule 25; 
 “Co-Owned Business Product Intellectual Property Right” means any Business Product Intellectual Property Right that is owned in part by a third party; 

“Co-Owned Transferred Product Intellectual Property Right” means any Transferred Product Intellectual Property Right that
is owned in part by a third party; 
 “Copyright” means any works of authorship, copyrights, database
rights, mask work rights and registrations and applications therefor; 
 “Cork FDA Matter” means the
deficiencies in GMP noted in the observations made by the FDA in a Form FDA 483 following an inspection of the Cork Site between 18 and 23 October 2013 which are the subject of the Warning Letter dated 18 March 2014 issued by the FDA to a
member of the Seller’s Group; 
 “Data Room” means the electronic data room containing documents and
information relating to the Business made available by Intralinks on behalf of the Seller, the contents of which are listed in the Disclosure Letter; 
 “Decision” means the issuing of any decision by a competition, antitrust, foreign investment, national, local, supranational or supervisory or other government, governmental,
quasi-governmental, trade, or regulatory body, agency, branch, subdivision, department, commission, official or authority, including any Tax Authority 

  
 6 

 
and any governmental department and any court or other tribunal, that would have the effect of prohibiting the acquisition of the Business by the Purchaser; 

“Deferred Employee” means any person to whom the Seller or any other member of the Seller’s Group has made an
offer of employment for a role within the Business in compliance with Clause 5 and whose employment in the Business will take effect on a date following the Closing Date, save that no person shall become a Deferred Employee unless and until the
Seller has provided to the Purchaser a copy of the offer letter setting out the agreed principal terms of employment and/or employment agreement (if executed) applicable to such person; 

“Delayed Business” means the Bangladesh Business, the India Business, the Saudi Business, the Thailand Business and the
Ukraine Business, each as defined in Schedule 25; 
 “Delayed Closing” means, in respect of a Delayed Business,
completion of the transfer of legal ownership of that Delayed Business to the relevant Designated Purchaser in accordance with Schedule 25; 
 “Delayed Closing Date” has the meaning given to it in paragraph 1.4 of Schedule 25; 
 “Delayed Contract” has the meaning given to it in Schedule 7; 

“Delayed Contract Transfer Date” has the meaning given to it in Schedule 7; 

“Delayed Employee Costs” has the meaning given to it in Schedule 25; 

“Delayed Employees” means (i) the Relevant Employees who immediately prior to the Closing Date work in any of the Delayed
Businesses, and (ii) any employees of any member of the Seller’s Group who are appointed to their position (whether by internal or external hire) on or after the Closing Date to work wholly or substantially in the Business in accordance with a
Controlled Business Instruction or Seller Involvement Instruction, and in each case for so long as they are not assigned to work other than wholly or substantially in the Business; 

“Delayed Local Payment Amount” has the meaning given to it in Clause 6.5; 

“Designated Purchaser” means any entity within the Purchaser’s Group acquiring part of the Business; 

“Development Plan” means the development plans and study protocols, including the target product profile, development
designs, timelines and costs of the studies and trials being undertaken by the Seller’s Group (whether or not approved by any Governmental Entity) in respect of each Product Expansion as at the date of this Agreement, including the Key Study
Plans; 
 “Direct Indemnity” has the meaning given to it in Schedule 18; 

“Disclosure Letter” means the letter dated on the same date as this Agreement from the Seller to the Purchaser disclosing
information constituting exceptions to the Seller’s Warranties; 

  
 7 

 “Distribution Contract” has the meaning given to it in Schedule 7;

 “Distribution Transfer Date” has the meaning given to it in the Transitional Distribution Services Agreement;

 “Divested Zofran Product” means Zofran (Ondansetron) in Australia, following the divestment by the Seller or
its Affiliates of its rights to Commercialise it in Australia only to Aspen Global Incorporated; 
 [***] 

“Effective Time” means 11.59 p.m. (local time in the relevant location) on the Closing Date or, if the Closing Date is
not the last day of a month but the first Business Day of a month, 11.59 p.m. on the last day of the immediately preceding month; 
 “Election Date” has the meaning set forth in Clause 4.2.3; 

“Employee Benefit Indemnification Amount” has the meaning given to it in Schedule 9; 

“Employee Benefits” has the meaning given to it in Schedule 9; 

“Employees” means, other than Excluded Employees, the employees of any member of the Seller’s Group who work
wholly or substantially in the Business from time to time including the International Assignees and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at
the date of this Agreement”, and “Employee” means any one of them; 
 “Encumbrance”
means any claim, charge, mortgage, lien, option, equitable right, power of sale, pledge, hypothecation, usufruct, retention of title, right of pre-emption, right of first refusal or other security interest of any kind or an agreement,
arrangement or obligation to create any of the foregoing, and for the avoidance of doubt, shall exclude any licences of, or claims of infringement relating to, Intellectual Property Rights; 

“ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, as amended, together with
its implementing regulations; 
 “Estimated Employee Benefit Adjustment” means the Seller’s reasonable
estimate (in so far as practicable), made in good faith after consulting with the Purchaser, of 95 per cent. of the anticipated aggregate of the Employee Benefit Indemnification Amounts, to be notified by the Seller to the Purchaser pursuant to
Clause 6.3.9. However, the Seller and the Purchaser may agree in writing to apply a different mechanism to determine and calculate the Estimated Employee Benefit Adjustment; 

“Estimated Business Consideration” means the Seller’s reasonable estimate of the Business Consideration, to be
notified by the Seller to the Purchaser pursuant to Clause 6.3.9; 
 “Estimated Company Intra-Group Debt” means
the Seller’s reasonable estimate of the Company Intra-Group Debt, to be notified by the Seller to the Purchaser pursuant to Clause 6.3.9; 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 8 

 “Estimated Share Consideration” means an amount equal to the product of:

 (x) the Headline Amount less the aggregate of the Estimated Business Consideration, the amount of the Estimated Company
Intra-Group Debt and any Estimated Employee Benefit Adjustment; and 
 (y) 100 divided by 100.5, 

to be notified by the Seller to the Purchaser pursuant to Clause 6.3.9; 

“Estimated Stamp Duty Amount” means an amount equal to 0.5% of the Estimated Share Consideration, to be notified by the
Seller to the Purchaser pursuant to Clause 6.3.9; 
 “Excluded Assets” means the property, rights
and assets referred to in Clause 2.3.2 or Part 1 of Schedule 3; 
 “Excluded Contracts” means,
collectively, each Contract: (i) which is not Exclusively Related to the Business; or (ii) which is listed in Part 2 of Schedule 3, and including, for the avoidance of doubt, until the OBM Transfer Date, any OBM Intellectual Property Contract;

 “Excluded Employees” means: (i) the employees of any member of the Seller’s Group who work
in the Discovery organisation as operated by the Seller’s Group and (ii) the employees of any member of the Seller’s Group who are referred to in Schedule 29; 
 “Excluded Liabilities” means all Liabilities, other than Ancillary Agreement Liabilities and any Liabilities relating to the Abandoned Patents, relating to: 

 

	 	(i)	the Business to the extent they have arisen or arise (whether before or after the applicable Liability Cut-off Time for that Liability) as a result of, or otherwise
relate to, an act, omission, fact, matter, circumstance or event undertaken, occurring, in existence or arising before the applicable Liability Cut-off Time for that Liability, other than any Relevant Pension and Employment Liability;

  

	 	(ii)	the Seller Group Retained Business; and 

  

	 	(iii)	any Seller Allowance, Rebate and Royalty Amount; 

 “Exclusively Related to the Business” means exclusively related to, or exclusively used or held for use exclusively in connection with, the Business; 

“Exploitation Arrangements” has the meaning given to it in Schedule 18; 

“FCA” means the Financial Conduct Authority; 

“FDA” means the United States Food and Drug Administration (or its successor); 

“France Assumed Liabilities” means the Assumed Liabilities to the extent they relate to the France Business; 

  
 9 

 “France Business” means that part of the Business, comprising the
activities of the France Employees; 
 “France Closing” has the meaning given to it in the France SPA;

 “France Employees” means those of the Employees who are employed in France; 

“France Offer Letter” means the letter from the Purchaser to the Seller in respect of the binding offer from the
Purchaser to acquire the France Business dated on or around the date hereof; 
 “France Put Option Exercise” has
the meaning given to it in the France Offer Letter; 
 “France SPA” OR “France APA” has
the meaning given to it in the France Offer Letter; 
 “FSMA” means the Financial Services and Markets
Act 2000; 
 “Full Disclosure” means disclosure by the Seller to the Purchaser of the material terms, including
financial terms, of a Relevant Part of a Shared Business Contract; 
 “Full Title Guarantee” means on the basis
that the covenants implied under Part 1 of the Law of Property (Miscellaneous Provisions) Act 1994 where a disposition is expressed to be made with full title guarantee are deemed to be given by the Seller (on behalf of the relevant Share Seller or
Business Seller) on Closing; 
 “Genmab” means Genmab A/S, a Danish corporation having its principal office at
Toldbodgade 33, DK-1253 Copenhagen K, Denmark; 
 “Genmab Agreement” means the co-development and
collaboration agreement between Genmab and Glaxo Group Limited dated 19 December 2006 (as amended from time to time) relating to the development, manufacturing and commercialisation of pharmaceutical products containing Ofatumumab; 

“Good Clinical Practices” or “GCP” means the then-current standards, practices and
procedures promulgated or endorsed by (i) the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practices for trials on medicinal products in the European Union; (ii) the FDA
as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA; and (iii) the equivalent Applicable Law in any relevant
country; 
 “Good Laboratory Practices” or “GLP” means the then-current
standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices as well as “The rules governing medicinal products in
the European Union,” Volume 3, Scientific guidelines for medicinal products for human use (ex-OECD principles of GLP); (ii) the then-current standards, practices and procedures promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58;
and (iii) the equivalent Applicable Law in any relevant country; 
 “Good Manufacturing Practices” or
“GMP” means the then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission 

  
 10 

 
Directive 91/356/EEC, as amended by Directive 2003/94/EC and 91/412/EEC respectively, as well as “The rules governing medicinal products in the European Union,” Volume 4, Guidelines for
good manufacturing practices for medicinal products for human and veterinary use; (ii) the FDA and the provisions of 21 C.F.R. Parts 210 and 211; (iii) the principles detailed in the ICH Q7A guidelines; and (iv) all Applicable Law with respect to
each of (i) through (iii); 
 “Governmental Entity” means any supra-national, federal, national, state,
county, local, municipal or other governmental, regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities exchange or automated
quotation service including, any governmental regulatory authority or agency responsible for the grant approval, clearance, qualification, licensing or permitting of any aspect of the research, development, manufacture, marketing, distribution or
sale of the Products including the FDA, the European Medicines Agency, or any successor agency thereto; 
 “Governmental
Liability” means any Liability arising out of, relating to or resulting from any claim, demand, action, suit, proceedings or investigation by a Governmental Entity (other than a Tax Authority) brought or undertaken in connection with
products sold or developed by, or operations or practices of, the Seller’s Group prior to Closing; 
 “Gross
Negligence” has the meaning given to it in Schedule 25; 
 “GSK Break Fee” has the meaning given to it
in the Implementation Agreement; 
 “Headline Amount” has the meaning given to it in Clause 3.1.1; 

“Healthcare Laws” means the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)); the Anti-Inducement Law
(42 U.S.C. § 1320a-7a (a)(5)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)); the Exclusion Laws (42 U.S.C. § 1320a-7); the Medicare statute (Title
XVIII of the Social Security Act), including Social Security Act §§ 1860D-1 to 1860D-43 (relating to Medicare Part D and the Medicare Part D Coverage Gap Program); the Medicaid statute (Title XIX of the Social Security Act); the Physician
Payment Sunshine Act (42 U.S.C. § 1320a-7h) and any analogous state laws; the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and
Clinical Health Act of 2009, and any other similar Law, including the price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to
the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8), any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the Veterans Health Care
Act (38 U.S.C. § 8126), regulatory requirements applicable to sales on the Federal Supply Schedule or under any state pharmaceutical assistance program or United States Department of Veterans Affairs agreement, all legal requirements relating
to the billing or submission of claims, collection of accounts receivable, underwriting the cost of, or provision of 

  
 11 

 
management or administrative services in connection with, any and all of the foregoing, by the Seller’s Group and any successor government programs, and all foreign equivalents of the
foregoing; 
 “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
together with its implementing regulations; 
 “Implementation Agreement” means the implementation
agreement dated the date of this Agreement between the Seller, and the Purchaser relating to, amongst other things, the implementation of the Transaction; 
 “Import Drug Licence” means any import drug licence held by a member of the Seller’s Group in respect of the importation of the China Products in China; 

“In-Market Inventory” means all inventory of Products for Commercialisation that, at any particular time: (i) is
beneficially owned by a member of the Seller’s Group; and (ii) is in finished packed form and released for Commercialisation; and (iii) is located: (a) in (or in transit to) the relevant Market; or (b) in (or in transit to) a multi-market
warehouse owned or operated by a member of the Seller’s Group or by a third party; or (c) at a primary or secondary manufacturing site pending despatch following release by the relevant qualified person to the relevant market or multi-market
warehouse; 
 “Information Technology” means computer, hardware, software and network; 

“Intellectual Property Assignment” means, collectively, (i) the intellectual property assignment agreements that may be
entered into between the Seller, the Purchaser or their respective Affiliates at Closing; and (ii) the intellectual property assignment agreement that may be entered into between the Seller (and/or its Affiliates) and the Company at Closing, in each
case on terms consistent with the Agreed Terms; 
 “Intellectual Property Rights” means all: (i) Patents;
(ii) Know-How; (iii) Trademarks; (iv) internet domain names; (v) Copyrights; (vi) rights in designs; (vii) database rights; and (viii) all rights or forms of protection, anywhere in the world, having equivalent or similar effect to the rights
referred to in paragraphs (i) to (vii) above, in each case whether registered or unregistered and including applications for registration of any such thing; 
 “International Assignees” means the employees of any member of the Seller’s Group as may be identified as International Assignees in the International Assignee list provided
to the Purchaser on 27 February 2015, subject to such further changes as the parties may agree; 
 “IP
Liability” means any Liability arising out of, relating to or resulting from any actual or alleged infringement, misappropriation or other violation of Intellectual Property Rights of third parties; 

“JTI” means Japan Tobacco Inc., a Japanese corporation having its principal office at 2-1Toranomon, 2-chome,
Minato-ku, Tokyo 105-8422, Japan; 

  
 12 

 “JTI Agreement” means the licence agreement between JTI and
SmithKline Beecham Corporation (doing business as GSK) dated 18 April 2006 (as amended from time to time); 

“Judgment” means any order, writ, judgment, injunction, decree, stipulation, determination, decision or award
entered by or with any Governmental Entity of competent jurisdiction; 
 “Key Financial Information” means: (i)
the gross profit (being net sales less standard costs, less third party royalties) for each of the Key Products in respect of the financial year ended 31 December 2013; and (ii) the net sales for the Key Products in respect of the financial years
ended 31 December 2012 and 31 December 2011, as set out in an annex to the Disclosure Letter; 
 “Key
Personnel” means the Employees listed in Schedule 20; 
 “Key Products” means Tykerb,
Promacta, Votrient, Arzerra, Tafinlar and Mekinist; 
 “Key Study Plans” means the plans relating to certain
combination studies involving the Products appended to this Agreement at Schedule 17; 
 “Know-How” means
all existing and available technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes and formulae, including all biological, chemical,
pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, preclinical and clinical data; 

“Liabilities” means all liabilities, claims, damages, proceedings, demands, orders, suits, costs, losses and
expenses of every description, whether deriving from contract, common law, statute or otherwise, whether present or future, actual or contingent, ascertained or unascertained or disputed and whether owed or incurred severally or jointly or as
principal or surety; 
 “Liability Cut-off Time” means (i) Closing in respect of any Liability that is a
Clinical Trials/Data Liability, Commercial Practices Liability, Governmental Liability, IP Liability, or Product Liability; (ii) Delayed Closing in respect of any Liability that relates to a Non-Controlled Delayed Business and is a Clinical
Trials/Data Liability, Commercial Practices Liabilities, Governmental Liability, IP Liability, or Product Liability (but, in respect of any such IP Liability or Product Liability that arises as a result of or otherwise relates to, any act, omission,
fact, matter or circumstance or event undertaken, occurring, in existence, or arising between Closing and Delayed Closing, only to the extent that such Liability arises due to the wilful default or Gross Negligence of the relevant Seller or any of
its Associated Persons); or (iii) the Effective Time in respect of any other Liability; 
 [***] 

“LIBOR” means the London interbank offered rate, being the interest rate offered in the London inter-bank market
for three month US dollar deposits as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the Closing Date; 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 13 

 “Licensed Intellectual Property Contract” means any Contract under
which Product Intellectual Property Rights have been licensed by a third party to the Seller or any Affiliate thereof or to a third party by the Seller or any Affiliate thereof, including any OBM Intellectual Property Contract; 

“Licensed Product Intellectual Property Rights” means all Intellectual Property Rights licensed to the Seller or
its Affiliates under any Transferred Intellectual Property Contract; 
 “Listing Rules” means the listing
rules made by the FCA under section 73A of FSMA; 
 “Local Payment Amount” has the meaning given to it in Clause
6.4; 
 “Local Transfer Document” has the meaning given to it in Clause 2.5; 

“Long Stop Date” has the meaning given to it in Clause 4.3; 

“Losses” means all losses, liabilities, costs (including legal costs and experts’ and consultants’
fees), charges, expenses, actions, proceedings, claims and demands; 
 “MA Costs” has the meaning given to it in
paragraph 4.1 of Part 2 of Schedule 6; 
 “MA Documentation” has the meaning given to it in
paragraph 1.6 of Part 2 of Schedule 6; 
 “Manufacture” or “Manufacturing” or
“Manufactured” means planning, purchasing of materials for, production, processing, compounding, storage, filling, packaging, labelling, leafleting, warehousing, quality control testing, waste disposal, quality release, sample
retention and stability testing of products; 
 “Manufacturing and Supply Agreement” means the manufacturing and
supply agreement to be entered into between an Affiliate of the Seller and an Affiliate of the Purchaser at Closing on terms consistent with the heads of terms in the Agreed Terms; 

“Manufacturing Licences” means any certificates, permits, licences, consents and approvals issued by any Governmental
Entity, used in the operation or conduct of Manufacturing any Product, and “Manufacturing Licence” shall be construed accordingly; 
 “Marketing Authorisation Data” means the existing and available dossiers containing the relevant Know-How used by the Seller and/or its Affiliates to obtain and maintain the
Marketing Authorisations including with respect to any Product Expansion Application; 
 “Marketing Authorisation
Holder” means the holder of the relevant Marketing Authorisation; 
 “Marketing Authorisation
Re-registration” has the meaning given to it in paragraph 1.1.2 of Part 2 of Schedule 6; 

  
 14 

 “Marketing Authorisation Re-Registration Date” means the date on which the
relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Re-registration; 

“Marketing Authorisation Transfer” has the meaning given to it in paragraph 1.1.1 of Part 2 of Schedule 6;

 “Marketing Authorisation Transfer Date” means the date on which the relevant Governmental Entity approves, or
is deemed to approve, the relevant Marketing Authorisation Transfer; 
 “Marketing Authorisation Transferee”
means the member of the Purchaser’s Group or, where no member of the Purchaser’s Group satisfies the requirements under Applicable Law to be transferred the relevant Marketing Authorisation, such Third Party as is nominated by the
Purchaser, in either case to whom the relevant Marketing Authorisation is to be transferred; 
 “Marketing
Authorisations” means the marketing authorisations issued or applications for marketing authorisations with respect to the Products and all supplements, amendments and revisions thereto including any pending Product Expansion
Application; 
 “Markets” means the markets in which the Products are marketed and sold under the relevant
Marketing Authorisation, and “Market” shall be construed accordingly; 
 “Material Adverse
Effect” means any matter, change, event or circumstance arising or discovered on or after the date of this Agreement and prior to Closing (including a breach of the Seller’s obligations under Clause 5 or Clause 9.1) (a
“Relevant Matter”) that, individually or in the aggregate with other Relevant Matters, if known to the Purchaser prior to the date of this Agreement, could reasonably have expected to have resulted in the Purchaser offering to
acquire the Business on the terms of this Agreement at a discount to the Headline Amount of 30 per cent. or more, and, in determining such reduction, regard shall be had to the actual basis on which the Purchaser determined the Headline Amount. A
Relevant Matter shall not constitute or count towards a “Material Adverse Effect” to the extent resulting or arising from: 
  

	 	(i)	any change that is generally applicable to, or generally affects, the industries or markets in which the Business operates (including changes arising as a result of
usual seasonal variations) or arises from or relates to changes in Applicable Law or accounting rules or changes in any authoritative interpretation of any Applicable Law by any Governmental Entity; 

 

	 	(ii)	any change in financial, securities or currency markets or general economic or political conditions or changes in prevailing interest rates or exchange rates;

  

	 	(iii)	the execution of this Agreement, the public announcement thereof or the pendency or consummation of the transactions contemplated hereby (including any cancellations of
or delays in customer orders or other decreases in customer demand, any reduction in revenues and any disruption in supplier, distributor, customer or similar relationships); or 

  
 15 

	 	(iv)	the taking of any action expressly required by this Agreement or by any Ancillary Agreement or otherwise taken with the advance written consent of the Purchaser,

 except, in relation to either paragraph (i) or paragraph (ii) above, if that change adversely affects
the Business in a disproportionate manner relative to other comparable businesses operating in the same industry and geographic markets as the Business (in which case it may constitute or count towards a “Material Adverse Effect”);

 “Material Employee Jurisdictions” means France, Germany, Japan, the United Kingdom and the United States
of America; 
 “Medical Information” means information relating to clinical and technical matters, such as
therapeutic uses for the approved indications, drug-disease information, and other product characteristics Exclusively Related to the Business which is available to or used by the Seller and/or its Affiliates; 

[***] 
 [***]

 [***] 

[***] 

“Moratorium Date” has the meaning given to it in Schedule 7; 

“Multi-Basket Tender” means any Tender other than a Products-Only Tender; 

“Netherlands APA” has the meaning given to it in the Netherlands Offer Letter; 

“Netherlands Assumed Liabilities” means the Assumed Liabilities to the extent they relate to the Netherlands Business;

 “Netherlands Business” means that part of the Business, comprising the activities of Netherlands Employees;

 “Netherlands Closing” has the meaning given to it in the Netherlands APA; 

“Netherlands Employees” means those of the Employees who are employed in the Netherlands; 

“Netherlands Offer Letter” means the letter from the Purchaser to the Seller in respect of the binding offer from the
Purchaser to acquire the Netherlands Business dated on or around the date hereof; 
 “Netherlands Put Option
Exercise” has the meaning given to it in the Netherlands Offer Letter; 
 “New Marketing Authorisation”
has the meaning given to it in paragraph 3.1 of Part 2 of Schedule 6; 
 “Non-Controlled Delayed Business”
has the meaning given to it in Schedule 25; 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 16 

 “Non-Transferring Tender” means: 

 

	 	(i)	any Products-Only Tender which is subject to public procurement law and regulation in the relevant Market and cannot be transferred under Applicable Law; and

  

	 	(ii)	any Multi-Basket Tender; 

“Non-US Benefit Plans” has the meaning given to it in paragraph 13.3.1 of Schedule 14; 

“Notice” has the meaning given to it in Clause 16.11.1; 

“Novartis Break Fee” has the meaning given in the Implementation Agreement; 

“OBM Transferred Rights” mean the OBM Intellectual Property Contracts, OBM Intellectual Property Rights, and the Seller
OBM Rights; 
 “OBM Transfer Date” means the date at which possession of the Ofatumumab Biological Materials is
divided between the Seller (or any member of its Group) and the Purchaser (or any member of its Group) in accordance with Annex 1 of the Manufacturing and Supply Agreement; 
 “OBM Intellectual Property Contracts” mean any Contract pursuant to which Intellectual Property Rights exclusively related to, exclusively used in, or exclusively held for use in
connection with Ofatumumab Biological Materials are licensed to the Seller (or any member of the Seller’s Group) from a Third Party as at the Closing Date; 
 “OBM Intellectual Property Rights” mean any Intellectual Property Rights (i) owned by the Seller (or any member of the Seller’s Group); and (ii) exclusively related to, exclusively
used in, or exclusively held for use in connection with the Ofatumumab Biological Materials as at the Closing Date; 

“Ofatumumab Autoimmune Business” means the business of the Seller’s Group of research, development, Manufacture and
Commercialisation of the Ofatumumab Compound, as carried out by or on behalf of the Seller’s Group pursuant to the Ofatumumab Intellectual Property Licence Agreement; 
 “Ofatumumab Agreements” means the Transferred Contracts and the Transferred Intellectual Property Contracts (excluding the OBM Intellectual Property Contracts) that relate to the
Ofatumumab Compound, including but not limited to (i) the Genmab Agreement, (ii) the side letter to the Genmab Agreement dated 8 June 2012, and (iii) the Cabilly Agreement; 
 “Ofatumumab Biological Materials” mean all tangible biological materials, cells, reference standards, assays and media that (i) are exclusively related to, exclusively used in, or
exclusively held for use in connection with, the Arzerra Product or the Ofatumumab Compound; and (ii) are not commercially available to the Purchaser on commercially standard terms, including (without limitation) the Ofatumumab Cell Line, Ofatumumab
MCB, Ofatumumab WCB and the cell line provided by American Type Culture Collection; 

  
 17 

 “Ofatumumab Cell Line” means the cell line(s) that express the Ofatumumab
Compound, including any derivatives, progeny or modifications thereof; 
 “Ofatumumab Compound” means the
compound Ofatumumab; 
 “Ofatumumab Indications” means: (i) multiple sclerosis; (ii) rheumatoid arthritis; (iii)
pemphigus; and (iv) neuromyelitis optica; 
 “Ofatumumab Indications Data” means any data or other information
owned by any member of the Seller’s Group as at the Closing Date relating exclusively to the use of the Ofatumumab Compound for the Ofatumumab Indications; 
 “Ofatumumab Intellectual Property Licence Agreement” means the intellectual property licence agreement to be entered into between members of the Seller’s Group and the
Purchaser’s Affiliate at Closing in respect of the grant of a licence from the Purchaser’s Affiliate to the Seller’s Affiliate of certain Intellectual Property Rights related to the Ofatumumab Compound; 

“Ofatumumab MCB” means the reference deposit or collection of vials of the Ofatumumab Cell Line, from which the
Ofatumumab WCB is derived; 
 “Ofatumumab WCB” means a vialed collection of serially subcultivated cells that is
derived from the Ofatumumab MCB, and used to establish seed cultures of the Ofatumumab Cell Line;” 
 “OIG”
has the meaning given to it in Clause 4.1.12; 
 “Oncology Development and Clinical Supply Agreement” means
the development and clinical supply agreement dated the date of this Agreement between the Seller and Novartis Pharma AG, pursuant to which the Seller will manufacture and supply certain development materials to Novartis Pharma AG; 

“Oncology Intellectual Property Licence Agreement” means the intellectual property licence agreement to be entered into
between Affiliates of the Seller and an Affiliate of the Purchaser at Closing in respect of the grant of licences from the Seller’s Affiliate to the Purchaser’s Affiliate of certain Intellectual Property Rights; 

“Ongoing Clinical Trials” means the ongoing clinical studies sponsored or supported by the Seller Group (including
post-approval studies) or otherwise recommended by a Governmental Entity, and regulatory commitments in respect of the Products, and “Ongoing Clinical Trial” shall mean any one of them; 

“Out of Scope Patent” means any Patent of the Seller’s Group at the Closing Date, but excluding: (i) the Business
Product Intellectual Property Rights; and (ii) any Patents licensed under the Oncology Intellectual Property Licence Agreement; 

“Owned Product Intellectual Property Rights” means the Intellectual Property Rights listed at Part 1 of Schedule 2 and
all other Intellectual Property Rights Exclusively Related to the Business that, in each case, are owned by the Company, including the Registered Owned Product Intellectual Property Rights and, for the avoidance of doubt, excluding any Intellectual
Property Rights in Seller Combination Compounds; 

  
 18 

 “PA Transfer Date” means, in relation to a Product, the date upon
which the relevant Governmental Entity approves and notifies the Product Approval (as applicable) naming the Purchaser or the relevant Affiliate of the Purchaser (or designee thereof) as the holder of such Product Approval in the relevant country or
territory covered by that Product Approval; 
 “Patents” means, patents, design patents, patent
applications, and any reissues, re-examinations, divisionals, continuations, continuations-in-part, provisionals, and extensions thereof or any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating
to any of the foregoing); 
 “Patent Term Extensions” means any and all extension of the term of a Patent
granted under the Patent laws or regulations of any country, the European Union (including any supplementary protection certificate), or any other Governmental Entity; 
 “Pending Marketing Authorisation” has the meaning given to it in paragraph 3.2 of Part 2 of Schedule 6; 
 “Permitted Cash Receivable” means a debt owed to the Company by a member of the Seller’s Group other than GlaxoSmithKline Finance plc, payable on demand to the Company or as the
Company directs, not exceeding £5 million multiplied by the number of months from and including 29 September 2014 to Closing; 
 “Permitted Encumbrance” means: 
  

	 	(i)	Encumbrances imposed by Applicable Law otherwise than in respect of Tax; 

  

	 	(ii)	Encumbrances imposed in the ordinary course of business which are not yet due and payable or which are being contested in good faith; 

 

	 	(iii)	Encumbrances which are listed in Schedule 5; and 

  

	 	(iv)	liens, title retention arrangements or deposits to secure the performance of bids, trade contracts (other than for borrowed money), conditional sales contracts, leases,
statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of the Business; 

 “Pharmacovigilance Agreement” means the agreement between the Seller and the Purchaser, to be entered into at Closing, in respect of pharmacovigilance and regulatory matters
relating to the Products; 
 “Pre-Closing Product Reorganisation” means the steps described in Part 1 of
Schedule 18 as may be amended from time to time in accordance with Part 3 of Schedule 18; 
 “Pre-Closing
Receivables” means all outstanding payments due to the Seller or any of its Affiliates related to the period prior to the Effective Time (whether such payments have arisen or arise before or after the Effective Time) for goods or
services supplied or rights licensed by it or on its behalf in the ordinary and usual course of carrying on the Business other than the Permitted Cash Receivable; 

  
 19 

 “Proceedings” means any legal actions, proceedings, suits,
litigations, prosecutions, investigations, enquiries, mediations or arbitrations; 
 “Product Approvals”
means all permits, licences, certificates, clearances, registrations or other authorisations or consents issued by any Governmental Entity to the Seller or one of its Affiliates with respect to the Products or the Product Expansions, or the
manufacture, use, research, development, marketing, distribution or sale thereof, including the Marketing Authorisations; 

“Product Expansion Applications” means all of the applications or planned applications for Product Expansions set
out in Schedule 1 including those listed in the column “Product Expansion Applications” in Part 1 of Schedule 1, with each individual application being a “Product Expansion Application”; 

“Product Expansion” means in relation to any Product: 

 

	 	(i)	the expansion of the indications or formulations for such Product for use as monotherapy; and 

 

	 	(ii)	the expansion of the indications or formulations for such Product for use in combination with any other compound including without limitation those set out in Part 2 of
Schedule 1 but excluding any Seller Combination Compounds; 

 “Product Filings” means all
filings, written representations, declarations, listings, registrations, reports or submissions with or to any Governmental Entity, including adverse event reports and all submitted data relating to each Product; 

“Product Intellectual Property Rights” means all Intellectual Property Rights related to, or used, or held for use
in connection with the Products or the manufacture, use, research, development, marketing, distribution or sale thereof, including for the avoidance of doubt, the OBM Intellectual Property Rights; 

“Product Liabilities” means any Liability arising out of, relating to or resulting from actual or alleged harm,
injury, damage or death to persons in connection with the use of any product (including in any clinical trial or study); 

“Product Partners” means any third parties which pursuant to a Contract with the Seller or any Affiliate of the
Seller co-develop, co-promote, co-market, or otherwise have a licence or other right to research, develop, manufacture, promote, distribute, market, or sell any Product, including all manufacturers and suppliers of any such Product; 

“Products” means the products set out under the heading “Products” in Part 1 of Schedule 1 (but
excluding the Divested Zofran Product); 
 “Products-Only Tender” means any Tender that relates solely to the
Products; 

  
 20 

 “Proprietary Information” means all confidential and proprietary
information of the Seller or its Affiliates that is Exclusively Related to the Business, including confidential Medical Information confidential Know-How and confidential Commercial Information; 

“Purchaser’s Group” means the Purchaser and its Affiliates from time to time, and includes the Company with
effect from Closing; 
 “Purchaser’s Lawyers” means Freshfields Bruckhaus Deringer LLP of 65 Fleet
Street, London EC4Y 1HS, United Kingdom; 
 “Purchaser Tax Indemnity” has the meaning given to it in
Schedule 18; 
 “Quality Agreement” means the agreement between the Seller and the Purchaser, to be
entered into at Closing, in respect of regulatory compliance and product safety and quality with respect to the manufacture of the Products; 
 “Rebate” means any amount payable or repayable to customers or Governmental Entities in respect of a contractual rebate or other rebate including under applicable Healthcare Laws
(or under similar laws or regulations) due on sales of the Products; 
 “Reduction Amount” has the meaning given
to it in Clause 6.3; 
 “Registered Business Product Intellectual Property Rights” means all Business
Product Intellectual Property Rights that are Registered Intellectual Property Rights, including those set out at Part 1 of Schedule 2; 
 “Registered Intellectual Property Product Rights” means all Registered Business Product Intellectual Property Rights, Registered Licensed Product Intellectual Property Rights and
Registered Shared Product Intellectual Property Rights; 
 “Registered Intellectual Property Rights”
means Intellectual Property Rights that are registered, issued, filed, or applied for under the authority of any Governmental Entity; 
 “Registered Licensed Product Intellectual Property Rights” means all Licensed Product Intellectual Property Rights that are Registered Intellectual Property Rights; 

“Registered Owned Product Intellectual Property Rights” means all Owned Product Intellectual Property Rights that are
Registered Intellectual Property Rights, including those set out at Part 1 of Schedule 2; 
 “Registered Shared Product
Intellectual Property Rights” means all Shared Product Intellectual Property Rights that are Registered Intellectual Property Rights; 
 “Registered Transferred Product Intellectual Property Rights” means all Transferred Product Intellectual Property Rights that are Registered Intellectual Property Rights, including
those set out at Part 1 of Schedule 2; 
 “Regulation” has the meaning given to it in Clause 4.1.1;

 “Relevant Development Product” has the meaning given to it in Clause 8.12; 

  
 21 

 “Relevant Employees” means the Employees immediately prior to the
Closing Date and “Relevant Employee” means any one of them; 
 “Relevant Employers”
means the Sellers and such other members of the Seller’s Group who employ the Relevant Employees; 
 “Relevant
Part” means the relevant part of the Shared Business Contracts which relates exclusively to the Business (or the relevant part of the Business that is transferred to the Purchaser at Closing); 

“Relevant Pension and Employment Liability” means (i) any Liabilities assumed by the Purchaser or a member of the
Purchaser’s Group as contemplated by Schedule 8; and (ii) any Transferred Employee Benefit Liabilities (as defined in Schedule 9) which the Purchaser agrees to assume in accordance with Schedule 9; 

“Relevant Period” means the period of two years prior to the date of this Agreement; 

“Relevant Purchaser Business” has the meaning given to it in Clause 4.1.12; 

“Relevant Working Day” means a normal working day in the relevant jurisdiction and excludes a Saturday or Sunday or a
public holiday in the relevant jurisdiction; 
 “Reporting Accountants” means the London office of Ernst &
Young or, if that firm is unable or unwilling to act in any matter referred to them under this Agreement, the London office of Deloitte or, if that firm is also unable or unwilling to act in any matter referred to them under this Agreement, an
internationally recognised and independent firm of accountants who does not act as auditor to the Seller or the Purchaser, to be agreed by the Seller and the Purchaser within seven days of a notice by one to the other requiring such agreement or,
failing such agreement, to be nominated on the application of either of them by or on behalf of the Institute of Chartered Accountants of England and Wales; 
 “Representatives” means, in relation to any party, any of its and/or any other member of the Purchaser’s Group’s or Seller’s Group’s directors, officers, employees,
agents, representatives, bankers, auditors, accountants, financial advisers, legal advisers and any other professional advisers; 

“Required Notifications” has the meaning given to it in Clause 4.2.1; 

“Restricted Group Employee” means any Transferred Employee who is at or above grade GG5 or GJFA3 (or in either case the
Purchaser’s equivalent from time to time); 
 “Royalty” means any royalty payable in respect of sales of
the Products; 
 [***] 
 “Sanctions Law” has the meaning given to it in paragraph 7 of Schedule 14; 
 “Seller Allowance, Rebate and Royalty Amount” means any Allowance, Rebate or Royalty payable after the Effective Time by the Purchaser or any member of the Purchaser’s Group, to the
extent it relates to the sales of any Products made prior to the Effective Time; 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 22 

 “Seller Articles of Association” means the articles of association
of the Seller in force and effect from time to time; 
 “Seller Combination Compounds” means any compounds owned
by the Seller or a member of the Seller’s Group (other than a Product) which are used in combination with the Products; 

“Seller Marks” means any Trademark of the Seller containing the marks listed in Schedule 23; 

“Seller OBM Rights” has the meaning given to it in Clause 2.3.1(x); 

“Seller Pipeline” means: 
  

	 	(i)	any research and development activities relating to any compound (other than the Products) at any stage of development by or on behalf of the Seller that is not yet
approved for marketing for use in humans and all assets, rights and contracts relating to those activities (except where those assets, rights and contracts relate to the Products, save in relation to (ii) below); and 

 

	 	(ii)	subject to Clause 8.5.3, assets, rights and contracts relating to pre-clinical research which do not relate exclusively to the Products; 

“Seller Partner” shall mean any counterparty to a development, contract research, commercialisation, manufacturing,
distribution, sales, marketing, supply, consulting or other collaboration Contract with the Seller or any Affiliate of the Seller; 
 “Seller Shareholder Meeting” has the meaning given to it in Clause 4.1.8; 
 “Seller Shareholder Resolution” has the meaning given to it in Clause 4.1.8; 
 “Seller Shareholders” means the holders of ordinary shares in the capital of the Seller from time to time; 
 “Seller’s Group” means the Seller and its Affiliates from time to time but excluding from Closing, the Company; 

“Seller’s Group Insurance Policies” means all insurance policies (whether under policies maintained with
third party insurers or any member of the Seller’s Group) maintained by the Seller or any member of the Seller’s Group in relation to the Business or under which, immediately prior to Closing, the Seller or any member of the Seller’s
Group in relation to the Business is entitled to any benefit, and “Seller’s Group Insurance Policy” means any one of them; 
 “Seller’s Group Retained Business” means all businesses of the Seller’s Group, including the manufacture and/or supply of the Divested Zofran Product pursuant to the Aspen
Agreements, but excluding the Business; 
 “Seller’s Indian Business” means that part of the Business
conducted by any member of the Seller’s Group in the Republic of India; 
 “Seller’s Intra-Group Licence
Agreement” means the: 

  
 23 

	 	(i)	licence agreement, effective from 31 December 2012, between GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property (No. 2) Limited relating to the Group 4 Sold
ROW Entrepreneurial Rights (as defined in such Seller’s Intra-Group Licence Agreement); 

  

	 	(ii)	licence agreement, effective from 31 December 2012, between GlaxoSmithKline LLC, GlaxoSmithKline Intellectual Property Holdings Limited and GlaxoSmithKline Intellectual
Property (No. 2) Limited relating to the Group 4 Contributed Entrepreneurial Rights (as defined in such Seller’s Intra-Group Licence Agreement); 

  

	 	(iii)	licence agreement, effective from 31 December 2012, between GlaxoSmithKline LLC, GlaxoSmithKline Intellectual Property Holdings Limited and GlaxoSmithKline Intellectual
Property (No. 2) Limited relating to the Group 4 Licensed ROW Entrepreneurial Rights (as defined in such Seller’s Intra-Group Licence Agreement); 

  

	 	(iv)	licence agreement, effective from 31 December 2012, between Glaxo Group Limited and GlaxoSmithKline Intellectual Property Management Limited relating to the Group 2
Entrepreneurial Rights (as defined in such Seller’s Intra-Group Licence Agreement); 

  

	 	(v)	licence agreement between SmithKline Beecham Corporation (now known as GlaxoSmithKline LLC) and SmithKline Beecham (Cork) Limited (which assigned its rights to
GlaxoSmithKline Consumer Healthcare Ireland IP Limited, effective from 26 January 2015) with an effective date of 1 January 1997 relating to Hycamtin; and 

  

	 	(vi)	licence agreement, effective from 31 December 2012, between Glaxo Group Limited and GlaxoSmithKline Intellectual Property Limited relating to the Non-Partnership Asset
Entrepreneurial Rights (as defined in such Seller’s Intra-Group Licence Agreement) 

 and
“Seller’s Intra-Group Licence Agreements” in the plural; 
 “Seller’s Knowledge” has
the meaning given to it in Clause 9.1.4; 
 “Seller’s Lawyers” means Slaughter and May of One
Bunhill Row, London EC1Y 8YY; 
 “Seller’s Warranties” means the warranties given by the Seller
pursuant to Clause 9.1 and Schedule 14, and “Seller’s Warranty” means any one of them; 

“Separation” has the meaning given to it in paragraph 3.4 of Schedule 7; 

“Service Provider” means an Associated Person who is a legal person; 

“Share” means the entire issued share capital of the Company; 

“Share Consideration” means an amount equal to the product of: 

  
 24 

 (x) the Headline Amount less the aggregate of the Business Consideration, the amount of the
Company Intra-Group Debt and any Employee Benefit Indemnification Amount; and 
 (y) 100 divided by 100.5; 

“Share Seller” means Glaxo Group Limited, a company incorporated in England and Wales with registered number 00305979;

 “Shared Business Contracts” means any Contract which relates both: 

 

	 	(i)	to the Business or any part of the Business to be transferred to the Purchaser at Closing; and 

 

	 	(ii)	to any part of the Seller’s Group Retained Business, any product other than the Products, or any Excluded Asset, 

and to which a member of the Seller’s Group is a party or in respect of which a member of the Seller’s Group has any right,
liability or obligation at Closing (including, for the avoidance of doubt, the Zofran Trade Mark and Domain Name Licence and the Multi Basket Tenders) and “Shared Business Contract” shall mean any of them; 

“Shared Product Intellectual Property Rights” means all Intellectual Property Rights which shall be licensed to
the Purchaser pursuant to the Oncology Intellectual Property Licence Agreement; 
 “Six-Month LIBOR”
means the London interbank offered rate, being the interest rate offered in the London inter-bank market for six month US dollar deposits as displayed on page LIBOR01 of the Reuters screen at 11 a.m. (London) on the second Business Day
prior to the date on which the Reduction Amount becomes payable; 
 [***] 

“Stamp Duty Amount” means an amount equal to 0.5% of the Share Consideration; 

“Target Asset Agreements” has the meaning given to it in the Implementation Agreement; 

“Taxation” or “Tax” has the meaning given to it in the Company Tax Indemnity; 

“Tax Authority” means any taxing or other authority competent to impose any liability in respect of Taxation or
responsible for the administration and/or collection of Taxation or enforcement of any law in relation to Taxation; 

“Tax Group” has the meaning given to it in the Company Tax Indemnity; 

“Tax Return” has the meaning given to it in the Company Tax Indemnity; 

“Tax Warranties” means the Seller’s Warranties set out in paragraph 11 of Schedule 14; 

“Tenders” means any Contracts or arrangements to which a member of the Seller’s Group is a party (itself or through
an agent) with a third party, entered into following a call for a tender by the relevant third party, for the supply by the Seller’s Group of 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 25 

 
products, including the Products in a Market pursuant to which Products may be sold after Closing; 
 “Third Party Claim” has the meaning given to it in Clause 11.4; 
 “Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from third parties: 

 

	 	(i)	in connection with any step of the Pre-Closing Products Reorganisation; and 

 

	 	(ii)	for the assignment or transfer to the Purchaser or any member of the Purchaser’s Group of any of the Transferred Contracts, Transferred Intellectual Property
Contracts (but excluding until the OBM Transfer Date, the OBM Intellectual Property Contracts), Co-Owned Transferred Product Intellectual Property Rights, or Shared Business Contracts, 

and “Third Party Consent” means any one of them; 
 “Time-Limited Excluded Liability” means an Excluded Liability which is: 
  

	 	(i)	a Contracts Liability; or 

  

	 	(ii)	a Commercial Practices Liability; 

“Trademarks” means trademarks, service marks, trade names, certification marks, service names, industrial designs,
brand names, brand marks, trade dress rights, identifying symbols, logos, emblems, and signs or insignia; 

“Transaction” has the meaning given to it in Clause 4.1.1; 

“Transfer Regulations” means the relevant national measure by which the employment of a Relevant Employee
automatically transfers to the Purchaser or a relevant member of the Purchaser’s Group; 
 “Transferred Books and
Records” means all books, ledgers, files, reports, plans, records, manuals and other materials (in any form or medium) to the extent of, or maintained predominantly for, the Business by the Seller’s Group (other than emails),
including (without limitation) all books, records and other materials relating to the research, development and pre-clinical trials for each of the Products and the Product Expansions but excluding: 

 

	 	(i)	any such items to the extent that: (A) they are related to any Excluded Assets or Excluded Liabilities, (B) they are related to any corporate, Tax, human resources or
stockholder matters of the Seller or its Affiliates, (C) any Applicable Law prohibits their transfer, (D) any transfer thereof otherwise would subject the Seller or any of its Affiliates to any material liability or (E) they are retained by the
Seller in accordance with Clause 8.8.2; 

  

	 	(ii)	any laboratory notebooks to the extent containing research and development information unrelated to the Business; 

 

	 	(iii)	 in relation to Products other than the Key Products, any books and records that are more than 5 years old containing, in whole or in part, research and

  

  
 26 

	 	
development information (other than any laboratory notebooks, books or records described in this paragraph (iii) that are maintained for the Business by the Seller’s Group); and

  

	 	(iv)	any books and records (including but not limited to the content of any personnel files) kept by the Seller’s Group relating to the employment of the Transferred
Employees with the Seller’s Group; 

 “Transferred Contracts” means Contracts (other
than the Transferred Intellectual Property Contracts) that (i) are listed in Part 2 of Schedule 2 or (ii) are between the Seller or a member of the Seller’s Group on the one hand and any third party on the other hand and are Exclusively Related
to the Business (including, without limitation, Products-Only Tenders), but excluding the Excluded Contracts, this Agreement and any Ancillary Agreement; 
 “Transferred Employees” means (i) the Relevant Employees to whom the Purchaser (or a member of the Purchaser’s Group) offers employment and who accept such employment and
become employed by the Purchaser (or a member of the Purchaser’s Group) in accordance with Schedule 8; and (ii) any Relevant Employees who transfer to the Purchaser (or a member of the Purchaser’s Group) by operation of the Transfer
Regulations and do not object to such transfer (to the extent permitted by the Transfer Regulations) in accordance with Schedule 8; and “Transferred Employee” means any one of them; 

“Transferred Intellectual Property Contracts” means Contracts relating to Intellectual Property Rights Exclusively
Related to the Business that are between the Seller or a member of the Seller’s Group on the one hand and any third party on the other hand including any such Contracts set out in Part 2 of Schedule 2 and including, for the avoidance of doubt,
the OBM Intellectual Property Contracts; 
 “Transferred Product Intellectual Property Rights” means the
Intellectual Property Rights listed at Part 1A of Schedule 2 (except where such Intellectual Property Rights are Owned Product Intellectual Property Rights) and all other Intellectual Property Rights Exclusively Related to the Business and owned by
any member of the Seller’s Group (other than the Company), including the Registered Transferred Product Intellectual Property Rights, the OBM Intellectual Property Rights, and, for the avoidance of doubt, excluding any Intellectual Property
Rights in Seller Combination Compounds; 
 “Transitional Services Agreement” means the transitional services
agreement to be entered into between the Seller or its Affiliate and the Purchaser or its Affiliate at Closing (and each local agreement entered into pursuant to such transitional services agreement) on terms consistent with the heads of terms in
the Agreed Terms; 
 “Transitional Distribution Services Agreement” means the transitional distribution services
agreement to be entered into between the Seller or its Affiliate and the Purchaser or its Affiliate at Closing (and each local agreement entered into pursuant to such transitional distribution services agreement) on terms consistent with the heads
of terms in the Agreed Terms; 

  
 27 

 “Ukraine Business” has the meaning given to it in Schedule 25; 

“US Benefit Plans” means all United States “employee benefit plans” (within the meaning of section 3(3)
of ERISA), severance, change in control or employment, vacation, incentive, bonus, stock option, stock purchase, or restricted stock plans, programmes, agreements or policies benefiting the Employees; 

“Vaccines Sale and Purchase Agreement” means the sale and purchase agreement dated the date of this Agreement (as
amended) between the Purchaser and the Seller relating to the sale and purchase of the Purchaser’s vaccines business; 

“VAT” means within the European Union such Taxation as may be levied in accordance with (but subject to derogations from)
Council Directive 2006/112/EC and outside the European Union any Taxation levied by reference to added value or sales; 

“WARN Act” means the Worker Adjustment and Retraining Notification Act of 1988 of the United States; and

 “Zofran Trade Mark and Domain Name Licence” means the trade mark and domain name licence agreement dated 30
November 2012 (as amended from time to time) between (i) Glaxo Group Limited; (ii) SmithKline Beecham (Australia) Pty Limited; (iii) GlaxoSmithKline Australia Pty Limited (together, as licensors); (iv) GlaxoSmithKline Intellectual Property
Management Limited and (v) Aspen Global Incorporated (as licensee), relating to the licensing of certain Intellectual Property Rights in Australia. 
  

	1.2	Singular, plural, gender 

References to one gender include all genders and references to the singular include the plural and vice versa. 

 

	1.3	References to persons and companies 

 References to: 
  

	 	1.3.1	a person include any individual, company, partnership or unincorporated association (whether or not having separate legal personality); and

  

	 	1.3.2	a company include any company, corporation or any body corporate, wherever incorporated. 

 

	1.4	Schedules etc. 

References to this Agreement shall include any Recitals and Schedules to it and references to Clauses and Schedules are to Clauses of, and
Schedules to, this Agreement. References to paragraphs and Parts are to paragraphs and Parts of the Schedules. 

  
 28 

	1.5	Reference to documents 

References to any document (including this Agreement), or to a provision in a document, shall be construed as a reference to such document
or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.6	References to enactments 

Except as otherwise expressly provided in this Agreement, any express reference to an enactment (which includes any legislation in any
jurisdiction) includes references (i) to that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement; (ii) any enactment which that enactment re-enacts (with or without
modification); and (iii) any subordinate legislation (including regulations) made before or after the date of this Agreement under that enactment as amended, consolidated or re-enacted as described in paragraph (i) or (ii) above, except to the
extent that any of the matters referred to in paragraphs (i) to (iii) occurs after the date of this Agreement and increases or alters the liability of the Seller or Purchaser under this Agreement. 

 

	1.7	Information 

 References
to books, records or other information mean books, records or other information in any form including paper, electronically stored data, magnetic media, film and microfilm. 

 

	1.8	References to “indemnify” 

 Unless specified to the contrary, references to “indemnify” and “indemnifying” any person against any circumstance include indemnifying and holding that person harmless on an after-Tax
basis and: 
  

	 	1.8.1	references to the Purchaser indemnifying each member of the Seller’s Group shall constitute undertakings by the Purchaser to the Seller for itself and on
behalf of each other member of the Seller’s Group; 

  

	 	1.8.2	references to the Seller indemnifying each member of the Purchaser’s Group shall constitute undertakings by the Seller to the Purchaser for itself and on
behalf of each other member of the Purchaser’s Group; 

  

	 	1.8.3	to the extent that the obligation to indemnify relates to the Share, the Company or any assets or liabilities transferred by a Business Seller or the Share
Seller (as the case may be) to a member of the Purchaser’s Group pursuant to this Agreement, references to the Seller indemnifying the Purchaser and references to the Seller indemnifying the Purchaser or any member of the Purchaser’s Group
shall constitute undertakings by the Seller to indemnify or procure indemnification of the relevant purchaser of the assets or liabilities or the Share transferred or to be transferred by that Business Seller or the Share Seller or the Company, and
references to the Purchaser indemnifying the Seller and references to the Purchaser indemnifying the Seller and each member of the Seller’s Group shall constitute undertakings by the Purchaser to indemnify or procure the indemnification of the
relevant member of the Seller’s Group; and 

  
 29 

	 	1.8.4	where under the terms of this Agreement one party is liable to indemnify or reimburse another party in respect of any costs, charges or expenses, the payment
shall include an amount equal to any VAT thereon not otherwise recoverable by the other party or any member of any group or consolidation of which it forms part for VAT purposes, subject to that party using reasonable endeavours to recover or
procure recovery of such amount of VAT as may be practicable. 

 For the purposes of this Clause, indemnifying and
holding harmless a person on an “after-Tax basis” means that the amount payable pursuant to the indemnity (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

 

	 	(i)	any Tax required to be deducted or withheld from the Payment and any additional amounts required to be paid by the payer of the Payment in consequence of such
withholding; 

  

	 	(ii)	the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other relief which would otherwise have been available to reduce
the Tax liabilities of any member of the Seller’s Group (or a member of the Purchaser’s Group, as the case may be), have become) payable by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group,
as the case may be) as a result of the Payments being subject to Tax in the hands of that person; and 

  

	 	(iii)	the amount and timing of any Tax benefit which is obtained by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group, as the
case may be) to the extent that such Tax benefit is attributable to the matter giving rise to the indemnity payment or to the receipt of the Payment, 

 which amount and timing is to be determined by the auditors of the recipient at the shared expense of both relevant parties and is to be certified as such to the party making the Payment, the recipient of
the Payment is in no better and no worse after Tax position as that in which it would have been if the matter giving rise to the indemnity payment had not occurred, provided that if either party to this Agreement shall have assigned or novated the
benefit of this Agreement in whole or in part or shall, after the date of this Agreement, have changed its Tax residence or the permanent establishment to which the rights under this Agreement are allocated then no Payment to that party shall be
increased by reason of the operation of paragraphs (i) to (iii) above to any greater extent than would have been the case had no such assignment, novation or change taken place. 

 

	1.9	References to wholly or substantially in the Business 

 References to “wholly or substantially in the Business” in relation to any employee employed by a member of the Seller’s Group means that such employee spends more than 70 per cent. of
their time working in the Business at the relevant time. 

  
 30 

	1.10	Legal terms 

 References
to any English legal term shall, in respect of any jurisdiction other than England and Wales, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction. 

 

	1.11	Non-limiting effect of words 

 The words “including”, “include”, “in particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them. 

 

	1.12	Currency conversion 

Other than in relation to conversion of the Company Intra-Group Debt, where the provisions of Clause 1.13 shall apply, any amount to be
converted from one currency into another currency for the purposes of this Agreement shall be converted into an equivalent amount at the Conversion Rate prevailing at the Relevant Date. For the purposes of this Clause: 

“Conversion Rate” means the spot reference rate for a transaction between the two currencies in question as quoted by the
European Central Bank on the Business Day immediately preceding the Relevant Date or, if no such rate is quoted on that date, on the preceding date on which such rates are quoted; 

“Relevant Date” means, save as otherwise provided in this Agreement, the date on which a payment or an assessment is to
be made, save that, for the following purposes, the date shall mean: 
  

	 	(i)	for the purposes of Clause 5, the date of this Agreement; 

  

	 	(ii)	for the purposes of Clause 10, the date of this Agreement; and 

  

	 	(iii)	for the purposes of the monetary amounts set out in Schedule 14, the date of this Agreement. 

 

	1.13	US$ Spot Rate 

  

	 	1.13.1	For the purposes of Clause 6.3.2, the amount of the Company Intra-Group Debt shall be converted from sterling to US$ at the spot rate of exchange for
sterling into US$ available as soon as possible after 04:00 am GMT on the Closing Date on the Bloomberg screen (the Intraday Chart) or where no such US$ rate is available for such date, at the rate quoted by Barclays Bank on such date.

  

	 	1.13.2	For the purposes of Clause 6.3.9, the estimate of the amount of the Company Intra-Group Debt shall be converted from sterling to US$ at the spot rate of exchange
for sterling into US$ available as soon as possible after 04:00 am GMT on the date on which such estimate is to be given on the Bloomberg screen (the Intraday Chart) or where no such US$ rate is available for such date, at the rate quoted by
Barclays Bank on such date. 

  
 31 

	2.	Sale and Purchase of the Business 

  

	2.1	Sale and Purchase of the Business 

 On and subject to the terms of this Agreement: 
  

	 	2.1.1	the Seller shall procure that the Business Sellers shall sell and assign that part of the Business which is not carried on by the Company immediately before
Closing; and 

  

	 	2.1.2	the Seller shall procure that the Share Seller shall sell the Share in accordance with Clause 2.2; 

 

	 	2.1.3	the Purchaser shall purchase and accept, or procure the purchase and acceptance by one or more other members of the Purchaser’s Group of that part of the
Business which is not carried on by the Company immediately before Closing; and 

  

	 	2.1.4	the Purchaser shall purchase and accept, or procure the purchase and acceptance by another member of the Purchaser’s Group of, the Share,

 such that the Seller shall directly or indirectly relinquish and the Purchaser shall directly or indirectly
acquire the Business as a going concern. 
  

	2.2	Sale of the Share 

  

	 	2.2.1	The Seller shall procure that: 

  

	 	(i)	the Share Seller shall sell the Share with Full Title Guarantee free from Encumbrances and together with all rights and advantages attaching to it as at Closing
(including the right to receive all dividends or distributions declared, made or paid on or after Closing); and 

  

	 	(ii)	on or prior to Closing, any and all rights of pre-emption over the Share and the equity interests in any subsidiaries are waived irrevocably by the person entitled
thereto. 

  

	 	2.2.2	If the Seller notifies the Purchaser under paragraph 4, Part 1 of Schedule 18 that it no longer wishes to proceed with the Pre-Closing Product Reorganisation,
then: 

  

	 	(i)	the provisions of sub-Clauses 2.1.2, 2.1.4 and 2.2.1 shall cease to have effect; and 

 

	 	(ii)	the parties acknowledge that amendments to this Agreement will be required to give effect to that notice such that, subject to any other amendments that may be agreed
by the parties that are not required to implement the Pre-Closing Product Reorganisation, the provisions of this Agreement will be the same as they were after it was amended and restated on 29 May 2014. 

  
 32 

	2.3	The Business, the Excluded Assets, the Assumed Liabilities and the Excluded Liabilities 

 

	 	2.3.1	The Assets to be sold under this Agreement, which shall be sold with Full Title Guarantee (save in respect of the Abandoned Patents and the Transferred Product
Intellectual Property Rights) and free from Encumbrances other than Permitted Encumbrances shall be: 

  

	 	(i)	the Transferred Books and Records; 

  

	 	(ii)	the Transferred Product Intellectual Property Rights (but excluding, until the OBM Transfer Date, the OBM Intellectual Property Rights); 

 

	 	(iii)	subject to and in accordance with Schedule 7, the Transferred Contracts, the Transferred Intellectual Property Contracts (but excluding, until the OBM Transfer Date,
the OBM Intellectual Property Contracts Rights), Co-Owned Transferred Product Intellectual Property Rights and if elected by the Purchaser in accordance with paragraph 3 of Schedule 7, the Relevant Parts of any Shared Business Contracts;

  

	 	(iv)	subject to and in accordance with Schedule 6, all Product Approvals (other than those relating to manufacturing), Product Expansions and all other permits, licences,
certificates, registrations, marketing or other authorisations or consents issued by a Governmental Entity Exclusively Related to the Business; 

  

	 	(v)	subject to and in accordance with Schedule 6, all Marketing Authorisation Data; 

 

	 	(vi)	all Commercial Information; 

  

	 	(vii)	all Medical Information; 

  

	 	(viii)	all rights of the Purchaser or a member of the Purchaser’s Group as contemplated by Schedule 8 and Schedule 9; 

 

	 	(ix)	the Business Goodwill; 

  

	 	(x)	with effect from the OBM Transfer Date, the rights of the Seller (or any member of the Seller’s Group) in the Ofatumumab Biological Materials (the “Seller
OBM Rights”); and 

  

	 	(xi)	all other property, rights and assets owned or held by any member of the Seller’s Group and Exclusively Related to the Business at Closing (other than any
property, rights and assets of the Business Sellers or the Company expressly excluded from the sale under this Agreement). 

  

	 	2.3.2	There shall be excluded from the sale of the Business under this Agreement the following: 

  
 33 

	 	(i)	the Seller’s Group Retained Business, including the Seller Pipeline, any Manufacturing, and any equipment, machinery, spare parts, tools and other tangible
property used by the Seller’s Group for Manufacturing products or in connection with the research and development of the Products or the Product Expansions and any rights or property related to the Seller Combination Compounds (save for, until
the OBM Transfer Date, the Ofatumumab Biological Materials); 

  

	 	(ii)	any Intellectual Property Right that is not a Business Product Intellectual Property Right, and any Contract relating to Intellectual Property Rights that is not a
Transferred Intellectual Property Contract or the Relevant Part of a Shared Business Contract; 

  

	 	(iii)	the Seller Marks; 

  

	 	(iv)	any product and any permits, licences, certificates, registrations, marketing or other authorisations or consents issued by any Governmental Entity in respect of any
products, or any applications therefor, other than the Products, Product Approvals and Product Expansion Applications; 

  

	 	(v)	the In-Market Inventory; 

  

	 	(vi)	any Information Technology; 

  

	 	(vii)	all cash, marketable securities and negotiable instruments, and all other cash equivalents, of the Seller and its Affiliates, other than the Share and the Permitted
Cash Receivable; 

  

	 	(viii)	all real property and any leases therefor and interests therein, together with all buildings, fixtures, and improvements erected thereon; 

 

	 	(ix)	the company seal, minute books, charter documents, stock or equity record books and such other books and records pertaining to the Seller or its Affiliates other than
the Company, as well as any other records or material relating to the Seller or its Affiliates generally and not involving or related to the Business; 

  

	 	(x)	any right of the Seller or its Affiliates to be indemnified in respect of Assumed Liabilities; 

 

	 	(xi)	all Tax assets (including Tax refunds and prepayments) other than those of the Company; 

 

	 	(xii)	all Tax Returns of the Seller’s Group other than the Company and all books and records (including working papers) related thereto; 

 

	 	(xiii)	any rights in respect of any insurance policies of the Seller’s Group as provided in Clause 14; 

 

	 	(xiv)	any rights in respect of Pre-Closing Receivables; 

  
 34 

	 	(xv)	any equity interest in any person other than the Company; 

  

	 	(xvi)	the Excluded Contracts; 

  

	 	(xvii)	the China Marketing Authorisations; and 

  

	 	(xviii)	all rights of the Seller’s Group under this Agreement and the Ancillary Agreements. 

 

	 	2.3.3	The Seller agrees to procure the transfer (to the extent it is able so to do) and the Purchaser agrees to accept (or procure the acceptance by another member of
the Purchaser’s Group of) the transfer of, and to assume, duly and punctually pay, satisfy, discharge, perform or fulfil (or procure that another member of the Purchaser’s Group will assume, duly and punctually pay, satisfy, discharge,
perform or fulfil) the Assumed Liabilities with effect from Closing. 

  

	 	2.3.4	Clause 2.3.3 shall not apply to, and the Purchaser shall not be obliged to accept or procure the acceptance by another member of the Purchaser’s Group
of the transfer of or to assume, pay, satisfy, discharge, perform or fulfil, or procure that another member of the Purchaser’s Group will assume, duly and punctually pay, satisfy, discharge, perform or fulfil: 

 

	 	(i)	any Excluded Liability; or 

  

	 	(ii)	any Liability to the extent it relates to an Excluded Asset. 

  

	 	2.3.5	The parties acknowledge that the Seller has notified the Purchaser of its intention to carry out the Pre-Closing Product Reorganisation and that the Seller may,
at its discretion, carry out the Pre-Closing Product Reorganisation provided that: 

  

	 	(i)	the Seller shall, in good faith, consult with, and take into account the reasonable views of, and any reasonable requests made by the Purchaser in relation to the
Pre-Closing Product Reorganisation steps and documents, including any proposals to reduce or avoid Liability or cost being suffered or incurred by any member of the Purchaser’s Group; 

 

	 	(ii)	all fees, costs and expenses of implementing the Pre-Closing Product Reorganisation (or any part thereof) shall be borne by the Seller’s Group (other than the
Company); and 

  

	 	(iii)	any modification or amendment of the steps set out in Part 1 of Schedule 18 shall require the prior written consent of the Purchaser, not to be unreasonably withheld or
delayed. Without prejudice to any other exercise of a discretion whether or not to give consent, the Purchaser shall not be acting unreasonably if it withholds or delays its consent because it believes in good faith that the modification or
amendment would result in exposure of any member of the Purchaser’s Group to any additional cost, loss of benefit or Liability; and 

  
 35 

	 	(iv)	for the avoidance of doubt, nothing done or agreed to by the Purchaser to comply with the provisions of this Clause 2.3.5, Clause 2.3.6 and Schedule 18 shall in any
respect reduce or restrict any rights the Purchaser or any member of the Purchaser’s Group may have to make a claim against the Seller under Clause 2.3.6, the Company Tax Indemnity or the Purchaser Tax Indemnity. 

 

	 	2.3.6	The Seller undertakes to the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group) that, with effect from Closing, the Seller
will indemnify on demand and hold harmless each member of the Purchaser’s Group against and in respect of the loss of any benefit (other than benefits in respect of Tax) and any and all Liabilities (other than Liabilities in respect of Tax),
including any and all Liabilities (other than Liabilities in respect of Tax) of any company whose shares are transferred to the Purchaser or a member of the Purchaser’s Group in connection with the Pre-Closing Product Reorganisation, arising in
connection with any Pre-Closing Product Reorganisation (or part thereof) including any such loss or Liability that would not have been suffered or incurred had such Pre-Closing Product Reorganisation (or part thereof) not been undertaken.

  

	2.4	Employees and Employee Benefits 

  

	 	2.4.1	The provisions of Schedule 8 shall apply in respect of the Employees. 

 

	 	2.4.2	The provisions of Schedule 9 shall apply in respect of Employee Benefits. 

 

	2.5	Local Transfer Documents 

  

	 	2.5.1	On Closing or at such other time as agreed between the parties, the Seller shall procure that the Business Sellers or the Share Seller execute, and the Purchaser
shall execute (or procure the execution by one or more other members of the Purchaser’s Group of), such agreements, transfers, conveyances and other documents, as may be required pursuant to the relevant local law and otherwise as may be agreed
between the Seller and the Purchaser to implement the transfer of the Business or the Share on Closing subject to the provisions of Schedule 25 (the “Local Transfer Documents” and each, a “Local Transfer Document”).
Title shall be transferred by the applicable Local Transfer Document. 

  

	 	2.5.2	To the extent that the provisions of a Local Transfer Document are inconsistent with or (except to the extent they implement a transfer in accordance with this
Agreement) additional to the provisions of this Agreement: 

  

	 	(i)	the provisions of this Agreement shall prevail; and 

  

	 	(ii)	 so far as permissible under the laws of the relevant jurisdiction, the Seller and the Purchaser shall procure that the provisions of the relevant Local
Transfer Document are adjusted, to the extent necessary to give effect to the provisions of this Agreement or, to the 

  
 36 

	 	
extent this is not permissible, the Seller shall indemnify the Purchaser against all Liabilities suffered by the Purchaser or its Affiliates or, as the case may be, the Purchaser shall indemnify
the Seller against all Liabilities suffered by the Seller or its Affiliates, in either case through or arising from the inconsistency between the Local Transfer Document and this Agreement or the additional provisions (except to the extent they
implement a transfer in accordance with this Agreement). 

  

	 	2.5.3	The Seller shall not, and shall procure that none of its Affiliates shall bring any claim against the Purchaser or any member of the Purchaser’s Group in
respect of or based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Business as contemplated by this Agreement. To the extent that the Seller or a member of the Seller’s Group does bring a claim
in breach of this Clause, the Seller shall indemnify the Purchaser and each member of the Purchaser’s Group against all Liabilities which the Purchaser or that member of the Purchaser’s Group may suffer through or arising from the bringing
of such a claim. 

  

	 	2.5.4	The Purchaser shall not, and shall procure that none of its Affiliates shall, bring any claim against the Seller or any member of the Seller’s Group in
respect of or based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Business as contemplated by this Agreement. To the extent that the Purchaser or a member of the Purchaser’s Group does bring a
claim in breach of this Clause, the Purchaser shall indemnify the Seller and each member of the Seller’s Group against all Liabilities which the Seller or any member of the Seller’s Group may suffer through or arising from the bringing of
such a claim. 

  

	3.	Amounts Payable 

  

	3.1	Consideration 

  

	 	3.1.1	Subject to Clause 3.4.1, the consideration for the purchase of the Business (including the Share) under this Agreement shall be an amount equal to
US$16,000,000,000 (the “Headline Amount”) less the Stamp Duty Amount and, if applicable, any Employee Benefit Indemnification Amount paid in accordance with Schedule 9 and any Reduction Amount, and shall include:

  

	 	(i)	the consideration for the purchase of the Share under this Agreement, being the Share Consideration; 

 

	 	(ii)	the “Business Consideration”, being the consideration for the purchase of that part of the Business not owned directly by the Company as at Closing, as
notified by the Seller to the Purchaser 5 Business Days prior to the Closing Date, and for the undertaking given by the Seller in Clause 12.1, and which is subject to Clause 6.3.3; and 

 

	 	(iii)	the amount of the Company Intra-Group Debt. 

  
 37 

	 	3.1.2	For the avoidance of doubt, the consideration provided for under Clause 3.1.1 includes the consideration payable in respect of the Delayed Businesses.

  

	3.2	Allocation 

 The
provisions of Schedule 10 shall apply. 
  

	3.3	VAT 

  

	 	3.3.1	The provisions of Schedule 11 shall apply. 

  

	 	3.3.2	The Seller and the Purchaser agree that the amount payable in respect of the sales and purchases described in Clause 2.1 above is exclusive of any VAT.

  

	 	3.3.3	To the extent that VAT is chargeable in respect of those sales and purchases or any part thereof, the Purchaser shall, against delivery of a valid VAT invoice
(or equivalent, if any), in addition to any other amount expressed in the Agreement to be payable by the Purchaser, pay or procure the payment to the Seller (on behalf of the relevant Business Seller or the Share Seller as applicable) any amount of
any VAT so chargeable for which the Seller (or the relevant member of the Seller’s Group, as the case may be) is liable to account, in accordance with Schedule 11. 

 

	 	3.3.4	The Seller shall indemnify each member of the Purchaser’s Group against any VAT chargeable in connection with the transfer of the Share under this
Agreement. 

  

	3.4	Treatment of Payments 

  

	 	3.4.1	If any payment is made by a member of the Seller’s Group to a member of the Purchaser’s Group or by a member of the Purchaser’s Group to a member
of the Seller’s Group, in either case in respect of any claim under, or for any breach of this Agreement or pursuant to an indemnity (or equivalent covenant to pay) under this Agreement, the payment shall be treated, so far as possible, as an
adjustment of the consideration paid by the Purchaser for the Share, the Owned Product Intellectual Property Rights or the Assets to which the payment and/or claim relates under this Agreement and the consideration shall be deemed to be increased or
reduced (as applicable) by the amount of such payment. 

 PROVIDED THAT this Clause 3.4.1 shall not require
any amount to be treated as an amount in respect of the Share Consideration or the Business Consideration for the purposes of Clause 16.10 if it would not otherwise have been so treated. 

 

	 	3.4.2	If: 

  

	 	(i)	 the payment and/or claim relates to: (A) more than one of the Assets, the Owned Product Intellectual Property Rights and the Share; and/or (B) to more
than one Asset or to more than one Owned Product Intellectual Property Right, it shall be allocated in a manner which 

  
 38 

	 	
reflects the impact of the matter to which the payment and/or claim relates, failing which it shall be allocated rateably to the Products concerned by reference to the percentages in which
amounts are to be allocated between the Products in accordance with Schedule 10; or 

  

	 	(ii)	the payment and/or claim relates to neither the Share nor any particular Assets or Owned Product Intellectual Property Rights, it shall be allocated rateably to the
Products by reference to the percentages in which amounts are to be allocated between the Products in accordance with Schedule 10, 

 and in each case the consideration shall be deemed to have been reduced by the amount of such payment. 
  

	4.	Conditions 

  

	4.1	Conditions Precedent 

 The
sale and purchase of the Business, including the sale and purchase of the Share, is conditional upon satisfaction or, where applicable, waiver of the following conditions, or their satisfaction subject only to Closing: 

 

	 	4.1.1	to the extent that the proposed acquisition of all or any of the Business (the “Transaction”) either constitutes (or is deemed to constitute
under Article 4(5) or Article 5(2))) a concentration with a Community dimension within the meaning of Council Regulation (EC) 139/2004 (as amended) (the “Regulation”) or is to be examined by the European Commission as a result of a
decision under Article 22(3) of the Regulation: 

  

	 	(i)	the European Commission taking a decision (or being deemed to have taken a decision) under Article 6(1)(b) or, if the Commission has initiated proceedings pursuant to
Article 6(1)(c), under Article 8(1) or 8(2) of the Regulation declaring the Transaction compatible with the common market; or 

  

	 	(ii)	the European Commission taking a decision (or being deemed to have taken a decision) to refer the whole or part of the Transaction to the competent authorities of one
or more Member States under Articles 4(4) or 9(3) of the Regulation; and 

  

	 	(a)	each such authority taking a decision with equivalent effect to Clause 4.1.1(i) with respect to those parts of the Transaction referred to it; and

  

	 	(b)	the European Commission taking any of the decisions under Clause 4.1.1(i) with respect to any part of the Transaction retained by it; 

 

	 	4.1.2	any waiting period (and any extension thereof) under the HSR Act applicable to the Transaction having expired; 

  
 39 

	 	4.1.3	to the extent required or otherwise agreed between the parties as appropriate to permit the parties to consummate the Transaction in the jurisdictions listed in
Schedule 21, any additional clearances, approvals, waivers, no-action letters and consents having been obtained and any additional waiting periods having expired under applicable antitrust, merger control or foreign investment rules set forth in
Schedule 21; 

  

	 	4.1.4	receipt of CFIUS Approval if CFIUS has initiated a review of the transactions contemplated by this Agreement, whether pursuant to Clause 4.2.3 or otherwise;

  

	 	4.1.5	the unconditional consent of JTI to the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group under the JTI
Agreement having been obtained; 

  

	 	4.1.6	the unconditional consent of Genmab to: 

  

	 	(i)	the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group under the Genmab Agreement having been obtained; and

  

	 	(ii)	a waiver of all non-compete provisions in the Genmab Agreement that would otherwise prevent the Purchaser and any member of the Purchaser’s Group from [***] having
been obtained; 

  

	 	4.1.7	no Governmental Entity having enacted, issued, promulgated, enforced or entered any Applicable Law or Judgment (whether temporary, preliminary or permanent) that
is in effect at the Closing Date and that has the effect of making the transactions contemplated by this Agreement illegal or otherwise restraining or prohibiting the consummation of such transactions; 

 

	 	4.1.8	the passing at a duly convened and held general meeting of the Seller Shareholders of an ordinary resolution validly approving the Target Asset Agreements (as
defined in the Implementation Agreement) and any sale and purchase under the Put Option Agreement (as defined in the Implementation Agreement) in accordance with the Seller Articles of Association, the Listing Rules and all other Applicable Law
(such resolution being the “Seller Shareholder Resolution” and such meeting being the “Seller Shareholder Meeting”); 

  

	 	4.1.9	the Purchaser not delivering a Novartis AG Board Certificate (as defined in the Implementation Agreement), in accordance with clause 3 of the Implementation
Agreement, prior to the conclusion of the vote on the Seller Shareholder Resolution at the Seller Shareholder Meeting; 

  

	 	4.1.10	there having been no disruption in the Seller Group’s supply chain, for any reason, which has caused a stock out at any of the Seller Group’s relevant
distribution centres in a manner which had, or would be reasonably likely to have, a Material Adverse Effect; 

  

	 	4.1.11	each of the other Target Asset Agreements having become unconditional in accordance with its terms (save for any condition in those agreements relating to this
Agreement or the other of those agreements having become unconditional); and 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 40 

	 	4.1.12	the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) not requiring that: 

 

	 	(i)	the full terms and conditions of the Corporate Integrity Agreement between OIG and GlaxoSmithKline LLC dated on or around 28 June 2012 (the “GSK CIA”);
or 

  

	 	(ii)	significant provisions of the GSK CIA which (a) are terms that are not currently applicable to the Relevant Purchaser Business under Novartis Pharmaceutical
Corporation’s own Corporate Integrity Agreement with the OIG, and (b) when applied to the Relevant Purchaser Business, would, in the aggregate, reasonably be expected to have an adverse effect on it, 

shall, by reason of the sale under this Agreement, bind or apply in respect of the Relevant Purchaser Business. 

In this Clause 4.1.12, the “Relevant Purchaser Business” means the entire (NPC) business and operations in the
United States of the pharmaceuticals division of the Purchaser. 
  

	4.2	Responsibility for Satisfaction 

  

	 	4.2.1	The Purchaser and the Seller shall prepare and file the notifications necessary for the fulfilment of the conditions in Clauses 4.1.1 to 4.1.3 (the
“Required Notifications”) as soon as reasonably practicable (with notifications under the HSR Act to be filed by 29 May 2014). Notwithstanding anything to the contrary contained in this Agreement, the Purchaser shall have primary
responsibility for obtaining all consents, approvals or actions of any Governmental Entity which are required in connection with the Required Notifications. 

 

	 	4.2.2	The Purchaser shall be responsible for payment of all filing and other fees and expenses in connection with the Required Notifications and the satisfaction of
the conditions in Clauses 4.1.1 to 4.1.3. 

  

	 	4.2.3	CFIUS 

  

	 	(i)	The Seller and the Purchaser shall consult, cooperate and keep each other reasonably informed regarding communications with, and requests for additional information
from, CFIUS with respect to the Transaction. The Seller and the Purchaser shall use their respective reasonable best efforts to provide promptly all information that is pursuant to a request by CFIUS. 

 

	 	(ii)	 Within 30 calendar days after the execution of this Agreement, any party wishing to submit a formal joint voluntary notice to CFIUS pursuant to 31
C.F.R. Section 800.401, et. seq. (“CFIUS Filing”) shall provide the other party with written notice of its intent to make a 

  
 41 

	 	
CFIUS Filing (“Election Date”). Prior to making its election to submit a CFIUS Filing, the party wishing to make a CFIUS Filing shall consult in good faith with senior executives
of the other party. If neither the Seller nor the Purchaser provides notice to submit a formal joint voluntary notice to CFIUS, a CFIUS Filing will not be made unless requested by CFIUS. 

 

	 	(iii)	If either the Seller or the Purchaser elects to make a CFIUS Filing following the procedures and consultations in Clause 4.2.3(ii) or if CFIUS requires a filing,
then: 

  

	 	(a)	the Seller and the Purchaser shall use their respective reasonable best efforts to submit a draft CFIUS Filing no later than 15 Business Days following the Election
Date, and a final CFIUS Filing the earlier of (1) five business days after submitting the draft CFIUS filing or (2) five calendar days after the receipt of any comments from CFIUS staff regarding the draft CFIUS Filing. 

 

	 	(b)	the Seller and the Purchaser will provide each other with the reasonable opportunity to review and comment on any information provided to CFIUS to the extent permitted
by Applicable Law, with the exception of personal identifier information required under Section 800.402(c)(6)(vi)(B) of the CFIUS regulations, 31 C.F.R.. Competitively sensitive information, or information not related to the transactions
contemplated by this Agreement, may be restricted to each party’s external counsel to the extent reasonably considered necessary or advisable by the providing party; 

 

	 	(c)	the Seller and the Purchaser shall each have an opportunity to approve and mutually agree on the joint contents of the CFIUS Filing and shall be jointly responsible for
the accuracy of such contents. The Seller and the Purchaser respectively, shall each be responsible for the accuracy of contents of the CFIUS Filing that exclusively relate to itself, its business, and any subsidiaries, parents or other related
parties; and 

  

	 	(d)	the Seller and the Purchaser shall use their respective reasonable best efforts to obtain CFIUS Approval as promptly as practicable and shall consult with each other on
strategic matters related to obtaining such CFIUS Approval, provided that the Purchaser shall have no obligation to agree to any mitigation or other restrictive provision that could reasonably be considered to have a substantial impact on either the
Business or the Purchaser. 

  

	 	4.2.4	The party responsible for satisfaction of each condition pursuant to this Clause 4.2 shall give notice to the other party of the satisfaction of the
relevant condition within one Business Day of becoming aware of the same. 

  
 42 

	 	4.2.5	The parties shall cooperate with each other in connection with the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3. The parties will consult
and cooperate reasonably with one another, consider in good faith the views of one another, and provide to the other party in advance any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents
make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree to (a) give each other reasonable advance notice of all meetings with any Governmental Entity, (b) give each other an opportunity to participate in each
of such meetings, (c) to the extent practicable, give each other reasonable advance notice of all substantive oral communications with any Governmental Entity, (d) if any Governmental Entity initiates a substantive oral communication promptly notify
the other party of the substance of such communication, (e) provide each other with a reasonable advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions
and proposals) with a Governmental Entity, (f) provide each other with copies of all written communications to or from any Governmental Entity, and (g) not advance arguments in connection with any regulatory review or litigation proceeding related
to this Agreement (other than litigation between the parties) over the objection of the other party that would reasonably be likely to have a significant adverse impact on that other party, provided however, that neither party shall be required to
comply with subsection (b) to the extent that the Governmental Entity objects to the participation of a party, or with subsections (e) or (f) to the extent that such disclosure may raise regulatory concerns (in which case, the disclosure may be made
on an outside counsel basis). 

  

	 	4.2.6	Subject to sub-Clause 4.2.7 and Applicable Law: 

  

	 	(i)	the parties shall cooperate with each other in connection with the satisfaction of the condition in Clause 4.1.12; 

 

	 	(ii)	the parties will consult and cooperate reasonably with one another, consider in good faith the views of one another, and provide to the other party in advance any
analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to the OIG; and 

  

	 	(iii)	 without limiting paragraphs (i) and (ii) of this Clause 4.2.6, the parties agree to (a) give each other reasonable advance notice of all
meetings with the OIG, (b) consult to determine if it is in the parties’ mutual interest for both parties give each other an opportunity to participate in each of such meetings, (c) to the extent practicable, give each other reasonable advance
notice of all substantive oral communications with the OIG, (d) if the OIG initiates a substantive oral communication promptly notify the other party of the substance of such communication, (e) provide each other with a reasonable advance
opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, 

  
 43 

	 	
briefs, arguments, opinions and proposals) with the OIG, (f) provide each other with copies of all written communications to or from the OIG, (g) not advance arguments in connection with any
regulatory review or litigation proceeding related to this Agreement (other than litigation between the parties) over the objection of the other party that would reasonably be likely to have a significant adverse impact on that other party, and (h)
provide each other with such information, documents and data as may be reasonably requested in preparation for any communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals) with the OIG, provided
however, that neither party shall be required to permit the participation of the other party in a meeting with the OIG following the consultation required to comply with subsection (b) to the extent that the parties fail to agree to such mutual
participation or the OIG objects to the participation of a party, to comply with subsections (e), (f) or (g) to the extent that such disclosure may raise regulatory concerns (in which case, the disclosure may be made on an outside counsel basis), or
permit the disclosure or use of information, documents and data provided under subsection (h) in any communications with the OIG if the providing party reasonably determines that the information is confidential or proprietary and disclosure or use
would be reasonably likely to have a significant adverse impact on that party. 

  

	 	4.2.7	The Seller shall not, and shall procure that no member of the Seller’s Group (including but not limited to GlaxoSmithKline LLC) or their directors,
officers, employees, agents or advisors shall, make any material or substantive communication or notification to the OIG regarding the Transaction without consulting and taking into account the views of the Purchaser. 

 

	 	4.2.8	 The Purchaser shall and, shall cause its Affiliates to, use its reasonable endeavours to procure the satisfaction of the conditions in
Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than the Long Stop Date). Notwithstanding any other provision of this Agreement to the contrary, the Purchaser shall and, shall cause its Affiliates to use
best endeavours to propose, negotiate, offer to commit and effect (and if such offer is accepted, commit to and effect), by consent decree, undertaking, hold separate order, or otherwise, the sale, divestiture, licence or disposition of its LGX818
and MEK162 products in development on a global basis (excluding existing manufacturing capabilities) as may be required or desirable in order to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible
(and, in any event, not later than the Long Stop Date) and to avoid the commencement of any Action or the issuing of any Decision to prohibit the acquisition or any other transaction contemplated by this Agreement or, if such Action is already
commenced, to avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other order in any Action so as to enable the Closing to occur as soon as reasonably possible (and, in any event, not later than the
Long Stop Date). Nothing in this Clause shall require the Purchaser to divest any currently 

  
 44 

	 	
marketed product indicated for use in renal cell carcinoma or any currently marketed Product indicated for use in melanoma, including but not limited to Mekinist, Tafinlar, Votrient and/or
Afinitor. 

  

	 	4.2.9	The Seller shall, and shall cause the Seller’s Group, to use its reasonable endeavours to cooperate with the Purchaser in connection with procuring the
satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than the Long Stop Date), including providing to the Purchaser such information with respect to the Business and the Products
as the Purchaser may reasonably require in connection with satisfaction of its obligations under this Clause. 

  

	 	4.2.10	The Purchaser and Seller shall cooperate to confirm, within 21 Business Days from signing of this Agreement, any additional merger notification requirements
reasonably required or advisable in respect of the Transaction in jurisdictions beyond those listed in Schedule 21, and shall cooperate with each other, within the meaning of Clause 4.2.5, in achieving any additional clearances, approvals,
consents, waivers, no- action letters or waiting period expirations in such jurisdictions. For the avoidance of doubt, Closing shall not be conditional upon such additional clearances, approvals and consents or waiting period expirations.

  

	 	4.2.11	The Purchaser and Seller shall cooperate, within the meaning of Clause 4.2.5, and use reasonable endeavours to ensure that no Governmental Entity shall
enact, issue, promulgate, enforce or enter any Applicable Law or Judgment as contemplated under Clause 4.1.7. In the event that any Governmental Entity enacts, issues, promulgates, enforces or enters any Applicable Law or Judgment as
contemplated under Clause 4.1.7, the Seller and the Purchaser shall cooperate and use reasonable endeavours to put in place arrangements that would allow the Transaction to complete to the greatest possible extent in compliance with the
relevant Applicable Law or Judgment. 

  

	 	4.2.12	The Seller shall use best efforts to obtain the consents referred to in Clauses 4.1.5 and 4.1.6 prior to the Closing Date. The cost of obtaining such
consents shall be borne by the Seller, including any payment or other incentive that may (whether required to be offered or not) be offered to JTI and/or Genmab or any of their respective Affiliates in order to obtain such consents. The
Purchaser shall, and shall cause its Affiliates to cooperate with the Seller in connection with obtaining the consents, referred to in Clauses 4.1.5 and 4.1.6 and use its reasonable endeavours to ensure that such conditions are satisfied at
Closing, including providing to the Seller such information as the Seller may reasonably require in connection with the satisfaction of its obligations under this Clause 4.2.12. 

 

	 	4.2.13	The Purchaser may at any time waive in whole or in part (and conditionally or unconditionally) the conditions set out in Clauses 4.1.5, 4.1.6, 4.1.10 and
4.1.12 by notice in writing to the Seller. 

  
 45 

	4.3	Non-Satisfaction by the Long Stop Date 

 If the conditions in Clause 4.1 are not satisfied (or waived in accordance with Clause 4.2.13) as of 22 October 2015 (the “Long Stop Date”), the Purchaser or the Seller may, in
its sole discretion, terminate this Agreement (other than Clauses 1, 13 and 16.2 to 16.15) and no party shall have any claim against the other under it, save for any claim arising from breach of any obligation contained in such Clauses or
Clause 4.2. Neither the Seller nor the Purchaser may terminate this Agreement after satisfaction or waiver of the conditions in Clause 4.1, except in accordance with this Agreement. 

 

	4.4	Termination 

  

	 	4.4.1	This Agreement may be terminated at any time prior to Closing: 

  

	 	(i)	by written consent of the Seller and the Purchaser; 

  

	 	(ii)	by either the Seller or the Purchaser by notice to the other party in the event that any Judgment restraining, enjoining or otherwise prohibiting the transactions
contemplated by this Agreement shall have become final and non-appealable, provided that the party seeking to terminate this Agreement pursuant to this Clause 4.4 has complied with the terms of the Implementation Agreement and this Agreement in
connection with having such Judgment vacated or denied; or 

  

	 	(iii)	by the Purchaser by notice to the Seller if: 

  

	 	(a)	a Material Adverse Effect occurs prior to Closing (which shall include any breach or breaches of Clause 9.1 which alone or together constitute a Material Adverse
Effect); or 

  

	 	(b)	the Seller fails to provide a Certificate immediately prior to Closing; or 

 

	 	(iv)	in accordance with the terms of the Implementation Agreement. 

  

	 	4.4.2	This Agreement shall terminate automatically at any time prior to Closing in the event that: 

 

	 	(i)	any other Target Asset Agreement terminates or is terminated in accordance with its terms; or 

 

	 	(ii)	the Novartis Break Fee and/or the GSK Break Fee becomes payable under clause 5.1 or clause 5.8 of the Implementation Agreement, respectively.

  

	 	4.4.3	 Save as provided in this Clause 4, neither party shall be entitled to terminate or rescind this Agreement (whether before or after
Closing). If this Agreement is terminated pursuant to this Clause 4.4, this Agreement shall be of no further force and effect and there shall be no further liability under this Agreement or any of the Ancillary Agreements on the part of
any party, 

  
 46 

	 	
except that Clauses 1, 13, and 16.2 to 16.15, in each case, to the extent applicable, shall survive any termination. 

 

	 	4.4.4	Nothing in this Clause 4.4 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this
Agreement prior to termination of this Agreement. 

  

	5.	Pre-Closing 

  

	5.1	The Seller’s Obligations in Relation to the Business 

  

	 	5.1.1	The Seller undertakes to procure that between the date of this Agreement and Closing, the relevant members of the Seller’s Group shall, so far as permitted
by Applicable Law, carry on the Business as carried on by the Seller Group as a going concern in the ordinary course as carried on immediately prior to the date of this Agreement save in so far as agreed in writing by the Purchaser (such consent not
to be unreasonably withheld or delayed). 

  

	 	5.1.2	Without prejudice to the generality of Clause 5.1.1 and subject to Clause 5.2, the Seller shall not, in each case with respect to the Business only,
between the date of this Agreement and Closing, and shall procure that each member of the Seller’s Group shall not, except as may be required to comply with this Agreement, without the prior written consent of the Purchaser (such consent not to
be unreasonably withheld or delayed), take any of the actions listed in Part 1 of Schedule 19. 

  

	 	5.1.3	Without prejudice to the generality of Clause 5.1.1, the Seller shall, in each case with respect to the Business only: (i) undertake to procure the
satisfaction of its obligations listed in paragraph 1, Part 2 of Schedule 19; and (ii) shall, and shall procure that each member of the Seller’s Group shall, between the date of this Agreement and Closing, comply with the requirements of
paragraph 2, Part 2 of Schedule 19. 

  

	5.2	Exceptions to Seller’s Obligations in Relation to the Conduct of Business 

Clause 5.1 shall not operate so as to prevent or restrict: 

 

	 	5.2.1	any matter undertaken by any member of the Seller’s Group to implement any Pre-Closing Product Reorganisation in accordance with Clauses 2.3.5 and
2.3.6; 

  

	 	5.2.2	any action to the extent it is required to be undertaken to comply with Applicable Law; or 

 

	 	5.2.3	any matter reasonably undertaken by any member of the Seller’s Group in an emergency or disaster situation with the intention of minimising any adverse
effect of such situation in relation to the Business and where any delay arising by virtue of having to give notice to the Purchaser and await consent would materially prejudice the Business, 

  
 47 

 provided that the Seller shall notify the Purchaser as soon as reasonably practicable of
any action taken or proposed to be taken as described in Clause 5.2.3, shall provide to the Purchaser all such information as the Purchaser may reasonably request and shall use reasonable endeavours to consult with the Purchaser in respect of
any such action. 
  

	5.3	Seller and Purchaser’s Rights and Obligations 

  

	 	5.3.1	Subject to Clause 5.3.2, the parties shall negotiate in good faith to agree definitive and legally binding documentation in respect of each of the Ancillary
Agreements for which the heads of terms are in the Agreed Terms, including the Manufacturing and Supply Agreement, on the date of this Agreement, and shall duly execute and deliver such definitive and legally binding documentation in respect of the
Ancillary Agreements at Closing. 

  

	 	5.3.2	In the event that the parties are unable to agree definitive and legally binding documentation in respect of an Ancillary Agreement referred to in
Clause 5.3.1 by Closing, the parties shall be subject to and shall adhere to the heads of terms in the Agreed Terms for that Ancillary Agreement, which terms shall be legally binding on the parties. 

 

	 	5.3.3	If required by the Seller, the Purchaser shall co-operate with the Seller and the relevant counterparty to procure the grant of a sub-licence or partial
assignment of certain rights under the Ofatumumab Agreements to the Seller for use in relation to the Ofatumumab Compound in the Ofatumumab Indications and in the field of autoimmune diseases under the Ofatumumab Intellectual Property Licence or
another agreement between the parties, effective from Closing. 

  

	 	5.3.4	If, at any time prior to Closing, the [***] determines that the terms and conditions of the [***] shall not bind or apply (in full or with respect to significant
provisions thereof) to the Relevant Purchaser Business, but does determine that they shall bind or apply in any respect to either all or part of the Business or the Employees, then, at any time prior to the date falling 5 Business Days prior to the
Closing Date, notwithstanding any provision in this Agreement to the contrary, the Purchaser shall be entitled not to make an offer of employment to any Employee who: 

 

	 	(i)	is not expected to transfer by operation of law to the Purchaser or any member of the Purchaser’s Group on Closing; and 

 

	 	(ii)	is or would reasonably be expected to be a “Covered Person” (as defined in the [***]) or is otherwise subject to or bound by any material obligation or term
of the [***] as applied to the Purchaser or any member of the Purchaser’s Group following Closing, 

 and,
where no offer of employment with the Purchaser or any member of the Purchaser’s Group is made in accordance with this Clause 5.3.4, such Employee shall remain employed by the Seller or the relevant member of the Seller’s Group on and
following Closing. 
  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 48 

	 	5.3.5	At any time prior to the date falling 18 months after the Closing Date, each relevant member of the Purchaser’s Group shall be entitled to terminate the
employment of any Employee: 

  

	 	(i)	whose employment has transferred to the Purchaser or any member of the Purchaser’s Group either by operation of law or by way of offer and acceptance; and

  

	 	(ii)	who is or would reasonably be expected to be a “Covered Person” (as defined in the [***], as applied to the Purchaser’s Group) or is otherwise subject to
or bound by any material obligation or term of the [***] as applied to the Purchaser or any member of the Purchaser’s Group following Closing, 

 if the [***] has determined or determines that the terms and conditions of the [***] shall apply or be binding (in whole or in part) to the Relevant Purchaser Business. The relevant member of the
Purchaser’s Group may effect such termination either by giving notice or transferring the Employee to a member of the Seller’s Group by agreement to be concluded between the relevant member of the Purchaser’s Group, the Employee
concerned and the relevant member of the Seller’s Group. The Seller shall be responsible for and shall indemnify and keep indemnified the Purchaser (for itself and as trustee for any relevant member of the Purchaser’s Group) against all
Liabilities from time to time made, suffered or incurred by the Purchaser (or any other member of the Purchaser’s Group) as a result of: 
  

	 	(iii)	the transfer of employment of such Employee to the Purchaser or any member of the Purchaser’s Group and the employment of such Employee from the Closing Date until
the termination of employment of such Employee as referred to in this Clause 5.3.5(iii) (or any other employment liabilities relating to such person); and 

 

	 	(iv)	the termination of such Employee’s employment. 

  

	 	5.3.6	Prior to Closing, the Seller shall be entitled to take and retain a full set of copies of the Ofatumumab Indications Data for use in accordance with the
Ofatumumab Intellectual Property Licence Agreement. For the avoidance of doubt, the Ofatumumab Indications Data constitutes part of the Ofatumumab Licensed IP Rights for the purposes of the Ofatumumab Intellectual Property Licence Agreement (as
such term is defined in the Ofatumumab Intellectual Property Licence Agreement). 

  

	6.	Closing 

  

	6.1	Date and Place 

 Save as
otherwise provided in this Agreement (including Schedule 25), Closing shall take place simultaneously with closing under the other Target Asset Agreements at the offices of Freshfields Bruckhaus Deringer, 65 Fleet Street, London EC4Y 1HS (other than
in respect of any Local Transfer Documents agreed between the parties to be executed in another jurisdiction) on the last 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 49 

 
Business Day of the month in which fulfilment or waiver of the last of the condition(s) set out in Clause 4.1 to be fulfilled or waived takes place, except that: 

 

	 	6.1.1	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the following month; and

  

	 	6.1.2	where less than five Business Days remain between such fulfilment or waiver and the last Business Day of the month, Closing shall take place:

  

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the month following the month referred to in
Clause 6.1.2(i); or 

  

	 	(iii)	at such other location, time or date as may be agreed between the Purchaser and the Seller in writing, provided that: 

 

	 	(a)	Closing shall not take place and shall not be effective in any circumstances unless closing also takes place under and in accordance with the terms of the other Target
Asset Agreements at the same time; and 

  

	 	(b)	in determining the date on which the last of the conditions set out in Clause 4.1 is fulfilled or waived, the date shall be the date on which the last of the
conditions set out in Clauses 4.1.1, 4.1.2, 4.1.3, 4.1.4, 4.1.5, 4.1.6, 4.1.8, 4.1.9 and 4.1.11 is fulfilled or waived unless any of the conditions set out in Clauses 4.1.7, 4.1.10 and 4.1.12 is not fulfilled or waived on that date, in
which case the date shall then be the first following date on which all of the conditions set out in Clauses 4.1.7, 4.1.10 and 4.1.12 are fulfilled or waived. 

 

	6.2	Closing Events 

  

	 	6.2.1	On Closing, but subject to the provisions of Schedule 25, the parties shall comply with their respective obligations specified in Schedule 12. The Seller
may waive some or all of the obligations of the Purchaser as set out in Schedule 12 and the Purchaser may waive some or all of the obligations of the Seller as set out in Schedule 12. 

 

	 	6.2.2	The parties acknowledge that the transfer of Product Approvals to the Purchaser or other members of the Purchaser’s Group may be subject to the approval of
applicable Governmental Entities, and that, notwithstanding anything in this Agreement to the contrary, each Product Approval shall continue to be held by the relevant member of the Seller’s Group from the Closing Date until the relevant PA
Transfer Date. 

  

	 	6.2.3	The parties shall perform their respective obligations with respect to: 

 

	 	(i)	the transfer of the Product Approvals as set out in Schedule 6; 

  
 50 

	 	(ii)	the transfer of Contracts (other than Product Approvals) and the Transferred Intellectual Property Contracts as set out in Schedule 7; 

 

	 	(iii)	to the extent the Purchaser has elected to have the Relevant Part of a Shared Business Contract transferred to it, the separation of each Shared Business Contract as
set out in Schedule 7; and 

  

	 	(iv)	the Delayed Businesses as set out in Schedule 25. 

  

	6.3	Payment on Closing and the Reduction Amount 

  

	 	6.3.1	Subject to the remainder of this Clause 6.3, on Closing the Purchaser shall pay (for itself and on behalf of each relevant member of the Purchaser’s
Group, and in accordance with Clause 16.6): 

  

	 	(i)	an amount in cleared funds to the Seller which is equal to the Headline Amount less the sum of: 

 

	 	(a)	the amount of the Company Intra-Group Debt; and 

  

	 	(b)	any Estimated Employee Benefit Adjustment; and 

  

	 	(c)	any amount to be deducted pursuant to Clause 6.3.6; and 

  

	 	(d)	the Estimated Stamp Duty Amount; and 

  

	 	(ii)	a further amount in cleared funds to the Seller which is equal to the amount of the Company Intra-Group Debt and which shall be applied as provided in paragraph 1.4 of
Schedule 12, 

 such that the total amount to be paid to the Seller and other members of the Seller’s Group
on Closing shall be the Headline Amount less the sum of the Estimated Stamp Duty Amount and, if applicable, any Estimated Employee Benefit Adjustment and, if applicable, any amount to be deducted under Clause 6.3.6. 

 

	 	6.3.2	On the Closing Date, as soon as possible after 04:00 a.m. (GMT) on the Closing Date when the US$ Spot Rate becomes available, the Seller shall deliver a written
statement to the Purchaser in the form of Schedule 24 setting out the amount of the Company Intra-Group Debt determined using the US$ Spot Rate, provided that such amount shall be no greater than the Headline Amount less the aggregate of the
Business Consideration, the Stamp Duty Amount and, if applicable, any Employee Benefit Indemnification Amount (the “Maximum Company Intra-Group Debt Amount”). If, after Closing, it is determined that the amount paid by the Purchaser
pursuant to Clause 6.3.1(ii) exceeded the Maximum Company Intra-Group Debt Amount, the Seller shall pay the Purchaser an amount equal to the difference on demand. 

  
 51 

	 	6.3.3	The amount of the Business Consideration shall be subject to the following: 

 

	 	(i)	in the event that, by the CombiD Outcome Longstop Date, neither the Category A Outcome nor the Category B Outcome is achieved, the Business Consideration shall be
reduced by $1.5 billion; and 

  

	 	(ii)	in the event that, by the CombiD Outcome Longstop Date, the Category A Outcome is not achieved but the Category B Outcome is achieved, the Business Consideration shall
be reduced by $1.0 billion, 

 the amount of any such applicable reduction being the “Reduction
Amount”. Clauses 6.3.5 and 6.3.6 below shall apply in respect of any Reduction Amount. 
  

	 	6.3.4	For the avoidance of doubt, in the event that, by the CombiD Outcome Longstop Date, the Category A Outcome is achieved, then (whether or not the Category B
Outcome is also achieved) no reduction or adjustment shall be made to the Business Consideration. 

  

	 	6.3.5	In the event that a reduction to the Business Consideration applies under Clause 6.3.3 above and the cause of such reduction occurs at or following 5 Business
Days prior to Closing, the Seller shall (against the Purchaser having paid the full amount of the Business Consideration at Closing) repay to the Purchaser: 

 

	 	(i)	an amount equal to the applicable Reduction Amount; and 

  

	 	(ii)	interest on the Reduction Amount at the rate of Six-Month LIBOR, such interest accruing on a daily basis from the Closing Date to (and including) the date of payment of
the Reduction Amount by the Seller to the Purchaser. 

 Any repayment to be made pursuant to this
Clause 6.3.5 shall be made within 5 Business Days of the CombiD Outcome Longstop Date, provided that, in circumstances where Conclusion of the CombiD Study has occurred and either or both of (a) the condition in Clause 6.3.7(i)(a) of the
Category A Outcome, and (b) the condition in Clause 6.3.7(ii)(a)(A) of the Category B Outcome are no longer capable of satisfaction, any resulting applicable reduction to the Business Consideration shall apply and take effect at (and any
payment in respect thereof made within the 5 Business Days following) the time at which the relevant condition or conditions are no longer capable of satisfaction. 
  

	 	6.3.6	In the event that a reduction applies under Clause 6.3.3 above and the cause of such reduction occurs prior to 5 Business Days prior to Closing, the
Purchaser shall be entitled to deduct an amount equal to the applicable Reduction Amount from the Business Consideration otherwise payable to the Seller at Closing. 

 

	 	6.3.7	The following terms used in this Clause 6.3 shall have the meaning ascribed below: 

  
 52 

	 	(i)	“Category A Outcome” means, in relation to the CombiD Study, all of the following: 

 

	 	(a)	that Statistical Significance is achieved for the Overall Survival Endpoint; 

 

	 	(b)	that the FDA accepts or agrees that Statistical Significance has been achieved for the Overall Survival Endpoint; and 

 

	 	(c)	the absence of a New Material Safety Signal; 

  

	 	(ii)	“Category B Outcome” means both of the following: 

  

	 	(a)	in relation to the CombiD Study, both: 

  

	 	(A)	achievement of a point estimate for the Hazard Ratio (HR) on the Overall Survival Endpoint that is [***] or better (that is, lower than [***]); and

  

	 	(B)	the absence of a New Material Safety Signal; and 

  

	 	(b)	the FDA not disallowing, within 12 months of Conclusion of the CombiD Study, continued use in the product insert of the claim that the Combination is more efficacious
than the constituent mono-therapies; 

  

	 	(iii)	“CombiD Outcome Longstop Date” means the later of (i) the date that is 12 months after Conclusion of the CombiD Study, and (ii) 31 December 2015;

  

	 	(iv)	“CombiD Study” means the Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor,
trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma (the “Combination”); 

 

	 	(v)	“Conclusion” means when the Overall Survival Endpoint is analysed and the CombiD Study is closed; 

 

	 	(vi)	“New Material Safety Signal” means a Safety Signal: 

  

	 	(a)	which is identified in the results of the CombiD Study; 

  

	 	(b)	which was not described in the approval of the Combination by the FDA or the respective approvals of the BRAF and MEK components of the Combination; and

  

	 	(c)	in respect of which, within 12 months of the Conclusion of the CombiD Study, the FDA requires inclusion of a “black box” on the product insert for the
Combination, the BRAF inhibitor and the MEK inhibitor; 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 53 

	 	(vii)	“Overall Survival Endpoint” means, as defined in the study protocol for the CombiD Study and the statistical analysis plan agreed with the FDA in
respect thereof, the time from randomization until death due to any cause, where: 

  

	 	(a)	all-cause mortality is used and censoring is performed using the date of the last known contact for those who were alive at the time of analysis; and

  

	 	(b)	overall survival is summarized using the Kaplan-Meier method and treatment comparisons are made using a stratified log rank test (stratified by LDH status and mutation
status); 

  

	 	(viii)	“Safety Signal” means information that arises from one or multiple sources that suggests a new, potentially causal association, or a new aspect of a
known association, between an intervention and event or set of related events, which is adverse; and 

  

	 	(ix)	“Statistical Significance” means a one-sided p-value less than [***]. 

 

	 	6.3.8	Notwithstanding any other provision in this Agreement or any Ancillary Agreement, the parties agree that the CombiD Study shall remain under the control of the
Seller until its Conclusion. 

  

	 	6.3.9	By no later than 5 Business Days prior to Closing, the Seller shall notify the Purchaser of: 

 

	 	(i)	any Estimated Employee Benefit Adjustment; 

  

	 	(ii)	the Estimated Business Consideration; 

  

	 	(iii)	the Estimated Company Intra-Group Debt; 

  

	 	(iv)	the Estimated Share Consideration; and 

  

	 	(v)	the Estimated Stamp Duty Amount, 

and at the same time provide to the Purchaser reasonable supporting calculations and information to enable the Purchaser to review the
basis on which each such amount has been determined. 
 The Estimated Stamp Duty Amount and the Estimated Employee Benefit
Adjustment shall be used for the purposes of calculating the payment to be made pursuant to Clause 6.3.1 such that the total amount to be paid to the Seller and other members of the Seller’s Group on Closing shall be the Headline Amount less
the sum of the Estimated Stamp Duty Amount and, if applicable, any Estimated Employee Benefit Adjustment and, if applicable, any amount to be deducted under Clause 6.3.6. 

 

	 	6.3.10	 If the Estimated Stamp Duty Amount exceeds the Stamp Duty Amount, the Purchaser shall, as soon as reasonable practicable (and in any event
within 5 Business Days) after the date on which the Stamp Duty Amount can be 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 54 

	 	
determined, pay to the Seller (by way of payment of consideration due under Clause 3.1.1) an amount equal to the excess. If the Estimated Stamp Duty Amount is less than the Stamp Duty Amount, the
provisions of Clause 16.8 shall apply. 

  

	 	6.3.11	The amounts payable in accordance with Clause 6.3.1 shall, in each case, include all amounts payable in respect of the Delayed Businesses.

  

	6.4	Local Payments 

 The
Purchaser shall procure that each relevant Designated Purchaser set out in column 2 of the table in Part 1 of Schedule 28 shall, subject to the terms of the relevant Local Transfer Document (and, for the avoidance of doubt, in partial satisfaction
of the amounts payable under Clause 3.1.1), pay to the relevant Business Seller the amount set out against its name in column 4 (each a “Local Payment Amount”) converted into the relevant currency set out in the relevant Local
Transfer Document as at the Closing Date, on: 
  

	 	(i)	the date falling 7 days after the Closing Date; or 

  

	 	(ii)	if this is not possible, the date falling 14 days after the Closing Date; or 

 

	 	(iii)	if this is not possible, the date falling 21 days after the Closing Date, or 

 

	 	(iv)	if this is not possible, the date falling 28 days after the Closing Date, or 

 provided that, in any event, all such payments shall be made by no later than the date falling 28 days after the Closing Date. 

 

	6.5	Delayed Local Payments 

In respect of each Delayed Business, the Purchaser shall procure that each relevant Designated Purchaser set out in column 2 of the table
in Part 2 of Schedule 28 shall, subject to the terms of the relevant Local Transfer Document (and, for the avoidance of doubt, in partial satisfaction of the amounts payable under Clause 3.1.1), pay to the relevant Business Seller set out in column
3 the amount set out against its name in column 4 in respect of that Delayed Business (each a “Delayed Local Payment Amount”) converted into the relevant currency set out in the relevant Local Transfer Document as at the relevant
Delayed Closing Date, as soon as reasonably practicable following the relevant Delayed Closing Date and, in any event, within 10 Business Days following the relevant Delayed Closing Date, in accordance with the terms of the relevant Local Transfer
Document. 
  

	6.6	Repayment of Local Payments and Delayed Local Payments 

 Where a Local Payment Amount or Delayed Local Payment Amount is received by a member of the Seller’s Group pursuant to Clause 6.4 or Clause 6.5, the Seller shall (on behalf of the relevant Business
Seller, in accordance with Clause 16.6) pay to the Purchaser in US Dollars an amount equal to such Local Payment Amount or Delayed 

  
 55 

 Local Payment Amount by way of repayment of all or part (as the case may be) of the amount
paid by the Purchaser on behalf of the Designated Purchaser that paid the relevant Local Payment Amount or Delayed Local Payment Amount, so as to ensure that the total amount received by members of the Seller’s Group under Clauses 6.3, 6.4 and
6.5 does not exceed the amount payable under Clause 3.1.1. 
  

	6.7	Breach of Closing Obligations 

 If any party fails to comply with any material obligation in Clause 6.2 or 6.3 or Schedule 12 in relation to Closing, the Purchaser, in the case of non-compliance by the Seller, or the Seller, in the
case of non-compliance by the Purchaser, shall be entitled (in addition to and without prejudice to all other rights or remedies available) by written notice to the Seller or the Purchaser to fix a new date for Closing which, except as agreed by the
parties, shall be the last day of the month next ending or, if that day is not a Business Day, the first Business Day falling after that day, in which case the provisions of Schedule 12 shall apply to Closing as so deferred, but provided such
deferral may only occur once. In all circumstances Closing shall only occur simultaneously with closing under the other Target Asset Agreements. 
  

	7.	Development Plans 

  

	7.1	As at the date of this Agreement, the Seller or the relevant member of the Seller’s Group intends to implement the studies of the Products set out in the
Key Study Plans in accordance with the Key Study Plans. Prior to Closing, the Seller (or the relevant member(s) of the Seller Group) shall continue to implement the Development Plans in the same manner and to the same standards as it has done so
prior to the date of this Agreement. 

  

	7.2	The Seller shall (and shall ensure that the relevant member(s) of the Seller Group), maintain and preserve the laboratory notebooks and other records detailing
the experiments and studies (including of any clinical trials) conducted pursuant to the Development Plans (the “Development Plan Records”) and shall require any sub-contractors to similarly maintain and preserve Development Plan
Records of their respective activities. 

  

	7.3	So far as permitted by Applicable Law and at the Purchaser’s risk: 

 

	 	7.3.1	the Seller shall provide the Purchaser with such information about the progress of the Development Plans as the Purchaser may reasonably request and shall
provide the Purchaser with copies of substantive correspondence with any Governmental Entity with respect to any Product Expansion Application. 

  

	 	7.3.2	 the Seller shall provide to the Purchaser monthly an update in relation to each Product Expansion with sufficient detail for the Purchaser to be
able to assess the progress of each Product Expansion against the relevant Development Plan and highlighting any areas, whether scientific, clinical or regulatory, which may have a material impact on the future development of the Product
Expansion. The form of update shall be agreed by the Seller and the Purchaser acting reasonably and in good faith. The Seller shall discuss matters relevant to the Product Expansion with representatives of the

  
 56 

	 	
Purchaser and consult the Purchaser on the progress of the Product Expansion and any material proposed amendments to the relevant Development Plan with respect to the particular Product
Expansion; and 

  

	 	7.3.3	the Seller shall promptly inform the Purchaser of any material unforeseen results, problems or difficulties with regards to any Product Expansion including with
respect to any communication from any Governmental Entity which indicates that the Development Plan in relation to such Product Expansion requires material amendment in order for the Product Expansion to be approved. The Seller shall consult
with the Purchaser with respect to any such matters and shall take account of the views of the Purchaser for resolving any such unforeseen results, problems or difficulties. 

 

	8.	Post-Closing Obligations 

  

	8.1	Indemnities 

  

	 	8.1.1	Indemnity by the Purchaser against Assumed Liabilities 

 The Purchaser hereby undertakes to the Seller (for itself and on behalf of each other member of the Seller’s Group, and their respective directors, officers, employees and agents) that with effect
from Closing, the Purchaser will indemnify on demand and hold harmless each member of the Seller’s Group and their respective directors, officers, employees and agents against and in respect of any and all Assumed Liabilities. 

 

	 	8.1.2	Indemnities by the Seller 

  

	 	(i)	Subject to Clause 8.1.3, the Seller hereby undertakes to the Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their
respective directors, officers, employees and agents) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member of the Purchaser’s Group and their respective directors, officers, employees and agents
against and in respect of any and all: 

  

	 	(a)	Excluded Liabilities; and 

  

	 	(b)	 Liabilities, including legal fees, to the extent they have arisen or arise (whether before or after Closing) as a result of or otherwise relate to any
act, omission, fact, matter, circumstance or event undertaken, occurring or in existence or arising before Closing so far as related to: (A) any anti-bribery warranty, including without limitation those set forth in paragraphs 7.1 through 7.6
of Schedule 14, not being true and correct when made; (B) any government inquiries or investigations involving the Seller, its Affiliates or their respective Associated Persons; (C) save to the extent in existence as at the date of this Agreement,
any limitation, restriction or other reduction in drug registrations, licences, listings or marketing approvals, government pricing or 

  
 57 

	 	
reimbursement rates relating to the Products including specifically the value of lost future profits as a result of any such limitation, restriction or reduction; or (D) any other claim,
litigation, investigation or proceeding to the extent related to any of the foregoing (A) to (C), including but not limited to costs of investigation and defence and legal fees. 

 

	 	(ii)	The Seller hereby undertakes to the Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their respective directors, officers,
employees and agents) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member of the Purchaser’s Group and their respective directors, officers, employees and agents against and in respect of any and
all Liabilities, including lost profits, arising from or in connection with any failure by the Seller or its Affiliates to Manufacture and supply Products in accordance with the terms of the Manufacturing and Supply Agreement or Transitional
Distribution Services Agreement, as applicable, to the extent such failure results from the Cork FDA Matter. 

  

	 	8.1.3	Limitations on Indemnities 

 Subject to Clause 8.1.4, the Seller shall not be liable under Clause 8.1.2(i) in respect of: 
  

	 	(i)	any Time-Limited Excluded Liability unless a notice of claim in respect of the matter giving rise to such Liability is given by the Purchaser to the Seller within ten
years of Closing, provided that this sub-Clause (i) shall not apply in respect of any claim by the Purchaser which relates to: 

  

	 	(a)	a Product Liability; 

  

	 	(b)	a Governmental Liability; 

  

	 	(c)	a Clinical Trials/Data Liability; 

  

	 	(d)	an Excluded Asset; or 

  

	 	(e)	an IP Liability; and 

  

	 	(ii)	any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the Liability (disregarding the provisions of this
Clause 8.1.3(ii))) in respect of any such claim or series of claims does not exceed US$10 million, provided that, for the avoidance of doubt, where the Liability in respect of any such claim or series of claims exceeds US$10 million, the
Liability of the Seller shall be for the whole amount of such claim(s) and not just the excess. 

  
 58 

	 	8.1.4	Disapplication of limitations 

 None of the limitations contained in Clause 8.1.3 shall apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the
consequence of, or which is delayed as a result of, fraud by any member of the Seller’s Group or any director, officer or employee of any member of the Seller’s Group. 

 

	8.2	Conduct of Claims 

  

	 	8.2.1	Assumed Liabilities 

  

	 	(i)	If the Seller becomes aware after Closing of any claim by a third party which constitutes or may constitute an Assumed Liability, the Seller shall as soon as reasonably
practicable: 

  

	 	(a)	give written notice thereof to the Purchaser setting out such information as is available to the Seller as is reasonably necessary to enable the Purchaser to assess the
merits of the potential claim; 

  

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Purchaser with periodic updates on the status of the claim upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim
without the prior written agreement of the Purchaser (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Seller shall, and shall procure that each Business Seller and the Share Seller shall, take such action as the Purchaser may reasonably request to avoid, dispute,
resist, appeal, compromise, defend or mitigate any claim which constitutes or may constitute an Assumed Liability subject to the Seller, the Share Seller and each Business Seller being indemnified and secured to their reasonable satisfaction by the
Purchaser against all Liabilities which may thereby be incurred. In connection therewith, the Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours all
relevant books of account, records and correspondence relating to the Business which have been retained by the Seller’s Group (and shall permit the Purchaser to take copies thereof at its expense) for the purposes of enabling the Purchaser to
ascertain or extract any information relevant to the claim. 

  

	 	8.2.2	Liabilities Indemnified by the Seller 

  

	 	(i)	 If the Purchaser becomes aware after Closing of any claim by a third party which constitutes or may constitute a Liability covered by Clause 8.1.2 or
relates to a Liability or any investigations related thereto, regardless of whether the Purchaser believes that such claim would be made against a member of the Purchaser’s Group or a

  
 59 

	 	
member of the Seller’s Group, the Purchaser shall as soon as reasonably practicable: 

  

	 	(a)	give written notice thereof to the Seller, setting out such information as is available to the Purchaser as is reasonably necessary to enable the Seller to assess the
merits of the potential claim; 

  

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Seller with periodic updates on the status upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the
prior written agreement of the Seller (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Purchaser shall take such action as the Seller may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim which constitutes
or may constitute a Liability covered by Clause 8.1.2 subject to the Purchaser being indemnified and secured to its reasonable satisfaction by the Seller against all Liabilities which may thereby be incurred. 

 

	 	(iii)	In addition, where any such claim or investigation involves a Governmental Entity, the Purchaser shall, subject to Applicable Law, the requirements of the relevant
Governmental Entity and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group, provide to the Seller, at least five Business Days in advance (or, where not possible, as soon as reasonably possible),
any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree, subject to the Applicable Law and the
requirements of the relevant Governmental Entity and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group to: 

 

	 	(a)	give the Seller reasonable advance notice of all meetings with any Governmental Entity; 

 

	 	(b)	give the Seller an opportunity to participate in each of such meetings; 

  

	 	(c)	to the extent practicable, give the Seller reasonable advance notice of all substantive oral communications with any Governmental Entity; 

 

	 	(d)	if any Governmental Entity initiates a substantive oral communication, promptly notify the Seller of the substance of such communication; 

  
 60 

	 	(e)	provide the Seller with a reasonable advance opportunity to review and comment upon all substantive written communications (including any substantive correspondence,
analyses, presentations, memoranda, briefs, arguments, opinions and proposals) that the Purchaser or its agents intend to make or submit to a Governmental Entity in connection with such claim; 

 

	 	(f)	provide the Seller with copies of all substantive written communications to or from any Governmental Entity; and 

 

	 	(g)	not advance arguments with the Governmental Entity without prior agreement of the Seller that would reasonably be likely to have a significant adverse impact on the
Seller, provided however, that the Purchaser shall not be required to comply with paragraph (b) above to the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent that
such disclosure may raise regulatory concerns (in which case, the disclosure may be made on an outside counsel basis). 

  

	 	(iv)	Other than in respect of any claim to the extent it relates to an IP Liability, a Commercial Practices Liability or a Governmental Liability (other than in respect of
any Liability arising solely by virtue of a breach of any Contract with any Governmental Entity which breach does not also constitute a breach of Applicable Law), the Seller shall be entitled at its own expense and in its absolute discretion, by
notice in writing to the Purchaser, to take such action as it shall deem necessary to avoid, dispute, deny, defend, resist, appeal, compromise or contest any such claim (including making counterclaims or other claims against third parties) in the
name of and on behalf of the Purchaser or other member of the Purchaser’s Group concerned and to have the conduct of any related proceedings, negotiations or appeals. In taking action on behalf of any member of the Purchaser’s Group as
permitted by this Clause 8.2, the Seller shall, in good faith, take into account and have due regard to any reputational matter or issue arising out of the claim for any member of the Purchaser’s Group or any of their respective directors,
officers, employees or agents which are brought to its attention by the Purchaser or a member of the Purchaser’s Group. 

  

	 	(v)	Without limitation to the Seller’s rights pursuant to Clause 8.7.2, the Purchaser shall make or procure to be made available to the Seller or its duly
authorised agents on reasonable notice during normal business hours full and free access to all relevant books of account, records and correspondence relating to the Business which are in the possession or control of the Purchaser or any member of
the Purchaser’s Group (and shall permit the Seller to take copies thereof) for the purposes of enabling the Seller to ascertain or extract any information relevant to the claim. 

  
 61 

	 	(vi)	The Purchaser shall, and shall procure that each other member of the Purchaser’s Group shall, on reasonable notice from the Seller, give such assistance to the
Seller as it may reasonably require in relation to the claim including providing the Seller or any member of the Seller’s Group and its representative and advisers with access to and assistance from directors, officers, managers, employees,
advisers, agents or consultants of the Purchaser and/or of each other member of the Purchaser’s Group (collectively, the “Relevant Persons”) and the Purchaser will use its reasonable endeavours to procure that such Relevant
Persons comply with any reasonable requests from the Seller and generally co-operates with and assists the Seller and other members of the Seller’s Group. 

 

	 	(vii)	When seeking assistance under Clauses 8.2.2(v) and (vi), the Seller, or any other relevant member of the Seller’s Group, shall use reasonable endeavours to
minimise interference with the Purchaser and the Purchaser’s Group’s conduct of the relevant business or the performance by the Relevant Persons of their employment duties. 

 

	8.3	Release of Guarantees 

  

	 	8.3.1	The Purchaser shall use reasonable endeavours to procure as soon as reasonably practicable after Closing, the release of the Sellers or any member of the
Seller’s Group from any securities, guarantees or indemnities given by or binding upon the Seller or any member of the Seller’s Group in respect of the Assumed Liabilities. Pending such release the Purchaser shall indemnify the Seller and
any member of the Seller’s Group against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such Assumed Liabilities. 

 

	 	8.3.2	The Seller shall use reasonable endeavours to procure by Closing or, to the extent not done by Closing, as soon as reasonably practicable after Closing, the
release of the Assets, the Owned Product Intellectual Property Rights and the Company from any securities, guaranties or indemnities given by or binding upon the Assets, the Owned Product Intellectual Property Rights and the Company in respect of
any liability of the Seller or any member of the Seller’s Group. Pending such release, the Seller shall indemnify the Purchaser and any member of the Purchaser’s Group against all amounts paid by any of them (acting reasonably) pursuant to
any such securities, guarantees and indemnities in respect of such liability of the Seller which arises after Closing. 

  

	8.4	Pre-Closing Receivables 

  

	 	8.4.1	The Purchaser shall not acquire the Pre-Closing Receivables, and accordingly the Seller or, as the case may be, the other relevant members of the Seller’s
Group (as applicable) shall remain entitled to the Pre-Closing Receivables in accordance with the terms of Clauses 8.4.2 and 8.4.3. 

  
 62 

	 	8.4.2	The Purchaser agrees that the Seller (or such other member(s) of the Seller’s Group as the Seller may nominate) (each, a “Collecting
Seller”) shall be responsible for the collection of any of the Pre-Closing Receivables and that: 

  

	 	(i)	each Collecting Seller shall be entitled to take such steps as it may think fit (having regard for maintaining good relationships with third parties from whom
Pre-Closing Receivables are being collected) to recover any Pre-Closing Receivables; 

  

	 	(ii)	the Purchaser shall not take, and shall procure that no other member of the Purchaser’s Group takes, any step to collect any of the Pre-Closing Receivables (unless
agreed in writing with the Seller or relevant Collecting Seller), and shall not do anything to hinder their collection by any Collecting Seller; and 

  

	 	(iii)	if the Purchaser or any other member of the Purchaser’s Group should receive any written communication or payment in respect of any Pre-Closing Receivable, the
Purchaser shall use reasonable efforts to give, or procure that there are given, written details of any such written communication or payment to the Seller as soon as reasonably practicable following receipt thereof. 

 

	 	8.4.3	In the event that, notwithstanding Clauses 8.4.1 and 8.4.2 above, a member of the Purchaser’s Group receives any monies in respect of any Pre-Closing
Receivables, then the Purchaser shall procure that those monies are paid by the recipient to the Seller or, as directed, its Affiliate, as soon as reasonably practicable after the amount is received. 

 

	8.5	Wrong Pockets Obligations and Pre-Clinical Research Licence 

  

	 	8.5.1	Except as provided in Schedule 6, Schedule 7, Schedule 8, Schedule 9 and Schedule 25, if any property, right or asset forming part of the Business (other than
any property, right or asset expressly excluded from the sale under this Agreement) has not been transferred to the Purchaser, or to another member of the Purchaser’s Group and should have transferred pursuant to the terms of this Agreement,
the Seller shall procure that such property, right or asset (and any related liability which is an Assumed Liability) is transferred to the Purchaser, or to such other member of the Purchaser’s Group as the Purchaser may nominate reasonably
acceptable to the Seller, as soon as practicable and at no cost to the Purchaser. For the avoidance of doubt, this Clause 8.5.1 shall not take effect in respect of the OBM Transferred Rights until the OBM Transfer Date. 

 

	 	8.5.2	 If, following Closing or, in respect of a Delayed Business, the relevant Delayed Closing, any property, right or asset not forming part of the
Business (other than any property, right or asset expressly included in the sale under this Agreement and the Permitted Cash Receivable) is found to have been transferred to the Purchaser or to another member of the Purchaser’s Group and should
not have transferred pursuant to the terms of this Agreement, the Purchaser shall procure that such property, right or asset is transferred to the transferor or another member of the Seller’s Group nominated by the Seller

  
 63 

	 	
reasonably acceptable to the Purchaser as soon as practicable and at no cost to the Seller (save that if such property, right or asset is or has been owned by the Company, the cost of
transferring such property, right or asset to a member of the Seller’s Group shall be borne by the Seller, provided that the consideration paid for any such transfer shall, unless otherwise required by Applicable Law, be of a nominal amount).

  

	 	8.5.3	The Seller shall, with effect from Closing, grant (and shall procure the grant by members of the Seller’s Group) to the extent it has the right to grant or
procure the grant to the Purchaser of a non-exclusive, irrevocable, royalty-free licence for use solely in relation to the Products of all Intellectual Property Rights (excluding for the avoidance of doubt any Intellectual Property Rights to the
extent relating to new chemical entities owned by or licensed to the Seller which are not Products) owned by or licensed to the Seller’s Group as at Closing relating to pre-clinical research which relate to (but do not exclusively relate to)
the Products and which are necessary or reasonably useful to research, develop, manufacture or Commercialise the Products, which licence shall be (a) sub-licensable by the Purchaser (i) to members of its Group and (ii) to third parties working with
it on the development of the Products; and (b) sub-licensable and assignable to other third parties solely in connection with the license, sub-license or assignment of all of the rights of the Purchaser in the relevant Product.

  

	8.6	Covenant not to sue 

  

	 	8.6.1	The Seller hereby undertakes not to enforce, at any time after Closing, any Out of Scope Patent against the Purchaser’s Group in relation to the
Purchaser’s Group carrying on the Business as at the date of Closing. 

  

	 	8.6.2	The Purchaser hereby undertakes not to enforce, at any time after Closing, any Patents constituting Business Product Intellectual Property Rights against the
Seller’s Group in relation to the Seller’s Group carrying on the Seller’s Group Retained Business as at the date of Closing. 

  

	8.7	The Purchaser’s Continuing Obligations 

  

	 	8.7.1	Except as provided in the Ancillary Agreements and Schedule 27, the Purchaser shall not, and shall procure that no member of the Purchaser’s Group shall,
after Closing, use any of the Seller Marks or any confusingly similar name or mark, any extensions thereof or developments thereto in any business which competes with the Seller’s business or any other business of the Seller or any member of
the Seller’s Group in which the Seller Marks are used for (i) a minimum period of five years following Closing; and (ii) thereafter for so long as any member of the Seller’s Group continues to retain an interest in the relevant Seller
Marks. 

  

	 	8.7.2	 The Purchaser shall, and shall procure that any relevant member of the Purchaser’s Group shall, retain for a period of 10 years from
Closing (and, upon notice from the Seller between 9 and 10 years from Closing, for a further period of 5 years), and not dispose of or destroy during that period, the books, records and documents of the Business to the extent they relate to

  
 64 

	 	
the period prior to Closing and shall, and shall procure that any relevant member of the Purchaser’s Group shall, if reasonably requested by the Seller, allow the Seller reasonable access
during that period to such books, records and documents (including the right to take copies at the Seller’s expense) and to the employees of the Business. 

 

	8.8	The Seller’s Continuing Obligations 

  

	 	8.8.1	The Seller shall retain and not dispose of or destroy and make or procure to be made available to the Purchaser or their duly authorised agents and/or
professional advisers on reasonable notice during normal business hours: 

  

	 	(i)	in each case for a period of one year from Closing (or from the relevant Delayed Closing Date in respect of emails relating to a Delayed Business), all emails relating
to the Business (and shall permit the Purchaser to take copies thereof); 

  

	 	(ii)	in each case for a period of 10 years from Closing (and, upon notice from the Purchaser between 9 and 10 years from Closing, for a further period of 5 years), all
relevant books, accounts, other records and correspondence (except, in each case, emails) Exclusively Relating to the Business which have not been, or to the extent they have not been, transferred to the Purchaser’s Group under this Agreement
(and shall permit the Purchaser to take copies thereof), save as otherwise agreed by the parties in relation to any books and records (including but not limited to the content of any personnel files) relating to the employment of the Transferred
Employees; 

  

	 	(iii)	in each case for a period of 10 years from Closing (and, upon notice from the Purchaser between 9 and 10 years from Closing, for a further period of 5 years),
reasonable access to employees of the Seller’s Group who have knowledge relating to any of the Products (including any inventor of the Products) for the purposes of the defence, prosecution or enforcement of any Business Product Intellectual
Property Rights or Licensed Product Intellectual Property Rights, any actual or potential regulatory or safety investigation involving any of the Products, or as required by Applicable Law or a Governmental Entity, provided that the Purchaser shall
promptly reimburse the Seller in relation to the provision of such access for (i) out of pocket expenses reasonably incurred by the Seller; and (ii) for the time of that employee of the Seller’s Group if it exceeds 25 man hours in aggregate per
annum; and 

  

	 	(iv)	 in each case for a period of 3 years from Closing, the Seller shall make or procure to be made available to the Purchaser or their duly authorised
agents on reasonable notice during normal business hours reasonable access to any employees of the Seller’s Group who have knowledge relating to the Business (including, for the avoidance of doubt and without limitation, any background
information relating to the legal position of the Products), to the 

  
 65 

	 	
extent that such employees are retained by the Seller after Closing, to answer any questions other than those covered by Clause (iii) that the Purchaser may reasonably ask in relation to the
Business, provided that: 

  

	 	(a)	the Purchaser shall promptly reimburse the Seller in relation to the provision of such access for the time of that employee of the Seller’s Group to the extent it
exceeds 25 man hours in aggregate per annum; 

  

	 	(b)	the Seller shall have no obligations under this Clause 8.8.1(iv) where such access to employees of the Seller’s Group is prohibited under Applicable Law;

  

	 	(c)	the Purchaser shall have no access rights under this Clause 8.8.1(iv) to employees of the Seller’s Group to the extent that such access is prohibited by applicable
antitrust rules or any undertakings, contractual arrangements or guidelines entered into or provided with the aim of reasonably ensuring compliance with applicable antitrust rules; and 

 

	 	(d)	without prejudice to any indemnity provided by the Seller to the Purchaser under this Agreement, no member of the Seller’s Group shall have any Liability to any
member of the Purchaser’s Group in connection with the provision of any information by employees of the Seller’s Group pursuant to this Clause 8.8.1(iv). 

 

	 	8.8.2	to the extent and for so long as required by, or to the extent and for so long as required in order to perform any obligations under, any Ancillary Agreement or
Applicable Law, or where otherwise agreed between the parties, the Seller shall be entitled to retain the original or a copy of any book, ledger, file, report, plan record, manual or other material (in any form or medium) which would otherwise
transfer to the Purchaser under this Agreement, provided that: 

  

	 	(i)	any copy or original retained is treated as strictly confidential in accordance with Clause 13.2; 

 

	 	(ii)	in the case of retained originals, a copy of such book, ledger, file, report, plan, record, manual or other material is provided to the Purchaser;

  

	 	(iii)	upon reasonable notice by the Purchaser, the Seller shall provide access to such retained book, ledger, file, report, plan, record, manual or other material in
accordance with Clause 8.8.1(ii); and 

  

	 	(iv)	upon expiry of the relevant obligation under the applicable Ancillary Agreement the Seller is entitled to retain a copy of any such book, ledger, file, report, plan,
record, manual or other material to comply with Applicable Law but shall transfer the original to the Purchaser. 

  
 66 

	8.9	Transfer of Marketing Authorisations and Tenders 

  

	 	8.9.1	The transfer of the Marketing Authorisations following Closing shall take place in accordance with Part 2 of Schedule 6 and the terms of the Transitional
Distribution Services Agreement. 

  

	 	8.9.2	Between the Closing Date and the Marketing Authorisation Transfer Date, the Seller agrees to assist the Purchaser in accordance with Part 3 of Schedule 6 in
respect of any tenders relating to the Products. 

  

	8.10	Joint tax election 

 If,
following Closing, the Seller so requests in writing to the Purchaser, the Purchaser and the Seller shall, each acting reasonably and in good faith, discuss the making of a joint election under subsection 56.4(7) of the Income Tax Act (Canada) and
the corresponding provisions of any applicable Canadian provincial statute. Any such election shall be made using the applicable prescribed form, if any, or otherwise filed in a manner acceptable to the Canada Revenue Agency or the applicable
Canadian provincial Tax Authorities, as the case may be. 
  

	8.11	Clinical Trials and Safety Database 

 Arrangements in relation to the Ongoing Clinical Trials and the safety database shall take place in accordance with the terms of the Transitional Services Agreement. 

 

	8.12	Ongoing collaboration 

  

	 	8.12.1	The Seller hereby grants to the Purchaser, as its preferred partner, with effect from Closing, the rights set out in Schedule 22 in relation to the
co-development and commercialisation of Relevant Development Products. “Relevant Development Products” means products in development for the treatment, palliation, diagnosis or prevention of any and all cancers, including without
limitation immunology, epigenetics and treatment of solid or hematologic tumours (but excluding in all cases vaccines). 

  

	 	8.12.2	In the event that the Seller elects to assign or sub-license the Ofatumumab Intellectual Property Licence Agreement in a transaction of the type described in
paragraph 1.1.1 of Schedule 22, then the provisions of Schedule 22 will apply to such assignment or sub-license (except where such assignment or sub-license is to a member of the Seller’s Group). For the avoidance of doubt, the Seller shall be
free at all times to pursue the co-development and commercialisation of the Ofatumumab Compound for use in relation to autoimmune diseases (including the Ofatumumab Indications), on its own or with third parties provided that if such co-development
or commercialisation falls within the activities described in paragraph 1.1.1 of Schedule 22, that schedule shall apply. 

  

	8.13	IP recordals 

  

	 	8.13.1	For the purposes of this Clause 8.13, the terms “Assignor” and “Assignee” shall have the meanings given to them in the relevant
Intellectual Property Assignment. 

  
 67 

	 	8.13.2	The Purchaser and its Affiliates shall be responsible for preparing and filing any documentation necessary for the recordal with any relevant intellectual
property office of the transfer of ownership of all of the Registered Transferred Intellectual Property Rights from the Assignor to the Assignee under each Intellectual Property Assignment. The Purchaser (or such of its Affiliates as it
nominates) shall be responsible for all out-of-pocket filing fees and other costs and expenses associated with those recordals. 

  

	 	8.13.3	Subject to Clauses 8.13.5 and 8.17, the Seller shall procure that each relevant member of the Seller’s Group shall, at the request and cost of any member of
the Purchaser’s Group, execute and deliver any further documents that may be reasonably necessary to secure the vesting in the Assignee under each Intellectual Property Assignment of all the Registered Transferred Intellectual Property Rights.

  

	 	8.13.4	Subject to Clause 8.17, the Seller shall procure that each relevant member of the Seller’s Group shall, at the request and cost of any member of the
Purchaser’s Group, (i) request that the applicable registrar for each of the Assigned Domain Names (as defined in the Intellectual Property Assignment), and any other domain name registration authorities that exercise authority over the
Assigned Domain Names, facilitate the transfer of the Assigned Domain Names from the relevant Assignor to the Assignee; and (ii) execute all such documentation and take all such further acts as are reasonably necessary to effect such transfer.
Within ten (10) Business Days of a date to be agreed by the parties, the Seller shall procure that each relevant member of the Seller’s Group shall (a) unlock the Assigned Domain Names; and (b) provide the Assignee with authorisation codes for
any Assigned Domain Names that have authorisation codes. 

  

	 	8.13.5	To the extent that any transfers of Registered Business Product Intellectual Property Rights to an Assignor or the Company have not been recorded prior to the
date of Closing (including any transfers of such Registered Business Product Intellectual Property Rights prior to the transfer of the same to the Assignor or the Company), and to the extent that such separate recordal is necessary to effect:

  

	 	(i)	the recordal referred to in Clause 8.13.2; or 

  

	 	(ii)	the recordal of any transfer of Owned Product Intellectual Property Rights that constitute Registered Intellectual Property Rights to the Company (or its predecessor in
title), 

 the Purchaser and its Affiliates shall be responsible for preparing and filing any documentation
necessary for the recordal with any relevant intellectual property office of the transfer of ownership to such Assignor or the Company (as applicable). 
 Subject to Clause 8.17, the Seller shall or shall procure that such Assignor shall provide to the Purchaser or a relevant Affiliate of the Purchaser any documentation or information that is reasonably
necessary to record such transfer in the name of the Assignor or the Company (as applicable) as soon 

  
 68 

 
as reasonably possible after receipt of a request for the same from the Purchaser or one of its Affiliates for the purposes of such recordal. The Seller (or such of its Affiliates as it
nominates) shall be responsible for all out-of-pocket filing fees and other costs and expenses associated with the recordal of any such transfer to the Assignor or to the Company (as applicable). 

 

	8.14	China Products 

 The
parties shall perform their respective obligations with respect to the China Products and the China Contracts as set out in Schedule 26. 
  

	8.15	Transitional Trademark Licence 

 The provisions of Schedule 27 shall apply to any use of the Seller Marks for a transitional period from Closing. 
  

	8.16	Abandoned Patent Applications 

  

	 	8.16.1	For the purposes of this Clause 8.16, the terms “Assignor” and “Assignee” shall have the meanings given to them in the relevant
Intellectual Property Assignment. 

  

	 	8.16.2	Subject to Clause 8.17, in respect of any Abandoned Patents, the Seller shall, on reasonable request from the Purchaser’s Group for assistance from any
member of the Seller’s Group, use reasonable endeavours to execute a document confirming the transfer of such rights as any member of the Seller’s Group has (if any) in such Abandoned Patent, to the extent not prohibited under Applicable
Law in the relevant country of any such Abandoned Patent, to the Assignee under each Intellectual Property Assignment, provided that: 

  

	 	(i)	if the Seller provides such assistance the Purchaser shall promptly reimburse the Seller for its reasonable costs; and 

 

	 	(iii)	a request from the Purchaser’s Group for assistance will be deemed to be not reasonable if: 

 

	 	(a)	the Assignee or any other member of the Purchaser’s Group is able to prove common ownership of (i) the Abandoned Patent and (ii) the relevant Patent(s) that
constitute Business Product Intellectual Property Rights(s) to the satisfaction of any relevant intellectual property office, court or tribunal without such assistance from any member of the Seller’s Group (provided further that in no event
shall the Purchaser’s Group be required to narrow the scope of protection of the claims of a Patent that constitutes a Business Product Intellectual Property Right in order to avoid its request being unreasonable); 

 

	 	(b)	 any member of the Seller’s Group is asked to take any steps to achieve an outcome that is the same or equivalent to an outcome the Assignee or any
other member of the 

  
 69 

	 	
Purchaser’s Group could achieve without such assistance from any member of the Seller’s Group (provided that the Seller’s Group shall not be required to narrow a Patent that
constitutes a Transferred Product Intellectual Property Right in order to avoid its request being unreasonable); or 

  

	 	(c)	it requires any member of the Seller’s Group to state that an Abandoned Patent was abandoned inadvertently or unavoidably when this was not the case.

  

	 	8.16.3	Notwithstanding anything to the contrary contained in this Agreement or any of the Ancillary Agreements, no representations are made and no warranties are given
(in each case, whether express or implied) by the Seller (or any member of the Seller’s Group) in relation to the Abandoned Patents (or transfer of the same) by the Seller (or a member of the Seller’s Group) to the Purchaser (or a member
of the Purchaser’s Group). 

  

	8.17	Sanctions 

  

	 	8.17.1	For the purposes of Clause 8.17 only, the terms below shall have the following meanings: 

 

	 	(i)	“Assignor” means an assignor under any Intellectual Property Assignment or any relevant member of the Seller’s Group’s (other than the
Company); 

  

	 	(iv)	“Assignee” means an assignee under any Intellectual Property Assignment or the Company; 

 

	 	(v)	“Further Assurance Obligations” means any obligation to be performed by an Assignor under Clause 8.13 (IP Recordals), 8.16 (Abandoned Patents) and
16.1.1 (Further Assurances); and 

  

	 	8.17.2	The parties agree that to the extent that Business Product Intellectual Property Rights which are the subject of a transfer pursuant to an Intellectual Property
Assignment are registered (or are the subject of an application to register) in Iran, Iraq, Democratic People’s Republic of Korea or Syria, the Assignor’s Further Assurance Obligations shall be modified as set out in Clauses 8.17.3 to
8.17.7 below. 

  

	 	8.17.3	If an Assignor is prevented from complying with its Further Assurance Obligations, with the effect that the recordal of assignment of legal title from the
Assignor to the Assignee under the Intellectual Property Assignment (or to effect a transfer which is the subject of Clause 8.13.5) cannot be completed for any Business Product Intellectual Property Rights by reason of:

  

	 	(i)	Applicable Law; 

  

	 	(vi)	other factors beyond the reasonable control of the Assignor; or 

  

	 	(vii)	application of the Assignor’s 

  

	 	(a)	internal sanctions and export control policy (or equivalent); or 

  
 70 

	 	(b)	anti-bribery and corruption policy, 

 in each case in force from time to time, provided that such policy applies to all Affiliates of the Assignor and the policy is applied in the same way it would apply if the Assignee were an Affiliate of
the Assignor, 
 each such Business Product Intellectual Property Right being an “Affected Right” and each of
(i), (ii) and (iii) being a “Restriction” and in the plural the “Restrictions”), Clauses 8.17.4 to 8.17.7 shall apply. 
  

	 	8.17.4	The relevant Assignor shall notify the Assignee as soon as reasonably practicable after Closing of: 

 

	 	(i)	each Affected Right and the country in which it is registered (or is the subject of an application to register); and 

 

	 	(ii)	the relevant Restriction. 

  

	 	8.17.5	As soon as reasonably practicable and, in any event within three months after the date that Assignor notifies the Assignee of an Affected Right under Clause
8.17.4 above the parties shall discuss in good faith the means by which the Assignee may be able to achieve protection in the relevant country which is equivalent or similar to the protection provided by the Affected Right. Such means may
include, without limitation: 

  

	 	(i)	the Assignee filing a new trade mark application and the Assignor providing to the Assignee the consent of the Assignor to the new application to endeavour to overcome
any objection raised by the relevant intellectual property registry on relative grounds based on the Affected Right; or 

  

	 	(ii)	the Assignor filing a WIPO trade mark application in the name of the Assignor, which shall be assigned by the Assignor to the Assignee on grant of registration or
earlier if possible. The reasonable costs incurred by the Assignor in filing and prosecuting that registration to grant to be met by the Assignee; or 

 

	 	(iii)	the Assignor withdrawing or cancelling any Affected Right subject to the written consent of the Assignee. 

The parties will agree such means as are possible in light of the limitations imposed by the Restrictions and both parties will use
reasonable efforts to achieve the agreed means. Neither party shall be obliged to take any action agreed pursuant to this Clause 8.17.5 to the extent that such party is prevented from doing so by a Restriction. 

The reasonable costs incurred by either party in fulfilling any such actions shall be met by the Assignee. 

 

	 	8.17.6	The relevant Assignor undertakes (at the cost of the Assignee), during the current registration period up to the next renewal date of the Affected Right:

  
 71 

	 	(i)	to take any action to comply with its Further Assurance Obligations to the extent it is able to do so given the Restrictions; 

 

	 	(ii)	to comply with its Further Assurance Obligations as soon as reasonably practicable if and to the extent that such obligations are no longer prevented by the
Restrictions; and 

  

	 	(iii)	not to take any other action in connection with an Affected Right without the consent of the Assignee. 

 

	 	8.17.7	The parties acknowledge that in relation to Business Product Intellectual Property Rights that are Trademarks, there is nothing in this Agreement to preclude the
Assignee from taking action to revoke or cancel an Affected Right and the Assignor hereby undertakes not to defend any such action. 

  

	8.18	Anti-bribery and corruption 

 The provisions of Schedule 31 shall apply in respect of the parties’ compliance with anti-bribery and corruption laws 
  

	9.	Warranties 

  

	9.1	The Seller’s Warranties 

  

	 	9.1.1	Subject to Clause 9.2, the Seller warrants (on behalf of the relevant Business Sellers or the Share Seller as applicable) to the Purchaser and each member
of the Purchaser’s Group to which Assets, the Owned Product Intellectual Property Rights or the Share are transferred pursuant to this Agreement (whether directly or indirectly) that the statements set out in Schedule 14 are true and accurate
as of the date of this Agreement. 

  

	 	9.1.2	Each of the Seller’s Warranties shall be separate and independent and shall not be limited by reference to any other paragraph of Schedule 14 or by anything
in this Agreement. 

  

	 	9.1.3	The Seller does not give or make any warranty as to the accuracy of the forecasts, estimates, projections, statements of intent or statements of opinion provided
to the Purchaser or any of its directors, officers, employees, agents or advisers on or prior to the date of this Agreement. 

  

	 	9.1.4	Any Seller’s Warranty qualified by the expression “so far as the Seller is aware” or to the “Seller’s
Knowledge” or any similar expression shall, unless otherwise stated, be deemed to refer to the knowledge of the following persons: [***], [***], [***], [***], [***], [***], [***], [***], [***], [***], [***], [***], [***] and [***], such
persons having made due and reasonable enquiry. 

  

	 	9.1.5	The Seller’s Warranties shall be deemed to be repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if
references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. Without prejudice to the provisions of Clause 10, the Seller shall have no liability for any breach of any Seller’s Warranty
where the Seller’s Warranty was true as at the date of this 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 72 

	 	
Agreement unless the fact, event or circumstances giving rise to the breach constitutes a Material Adverse Effect. The Seller shall have no liability under this Clause 9.1.5 if the
Purchaser has exercised its termination right in accordance with Clause 4.4.1(iii). 

  

	9.2	Seller’s Disclosures 

  

	 	9.2.1	The Seller’s Warranties are subject to all matters which are fairly disclosed in this Agreement or in the Disclosure Letter. 

 

	 	9.2.2	References in the Disclosure Letter to paragraph numbers shall be to the paragraphs in Schedule 14 to which the disclosure is most likely to relate. Such
references are given for convenience only and, shall not limit the effect of any of the disclosures, all of which are made against the Seller’s Warranties as a whole. 

 

	9.3	The Purchaser’s Warranties 

 The Purchaser warrants to the Seller that the statements set out in Schedule 15 are true and accurate as of the date of this Agreement. 

 

	10.	Limitation of Liability 

  

	10.1	Time Limitation for Claims 

 The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty in respect of any claim unless a notice of the claim is given by the Purchaser to the Seller specifying the
matters set out in Clause 11.2: 
  

	 	10.1.1	in the case of a claim under paragraphs 1 and 2.2 of Schedule 14, within the applicable statutory limitations period; 

 

	 	10.1.2	in the case of a claim under paragraph 3 of Schedule 14, within 6 years of the Closing Date; 

 

	 	10.1.3	in respect of claims under the Tax Warranties, before the date falling six months after the expiry of the period specified by statute during which an assessment
of the relevant liability to Tax may be issued by the relevant Tax Authority; and 

  

	 	10.1.4	in the case of any other claim, within two years of the Closing Date. 

 

	10.2	Minimum Claims 

  

	 	10.2.1	The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty in respect of any individual claim (or a series of claims arising
from similar or identical facts or circumstances) where the liability agreed or determined (disregarding the provisions of this Clause 10.2) in respect of any such claim or series of claims does not exceed 0.1 per cent of the Headline Amount.

  

	 	10.2.2	 Where the liability agreed or determined in respect of any such claim or series of claims exceeds 0.1 per cent. of the Headline Amount, the
liability of 

  
 73 

	 	
the Seller shall be for the whole amount of such claim(s) and not just the excess. 

  

	10.3	Aggregate Minimum Claims 

  

	 	10.3.1	The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty (other than any Tax Warranty) in respect of any claim unless the
aggregate amount of all claims for which the Seller would otherwise be liable under this Agreement for breach of any Seller’s Warranty (disregarding the provisions of this Clause 10.3) exceeds 1 per cent of the Headline Amount.

  

	 	10.3.2	Where the liability agreed or determined in respect of all claims exceeds 1 per cent of the Headline Amount, the Seller shall be liable for the aggregate
amount of all claims as agreed or determined and not just the excess. 

  

	 	10.3.3	For the avoidance of doubt, the Purchaser may give notice of any single claim in accordance with and for the purposes of Clause 10.1 above, irrespective of
whether, at the time the notice is given, the amount set out in Clause 10.3.1 has been exceeded. 

  

	10.4	Maximum Liability 

 The
aggregate liability of the Seller in respect of any breaches: 
  

	 	10.4.1	of the Seller’s Warranties (other than Tax Warranties and the Seller’s Warranties contained in paragraphs 1, 2.2 or 3 of Schedule 14) shall not
exceed an amount equal to 30 per cent. of the Headline Amount; 

  

	 	10.4.2	of the Seller’s Warranties contained in paragraph 3 of Schedule 14 shall not exceed an amount equal to 60 per cent. of the Headline Amount; and

  

	 	10.4.3	of the Seller’s Warranties contained in paragraphs 1 or 2.2 of Schedule 14 shall not exceed the Headline Amount. 

 

	10.5	Contingent Liabilities 

The Seller shall not be liable under this Agreement for breach of any Seller’s Warranties in respect of which the liability is
contingent, unless and until such contingent liability becomes an actual liability and is due and payable (but the Purchaser has the right under Clause 11.1 to give notice of such claim before such time). For the avoidance of doubt, the fact
that the liability may not have become an actual liability by the relevant date provided in Clause 10.1 shall not exonerate the Seller in respect of any claim properly notified before that date. 

 

	10.6	Matters Arising Subsequent to this Agreement 

 The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty in respect of any matter, act, omission or circumstance (or any combination thereof) to the extent that the
same would not have occurred but for: 
  

	 	10.6.1	Agreed matters 

  
 74 

 any matter or thing done or omitted to be done by the Seller or any member of the
Seller’s Group before Closing pursuant to and in compliance with this Agreement or otherwise at the request in writing of the Purchaser; or 
  

	 	10.6.2	Changes in legislation 

the passing of, or any change in, after the Closing Date, any Applicable Law or administrative practice of any government, governmental
department, agency or regulatory body having the force of the law including (without prejudice to the generality of the foregoing) any increase in the rates of Taxation or any imposition of Taxation or any withdrawal of relief from Taxation not in
force at the Closing Date. 
  

	10.7	Insurance 

 Without
prejudice to Clause 14, the Seller’s Liability under this Agreement for breach of any Seller’s Warranty shall be reduced by an amount equal to any loss or damage to which such claim related which has actually been recovered under a
policy of insurance held by the Purchaser (after deducting any reasonable costs incurred in making such recovery including the amount of any excess or deductible). 
  

	10.8	Purchaser’s Right to Recover 

 If the Seller has paid an amount in discharge of any claim under this Agreement for breach of any Seller’s Warranty and subsequently the Purchaser recovers (whether by payment, discount, credit,
relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Purchaser (in whole or in part) in respect of the loss or liability which is the subject matter of the claim, the Purchaser shall pay to the Seller as soon
as practicable after receipt an amount equal to (i) the sum recovered from the third party less any costs and expenses incurred in obtaining such recovery and any Tax on any amounts recovered (or Tax that would have been payable on such amounts but
for the availability of any Tax relief), or if less (ii) the amount previously paid by the Seller to the Purchaser. Any payment made by the Purchaser to the Seller under this Clause shall be made or procured by way of further adjustment of the
consideration paid by the Purchaser and the provisions of Clause 3.3 to 3.4 shall apply mutatis mutandis. 
  

	10.9	No Double Recovery and no Double Counting 

 A party shall be entitled to make more than one claim under this Agreement arising out of the same subject matter, fact, event or circumstance but shall not be entitled to recover under this Agreement or
otherwise more than once in respect of the same Losses suffered or amount for which the party is otherwise entitled to claim (or part of such Losses or amount), regardless of whether more than one claim arises in respect of it. No amount
(including any relief) (or part of any amount) shall be taken into account, set off or credited more than once under this Agreement or otherwise, with the intent that there will be no double counting under this Agreement or otherwise. 

 

	10.10	Fraud 

 None of the
limitations contained in this Clause 10 shall apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises 

  
 75 

 
or is increased, as the consequence of, or which is delayed as a result of, fraud by any director or officer of any member of the Seller’s Group. 

 

	11.	Claims 

  

	11.1	Notification of Potential Claims 

 Without prejudice to the obligations of the Purchaser under Clause 11.2, if the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against the Seller under this
Agreement for breach of any Seller’s Warranty (ignoring for these purposes the application of Clauses 11.2 or 11.3), the Purchaser shall as soon as reasonably practicable give a notice in writing to the Seller of such facts, matters or
circumstances as are then available regarding the potential claim. Failure to give notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this Agreement for breach of any Seller’s Warranty, except
that the failure shall be taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced as a result of such failure. 

 

	11.2	Notification of Claims under this Agreement 

 Notices of claims under this Agreement for breach of Seller’s Warranty shall be given by the Purchaser to the Seller within the time limits specified in Clause 10.1 and shall specify information
(giving reasonable detail) in relation to the basis of the claim and setting out the Purchaser’s estimate of the amount of Losses which are, or are to be, the subject of the claim. 

 

	11.3	Commencement of Proceedings 

 Any claim notified pursuant to Clause 11.2 shall (if it has not been previously satisfied, settled or withdrawn) be deemed to be irrevocably withdrawn 9 months after the relevant time limit set out
in Clause 10.1 unless, at the relevant time, legal proceedings in respect of the relevant claim have been commenced by being both issued and served except: 
  

	 	11.3.1	where the claim relates to a contingent liability, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been
commenced by being both issued and served with 9 months of it having become an actual liability; or 

  

	 	11.3.2	where the claim is a claim for breach of a Seller’s Warranty of which notice is given for the purposes of Clause 10.1 at a time when the amount set out
in Clause 10.3.1 has not been exceeded, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 9 months of the date of any subsequent
notification to the Seller pursuant to Clause 11.1 above of one or more claims which result(s) in the total amount claimed in all claims notified to the Seller pursuant to Clause 10.1 exceeding the amount set out in Clause 10.3.1 for
the first time. 

  
 76 

	11.4	Conduct of Third Party Claims 

  

	 	11.4.1	If the matter or circumstance that may give rise to a claim against the Seller under this Agreement for breach of any Seller’s Warranty is a result of or in
connection with a claim by a third party (a “Third Party Claim”) then: 

  

	 	(i)	the Purchaser shall as soon as reasonably practicable give written notice thereof to the Seller and thereafter shall provide the Seller with periodic updates upon
reasonable request and shall consult with the Seller so far as reasonably practicable in relation to the conduct of the Third Party Claim and shall take reasonable account of the views of the Seller in relation to the Third Party Claim;

  

	 	(ii)	the Third Party Claim shall not be admitted, compromised, disposed of or settled without the written consent of the Seller (such consent not to be unreasonably withheld
or delayed); and 

  

	 	(iii)	subject to the Seller indemnifying the Purchaser or other member of the Purchaser’s Group concerned against all reasonable costs and expenses (including legal and
professional costs and expenses) that may be incurred thereby, the Purchaser shall, or the Purchaser shall procure that any other members of the Purchaser’s Group shall, take such action as the Seller may reasonably request to avoid, dispute,
deny, defend, resist, appeal, compromise or contest the Third Party Claim, provided that this Clause 11.4.1(iii) shall not apply where the claim by the third party relates to matters or circumstances referred to in paragraphs 3 or 7 of
Schedule 14 and the Purchaser shall then have the right to conduct the claim at its discretion (subject to Clauses 11.4.1(i) and (ii)), 

 provided that failure to give notice in accordance with Clause 11.4.1(i) shall not affect the rights of the Purchaser to make a relevant claim under this Agreement for breach of any Seller’s
Warranty, except that the failure shall be taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced as a result of such failure.

  

	 	11.4.2	Notwithstanding the provisions of Clause 11.4.1, if a Third Party Claim may also give rise to an indemnity claim under Clause 8.1.2, the provisions of Clause
8.2.2 shall apply instead of the provisions of Clause 11.4.1. 

  

	11.5	Clinical Employees 

During the period between the Closing Date and the Clinical Employee Transfer Date: 

 

	 	11.5.1	the Seller shall retain operational and management control over the Clinical Employees; and 

 

	 	11.5.2	the Seller shall procure that the Seller’s Oncology Unit leader (being a Clinical Employee) will: 

  
 77 

	 	(i)	liaise with the Purchaser’s Head of Development OGD & GMA regarding the strategic direction of the clinical development activities in relation to the Products
or the Business; 

  

	 	(ii)	supervise the services provided by the Clinical Employees; and 

  

	 	(iii)	ensure the execution of such services in accordance with the strategic direction given by the Purchaser. 

 

	12.	Restrictive Covenants 

  

	12.1	Non-Compete 

 In
consideration of the payment by the Purchaser of $1,600,000,000, the Seller will not, and undertakes to procure that each member of the Seller’s Group will not, do any of the following things: 

 

	 	12.1.1	for three years from the Closing Date, manufacture, sell, commercialise, market or licence (whether as a result of M&A activity or otherwise) any oncology
product which has or is proposed to have (i) the same mechanism of action as any Product; and/or (ii) the same indication as any Product or any Product Expansion (a “Competing Product”); or 

 

	 	12.1.2	for three years from the Closing Date, solicit the custom of any person to whom goods or services have been sold by any Business Seller in the course of the
Business during the two years before the Closing Date, in each case only to the extent that such solicitation is in respect of products referred to in Clause 12.1.1. 

 

	12.2	Exceptions to the non-compete 

 The restrictions in Clause 12.1 shall not apply to: 
  

	 	12.2.1	any activities of any nature undertaken or developed by the Seller’s Group in relation to vaccines; 

 

	 	12.2.2	any Affiliate of Seller in which a person who is not a member of the Seller’s Group holds equity interests and with respect to whom a member of the
Seller’s Group has existing contractual or legal obligations limiting its discretion to impose non-competition obligations; 

  

	 	12.2.3	the holding of shares in a company or other entity for investment purposes provided the Seller does not exercise, directly or indirectly, Control over that
company or entity; 

  

	 	12.2.4	 any business activity that would otherwise violate Clause 12.1 that is acquired in connection with an acquisition so long as the relevant
member of the Seller’s Group divests all or substantially all of the business activity that would otherwise violate Clause 12.1 or otherwise terminates or disposes of such business activity, product line or assets of such acquired business
that would otherwise violate Clause 12.1 within nine months after the consummation of the relevant acquisition, or such longer period as may 

  
 78 

	 	
reasonably be necessary to comply with Applicable Law (provided that in those circumstances the Seller shall procure that the such competing business activity is disposed of as soon as reasonably
practicable); 

  

	 	12.2.5	passive investments by a pension or employee benefit plan or trust for present or former employees; 

 

	 	12.2.6	performance of any obligation of the Seller’s Group under this Agreement or any of the Ancillary Agreements, as amended from time to time in accordance with
their terms; 

  

	 	12.2.7	any manufacturing of products that are not Competing Products by any member of the Seller’s Group for the Seller’s Group or any third party;

  

	 	12.2.8	any manufacturing and supply of the Divested Zofran Product by any member of the Seller’s Group exclusively for or to the order of Aspen Global Incorporated
and its Affiliates for sale in Australia to the extent required under the Aspen Agreements; 

  

	 	12.2.9	performance of any obligation of the Seller’s Group under the [***], as amended to the extent permitted by this Agreement from time to time;

  

	 	12.2.10	provision of data or other content to or in connection with business conducted by any person, in each case as required by Applicable Law.

  

	12.3	Non-solicit 

 The Seller
will not, and undertakes to procure that each member of the Seller’s Group will not, for a period of two years after the Closing Date, solicit or induce any Restricted Group Employee to become employed or engaged whether as employee, consultant
or otherwise by any member of the Seller’s Group. 
  

	12.4	Exceptions to the non-solicit 

 The restrictions in Clause 12.3 may be relaxed or additional exceptions allowed by written approval of the Purchaser’s Division Head of HR and shall in any event not apply to the solicitation,
inducement or recruitment of any person: 
  

	 	12.4.1	through the placing of advertisements of posts available to the public generally; 

 

	 	12.4.2	through an employment agency, provided that no member of the Seller’s Group encourages or advises such agency to approach any such person;

  

	 	12.4.3	who is no longer employed by the Purchaser’s Group; or 

  

	 	12.4.4	who is under formal notice of termination from his employer, provided that this exception only applies if the employment or engagement by the member of the
Seller’s Group is offered with a start date which is no earlier than the day after the last scheduled date of the person’s employment with the Purchaser’s Group. 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 79 

	12.5	Reasonableness of Restrictions 

 Each undertaking contained in this Clause 12 shall be construed as a separate undertaking and if one or more of the undertakings is held to be against the public interest or unlawful or in any way an
unreasonable restraint of trade, the remaining undertakings shall continue to bind the Seller. 
  

	13.	Confidentiality 

  

	13.1	Announcements 

 No
announcement, communication or circular concerning the existence or the subject matter of this Agreement shall be made or issued by or on behalf of any member of the Seller’s Group or the Purchaser’s Group without the prior written
approval of the Seller and the Purchaser (such consent not to be unreasonably withheld or delayed). This shall not affect any announcement, communication or circular required by law or any governmental or regulatory body or the rules of any stock
exchange on which the shares of any party (or its holding company) are listed but the party with an obligation to make an announcement or communication or issue a circular (or whose holding company has such an obligation) shall consult with the
other parties (or shall procure that its holding company consults with the other parties) insofar as is reasonably practicable before complying with such an obligation. 

 

	13.2	Confidentiality 

  

	 	13.2.1	Subject to Clause 13.1 and Clause 13.2.2, each of the parties shall treat as strictly confidential and not disclose or use any information received or
obtained as a result of entering into this Agreement, the Ancillary Agreements (or any other agreement entered into pursuant to this Agreement) which relates to: 

 

	 	(i)	the existence and provisions of this Agreement, the Ancillary Agreements and of any other agreement entered into pursuant to this Agreement; 

 

	 	(ii)	the negotiations relating to this Agreement, the Ancillary Agreements and any such other agreement; 

 

	 	(iii)	(in the case of the Seller) any information relating to the Business following Closing and any other information relating to the business, financial or other affairs
(including future plans and targets) of the Purchaser’s Group; or 

  

	 	(iv)	(in the case of the Purchaser) any information relating to the business, financial or other affairs (including future plans and targets) of the Seller’s Group
including, prior to Closing, any information relating to the Business. 

  

	 	13.2.2	Clause 13.2.1 shall not prohibit disclosure or use of any information if and to the extent: 

  

  
 80 

	 	(i)	the disclosure or use is required by law, any governmental or regulatory body or any stock exchange on which the shares of any party (or its holding company) are
listed; 

  

	 	(ii)	the disclosure or use is required to vest the full benefit of this Agreement or the Ancillary Agreements in any party; 

 

	 	(iii)	the disclosure or use is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement, the Ancillary Agreements or any other agreement
entered into under or pursuant to this Agreement; 

  

	 	(iv)	the disclosure is made to a Tax Authority in connection with the Tax affairs of the disclosing party; 

 

	 	(v)	the disclosure is made to a ratings agency on a confidential basis in connection with the affairs of the disclosing party; 

 

	 	(vi)	the disclosure is made by the Purchaser to any of its Representatives, any member of the Purchaser’s Group and/or any of their respective Representatives, or by
the Seller to any of its Representatives, any member of the Seller’s Group and/or any of their respective Representatives, in each case on a “need-to-know” basis and provided they have a duty (contractual or otherwise) to keep such
information confidential; 

  

	 	(vii)	the information was lawfully in the possession of that party without any obligation of secrecy prior to its being received or held, in either case as evidenced by
written records; 

  

	 	(viii)	the information is or becomes publicly available (other than by breach of this Agreement); 

 

	 	(ix)	the other party has given prior written approval to the disclosure or use; or 

 

	 	(x)	the information is independently developed, 

 provided that prior to disclosure or use of any information pursuant to Clause 13.2.2(i), (ii) or (iii), the party concerned shall, where not prohibited by law, promptly notify the other parties of
such requirement with a view to providing the other parties with the opportunity to contest such disclosure or use or otherwise to agree the timing and content of such disclosure or use. 

 

	14.	Insurance 

  

	14.1	No cover under Seller’s Group Insurance Policies from Closing 

 The Purchaser acknowledges and agrees that following Closing: 
  

	 	14.1.1	 the Purchaser shall not have or be entitled to the benefit of any Seller’s Group Insurance Policy in respect of any event, act or omission
that takes place after Closing and it shall be the sole responsibility of the Purchaser to 

  
 81 

	 	
ensure that adequate insurances are put in place in relation to the Business with effect from Closing; 

 

	 	14.1.2	except in respect of any Delayed Business until the appropriate Delayed Closing Date, neither the Seller nor any member of the Seller’s Group shall be
required to maintain any Seller’s Group Insurance Policy in relation to the Business; and 

  

	 	14.1.3	the Purchaser shall not be entitled to make or notify a claim under any Seller’s Group Insurance Policy in respect of any event, act or omission that
occurred prior to the Closing Date. 

  

	15.	France Business and Netherlands Business 

  

	15.1	France Business 

Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement to sell or purchase the
France Business, provided that: 
  

	 	15.1.1	in the event that the France Put Option Exercise occurs before Closing, this Clause 15.1 (other than this Clause 15.1.1) shall terminate and shall
cease to have effect and the sale of the France Business shall be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

 

	 	15.1.2	in the event that the France Put Option Exercise does not occur before Closing: 

 

	 	(i)	the provisions of Clauses 2 and 6 (the “Disapplied Provisions”) shall not apply to the France Business; 

 

	 	(ii)	prior to the France Closing, the provisions of Clause 12, Schedule 8 and Schedule 9 (the “Suspended Provisions”) shall not apply to the France
Business; and 

  

	 	(iii)	in respect of the Disapplied Provisions and, prior to the France Closing, the Suspended Provisions only: 

 

	 	(a)	the term “Business” shall be deemed to exclude the France Business; 

 

	 	(b)	the term “Assumed Liabilities” shall be deemed to exclude the France Assumed Liabilities; and 

 

	 	(c)	the term “Employees” shall be deemed to exclude the France Employees; 

 

	 	15.1.3	with effect from the France Closing, the Suspended Provisions shall apply to the France Business mutatis mutandis save that in respect of the Suspended
Provisions only (A) the term “Closing” shall be deemed to refer to the France Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the France Closing; and 

  
 82 

	 	15.1.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any of the Ancillary Agreements as are required in order to give effect
to the principles set forth in this Clause 15.1 for the purposes of complying with the information and consultation requirements in respect of the relevant works council in respect of the France Business; and 

 

	 	15.1.5	the provisions of Clause 10 shall apply to the France Business as if the remaining provisions of this Clause 15.1 did not have any force or effect.

  

	15.2	Netherlands Business 

Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement to sell or purchase the
Netherlands Business, provided that: 
  

	 	15.2.1	in the event that the Netherlands Put Option Exercise occurs before Closing, this Clause 15.2 (other than this Clause 15.2.1) shall terminate and shall
cease to have effect and the sale of the Netherlands Business shall be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

 

	 	15.2.2	in the event that the Netherlands Put Option Exercise does not occur before Closing: 

 

	 	(i)	the Disapplied Provisions shall not apply to the Netherlands Business; 

  

	 	(ii)	prior to the Netherlands Closing, the Suspended Provisions shall not apply to the Netherlands Business; and 

 

	 	(iii)	in respect of the Disapplied Provisions and, prior to the Netherlands Closing, the Suspended Provisions only: 

 

	 	(a)	the term “Business” shall be deemed to exclude the Netherlands Business; 

 

	 	(b)	the term “Assumed Liabilities” shall be deemed to exclude the Netherlands Assumed Liabilities; and 

 

	 	(c)	the term “Employees” shall be deemed to exclude the Netherlands Employees; 

 

	 	15.2.3	with effect from the Netherlands Closing, the Suspended Provisions shall apply to the Netherlands Business mutatis mutandis save that in respect of the Suspended
Provisions only (A) the term “Closing” shall be deemed to refer to the Netherlands Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the Netherlands Closing; and

  

	 	15.2.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any of the Ancillary Agreements as are required in order to give effect
to the principles set forth in this Clause 15.2 for the purposes of complying with the information and consultation requirements in respect of the relevant works council in respect of the Netherlands Business; and 

  
 83 

	 	15.2.5	the provisions of Clause 10 shall apply to the Netherlands Business as if the remaining provisions of this Clause 15.2 did not have any force or
effect. 

  

	16.	Other Provisions 

  

	16.1	Further Assurances 

  

	 	16.1.1	Without prejudice to any restriction or limitation on the extent of any party’s obligations under this Agreement, each of the parties shall from time to
time, so far as each is reasonably able, do or procure the doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the party concerned as they consider necessary to transfer the
Business to the Purchaser or otherwise to give the other party the full benefit of this Agreement. 

  

	 	16.1.2	If the parties determine at any time after Closing that, in respect of any country in which Assets are required to transfer under this Agreement, the transfer of
certain such Assets is prohibited or restricted in such country under Applicable Law, the parties agree that such country shall be treated as a Delayed Business and the provisions of Schedule 25 shall apply to the transfer of Assets and/or Employees
(as applicable) in such country. 

  

	16.2	Whole Agreement 

  

	 	16.2.1	This Agreement and the Ancillary Agreements contain the whole agreement between the parties relating to the subject matter of this Agreement at the date hereof
to the exclusion of any terms implied by law which may be excluded by contract and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Agreement. 

 

	 	16.2.2	The Purchaser acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated
into it. 

  

	 	16.2.3	Each of the parties agrees and acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection
with this Agreement shall be for breach of the terms of this Agreement and each of the parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking.

  

	 	16.2.4	In Clauses 16.2.1 to 16.2.3, “this Agreement” includes the Ancillary Agreements and all other documents entered into pursuant to this Agreement.

  

	 	16.2.5	Nothing in this Clause 16.2 excludes or limits any liability for fraud. 

  
 84 

	16.3	No Assignment 

 No party
may without the prior written consent of the other parties, assign, grant any security interest over, hold on trust or otherwise transfer the benefit of the whole or any part of this Agreement. 

 

	16.4	Third Party Rights 

  

	 	16.4.1	Subject to Clause 16.4.2, the parties to this Agreement do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts
(Rights of Third Parties) Act 1999, by any person who is not a party to this Agreement. 

  

	 	16.4.2	Certain provisions of this Agreement confer benefits on the Affiliates of the Purchaser and the Affiliates of the Seller (each such Affiliate being, for the
purposes of this Clause 16.4, a “Third Party”) and, subject to Clause 16.4.3, are intended to be enforceable by each Third Party by virtue of the Contracts (Rights of Third Parties) Act 1999. 

 

	 	16.4.3	Notwithstanding Clause 16.4.2, this Agreement may be varied in any way and at any time without the consent of any Third Party. 

 

	16.5	Variation or waiver 

  

	 	16.5.1	No variation of this Agreement shall be effective unless in writing and signed by or on behalf of each of the parties. 

 

	 	16.5.2	No failure or delay by a party in exercising any right or remedy provided by Applicable Law or under this Agreement or any Ancillary Agreement shall impair such
right or remedy or operate or be construed as a waiver or variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any
other remedy. 

  

	16.6	Method of Payment and set off 

  

	 	16.6.1	Payments (including payments pursuant to an indemnity, compensation or reimbursement provision) made or expressed to be made by the Purchaser or the Seller
pursuant to this Agreement or any claim for breach of this Agreement shall, insofar as the payment or claim relates to or affects the Share (including the Company by reason of the transfer of the Share) or any assets or liabilities transferred
pursuant to this Agreement, be made or received (as the case may be) by: 

  

	 	(i)	the Seller, for itself or as agent on behalf of the relevant Business Seller or the Share Seller (each in respect of the assets and liabilities to be transferred by it
pursuant to this Agreement including, in the case of the Share Seller, the Share); and 

  

	 	(ii)	 the Purchaser, for itself or as agent on behalf of the relevant members of the Purchaser’s Group (each in respect of the assets

  
 85 

	 	
and liabilities to be transferred to it pursuant to this Agreement, including the Share). 

  

	 	16.6.2	Payments pursuant to this Agreement shall be settled by payments between the Seller, on behalf of the relevant members of the Seller’s Group, and the
Purchaser, on behalf of the relevant members of the Purchaser’s Group. 

  

	 	16.6.3	Any payments pursuant to this Agreement shall be made in full, without any set-off, counterclaim, restriction or condition and without any deduction or
withholding (save as may be required by law or as otherwise agreed). 

  

	 	16.6.4	Any payments pursuant to this Agreement shall be effected by crediting for same day value the account specified by the Seller or the Purchaser (as the case may
be) on behalf of the party entitled to the payment (reasonably in advance and in sufficient detail to enable payment by telegraphic or other electronic means to be effected) on or before the due date for payment. 

 

	 	16.6.5	Payment of a sum in accordance with this Clause 16.6 shall constitute a payment in full of the sum payable and shall be a good discharge to the payer (and
those on whose behalf such payment is made) of the payer’s obligation to make such payment and the payer (and those on whose behalf such payment is made) shall not be obliged to see to the application of the payment as between those on whose
behalf the payment is received. 

  

	16.7	Costs 

  

	 	16.7.1	Except as otherwise expressly provided for in this Agreement, the Seller shall bear all costs incurred by it and its Affiliates in connection with the
preparation and negotiation of, and the entry into, this Agreement, any Ancillary Agreement and the sale of the Business. 

  

	 	16.7.2	Except as otherwise expressly provided for in this Agreement, the Purchaser shall bear all such costs incurred by it and its Affiliates in connection with the
preparation and negotiation of, and the entry into, this Agreement, any Ancillary Agreement and the purchase of the Business. 

  

	16.8	Notarial Fees, Registration, Stamp and Transfer Taxes and Duties 

 Subject to Clause 8.13, the Seller shall bear the cost of all notarial fees and all registration, stamp and transfer taxes and duties (including, for the avoidance of doubt, stamp duty reserve tax) or
their equivalents (“Transfer Taxes”) in all jurisdictions where such fees, taxes and duties are payable as a result of the transactions contemplated by this Agreement. The Purchaser shall be responsible for arranging the payment of
all Transfer Taxes payable as a result of transactions taking place at or after Closing, including fulfilling any administrative or reporting obligation imposed by the jurisdiction in question in connection with such payment. The Seller shall
indemnify the Purchaser or any other member of the Purchaser’s Group against any Transfer Taxes payable as a result of the transactions contemplated by this Agreement to the extent that such amounts have not already been deducted from the
amount payable by the Purchaser at Closing under Clause 6.3.1(i)(d). 

  
 86 

	16.9	Interest 

 If any party
defaults in the payment when due of any sum payable under this Agreement, the liability of that party shall be increased to include interest on such sum from the date when such payment is due until the date of actual payment (as well after as before
judgment) at a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 
  

	16.10	Grossing-up 

  

	 	16.10.1	All sums payable under this Agreement and the Local Transfer Documents shall be paid free and clear of all deductions, withholdings, set-offs or counterclaims
whatsoever save only as required by Applicable Law or as may be otherwise agreed. Subject to Clauses 16.10.2 to 16.10.7 if any deductions or withholdings are required by law the party making the payment shall (except in the case of any
interest payable under Clause 16.9) be obliged to pay to the other party such sum as will after such deduction or withholding has been made leave the other party with the same amount as it would have been entitled to receive in the absence of
any such requirement to make a deduction or withholding, provided that if either party to this Agreement shall have assigned or novated the benefit in whole or in part of this Agreement or shall, after the date of this Agreement, have changed its
tax residence or the permanent establishment to which the rights under this Agreement are allocated then the liability of the other party under this Clause 16.10.1 shall be limited to that (if any) which it would have been had no such
assignment, novation or change taken place. 

  

	 	16.10.2	If either party is or becomes aware of any facts making it reasonably likely that the Purchaser, or any relevant member of the Purchaser’s Group, will be
required to deduct or withhold any amount in respect of the Business Consideration and/or the Share Consideration (a “Relevant Tax Deduction”), then that party shall, as soon as reasonably practicable, give notice to the other party
(including details of the relevant facts and, so far as possible, details of the rate and basis of such withholding). 

  

	 	16.10.3	The Seller and the Purchaser shall, and shall procure that the members of their respective groups shall (at the Seller’s cost), co-operate with each other
in good faith and use all reasonable efforts to reduce or mitigate any Relevant Tax Deduction (or its amount) and/or to enable the Seller or the relevant Business Seller or Share Seller to obtain any available credit or refund in respect of such
Relevant Tax Deduction, including, without limitation, making any available claim under an applicable double taxation treaty. 

  

	 	16.10.4	 Without prejudice to the generality of Clause 16.10.3, the Seller and the Purchaser shall co-operate in good faith to establish or agree
the amount or basis of calculation of any Relevant Tax Deduction prior to Closing (and in this regard the Purchaser shall consider reasonably any relevant information or evidence provided or obtained by the Seller) including, if requested by the
Seller and at the Seller’s expense, by seeking to obtain a ruling or 

  
 87 

	 	
confirmation from a relevant Tax Authority, or obtaining an opinion from reputable local tax counsel or a firm of accountants of international standing satisfactory to the Purchaser (acting
reasonably) and instructed jointly by the Seller and the Purchaser. 

  

	 	16.10.5	The Purchaser shall, or shall procure that the relevant member of the Purchaser’s Group shall, make any Relevant Tax Deduction in the minimum amount
required by Applicable Law, provided that: 

  

	 	(i)	if a double taxation treaty between the jurisdiction under the laws of which the Relevant Tax Deduction is required and the jurisdiction of residence of the Seller or
the relevant Share Seller or Business Seller is in force, the Purchaser shall (and shall procure that any relevant member of the Purchaser’s Group shall) make any Relevant Tax Deduction in an amount not exceeding the rate specified in such
double taxation treaty (which may be nil), provided that the Seller has provided the Purchaser with such evidence as is required under Applicable Law to establish the entitlement of the Seller (or relevant Share Seller or Business Seller) to the
benefit of the applicable treaty; and 

  

	 	(ii)	if an opinion from reputable local counsel or a firm of accountants of international standing has been obtained as envisaged by Clause 16.10.4, the Purchaser shall
(and shall procure that any relevant member of the Purchaser Group shall) make such Relevant Tax Deduction in an amount or on a basis which is consistent with that opinion (which may result in no withholding or deduction), provided that the Seller
has indemnified the Purchaser and any relevant member of the Purchaser’s Group, to the Purchaser’s reasonable satisfaction, against any Liabilities arising (including any interest and penalties) should such opinion be wholly or partly
incorrect. 

  

	 	16.10.6	The Purchaser shall promptly provide the Seller with evidence reasonably satisfactory to the Seller that a Relevant Tax Deduction has been made and an
appropriate amount paid to the relevant Tax Authority. 

  

	 	16.10.7	If any Relevant Tax Deduction is required, an additional sum shall be payable in accordance with Clause 16.10.1 only if and to the extent that such
deduction or withholding would not have been required had the Purchaser and each member of the Purchaser’s Group making such payment or to which such payment relates been resident for Tax purposes only in Switzerland. 

 

	16.11	Notices 

  

	 	16.11.1	Any notice or other communication in connection with this Agreement (each, a “Notice”) shall be: 

 

	 	(i)	in writing in English; and 

  
 88 

	 	(ii)	delivered by hand, fax, or by courier using an internationally recognised courier company. 

 

	 	16.11.2	A Notice to the Seller shall be sent to such party at the following address, or such other person or address as the Seller may notify to the Purchaser from time
to time: 

 GlaxoSmithKline plc 
 980 Great West Road 
 Brentford 

Middlesex TW8 9GS 
  

			
	Fax:	  	+44 (0)208 0476904
		
	Attention:	  	Company Secretary

 with a copy to the Seller’s Lawyers, marked for the urgent attention of Simon Nicholls
(delivery of such copy shall not itself constitute valid notice). 
  

	 	16.11.3	A Notice to the Purchaser shall be sent to such party at the following address, or such other person or address as the Purchaser may notify to the Seller from
time to time: 

 Novartis AG 
 Postfach 
 CH-4002 Basel 

Switzerland 
  

			
	Fax:	  	+41 613244300
		
	Attention:	  	Head Legal M&A, Novartis International AG

 with a copy to the Purchaser’s Lawyers, marked for the urgent attention of Jennifer Bethlehem
(delivery of such copy shall not itself constitute valid notice). 
  

	 	16.11.4	A Notice shall be effective upon receipt and shall be deemed to have been received: 

 

	 	(i)	at the time of delivery, if delivered by hand or courier; 

  

	 	(ii)	at the time of transmission in legible form, if delivered by fax. 

  

	16.12	Invalidity or Conflict 

  

	 	16.12.1	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion
or modification is necessary so that the provision is legal, valid and enforceable and gives effect to the commercial intention of the parties. 

  

	 	16.12.2	 To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 16.12.1, then such provision or part
of it shall, to the extent that it is illegal, invalid or unenforceable, be deemed not to form part of this Agreement and the legality, validity and enforceability of 

  
 89 

	 	
the remainder of this Agreement shall, subject to any deletion or modification made under Clause 16.12.1, not be affected. 

 

	 	16.12.3	If there is any conflict between the terms of this Agreement and any of the Ancillary Agreements this Agreement shall prevail (as between the parties between
this Agreement and as between any member of the Seller’s Group and any member of the Purchaser’s Group) unless (i) such Ancillary Agreement expressly states that it overrides this Agreement in the relevant respect and (ii) the Seller and
the Purchaser are either also parties to that Ancillary Agreement or otherwise expressly agree in writing that such Ancillary Agreement shall override this Agreement in that respect. 

 

	 	16.12.4	For the avoidance of doubt, nothing in this Agreement is intended to limit or exclude the Liabilities of any party under any Ancillary Agreement.

  

	16.13	Counterparts 

 This
Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. Any party may enter into this Agreement by executing any such counterpart. Delivery of a counterpart of
this Agreement by email attachment shall be an effective mode of delivery. 
  

	16.14	Governing Law and Submission to Jurisdiction 

  

	 	16.14.1	This Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and any non-contractual obligations arising out of or
in connection with the Agreement and such documents shall be governed by and construed in accordance with English law. 

  

	 	16.14.2	Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in
connection with this Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and that accordingly any proceedings arising out of or in connection with this Agreement and the documents to be entered into
pursuant to it shall be brought in such courts. Each of the parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have
been brought in an inconvenient forum. 

  

	16.15	Appointment of Process Agent 

  

	 	16.15.1	The Purchaser hereby irrevocably appoints Hackwood Secretaries Limited of One Silk Street, London EC2Y 8HQ as its agent to accept service of process in England
and Wales in any legal action or proceedings arising out of this Agreement, service upon whom shall be deemed completed whether or not forwarded to or received by the Purchaser. 

 

	 	16.15.2	The Purchaser agrees to inform the Seller in writing of any change of address of such process agent within 28 days of such change. 

  
 90 

	 	16.15.3	If such process agent ceases to be able to act as such or to have an address in England and Wales, the Purchaser irrevocably agrees to appoint a new process
agent in England and Wales and to deliver to the Seller within 14 days a copy of a written acceptance of appointment by the process agent. 

  

	 	16.15.4	Nothing in this Agreement shall affect the right to serve process in any other manner permitted by law. 

This Agreement has been entered into on the date stated at the beginning. 

 

	
	SIGNED by
	
	And
	
	For and on behalf of
	NOVARTIS AG
	
	SIGNED by
	
	For and on behalf of
	GLAXOSMITHKLINE PLC

  
 91 

 CONTENTS 

 

			
	CLAUSE	 	PAGE

  

 Schedule 1 
 Products 
 Part 1 

Products 
  

															
	 No
	 	 Brand
name
	 	 Active
Ingredient
	  	 Product Description
	  	 Marketing
Authorisation details
(includes
all countries
that have product
approval; NOTE; for
products with multiple
indications, some
countries may not have
yet have approval for
all indications)
	 	 Product Expansion
Applications

(includes only those
submitted or currently
under regulatory review)
	 	 ATC Code
	 	 Dosage

	1	 	Tafinlar	 	Dabrafenib	  	 Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is
N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. It has the molecular formula C23H20
F3N5O2S2•
 CH4O3S and a molecular weight of 615.68.
	  	Australia, Austria, Belgium, Bulgaria, Canada, Chile, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia,
Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States	 	 Combination w/ MEK (regulatory reviews ongoing in certain markets, i.e. Switzerland); proposed indication below:

 
 TAFINLAR in combination with trametinib is indicated for the treatment of patients
with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
	 	 Antineoplastic agents, protein kinase inhibitor
 L01XE23
	 	The recommended dose of TAFINLAR is 150 mg orally twice daily as a single agent or in combination with trametinib 2 mg orally once daily.
								
	2	 	Mekinist	 	Trametinib	  	 Trametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-
iodophenyl)
 amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-
	  	Australia, Canada, Switzerland, United States	 	 EU opinion for Mekinist monotherapy on track for April CHMP meeting:

 
 Trametinib is indicated in monotherapy for the treatment of adult
	 	 Antineoplastic agents, protein kinase inhibitor
 L01XE23
	 	The recommended dosage regimens of MEKINIST are 2 mg orally once daily as a single agent or in combination with dabrafenib 150 mg
orally

  
 92 

															
		 		 		  	 trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with 1,1’-sulfinylbis

[methane] (1:1). It has a molecular formula C26H23
FIN5O4•C2
 H6OS with a
molecular mass of 693.53.
	  		 	patients with unresectable or metastatic melanoma with a BRAF V600 mutation	 		 	twice daily
								
	3	 	Votrient	 	Pazopanib	  	 VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented as

the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)
 methylamino]-2-pyrimidinyl]
 amino]-2-methylbenzenesul

fonamide monohydrochloride. It has the molecular formula C21H23
N7O2S•HCl and
a molecular weight of 473.99.
	  	Albania, Argentina, Aruba, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile, Colombia, Costa
Rica, Croatia, Cuba, Curacao, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Germany, Greece, Guatemala, Guyana, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy,
Japan, Kazakhstan, Korea, Republic of, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macao, Macedonia, Malaysia, Malta, Mexico, Morocco, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal,
Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Suriname, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Thailand, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay,
Venezuela, Yemen	 	EU withdrawal of maintenance treatment of women with FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal cancer who had not progressed after receiving
first-line chemotherapy.	 	 Antineoplastic agents, other antineoplastic agents, protein- kinase inhibitors,
 ATC code: L01XE11
	 	The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily.
								
	4	 	Tykerb/ Tyverb	 	Lapatinib	  	Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the monohydrate of the ditosylate salt, with	  	Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Cambodia, Chile, Colombia, Croatia, Cyprus, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France, Germany, Greece, Guatemala, Guyana, Honduras, Hungary, Iceland, Indonesia,	 	Awaiting results of ALTTO to support submission along with NeoALTTO.	 	Antineoplastic agent, other antineoplastic agents, protein kinase inhibitor, ATC code:	 	 Tyverb / capecitabine combination:
  

The recommended dose of Tyverb is 1250 mg (i.e. five tablets) once daily continuously.
 The recommended dose of capecitabine is 2000

  
 93 

															
		 		 		  	 chemical name N-(3

 
 chloro-4-{[(3-fluorophenyl)
 methyl]oxy}
 phenyl)-6-[5-({[2

 
 (methylsulfonyl)
 ethyl]amino}
 methyl)-2-furanyl]-4-quinazolinamine bis(4

 
 methylbenzenesul
 fonate) monohydrate. It has the molecular formula C29H26ClFN4O4S
  

(C7H8O3S)2
H2O and a molecular weight of 943.5.
	  	Ireland, Israel, Italy, Kazakhstan, Korea, Republic of, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Moldova, Morocco, Netherlands, Norway, Oman, Pakistan, Paraguay,
Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, Syrian Arab Republic, Turkey, Ukraine, United Kingdom, United States, Yemen, Algeria, Armenia, Belarus, Bosnia and
Herzegovina, Canada, China, Costa Rica, Curacao, Dominican Republic, El Salvador, Georgia, Hong Kong ,India ,Jamaica, Japan, Jordan, Kuwait, Lebanon, Macao, Macedonia, New Zealand, Nicaragua, Panama, Qatar, Saudi Arabia, South Africa, Suriname,
Taiwan, Thailand, Trinidad and Tobago, United Arab Emirates, Uruguay, Venezuela	 		 	L01XE07	 	 mg/m2/day taken in 2 doses 12 hours apart on days 1-14 in a 21 day cycle

 
 Tyverb / trastuzumab combination:

 
 The recommended dose of Tyverb is 1000 mg (i.e. four tablets) once daily
continuously.
 The recommended dose of trastuzumab is 4 mg/kg administered as an intravenous (IV) loading dose, followed by 2 mg/kg IV
weekly
  
 Tyverb / aromatase inhibitor combination:

 
 The recommended dose of Tyverb is 1500 mg (i.e. six tablets) once daily
continuously.
  
 U.S. FDA Label:

 
 HER2-Positive Metastatic Breast Cancer: The recommended dose of TYKERB
is 1,250 mg given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21-day cycle.

 
 Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer: The
recommended dose of TYKERB is 1,500 mg given orally once daily continuously in combination with letrozole.

  
 94 

															
		 		 		  		  		 		 		 	When coadministered with TYKERB, the recommended dose of letrozole is 2.5 mg once daily.
								
	5	 	Promacta/ Revolade	 	Eltrombopag	  	 Eltrombopag olamine is a biphenyl hydrazone. The chemical name for eltrombopag olamine is
3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]
 hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid -
2-aminoethanol (1:2). It has the molecular formula
C25H
22N4O4
•2
 (C2H7
NO). The molecular weight is 564.65 for eltrombopag olamine and 442.5 for eltrombopag free acid.
	  	Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile,
Colombia, Costa Rica, Croatia, Curacao, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, EI Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Guyana, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia,
Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Korea Republic of, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macao, Macedonia, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman,
Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Sudan (North part), Suriname, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Thailand,
Trinidad and Tobago, Turkey, United Arab Emirates, United Kingdom, United States, Uruguay, Yemen	 	 sNDA filed 27 Feb 2014: Proposed Indication below:

 
 PROMACTA is indicated for the treatment of cytopenias in patients with severe
aplastic anemia who have had an insufficient response to immunosuppressive therapy
	 	Antihemorrhagics, other systemic hemostatics. ATC code: B02BX 05	 	 US FDA Label:
  

Promacta has four FDA approved dosages: 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg tablets.

								
	6	 	Arzerra	 	Ofatumumab	  	ARZERRA (ofatumumab) is an IgG1K human monoclonal antibody with a molecular weight of approximately 149 kDa. The antibody was generated via transgenic mouse and hybridoma technology and is produced in a recombinant murine cell line
(NS0) using standard	  	Argentina, Australia, Austria, Bahrain, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Japan, Kazakhstan, Kuwait, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Panama, Poland, Portugal, Qatar, Romania, Russian Federation,	 	Arzerra in combination with alkylator (e.g. chlorambucil) is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in previously untreated patients PDUFA date
(4/18)	 	monoclonal antibodies, ATC code: L01XC10	 	The recommended dose is 300 mg ofatumumab for the first infusion and 2,000 mg ofatumumab for all subsequent infusions. The infusion schedule is 8 consecutive weekly infusions,
followed 4-5 weeks later by 4 consecutive monthly (i.e. every 4 weeks) infusions.

  
 95 

															
		 		 		  	mammalian cell cultivation and purification technologies.	  	Slovakia, Slovenia, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States	 		 		 	 U.S. FDA Label:
  

Previously Untreated CLL:
  

The recommended dosage and schedule is:
  

•      300 mg on Day 1 followed 1 week later by 1,000 mg on Day 8 (Cycle 1)
followed by
  

•      1,000 mg on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles
until best response or a maximum of 12 cycles.
  
 Refractory
CLL: The recommended dosage and schedule is 12 doses administered as follows:

•      300 mg initial dose (Dose 1), followed 1 week later by

 

•      2,000 mg weekly for 7 doses (Doses 2 through 8), followed 4 weeks later
by
  

•      2,000 mg every 4 weeks for 4 doses (Doses 9 through
12).

								
	7	 	Hycamtin	 	Topotecan	  	 HYCAMTIN (topotecan hydrochloride) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase
I-inhibitory activity.
 HYCAMTIN for Injection is supplied as a sterile lyophilized, buffered, light yellow to greenish powder available in
single-dose vials. Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base.
 The chemical name
for
	  	Albania, Argentina, Aruba, Australia, Austria, Bahrain, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile, China, Colombia, Costa Rica,
Croatia, Curacao, Cyprus, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Gabon, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jamaica, Japan, Jordan,
Kazakhstan, Kenya, Korea, Republic of Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macedonia, Madagascar,	 	None	 	Other antineoplastic agents: ATC code: L01XX17	 	 Hycamtin IV infusion

Ovarian & Small Cell Lung Cancer:
  

The recommended dose of topotecan is 1.5 mg/m2 body surface area/day administered by intravenous
 2 infusion over 30 minutes daily for five consecutive days with a three week interval between the start of each course.
  

Cervical Carcinoma: The recommended dose of topotecan is 0.75 mg/m2/day administered as 30 minute intravenous infusion daily
on

  
 96 

															
		 		 		  	 topotecan hydrochloride is (S)-10-[(dimethylamino)
 methyl]-4 ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino[1,2-b]quinoline-3, 14-(4H,12H)-dione
 monohydrochloride. It has the molecular formula C23H23N3O5•HCl and a molecular weight of 457.9.
	  	Malaysia, Maldives, Malta, Moldova, Morocco, Namibia, Netherlands, New Zealand, Nicaragua, Niger, Norway, Oman, Pakistan, Palestine, Panama, Peru, Philippines, Poland, Portugal,
Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Thailand, Trinidad and Tobago, Ukraine, United Arab Emirates, United Kingdom,
United States, Uruguay	 		 		 	 days 1, 2 and 3. Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan
dose.
  
 Hycamtin Capsules (per US FDA label)

 
 The recommended dose of HYCAMTIN capsules is 2.3 mg/m2 /day once daily for 5
consecutive days repeated every 21 days. Round the calculated oral daily dose to the nearest 0.25 mg, and prescribe the minimum number of 1 mg and 0.25 mg capsules. The same number of capsules should be prescribed for each of the 5 dosing
days.

								
	8	 	Argatroban  	 	Argatroban	  	 Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. The chemical name for Argatroban is
1-[5-[(aminoiminomethyl)
 amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8quinolinyl)
 sulfonyl]amino]
 pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4
asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S 
	  		 	None	 	B01AE03	 	 Heparin-Induced Thrombocytopenia (HIT/HITTS): Initial Dosage: Before administering Argatroban, discontinue heparin
therapy and obtain a baseline aPTT. The recommended initial dose of Argatroban for adult patients without hepatic impairment is 2 mcg/kg/min, administered as a continuous infusion
 Percutaneous Coronary Interventions (PCI) in HIT/HITTS Patients: Initial Dosage: An infusion of Argatroban should be
started

  
 97 

															
		 		 		  	 stereoisomers at a ratio of approximately 65:35.
 The molecular formula of Argatroban is C23H36N6O5S•H2O. Its molecular weight is 526.66.
	  		 		 		 	at 25 mcg/kg/min and a bolus of 350 mcg/kg administered via a large bore intravenous (IV) line over 3 to 5 minutes (see Table 9). Activated clotting time (ACT) should be checked 5
to 10 minutes after the bolus dose is completed. The procedure may proceed if the ACT is greater than 300 seconds.
								
	9	 	Zofran	 	Ondansetron	  	 The active ingredient in ZOFRAN Injection is ondansetron hydrochloride (HCl), the racemic form of ondansetron and a selective blocking
agent of the serotonin 5-HT3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4Hc o e o u
 The empirical formula is C18H19N3O•
 HCl•2H2O,
representing a molecular weight of 365.9.
	  		 	None	 	A04AA01	 	 Prevention of Chemotherapy-Induced Nausea and Vomiting: Adult Dosing: The recommended I.V. dosage of ZOFRAN for
adults is a single 32-mg dose or three 0.15-mg/kg doses. A single 32-mg dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. The recommended infusion rate should not be exceeded (see OVERDOSAGE). With the
three-dose (0.15-mg/kg) regimen, the first dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of ZOFRAN.

 
 Prevention of Postoperative Nausea and Vomiting: Adult Dosing:

  
 98 

															
		 		 		  		  		 		 		 	 The recommended
 I.V. dosage of
ZOFRAN for adults is 4 mg undiluted administered intravenously in not less than 30 seconds, preferably over 2 to 5 minutes, immediately before induction of anesthesia, or postoperatively if the patient experiences nausea and/or vomiting
occurring shortly after surgery.

								
	10	 	Arranon/ Atriance	 	Nelarabine	  	 ARRANON (nelarabine) is a pro-drug of the cytotoxic deoxyguanosine analogue, 9-ß-D-250
arabinofuranosylguanine (ara-G).
  
 The chemical name for nelarabine is
2-amino-9-ß-D-arabinofuranosyl-6-methoxy-9H-purine. It has the molecular formula C11H15
N5O5 and a
molecular weight of 297.27.
	  		 	None	 	 Antineoplastic agents, antimetabolites, purine analogues, ATC code:
 L01B B 07
	 	 Adults and adolescents (aged 16 years and older): 
 The recommended dose of nelarabine for adults is 1,500 mg/m2 administered intravenously over two hours on days 1, 3 and 5 and repeated every 21 days.

 
 Paediatric population: 

Children and adolescents (aged 21 years and younger): 
 The recommended dose of nelarabine for children and adolescents is 650 mg/m2 administered

intravenously over one hour daily for 5 consecutive days, repeated every 21 days.

								
	11	 	 AKT GSK2141

795
	 	-	  	An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2141795 binds to and inhibits
the activity of Akt,	  	None	 	None	 	Antineoplastic agents, protein kinase inhibitor	 	n/a

  
 99 

															
		 		 		  	which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway
is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents	  		 		 		 	
								
	12	 	 GSK2110
 183
	 	Afuresertib	  	An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity
of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and
dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	  	None	 	None	 	Antineoplastic agents, protein kinase inhibitor	 	n/a
								
	13	 	LGD4665 also known by	 		  		  		 		 		 	

  
 100

															
		 	 the GSK reference number GSK22

85921
	 		  		  		 		 		 	

  
 101

 Schedule 1 
 Part 2 
 Product Expansions – Combos 

[***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 102

 CONTENTS 

 

			
	CLAUSE	 	PAGE

  

 Schedule 2 
 Certain Intellectual Property Rights Matters (Clause 2.3.1) 
 Part 1: Registered
Transferred Product Intellectual Property Rights 
 Patents 
 [***] 
 Registered Trade Marks and Copyright 

[***] 
 Part 2: List of Transferred
Contracts and Transferred IP Contracts 
 [***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 103

 CONTENTS 

 

			
	CLAUSE	 	PAGE

  

  
 104

 Schedule 3 
 Excluded Assets and Excluded Contracts (Clause 2.3.2) 
 Part 1 Excluded Assets

 The Import Drug Licence 

Part 2 Excluded Contracts 
 The China
Contracts 

  
 105

 Schedule 4 
 Excluded Liabilities (Clause 2.3.4) 
 Not Used 

  
 106

 Schedule 5 
 Permitted Encumbrances (Clause 1.1) 
 (i) Co-Owned Business Product Intellectual Property
Rights listed at Part 1 of Schedule 2. 

  
 107

 Schedule 6 
 Product Approvals (Clause 6.2.2) 
 Part 1 Terms relating to the Product Approvals

  

	1.	General Provisions 

  

	1.1	The Purchaser shall do all things necessary to effect the transfer of each Product Approval, including complying with requirements and requests of Governmental
Entities with respect to the transfer of each Product Approval. 

  

	1.2	The Marketing Authorisations shall be transferred in accordance with Part 2 of this Schedule 6. 

 

	2.	Fees and expenses 

 From
and after the Closing Date, the Purchaser shall promptly reimburse the relevant members of the Seller’s Group for all maintenance and renewal fees and similar fees paid, and all out of pocket expenses reasonably incurred in connection with the
satisfaction of any commitments or obligations by such member of the Seller’s Group with respect to each Product Approval. 
  

	3.	Product Expansion Applications 

  

	3.1	The Purchaser shall file or cause to be filed applications for the transfer of each Product Expansion Application in each country or territory in which such
transfer is required to be submitted as soon as possible after the Closing Date. 

  

	3.2	Pending the transfer of each Product Expansion Application the Seller shall, and shall cause the relevant members of the Seller’s Group to:

  

	 	3.2.1	upon reasonable request from the Purchaser and at the Purchaser’s expense, reasonably cooperate and coordinate with the Purchaser in relation to the
transfer of the Product Expansion Applications, including by providing the Purchaser with regulatory documentation concerning the Products owned or controlled by Seller or its Affiliates; 

 

	 	3.2.2	perform such acts and services as may be requested by the Purchaser that are reasonably necessary or required by any Governmental Entity to maintain or renew any
Product Expansion Application or are reasonably necessary for the Purchaser to pursue the regulatory approval for any Product Expansion Application, including conducting any studies, including clinical and stability studies, concerning the Products
and the Product Expansions; and 

  

	 	3.2.3	notify the Purchaser as soon as is reasonably practicable of any written communication received by the Seller or any member of the Seller’s Group with
respect to any Product Expansion Application and shall consult with the Purchaser with respect to such communication and take into account the Purchaser’s views as to the form and content of any communication with any Governmental Entity
concerning such Product Expansion Application. 

  
 108

 Part 2 Marketing Authorisation Transfer Provisions 

 

	1.	Transfer of Marketing Authorisations 

Marketing Authorisation Transfer and Marketing Authorisation Re-registration 

 

	1.1	The Seller and the Purchaser hereby agree they will each use, and will procure that their respective Affiliates will use, all reasonable endeavours to ensure
that, as soon as reasonably practicable after the Closing Date: 

  

	 	1.1.1	subject to paragraphs 1.1.2 and 1.1.3, each Marketing Authorisation shall be transferred in accordance with Applicable Law by the Marketing
Authorisation Holder to the Marketing Authorisation Transferee (“Marketing Authorisation Transfer”); 

  

	 	1.1.2	where Applicable Law does not permit Marketing Authorisation Transfer, a new marketing authorisation shall be registered in the name of the Marketing
Authorisation Transferee to replace the existing Marketing Authorisation (“Marketing Authorisation Re-registration”) and the Seller shall procure that the relevant Marketing Authorisation Holder takes all necessary steps to
withdraw, abandon, cancel or allow to lapse the superseded Marketing Authorisation as soon as practicable after the Marketing Authorisation Re-registration Date; and 

 

	 	1.1.3	good faith discussions are held between the Seller and the Purchaser (or their respective Affiliates) to determine whether a structure may be implemented such
that the Marketing Authorisation Transfers in Brazil may be effected without the need for a Marketing Authorisation Re-registration, such as by means of a spin-off structure under Applicable Law (the “Brazilian Spin-off”). For the
avoidance of doubt, nothing in this sub-paragraph 1.1.3 shall oblige the Seller or the Purchaser to carry out any Brazilian Spin-off. 

  

	1.2	Without prejudice to any rights the Purchaser may have under the terms of this Agreement, to the extent that, before Closing, and in the event that, at Closing,
the Marketing Authorisation Holder of the Marketing Authorisation for Argatroban in the United States and Canada (the “Argatroban MA”) is not the Seller or a member of the Seller’s Group, the Seller shall use all reasonable
endeavours to procure or assist the Purchaser to procure the transfer of (i) the Argatroban MA and (ii) all data relevant to Argatroban held in the safety database of the Marketing Authorisation Holder of the Argatroban MA (or any of its Affiliates)
(the “Argatroban Safety Data”) to the Marketing Authorisation Transferee as soon as reasonably practicable. The Seller shall use all reasonable endeavours to procure that the Marketing Authorisation Holder of the Argatroban MA shall
continue to support the Argatroban MA for pharmacovigilance activities until the Argatroban Safety Data has transferred to a member of the Purchaser’s Group. 

 

	1.3	The parties agree that the transfer of any Marketing Authorisation from the Marketing Authorisation Holder to the Marketing Authorisation Transferee in respect
of any Delayed Business shall not complete until on or after the relevant Delayed Closing Date. 

  
 109

	1.4	Any Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) shall each be effected on a Market-by-Market basis (such that
there shall not be any staggered Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as the case may be) on a Product-by-Product basis in any Market), unless otherwise agreed between the Seller and the Purchaser.

  

	1.5	With effect from the Closing Date until the Marketing Authorisation Transfer Date or the Marketing Authorisation Re-registration Date (as applicable), the Seller
shall procure that each Marketing Authorisation Holder shall hold the Marketing Authorisation(s) in its name but for the account, risk and benefit of the relevant Marketing Authorisation Transferee. 

Submission of MA Documentation 
  

	1.6	Without prejudice to paragraph 1.7, the Purchaser shall be responsible for preparing and submitting, or for procuring that there is prepared and submitted
(in any such case at the Purchaser’s cost and expense), all notices, applications, submissions, reports and any other instruments, documents, correspondence or filings necessary to complete Marketing Authorisation Transfer or Marketing
Authorisation Re-registration (as applicable) (the “MA Documentation”). The MA Documentation shall be prepared in accordance with Applicable Law as soon as reasonably practicable. 

 

	1.7	At the Seller’s election, the Purchaser shall procure that advanced drafts of the MA Documentation are submitted to the Seller so as to allow the Seller
and/or the Marketing Authorisation Holder a reasonable opportunity to provide comments on such MA Documentation before it is submitted to the relevant Governmental Entity. The Purchaser shall incorporate all comments on such drafts as may reasonably
be made by the Seller and/or the Marketing Authorisation Holder PROVIDED THAT the Purchaser shall not be obliged to incorporate any comments if the Purchaser considers, acting reasonably that to do so would materially delay Marketing Authorisation
Transfer or Marketing Authorisation Re-registration (as applicable). 

  

	1.8	Where under Applicable Law the MA Documentation is required to be submitted to the relevant Governmental Entity: 

 

	 	1.8.1	by the Marketing Authorisation Holder, the Purchaser shall procure that the finalised MA Documentation is provided to the Seller after such MA Documentation is
finalised in accordance with paragraph 1.7 above and the Seller shall, in turn, procure that the Marketing Authorisation Holder submits such MA Documentation to the relevant Governmental Entity (the timing and date of such submission to be
agreed with the Purchaser) and the Seller shall promptly thereafter advise the Purchaser of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Purchaser; and 

 

	 	1.8.2	 by the Marketing Authorisation Transferee, the Purchaser shall procure that the relevant Marketing Authorisation Transferee submits the
finalised MA Documentation to the relevant Governmental Entity as soon as reasonably practicable after such MA Documentation is finalised in accordance with paragraph 1.7 above and the Purchaser shall promptly thereafter advise the

  
 110

	 	
Seller of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Seller. 

 

	 	1.8.3	From the Closing Date, the Seller shall procure that the relevant Marketing Authorisation Holder shall, as soon as reasonably practicable, sign any notices,
applications, submissions, reports and other instruments, documents, correspondence or filings presented to it by the Purchaser or the relevant Marketing Authorisation Transferee that are necessary to effect Marketing Authorisation Transfer or
Marketing Authorisation Re-registration (as applicable). The Marketing Authorisation Holder shall: 

  

	 	(i)	provide notice of its consent to a Marketing Authorisation Transfer or Marketing Authorisation Re-registration if required by any Governmental Entity; and

  

	 	(ii)	provide to the Purchaser or the relevant Marketing Authorisation Transferee any information or other data or technical or other information in its possession that
relates to the relevant Marketing Authorisation and that is required by a relevant Governmental Entity or otherwise reasonably required by the Purchaser or the relevant Marketing Authorisation Transferee to assist the Purchaser or the relevant
Marketing Authorisation Transferee to effect the relevant Marketing Authorisation Transfer or Marketing Authorisation Re-registration; 

  

	 	(iii)	in the event of any request for information or any query from any relevant Governmental Entity in respect of Marketing Authorisation Transfer or the Marketing
Authorisation Re-registration (as applicable), the relevant party receiving such request or query shall provide copies of any such request or query to the Seller or, as the case may be, to the Purchaser. The Purchaser shall be responsible for
preparing, or shall be responsible for procuring that there is prepared, (at the Purchaser’s cost and expense) any response to such a request or query with the intention that such request or query shall be dealt with as promptly and efficiently
as possible. In advance of finalising any such response, the Purchaser shall procure that the relevant response is submitted to the Seller so as to allow the Seller and/or the relevant Marketing Authorisation Holder a reasonable opportunity to
provide comments on such response before it is submitted to the Governmental Entity. The Purchaser shall procure that relevant Marketing Authorisation Transferee (i) shall submit the response to the relevant Governmental Entity as soon as reasonably
practicable after the same has been finalised in accordance with this paragraph 1.8.3(iii) and (ii) shall provide a copy of the relevant response (in the form submitted) to the Seller. 

  
 111

	2.	Obligations Pending Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

 

	2.1	Unless otherwise required by Applicable Law or a relevant Governmental Entity (or unless otherwise agreed in writing by the Seller and the Purchaser), from the
Closing Date until the applicable Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date: 

  

	 	2.1.1	the Seller shall: 

  

	 	(i)	maintain in force (or procure that there is maintained in force) each Marketing Authorisation, and shall not voluntarily amend, cancel or surrender any Marketing
Authorisation unless requested to do so in writing by the Purchaser or required to do so by any Applicable Law or any Governmental Entity; 

  

	 	(ii)	with the Purchaser’s consent (not to be unreasonably withheld or delayed) progress (or procure that there is progressed) any registrations, variations or renewals
to Marketing Authorisations initiated by the Seller (or any other member of the Seller’s Group) prior to the Closing Date or withdraw them upon the request of the Purchaser; 

 

	 	(iii)	procure that each Marketing Authorisation Holder shall comply with the terms of any Marketing Authorisation and shall notify the Purchaser as soon as reasonably
practicable of the details of any variations or renewals initiated following the Closing Date; 

  

	 	(iv)	inform the Purchaser of any impending renewals of Marketing Authorisations as at the Closing Date and the parties shall discuss in good faith to what extent any such
renewal will be pursued or withdrawn (it being agreed that the Purchaser shall have the final decision in any such matter); 

  

	 	(v)	not without the consent of the Purchaser, initiate any additional variations or amendments to the Marketing Authorisations, except to the extent required by any
Governmental Entity or where failure to do so would breach Applicable Law; and 

  

	 	(vi)	consider in good faith any request by the Purchaser to apply for a new marketing authorisation in respect of a Product PROVIDED THAT if the Seller agrees to submit such
application, any costs or expenses incurred by the Seller in making such application shall be for the Purchaser’s account and shall constitute MA Costs; 

 

	 	2.1.2	 without prejudice to the generality of the foregoing paragraph 2.1.1(iii), the Purchaser acknowledges and agrees that each Marketing
Authorisation Holder shall be entitled to do (or to procure that there is done) any or all of the following (and the Purchaser acknowledges that, where the relevant Marketing Authorisation Holder so chooses and unless otherwise agreed,

  
 112

	 	
responsibility for each of the following activities shall rest with the relevant Marketing Authorisation Holder): 

 

	 	(i)	pharmacovigilance activities related to the Marketing Authorisations, which activities shall be conducted in accordance with the Applicable Law, the Pharmacovigilance
Agreement, and the standards, policies and procedures of the Seller’s Group from time to time in force; and 

  

	 	(ii)	conducting any and all communications with a Governmental Entity in respect of a Marketing Authorisation (including, without limitation to the generality of the
foregoing, attending any meetings with relevant Governmental Entities and filing and submitting all reports and other documents which it reasonably considers necessary to be submitted in order to comply with Applicable Law or its obligations under
this Agreement), PROVIDED THAT responsibility for (a) the costs of preparation of any such documents, reports and/or filings shall be borne by the Purchaser (or the relevant Marketing Authorisation Transferee) to the extent such costs are reasonably
necessary, and (b) the submission of MA Documentation shall be the responsibility of the Purchaser in accordance with paragraph 1.6 above, PROVIDED THAT the Seller shall ensure that the Purchaser is kept fully and promptly informed of any such
communications or submissions in advance, to the extent reasonably practicable; and 

  

	 	2.1.3	the Seller shall procure that each Marketing Authorisation Holder shall act in accordance with the reasonable instructions of the Purchaser or the Marketing
Authorisation Transferee in respect of each Marketing Authorisation in respect of which such Marketing Authorisation Holder is the holder, PROVIDED THAT no Marketing Authorisation Holder shall be obliged to comply with such instructions to the
extent the same: (i) infringe the terms of the relevant Marketing Authorisation(s); or (ii) are otherwise inconsistent with the provisions of the Pharmacovigilance Agreement relating to the Seller; 

 

	 	2.1.4	the Purchaser shall only request artwork changes to the extent such changes are required in order to comply with Applicable Law; and 

 

	 	2.1.5	 the Purchaser shall submit to the Seller (or shall procure that there is submitted) written details (in such form and with such supporting
materials as the Seller may reasonably request) of any new, amended or proposed advertising and promotional activity or training materials in respect of any Product Commercialised pursuant to any Marketing Authorisation (including (without
limitation) any material reasonably requested by the Seller in order to validate new and/or amended promotional or training materials), and the Purchaser acknowledges and agrees that no such advertising, promotional or training activity shall be
implemented, undertaken or otherwise commenced without the prior written consent of the Seller (for itself and on behalf of the relevant Marketing Authorisation Holder), such consent not to be unreasonably withheld. The Purchaser further agrees
and acknowledges that, if it so chooses, the Seller shall be entitled to assume responsibility for 

  
 113

	 	
obtaining (or procuring that there is obtained) the consent(s) and approval(s) of any relevant Governmental Entity required for such new, amended or proposed advertising and promotional activity
or training activity; and 

  

	 	2.1.6	to the extent permitted by the terms of the relevant Marketing Authorisation and provided for in the Transitional Distribution Services Agreement, the Purchaser
or any other member of the Purchaser’s Group shall Commercialise the Product(s) which are the subject of such Marketing Authorisation (notwithstanding that such Marketing Authorisation is held in the name of the relevant Marketing Authorisation
Holder and, for the avoidance of doubt, the proceeds of any such Commercialisation shall be for the benefit of the Purchaser’s Group) and the Purchaser shall: 

 

	 	(i)	indemnify each member of the Seller’s Group against any and all actions, claims, demands, investigations, judgments, proceedings, liabilities, loss, damages,
payments, costs and expenses arising in relation to the Commercialisation of the Product(s) by the Purchaser or any other member of the Purchaser’s Group under this paragraph 2.1.6; and 

 

	 	(ii)	procure that such Product(s) are Commercialised in compliance with the terms of the relevant Marketing Authorisation and/or the requirements of the relevant
Governmental Entity. 

  

	2.2	Unless otherwise required by Applicable Law or a relevant Governmental Entity, from the Closing Date until the applicable Marketing Authorisation Transfer Date
or Marketing Authorisation Re-registration Date, where any Market Authorisation Holder is required by Applicable Law to consult with a Governmental Entity in order to negotiate the discounts, rebates or other pricing mechanisms (including
reimbursement) (the “Pricing”) applicable to the Commercialisation of the Products in the relevant Market (a “Pricing Negotiation”): 

 

	 	2.2.1	the Seller shall (or shall procure that the Marketing Authorisation Holder shall) notify the Purchaser as soon as reasonably practicable after the Marketing
Authorisation Holder becomes aware of any opportunity or requirement to enter into a Pricing Negotiation; 

  

	 	2.2.2	the Purchaser shall be responsible for preparing or procuring that there is prepared (at the Purchaser’s cost) all notices, submissions and reports, and any
other documents or correspondence necessary for the purposes of the Pricing Negotiation (the “Pricing Negotiation Documentation”); 

  

	 	2.2.3	the Seller shall (or shall procure that the Marketing Authorisation Holder shall) co-operate with the Purchaser and provide the Purchaser with such data and
information as the Purchaser may reasonably request for the purposes of preparing the Pricing Negotiation Documentation; 

  

	 	2.2.4	 the Purchaser shall procure that the Pricing Negotiation Documentation is provided to the Seller and/or Marketing Authorisation Holder prior to
the intended date of submission to the relevant Governmental Entity with such advance notice as is reasonably sufficient for the Seller and/or the Marketing 

  
 114

	 	
Authorisation Holder to determine whether any of the information or any proposal included in the Pricing Negotiation Documentation would constitute or result in a breach of Applicable Law by the
Marketing Authorisation Holder or any other member of the Seller’s Group; 

  

	 	2.2.5	if the Seller and/or the Marketing Authorisation Holder believes (acting reasonably) that any of the information or any proposal included in the Pricing
Negotiation Documentation prepared by the Purchaser (or a member of the Purchaser’s Group) would constitute or result in a breach of Applicable Law by the Marketing Authorisation Holder, then it shall submit to the Purchaser (or relevant member
of the Purchaser’s Group) within 10 Business Days of the date of receipt of the Pricing Negotiation Documentation from the Purchaser pursuant to paragraph 2.2.4, a written legal opinion specifying why any of the information or any proposal
included in the Pricing Negotiation Documentation would constitute or result in a breach of Applicable Law. Following receipt of the legal opinion by the Purchaser (or relevant member of the Purchaser’s Group), the parties shall consult with
each other, in good faith, in order to agree amendments to the Pricing Negotiation Documentation that are reasonably required in order to ensure compliance with Applicable Law and the Seller (or the relevant Marketing Authorisation Holder) shall
submit the revised Pricing Negotiation Documentation to the relevant Governmental Entity as soon as possible thereafter; 

  

	 	2.2.6	if the Seller and/or Marketing Authorisation Holder believes (acting reasonably) that neither the information nor any proposal included in the Pricing
Negotiation Documentation would constitute or result in a breach of Applicable Law by the Marketing Authorisation Holder or any other member of the Seller’s Group, then the relevant member of the Purchaser’s Group shall submit such Pricing
Negotiation Documentation directly to the Governmental Entity unless prohibited by Applicable Law or by the Governmental Entity, in which case, the Seller shall procure that the Marketing Authorisation Holder makes the submission to the Governmental
Entity as soon as reasonably practicable after it is received from the Purchaser (or relevant member of the Purchaser’s Group); 

  

	 	2.2.7	the Purchaser (or a member of the Purchaser’s Group) shall be entitled to correspond with and attend all meetings with the Governmental Entity in relation
to the Pricing Negotiation and, to the extent that the Marketing Authorisation Holder is required to be present at any such meetings under Applicable Law or by the Governmental Entity, the Seller shall procure that the Marketing Authorisation Holder
shall jointly attend any such meetings with the relevant member of the Purchaser’s Group; 

  

	 	2.2.8	 the Purchaser (or a member of the Purchaser’s Group) shall be entitled to conduct the Pricing Negotiation unless prohibited under
Applicable Law or by the Governmental Entity, in which case, the Seller shall procure that the Marketing Authorisation Holder shall conduct the Pricing Negotiation and in any event enter into any related agreement with the Governmental Entity in

  
 115

	 	
accordance with the reasonable instructions of the Purchaser (or a member of the Purchaser’s Group); and 

 

	 	2.2.9	the Seller undertakes (and shall procure that the Marketing Authorisation Holder undertakes) to ensure that the Pricing Negotiation Documentation and any
information received in connection with or as part of the Pricing Negotiation: (i) is kept confidential and is only disclosed to employees of the Seller’s Group on a need to know and confidential basis; and (ii) is used by the Seller, the
Marketing Authorisation Holder and/or employees of the Seller’s Group for the sole purpose of making a determination under sub-paragraph 2.2.4 above. 

  

	2.3	Subject to paragraph 2.4, the parties agree that nothing in paragraph 2.2 above shall preclude the Seller and/or Marketing Authorisation Holder from: (i)
preparing and submitting to any Governmental Entity any notices, submissions and reports, and any other documents or correspondence, (ii) attending meetings with any Governmental Entity, (iii) making representations to any Governmental Entity, and
(iv) taking any and all steps as the Seller and/or Marketing Authorisation Holder shall consider necessary or desirable, in each case in relation to the negotiation of Pricing applicable to the products that form part of the Seller’s Group
Retained Business (and, for the avoidance of doubt, excluding the Products). 

  

	2.4	Where Applicable Law does not permit the Purchaser to participate in a Pricing Negotiation as contemplated by paragraph 2.2 above or the Seller’s interest
in respect of the outcome of a Pricing Negotiation conflicts or is reasonably likely to conflict with the interests of the Purchaser in the outcome of the Pricing Negotiation, the Seller shall (or shall procure that the relevant Marketing
Authorisation Holder shall): 

  

	 	2.4.1	notify the Purchaser of such conflict of interest as soon as reasonably practicable after becoming aware of it; and 

 

	 	2.4.2	afford the Purchaser to the fullest extent permissible under Applicable Law, the rights it has under paragraph 2.2 above. 

Following notification of a conflict of interest the parties shall, to the extent permitted by Applicable Law, consult together to agree
the approach to be taken by the Seller (or the relevant Marketing Authorisation Holder) to minimise the impact of the conflict of interest on the Purchaser’s interests and if the parties cannot agree on the approach to be taken, the matter
shall be escalated at the Purchaser’s request to the chief financial officers of each party, or their nominees, for resolution. 
  

	3.	New and Pending Marketing Authorisations in Respect of the Products 

 

	3.1	If, at any time prior to Closing, any member of the Seller’s Group is granted or otherwise comes to hold any marketing authorisation which relates
exclusively to one or more Products (a “New Marketing Authorisation”) then: 

  

	 	3.1.1	 the Seller undertakes to the Purchaser to notify the Purchaser as soon as reasonably practicable following the date on which the relevant member
of 

  
 116

	 	
the Seller’s Group is granted, or becomes entitled to, the New Marketing Authorisation; and 

  

	 	3.1.2	the provisions of paragraphs 1 and 2 above shall apply to that new Marketing Authorisation. 

 

	3.2	Where a member of the Seller’s Group has submitted to any Governmental Entity any application relating to the grant of a new marketing authorisation in
respect of the Business which is pending or in process as at the date of this Agreement (a “Pending Marketing Authorisation”): 

  

	 	3.2.1	the Seller shall continue to be responsible for preparation and submission of all documents required to register such Pending Marketing Authorisation but,
following Closing, it shall do so at the Purchaser’s cost and shall pass responsibility for such Pending Marketing Authorisation to the Purchaser (or such member of the Purchaser’s Group as the Purchaser may nominate) as soon reasonably
possible after Closing, subject to Applicable Law; 

  

	 	3.2.2	from the Closing Date, the provisions of paragraph 1 shall apply mutatis mutandis to any registration process for any Pending Marketing Approval.

  

	4.	MA Costs 

  

	4.1	From the Closing Date, the Purchaser shall be responsible for all necessary costs of preparation and submission of MA Documentation and, save as expressly
provided in this Agreement, any other necessary costs incurred by the Seller or a member of the Seller’s Group in connection with the maintenance and any variations, amendments and renewals of the Marketing Authorisations relating to the
Products or for any matter requested by the Purchaser pursuant to this Part 2 of Schedule 6 and for all fees and costs reasonably incurred by the relevant member of the Seller’s Group in complying with its obligations in respect of a Marketing
Authorisation Transfer or Marketing Authorisation Re-registration (“MA Costs”). 

  

	5.	Obligations following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

 

	5.1	On and from the relevant Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date (as applicable), the Purchaser shall procure that
each Marketing Authorisation Transferee shall assume and be solely responsible for: 

  

	 	5.1.1	all obligations as the holder of such Marketing Authorisation including (subject to the terms of the Pharmacovigilance Agreement) pharmacovigilance activities
related to such Marketing Authorisation; 

  

	 	5.1.2	all activities and actions required by Applicable Law in connection with such Marketing Authorisation; and 

 

	 	5.1.3	any and all outstanding commitments and obligations to the relevant Governmental Entities with respect to the relevant Marketing Authorisation, save for any such
commitments or obligations arising from a breach of this Agreement by the Seller. 

  
 117

	5.2	In the event that, following Marketing Authorisation Transfer or Marketing Authorisation Re-registration in respect of any Product, the Seller wishes to apply
for a marketing authorisation in respect of a retained product, the Purchaser shall (and shall procure that the relevant Marketing Authorisation Transferee shall) co-operate with and provide all reasonable assistance to the Seller (or the relevant
member of the Seller’s Group) at the Seller’s costs as may be reasonably required for the purposes of applying for such new marketing authorisation, including (without limitation) providing the Seller (or the relevant member of the
Seller’s Group) and/or any Governmental Entity with such access to Marketing Authorisation Data or such other data or technical or other information as is reasonably requested by the relevant Governmental Entity or is otherwise reasonably
required by the Seller or the relevant member of the Seller’s Group. 

  

	5.3	Except to the extent provided for in the Ofatumumab Intellectual Property Licence Agreement, nothing in paragraph 5.2 above shall require the Purchaser to
consent to or assist the Seller or any member of the Seller’s Group to apply for a marketing authorisation for any product which contains the same compound as any Product. 

 

	Part	3 Tenders 

  

	1.1	From Closing until the Marketing Authorisation Transfer Date in any Market, the Seller shall, and shall procure that each member of the Seller’s Group and
the relevant Marketing Authorisation Holder shall, to the extent permitted by Applicable Law: 

  

	 	1.1.1	inform the Purchaser in writing of any Call for New Tender as soon as reasonably practicable following receipt; and 

 

	 	1.1.2	co-operate with and provide reasonable assistance to the Purchaser (or the relevant member of the Purchaser’s Group) for the purposes of responding to the
Call for New Tender or otherwise applying for a new tender; and 

  

	 	1.1.3	where Applicable Law requires such responses or applications to be made by the Marketing Authorisation Holder, the Seller shall procure that the Marketing
Authorisation Holder submits such responses or applications on behalf of the Purchaser PROVIDED THAT the Purchaser shall indemnify the Seller and/or the relevant Marketing Authorisation Holder (as the case may be) for any and all costs, expenses and
liabilities suffered or reasonably incurred by the Seller and/or the Marketing Authorisation Holder in complying with or as a result of the provisions of this paragraph. 

 

	1.2	If, prior to Closing, the Seller or any member of the Seller’s Group has submitted a bid in any Market in response to any call for a tender (whether a new
tender or the renewal of an existing tender) which includes the Products (the “Bid”), then, following Closing: 

  

	 	1.2.1	 to the extent that the Purchaser (or any member of the Purchaser’s Group) is prohibited from progressing the Bid in place of the relevant
member of the Seller’s Group under Applicable Law, the Seller shall (or shall procure that the relevant member of the Seller’s Group shall) take all steps as may be reasonably required in order to progress the Bid, including responding to
all 

  
 118

	 	
questions raised by the relevant third party and the Purchaser shall provide all assistance (including access to the Purchaser’s employees) reasonably requested by the Seller to enable it to
progress the Bid; and 

  

	 	1.2.2	if the Bid is successful, then either: 

  

	 	(i)	if permitted by Applicable Law and the relevant third party consents, the Purchaser (or any member of the Purchaser’s Group as the Purchaser shall nominate) shall
enter into any contracts or other arrangements as are required to give effect to the tender with the relevant third party and no member of the Seller’s Group shall be obliged to enter into any such contracts or arrangements; or

  

	 	(ii)	if paragraph (i) does not apply, the Seller (or any member of the Seller’s Group as the Seller shall nominate) shall enter into any contracts or other arrangements
as are required to give effect to the tender with the relevant third party and the tender shall be deemed to be a Transferred Contract, Shared Business Contract and/or a Non-Transferring Tender (as the case may be) and the provisions of Schedule 7
shall apply accordingly. 

  
 119

 Schedule 7 
 Transferred Contracts, Transferred Intellectual Property Contracts, Co-Owned 

Transferred Product Intellectual Property Rights, and 
 Shared Business Contracts 
 (Clause 2.3.1) 

 

	1.	Delayed Transfer of Certain Transferred Contracts and Shared Business Contracts 

 

	1.1	Subject to paragraph 4.6, any Transferred Contract, Transferred Intellectual Property Contract or Shared Business Contract relating to a Delayed Business
(“Delayed Business Contracts”) shall not be transferred to the relevant member of the Purchaser’s Group until the relevant Delayed Closing Date and references in this Schedule 7 to “Closing”, “Closing Date”
or “Effective Time” shall be deemed to be to “Delayed Closing Date” insofar as they relate to such Delayed Business Contracts except, in paragraphs 2, 3.1, 3.2, and 4.1 (in relation to Delayed Businesses that are not
Non-Controlled Delayed Businesses). 

  

	2.	Disclosure 

 From Closing,
the Purchaser shall have the right to full disclosure of all Transferred Contracts and Full Disclosure of the Relevant Part of the Shared Business Contracts and the Seller shall use reasonable efforts to facilitate such disclosure as soon as
reasonably practicable. 
  

	3.	Separation of Shared Business Contracts 

  

	3.1	Prior to Closing, the Seller and the Purchaser shall discuss and agree in good faith a process to identify all material Shared Business Contracts.

  

	3.2	The Seller shall use its reasonable efforts to maintain relationships under the Shared Business Contracts and continue to operate the Shared Business Contracts,
including without limitation fulfilling all its obligations under the Shared Business Contracts (excluding the Relevant Parts), in the same manner as it has for the twelve months prior to the date of this Agreement. 

 

	3.3	The Purchaser may, by notice to the Seller at any time prior to the later of: 

 

	 	3.3.1	the date falling 90 days after the Closing Date or, if the Seller has not provided Full Disclosure of a Shared Business Contract on or prior to Closing, the date
falling 90 days after the date on which Full Disclosure of the relevant Shared Business Contract is made; and 

  

	 	3.3.2	the Marketing Authorisation Transfer Date in respect of the relevant Product in the relevant territory 

(the “Relevant Election Date”), 
 elect to take the rights and obligations of the Relevant Part of any Shared Business Contract. For the purposes of paragraph 3.3.2 above only, if a Shared Business Contract is in relation to more than one
Product and/or territory, the first Marketing 

  
 120

 
Authorisation Transfer Date in respect of a Product covered by that Shared Business Contract shall be the relevant date. 

 

	3.4	If the Purchaser makes an election under paragraph 3.3 above: 

  

	 	3.4.1	the Seller and the Purchaser shall use their respective reasonable endeavours to procure that an arrangement is entered into with the relevant counterparty to
each Shared Business Contract, the effect of which shall be that, with effect from whichever is the later of the Marketing Authorisation Transfer Date and the date of the relevant arrangement, the benefit and burden of the Relevant Part is severed
from such Shared Business Contract and an agreement or arrangement equivalent to such Shared Business Contract is entered into between the relevant counterparty and a member of the Purchaser’s Group (or the Relevant Part of the Shared Business
Contract is sub-licensed to such Purchaser) (a “Separation”). For the avoidance of doubt, no part of any such Shared Business Contract shall be severed and transferred to any member of the Purchaser’s Group in so far as it
relates to the Seller’s Group Retained Business, any product other than the Products or any Excluded Asset; and 

  

	 	3.4.2	in the event that the Marketing Authorisation Transfer Date occurs before the effective date of a Separation, the provisions of sub-paragraphs 5.2.1, 5.2.2 and
6.1 of this Schedule shall apply in respect of such Shared Business Contracts. 

  

	3.5	If no election is made by the Purchaser under paragraph 3.3 above by the Relevant Election Date, the provisions of sub-paragraphs 5.2.1 and 5.2.2 of this
Schedule shall apply in respect of the Relevant Part of such Shared Business Contract until: 

  

	 	3.5.1	in the case of any Shared Business Contract that is not a development contract or otherwise related to any Ongoing Clinical Trials, the earlier of 9 months from
the Relevant Election Date and the date on which the Purchaser notifies the Seller that an alternative arrangement has been put in place; and 

  

	 	3.5.2	in the case of any Shared Business Contract that is a development contract or which otherwise relates to any Ongoing Clinical Trials, the end of the period
specified in the Transitional Services Agreement which in any event shall be no less than 9 months from Closing. 

  

	3.6	For the avoidance of doubt, (i) paragraphs 3.3, 3.4 and 3.5 shall not apply in respect of any Shared Business Contract which terminates before the Relevant
Election Date, and (ii) paragraph 4.6 shall not apply in respect of Shared Business Contracts. 

  

	3.7	The parties acknowledge that the Purchaser has elected to take the rights and obligations of the Zofran Trade Mark and Domain Name Licence from Closing in so far
as such agreement relates to Business Product Intellectual Property Rights. 

  

	4.	Obligation to obtain Third Party Consents 

  

	4.1	 Subject to paragraphs 3.4 and 4.4, in relation to any Transferred Contract (excluding, for the purposes of this Schedule, any Product Approval)
or Transferred Intellectual 

  
 121

	 	
Property Contract or rights in a Co-Owned Transferred Product Intellectual Property Right which is not assignable or sub-licensable without a Third Party Consent or a Separation of a Shared
Business Contract which is not separable without a Third Party Consent, this Agreement shall not be construed as an assignment, an attempted assignment, a sub-licensing or an attempted sub-licensing and the Seller and the Purchaser shall each use
their respective reasonable endeavours both before and after Closing (or, in the case of OBM Intellectual Property Contracts, before and after the OBM Transfer Date) to obtain all necessary Third Party Consents as soon as possible and shall keep the
other informed of progress in obtaining such Third Party Consents. The Seller shall deliver to the Purchaser, on Closing or, if later, as soon as possible after receipt, any Third Party Consent. 

 

	4.2	In connection with the obtaining of any Third Party Consent referred to in paragraph 4.1, the Purchaser shall supply to the Seller such information as may
be reasonably requested by the Seller or any relevant third party. 

  

	4.3	Subject to paragraph 4.4, and save as otherwise provided in this Agreement, the cost of any fee demanded by the third party as consideration for giving the Third
Party Consent shall be borne by the Purchaser, provided that: 

  

	 	4.3.1	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

 

	 	4.3.2	no party shall be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent. 

 

	4.4	In relation to any rights in a Co-Owned Transferred Product Intellectual Property Right for which a Third Party Consent is required for the satisfaction of any
step of the Pre-Closing Products Reorganisation, the following shall apply: 

  

	 	4.4.1	the Seller shall use reasonable endeavours to obtain all necessary Third Party Consents required for: 

 

	 	(i)	the satisfaction of any step of the Pre-Closing Products Reorganisation that takes place prior to the Closing Date; and 

 

	 	(ii)	the assignment or transfer to the Purchaser or any member of the Purchaser’s Group of the Co-Owned Transferred Product Intellectual Property Rights after the
Closing Date; 

  

	 	4.4.2	If the Seller has not, prior to the date on which Step 5 of the Pre-Closing Products Reorganisation takes effect, obtained all of the Third Party Consents
referred to in paragraphs 4.4.1(i) and (ii) above which are required for the transfer of any Co-Owned Transferred Product Intellectual Property Rights: 

  

	 	(i)	the legal title in that Co-Owned Transferred Product Intellectual Property Right shall not be transferred to the Company pursuant to Schedule 18; and

  

	 	(ii)	the terms of paragraphs 5 and 6 shall apply to that Co-Owned Transferred Product Intellectual Property Right; and 

  
 122

	 	4.4.3	the cost of any fee demanded by the third party as consideration for giving any Third Party Consent in connection with paragraph 4.4.1 shall be paid by the
Seller and shall be allocated between the Seller and Purchaser as follows: 

  

	 	(i)	the Seller shall meet the cost of any fee demanded by the third party as consideration for giving any Third Party Consent in connection with 4.4.1(i);

  

	 	(ii)	the Purchaser shall meet the cost of any fee demanded by the third party as consideration for giving any Third Party Consent in connection with 4.4.1(ii) provided that:

  

	 	(a)	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

 

	 	(b)	the Purchaser shall not be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent; and

  

	 	(iii)	if the cost of any fee demanded by the third party as consideration for giving any Third Party Consent does not distinguish between consent provided for the purposes of
paragraph 4.4.1(i) and 4.4.1(ii), the Seller and Purchaser shall discuss in good faith the allocation of the fee that should be payable by each in connection with any Third Party Consent. If the Seller and Purchaser are unable to agree on the
allocation within a period of 14 calendar days the allocation of the fee payable by each of the Seller and Purchaser shall be split equally. 

  

	4.5	The parties agree that the provisions of any document entered into in connection with a Third Party Consent (including by way of novation) shall be without
prejudice to the provisions of Clauses 8.1, 8.2 and 13 of this Agreement. 

  

	4.6	Without prejudice to the obligation in paragraph 4.1 for the Seller and the Purchaser to use their respective reasonable endeavours to obtain Third Party
Consents as soon as possible, the transfer to the Purchaser (or any member of the Purchaser’s Group or its third party nominee) of any Transferred Contract shall not occur on Closing or, if later, the date on which the relevant Third Party
Consent is obtained (a “Delayed Contract”), in the following circumstances: 

  

	 	4.6.1	if the Seller or the relevant Business Seller and a member of the Purchaser’s Group agree in writing in respect of a specific Market that the Delayed
Contract shall transfer at a later agreed date (a “Delayed Contract Transfer Date”) in which case such Delayed Contract shall transfer on the Delayed Contract Transfer Date; 

 

	 	4.6.2	 if a Delayed Contract Transfer Date has not been agreed under sub-paragraph 4.6.1 and such Delayed Contract relates to an Ongoing Clinical Trial
(a “Clinical Trial Agreement”), the Clinical Trial Agreement shall not 

  
 123

	 	
transfer before 1 May 2015 and shall transfer after that date but only to the extent permitted by Applicable Law; or 

 

	 	4.6.3	if a Delayed Contract Transfer Date has not been agreed under sub-paragraph 4.6.1 and such Delayed Contract is required to facilitate the provision of services
by the Seller’s Group under the Transitional Distribution Services Agreement in any Market (a “Distribution Contract”), such Delayed Contract shall transfer in accordance with paragraph 4.7. 

The Parties agree that the provisions of this paragraph 4.6 shall not apply where a Contract is required under Applicable Law to transfer
at a date earlier than the dates set out in sub-paragraphs 4.6.1 to 4.6.3 and paragraph 4.7. 
  

	4.7	The parties agree that no Distribution Contracts shall transfer to the Purchaser (or a member of the Purchaser’s Group) before the date falling 90 days
after the Closing Date (the “Moratorium Date”) (unless such Distribution Contract relates to distribution services provided in the USA). Following the Moratorium Date (or after the Closing Date if the Distribution Contract relates
to distribution services in the USA), the Distribution Contracts shall transfer to the Purchaser (or a member of the Purchaser’s Group) as soon as possible after any relevant Third Party Consent is obtained unless either party notifies the
other by the date which is 15 Business Days prior to the Moratorium Date that it believes (acting reasonably) that the transfer of the relevant Distribution Contract prior to the Planned Distribution Transfer Date will result in one or more
Identified Risks, in which case, the relevant Distribution Contract shall not transfer to the Purchaser (or a member of the Purchaser’s Group) until the relevant Distribution Transfer Date unless any and all of the Identified Risks have been
resolved to the reasonable satisfaction of the party that may be adversely affected by the relevant Identified Risks before such date. 

  

	4.8	From the Effective Time until the transfer of any Delayed Contract is effected in accordance with sub-paragraphs 4.6 or 4.7, the provisions of paragraph 5 of
this Schedule shall apply to such Delayed Contracts. Nothing in this sub-paragraph 4.8 shall preclude the Purchaser or any member of the Purchaser’s Group from informing the counterparty to any Delayed Contract of the transfer of the Business
to it or from engaging with such counterparty with respect to any matter relating to such Delayed Contract. 

  

	4.9	The provisions of sub-paragraphs 3.3 to 3.6 (inclusive), sub-paragraphs 4.1 to 4.8 (inclusive) and the entirety of paragraph 6 of this Schedule 7 shall not apply
to Non-Transferring Tenders. The parties agree that each Non-Transferring Tender shall remain with the relevant member of the Seller’s Group that is the contracting party to the Non-Transferring Tender as at the date of this Agreement and no
Third Party Consents shall be sought in respect of any Non-Transferring Tenders. 

  

	5.	Obligations until Third Party Consents are obtained/where Third Party Consents are refused and with respect to Non-Transferring Tenders 

 

	5.1	 Subject to paragraph 5.2 and the Seller’s obligations under the Transitional Distribution Services Agreement, the Purchaser shall (or
shall procure that the relevant member of the Purchaser’s Group shall) assume, carry out, perform and 

  
 124

	 	
discharge the Seller’s and the Business Sellers’ obligations arising under the Transferred Contracts, the Transferred Intellectual Property Contracts, the Co-Owned Transferred Product
Intellectual Property Right, and the Relevant Part of the Shared Business Contracts as from the Effective Time (or, in the case of OBM Intellectual Property Contracts, as from the OBM Transfer Date) but only to the extent such obligations do not
constitute Excluded Liabilities. 

  

	5.2	In respect of any Transferred Contract (other than a Products-Only Tender that is a Non-Transferring Tender) or Transferred Intellectual Property Contract,
Relevant Part of any Shared Business Contract (other than a Non-Transferring Tender) or Co-Owned Transferred Product Intellectual Property Right from the Effective Time (or, in the case of OBM Intellectual Property Contract, as from the OBM Transfer
Date) until the relevant Third Party Consent has been obtained as contemplated by paragraphs 4.1 or 4.4 or where the Third Party Consent has been refused and in respect of the Non-Transferring Tenders: 

 

	 	5.2.1	the relevant Business Seller shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where holding on trust
is not possible under local law or otherwise impracticable, the relevant Business Seller and the relevant member of the Purchaser’s Group shall make such other arrangements between themselves to provide to the relevant member of the
Purchaser’s Group the benefits of the Contract (other than (i) amounts corresponding to any Tax payable by the relevant Business Seller in respect of amounts due under the Transferred Contract or Transferred Intellectual Property Contract or
Relevant Part of the Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right or any Non-Transferring Tender and (ii) any Pre-Closing Receivables), including the enforcement at the cost and for the account of the relevant
member of the Purchaser’s Group of all rights of the relevant Business Seller against any other party thereto; 

  

	 	5.2.2	to the extent that the Purchaser (or the relevant member of the Purchaser’s Group) is lawfully able to do so and subject to the Seller’s obligations
under the Transitional Distribution Services Agreement, the Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) perform the relevant Business Seller’s obligations under the Contract (but only to the
extent such obligations do not constitute Excluded Liabilities) as agent or sub-contractor and shall indemnify the Seller and the relevant Business Seller if the Purchaser or the relevant member of the Purchaser’s Group fails to do so;

  

	 	5.2.3	to the extent that the Purchaser (or a member of the Purchaser’s Group) is not lawfully able to perform such obligations, the Seller shall procure that
relevant Business Seller shall, (subject to being indemnified by the Purchaser for any Losses the Seller or the relevant Business Seller may incur in connection therewith) do all such things as the Purchaser (or the relevant member of the
Purchaser’s Group may direct or reasonably require to enable due performance of the Contract; 

  
 125

	 	5.2.4	the Seller shall (or shall procure that the relevant Business Seller shall) act in accordance with any reasonable instructions or directions provided to it by
the Purchaser (or a relevant member of the Purchaser’s Group) in relation to the management and operation of any Transferred Contract or Relevant Part of any Shared Business Contract (excluding, for the avoidance of doubt, any part of any
Shared Business Contract which relates exclusively to the Seller Group’s Retained Business), and the Purchaser shall indemnify the relevant Business Seller in respect of any Losses that Business Seller may incur in connection therewith,
provided that should the Seller (or relevant Business Seller) believe (acting reasonably) that compliance with any instruction or direction given by the Purchaser (or a member of the Purchaser’s Group) pursuant to this sub-paragraph 5.2.4 will
result in a breach of Applicable Law (including a breach of the terms of the relevant Contract): (i) the Seller (or relevant member of the Seller’s Group), shall inform the Purchaser (or the member of the Purchaser’s Group which gave the
instruction) and shall not be required to implement such instruction or direction; and (ii) the parties shall discuss the concerns of the relevant member of the Seller’s Group in good faith, to determine whether an agreement can be reached such
that the relevant instruction or direction can be implemented by the Seller (or the relevant Business Seller). 

  

	 	5.2.5	without prejudice to the provisions of paragraph 5.2.2, the Seller shall provide (or procure that the relevant Business Seller shall provide) the Purchaser (or
the relevant member of the Purchaser’s Group) with such information and assistance as the Purchaser (or the relevant member of the Purchaser’s Group) may reasonably require (including licensing the relevant member of the Purchaser’s
Group any relevant Intellectual Property Rights owned by, or licensed to, the Seller’s Group) with respect to any Transferred Contract, the Transferred Intellectual Property Contract, the Co-Owned Transferred Product Intellectual Property
Right, and the Relevant Part of the Shared Business Contract which is subject to the provisions of this paragraph 5; 

  

	 	5.2.6	in respect of any Contract for the sale of any Product or Products and any Non-Transferring Tender, the amount of any profit arising from sales pursuant to any
such Contract shall be calculated and remitted to the Purchaser in accordance with the relevant provisions of the Transitional Distribution Services Agreement. 

 

	6.	Failure to Obtain Third Party Consents 

  

	6.1	If a Third Party Consent is refused or otherwise not obtained on terms reasonably acceptable to the Purchaser within 18 months of Closing (or in the case of OBM
Intellectual Property Contracts, within 18 months of the OBM Transfer Date), or in the case of a Separation, 18 months of the Relevant Election Date applicable to such Shared Business Contract: 

 

	 	6.1.1	 the Seller shall be entitled to procure the termination of the Transferred Contract, Transferred Intellectual Property Contract or the Relevant
Part of the Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right and the obligations of the parties under this Agreement in 

  
 126

	 	
relation to such Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right
shall cease forthwith; 

  

	 	6.1.2	references in this Agreement to the Transferred Contracts, Transferred Intellectual Property Contracts or Relevant Part of the Shared Business Contract or
Co-Owned Transferred Product Intellectual Property Right (other than in this paragraph 6) shall be construed as excluding such Transferred Contract, Transferred Intellectual Property Contract or the Relevant Part of the Shared Business Contract
or Co-Owned Transferred Product Intellectual Property Right; and 

  

	 	6.1.3	the Seller and the Purchaser shall each use all reasonable efforts to put in place alternative arrangements so as to give the Purchaser equivalent benefits or
rights as would have been enjoyed under the terminated Transferred Contract, Transferred Intellectual Property Contract or the Relevant Part of the Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right.

  

	7.	Non-Transferring Tenders 

  

	7.1	Subject to the termination of any Non-Transferring Tender (or any Relevant Part thereof) pursuant to sub-paragraphs 7.2 and 7.3 below, the provisions of
sub-paragraph 5.2 of this Schedule 7 shall continue to apply in respect of a Non-Transferring Tender for the term of the relevant Non-Transferring Tender. 

  

	7.2	The Purchaser may serve written notice on the Seller requesting it at its absolute discretion to (i) terminate (or to procure the termination of) any
Non-Transferring Tender which is a Product-Only Tender (an “NTT Products-Only Tender”) or (ii) amend or to procure the amendment of any Non-Transferring Tender which is a Multi-Basket Tender (a “NTT Multi-Basket
Tender”) such that the Relevant Part thereof shall be terminated. 

  

	7.3	Upon receipt of such notice, the Seller shall as soon as reasonably practicable thereafter (i) take such steps as are reasonably necessary to terminate the
relevant NTT Products-Only Tender and (ii) use its reasonable endeavours to procure an amendment of the relevant NTT Multi-Basket Tender. Where the Purchaser serves such a request: 

 

	 	7.3.1	any and all actions, claims, demands, proceedings, judgments, liabilities, loss, damages, payments, costs and expenses arising in connection with such
termination or amendment (including in respect of any early termination or similar fee or payment and all liabilities costs, expenses and payments suffered or reasonably incurred by the Business Seller in procuring such termination or amendment (as
applicable)) shall be for the account of the Purchaser and the Purchaser shall indemnify the relevant Business Seller in respect thereof; and 

  

	 	7.3.2	 the Purchaser shall be solely responsible for putting in place its own arrangements in respect of the matters the subject of such terminated NTT
Products-Only Tender or amended NTT Multi-Basket Tender (as the case 

  
 127

	 	
may be) and no member of the Seller’s Group shall have any responsibility for putting in place any such arrangements. 

 

	7.4	For the avoidance of doubt, if any NTT Products-Only Tender is terminated (or, in the case of a NTT Multi-Basket Tender, amended such that the Relevant Part
thereof is terminated) by the relevant Business Seller pursuant to sub-paragraph 7.2 then no member of the Seller’s Group shall be liable to make any payment to the Purchaser or any other member of the Purchaser’s Group in respect of any
consideration payable or allocation made under this or any other Ancillary Agreement. 

  

	8.	[***] 

  

	9.	For the purposes of this Schedule, the following terms shall have the following meanings: 

“Separation Plan” has the meaning given to it under the Transitional Distribution Services Agreement; 

“Identified Risk” means a specifically identified adverse operational, legal or tax impact affecting either the
Seller’s Group or the Purchaser’s Group (including an impact on the ability of the Seller’s Group to perform its obligations under the Transitional Distribution Services Agreement) which would arise or which would increase (by more
than a de minimis amount) solely by reason of the relevant Distribution Contract transferring to the Purchaser (or the relevant member of the Purchaser’s Group) on a date prior to the Planned Distribution Transfer Date; and 

“Planned Distribution Transfer Date” means the Distribution Transfer Date for the applicable Market as set out in the
Separation Plan. 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 128

 Schedule 8 
 Employees 
 (Clause 2.4.1) 

 

	1.	Information and consultation 

  

	1.1	At such time as the parties agree to be appropriate following the public announcement of the matters contemplated by this Agreement, the Seller and the Purchaser
or the relevant member of the Purchaser’s Group shall jointly communicate to the Employees an agreed notice which shall (other than to the extent the parties agree otherwise): 

 

	 	1.1.1	inform the Employees that following Closing those Employees who continue to be employed in the Business would be employed by the Purchaser or relevant member of
the Purchaser’s Group; and 

  

	 	1.1.2	comply with the requirements of any applicable national law. 

 For the avoidance of doubt, the parties may agree to issue such notice to different Employees or categories of Employees at different times and in different forms. 

 

	1.2	Notwithstanding the operation of paragraph 1.1 above, the Seller and the Purchaser agree to comply with any more onerous notice requirements imposed by local
laws. 

  

	1.3	The Purchaser (on its own behalf and on behalf of any relevant member of the Purchaser’s Group) shall provide the Seller (for itself and any relevant member
of the Seller’s Group) with such information and assistance at such times as the Seller may reasonably request or as may be reasonably necessary for the Seller or any other member of the Seller’s Group to comply with any formal or informal
requirement to inform or consult with the Employees, a relevant trade union, a relevant works council, or any other employee representatives in connection with the matters contemplated by this Agreement (which formal or informal requirements the
Seller hereby undertakes to comply or procure compliance with). Where reasonably necessary to ensure compliance with any formal or informal requirements or obligations to inform or consult with Employees, a relevant trade union, a relevant works
council or any other employee representatives in connection with the matters contemplated by this Agreement, the Seller (for itself and for each member of the Seller’s Group) and the Purchaser (for itself and for each member of the
Purchaser’s Group) agree that the Purchaser or relevant member of the Purchaser’s Group shall cooperate with and participate in any information, negotiation and/or consultation process as reasonably required by the Seller.

  

	1.4	As soon as practicable following the date of this Agreement, the Purchaser agrees to provide on a timely basis such information, in writing, in respect of its
existing terms and conditions of employment as may reasonably be required by the Seller so as to facilitate the Seller’s information and consultation exercise with its Employees in respect of the matters set out in this Agreement.

  

	2.	Employees 

  

	2.1	General 

  
 129

	2.1.1	The Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) fulfil all its duties and obligations under Applicable Law in
relation to the Employees. Where the provisions of local law do not provide for an automatic transfer of the employment of the Employees to the Purchaser or a relevant member of the Purchaser’s Group with effect from (and including) the Closing
Date, then paragraph 2.2 below shall apply. Where the provisions of local law do provide for an automatic transfer of employment of the Relevant Employees to the Purchaser or the relevant member of the Purchaser’s Group with effect from (and
including) the Closing Date, then paragraph 2.3 below shall apply. 

  

	2.1.2	The parties acknowledge and agree that: 

  

	 	(i)	any Deferred Employee shall be treated for all purposes under this Agreement as if such Deferred Employee were an Employee; and 

 

	 	(ii)	the Purchaser’s obligations under this Schedule 8 shall apply in respect of each Deferred Employee in the same way as they do to each Employee; and

  

	 	(iii)	if any Deferred Employee accepts an offer of employment made by the Purchaser under paragraph 2.2.1 below, such Deferred Employee shall further be treated for all
purposes under this Agreement as a Transferred Employee. 

  

	2.1.3	For the avoidance of doubt, this paragraph 2 shall not apply to any Excluded Employee, who will remain employed by the Seller or the relevant member of the
Seller’s Group. 

  

	2.1.4	The parties agree that no provisions in this paragraph 2 shall require the Purchaser or another member of the Purchaser’s Group to employ a Relevant
Employee on and from the Closing Date until such time as such employee has the right (including, for the avoidance of any doubt, under any grace period) or is otherwise permitted under Applicable Law to accept an offer to work for the Purchaser or
relevant member of the Purchaser’s Group and to commence working for the Purchaser or relevant member of the Purchaser’s Group. Any such employee will only be a “Transferred Employee” for the purposes of this Agreement from the
time (the “Transfer Date”) he becomes an employee of a member of the Purchaser’s Group, and any provisions relating to Transferred Employees in this Agreement shall only apply to any such employee with effect on and from the
Transfer Date and with the following amendments: 

  

	 	(i)	references to the “Closing Date” and the “Effective Time” in paragraphs 4.1, 4.3.1, 4.3.2 and 4.4 shall be replaced with references to the
“Transfer Date”; 

  

	 	(ii)	 references to an “Employee” in paragraphs 4.2.1, 4.2.2 and 4.3.5 shall be extended to refer to such Transferred Employee, and to the extent
required in respect of such Transferred Employee references 

  
 130

	 	
to the “Closing Date” and “Effective Time” shall be replaced with references to the “Transfer Date”; 

 

	 	(iii)	the reference to “basic salary” in paragraph 5.1.1 shall mean the basic salary that applied to such Transferred Employee immediately prior to the Transfer
Date; 

  

	 	(iv)	references to the “Closing Date” and the “Effective Time” in paragraph 6.2 shall be replaced with references to the “Transfer Date”;

  

	 	(v)	for the purposes of paragraphs 10.2 and 10.8, references to “Closing” and the “Closing Date” shall be construed as references to the “Transfer
Date”; and 

  

	 	(vi)	such other amendments as the parties may agree, each acting in good faith. 

 

	2.1.5	Notwithstanding any other provisions of this Agreement the parties agree that a Relevant Employee who works in France and is an employee representative (a
“French Employee”) shall not transfer to the Purchaser’s Group until such time as the French Labour Inspectorate has authorised such French Employee to transfer to and commence working for the Purchaser or relevant member of
the Purchaser’s Group. Any such French Employee will only be a “Transferred Employee” for the purposes of this Agreement from the time (the “French Transfer Date”) he becomes an employee of a member of the
Purchaser’s Group, and any provisions relating to Transferred Employees in this Agreement shall only apply to any French Employee with effect on and from the French Transfer Date and with the following amendments: 

 

	 	(i)	references to the “Closing Date” and the “Effective Time” in paragraphs 4.1, 4.3.1, 4.3.2 and 4.4 shall be replaced with references to the
“French Transfer Date”; 

  

	 	(ii)	references to an “Employee” in paragraphs 4.2.1, 4.2.2 and 4.3.5 shall be extended to refer to such French Employee, and to the extent required in respect of
such French Employee references to the “Closing Date” and the “Effective Time” shall be replaced with references to the “French Transfer Date; 

 

	 	(iii)	the reference to “basic salary” in paragraph 5.1.1 shall mean the basic salary that applied to such French Employee immediately prior to the French Transfer
Date; 

  

	 	(iv)	references to the “Closing Date” and “Effective Time” in paragraph 6.2 shall be replaced with references to the “French Transfer Date”;

  

	 	(v)	for the purposes of paragraphs 10.2 and 10.8, references to “Closing” and the “Closing Date” shall be construed as references to the “French
Transfer Date”; and 

  
 131

	 	(vi)	such other amendments as the parties may agree, each acting in good faith. 

 

	2.2	Where no automatic transfer of employment 

  

	 	2.2.1	In such timescale as the parties may agree, in order to comply with Applicable Law, but in any event at least 15 days prior to the Closing Date, unless agreed
otherwise by the parties (such agreement not to be unreasonably withheld by any party), the Purchaser or relevant member of the Purchaser’s Group shall make an offer to each Employee employed by the Seller or a member of the Seller’s Group
to employ him or her under a new contract of employment to commence with effect from (and including) the Closing Date provided that such employee continues to be an Employee until the Closing Date. Save as otherwise agreed with the Seller (such
agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that Employee immediately prior to the Closing Date. The Purchaser shall
keep the Seller updated throughout the offer process on when offers are made and accepted or rejected. 

  

	 	2.2.2	If the Employee wishes to accept the offer of employment from the Purchaser or the relevant member of the Purchaser’s Group, then the Seller shall (or shall
procure that the relevant member of Seller’s Group shall), insofar as it is permitted by Applicable Law, waive the requirement on the Employee concerned to give any period of notice of termination of his or her employment under the terms of his
or her employment so as to allow the Employee to commence employment with the Purchaser or relevant member of the Purchaser’s Group with effect from (and including) the Closing Date. 

 

	 	2.2.3	The parties agree that where: (i) a Relevant Employee in the United States is absent on short term disability (including, without limitation, maternity) leave or
military leave; (ii) a Relevant Employee in Russia is on maternity leave; or (iii) such other Relevant Employee, as the parties may agree in writing prior to the Closing Date, is on leave (each being a “Leave Employee”) in each case
where such leave will end on or after the Closing Date, and where such Leave Employee would otherwise have been made an offer of employment to commence with effect from (and including) the Closing Date by the Purchaser or relevant member of the
Purchaser’s Group, such an offer shall be made, but employment pursuant to such offer shall commence only with effect from (and including) the date on which such Leave Employee returns to work at the end of such period of such leave, provided
always that the date of such return to work is no more than six months after the date on which such leave began or such later date as may be agreed by the parties. Any such employee will only be a “Transferred Employee” for the purposes of
this Agreement from the time (the “Transfer Date”) he becomes an employee of a member of the Purchaser’s Group, and any provisions relating to Transferred Employees in this Agreement shall only apply to any such employee with
effect on and from the Transfer Date and with the following amendments: 

  
 132

	 	(i)	references to the “Closing Date” and the “Effective Time” in paragraphs 4.1, 4.3.1, 4.3.2 and 4.4 shall be replaced with references to the
“Transfer Date”; 

  

	 	(ii)	references to an “Employee” in paragraphs 4.2.1, 4.2.2 and 4.3.5 shall be extended to refer to such Transferred Employee, and to the extent required in
respect of such Transferred Employee references to the “Closing Date” and the “Effective Time” shall be replaced with references to the “Transfer Date; 

 

	 	(iii)	the reference to “basic salary” in paragraph 5.1.1 shall mean the basic salary that applied to such Transferred Employee immediately prior to the Transfer
Date; 

  

	 	(iv)	references to the “Closing Date” and the “Effective Time” in paragraph 6.2 shall be replaced with references to the “Transfer Date”;

  

	 	(v)	for the purposes of paragraphs 10.2 and 10.8, references to “Closing” and the “Closing Date” shall be construed as references to the “Transfer
Date”; and 

  

	 	(vi)	such other amendments as the parties may agree, each acting in good faith. 

 

	 	2.2.4	If any Leave Employee has not returned to work by the date falling six months after the date on which such leave began or such later date as may be agreed
between the parties, then such Leave Employee shall be treated for all purposes under this Agreement as an Excluded Employee. 

  

	 	2.2.5	Transfer of Relevant Employees on a Relevant Working Day 

 If in relation to any Relevant Employee, the day prior to the Closing Date occurs on a day which is not a Relevant Working Day in the jurisdiction in which that Employee is employed, the parties may agree
(such agreement not to be unreasonably withheld by any party), that such Relevant Employees (the “Working Day Relevant Employees”) shall remain employees of the Seller or a member of the Seller’s Group until the first Relevant
Working Day on or after the Closing Date (the “Working Day Employee Termination Date”). If so agreed, the parties agree that the transfer of employment of the Working Day Relevant Employees to the Purchaser or one of its
Affiliates shall take effect on and from the day following the Working Day Employee Termination Date which applies to the relevant Working Day Relevant Employee. The Purchaser acknowledges that it will be responsible for the total amount actually
paid by the Seller or its Affiliate for compensation and benefits, including any withholding taxes and payroll taxes paid by the Seller’s Group, to or in respect of the Working Day Relevant Employees in relation to their ordinary course of
employment for the period on and from the Effective Time to (and including) the Working Day Employee Termination Date which applies to the relevant Working Day Relevant Employee. 

  
 133

	2.3	Where automatic transfer of employment 

 If the Transfer Regulations do not or are found not to or are alleged not to apply to any person who is a Relevant Employee, and to whom paragraph 2.2 does not apply, the Purchaser agrees that following
Closing: 
  

	 	2.3.1	in consultation with the Seller, the Purchaser or relevant member of the Purchaser’s Group shall within 10 Business Days of being so requested by the Seller
(as long as the request is made no later than 3 months after Closing) (or if the Purchaser so chooses), make such Relevant Employee an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, a
date agreed between the parties and such employee; and 

  

	 	2.3.2	save as otherwise agreed with the Seller (such agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions
(including as to period of continuous employment) as were provided to that Relevant Employee immediately prior to the Closing Date. 

  

	3.	Wrong-pocket arrangements for persons other than Relevant Employees 

 

	3.1	If the contract of employment of any person other than a Relevant Employee is found or alleged to have effect upon Closing as if originally made with the
Purchaser or another member of the Purchaser’s Group as a consequence of this Agreement, the Seller agrees that following Closing: 

  

	 	3.1.1	in consultation with the Purchaser, the Seller or relevant member of the Seller’s Group may within 10 Business Days of being so requested by the Purchaser
(as long as the request is made no later than 3 months after Closing) (or if the Seller so chooses), make to that person an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, the termination
referred to below; and 

  

	 	3.1.2	the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that person immediately prior
to the Closing Date. 

  

	3.2	After the expiry of the 10 Business Days referred to at paragraph 3.1 above, and provided that the relevant member of the Purchaser’s Group takes such steps
as are legally possible to terminate the employment of the person concerned as soon as reasonably practicable after becoming aware of the finding or allegation referred to at paragraph 3.1 above (either by giving notice or transferring the person by
agreement to be concluded between the relevant member of the Purchaser’s Group, the person concerned and the relevant member of the Seller’s Group), the Seller shall be responsible for and shall indemnify and keep indemnified the Purchaser
(for itself and as trustee for any relevant member of the Purchaser’s Group) against all Losses from time to time made, suffered or incurred by the Purchaser (or any other member of the Purchaser’s Group) as a result of:

  
 134

	 	3.2.1	the actual or alleged transfer to a member of the Purchaser’s Group and (regardless of whether there has been such a transfer) any employment liabilities
relating to such person; 

  

	 	3.2.2	employing such person on and from the Closing Date until such termination (up to the time reasonably expected to have achieved such termination in accordance
with the terms of the contract of employment and Applicable Law) but subject to a maximum period of 6 months unless prevented by the terms of the contract of employment or Applicable Law; and 

 

	 	3.2.3	such termination. 

  

	3.3	The parties agree to co-operate in good faith to minimise the Losses which are subject to the indemnity referred to in paragraph 3.2 above.

  

	4.	Employment liabilities 

  

	4.1	All wages, salaries, employer’s liabilities in respect of associated Taxes and other periodic outgoings in respect of the Transferred Employees which relate
to a period: 

  

	 	4.1.1	on and after the Effective Time shall be borne or discharged by the Purchaser or relevant member of the Purchaser’s Group; and 

 

	 	4.1.2	before the Effective Time shall be borne or discharged by the Seller or relevant member of the Seller’s Group. 

 

	4.2	Subject to paragraph 4.1, the Seller shall (for itself and for each member of the Seller’s Group) indemnify and keep indemnified the Purchaser (for itself
and as trustee for each other member of the Purchaser’s Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 9) in respect of: 

 

	 	4.2.1	the employment of any Employee at any time prior to the Effective Time (excluding any Transferred Employee Benefit Liabilities (as defined in Schedule 9) which
the Purchaser agrees to assume in accordance with Schedule 9); 

  

	 	4.2.2	any termination of the employment of any Employees prior to the Effective Time and any termination of the employment of any Employees on and after the Effective
Time but prior to the Closing Date which are not otherwise covered by paragraph 4.3.2 including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination and similar obligations (excluding any
liability arising directly as a result of any breach of the commitments set out in paragraph 5 or 6 below by the Purchaser or a member of the Purchaser’s Group and any act or omission by the Purchaser or any member of the Purchaser’s Group
in relation to any Employee before the Closing Date as a result of which that Employee treats his employment as having been terminated prior to the Closing Date); 

 

	 	4.2.3	 any amount which becomes payable to any Employee or benefit to which any Employee becomes entitled by reason of this Agreement or the matters it
contemplates, including any change of control or other payment or benefit 

  
 135

	 	
(and including any enhancement of severance terms on a subsequent termination of employment but excluding any Losses relating to any share-based incentive schemes, as to which see paragraph 10
below); 

  

	 	4.2.4	any failure by the Seller or any other member of the Seller’s Group to comply with any obligation to inform or consult with employee representatives in
connection with the matters contemplated by this Agreement (other than as a result of any failure set out in paragraph 4.3.3 below); and 

  

	 	4.2.5	any breach by the Seller or any other member of the Seller’s Group of paragraph 4.1.2 above or paragraph 4.4, 4.5 or 9 below. 

 

	4.3	The Purchaser shall (for itself and for each member of the Purchaser’s Group) indemnify and keep indemnified the Seller (for itself and as trustee for each
other member of the Seller’s Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 9) in respect of: 

 

	 	4.3.1	the employment of any of the Transferred Employees on and after the Effective Time (including, without limitation, any changes to terms and conditions of
employment by the Purchaser or any other member of the Purchaser’s Group); 

  

	 	4.3.2	any termination of the employment of any Transferred Employees on and after the Effective Time and any termination of the employment of any Employees by a member
of the Seller’s Group on and after the Effective Time but prior to the Closing Date who would, but for such termination of employment by a member of the Seller’s Group, have been Transferred Employees (save in each case where such
termination is in order to facilitate the transfer of any Relevant Employee pursuant to paragraph 2 of this Schedule 8 or is otherwise in connection with any rejection or objection to such transfer in circumstances where paragraph 4.3.5 does not
apply) including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination and similar obligations except as contemplated under paragraph 3.2 above; 

 

	 	4.3.3	any failure by the Purchaser or any other member of the Purchaser’s Group to provide information and reasonable assistance to the Seller to enable the
Seller or any other member of the Seller’s Group to comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Agreement; 

 

	 	4.3.4	any breach by the Purchaser or any other member of the Purchaser’s Group of paragraph 4.1.1 above or paragraph 4.4 or 4.5 below; and

  

	 	4.3.5	any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before the Closing Date as a result of which that
Employee treats his employment as having been terminated prior to the Closing Date. 

  

	4.4	 Any amount payable to or in respect of any Transferred Employee on or after the Closing Date (including without limitation amounts paid under
paragraph 4.5 below) 

  
 136

	 	
which (ignoring vesting conditions and any amount payable in respect of Employee Benefits or otherwise in accordance with Schedule 9) is referable to the period prior to the Effective Time is
payable by the Seller (for itself or on behalf of the relevant Business Seller). Responsibility for amounts payable which are only partly referable to the period prior to the Effective Time (again ignoring vesting conditions) is to be shared between
the Seller (for itself or on behalf of the relevant Business Seller) and the Purchaser (for itself or on behalf of the relevant member of the Purchaser’s Group) such that the Seller bears S per cent. of the cost and the Purchaser bears P per
cent., where S is the percentage of the period by reference to which the amount was earned which fell before the Effective Time and P is the percentage of that period which falls on and after the Effective Time. Save for the payments described in
paragraph 4.5 below, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, pay such amounts when due to the relevant Transferred Employees on or after the Closing Date and shall deduct and/or pay and
account for any Tax payable or accountable for by the employer in respect of such amounts. The Seller covenants to reimburse the Purchaser in respect of any such amount (or S per cent. of it where relevant), including any Tax payable or accountable
for by the employer in respect of such amount, within 30 days of receiving notification that it has been paid. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made.

  

	4.5	Following the Closing Date: 

  

	 	4.5.1	the Seller shall, or shall procure that a member of the Seller’s Group shall, pay a pro-rated cash bonus for the current bonus year as at the Effective Time
and any unpaid cash bonus for the bonus year which ended before the Effective Time to each Transferred Employee who participated in such annual cash bonus plan within 90 days following the Closing Date; and 

 

	 	4.5.2	where the Seller is able to determine performance, any such bonus payment made to such eligible employees will be based on the Seller’s determination of
performance to the Effective Time and (where applicable) pro-rated to the Effective Time; or 

  

	 	4.5.3	where the Seller is unable to determine performance (either business or individual), for example, because the Effective Time occurs near the start of the bonus
year, the Seller shall calculate any such bonus payment based on a deemed achievement of performance conditions at target level pro-rated to the Effective Time; and 

 

	 	4.5.4	as soon as reasonably practicable after the Closing Date, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall,
provide such information as the Seller requires in order for the Seller to calculate the Tax payable or accountable for by the employer in respect of such bonus payments; 

 

	 	4.5.5	if and to the extent permitted by Applicable Law, the Seller shall, or shall procure that such other member of the Seller’s Group shall, deduct and/or
account for any Tax payable or accountable for by the employer in respect of such bonus payments; or 

  
 137

	 	4.5.6	if and to the extent paragraph 4.5.5 above is not permitted by Applicable Law, the Purchaser shall, or shall procure that such other member of the
Purchaser’s Group shall, pay and/or account for any Tax payable or accountable for by the employer in respect of such bonus payments and the Seller shall reimburse the Purchaser in respect of such amounts so paid and/or accounted for; and

  

	 	4.5.7	where any amount in respect of payments made by the Seller or any other member of the Seller’s Group pursuant to this paragraph 4.5 is reflected in the
Closing Statement, the Purchaser shall reimburse the Seller in respect of the amount so reflected. For the avoidance of doubt, no reimbursement by the Purchaser shall be due in respect of any such payment to the extent it is not reflected in the
Closing Statement. 

  

	4.6	If any loan made by a member of the Seller’s Group to a Transferred Employee (an “Employee Loan”) remains outstanding at the Closing Date,
then the parties shall co-operate in good faith to procure an outcome such that: 

  

	 	4.6.1	the Employee Loan shall be discharged in full within a reasonable period after the Closing Date and the relevant member of the Seller’s Group shall receive
all outstanding amounts of principal and interest under the Employee Loan either from the relevant Transferring Employee or from a member of the Purchaser’s Group; and 

 

	 	4.6.2	a loan in the same amount and on the same terms as to interest and repayment as the outstanding portion of the Employee Loan shall be made available by the
Purchaser to the relevant Transferred Employee. 

  

	5.	Protection of terms and conditions and termination rights post-Closing 

 

	5.1	Without prejudice to paragraph 5.4 below, the Purchaser shall procure that for a period of 24 months following the Closing Date: 

 

	 	5.1.1	each Transferred Employee will (for so long as such Transferred Employee continues in the same role with any member of the Purchaser’s Group save that the
Purchaser shall not seek to demote any Transferred Employee to avoid the application of this provision) continue to receive at least the same basic salary; and 

 

	 	5.1.2	each Transferred Employee will continue to receive contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term
incentive plans) which the Purchaser reasonably considers to be substantially comparable, taken as a whole, to the contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) of
such Transferred Employee immediately prior to the Closing Date; and 

  

	 	5.1.3	 no Transferred Employee will suffer a change to his overall employment terms (whether contractual or otherwise) and including, without
limitation, any related to length of service (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans), which, when 

  
 138

	 	
taken as a whole viewed in the round (including to the extent relevant alongside any other changes being made at the same time to that Transferred Employee’s employment terms), would in the
Purchaser’s reasonable opinion acting in good faith be regarded as materially detrimental. 

  

	5.2	The Purchaser confirms that, following the Closing Date and for so long as the Transferred Employees continue in the employment of any member of the
Purchaser’s Group, the Transferred Employees will be eligible to participate in those share-based incentive schemes or other long-term incentive plans that are operated by the Purchaser or relevant members of the Purchaser’s Group from
time to time for employees of equivalent status, subject always to the rules of such share-based incentive schemes or long-term incentive plans and any qualifying conditions. 

 

	5.3	The Seller shall provide or shall cause to be provided to any member of the Purchaser’s Group such information reasonably requested in writing by any member
of the Purchaser’s Group to enable the Purchaser to comply with its obligations in paragraph 5.1 above. 

  

	5.4	If the employment of any Transferred Employee is terminated by reason of redundancy within 24 months following the Closing Date, the Purchaser shall procure that
there shall be provided to such Transferred Employee benefits which are equivalent to those provided under such redundancy and severance policies and benefits (whether contractual or otherwise and giving due credit to the Transferred Employees for
any additional service or earnings from the Closing Date onwards) (but excluding Employee Benefits other than the Agreed UK Restructuring Arrangement) as were applicable in respect of the particular Transferred Employee immediately prior to the
Closing Date, to the extent that such policies and benefits are notified in writing to the Purchaser prior to the Closing Date. If, at any time during the 24 month period immediately following the Closing Date, the Purchaser places any
Transferred Employee into a redundancy selection process, the Purchaser undertakes that, in determining such selection, it will or will procure that the relevant member of the Purchaser’s Group will take no account of the costs of dismissal of
any person within the relevant selection pool (including such Transferred Employee). For the avoidance of doubt, redundancy payments of the type described in this paragraph 5.4 (whether paid within 24 months of Closing or later) are not intended to
be covered by the apportionment mechanism at paragraph 4.4 above. 

  

	5.5	For the avoidance of doubt, the provisions of this paragraph 5 are without prejudice to the operation of any rule of law in relation to the terms and conditions
of employment of the Transferred Employees. 

  

	6.	Benefits arrangements/service continuity 

  

	6.1	 Each Transferred Employee shall have their service with the Seller’s Group and their respective predecessors recognised under any employee
benefit plans or arrangements of the Purchaser’s Group for all purposes of eligibility, vesting and accrual of benefits to the extent past service was recognised for such Transferred Employee under a comparable plan or arrangement immediately
prior to the Closing Date. Notwithstanding the foregoing, nothing in this paragraph 6.1 shall be construed 

  
 139

	 	
to require recognition of service for the purposes of calculation of Employee Benefits or that would result in: 

 

	 	6.1.1	any additional liability being assumed by the Purchaser’s Group in respect of Employee Benefits other than subject to and in accordance with the provisions
of Schedule 9; 

  

	 	6.1.2	duplication of benefit; 

  

	 	6.1.3	recognition of service for any purposes under any plan or arrangement for which participation, service and/or benefits accrual is frozen or any post-retirement
medical plan; or 

  

	 	6.1.4	recognition of service under a newly established plan or arrangement for which prior service is not taken into account for employees of the Purchaser’s
Group generally. 

  

	6.2	Without limiting the foregoing, with respect to the Transferred Employees, the Purchaser shall, or shall cause such other member of the Purchaser’s Group
to, be responsible for all paid time off benefits, including vacation pay, sick pay, banked leave, flexitime and other payments for time off of normal work hours accrued by the Transferred Employees up to the Closing Date provided that if the value
of such matters (excluding normal accrued but untaken annual leave for the year current as at the Closing Date) would exceed US$7.5 million if accrued for in a balance sheet in accordance with IFRS prior to the Effective Time then the Seller shall
compensate the Purchaser for such matters accrued prior to the Effective Time (again excluding normal accrued but untaken annual leave for the year current as at the Closing Date) by paying the Purchaser an amount equal to that value, less any
amount actually accrued and transferred to the Purchaser for such matters. 

  

	6.3	With respect to any welfare plan maintained by the Purchaser or any other member of the Purchaser’s Group in which Transferred Employees are eligible to
participate after the Closing Date, the Purchaser shall: 

  

	 	6.3.1	waive all limitations as to pre-existing conditions, exclusions, evidence of insurability provisions, waiting periods with respect to such participation and
coverage requirements or similar provisions under a Purchaser’s benefit plans that are welfare plans (as defined in section 3(1) of ERISA or any equivalent Applicable Law) applicable to such employees to the extent such conditions, exclusions
and waiting periods or other provisions were satisfied or did not apply to such employees under welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing Date; and 

 

	 	6.3.2	provide each Transferred Employee with credit for any co-payments and deductibles paid prior to the Closing Date in satisfying any analogous deductible or
out-of-pocket requirements to the extent applicable under any such plan in the year in which Closing occurs, to the extent credited under the welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing
Date. 

  
 140

	7.	US Transferred Employees 

With effect on and from the Closing Date, the Purchaser shall, or shall procure that such other members of the Purchaser’s Group
shall, assume the responsibility and obligation to provide COBRA continuation coverage to all Transferred Employees who are employed in the United States and/or covered by US Benefit Plans and whose employment is terminated after the Closing Date
and their eligible dependents. 
  

	8.	International Assignees 

Where Applicable Law does not provide for the automatic transfer of employment of any International Assignee and/or the other terms
governing their international assignment, the Purchaser shall assume and agree to be bound by the individual contract of employment and such other terms governing their international assignment including any tax equalisation agreement entered into
between an International Assignee and a member of the Seller’s Group provided that such employee becomes a Transferred Employee and the Seller has disclosed to the Purchaser the template international assignment terms of the Seller’s Group
prior to the Closing Date. 
  

	9.	Liability for retention arrangements 

 The Seller or any other member of the Seller’s Group has or will put in place certain retention arrangements (in the form of cash) to retain key employees in connection with the matters contemplated
by this Agreement. To the extent that details of such retention arrangements are disclosed to the Purchaser prior to the Closing Date, and in respect of arrangements put in place after the date of this Agreement, with the agreement of the Purchaser,
the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, make the cash retention payments when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax
payable or accountable for by the employer in respect of such cash payments. The Seller covenants to reimburse the Purchaser in respect of any cash retention payments, whether or not disclosed (including any Tax payable or accountable for by the
employer in respect of such payments), which are put in place prior to the Closing Date. The Seller acknowledges that the Purchaser may ask the Seller to put in place more generous retention arrangements than those proposed by the Seller (including,
where practicable, putting in place retention arrangements which last for a period of at least six months following Closing) and will not unreasonably withhold consent to such arrangements provided that any incremental cost of such arrangements over
and above the cost of the Seller’s own proposals will be for the Purchaser’s account. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

 

	10.	Share-based incentive schemes 

  

	10.1	This paragraph 10 applies notwithstanding any other provision of this Agreement. 

 

	10.2	 The Seller undertakes that share-based awards held by Transferred Employees pursuant to a share-based incentive scheme operated by the Seller or
another member of the Seller’s Group (“Relevant Awards”) shall be treated in a manner 

  
 141

	 	
consistent with the “good leaver treatment” pursuant to the default position under those share-based incentive schemes. Where Relevant Awards are subject to performance (or other)
conditions and it is not possible to determine whether or not such conditions have been met at the applicable early vesting date (or within a reasonable period thereafter), the Seller and Purchaser agree that performance shall be deemed “on
target”. 

 For the avoidance of doubt, such “good leaver treatment” provides that: 

 

	 	10.2.1	Relevant Awards shall not lapse or be forfeited as a result of Closing except to the extent that they do not vest in accordance with paragraphs 10.2.2 and/or
10.2.3 below; 

  

	 	10.2.2	Relevant Awards shall vest early as a result of Closing and shall be time pro-rated to take account of the reduced period of time, as a proportion of the
original vesting period, that the relevant Transferred Employee worked within the Seller’s Group (calculated on the basis of the number of years of service as at the Closing Date, where part years of service are rounded up); and

  

	 	10.2.3	Relevant Awards that vest after the Closing Date shall remain subject to any relevant performance (or other) conditions, adjusted as necessary to take account of
Closing and measured up to the applicable early vesting date. 

 For the purposes of this paragraph 10.2, “on
target” performance shall not be construed as permitting share-based awards to vest in full. 
  

	10.3	The Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with the Relevant Awards, including any Tax. The Purchaser agrees to use its best endeavours to seek any applicable Tax relief in respect of the Relevant Awards and to indemnify the Seller in respect of any Tax relief obtained, provided
always that the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner. 

  

	10.4	Subject to paragraph 10.5, the Seller undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the Relevant Awards and to provide, in a
timely manner, details of the Relevant Awards that so vest or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and pay any Tax for which the Purchaser’s Group is liable in respect of the Relevant
Awards to the relevant Tax Authority within any applicable timescale. 

  

	10.5	To the extent permitted under the relevant plan rules and any Applicable Law, the Seller undertakes to sell such number of the shares underlying the Relevant
Awards as may be necessary for the sale proceeds to satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any applicable timescale,
provided always that the Purchaser provides the Seller with any information that the Seller may reasonably request in this respect in a timely manner. 

  
 142

	10.6	The Seller undertakes to procure that each relevant member of the Seller’s Group will pay any Tax for which each member is liable in respect of the Relevant
Awards to the relevant Tax Authority within any applicable timescale. 

  

	10.7	The Seller undertakes to complete any relevant Tax Return in respect of the Relevant Awards and to submit any such Tax Return to the relevant Tax Authority
within any applicable timescale. 

  

	10.8	This paragraph shall apply where Relevant Awards lapse or are forfeited (or will lapse or be forfeited) either in whole or in part as a result of Closing. As
soon as practicable following Closing with the intention being, where possible, to grant within 30 days of the Closing Date or the first date after the Closing Date when dealing restrictions do not apply (and, in any event, by the later of 90 days
from the Closing Date and 90 days from the first date after the Closing Date when the granting of share-based awards is not prevented by dealing restrictions), subject in both cases to the relevant plan rules and any Applicable Law, the Purchaser
(or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the portion of
their Relevant Awards which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (valued as at the Closing Date), where relevant disregarding any loss (or expected loss) of Tax-favourable treatment (each a
“Compensation Award”). To the extent that (i) it could reasonably have been expected that any related matching share award and/or free share award would have been granted to a Transferred Employee following Closing in connection
with any Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (each a “Relevant Matching Award”), and (ii) such Relevant Matching Award has not been granted (or will not be granted) as
a result of Closing, on or around the date on which such Relevant Matching Award would, in the ordinary course of business, have been made by the Seller (or member of the Seller’s Group), the Purchaser (or member of the Purchaser’s Group)
shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of such Relevant Matching Award (valued as at the date of grant
of the related Matching Award, defined below), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Matching Award”), subject to the relevant plan rules and any Applicable Law.

 Such Compensation Awards and Matching Awards shall be granted pursuant to the rules of whichever share-based
incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Seller’s Group pursuant to which the related Relevant Award had been
granted (or related Relevant Matching Award would have been granted) but will vest according to a vesting schedule substantially similar to the vesting schedule that would have otherwise applied to the related Relevant Award or related Relevant
Matching Award if Closing had not occurred. In such cases: 
  

	 	10.8.1	 the Purchaser undertakes to seek any applicable Tax relief in respect of the Compensation Awards and Matching Awards and to indemnify the Seller
in respect of 50 per cent. of any Tax relief obtained, provided always that the 

  
 143

	 	
Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

 

	 	10.8.2	where a Compensation Award or Matching Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to
section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other
party to waive this obligation in respect of certain Compensation Awards or certain Matching Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph 10.8.2 shall not apply in respect of such
Compensation Awards or Matching Awards; and 

  

	 	10.8.3	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for 50 per cent. of any Liabilities borne by the Purchaser’s
Group in connection with such Compensation Awards and Matching Awards, including any Tax, provided that: 

  

	 	(i)	the Seller shall not indemnify the Purchaser (or relevant member of the Purchaser’s Group) to the extent that the Purchaser (or member of the Purchaser’s
Group) compensates Transferred Employees for any loss (or expected loss) of Tax-favourable treatment in respect of Relevant Awards or for any Liabilities to Tax as contemplated in paragraph 10.9 below; 

 

	 	(ii)	the Seller only agrees to indemnify the Purchaser (or member of the Purchaser’s Group) to a maximum of 50 per cent. of the total of: (i) the value of the
portion of such Relevant Awards that lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing, (ii) the value of the Relevant Matching Awards, and (iii) any related Liabilities, including any Tax; and

  

	 	(iii)	for the avoidance of doubt, the Seller shall not indemnify the Purchaser (or member of the Purchaser’s Group) for any lapse or forfeiture (or expected lapse or
forfeiture) due to a failure to meet any applicable performance (or other) conditions. 

 For these purposes, the
compensation in respect of the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall not exceed the difference between (i) the value of the Relevant Award which could reasonably have
been expected to vest on the normal vesting date but for Closing (subject, where applicable, to performance (or other) conditions), and (ii) the value of the Relevant Award which actually vested (or will vest) as a result of Closing. 

For the purposes of this paragraph 10.8: 
  

	 	10.8.4	the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall be valued on the basis of the average
price of an ordinary share in the capital of the Seller over the five trading days immediately prior to Closing; 

  
 144

	 	10.8.5	the value of a Compensation Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the
five trading days immediately prior to the date of grant; 

  

	 	10.8.6	the value of a Relevant Matching Award shall be valued on the basis of the average price of an ordinary share in the capital of the Seller over the five trading
days immediately prior to the date of grant of the related Matching Award; 

  

	 	10.8.7	the value of a Matching Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five
trading days immediately prior to the date of grant; and 

  

	 	10.8.8	any currency conversion shall be made in accordance with Clause 1.12 of this Agreement. 

 

	10.9	To the extent that any payment to a Transferred Employee (whether by the Seller’s Group or by the Purchaser’s Group) would trigger Liabilities to Tax
under section 280G of the United States Internal Revenue Code (“Section 280G”), the relevant Transferred Employee shall be allowed to choose whether to accept the full payment (and pay any relevant Section 280G Tax) or to receive
such lower payment as may be necessary in order to fall below the Section 280G threshold for Tax. To the extent that any similar Tax would arise pursuant to any Applicable Law in another jurisdiction, this paragraph 10.9 shall apply mutatis
mutandis. 

  

	10.10	This paragraph shall apply where: (i) a Transferred Employee would, in the ordinary course of business, have been granted a share-based award pursuant to a
share-based incentive scheme operated by the Seller or another member of the Seller’s Group on the basis of performance criteria linked to the Seller’s Group’s 2014 financial year (which may, for the avoidance of doubt, be business
and/or individual performance criteria and assessment) (each a “2014 Performance Award”), and (ii) Closing occurs prior to the grant of such 2014 Performance Award. As soon as practicable following Closing (and, in any event,
by the later of 30 days from the Closing Date and 30 days from the date when the value of each 2014 Performance Award has been determined), the Seller shall notify the Purchaser in writing of the value of each 2014 Performance Award and under which
share-based incentive plan operated by the Seller’s Group the related 2014 Performance Award would have been granted. As soon as practicable following the receipt of such notice (and, in any event, by the later of 30 days from the receipt of
such notice and 30 days from the first date following the receipt of such notice when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any Applicable Law), the
Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the 2014
Performance Award which would have been granted but for the occurrence of Closing. Such 2014 Performance Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of
grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Seller’s Group pursuant to which the related 2014 Performance Award would have been granted. In such cases: 

  
 145

	 	10.10.1	the Purchaser undertakes to seek any applicable Tax relief in respect of the 2014 Performance Awards and to indemnify the Seller in respect of any Tax relief
obtained, provided always that the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

 

	 	10.10.2	where a 2014 Performance Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of
the Income Tax (Earnings and Pensions) Act 2003 (or, as applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive
this obligation in respect of certain 2014 Performance Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph 10.10.2 shall not apply in respect of such 2014 Performance Awards; and

  

	 	10.10.3	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with such 2014 Performance Awards, including any Tax. 

 The grant of a 2014 Performance Award to a
Transferred Employee shall be taken into account by the Purchaser when determining the extent to which that Transferred Employee shall participate in incentive arrangements (other than any Compensation Award or Matching Award) operated by the
Purchaser’s Group following Closing. 
 For the purposes of this paragraph 10.10: 

 

	 	10.10.4	the value of a 2014 Performance Award to be granted shall: (i) be determined by the Seller acting reasonably and in good faith, (ii) be consistent with past
practice, (iii) take into account the relevant business and/or individual performance criteria linked to the Seller’s Group’s 2014 financial year, and (iv) if Closing occurs before 31 December 2014, be time pro-rated to take account
of the reduced period of time, as a proportion of the Seller’s Group’s 2014 financial year, that the relevant Transferred Employee worked within the Seller’s Group (calculated on the basis of the number of complete months of service
as at the Closing Date); 

  

	 	10.10.5	the number of shares to be placed under a 2014 Performance Award shall be valued on the basis of the average price of an ordinary share in the capital of the
Purchaser over the five trading days immediately prior to the date of grant; and 

  

	 	10.10.6	any currency conversion shall be made in accordance with Clause 1.12 of this Agreement. 

 

	11.	Clinical Employees 

  

	11.1	The parties intend and agree that: 

  

	 	11.1.1	 the employment of the Clinical Employees shall not be transferred by the Seller or another member of the Seller’s Group to a member of the

  
 146

	 	
Purchaser’s Group on and from the Closing Date but shall transfer on and from the Clinical Employee Transfer Date; 

 

	 	11.1.2	notwithstanding the intention at paragraph 11.1.1 above, if the contract of employment of any Clinical Employee is found or alleged to have effect at any time
prior to the Clinical Employee Transfer Date as if originally made with the Purchaser or another member of the Purchaser’s Group as a consequence of this Agreement, paragraph 3 shall not apply in relation to that Clinical Employee and as a
result the parties shall in good faith seek to agree as soon as reasonably practicable how best to deal with such unintended transfer or allegation of transfer provided that, if the parties are unable to reach such agreement within a reasonable
period and if it is agreed that such Clinical Employee’s contract of employment has so transferred, then such Clinical Employee shall be treated from the time he actually became so employed as a “Transferred Employee” (and no longer a
Clinical Employee) for the purposes of this Agreement; 

  

	 	11.1.3	no provisions in paragraph 2 shall require the Purchaser or another member of the Purchaser’s Group to employ, or make an offer to employ, a Clinical
Employee, on and from the Closing Date; 

  

	 	11.1.4	paragraph 2.2 shall be amended to the extent required so that it applies to Clinical Employees and, in respect of such Clinical Employees, references to the
“Closing Date” shall be replaced with references to the “Clinical Employee Transfer Date”; 

  

	 	11.1.5	paragraph 2.3 shall be amended to the extent required so that it applies to Clinical Employees and, in respect of such Clinical Employees, references to the
“Closing Date” or “Closing” shall be replaced with references to the “Clinical Employee Transfer Date”; and 

  

	 	11.1.6	paragraph 3 shall be amended to the extent required so that it applies on the Clinical Employee Transfer Date in respect of any person who is not at that time a
Clinical Employee and any references to the “Closing Date” or “Closing” shall be replaced with references to the “Clinical Employee Transfer Date”. 

 

	11.2	Notwithstanding the provisions of paragraph 11.1 above, the parties agree that each Clinical Employee shall, with effect from and including the Closing Date, be
treated for economic purposes as if he is employed by a member of the Purchaser’s Group, and as a consequence will be deemed to be a “Transferred Employee” (meaning that the Purchaser will be economically responsible for all costs and
liabilities relating to his employment on and from the Effective Time or termination of his employment on and from the Effective Time) provided that such treatment shall not result, in relation to any Clinical Employee, in any member of the
Purchaser’s Group being liable for any costs and liabilities under this Schedule to the extent that any such costs and liabilities arise from: 

  

	 	11.2.1	 any failure by the relevant member of the Seller’s Group prior to the Clinical Employee Transfer Date, without good reason, to comply with
any instruction 

  
 147

	 	
from the Purchaser or a member of the Purchaser’s Group in relation to that Clinical Employee; or 

 

	 	11.2.2	any failure by the relevant member of the Seller’s Group prior to the Clinical Employee Transfer Date to supervise the Clinical Employees in accordance with
standard industry practice; or 

  

	 	11.2.3	any claim by a Clinical Employee as a result of any breach of contract or Applicable Law by the Seller (other than in express compliance with any instruction
from the Purchaser or a member of the Purchaser’s Group or as otherwise expressly agreed in writing by the Purchaser) in respect of such Clinical Employee. 

 For the avoidance of doubt, no provision of this paragraph 11.2 shall entitle any member of the Seller’s Group to recover any amount in respect of any Clinical Employee if that would entitle the
Seller’s Group to recover more than once in respect of the same amount under this Agreement or any Ancillary Agreement. 
  

	11.3	For the purposes of paragraphs 10.2 and 10.8 above, in relation to Clinical Employees only, references to “Closing” and the “Closing Date”
shall be construed as references to the Clinical Employee Transfer Date. 

  

	11.4	The parties intend and agree that, if any Relevant Employee is at Closing determined to be both a Clinical Employee and a Delayed Employee (as defined in
paragraph 12 below): 

  

	 	11.4.1	such Relevant Employee shall be treated for the purposes of this Agreement as a Clinical Employee until such time immediately prior to the Clinical Employee
Transfer Date and thereafter as a Delayed Employee in accordance with the terms of paragraph 12 below; and 

  

	 	11.4.2	the employment of such Relevant Employee shall not be transferred by the Seller or another member of the Seller’s Group to a member of the Purchaser’s
Group on and from the Clinical Employee Transfer Date but shall transfer in accordance with the terms of paragraph 12 below. 

  

	12.	Delayed Employees 

  

	12.1	The parties intend and agree that: 

  

	 	12.1.1	the employment of the Delayed Employees shall not be transferred by the Seller or another member of the Seller’s Group to a member of the Purchaser’s
Group on and from the Closing Date but shall transfer on and from the Delayed Closing Date which relates to the Delayed Business associated with that Delayed Employee; 

 

	 	12.1.2	 notwithstanding the intention at paragraph 12.1.1 above, if the contract of employment of any Delayed Employee is found or alleged to have
effect at any time prior to the Delayed Closing Date as if originally made with the Purchaser or another member of the Purchaser’s Group as a consequence of this Agreement, paragraph 3 shall not apply in relation to that Delayed Employee and as
a result the parties shall in good faith seek to agree as 

  
 148

	 	
soon as reasonably practicable how best to deal with such unintended transfer or allegation of transfer having regard to the reason why the individual’s transfer to the Purchaser or another
member of the Purchaser’s Group was delayed but provided that, if the parties are unable to reach such agreement within a reasonable period and if it is agreed that such Delayed Employee’s contract of employment has so transferred, then
such Delayed Employee shall be treated from the time he actually became so employed as a “Transferred Employee” (and no longer a Delayed Employee) for the purposes of this Agreement; 

 

	 	12.1.3	no provisions in paragraph 2 shall require the Purchaser or another member of the Purchaser’s Group to employ, or make an offer to employ, a Delayed
Employee, on and from the Closing Date; 

  

	 	12.1.4	paragraph 2.2 shall be amended to the extent required so that it applies to Delayed Employees and, in respect of such Delayed Employees, references to the
“Closing Date” shall be replaced with references to the “Delayed Closing Date which relates to the Delayed Business associated with that Delayed Employee”; 

 

	 	12.1.5	paragraph 2.3 shall be amended to the extent required so that it applies to Delayed Employees and, in respect of such Delayed Employees, references to the
“Closing Date” or “Closing” shall be replaced with references to the “Delayed Closing Date which relates to the Delayed Business associated with that Delayed Employee”; and 

 

	 	12.1.6	paragraph 3 shall be amended to the extent required so that it applies on each Delayed Closing Date in respect of any person who is not at that time a Delayed
Employee and any references to the “Closing Date” or “Closing” shall be replaced with references to that “Delayed Closing Date”. 

 

	12.2	 Notwithstanding the provisions of paragraph 12.1 above, the parties agree that each Delayed Employee shall, with effect from and including the
Closing Date, be treated for economic purposes as if he is employed by a member of the Purchaser’s Group, and as a consequence will be deemed to be a “Transferred Employee” (meaning that the Purchaser will be economically responsible
for all costs and liabilities relating to his employment on and from the Effective Time or termination of his employment on and from the Effective Time) provided that such treatment shall not result, in relation to any Delayed Employee, in any
member of the Purchaser’s Group being liable for any costs and liabilities under this Schedule to the extent that any such costs and liabilities arise from: (i) any failure by the relevant member of the Seller’s Group prior to a Delayed
Employee’s Delayed Closing Date, without good reason, to comply with any Controlled Business Instruction or Seller Involvement Instruction in relation to that Delayed Employee; or (ii) any claim by a Delayed Employee as a result of any breach
of contract or Applicable Law by the relevant member of the Seller’s Group (other than in express compliance with any Controlled Business Instruction or Seller Involvement Instruction or as otherwise expressly agreed in writing by the
Purchaser) in respect of such Delayed Employee. Any amounts payable pursuant to this paragraph 12.2 shall be paid in accordance with paragraph 4 of Schedule 25. For the avoidance of doubt, no provision of this

  
 149

	 	
paragraph 12.2 shall entitle the Seller or any member of the Seller’s Group to recover any amount in respect of any Delayed Employee if that would entitle the Seller or member of the
Seller’s Group to recover more than once in respect of the same amount under this Agreement or any Ancillary Agreement. 

  

	12.3	For the purposes of paragraphs 10.2 and 10.8 above, references to “Closing” and the “Closing Date” shall be construed as references to the
relevant Closing, Closing Date or Delayed Closing Date which applies to each of the relevant Transferred Employees. 

  
 150

 Schedule 9 
 Employee Benefits 
 (Clause 2.4.2) 

In this Schedule 9: 
 “Delayed
Employees” has the meaning given in Schedule 8; 
 “Employee Benefits” means benefits to or in respect of any current
or former employee, including without limitation, any pension, early retirement, disability, death benefit, long service awards, termination indemnity (such as Italian TFR) or post-retirement medical benefits or deferred compensation linked to
retirement, disability or death benefits or old age part-time benefits (such as German ATZ) and jubilee payments; 
 “Employee Benefit
Liabilities” means liabilities and obligations (whether funded or unfunded) in respect of any employee benefit promise, scheme, plan, fund, program, policy, practice or other individual or collective arrangement providing Employee Benefits;

 “Purchaser Funding Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the
Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), and there is a
local obligation or practice prior to the date of this Agreement to pre-fund or externally fund those similar or comparable benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for
example, be the case in relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those similar or comparable benefits immediately prior to the date of this Agreement (so,
taking the example of UK defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully
funded on that basis at any relevant time); 
 “Purchaser IFRS Assumptions” means, in relation to any Transferred Employee
Benefits, where a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement
of accrual etc), the method and assumptions used most recently prior to the date of this Agreement to value those similar or comparable benefits by the Purchaser’s Group (or any relevant member thereof) for IFRS accounting purposes; 

“Seller Funding Assumptions” means, in relation to any Transferred Employee Benefits, if there is a local obligation or practice prior
to the date of this Agreement to pre-fund or externally fund those Transferred Employee Benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the case in relation to
UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those Transferred Employee Benefits immediately prior to the date of this Agreement (so, taking the example of UK defined
benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully funded on that basis at any
relevant time); 

  
 151

 “Seller IFRS Assumptions” means, in relation to any Transferred Employee Benefits, the
method and assumptions used by the Seller’s Group (or the most relevant member thereof) most recently prior to the date of this Agreement to value those Transferred Employee Benefits for IFRS accounting purposes; 

“Swiss Actuary” means an actuary: (a) who can reasonably be viewed: (i) as independent of both the Purchaser and the Seller; and (ii) as
familiar with Swiss pension issues; and (b) whom the Purchaser and the Seller have agreed should be jointly appointed by them for the purposes of determining the Swiss Assumptions or who in default of such agreement has been appointed by the Swiss
Association of Actuaries or other industry body of actuaries in Switzerland as agreed by the Seller and the Purchaser; 
 “Swiss
Assumptions” means, in relation to any Transferred Employee Benefits in Switzerland, the Seller IFRS Assumptions adjusted: 
  

	(a)	by replacing any assumed “cash balance” annuity conversion rate in the Seller IFRS Assumptions with a conversion rate which the Swiss Actuary certifies to the
Purchaser and the Seller as representing a reasonable estimate of the likely effective overall blended conversion rate which will apply in relation to the Transferred Employee Benefits in question, having regard to the changes to the rate which can
(having regard to longevity projections, legal and governance constraints around Swiss pension structures and such other matters as the Swiss Actuary considers relevant) in the Swiss Actuary’s opinion reasonably be expected to occur during the
expected service lives of the Transferred Employees to whom the Transferred Employee Benefits relate, and weighting the impact of those changes by reference to the ages of the relevant employees (and so the extent to which the changes will in fact
operate to reduce the effective liability on the Purchaser); and 

  

	(b)	by removing any reserve for death or disability benefits to the extent that the Swiss Actuary certifies to the Purchaser and the Seller that it constitutes a reserve
for liabilities to and in respect of the relevant Transferred Employees which could reasonably be externally insured by the Purchaser without introducing a new ongoing cost on the Purchaser which was not reflected in the Seller’s ongoing cost
base prior to the date of this Agreement; 

 “Temporary Participation Plan” means any plan or arrangement
(whether funded or unfunded) for the provision of Employee Benefits in which Transferred Employees participate prior to Closing and continue (for any reason, whether by special arrangement or because they are Delayed Employees, or otherwise) to
participate for a temporary period after Closing; 
 “Temporary Participation Cessation Date” means, in relation to any
Temporary Participation Plan, the date on which Transferred Employees cease to participate in the relevant plan or arrangement; and 

“Vaccines Funding Assumptions” means in relation to any Transferred Employee Benefits which are similar or comparable to benefits in the
same country which are Transferred Employee Benefits under the Vaccines Sale and Purchase Agreement (the “Equivalent Vaccines Benefits”), the method and assumptions used under the Vaccines Sale and Purchase Agreement to value those
Equivalent Vaccines Benefits. For avoidance of doubt, the Vaccines Funding Assumptions are only available in respect of Transferred Employee Benefits for which there are Equivalent Vaccines Benefits. 

  
 152

 For the purposes of each of the Purchaser Funding Assumptions, the Purchaser IFRS Assumptions, the Seller
Funding Assumptions, the Seller IFRS Assumptions, the Swiss Assumptions (and, for the avoidance of doubt, the Vaccines Funding Assumptions), any economic and financial assumptions which are based (whether expressly or implicitly) on yields, rates or
indices shall be updated for the purposes of such definitions to take account of those yields, rates or indices as at the Effective Time (or the latest practicable time prior to the Effective Time). 

 

	1.	Except to the extent otherwise requested by the Seller and expressly agreed by the Purchaser before Closing (such Purchaser agreement not to be unreasonably withheld to
the extent that it is not reasonably possible for the Seller or its Affiliates to retain the relevant Employee Benefit Liabilities – for example, where liability unavoidably transfers by operation of law under European Council Directive
2001/23/EC or its local implementing legislation), any Employee Benefit Liabilities in respect of service in the Business or with any member of the Seller’s Group or in any plan or arrangement in which any member of the Seller’s Group
participates or has participated: 

  

	 	(a)	(in the case of a Transferred Employee) prior to Closing; or 

  

	 	(b)	(in the case of any other person) at any time, 

 (together, “Pre-Closing EB Liabilities”) will stay with or be assumed by the Seller or its Affiliates and the Seller shall fully indemnify the Purchaser and its Affiliates against any
such Employee Benefit Liabilities and against any liabilities and obligations to or in respect of any plan or arrangement for the provision of Employee Benefits in which any member of the Seller’s Group participates or participated prior to
Closing. For the avoidance of doubt, the Purchaser’s agreement under this paragraph 1 may, if the Purchaser so determines, relate only to certain specified categories or tranches of Pre-Closing EB Liabilities under a particular benefit
programme (in other words, it does not need to be “all or nothing”), in which case it is only those specified Pre-Closing EB Liabilities which are excluded from the scope of the Purchaser’s indemnity entitlement hereunder. 

 

	2.	Where and to the extent that the Purchaser agrees under paragraph 1 that any Pre-Closing EB Liabilities may transfer to or remain with the Purchaser and/or its
Affiliates (such Pre-Closing EB Liabilities being the “Transferred Employee Benefit Liabilities” and the benefits to which they relate being the “Transferred Employee Benefits”), the Purchaser will be compensated in
respect of such Transferred Employee Benefit Liabilities as set out in the rest of this Schedule 9. Subject to being so compensated but without prejudice to paragraphs 9 and 11, the Purchaser shall, or shall procure that its relevant Affiliate
shall, assume, with a full discharge for the Seller and its Affiliates, the Transferred Employee Benefit Liabilities. The Purchaser acknowledges its agreement to the principle that the post-retirement medical healthcare plan to which it admits US
Transferred Employees who immediately before Closing were members of such a plan will take account of periods of employment with the Seller’s Group to the extent previously recognised under the equivalent Seller’s Group plan for the
purposes of determining eligibility, contributions, and vesting; again, therefore, subject to appropriate identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule
9, they will become Transferred Employee Benefit Liabilities. 

  
 153

	2A	This paragraph 2A applies where there are Transferred Employee Benefits in a Temporary Participation Plan. In such a case, notwithstanding that the Transferred Employee
Benefit Liabilities may (subject to the Purchaser’s agreement as per 1 above) include liabilities in respect of service after the Effective Time, the Transferred Employee Benefit Liabilities which are included in the calculation of the Employee
Benefit Indemnification Amount as per paragraph 3 below shall (unless the Seller and the Purchaser agree otherwise in any particular case) comprise only those liabilities attributable to service before the Effective Time. Conversely, although the
Transferred Employee Benefit Liabilities will not for the purposes of paragraphs 1 and 2 above include Liabilities in respect of Transferred Employees or other individuals who leave employment or crystallise benefits before the Temporary
Participation Cessation Date in relation to the relevant Temporary Participation Plan (unless the Seller and the Purchaser agree otherwise in any particular case and without prejudice to the Purchaser or its Affiliates’ obligation to comply
with any requirements in relation to such individuals before they leave employment or crystallise benefits), the parties agree that the calculation of the Employee Benefit Indemnification Amount under paragraph 3 below in relation to any Temporary
Participation Plan shall be carried out on the basis of a conclusive presumption (regardless of any actual knowledge to the contrary) that: 

 2A.1    any individual who is a Delayed Employee on the day after the Closing Date is or will become a Transferred Employee, and 

2A.2    no Contingent Individual will leave employment or crystallise benefits before the relevant Temporary
Participation Cessation Date. For these purposes a “Contingent Individual” is a Transferred Employee or other individual who on the day after the Closing Date has not left employment or crystallised benefits and in respect of whom
liabilities: (a) would become Transferred Employee Benefit Liabilities if he does not leave employment or crystallise benefits before the relevant Temporary Participation Cessation Date; but (b) would not otherwise become Transferred Employee
Benefit Liabilities. 
  

	3.	The value of the Transferred Employee Benefit Liabilities shall be determined on employee census data and plan provision as at the Effective Time (and making the
conclusive presumptions at 2A.1 and 2A.2 above) on the Vaccines Funding Assumptions if available, but if not available then on: 

  

	3.1	in relation to any Transferred Employee Benefits in Switzerland, the Swiss Assumptions; and 

 

	3.2	in relation to any other Transferred Employee Benefits, the Seller IFRS Assumptions, PROVIDED that if any of the following values is available and is greater than the
value derived using the Seller IFRS Assumptions then that value will be used instead (and if more than one of these values is available then the one which would place the greatest value on the relevant Transferred Employee Benefit Liabilities will
be used): 

  

	 	3.2.1	if a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee
Benefits relate (regardless of differences in the terms of entitlement of accrual etc), the value which is midway between the value based on the Seller IFRS Assumptions and the Purchaser IFRS Assumptions; 

  
 154

	 	3.2.2	if there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding target
which is determined by reference to a method and assumptions other than IFRS, the value derived using the Seller Funding Assumptions; and 

  

	 	3.2.3	if there is both: (i) a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding
target which is determined by reference to a method and assumptions other than IFRS; and (ii) a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred
Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), the value which is midway between the value based on the Seller Funding Assumptions and the Purchaser Funding Assumptions. 

Where there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or
other vehicle established for the purposes of meeting such Transferred Employee Benefit Liabilities, and the actuary chosen by the Seller and the actuary chosen by the Purchaser agree under paragraph 4 (or it is otherwise determined under paragraph
5) that having regard to all relevant matters as they subsisted immediately after Closing it would be reasonable to expect all or part of such assets to be or remain available to the Purchaser or its Affiliates to meet the cost of such
Transferred Employee Benefit Liabilities (whether by transfer out to another vehicle or because the Purchaser and/or any Affiliate is expected to remain affiliated to the vehicle on more than a merely temporary basis), then the value as at the
Effective Time of the assets which ignoring matters arising after Closing they would expect to be made or remain so available (the “Available Assets) (including for the avoidance of doubt, in the case of Switzerland, the Swiss Assets to
the extent that they are so agreed or determined) as agreed under paragraph 4 or determined under paragraph 5 will be deducted from the value of the Transferred Employee Benefit Liabilities, and the remaining value of the Transferred Employee
Benefit Liabilities (if any) is the “Employee Benefit Indemnification Amount”. The determination of the Employee Benefit Indemnification Amounts shall be carried out on a country-by-country basis and, where necessary, on a
plan-by-plan basis. If any Employee Benefit Indemnification Amount is greater than the amount paid in respect of it via the Estimated Employee Benefit Adjustment (or, where no such estimate was made, greater than zero), the Seller shall pay or
procure payment, by way of a reduction in the Share Consideration, an amount equal to the difference (or, where no such payment was made, such amount) to the Purchaser, or at the request of the Purchaser to an Affiliate of the Purchaser, as
compensation for the Transferred Employee Benefit Liabilities. If any Employee Benefit Indemnification Amount is less than the amount paid in respect of it via the Estimated Employee Benefit Adjustment (if any), the Purchaser shall pay an amount
equal to the difference to the Seller. 
  

	4.	 The Seller and its Affiliates shall, within 45 days after Closing, provide its actuary, the Swiss Actuary (if relevant) and the actuary chosen by the
Purchaser with all relevant plan, asset, assumptions and employee census information needed to calculate the Employee Benefit Indemnification Amounts in respect of any Transferred Employees or Delayed Employees to the extent not otherwise within the
control of the Purchaser or its Affiliates. The actuary chosen by the Seller shall provide the actuary chosen by 

  
 155

	 	
the Purchaser with its calculation of the Employee Benefit Indemnification Amounts (including, but not limited to, any supporting documentation on which it relied as well as the methodologies it
employed in calculating the Employee Benefit Indemnification Amounts), on a plan-by-plan basis, within 90 days following Closing. The actuary chosen by the Purchaser shall review the calculation of the Employee Benefit Indemnification Amounts of the
Seller’s actuary within 120 days following Closing. The Employee Benefit Indemnification Amounts shall be determined, on a plan-by-plan basis, by mutual agreement between the parties within 180 days following the Closing Date.

  

	5.	If the parties cannot agree on any Employee Benefit Indemnification Amount within the 180-day period referred to in paragraph 4, the parties shall appoint within 5 days
an independent actuary acceptable to both parties, or such actuary shall be selected by the President of the Institute and Faculty of Actuaries in the UK if they cannot agree, and the independent actuary thus appointed shall review their
calculations and, within 75 days after appointment, render a final and binding decision on the amount of that Employee Benefit Indemnification Amount, and, in making such decision, shall be limited to adopting the position taken by either one of the
parties. The cost of any independent actuary shall be borne jointly by the parties. 

  

	6.	In connection with the procedures referred to in this Schedule 9, the parties shall provide each other and the actuaries referred to in this Schedule 9 with access to
the relevant business records and other relevant documents and information as may reasonably be requested. All documents, records and information provided for the purposes of this Schedule 9 must be accurate and complete in all material respects.

  

	7.	Each payment in respect of an Employee Benefit Indemnification Amount shall be made by the Seller (by way of a reduction in the Share Consideration) within 14 days
following its final determination. The Seller may make an accelerated or advance payment at its own discretion (which, for the avoidance of doubt, includes in relation to each Employee Benefit Indemnification Amount so much (if any) of the
Estimated Employee Benefit Adjustment as the Seller notified pursuant to Clause 6.4 was intended to relate to that Employee Benefit Indemnification Amount). Each Employee Benefit Indemnification Amount shall include interest calculated from the
Effective Time to (and including) the date of payment at a rate per annum of LIBOR (but where amounts are prepaid or paid in stages or treated as paid via inclusion in the Estimated Employee Benefit Adjustment then the interest will cease to accrue
on so much of the Employee Benefit Indemnification Amount as has been paid). Such interest shall accrue from day to day. Any such payment shall be made in US dollars (and any underlying values shall be expressed in US dollars) and any currency other
than US dollars shall be converted into US dollars at the exchange rates determined in accordance with Clause 1.13 of this Agreement on the Closing Date. 

  

	8.	To the extent (if any) that there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or other
vehicle established for the purposes of meeting such Transferred Employee Benefit Liabilities, the Purchaser will, if requested by the Seller before Closing (or the relevant Temporary Participation Cessation Date) and unless it is not reasonably
practicable to do so, establish or nominate a trust or other vehicle which is capable of receiving a transfer of assets from the pre-Closing trust or other vehicle to the extent that such assets relate to the Transferred Employee Benefit
Liabilities. 

  
 156

	9.	If, within one year of Closing, the Seller or the Purchaser notifies the other that the membership or other benefit data (the “Data”) used for
calculating any Employee Benefit Indemnification Amount may be inaccurate, other than by reason of an Excluded Matter, then a “Data Dispute” has arisen and the following provisions shall apply: 

 

	 	9.1	On such notification, the Seller shall procure that its actuary and the Purchaser shall procure that its actuary consult each other with a view to agreeing whether the
Data is inaccurate and if so, what the accurate Data should be. If the Seller’s actuary and the Purchaser’s actuary agree that the Data is inaccurate, they will jointly certify this to be the case and advise on what the accurate Data
should be. The notification is deemed to have occurred on the date of the certification. 

  

	 	9.2	If the Seller’s actuary and the Purchaser’s actuary fail to agree whether the Data is inaccurate within 60 days of the notification by one party to the other
that the Data may be inaccurate, paragraph 5 shall apply mutatis mutandis. The notification is deemed to have occurred when the independent actuary advises that the Data is inaccurate and what the accurate Data should be. 

 

	 	9.3	On the occurrence of the Data Dispute, the Seller and the Purchaser shall respectively procure that a valuation of the relevant Employee Benefit Indemnification Amount
is carried out in accordance with paragraphs 3 and 4 (mutatis mutandis) but on the basis of the accurate Data as agreed under paragraph 9.1 or determined under paragraph 9.2. 

 

	 	9.4	If as a consequence of paragraph 9.3, the Seller has paid to the Purchaser an amount which on the basis of the further valuation is not payable, such amount (the
“Overpayment”) shall be repaid within 21 days of the amount of the Overpayment being agreed or determined. Any such payment shall bear interest calculated from (and including) the date the Overpayment was made to (and including) the
date the payment is made in full in accordance with this paragraph 9.4 at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	 	9.5	If as a consequence of paragraph 9.3, the Seller has not paid to the Purchaser an amount which on the basis of the further valuation is payable, such amount (the
“Outstanding Amount”) shall be paid within 21 days of the amount of the Outstanding Amount being agreed or determined. Any such payment shall bear interest calculated from (and including) the Closing Date to (and including) the date
the payment is made in full in accordance with this paragraph 9.5 at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	 	For the purposes of this paragraph 9, the “Excluded Matters” are: 

 

	 	•	assets which were assumed to be Available Assets ultimately turning out not to be available to the Purchaser or its Affiliates to meet the cost of the Transferred
Employee Benefit Liabilities to which they related, and 

  

	 	•	liabilities in respect of individuals being assumed to be Transferred Employee Benefit Liabilities but turning out not to be because the individuals leave service or
crystallise benefits before the date liabilities are transferred. 

  

	10.	 Except as otherwise agreed by the Seller, the Purchaser shall where a trust or other vehicle has been established under paragraph 8, procure that all
of the assets 

  
 157

	 	
transferred as envisaged by paragraph 8 are paid into such trust or other vehicle. If, after such payment or transfer, or after payment of an Employee Benefit Indemnification Amount or after
making an Estimated Employee Benefit Adjustment, the Purchaser and/or its Affiliates achieves a reduction in its liability to any Tax in respect of or in connection with the payment or transfer, the Purchaser shall pay to Seller (for itself or on
behalf of the relevant Share Seller or Business Seller as applicable), within 30 days after the Purchaser would otherwise have been liable to pay the saved Tax, a sum equal to the amount of that Tax reduction by way of an increase in the Share
Consideration. This paragraph 10 applies for a period of four years following the later of the date on which a transfer of assets is made, or payment of any Employee Benefit Indemnification Amount or Estimated Employee Benefit Adjustment is made to
the Purchaser. 

  

	11.	The Seller covenants with the Purchaser to pay to the Purchaser an amount equal to any cost, claim or liability incurred by any member of the Purchaser’s Group
which it is or becomes liable to make on or at any time after Closing by reason of any change or purported change made to the terms of any Transferred Employee Benefits prior to Closing proving to be or have been legally ineffective or by reason of
such terms and/or benefits failing to comply with any mandatory legal requirements (excluding any obligation to equalise guaranteed minimum pensions in the United Kingdom). The Seller shall not be liable under this paragraph 11 in respect of any
individual claim (or a series of claims arising from similar or identical facts or circumstances) unless the liability in respect of such claim or series of claims exceeds US$100,000. If the Purchaser becomes aware of any fact, matter or
circumstance that may give rise to a claim against the Seller under this paragraph 11, the Purchaser shall as soon as reasonably practicable give notice in writing to the Seller of such facts, matters or circumstances as are then available regarding
the potential claim. Failure to give such notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this paragraph 11, except that the Seller shall not be liable for any increase in the amount of such
claim arising from such failure. The latest date on which the Purchaser may give notice of a claim under this paragraph 11 is the fourth anniversary of the Closing Date. 

 

	12.	Notwithstanding any general provision to the contrary in Schedule 8 and subject to being compensated in accordance with this Schedule 9, the Purchaser shall admit
Transferred Employees in the United States who participated in a post-retirement medical plan immediately prior to Closing to its own post-retirement medical plan. Subject to being compensated in accordance with this Schedule 9, periods of
employment with the Seller’s Group (including, without limitation, any current or former Affiliate of the Seller, to the extent previously recognised under the applicable benefit plan arrangement provided by the Seller’s Group), shall be
taken into account for the purposes of determining, as applicable, the eligibility for participation, contributions, and vesting for any employee under such post-retirement medical plan. 

 

	13.	 Notwithstanding any general provision to the contrary in Schedule 8, the US Transferred Employees shall, as of the Closing Date, become eligible to
participate in a US tax-qualified defined contribution plan to the extent such plan is sponsored by the Purchaser or a relevant member of the Purchaser’s Group. The Purchaser agrees that it will use commercially reasonable efforts to cause such
plan to accept rollovers of the account balances of the US Transferred Employees (including participant loan 

  
 158

	 	
promissory notes) from the relevant employer’s tax-qualified retirement plans; provided that (i) the Purchaser will not be required to accept any such rollovers that might result in material
liability to the Purchaser or may otherwise cause the relevant plan to cease to qualify under Section 401(a) of the Code and (ii) the Purchaser will not be required to amend any plan to permit participant loans. 

 

	14.	By way of exception to the general principle at paragraph 1, where a UK Transferred Employee who had joined service with the Seller’s Group before 1 April 2005 is
made redundant within 24 months of Closing, then the Purchaser shall pay the Seller an amount equal to the cost of applying the Agreed UK Restructuring Arrangement to an employee of the employee’s actual age at the date he is made redundant,
but only to so much of the employee’s benefits in a Seller’s Group plan as were accrued prior to Closing; and provided further that the Purchaser’s aggregate liability under this paragraph in respect of all such UK Transferred
Employees who are so made redundant is capped at £1 million. This cost shall be calculated on a basis consistent with that which is used across the Seller’s Group retained business for internal cost-charging purposes in relation to the
Agreed UK Restructuring Arrangement, and the Seller shall supply the Purchaser with such evidence as the Purchaser may reasonably require to verify that. Subject to receipt of such payment, the Seller shall apply the Agreed UK Restructuring
Arrangement to the relevant employee’s Seller’s Group plan benefits. This provision shall cease to apply 24 months after Closing, whereafter the Purchaser shall procure that neither it nor its Affiliates offers or indicates the
availability of the Agreed UK Restructuring Arrangement to any Transferred Employee. 

  

	15.	The parties agree that where any Transferred Employee has accrued defined contribution benefits prior to Closing in a Seller’s Group arrangement then:

  

	 	15.1	the Seller shall use commercially reasonable efforts to procure the vesting of those benefits (if they would otherwise lapse as a result of Closing);

  

	 	15.2	the parties shall, provided this will not impose unreasonable administrative burdens on the Purchaser’s Group, co-operate in good faith to procure a transfer of
the account balances of such Transferred Employee from the Seller’s Group arrangement to a Purchaser’s Group arrangement; and 

  

	 	15.3	for the avoidance of doubt, the Purchaser will comply with the provisions of paragraph 6.1 of Schedule 8. 

Temporary periods of participation 
  

	16.	The Seller and Purchaser may agree that an employing entity in the Purchaser’s Group shall be admitted to participate, for a temporary period with effect from
Closing, in one or more Employee Benefit plans operated by a member of the Seller’s Group, or in which a member of the Seller’s Group participates. 

 

	17.	In such event, the Seller and Purchaser shall use all reasonable endeavours to enter into an agreement with the provider or board of trustees of the relevant Employee
Benefit plan on such terms as the provider or board of trustees may reasonably require. 

 Jubilee payments 

  
 159

	18.	For the purposes of calculating the amount of jubilee payments and long service awards falling within the definition of “Transferred Employee Benefit
Liabilities” the following principles shall apply: 

  

	 	18.1	in relation to Employees in respect of whom each of the following applies: 

 

	 	(a)	liabilities to make jubilee payments or grant long service awards transfer to a member of the Purchaser’s Group by operation of law; and 

 

	 	(b)	the relevant member of the Purchaser’s Group replicates or will replicate the benefits which applied while they were employees of the Seller’s Group,

 liabilities to make jubilee payments or grant long service awards will be treated as falling within the
Transferred Employee Benefit Liabilities and shall be calculated on the basis of the benefit scales which applied while the Employees were employees of the Seller’s Group; 

 

	 	18.2	in relation to Employees for whom either: 

  

	 	(i)	liabilities to make jubilee payments or grant long service awards do not transfer by operation of law but the relevant member of the Purchaser’s Group provides or
will provide replacement benefits which replicate the benefits provided by the Seller’s Group); or 

  

	 	(ii)	the relevant member of the Purchaser’s Group provides or will provide replacement jubilee or long service benefits but does not or will not replicate the benefits
which applied while they were employees of the Seller’s Group, 

 liabilities to make jubilee payments or
grant long service awards will be treated as falling within the Transferred Employee Benefit Liabilities and shall be calculated on the basis of the benefit scales which applied while the Employees were employees of the Seller’s Group or, if
less, the value of the actual benefit to be provided by the relevant members of the Purchaser’s Group. 
  

	 	18.3	for the avoidance of doubt, no amount will be included within “Transferred Employee Benefit Liabilities” in respect of jubilee payments or long service awards
in relation to Employees for whom liabilities to make such payments or grant such awards do not transfer by operation of law and no replacement benefits are provided by any member of the Purchaser’s Group; 

 

	 	18.4	the Purchaser and the Seller will negotiate in good faith with a view to agreeing an appropriate and simple method in each jurisdiction for valuing jubilee payments and
long service awards which are not disproportionate to the amounts of such payments but which is suitably even-handed as between the parties. Any such agreement will override the foregoing provisions of this paragraph 18 to the extent there is
any inconsistency. 

  
 160

 Schedule 10 
 Allocation 
 (Clause 3.2) 

 

	1.	The Seller and the Purchaser agree that to the extent it is necessary for Tax purposes to allocate any amount as between: 

 

	1.1	all of the Products, such amount shall be allocated for those Tax purposes as between the Products in proportions reflected as whole number percentages, to be
agreed in accordance with the remaining paragraphs of this Schedule 10; or 

  

	1.2	some but not all of the Products, such amount shall be allocated for those Tax purposes as between those particular Products in accordance with the relative
proportions reflected in the whole number percentages agreed in accordance with the remaining paragraphs of this Schedule 10. 

  

	2.	The Seller shall prepare, or procure the preparation of, a draft of the Allocation Statement, which shall be delivered to the Purchaser within 105 Business Days
of the date of this Agreement (the “Draft Allocation Statement”). 

  

	3.	The Purchaser shall have a period of 20 Business Days (the “Review Period”) after the delivery to it of the Draft Allocation Statement to review
the Draft Allocation Statement and may at any time during the Review Period request (in writing to the Seller) an adjustment to be made to any amount set out therein (an “Adjustment Request”). 

 

	4.	If no Adjustment Request is presented to the Seller within the Review Period, the Draft Allocation Statement shall be deemed to have been agreed and approved by
the Seller and the Purchaser, shall be final and binding upon them and shall constitute the “Allocation Statement” for the purposes of this Agreement. 

 

	5.	If an Adjustment Request is presented to the Seller within the Review Period: 

 

	5.1	the Purchaser and the Seller shall attempt to resolve the matter in dispute between them in good faith negotiations and before the date falling 20 Business Days
before Closing; and 

  

	5.2	in the event that the Purchaser and the Seller fail to agree the matter in dispute between them within 10 Business Days following delivery to the Seller of the
Adjustment Request, and unless the Seller and the Purchaser agree in writing to extend the period in which they may agree such allocation (subject to such extension not falling past Closing), the matter will be referred to the Reporting Accountants,
to be instructed jointly by the Purchaser and the Seller to determine the relevant allocation as soon as practicable and in any case before the date falling five Business Days before Closing. 

  
 161

	6.	If following agreement or determination of the Allocation Statement in accordance with paragraphs 4 and 5, the consideration payable by the Purchaser under
this Agreement is adjusted in accordance with any provision of this Agreement or any Ancillary Agreement: 

  

	6.1	if the adjustment of the consideration payable by the Purchaser relates specifically to one or more, but not all, of the Products, or relates to all of the
Products but to some more than others, the Purchaser and the Seller shall discuss in good faith the extent to which the percentage proportion allocated to the Products shall be adjusted and the Allocation Statement shall be amended to reflect the
outcome of those discussions (unless no agreement is reached, in which case paragraph 5.2 shall apply mutatis mutandis). 

  

	7.	The agreed or determined allocation set out in the Allocation Statement (as adjusted, where applicable) at Closing shall be binding on the parties and the
Purchaser and the Seller, or as the case may be, the Company, the Share Seller, the relevant Business Seller and the Purchaser, shall: 

  

	7.1	not in any Tax Return, or other document or filing, or in any Tax proceeding, take a position in relation to any of the allocation set out therein which is
inconsistent with the agreed or determined allocation; and 

  

	7.2	where reasonably necessary, make joint elections or otherwise cooperate in good faith to have the agreed or determined allocation respected for applicable Tax
purposes by any relevant Tax Authority. 

  

	8.	For the avoidance of doubt, it is understood and agreed by the parties that any valuation of the Products used in order to determine the allocation pursuant to
this Schedule 10 is not intended to be, and shall not be interpreted as, any assurance by any party as to the value of the Products (including the related assets and liabilities) being transferred. 

  
 162

 Schedule 11 
 VAT 
  

	1.	VAT: Records 

  

	1.1	The Seller, the Share Seller or any Business Seller may, on or before the Closing Date, obtain a direction from the relevant Tax Authority for the retention and
preservation by it of any VAT records relating to its period of ownership of the Business or the Share (as the case may be) and, where any such direction is obtained, the Seller undertakes to, or to procure that the relevant Business Seller or the
Share Seller (as the case may be) will: 

  

	 	1.1.1	preserve the records to which that direction relates in such a manner and for such period as may be required by the direction or by Applicable Law; and

  

	 	1.1.2	allow the Purchaser, upon the Purchaser giving reasonable notice, reasonable access to and copies of such records where reasonably required by the Purchaser for
its Tax purposes. 

  

	1.2	If no such direction as is referred to in paragraph 1.1 above is obtained before the Closing Date and any documents in the possession or control of a member
of the Seller’s Group are required by law to be preserved by the Purchaser, the Seller shall, as soon as reasonably practicable after Closing, deliver such documents to the Purchaser. 

 

	2.	VAT: Going Concern - EU Member States 

  

	2.1	The Seller and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT
to any Tax Authority or entering into a written agreement) to secure that, to the extent reasonably possible, the sale of all or any part of the Business, so far as carried on in the European Union, is treated as neither a supply of goods nor a
supply of services for the purposes of the laws governing VAT in each relevant member state. 

  

	2.2	Each Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Business, so far as
carried on in the relevant member state, should be treated as neither a supply of goods nor a supply of services for the purposes of the laws governing VAT in that member state and to account for VAT (and accordingly to seek an additional payment
from the Purchaser under Clause 3.3.3) in accordance with that ruling. The Seller shall not be obliged to challenge (or to procure that any relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If
the Purchaser wishes to challenge, or to require the relevant Business Seller to challenge, any such ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising
from or in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. 

 

	2.3	 Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the Seller shall determine in good faith if (or the
extent to which) VAT is payable in 

  
 163

	 	
respect of the sale of the Business and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination. 

 

	3.	VAT: Going Concern - non-EU Jurisdictions 

  

	3.1	To the extent that any state outside the European Union provides for relief or exemption from VAT on the transfer of a business or a company or treats such a
transaction as being non-taxable for VAT purposes, the Seller and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into
a written agreement) to secure such relief, exemption or treatment, to the extent reasonably possible, as regards the sale of all or part of the Business (insofar as carried on in the relevant state) under this Agreement. 

 

	3.2	The relevant Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Business, so far
as carried on in the relevant state, is eligible for a relief or exemption or is otherwise eligible to be treated as non-taxable for the purposes of the laws governing VAT in that state and to account for VAT (and accordingly seek an additional
payment from the Purchaser under Clause 3.3.3 in accordance with that ruling). The Seller shall not be obliged to challenge (or to procure then the relevant Business Seller challenges) that ruling unless required to do so by the
Purchaser. If the Purchaser wishes to challenge, or to require the relevant Business Seller to challenge, any ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any
loss arising from or in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. Insofar as no ruling has been obtained from a relevant Tax Authority
prior to Closing, the Seller shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Business and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such
determination. 

  

	4.	VAT: Time, Manner and Currency of Payment 

  

	4.1	Any amounts which the Purchaser is obliged to pay to the Seller under this Agreement in respect of VAT shall be paid by the Purchaser, on its own account or on
behalf of another member of the Purchaser’s Group, to the Seller or to such member of the Seller’s Group as the Seller may direct. Such amounts shall be paid in the currency in which the VAT in question must be accounted for to the
relevant Tax Authority. 

  

	4.2	Subject to any provision or express agreement to the contrary, any amounts in respect of VAT payable in any jurisdiction in respect of the transfer at Closing of
any of the Business shall be paid in accordance with paragraph 4.1 above at Closing against production of a valid VAT invoice (or equivalent, if any). 

 

	4.3	Notwithstanding any other provision of this Agreement, the Purchaser shall not be liable to account to the Seller or any member of the Seller’s Group for or
in respect of penalties or interest arising solely from the failure of the Seller or any other member of the Seller’s Group to account promptly for VAT to the relevant Tax Authority following the Seller having been placed in the appropriate
amount of funds for that purpose by the Purchaser. 

  
 164

 Schedule 12 
 Closing Obligations 
  

	1.	General Obligations 

  

	1.1	The Seller’s Obligations 

 On Closing, the Seller shall deliver or make available to the Purchaser the following: 
  

	 	1.1.1	the Ancillary Agreements (other than the France SPA and the Netherlands APA and any other Ancillary Agreements that have not been agreed and are subject to
Clause 5.3.2) duly executed by the relevant members of the Seller’s Group; 

  

	 	1.1.2	a valid power of attorney or such other evidence reasonably satisfactory to the Purchaser that the Seller, and each of its relevant Affiliates, are authorised to
execute this Agreement, the Ancillary Agreements and the Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Schedule 12), in each case to the extent that they are parties thereto; 

 

	 	1.1.3	the Certificate duly executed by the Seller; 

  

	 	1.1.4	a duly executed transfer in respect of the Share in favour of the Purchaser (or its Affiliate or its nominee); 

 

	 	1.1.5	a (i) power of attorney in the terms agreed between the Seller and the Purchaser to allow the Purchaser (or its Affiliate or its nominee) to vote the Share and
(ii) letter of direction in the terms agreed between the Seller and the Purchaser to allow the Purchaser (or its Affiliate or nominee) to receive all dividends, distributions and other benefits attaching to the Share from Closing;

  

	 	1.1.6	the statutory books of the Company (which shall be written up to but not including the Closing Date), the certificate of incorporation of the Company and share
certificate in respect of all the issued share capital of the Company; and 

  

	 	1.1.7	the interim accounts of the Company as at the Closing Date (immediately prior to Closing) which reflect the Company Intra-Group Debt. 

 

	1.2	In addition, the Seller shall procure: 

  

	 	1.2.1	any then present directors and officers (if any) of the Company resign their offices to take effect at Closing as such and to relinquish any rights which they
may have under any contract with the Company or under any statutory provisions (including any right to damages or compensation for breach of contract, loss of office, redundancy or unfair dismissal or on any other account whatsoever) and to confirm
that no agreement or arrangement is outstanding under which the Company has or could have any obligation to any of them including in respect of remuneration or expenses; and 

  
 165

	 	1.2.2	a board meeting of the Company is held, or written resolutions of the board are passed, at or by which: 

 

	 	(i)	it shall be resolved that the transfer relating to the Share shall, so far as possible, be approved for registration; and 

 

	 	(ii)	any person nominated by the Purchaser shall be appointed director, such appointments to take effect on Closing. 

 

	1.3	The Purchaser’s Obligations 

 On Closing, the Purchaser shall deliver or make available to the Seller the following: 
  

	 	1.3.1	the Ancillary Agreements (other than the France SPA and the Netherlands APA and any other Ancillary Agreements that have not been agreed and are subject to
Clause 5.3.2) duly executed by the relevant members of the Purchaser’s Group; and 

  

	 	1.3.2	a valid power of attorney or such other evidence reasonably satisfactory to the Seller that the Purchaser, and each of its relevant Affiliates, are authorised to
execute this Agreement and the Ancillary Agreements (as appropriate), in each case to the extent that they are parties thereto. 

  

	1.4	Discharge of the Company Intra-Group Debt 

 Immediately following the above, the amount held by the Seller as a result of the payment by the Purchaser pursuant to Clause 6.3.1(ii) shall be applied to the settlement by the Purchaser (as agent for
the Company) of the Company Intra-Group Debt. 
  

	2.	Transfer of the Assets 

  

	2.1	General Transfer Obligations 

 On Closing or such other date as agreed between the parties, the Seller shall procure that the Business Sellers shall, and the Purchaser shall, take such steps as are required to transfer the Assets (save
for the OBM Transferred Rights) and Assumed Liabilities not held by the Company in accordance with this Agreement. The Seller shall procure that the Business Sellers shall, and the Purchaser shall, take such steps as are required to transfer the OBM
Transferred Rights at the OBM Transfer Date, provided that nothing in this Agreement shall affect each Party’s right to possess a share of the Ofatumumab Biological Materials in accordance with the terms of the Manufacturing and Supply
Agreement. 

  
 166

 Schedule 13 
 Not Used 

  
 167

 Schedule 14 
 Warranties given under Clause 9.1 
  

	1.	Authority and Capacity 

  

	1.1	Incorporation 

  

	 	1.1.1	The Seller and each Business Seller is validly existing and is a company duly incorporated and registered under the law of its jurisdiction of incorporation.

  

	 	1.1.2	The Company is duly incorporated, validly existing and in good standing, under the laws of its jurisdiction of organisation. 

 

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Seller has the legal right and full power and authority to enter into and perform this Agreement and the Seller, the Share Seller, each Business Seller and
the Company has the legal right and full power and authority to enter into and perform any other documents to be executed by it pursuant to or in connection with this Agreement. 

 

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Seller, the Share Seller, each Business
Seller and the Company in accordance with their respective terms. 

  

	 	1.2.3	Except as referred to in this Agreement the Seller: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, in each case in connection with the performance of this Agreement or any other document
referred to in paragraph 1.2.1. 

  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Seller, the Share Seller, each Business Seller and the
Company of their respective obligations under them, will not: 

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the
Seller’s Group; 

  

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Seller’s Group is party or by which the
relevant member of the Seller’s Group is bound where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Seller’s Group is bound and
where such breach is material to their ability to perform their obligations under such documents. 

  
 168

	1.3	Authorisation 

 The
Seller, the Share Seller, each Business Seller and the Company has taken, or will have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party
and any other documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 
  

	2.	Warranties relating to the Business 

  

	2.1	Organisation and Standing of the Assets 

  

	 	2.1.1	Schedule 1 sets out a complete and accurate list of each of the Products, together with details of each Product Expansion which is a combination study and which
is the subject of a phase II or later clinical trial. 

  

	 	2.1.2	The summary details relating to the Products set out in Schedule 1 are true and accurate. 

 

	2.2	The Assets and the Share 

  

	 	2.2.1	Save in relation to the Transferred Product Intellectual Property Rights either the Seller or one of the Business Sellers has good and valid title to the Assets,
free and clear of all Encumbrances other than Permitted Encumbrances. 

  

	 	2.2.2	GGL is the legal and beneficial owner of the Share. 

  

	 	2.2.3	There is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance or equity on, over or affecting the Share and there
is no agreement or commitment to give or create any. 

  

	 	2.2.4	The Share has been duly authorised and validly issued and is fully paid and non-assessable. There are no options, warrants, rights, convertible, exercisable or
exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which any member of the Seller Group is a party or by which it
is bound obligating any member of the Seller Group to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible into, or exercisable or exchangeable
for, any capital stock of, or other equity interest in, the Company. 

  

	 	2.2.5	There are no outstanding Contracts to which any member of the Seller Group is a party or is otherwise bound to repurchase, redeem or otherwise acquire any
shares, capital stock or other equity interest of the Company. 

  

	 	2.2.6	The Share is not subject to and was not issued in violation of any purchase option, call option, right of first refusal, pre-emptive right, subscription right or
similar right or any provision of Applicable Law or the constitutional documents of the Company. 

  
 169

	2.3	Key Financial Information 

  

	 	2.3.1	The Key Financial Information has been prepared by the Seller: 

  

	 	(i)	in good faith and with all due care and attention; 

  

	 	(ii)	in a manner applying the accounting policies and practices of the Seller’s Group on a consistent basis; 

 

	 	(iii)	in accordance with International Financial Reporting Standards as adopted by the European Union; 

 

	 	(iv)	is based on information properly extracted from the Seller’s Group accounting records without adjustment; and 

 

	 	(v)	having regard to the purpose for which they were prepared, the Key Financial Information presents fairly, in all material respects, the gross profit and revenue in
respect of each of the Key Products. 

  

	2.4	Changes Since 31 December 2013 

 Except as a result of the execution and delivery of this Agreement from 31 December 2013 to the date of this Agreement: 
  

	 	2.4.1	the Business has been conducted in all material respects in the ordinary and usual course; 

 

	 	2.4.2	no member of the Seller’s Group has entered into any material contract or commitment outside the ordinary course of business in respect of the Business as
conducted prior to 31 December 2013; and 

  

	 	2.4.3	to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference
in the definition of “Material Adverse Effect” to the date of this Agreement were to 31 December 2013). 

  

	3.	Intellectual Property 

  

	3.1	Part 1 of Schedule 2 sets out a complete and accurate list of each item of Registered Business Product Intellectual Property Rights, including for each such
item, as applicable, (i) the identity of the record owner, (ii) the registration or application number, and (iii) the jurisdiction of issuance or registration. To the Seller’s Knowledge, all Patents forming part of Registered Business Product
Intellectual Property Rights for the Key Products and all Patents forming part of Registered Licensed Product Intellectual Property Rights for the Key Products are subsisting, valid and enforceable and have not lapsed or been abandoned.

  

	3.2	 All documents and instruments necessary to maintain and preserve any extension of patent terms (including any Patent Term Extensions and Patent
Term Adjustments) in relation to (i) Registered Business Product Intellectual Property Rights with respect to the Key Products; and (ii) Registered Licensed Product Intellectual Property Rights with respect to the Key Products where the Seller or
its Affiliates controls prosecution and maintenance; and in each case, where such applications have a reasonable 

  
 170

	 	
prospect of success, have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Entity. For the purposes of this warranty, the Patent Term
Extension application relating to patent number US7378423 shall be deemed to have a reasonable prospect of success. 

  

	3.3	Each of the patents and patent applications included in the Registered Business Product Intellectual Property Rights for the Key Products and, to the
Seller’s Knowledge, in the Registered Licensed Product Intellectual Property Rights for the Key Products, correctly identifies by name each inventor thereof as determined in accordance with the Applicable Law of each jurisdiction in which such
patent issued and/or patent application is pending. 

  

	3.4	All renewal, application and registry fees required for the maintenance, prosecution and enforcement of the Business Product Intellectual Property Rights
relating to the Key Products have been paid. 

  

	3.5	Part 2 of Schedule 2 sets out a complete and accurate list of each material Transferred Intellectual Property Contract (excluding the OBM Intellectual Property
Contracts). No member of the Seller’s Group is in default under any such Transferred Intellectual Property Contract and, to the Seller’s Knowledge, no third party is in default under any such material Transferred Intellectual Property
Contract nor has the Seller nor any of its Affiliates given, or received, written notice to terminate any such Transferred Intellectual Property Contract. 

  

	3.6	The Seller and its Affiliates between them own all Business Product Intellectual Property Rights free of all Encumbrances except Permitted Encumbrances.

  

	3.7	To the Seller’s Knowledge, the manufacture, use, research, development, marketing, distribution, and sale of the Products does not infringe or
misappropriate any Intellectual Property Rights of any third party and neither the Seller nor any of its Affiliates is a party to any Proceeding (public or private) in relation to such infringement or misappropriation under which the same is
alleged. Neither the Seller nor any of its Affiliates has received any written notice of such infringement or misappropriation. 

  

	3.8	To the Seller’s Knowledge, no person (including any employees and former employees of the Seller or its Affiliates) is infringing or misappropriating any
Business Product Intellectual Property Rights, Registered Licensed Product Intellectual Property Rights under the Genmab Agreement, Registered Licensed Product Intellectual Property Rights under the JTI Agreement or Proprietary Information, and
neither Seller nor any of its Affiliates have made any such claims against any such person nor, to the Seller’s Knowledge, is there any basis for such a claim. 

 

	3.9	 The Business Product Intellectual Property Rights, the Shared Product Intellectual Property Rights and the Licensed Product Intellectual
Property Rights constitute all the material Intellectual Property Rights used in the manufacture, use, research, development, marketing, distribution and sale of the Products as currently conducted by the Seller and its Affiliates on a worldwide
basis, provided however that the foregoing is not a representation of non-infringement, non-misappropriation or any 

  
 171

	 	
other non-violation of Intellectual Property Rights of any third party, which representation is solely set out in paragraph 3.7 above. 

 

	3.10	Each of the Seller and its Affiliates has taken reasonable steps to protect the confidentiality of Proprietary Information and Know-How relating to the Products.

  

	3.11	Except to the extent the Seller is prohibited from doing so under Applicable Law, all material information relating to the COMBI-D trial has been disclosed to
the Purchaser and there are no material omissions or inaccuracies in such material. 

  

	3.12	In relation to each Seller’s Intra-Group Licence Agreement being assigned under an Intellectual Property Assignment (if any), each relevant Assignor hereby
represents and warrants that immediately following: 

  

	 	3.12.1	the Delayed Closing Date in respect of the Ukraine Business, all sub-licences of the rights granted by the licensee(s) under any such Seller’s Intra-Group
Licence Agreement in respect of any Transferred Product Intellectual Property Rights that are registered or held exclusively for use in Ukraine (“Ukrainian IP Rights” for the purposes of this paragraph 3.12) shall terminate insofar as they
relate to such Ukrainian IP Rights; and 

  

	 	3.12.2	Closing, all sub-licences of the rights granted by the licensee(s) under any such Seller’s Intra-Group Licence Agreement in respect of any Transferred
Product Intellectual Property Rights other than Ukrainian IP Rights shall terminate insofar as they relate to such Transferred Product Intellectual Property Rights. 

 

	4.	Contracts 

  

	4.1	No Business Seller nor the Company is a party to or subject to any contract, transaction, arrangement, understanding or obligation (other than in relation to any
property, lease, contract of employment, Information Technology or Intellectual Property Right) which is material to the manufacture, use, research, development, marketing, distribution and sale of the Products and which: 

 

	 	4.1.1	is not in the ordinary course of business or is unduly onerous; 

  

	 	4.1.2	is not on an arm’s length basis; 

  

	 	4.1.3	has an unexpired term or likely duration of 5 years or more; 

  

	 	4.1.4	restricts its freedom to carry on its business in any part of the world in such manner as it thinks fit; 

 

	 	4.1.5	involves an aggregate outstanding expenditure by it of more than US$50 million, exclusive of VAT; or 

 

	 	4.1.6	involves the sale of goods and services, the aggregate sales value of which (exclusive of VAT) will be more than 5 per cent of turnover of the Business
(exclusive of VAT) for the preceding financial year. 

  

	4.2	 Save in relation to a Transferred Intellectual Property Contract, no member of the Seller’s Group is in material default under any material
Contract which is relevant to 

  
 172

	 	
the Business and to which it is party, and no third party is in material default under any material Contract which is relevant to the Business to which a member of the Seller’s Group is a
party, and to the Seller’s Knowledge, there are no circumstances in either case likely to give rise to such a default. 

  

	4.3	Other than the Contracts entered into by the Company pursuant to the Pre-Closing Product Reorganisation, Transferred Contracts, Transferred Intellectual Property
Contracts and Shared Business Contracts there are no other Contracts which are material to the Business. 

  

	5.	Agreements with Connected Parties 

  

	5.1	There are no existing contracts or arrangements material to the Business between, on the one hand, any Business Seller or the Company and, on the other hand, the
Seller or any member of the Seller’s Group other than on normal commercial terms in the ordinary course of business. 

  

	6.	Sufficiency of Assets 

  

	6.1	Each of the Assets and the Owned Product Intellectual Property Rights is owned both legally and beneficially by a Business Seller or the Company and each of
those Assets and the Owned Product Intellectual Property Rights capable of possession is, save where in the possession of third parties in the ordinary course of business, in the possession of a Business Seller or the Company.

  

	6.2	Save for Permitted Encumbrances, no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance (excluding licences of
Intellectual Property or Know-How) or equity on, over or affecting the whole or any part of the Assets or the Owned Product Intellectual Property Rights is outstanding and, save in relation to Permitted Encumbrances, there is no agreement or
commitment entered into by any member of the Seller’s Group to give or create any and no claim has been made against any member of the Seller’s Group by any person entitled to any. 

 

	6.3	The Assets and the Owned Product Intellectual Property Rights, when taken together with the rights and services under the Ancillary Agreements and for the
respective terms thereof: 

  

	 	6.3.1	comprise all of the assets required to carry out the Business in substantially the same manner as it has been during the twelve months prior to the date of this
Agreement; and 

  

	 	6.3.2	are sufficient in all material respects to carry out the Business after Closing substantially as conducted by the Seller and its Affiliates as of the date of
this Agreement, 

 provided however, that the foregoing is not a warranty of non-infringement, non-misappropriation
or any other non-violation of Intellectual Property Rights of any third party, which warranty is solely set out in paragraph 3.7. 

  
 173

	7.	Compliance with Laws, Permits and Anti-Bribery 

  

	7.1	Neither the Seller nor any of its Affiliates is in breach of any Applicable Law where such breach is reasonably likely to be material to the Business.

  

	7.2	Neither the Seller nor any of its Affiliates has received any written notice from any Governmental Entity that it is not in compliance (or any warning letter
that it may not be in compliance) with any Applicable Law or is not in possession of any permits, licences, certificates or other authorisations or consents of a Governmental Entity in each case as is necessary for the conduct of the Business in all
material respects as presently conducted (each a “Permit” and, collectively, the “Permits”), except where such non-compliance or non-possession does not remain outstanding or uncured as of Closing or would not
reasonably be expected to have a material effect on the Business. 

  

	7.3	With respect to the Business, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees
and, to the Seller’s Knowledge, no Seller Partner has, directly or indirectly: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or to influence official
action; (ii) made or offered to make any unlawful payment to any foreign or domestic government official or employee, or agent, political party or any official of such party, or political candidate from corporate funds; (iii) made or offered to make
any bribe, rebate, payoff, influence payment, money laundering, kickback or other unlawful payment; or (iv) violated or is in violation of any provision of any applicable Anti-Bribery Law; and with respect to the Business, the Seller and its
relevant Affiliates have instituted and maintain policies and procedures reasonably designed to ensure compliance with applicable Anti-Bribery Law. 

  

	7.4	With respect to the Business, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the
Seller’s Knowledge, no Seller Partner: (i) is currently the subject of, nor has it been since 1 January 2009, the subject of, any action alleging a violation, or possible violation, of any Anti-Bribery Law, or been since 1 January 2009, the
recipient of a subpoena, letter of investigation or other document alleging a violation, or possible violation, of any Anti-Bribery Law, or (ii) has, since 1 January 2009, improperly or inaccurately recorded in any books and records (A) any
payments, cash, contributions, gifts, hospitalities or entertainment to a foreign or domestic government official, employee of an enterprise owned or controlled in whole or in part by any foreign government, official of a foreign or domestic
political party or campaign, or a foreign or domestic candidate for political office; or (B) other expenses related to political activity or lobbying. 

  

	7.5	 With respect to the Business, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors or
officers, and, to the Seller’s Knowledge, none of their respective employees has received notice that any such person is or has been alleged to be in violation of any sanctions administered by the Office of Foreign Assets Control of the U.S.
Department of the Treasury or by the U.S. Department of State or equivalent measures of the United Kingdom, European Union, or the United Nations (the “Sanctions Law”). With respect to the Business, neither the Seller nor any
of its Affiliates, nor any of their respective directors or 

  
 174

	 	
officers, and, to the Seller’s Knowledge, none of their respective employees has conducted any of their business activities whatsoever with, or for the benefit of, a government, national or
legal entity to the extent such actions would violate any Sanctions Law. None of the execution, delivery and performance of this Agreement and the direct or indirect use of proceeds from any transaction contemplated hereby or the fulfilment of the
terms hereof will result in a violation by any person of any Sanctions Law. 

  

	7.6	Each member of the Seller’s Group, in connection with the Products, the Product Approvals, the Transferred Contracts, the Shared Business Contracts and the
Transferred Intellectual Property Contracts requires its Service Providers to act in accordance with the requirements of applicable Anti-Bribery Law and uses all reasonable endeavours to procure that they do so. Each such Service Provider has in
place policies, systems, controls and procedures designed to prevent, and which are reasonably expected to continue to prevent, it and its Associated Persons from violating applicable Anti-Bribery Law. 

 

	8.	Product Approvals 

  

	8.1	The Seller or one of its Affiliates is the registered holder of each of the Product Approvals. All material Product Approvals held by Seller or its Affiliates
are in full force and effect. No material deficiencies have been asserted by any applicable Government Entity with respect to any Product Approval or Product Filing, nor, to the Seller’s knowledge, are there any facts or circumstances that
would be likely to lead to such assertions being made. 

  

	8.2	Each Product was and is being researched, developed, manufactured, marketed or sold in all material respects in accordance with the specifications and standards
contained in the relevant Product Approval and the related Marketing Authorisation Data and in accordance with Applicable Law. 

  

	8.3	Neither the Seller or any of its Affiliates has received any written notice that any Governmental Entity with jurisdiction over the Products has commenced or
will commence any action: (i) to withdraw the approval of any Product or otherwise revoke or materially amend any Product Approval or Marketing Authorisation Data or (ii) enjoin production, marketing or sale of any Product and, to the Seller’s
knowledge, no such action has been threatened. 

  

	8.4	All application and renewal fees due and payable with respect to all material Product Approvals have been paid. 

 

	8.5	All preclinical and clinical investigations with respect to the Products are being and have been conducted in compliance with Applicable Law in all material
respects. The Seller and its Affiliates have not, and to the Seller’s Knowledge, none of its Product Partners or any other third party under any Licensed Intellectual Property Contract has received since 1 January 2009, any written notices or
other correspondence from any Governmental Entity with respect to any on-going clinical or pre-clinical studies or tests of any Product requiring the termination, suspension or material modification of such studies or tests.

  
 175

	8.6	None of the Seller or its Affiliates or, to the Seller’s Knowledge, any Product Partner or any other third parties pursuant to any Licensed Intellectual
Property Contract, has any knowledge of any adverse event, arising since the date three years prior to the date of this Agreement, reportable with respect to the safety or efficacy of any Product which is or would reasonably be expected to be
material. 

  

	9.	Product Recall 

 No
Product (or any component thereof) has been recalled, suspended, withdrawn, seized, discontinued or the subject of a refusal to file, clinical hold, deficiency or similar action letter (including any correspondence questioning data integrity) as a
result of any action by any Governmental Entity, by the Seller or any of its Affiliates; nor are any such actions pending or under consideration (or any facts, conditions, or circumstance known) by the Seller or any of its Affiliates, or, to the
Seller’s Knowledge, by any Governmental Entity. There is not, to the Seller’s Knowledge, pending or threatened litigation anywhere in the world seeking the recall, withdrawal, suspension, seizure or discontinuance of any of the Products.

  

	10.	Product Liability 

 The
Products sold by the Business during the Relevant Period have complied in all material respects with all applicable product specifications and have been Manufactured in all material respects in accordance with applicable requirements of then current
GMP and any Applicable Law, except for any such non-compliance that is not, and would not reasonably be expected to have, a materially adverse impact on the relevant Product. 

 

	11.	Taxes 

  

	11.1	The Company, each Business Seller and (in either case) each Tax Group to which it belongs has, and every member of the Seller’s Group with an interest in
the Business has in respect of the Business, duly, and within any appropriate time limits, filed all Tax Returns required to be filed and has maintained all records required to be maintained for tax purposes in relation to the assets comprised in
the Business; all such information was and remains complete and accurate in all material respects and all such Tax Returns were complete and accurate in all material respects and were made on the proper basis. 

 

	11.2	There are no Tax liens on the Share, any Asset or any Owned Product Intellectual Property Rights comprised in the Business (other than Permitted Encumbrances).

  

	11.3	No member of the Seller’s Group with an interest in the Business (including the Company) has received notice from a Tax Authority of, and so far as the
Seller is aware, there is not any dispute or disagreement outstanding at the date of this Agreement with any Tax Authority regarding the proper method of computing the profits of the Business (or any part of it) or of the Company for Tax purposes or
the proper treatment for VAT purposes of any supplies of goods or services made (or treated as made) in the course of the Business or by the Company and, so far as the Seller is aware, there are no circumstances which make it likely that any such
dispute or disagreement will commence. 

  
 176

	11.4	So far as the Seller is aware, no Tax Authority has within the past three years operated or agreed to operate any special arrangement (being an arrangement which
is not based on relevant legislation or any published practice) in relation to any Assets or Owned Product Intellectual Property Rights comprised in the Business or in relation to the Company or the Share. 

 

	11.5	In respect of all documents which establish or are necessary to establish the title of the relevant member of the Seller’s Group to the Share and to each
material asset comprised in the Business, or by virtue of which the relevant member of the Seller’s Group has any right in respect of each such asset, all applicable stamp duties, transfer taxes, registration charges or similar duties or
charges have been duly paid. 

  

	12.	Employees 

  

	12.1	The Disclosure Letter contains a true, complete and correct list of the following information in respect of each Employee as of 31 March 2014 (organised by
country): (A) employee identification details; (B) date of birth; (C) employment status (part-time or full-time); (D) employment start date; (E) base salary; (F) target annual incentive for 2014 (and actual bonus for 2013); and (G) target long-term
incentive for 2014 (and actual long-term incentive for 2013). 

  

	12.2	In each of the Material Employee Jurisdictions except as would not be reasonably expected to have a Material Adverse Effect: 

 

	 	12.2.1	as of the date of this Agreement there is not, and in the two years prior to the date of this Agreement there has not been, nor to the Seller’s Knowledge is
there pending or threatened, any labour strike, dispute, work stoppage or lockout by any group of Employees; 

  

	 	12.2.2	no trade union or works council is recognised in any way for bargaining, information or consultation purposes in relation to any of the Employees and no
collective bargaining negotiations, whether voluntary or mandatory, are currently taking place with respect to any of the Employees and, as of the date of this Agreement, no Business Seller is a party to any agreement (whether legally binding or
not) with any trade union or works council affecting any Employee and there is no existing dispute with any such representative body (or, to the Seller’s Knowledge, pending or threatened) in relation to the Business; 

 

	 	12.2.3	there is no material litigation, claim or other dispute existing, nor, to the Seller’s Knowledge, pending or threatened by or in respect of any Employees in
respect of their employment or any matter arising from their employment; and 

  

	 	12.2.4	no Business Seller has, within the 2 years prior to the date of this Agreement, closed any plant or facility, effectuated any layoffs of employees or implemented
any early retirement, separation or similar programme in each case in violation of the WARN Act, nor has any Business Seller announced any such action or programme for the future. 

  
 177

	12.3	No Key Personnel has given notice terminating his or her contract of employment, nor is under notice of dismissal. 

 

	12.4	The severance costs disclosed in the Data Room at document 2.2.1.11 represent the Seller’s estimation, calculated in good faith, of the indicative severance
cost for a full-time employee at middle-management level in each of the countries listed therein. 

  

	12.5	Since 31 December 2013, no material change has been made, announced or proposed to the emoluments or other terms of employment of any Employee, and no such
change, and no negotiation or request for such a change, is due or expected within 12 months from the date of this Agreement, and the employing company is under no obligation to make such a change (with or without retrospective operation) other than
any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 10 of Schedule 8. 

  

	12.6	The Company has no employees and has never had any, and nor has it ever entered into any service contract or similar arrangements (whether formal or otherwise)
with any person. 

  

	13.	Employee Benefits 

  

	13.1	The Disclosure Letter contains a true, complete and correct list of all bonus, staff incentives (including any share-based incentive schemes), redundancy or
other benefits payable on termination of employment (whether voluntary or involuntary but excluding arrangements required in accordance with Applicable Law), ill-health, Employee Benefits or other benefits which are the material benefits available
to the Employees in the Material Employee Jurisdictions. To the Seller’s Knowledge, other than any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 10 of Schedule 8, no Business
Seller has made any promises or commitments to make available any additional benefits to the Employees in the Material Employee Jurisdictions, or to modify or change in any material way any existing benefits in the Material Employee Jurisdictions,
or to continue or maintain the level of any existing benefits generally for any period, which in each case could reasonably be expected to have a Material Adverse Effect. 

 

	13.2	The Disclosure Letter contains true and complete copies of all documents of any written benefit schemes, plans or arrangements referred to in paragraph 13.1
above applicable to Employees in the Material Employee Jurisdictions containing material terms (including governing documents, and for benefit plans that are not share-based incentive schemes, related trust agreements or other funding documents) and
a true, complete and correct summary of the material terms of any unwritten benefit schemes, plans or arrangements referred to in paragraph 13.1 above. 

 

	13.3	Benefit Plans 

  

	 	13.3.1	 In the Material Employee Jurisdictions, all benefit and compensation schemes, plans, funds, contracts, policies, agreements or arrangements (other than
the US Benefit Plans and any schemes, plans, funds, contracts, policies, agreements or arrangements operated by any Governmental Entity) (A) operated by or on behalf of a Business Seller, with respect to Employees, (B) in respect of which any
Business Seller, with respect to Employees, the 

  
 178

	 	
Seller or any member of the Seller’s Group contributes or has contributed or (C) in respect of which any Business Seller, with respect to Employees, has any liability (whether actual or
contingent), including, but not limited to, plans providing Employee Benefits or during periods of sickness or disablement, or any deferred or incentive compensation, welfare, healthcare, medical, stock or stock-related award plans, including
individual pension commitments, “jubilee” pension benefits and retirement and termination indemnity arrangements, and in relation to Switzerland, all plans, funds, contracts, policies, agreements or arrangements providing pension or other
benefits on retirement (such schemes, plans, funds, contracts, policies, agreements and arrangements hereinafter being referred to as “Non-US Benefit Plans”) and the US Benefit Plans have been administered in accordance with their
terms and are in compliance with Applicable Law, except for any failures to so administer or be in compliance that, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. All required filings for all
Benefit Plans have been made on time and with the appropriate Governmental Entity, except for any failures to timely file that, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. As of the date of
this Agreement there is no existing, pending or, to the Seller’s Knowledge, threatened material litigation, claim or other dispute relating to Benefit Plans. 

 

	 	13.3.2	The Business Sellers, with respect to Employees in each Material Employee Jurisdiction, (A) are in material compliance with all Applicable Law respecting
employment, employment practices, terms and conditions of employment, occupational health, safety, wages and hours, (B) have withheld all amounts required by Applicable Law, collective bargaining agreements or the Benefit Plans to be withheld from
the wages, salaries or other payments to the Employees, (C) in respect of the Employees, are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any arrears, wages, Taxes, other than payments not yet due, or
any penalty for failure to comply with the foregoing and (D) are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any payment to any trust or other fund or to any Governmental Entity with respect to
unemployment compensation benefits, workers compensation, social security or other benefits for Employees, other than payments not yet due, except, in each case, for any failures to comply, failures to withhold or liabilities that, individually and
in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

  

	 	13.3.3	All material contributions that the Business Sellers, with respect to Employees in a Material Employee Jurisdiction, and Switzerland, are required to make to any
Benefit Plan in respect of the period on or before the date of this Agreement have been fully and timely paid when due. 

  

	13.4	The Company has never established, sponsored, participated in or contributed to any arrangement or agreed to do so for providing pensions or other benefits on,
or in anticipation of, the retirement, death, accident or sickness of any current or former director or employee of any company. 

  
 179

	14.	Litigation 

  

	14.1	No Business Seller nor the Company is involved whether as claimant or defendant or other party in any claim or Proceeding (other than as claimant in the
collection of debts arising in the ordinary course of its business none of which exceeds US$5 million) which is material to the Business or a Key Product. 

  

	14.2	To the Seller’s Knowledge, no such claim or Proceeding of material importance is pending or threatened by or against any Business Seller or the Company.

  

	15.	Insolvency 

  

	15.1	No order has been made and no resolution has been passed for the winding up of any Business Seller, the Share Seller or the Company or for the appointment of any
administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Business Seller, the Share Seller or the Company.

  

	15.2	No petition has been presented or meeting convened for the purpose of considering a resolution or resolution circulated for the winding up of any Business
Seller, the Share Seller or the Company, or for the appointment of any administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of
any Business Seller, the Share Seller or the Company. 

  

	15.3	Each of the Business Sellers, the Share Seller and the Company has not stopped payment or suspended payment of its debts generally, is not insolvent or deemed
unable to pay its debts as they fall due. 

  

	16.	Insurance 

 All material
insurance policies relating to the Business are in full force and effect and, to the Seller’s Knowledge, no notice of cancellation, termination or default has been received with respect to any such insurance policy. All premiums due and payable
on such policies covering periods up to Closing have been paid in full or accrued. 
  

	17.	Consents and Licences 

  

	17.1	All governmental and quasi-governmental licences, consents, permissions, waivers, exceptions and approvals required for carrying on the Business, the absence of
which, individually or in the aggregate, would be material to the Business, are in force and, to the Seller’s Knowledge, no written notice has been received by the Seller or any member of the Seller’s Group which indicates that any such
licence, consent, permission, waiver, exception or approval is likely to be revoked or which may confer a right of revocation. 

  

	18.	Delinquent and Wrongful Acts 

  

	18.1	To the Seller’s Knowledge, no member of the Seller’s Group has, during the Relevant Period, committed any criminal or illegal act which relates to the
Business. 

  
 180

	18.2	No member of the Seller’s Group has, during the Relevant Period, received notification that any investigation or inquiry is being or has been conducted by
any supranational, national or local authority or governmental agency specifically related to the Business, which is material in respect of the Business. 

  

	19.	Compliance 

  

	19.1	No member of the Seller’s Group has received in the Relevant Period any written notification or written claim (in each case, which remains outstanding) that
it has conducted the Business with respect to the research, development, manufacturing, distribution and sale of the Products in a manner which does not in any respect comply with all Applicable Law, or which in any respect is defective or
dangerous, where the pursuit of any such notification or claim is, or would reasonably be expected to be, material in respect of the Business or any of the Key Products. 

 

	19.2	So far as the Seller is aware, the Business has, and has during the Relevant Period been, operated in all material respects in compliance with all Applicable Law
or standards and to the Seller’s Knowledge there are no circumstances that could involve or lead to a material violation of any material Applicable Laws or standards. 

 

	20.	Pipeline Products 

  

	20.1	The information set out in Schedule 1 with respect to the Product Expansions is true and accurate. 

 

	20.2	The Seller or one of its Affiliates is the registered holder of each of the Product Expansion Applications, and each Product Expansion Application can be
transferred to the Purchaser (or another member of the Purchaser’s Group) regardless as to whether such transfer occurs directly (whether by way of transfer, reissuance or any other equivalent mechanism under Applicable Law of the relevant
jurisdiction) or indirectly (through the transfer to a member of the Purchaser Group). 

  

	20.3	All development activities in relation to the Product Expansions have been conducted in the ordinary course and in accordance with Applicable Law and standards
and to the Seller’s Knowledge there are no circumstances relating to the development of the Product Expansions that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	20.4	No material regulatory, clinical or safety event has occurred in relation to the Products and no member of the Seller’s Group has received any notification
or claim from any person of any such event (or the possibility of any such event). 

  

	21.	Manufacturing Licences and Manufacture 

  

	21.1	All Manufacturing Licences which are material to the manufacture of the Products, are in effect and are validly held by a member of the Seller’s Group and
during the Relevant Period, to the Seller’s Knowledge, no member of the Seller’s Group has received any written notice of any suit, action or proceeding regarding the revocation or modification of any such Manufacturing Licence.

  
 181

	21.2	No directive, order or notice has been given to the Seller or any member of the Seller’s Group by any relevant regulatory authority to update, modify,
amend, vary, supplement or delete any process and/or methodology relevant to the manufacture of any Product and, so far as the Seller is aware, no such directive, order or notice is pending. 

 

	22.	The Company 

  

	22.1	The Company does not have outstanding any borrowing or indebtedness with any person who is not a member of the Seller’s Group. 

 

	22.2	The Company does not have any derivative, hedging or swap arrangements or contracts or anything similar in nature to such documentation.

  
 182

 Schedule 15 
 Warranties given by the Purchaser under Clause 9.3 
  

	1.	Authority and Capacity 

  

	1.1	Incorporation 

 The
Purchaser is validly existing and is a company duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Purchaser has the legal right and full power and authority to enter into and perform this Agreement and any other documents to be executed by it pursuant to
or in connection with this Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Purchaser in accordance with their
respective terms. 

  

	 	1.2.3	Except as referred to in this Agreement, the Purchaser: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 

 

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Purchaser and each member of its Group of their
respective obligations under them, will not: 

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the
Purchaser’s Group; 

  

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Purchaser’s Group is party or by which the
relevant member of the Purchaser’s Group is bound where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Purchaser’s Group is bound and
where such breach is material to their ability to perform their obligations under such documents. 

  

	1.3	Authorisation 

 The
Purchaser has taken, or will have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant
to or in connection with this Agreement or any Ancillary Agreement. 

  
 183

 Schedule 16 
 Certificate 
 (Clause 4.4) 

To: Novartis AG 
 [Date] 

Certificate 
 This Certificate is issued in
accordance with Clause 4.4.1(iii)(b) and paragraph 1.1.3 of Schedule 12 of the sale and purchase agreement between Novartis AG and GlaxoSmithKline plc dated 22 April 2014 (as amended) (the “Agreement”). Unless otherwise
defined, capitalised words used in this Certificate shall have the meanings given to them in the Agreement. 
 We confirm that: 

 

	1.	no Material Adverse Effect has occurred between the date of the Agreement and the date of this Certificate; 

 

	2.	having made due and careful enquiry, we are not aware of any breach or breaches of Clause 9.1 which alone or together give rise to a Material Adverse
Effect; and 

 [either] 
  

	3.	having made due and careful enquiry, we are not aware of any breach or breaches of the Seller’s Warranties that would have occurred and that would, alone or
together, have given rise to a Material Adverse Effect had the Seller’s Warranties been repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to
the date of this Agreement were references to the Closing Date. 

 [or] 

 

	3.	having made due and careful enquiry, we are aware of the following material breaches of the Seller’s Warranties that would, alone or together, be material and have
occurred had the Seller’s Warranties been repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement were references to
the Closing Date. 

  

	
	[description of material breaches.]
	
	  

	For and on behalf of GlaxoSmithKline plc

  
 184

 Schedule 17 
 Key Study Plans 
 [***] 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 185

 Schedule 18 
 Pre-Closing Product Reorganisation 
 Part 1 Description of the Pre-Closing Product
Reorganisation 
  

	1.	For the purposes of this Schedule: 

 “Category 1A Assets” means: 
  

	 	(i)	all the Transferred Product Intellectual Property Rights which are owned directly by GIPL and relate to Votrient (including the right to call for full legal title to
such Transferred Product Intellectual Property Rights for no consideration), other than legal title to such Transferred Intellectual Property Rights; and 

  

	 	(ii)	for so long as the Votrient LLC Licence remains in force, the licensed interest in all Transferred Product Intellectual Property Rights licensed under the Votrient LLC
Licence, 

 and which for the avoidance of doubt shall not include any Transferred Intellectual Property Contracts
but shall, for the purposes of steps 9 to 12, include any Category 2 Assets which have merged by operation of law with those Transferred Product Intellectual Property Rights following Step 6; 

“Category 1B Assets” means: 
  

	 	(i)	all the Transferred Product Intellectual Property Rights which are owned directly by SB Cork and relate to Tykerb (including the right to call for full legal title to
such Transferred Product Intellectual Property Rights for no consideration), other than legal title to such Transferred Product Intellectual Property Rights; and 

 

	 	(ii)	for so long as the Tykerb LLC Licence remains in force, the licensed interest in all the Transferred Product Intellectual Property Rights licensed under the Tykerb LLC
Licence, 

 and which for the avoidance of doubt shall not include any Transferred Intellectual Property Contracts
but shall, for the purposes of steps 9 to 12, include any Category 2 Assets which have merged by operation of law with those Transferred Product Intellectual Property Rights following Step 6; 

“Category 2 Assets” means full legal and beneficial economic ownership of all the Transferred Product Intellectual
Property Rights, other than the Category 1A Assets and Category 1B Assets, that relate to Votrient or Tykerb and are owned by GSK LLC, SB Cork, GIPL, GlaxoSmithKline Inc, GlaxoSmithKline K.K, SmithKline Beecham Limited, GlaxoSmithKline GMBH &
CO. KG, GlaxoSmithKline BRASIL LIMITADA, GlaxoSmithKline Korea Limited, GlaxoSmithKline EOOD, GlaxoSmithKline D.O.O., GlaxoSmithKline OY, Groupe GlaxoSmithKline S.A.S., GlaxoSmithKline Medical And Healthcare Products Limited, GlaxoSmithKline S.P.A.,
GlaxoSmithKline Slovakia S.R.O., GlaxoSmithKline Holding AS or GGL and which for the avoidance of doubt shall not include any Transferred Intellectual Property Contracts; 

  
 186

 “Company” means Leo Osprey Limited, a company incorporated in England and
Wales on 16 April 2014 under company number 9000270, whose registered office is 980 Great West Road, Brentford, TW8 9GS, United Kingdom, which has an issued share capital of one share of £1 and whose sole shareholder is Glaxo Group Limited;

 “Company Intra-Group Debt” means all sums owed by the Company to GlaxoSmithKline Finance plc at the Closing
Date (immediately prior to Closing) as shall be notified by the Seller to the Purchaser in accordance with Clause 6.3.2; 

“Company Tax Indemnity” means the deed of tax covenant relating to the Company, in the Agreed Terms; 

“Direct Indemnity” means the deed of covenant directly in favour of the Company in the form of Clause 2.3.6 of this
Agreement and of the Company Tax Indemnity, mutatis mutandis, in the Agreed Terms; 
 “GFplc” means
GlaxoSmithKline Finance plc; 
 “GGL” means Glaxo Group Limited; 

“GIPL” means GlaxoSmithKline Intellectual Property Limited; 

“GIPL B Share” means one share in GIPL carrying a right to a preferential special dividend by GIPL of the
Category 1A Assets, whereupon the GIPL B Share shall convert into a deferred share having no voting rights and economic rights typical of deferred shares created in a B share scheme implemented by an English public limited company; 

“GIPL Estimated Value” means £2,934,000,000; 

“GSKHIL” means GlaxoSmithKline Holdings (Ireland) Limited; 

“GSKHIL B Share” means one share in GSKHIL carrying a right to a preferential dividend by GSKHIL of the Category 1B
Assets, whereupon the GSKHIL B Share shall convert into a deferred share having no voting rights and economic rights typical of deferred shares created in a B share scheme implemented by an English public limited company; 

“GSKHIL Estimated Value” means £147,000,000; 

“GSK LLC” means GlaxoSmithKline LLC; 
 “Purchaser Tax Indemnity” means the deed of tax covenant relating to the Purchaser’s Group, in the Agreed Terms; 

“SB Cork” means SmithKline Beecham (Cork) Limited; 

“Setfirst” means Setfirst Limited; 
 “Share” means the entire issued share capital of the Company; 

“Tykerb LLC Licence” means the licence agreement dated 1 January 2004 between GSK LLC and SB Cork relating to Tykerb (as
amended from time to time); and 

  
 187

 “Votrient LLC Licence” means the licence agreement dated 1 July 2008
between GSK LLC and GIPL relating to Votrient (as amended from time to time). 
  

	2.	Subject to paragraphs 3 and 4 below, and to Part 4 of this Schedule, the Pre-Closing Product Reorganisation shall consist of all of the following steps.

  

	2.1	The Seller shall procure that the following steps are taken in the order set out below. 

Preliminary step(s) 
  

	 	(A)	Any steps necessary to procure that GGL has full legal and beneficial ownership of the Share. 

Step 1 
  

	 	(B)	The Company shall receive funding sufficient to carry out Step 3 and Step 3A in the form of (i) an intra-group interest-bearing loan from GFplc on terms standard within
the Seller’s Group, and (ii) a subscription for ordinary shares by GGL. 

  

	 	(C)	GFplc shall provide the Company with an interest-bearing on demand loan facility (which shall terminate at Closing) on terms standard within the Seller’s Group,
under which the Company can draw down any further funds it requires to pay any purchase price adjustment on the GIPL B Share or the GSKHIL B Share, as required under paragraph (F)(ii) or (I)(ii) below. 

The loans referred to in paragraphs (B)(i) and (C) shall take the form of a single facility. 

Step 2 
  

	 	(D)	GIPL shall reclassify one ordinary share in its capital, held by GGL, as the GIPL B Share. 

Step 3 
  

	 	(E)	Promptly after completion of Step 2, the Company shall purchase the GIPL B Share from GGL for consideration reflecting the percentage allocated to Votrient in
accordance with Schedule 10 less the fair market value of (i) all the royalty rights in respect of Votrient which are held by members of the Seller’s Group other than the Company and (ii) any Transferred Intellectual Property Contracts to the
extent relating to Votrient, as at Closing (the “GIPL Agreed Value”). 

  

	 	(F)	The sale terms in respect of the sale and purchase of the GIPL B Share shall provide that: 

 

	 	(i)	the GIPL B Share shall be transferred to the Company for the GIPL Estimated Value; and 

 

	 	(ii)	 as soon as reasonably practicable after the GIPL Agreed Value has been agreed or determined pursuant to Schedule 10, the Company or GGL shall pay the
other an amount equal to the difference 

  
 188

	 	
between the GIPL Agreed Value and the GIPL Estimated Value, as appropriate, to ensure that the total amount paid for the GIPL B Share is equal to the GIPL Agreed Value. 

 

	 	(G)	The Seller shall procure that, at the Seller’s cost (such that, if any such costs are paid by the Purchaser, the Seller shall reimburse the Purchaser for the
amount of such costs): (i) all steps are taken which are necessary to pay any stamp duty and/or stamp duty reserve tax in respect of the sale of the GIPL B Share under this Step 3, and (ii) the GIPL B Share is registered in the name of the Company.

 The Company shall subsequently (but before Step 4) enter into arrangements with another member of the
Seller’s Group for the exploitation and management of any intellectual property that it may come to hold (the “Exploitation Arrangements”). The material terms of the Exploitation Arrangements will be provided to the Purchaser
in advance in the form of summaries. 
 Step 3A 

 

	 	(H)	Promptly after completion of Step 2, the Company shall purchase the GSKHIL B Share from Setfirst for consideration reflecting the percentage allocated to Tykerb in
accordance with Schedule 10 less the fair market value of (i) all the royalty rights in respect of Tykerb which are held by members of the Seller’s Group other than the Company and (ii) any Transferred Intellectual Property Contracts to the
extent relating to Tykerb, as at Closing (the “GSKHIL Agreed Value”). At the time at which the Company acquires the GSKHIL B Share, a wholly-owned subsidiary of GSKHIL will hold all of the Category 1B Assets. Full beneficial and
economic ownership of the Category 1B Assets will be transferred to GSKHIL by its wholly-owned subsidiary by way of dividend. 

  

	 	(I)	The sale terms in respect of the sale and purchase of the GSKHIL B Share shall provide that: 

 

	 	(iii)	the GSKHIL B Share shall be transferred to the Company for the GSKHIL Estimated Value; and 

 

	 	(iv)	as soon as reasonably practicable after the GSKHIL Agreed Value has been agreed or determined pursuant to Schedule 10, the Company or GSKHIL shall pay the other an
amount equal to the difference between the GSKHIL Agreed Value and the GSKHIL Estimated Value, as appropriate, to ensure that the total amount paid for the GSKHIL B Share is equal to the GSKHIL Agreed Value. 

 

	 	(J)	The Seller shall procure that, at the Seller’s cost (such that, if any such costs are paid by the Purchaser, the Seller shall reimburse the Purchaser for the
amount of such costs): (i) all steps are taken which are necessary to pay any stamp duty and/or stamp duty reserve tax in respect of the sale of the GSKHIL B Share under this Step 3, and (ii) the GSKHIL B Share is registered in the name of the
Company. 

  
 189

 Step 4 

 

	 	(K)	After completion of Step 3, GIPL shall declare a special dividend of the Category 1A Assets on the GIPL B Share and full beneficial and economic ownership of the
Category 1A Assets shall be assigned to the Company (the “GIPL Distribution”). GIPL shall not carry out a capital reduction in connection with such special dividend. The assignment of the Category 1A Assets will become effective at
exactly the same time as the assignment of the Category 1B Assets under Step 4A. 

 Step 4A

  

	 	(L)	On 29 August 2014, GSKHIL shall become resident solely in the UK for UK Tax purposes and shall thereafter remain solely resident in the UK for UK Tax purposes until at
least Closing. 

  

	 	(M)	After having become resident in the UK for Tax purposes in accordance with paragraph (L) above, GSKHIL shall: 

 

	 	(i)	carry out a reduction of capital in order to create distributable reserves; and 

 

	 	(ii)	declare a special dividend of the Category 1B Assets on the GSKHIL B Share, to be paid solely out of profits available for distribution at the time the dividend is paid
that arose on or after the Company’s acquisition of the GSKHIL B Share, 

 and full beneficial and economic
ownership of the Category 1B Assets shall be assigned to the Company (the “GSKHIL Distribution”). The assignment of the Category 1B Assets will become effective at exactly the same time as the assignment of the Category 1A Assets
under Step 4. 
  

	2.2	After Step 4 and Step 4A and on or before the Business Day before Closing, the Seller shall procure that the following steps are taken. 

Step 5 
  

	 	(A)	The Company shall sell the GIPL B Share for a nominal amount to a company that is UK resident for UK Tax purposes and is in the same group (within the meaning of
section 170 of the Taxation of Chargeable Gains Act 1992) as the Company. 

  

	 	(B)	The Company shall exercise its rights under the Transferred Product Intellectual Property Rights falling with limb (i) of the definition of “Category 1A
Assets” to procure that registered legal title to the Category 1A Assets is transferred to the Company for no consideration. If all Third Party Consents relevant to any particular Category 1A Asset are not obtained, that Category 1A
Asset shall be treated in accordance with paragraph 2.5 below. 

 Step 5A 

 

	 	(C)	 The Company shall sell the GSKHIL B Share for a nominal amount to a company that is UK resident for UK Tax purposes and is in the same group

  
 190

	 	
(within the meaning of section 170 of the Taxation of Chargeable Gains Act 1992) as the Company. 

  

	 	(D)	The Company shall exercise its rights under the Transferred Product Intellectual Property Rights falling with limb (i) of the definition of “Category 1B
Assets” to procure that registered legal title to the Category 1B Assets is transferred to the Company for no consideration. If all Third Party Consents relevant to any particular Category 1B Asset are not obtained, that Category 1B Asset shall
be treated in accordance with paragraph 2.5 below. 

  

	2.3	After completion of Step 5 and Step 5A and before the Closing Date the Seller shall procure the following actions are taken: 

Step 6A 
  

	 	(A)	The Company shall transfer full beneficial and economic ownership of the Category 1A Assets and the Category 1B Assets, insofar as each of them relate to Ukraine, to
GGL. 

  

	2.4	After completion of Step 6A and on or before 00:01 (GMT) on the Closing Date the Seller shall procure the following actions are taken. 

Step 6B 
  

	 	(A)	The Company shall acquire the Category 2 Assets, except insofar as such Category 2 Assets relate to the Ukraine, from the relevant members of the Seller’s Group,
either: (i) for consideration in cash reflecting, in respect of each Category 2 Asset, the percentage allocated to the Product to which that Category 2 Asset is attributable in accordance with Schedule 10 less that part attributable to that Product
other than that Category 2 Asset; or (ii) to the extent that particular Category 2 Asset represents bare legal title and carries no rights to royalties, for no consideration. If all Third Party Consents relevant to any particular Category 2 Asset
are not obtained, that Category 2 Asset shall be treated in accordance with paragraph 2.5 below. 

  

	 	(B)	In order to acquire the Category 2 Assets, the Company shall be funded in the form of (i) an intra-group interest-bearing loan from GFplc on terms standard within the
Seller’s Group, (ii) an ordinary share subscription from GGL, or (iii) a combination of both. 

  

	 	(C)	GSK LLC shall transfer its rights in the Category 2 Assets, insofar as they relate to Ukraine, to GGL. 

 

	2.5	If a Third Party Consent has not been obtained in respect of any Category 1A Asset, Category 1B Asset or Category 2 Asset before the date on which Step 5 takes
effect: 

  

	 	(A)	the legal title in the relevant Category 1A Asset, Category 1B Asset or Category 2 Asset affected by the Third Party Consent shall not be transferred to the Company
pursuant to Step 5, Step 5A or Step 6; and 

  
 191

	 	(B)	the relevant Category 1A Asset, Category 1B Asset or Category 2 Asset affected by the Third Party Consent will be dealt with in accordance with paragraphs 4 to 6 of
Schedule 7. 

  

	2.6	After completion of Step 6, the Votrient LLC Licence and the Tykerb LLC Licence shall terminate in so far as such licences relate to Business Product
Intellectual Property Rights owned by or transferred to the Company. In the event that such termination does not terminate the Tykerb LLC Licence and the Votrient LLC Licence entirely, the licensee interest in the Votrient LLC Licence and the
licensee interest in the Tykerb LLC Licence shall then be assigned by the Company to another member of the Seller’s Group. 

 Step 7 
  

	 	(A)	The Company shall: 

  

	 	(i)	pay to GFplc an amount equal to the sum of any after-Tax profits generated in respect of the Category 1A Assets since the GIPL Distribution and any after-Tax profits
generated in respect of the Category 1B Assets since the GSKHIL Distribution to partly discharge the debt owed by the Company to GFplc; and 

  

	 	(ii)	sell to another member of the Seller’s Group any rights to receive future adjustment payments under the Exploitation Arrangements in respect of the use of its
assets prior to Closing, in consideration of the payment of £1 and the assumption of any obligations to make payments in respect of the use of such assets prior to Closing. 

 

	2.7	On: 

  

	 	(A)	the day before Closing, the Seller shall procure that the then current accounting period of the Company is terminated on that day; and 

 

	 	(B)	the Closing Date but prior to Closing, the Company Intra-Group Debt shall be refinanced into interest-free debts denominated in US dollars in accordance with Clause
6.3.2. 

 Step 8(a) 
  

	2.8	On Closing: 

  

	 	(A)	the Seller shall procure that GGL will sell; and 

  

	 	(B)	the Purchaser shall purchase, or shall procure that a member of the Purchaser Group, will purchase, 

the Share in accordance with the terms of this Agreement (and whichever member of the Purchaser’s Group acquires the Share shall be
the “Novartis Purchaser” for the purposes of this Schedule). 
  

	2.9	On Closing, the Purchaser shall procure that the Company will discharge the Company Intra-Group Debt. 

  
 192

 Step 8(b) 

 

	2.10	For the purpose of discharging the Company Intra-Group Debt in paragraph 2.9, the Company shall receive funding in the form of: (i) a loan from a member of the
Purchaser’s Group; (ii) a subscription for ordinary shares in the Company by the Novartis Purchaser; or (iii) a combination of both. Subject to those constraints, the Purchaser shall be free to decide the form in which this funding is provided
to the Company at Closing. 

 Step 9 
  

	2.11	Within four weeks after Closing, the relevant member of the Purchaser’s Group shall waive or convert into ordinary shares in the Company any loan provided
to the Company under paragraph 2.10, which step may be preceded by a transfer of such loan within the Purchaser’s Group. The loan may be converted into ordinary shares (rather than being waived) only if the Novartis Purchaser is the
creditor under the loan at the time of such conversion. 

 Step 10 

 

	2.12	By the later of (a) four weeks after Closing and (b) two weeks after the Seller provides any material which it is required to provide under paragraph 3, the
Company shall effect a reduction of share capital using the method prescribed in sections 642-644 of the Companies Act 2006 (reduction of share capital supported by solvency statement) to create an amount of additional distributable reserves at
least sufficient for it to distribute the Category 1A Assets and the Category 1B Assets. Prior to Closing, the Seller shall enter into the Direct Indemnity. 

 Step 11 
  

	2.13	By the later of (a) four weeks after Closing and (b) two weeks after the Seller provides any material which it is required to provide under paragraph 3, the
Company shall declare a distribution in specie of the Category 1A Assets and the Category 1B Assets and accordingly transfer the Category 1A Assets and the Category 1B Assets to the Novartis Purchaser. 

Step 12 
  

	2.14	By the later of (a) six weeks after Closing and (b) four weeks after the Seller provides any material which it is required to provide under paragraph 3, and to
the extent only that the Category 2 Assets continue to have an existence separate to that of the Category 1A Assets and the Category 1B Assets following Step 6, the Company shall either: 

 

	 	(A)	sell the Category 2 Assets to the Novartis Purchaser for consideration in cash or one or more debt instruments reflecting, in respect of each Category 2 Asset, the
percentage allocated to that Category 2 Asset in accordance with Schedule 10; or 

  

	 	(B)	declare a distribution in specie of the Category 2 Assets and transfer the Category 2 Assets to the Novartis Purchaser. 

  
 193

 Step 13 
 At the Delayed Closing Date in respect of the Ukraine Business, GGL shall transfer its rights in the Category 1A Assets and the Category 1B Assets, insofar as they relate to Ukraine, to Novartis Pharma AG
or its designee for nominal consideration. 
  

	3.	The parties shall co-operate in good faith, and the Seller shall provide any assistance reasonably requested by the Purchaser, in connection with the
implementation of any of Steps 9 to 12. In particular, the parties shall consult before Closing on whether any interim accounts or other material are required to support the reduction of capital at Step 10 and/or the distribution in specie at
Step 11. If the Purchaser considers (acting reasonably and in good faith) that any such material is required, and notifies the Seller of this, then the Seller shall, at its own cost, procure the preparation of this material, with the input and
cooperation of the Purchaser, by the later of (a) thirty Business Days after receipt of such notice and (b) ten Business Days before Closing. 

  

	4.	The Seller may notify the Purchaser in writing, at any time up to five Business Days before Closing, that the Seller no longer wishes to proceed with the
Pre-Closing Product Reorganisation set out in this Schedule. If the Seller notifies the Purchaser to this effect, then: 

  

	 	(A)	the Seller shall not be entitled to sell the Share to the Purchaser at Closing; and 

 

	 	(B)	the Seller shall reimburse the whole of any reasonable out of pocket costs and expenses incurred by the Purchaser and/or any other member of the Purchaser’s Group
in connection with their assessment of the Pre-Closing Product Reorganisation or with any preparation undertaken for Steps 8 to 12 (to the extent that those costs and expenses would not have been incurred had the sale and purchase of the Category 1A
Assets, the Category 1B Assets and the Category 2 Assets always been structured as a direct sale of those assets from a member of the Seller’s Group to a member of the Purchaser’s Group). 

 

	5.	The Seller acknowledges that any decision to proceed with Steps 9 to 12 shall be a matter for the Purchaser and for the then directors of the Company, and that
neither the Purchaser nor the Company shall be under any obligation to implement all or any of those steps. 

 Part 2 Seller
undertakings 
  

	1.	The Seller undertakes to procure that, between the date of this Agreement and Closing: 

 

	 	(A)	the Company will not acquire any assets which are not the Category 1A Assets, Category 1B Assets, Category 2 Assets or assets arising under or pursuant to the
Exploitation Arrangements; 

  

	 	(B)	the Company will not carry on any business or other activities, other than the acquisition, management and exploitation of the Category 1A Assets, the Category 1B
Assets and Category 2 Assets; 

  
 194

	 	(C)	the Company will not have any employees; 

  

	 	(D)	any agreements which the Company enters into in connection with the management and exploitation of the Category 1A Assets, the Category 1B Assets and Category 2 Assets
shall be terminated, with immediate effect, by the Company immediately before Closing; and 

  

	 	(E)	the Company will not be a member of any VAT group, party to any group payment arrangement or otherwise party to any Tax allocation, contribution, indemnification or
sharing arrangement, Tax consolidation or fiscal unity, 

 except as may be required in connection with the
provisions listed in Part 1 of this Schedule or as agreed by the parties. 
  

	2.	The Seller undertakes that the Company will have no Third Party Indebtedness at Closing, except as agreed by the parties. 

 

	3.	The Seller shall procure that on Closing the Company will have no debts (other than the Company Intra-Group Debt). 

 

	4.	For the avoidance of doubt, the Seller acknowledges that the indemnity in Clause 2.3.6 of this Agreement shall apply to the Pre-Closing Product
Reorganisation set out in this Schedule. 

  

	5.	The Seller shall procure that, at Closing, the Company will have a Permitted Cash Receivable equal to the amount for which the Seller would be liable under
clause 2 of the Company Tax Indemnity in the absence of clause 3.1(A) of the Company Tax Indemnity. 

 Part 3 Co-operation
between the parties; modifications 
  

	1.	At any time, the parties shall, on the request of the Seller and at the Seller’s expense, cooperate in good faith to identify and, subject to
paragraph 4 below, to implement any reasonable steps which can be taken to mitigate or remove any risk in relation to Swiss Tax which will result in a liability or potential liability for the Seller under clause 2 of the Purchaser Tax
Indemnity. For the avoidance of doubt, a step shall not be considered “reasonable” for the purposes of this Part 3 of this Schedule if it may have the effect on increasing an unindemnified Liability of the Purchaser’s Group.

  

	2.	Subject to paragraph 4 below, such reasonable steps may include: 

 

	 	(A)	the Purchaser seeking a ruling from the Swiss Tax authorities, with both parties having input into the drafting of any ruling application and subsequent correspondence,
and with the Seller being consulted in good faith on the approach which should be taken at any discussion, meetings or negotiations with the Swiss Tax authorities to discuss the ruling application, so far as permitted under Swiss law and being
informed within a reasonable time thereafter of the outcome of any such discussion, meeting or negotiation (but without giving the Seller any rights to attend); and 

 

	 	(B)	 amending the steps set out in Part 1 of this Schedule (at the Seller’s sole expense and risk) if, pursuant to their good faith cooperation under

  
 195

	 	
paragraph 1 of this Part 3, the parties identify any alternative or additional reasonable steps for implementing the Pre-Closing Product Reorganisation set out in this Schedule in a way
which reduces or removes any risk indemnified under the Purchaser Tax Indemnity. 

  

	3.	The parties shall co-operate in good faith in relation to the Company’s affairs with a view to minimising the Company’s balance sheet assets and
liabilities, and winding the Company up as soon as commercially practicable, in each case following completion of Step 8 and, if undertaken, Steps 9 to 12 and any agreed modifications to any of those Steps. 

 

	4.	Any modification or amendment of (including any addition to) the steps set out in Part 1 of this Schedule (other than the Seller electing at any time not to
proceed with the Pre-Closing Product Reorganisation) shall require the prior written consent of the Purchaser, not to be unreasonably withheld or delayed. Without prejudice to any other exercise of a discretion whether or not to give consent,
the Purchaser shall not be acting unreasonably if: 

  

	 	(A)	it withholds or delays its consent because it believes in good faith that the modification or amendment would result in exposure of any member of the Purchaser’s
Group to cost, loss of benefit or Liability; and 

  

	 	(B)	the relevant member or members of the Purchaser’s Group would not be indemnified (and the Seller does not agree to indemnify them), in each case to the
Purchaser’s reasonable satisfaction, in respect of that cost, loss of benefit or Liability. 

  

	5.	The parties agree that the Company’s accounts shall record both (i) the redenomination of the Company Intra-Group Debt pursuant to Clause 6.3.2, and (ii)
the discharge of the Company Intra-Group Debt on Closing at Step 8(a), using the US$ Spot Rate (as defined in Clause 1.13) as the appropriate spot exchange rate. 

 

	6.	Nothing done by or at the request of the Seller pursuant to this Part 3 of this Schedule shall in any respect reduce or restrict any rights the Purchaser may
have to make a claim against the Seller under the Company Tax Indemnity or the Purchaser Tax Indemnity. 

 Part 4 Definitions

  

	1.	In this Schedule, the following expressions shall have the following meanings: 

“Indebtedness” means all loans and other financing liabilities and obligations in the nature of borrowed moneys and
overdrafts and moneys borrowed, but excluding trade debt and liabilities arising in the ordinary course of business; 

“Third Party Indebtedness” means any Indebtedness owed by the Company to any third party and, for the purposes of this
definition, third party shall exclude any member of the Seller’s Group; 

  
 196

 Part 5 Details of the Company 

 

			
	 Name of Company:
	  	Leo Osprey Limited (the “Company”)
		
	 Registered Number:
	  	9000270
		
	 Registered Office:
	  	980 Great West Road,
		
		  	Brentford, TW8 9GS
		
		  	United Kingdom
		
	 Date and place of incorporation:
	  	16 April 2014, United Kingdom
		
	 Issued share capital:
	  	one share of £1
		
	 Shareholders and shares held:
	  	Glaxo Group Limited            1 (100%)

  
 197

 Schedule 19 
 Pre-Closing Obligations 
 (Clause 5) 

Part 1 Seller’s Group Restrictions 

The actions for the purposes of Clause 5.1.2 are: 
  

	1.1	(a) terminate, materially amend (or amend in any respect in relation to a Key Product) or grant any material waiver under (or any waiver in relation to a Key
Product) any Transferred Intellectual Property Contract, or (b) terminate any Transferred Contract other than in the ordinary course of business; 

  

	1.2	fail to comply in all material respects with all Applicable Law, Product Approvals and Marketing Authorisations applicable to the operation of the Business;

  

	1.3	assign, dispose of, license (save in respect of non-exclusive licences relating to the Seller’s research, development or Commercialisation of the Products
or in respect of any transfers to Glaxo Group Limited as a preliminary step before their sale by Glaxo Group Limited to the Purchaser pursuant to this Agreement) or abandon any material Business Product Intellectual Property Rights (or any Business
Product Intellectual Property Rights in respect of a Key Product) or cease to prosecute or fail to maintain, defend, or pursue applications for any material Business Product Intellectual Property Rights (or any Business Product Intellectual Property
Rights in respect of a Key Product). Notwithstanding the foregoing, the parties agree that the restrictions set out in this paragraph 1.3 will not apply in respect of the Abandoned Patents abandoned prior to 22 April 2014;

  

	1.4	save where requested in writing by the Purchaser or required by any applicable Governmental Entity, cancel, surrender or materially amend (or amend in any
respect in relation to a Key Product) any applications, submissions or filings with respect to Registered Business Product Intellectual Property Rights; 

  

	1.5	take any further steps to abandon US patent with publication number 2012/0202822; 

 

	1.6	terminate (except for good cause) the employment of any Key Personnel; 

 

	1.7	take any steps to increase or reduce the proportion of time spent working in the Business by any employee of any member of the Seller’s Group or to transfer
the employment of any Employee to another member of the Seller’s Group or to employ or offer to employ or engage any new persons in the Business other than in the ordinary course of business consistent with past practice and subject to an
aggregate increase of not more than 2.5 per cent. in total staff costs of the Business per annum; 

  

	1.8	 make, or commit to make, any changes to the terms and conditions of employment (including pension fund commitments or any increase to
remuneration) or to any employee benefit plan of any Employee, other than (a) those required by Applicable Law or (b) pursuant to normal annual pay reviews in the ordinary course of business consistent with past practice and subject to an aggregate
increase of not more than 5 per cent. in total staff costs of the Business per annum or (c) retention arrangements (in the form of cash or shares) to retain key employees in connection with the matters

  
 198

	 	
contemplated by this Agreement as described in paragraphs 9 and 10 of Schedule 8 or (d) those changes to share-based incentive schemes made for the purpose of complying with
paragraph 10 of Schedule 8; 

  

	1.9	make any promises or commitment to any Employees or employee representative body concerning the matters contemplated by this Agreement or offer or otherwise give
any assurances to any Employees as to the possibility of continued employment with the Purchaser’s Group after Closing; 

  

	1.10	make any change or commitment to make any change to the terms of any redundancy policy or practice applying to the Employees (including amounts payable on
redundancy); 

  

	1.11	enter into (where there is no existing agreement) or materially amend any collective bargaining agreement or other contract with a labour organisation, works
council or employee organisation to create new or additional obligations for any member of the Seller’s Group, in each case in relation to the Business; 

 

	1.12	instigate, cease, compromise or settle any litigation or arbitration proceedings related to the Business or the Company in relation to a claim for which the
potential liability attaching thereto is in excess of US$5 million; 

  

	1.13	make any material amendment to any Marketing Authorisation, except to the extent required by: (a) Applicable Law; (b) any Governmental Entity, or (c) the
standards, policies and procedures of the Seller’s Group as then in force; 

  

	1.14	enter into or amend in any material respect any Transferred Contract, or incur any commitment, which is not capable of being terminated without compensation at
any time with twelve months’ notice or less or which is not in the ordinary course of business, or which involves or may involve total annual expenditure in excess of US$10 million, exclusive of VAT; 

 

	1.15	enter into any contract which would materially restrict the freedom of the Business to operate in any part of the world; 

 

	1.16	save in respect of Intellectual Property Rights, sell, lease, license, transfer or dispose of, or create any Encumbrance (other than a Permitted Encumbrance)
over, any material assets (other than any Excluded Asset) of the Business; 

  

	1.17	undertake any recall or withdrawal of any Product (other than in the ordinary course of business or to comply with Applicable Law); 

 

	1.18	amend or otherwise modify the constitutional documents of the Company other than minor or administrative amendments or modifications which are not adverse to the
Business or to the Purchaser or any member of the Purchaser’s Group; 

  

	1.19	create, allot or issue, or grant an option or right to subscribe for or purchase, any share capital or other securities or loan capital of the Company;

  

	1.20	repay, redeem or repurchase any share capital, or other securities of the Company; and 

  
 199

	1.21	cause or permit the Company to be subject to Tax in any jurisdiction other than in the United Kingdom. 

Part 2 Seller’s Group Obligations 
  

	1.	Obligations to be satisfied prior to the Closing Date 

  

	1.1	The Seller shall procure that the relevant member of the Seller Group shall notify, Pharmacare Limited in writing, in relation to: 

 

	 	1.1.1	the distribution agreement dated 27 November 2009 between Pharmacare Limited and Glaxo South Africa (Proprietary) Limited (the “SA Distribution
Agreement”); and 

  

	 	1.1.2	the SSA Collaboration Agreement dated 27 November 2009 between Pharmacare Limited, Glaxo Export Limited (the “SSA Collaboration Agreement”),

 of the withdrawal of the Products to the extent relevant from the agreements set out in the SA Distribution
Agreement and the SSA Collaboration Agreement, in each case with effect from Closing. 
  

	1.2	The Seller shall procure that the relevant member(s) of the Seller’s Group shall use best efforts to: 

 

	 	1.2.1	obtain the unconditional consent of [***] to the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group
under each of the [***] (at the Seller’s cost); and 

  

	 	1.2.2	obtain the unconditional consent of [***] to the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group
under the [***] (at the Seller’s cost). 

  

	1.3	At least 5 Business Days prior to the Closing Date, the Seller shall provide the Purchaser with a list of any required actions that must be taken by the
Purchaser within three (3) months after Closing with respect to the payment of any registration, maintenance, or renewal fees or the filing of any documents, applications or certificates in order to maintain Registered Intellectual Property Product
Rights in full force and effect. 

  

	2.	Obligations from the date of the Agreement to the Closing Date 

 The requirements for the purposes of Clause 5.1.3 are: 
  

	2.1	so far as permitted by Applicable Law, inform the Purchaser promptly if it becomes aware of, or has reasonable grounds for suspecting any violation of
Anti-Bribery Law which is reasonably likely to have an impact on the Business; 

  

	2.2	maintain in force all Seller’s Group Insurance Policies for the benefit of the Business; 

 

	2.3	 allow the Purchaser and its respective agents, upon reasonable notice, reasonable access to personnel, and such information as the Seller
considers reasonable, provided that the obligations of the Seller under this Clause shall not extend to 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 200

	 	
allowing access to information which is (i) reasonably regarded as confidential to the activities of the Seller and the Seller’s Group otherwise than in relation to the Business or (ii)
commercially sensitive or other information which is related to the Business if such information cannot be shared with the Purchaser prior to Closing in compliance with Applicable Law; 

 

	2.4	in so far as it relates to the Business, continue to take such steps as are currently planned by the Seller’s Group in relation to the remediation of the
manufacturing site operated by the Seller’s Group in Cork, Ireland; 

  

	2.5	maintain and keep any Business Product Intellectual Property Rights and ensure that all filings and notifications required to be made in respect of the same are
made in accordance with past practice; 

  

	2.6	progress, in accordance with past practice, any applications, submissions, filings or other correspondence relating to the grant of new Business Product
Intellectual Property Rights; 

  

	2.7	continue to conduct the Ongoing Clinical Trials in accordance with GCP and the Seller Group’s policies and procedures; 

 

	2.8	notify the Purchaser in writing of any actual safety or quality issue in respect of any Product or the manufacture of any Product (as soon as reasonably
practicable after becoming aware of the same) which issue the relevant member of the Seller’s Group, acting reasonably and in good faith, considers material in the context of the manufacture or commercialisation of such Product;

  

	2.9	so far as permitted by Applicable Law, report periodically to the Purchaser concerning the status of the Business, including delivering to the Purchaser as soon
as reasonably practicable each month: 

  

	 	2.9.1	an update on material commercial developments in relation to the Business and the Products during the previous month; 

 

	 	2.9.2	the gross profit for each Product in respect of the previous month; and 

 

	 	2.9.3	a report on the month-end in-trade inventory in respect of each Product for the previous month prepared in the ordinary course of business consistent with past
practice, together with a comparison against the comparable period of trading for the prior year; 

  

	2.10	not discontinue or cease to operate or materially reduce the resources applied to any part of the Business related to the Products or the Product Expansions;

  

	2.11	continue to promote, market and Commercialise the Products in a manner consistent with past practice; 

 

	2.12	 maintain levels of in-trade inventory in accordance with past practice and not materially accelerate or increase the quantity of the Products
distributed to the relevant distributors and/or wholesalers, except in respect of a bona fide increase in demand for the relevant Product by the relevant distributor and/or wholesaler which has not been stimulated in any way by discounts, rebates,
claw-backs or the like 

  
 201

	 	
outside of the ordinary course or the grant of preferred terms offered by the Seller’s Group outside of the ordinary course; and 

	2.13	continue to respond to any Call For New Tender in accordance with past practices in the relevant market. 

  
 202

 Schedule 20 
 Key Personnel 
 [***] 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 203

 Schedule 21 
 Regulatory Approvals 
  

	1.	The following table provides the additional jurisdictions and applicable antitrust, merger control, or foreign investment rules referenced in Clause 4.1.3
of the Agreement. 

  

	2.	This list of jurisdictions and statutes is not meant to be indicative of a known filing or approval requirement in these jurisdictions. To the extent that
clearances, approvals, waivers, no action letters or consents are not required to be obtained or not otherwise agreed by the parties to be appropriate and waiting periods are not required to have expired in these jurisdictions prior to closing of
the transactions contemplated by the Agreement, such clearances, approvals, waivers, no action letters, consents, and waiting period expirations will not be conditions precedent to closing of the transactions contemplated by the Agreement.

  

			
	 Country
	  	
Statute Under Which Filing/Approval Is Required

		
	 Australia
	  	The Competition and Consumer Act of 2010
		
	 Brazil
	  	Law No. 12,529 of November 30, 2011
		
	 Canada
	  	The Competition Act
		
	 China
	  	The Chinese Anti-Monopoly Law
		
	 India
	  	The Competition Act of 2002, as amended by The Competition (Amendment) Act of 2007
		
	 Israel
	  	The Restrictive Trade Practices Law, 5748-1988
		
	 Japan
	  	The Act on Prohibition of Private Monopolisation and Maintenance of Fair Trade No. 54 of 1947
		
	 Mexico
	  	The Federal Law on Economic Competition
		
	 New Zealand
	  	The Commerce Act of 1986
		
	 Russia
	  	Federal Law No. 135-FZ of July 16, 2006 on Protection of Competition
		
	 South Africa
	  	The Competition Act 89 of 1998
		
	 South Korea
	  	The Monopoly Regulation and Fair Trade Act
		
	 Taiwan
	  	The Fair Trade Law of 1991
		
	 Turkey
	  	The Law on Protection of Competition No. 4054 of 1994

  
 204

 Schedule 22 
 Ongoing Collaboration 
  

	1.	Subject to paragraph 4 below, in the event that: 

  

	 	1.1.1	any member of the Seller’s Group decides in its applicable governance committee (and in any event before approaching any third party) to seek a third party
partner for global or major market (that is, pan-EU, Spain, Italy, UK, Germany, France, US, a group of emerging markets, Switzerland, Japan, Canada or China) co-development or commercialisation of, or to whom to divest rights to, any Relevant
Development Product (the “In-scope Relevant Development Product”); or 

  

	 	1.1.2	any member of the Seller’s Group proposes to seek a marketing authorisation in a major market (that is, EU, US, Switzerland, Japan, Canada or China) for an
In-Scope Relevant Development Product, 

 the Seller shall (prior to (in the case of paragraph 1.1.1 above)
entering into any such discussions with any third party or (in the case of paragraph 1.1.2 above) filing an application for any such marketing authorisation) first notify the Purchaser of the same, including in such notification details of the
geographic markets in which it would intend to explore opportunities with the third party. The Purchaser shall then have a period of 30 days to confirm whether or not it is in principle interested in pursuing discussions regarding the
co-development and commercialisation or acquisition of the In-scope Relevant Development Product, and shall specify to the Seller the geographic markets in which it is interested in the opportunity (which need not be limited to the markets specified
by the Seller and may be worldwide). If the Purchaser declines the same or confirms in writing that it is not interested, then the provisions of this Schedule shall cease to apply with respect to such In-scope Relevant Development Product for
the following 24 months. 
  

	2.	If the Purchaser confirms its interest in pursuing discussions, then, during the 6 month period from the date of such notification (the “Negotiation
Period”): 

  

	2.1	the Seller shall not (and shall procure that no other member of its Group shall) enter into any discussions or negotiations with any third party in relation to
possible co-development and commercialisation arrangements in respect of or the divestment of the In-scope Relevant Development Product in all territories specified by the Seller and/or the Purchaser in the foregoing notifications;

  

	2.2	the Seller shall make available to the Purchaser, subject to reasonable obligations and appropriate arrangements of confidence and compliance, all information
reasonably necessary for the Purchaser to assess the opportunity, including information regarding project budgets and costs, timelines and relevant clinical plans and data; and 

 

	2.3	 the Seller and the Purchaser (or the relevant members of their respective Groups) shall negotiate in good faith, the terms and conditions of a
co-development and commercialisation arrangement for or divestment of the In-Scope Relevant Development Product, including (without limitation) financial terms, allocation of costs

  
 205

	 	
and responsibilities, project governance arrangements and appropriate intellectual property licences, which terms and conditions shall include (without limitation), exclusive commercialization
rights in favour of the Purchaser with respect to the In-Scope Relevant Development Product and otherwise be reasonable and customary (for similarly situated products). 

 

	3.	In the event that the Negotiation Period expires and the Seller and the Purchaser (or the relevant members of their respective Groups) have not entered into a
binding agreement in relation to the co-development or commercialisation or acquisition of the In-scope Relevant Development Product, then the Seller (or the relevant member of its Group) shall be free: 

 

	 	3.1.1	to pursue the continued internal development and commercialisation of such In-scope Relevant Development Product; or 

 

	 	3.1.2	at any time thereafter, to enter into discussions and/or negotiations with a third party in relation to the same, provided that for a period of 18 months after
such expiration, the Seller shall not enter into an agreement with a third party involving any such co-development and/or commercialisation arrangement for or divestment of the In-scope Relevant Development Product on terms that are more favourable
to the third party than those last offered by the Seller to the Purchaser without first notifying the Purchaser of the material terms thereof and offering the Purchaser the right to match the offer by entering into an agreement on such terms (or
substantially similar terms if any of such terms are unique to the third party). In the event that such an offer is made by the Seller, the Purchaser shall have a period of 30 days to accept it. If the Purchaser does not do so within such
period, then the Seller shall be free to proceed with the agreement with the third party on substantially such terms without further restrictions hereunder; provided, that, in the spirit of partnership, the Seller will in any event notify the
Purchaser at least 5 days prior to entering into an agreement with a third party regarding such an arrangement or divestment, including (where not restricted by law or contract from doing so) the material terms thereof (it being understood that,
other than as provided above, no match right will apply), 

 and, save as provided in paragraph 3.1.2 above,
the provisions of this Schedule shall cease to apply with respect to such In-scope Relevant Development Product. 
  

	4.	The provisions of this Schedule: 

  

	4.1	shall expire 12 years and six months after Closing unless renewed by mutual agreement; 

 

	4.2	shall apply subject to the Seller’s existing written agreements with third parties, provided that the Seller represents and warrants that neither it nor any
member of its Group is party to any agreement or arrangement with a third party which would materially impact the expected benefit to the Purchaser of the arrangement set out in this Schedule; 

  
 206

	4.3	shall apply notwithstanding Clause 12.1 (Non-compete) and, subject to the provisions of this Schedule, shall not restrict any activities of the
Seller’s Group in relation to the research and development (including manufacturing for development) of or relating to Relevant Development Products; 

  

	4.4	shall not apply to situations where the Seller is seeking a third party partner for the co-development or commercialisation of a broad portfolio of products
where the majority of such portfolio is not comprised of Relevant Development Products; and 

  

	4.5	for the avoidance of doubt, shall not apply to situations where the Seller is seeking a third party contractor to provide research or development services.

  
 207

 Schedule 23 
 Seller Marks 
 GLAXOSMITHKLINE 
 GLAXO 
 GSK 
 SMITHKLINE 
 SMITHKLINE BEECHAM 
 SB 
 STERLING 
 STIEFEL 
 WELLCOME 
 GLAXO WELLCOME 
 GSK Logo 
 GLAXOSMITHKLINE Logo 
 STIEFEL Logo 

  
 208

 Schedule 24 
 Statement of Company Intra-Group Debt 
 Amount of the Company Intra-Group Debt in US$, as
determined by the Seller using the US$ Spot Rate: 

US$                        
                                         
                    
 Agreed and accepted:

  

                         
                            
 For and on behalf of the Seller 
  
                                  
                    
 For and on behalf of
the Purchaser 
  

                         
                            
 For and on behalf of the Purchaser 

  

  
 209

 Schedule 25 
 Delayed Jurisdictions 
  

	1.	Definitions used in this Schedule 

  

	1.1	In this Schedule: 

“Bangladesh Business” means the assets and liabilities transferring from GlaxoSmithKline Bangladesh Limited to the
Designated Purchaser in accordance with this Agreement and the relevant Local Transfer Document; 
 “Bangladesh Transfer
Documents” means the Local Transfer Document in respect of the transfer of the Bangladesh Business to the Designated Purchaser; 
 “Contract Amount” means the revenues minus the costs derived from the operation of a Contract in respect of a Delayed Business which, if Closing had occurred in respect of the relevant
Delayed Business, would be a Transferred Contract, a Transferred Intellectual Property Contract, the Relevant Part of a Shared Business Contract or a Non-transferring Tender, but excluding any amounts taken into consideration in paragraph 4.2 of
this Schedule 25; 
 “Controlled Delayed Business” means a Delayed Business other than a Non-Controlled Delayed
Business; 
 “Delayed Business Representative” has the meaning given to in paragraph 3.3 of this Schedule 25;

 “Delayed Employee Costs” means the FTE costs incurred by the Seller’s Group in connection with the
employment of the Delayed Employees by the Seller’s Group as provided in paragraph 12.2 of Schedule 8; 
 “Delayed
Indemnity Parties” has the meaning given to it in paragraph 3.12 of this Schedule 25; 
 “Delay
Milestone” means the milestone set out next to the relevant Delayed Business in the Appendix to this Schedule; 

“Delay Period” has the meaning given to it in paragraph 4.1 of this Schedule 25; 

“Foreign Business Licence” means a foreign business certificate or a foreign business licence from the Thailand Ministry
of Commerce to provide transitional services and/or transitional distribution services in Thailand; 
 “Incremental Delay
Liabilities” has the meaning given to it in paragraph 3.12 of this Schedule 25; 
 “India Business”
means the assets and liabilities transferring from GlaxoSmithKline Pharmaceuticals Limited to the Designated Purchaser in accordance with this Agreement and the relevant Local Transfer Document; 

“India Transfer Documents” means the Local Transfer Document in respect of the transfer of the India Business to the
Designated Purchaser; and 

  
 210

 “Non-Controlled Delayed Business” means each of the Bangladesh Business,
the India Business and the Ukraine Business; 
 “Profit” means the profit or loss deriving from sales of the
Products by a Delayed Business in the relevant period calculated in accordance with clause 4.1 of the Transitional Distribution Services Agreement; 
 “Provider Costs” means those costs set out in clause 4.3(E) to (G) (inclusive) of the Transitional Distribution Services Agreement; 

“R&D Costs” mean the research and development costs which do not arise under or relate to a Clinical Trial Agreement
incurred by any member of the Seller’s group in relation to Ongoing Clinical Trials undertaken directly by the Seller’s Group but excluding any Delayed Employee Costs; and 

“Saudi Business” means the assets and liabilities transferring from Glaxo Saudi Arabia Limited to the Designated
Purchaser in accordance with this Agreement and the relevant Local Transfer Document; 
 “Saudi Transfer
Documents” means the Local Transfer Document in respect of the transfer of the Saudi Business to the Designated Purchaser; 
 “Seller Involvement Instruction” has the meaning given to it in paragraph 3.9 of this Schedule 25; 
 “Thailand Business” means the assets and liabilities transferring from GlaxoSmithKline (Thailand) Limited to the Designated Purchaser in accordance with this Agreement and the relevant
Local Transfer Document; 
 “Thailand Transfer Documents” means the Local Transfer Document in respect of the
transfer of the Thailand Business to the Designated Purchaser; 
 “Ukraine Business” means the assets and
liabilities transferring from GlaxoSmithKline Pharmaceuticals Ukraine LLC to the Purchaser in accordance with this Agreement and the relevant Local Transfer Document; and 
 “Ukraine Transfer Document” means the Local Transfer Document in respect of the transfer of the Ukraine Business to the Designated Purchaser. 

 

	1.2	The parties agree that legal ownership of the Delayed Businesses shall not be transferred by the Seller to the Purchaser at Closing but that the Delayed Businesses
shall be operated by Seller and that the benefit and burden of such Delayed Business shall be for the Purchaser with effect from the Effective Time on the terms set out in this Schedule. 

 

	1.3	The Seller and the Purchaser shall (and shall procure that their respective Affiliates shall) use all reasonable endeavours to procure the achievement of each Delay
Milestone as soon as possible after the Closing Date. 

  

	1.4	Delayed Closing in respect of a Delayed Business shall occur on the date which is the last Business Day of the month in which the relevant Delay Milestone has been
achieved except that: 

  

	 	1.4.1	where the last day of such month is not a Business Day, the Delayed Closing shall take place on the first Business Day of the following month; and

  
 211

	 	1.4.2	where less than five (5) Business Days remain between achievement of the Delay Milestone and the last Business Day of the month, Delayed Closing shall take place:

  

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, the Delayed Closing shall take place on the first Business Day of the month following the month referred to in
paragraph 1.4.2(i) of this Schedule 25; or 

  

	 	(iii)	on such other date as may be agreed between the Purchaser and the Seller, 

 (the “Delayed Closing Date”). 
  

	2.	Obligations on Delayed Closing Date 

  

	2.1	The Sellers’ Obligations 

 On each Delayed Closing Date, the Seller shall deliver to the Purchaser any relevant Ancillary Agreements relating to the Delayed Business (including, without limitation, any Local Transfer Documents)
duly executed by the relevant member of the Seller’s Group. 
  

	2.2	The Purchaser’s Obligations 

  

	 	2.2.1	On each Delayed Closing Date, the Purchaser shall deliver to the Seller any relevant Ancillary Agreements relating to the Delayed Business (including, without
limitation, the Local Transfer Documents) duly executed by the relevant member of the Purchaser’s Group. 

  

	 	2.2.2	For the purposes of compliance with paragraphs 2.1 and 2.2.1 of this Schedule 25, the Seller and the Purchaser shall, between the date of this Agreement and the Delayed
Closing Date, negotiate in good faith any and all Ancillary Agreements relating to the Delayed Business (including, without limitation, if required, any Local Transfer Documents) such that they are consistent with the equivalent Ancillary Agreements
executed at Closing and shall take all such steps as are required to transfer the Delayed Businesses in accordance with this Agreement and the other Ancillary Agreements. 

 

	2.3	Tax Indemnity 

 References
in paragraphs 2.1 to 2.2 above to Ancillary Agreements shall not include the Company Tax Indemnity, the Direct Indemnity or the Purchaser Tax Indemnity. 
  

	3.	Management and Control of Delayed Business 

  

	3.1	To the maximum extent permissible by Applicable Law and the terms of the Product Approvals and Product Expansion Applications, the parties intend that, pursuant to this
Schedule 25, all management and control rights and powers that the Seller (or any member of the Seller’s Group) has in relation to a Controlled Delayed Business shall transfer to the Purchaser with effect from Closing. 

 

	3.2	 As soon as reasonably practicable after Closing, the Purchaser shall notify the Seller of the names of its personnel permitted to provide Controlled
Business Instructions (“Instructing Personnel”) and the Seller shall be entitled to rely on and act in accordance with Controlled Business Instructions from Instructing Personnel without further verification. Instructions

  
 212

	 	
provided by or on behalf of the Purchaser shall not be required to be in writing if they are provided by the Instructing Personnel. The Purchaser shall be free to change its Instructing Personnel
from time to time by providing 10 Business Days’ written notice to the Seller’s Delayed Business Representative. 

  

	3.3	In order to cooperate in managing the implementation of the provisions of this Schedule, the Seller and the Purchaser shall each notify the other of the identity of a
senior member of management (the “Delayed Business Representative”) who shall be the primary point of contact in the event that there is any issue in connection with the operation of the provisions in this Schedule. The parties
shall notify each other in writing of the contact details for their respective Delayed Business Representatives from time to time. 

  

	3.4	From Closing until the relevant Delayed Closing Date, in respect of any Controlled Delayed Business, the Seller (or relevant member of the Seller’s Group) shall:

  

	 	3.4.1	subject to paragraph 3.10 of this Schedule 25 and to the maximum extent permitted by Applicable Law and the terms of any relevant Product Approvals and Product
Expansion Applications, act in accordance with any instructions provided to it by any of the Instructing Personnel in relation to any aspect of the management and operation of that Controlled Delayed Business or any part of it, whether in relation
to sales, marketing, distribution, research and development or any other activities of that Controlled Delayed Business, the making (or otherwise) of expenditure, investments, employee matters (including the hiring or dismissal of any Delayed
Employee), and in each case with the effect that the Purchaser shall have, to the maximum extent permissible by Applicable Law and the terms of any relevant Product Approvals or Production Expansion Applications, the same powers in relation to the
relevant Controlled Delayed Business as it would have following the Delayed Closing Date of that Controlled Delayed Business (in each case, a “Controlled Business Instruction”); 

 

	 	3.4.2	comply with the provisions of Schedule 6 in relation to Product Approvals and Product Expansion Applications relating to the Controlled Delayed Businesses; and

  

	 	3.4.3	except to the extent otherwise instructed by the Purchaser’s Instructing Personnel in accordance with this paragraph 3.4 or as required by Schedule 6, ensure that
the Controlled Delayed Business is carried on in the ordinary course of business consistent with past practice in relation to that Controlled Delayed Business, 

 and provided that the Seller shall not be required pursuant to a Controlled Business Instruction to take any action (or omit to take any action) in relation to any of its business (or the business of the
Seller’s Group) that is not a Delayed Business. 
  

	3.5	The provisions of Clause 5 and Schedule 19 shall not apply in respect of any Controlled Delayed Business following Closing and the provisions of Clause 12.1 shall not
apply in respect of any Delayed Business from Closing. 

  

	3.6	The Purchaser shall (or shall procure that its Affiliates shall) supply such assistance and access (including the supply of products, the supply of services and access
to Transferred Books and Records and Commercial Information, but excluding any access to Intellectual Property Rights except as referred to in paragraph 3.7 below) as shall be reasonably necessary to allow the Seller to operate each Delayed Business
in accordance with this Schedule. 

  
 213

	3.7	The Purchaser shall (or shall procure that its Affiliates shall) grant the Seller from Closing a non-exclusive, fully paid up, royalty free and sub-licensable licence
or sub-licence (as applicable) to use, notwithstanding any other provision of this Agreement or any of the Ancillary Agreements, the Transferred Intellectual Property Rights and Intellectual Property Rights licensed to the Purchaser under any
Ancillary Agreement for the sole purpose of (i) operating each Delayed Business in accordance with the provisions of this Schedule 25; and (ii) exercising the Seller’s rights to research, Develop, Manufacture, and Commercialise the Ofatumumab
Product in the Field solely in accordance with the Permitted Uses (as defined in the Ofatumumab Intellectual Property Licence Agreement). This licence shall continue on a country by country basis, in relation to each Delayed Business until the date
on which that Delayed Business has been transferred by the Seller to the Purchaser in accordance with this Schedule. 

  

	3.8	Delayed Employees who are engaged in a Controlled Delayed Business shall report to the management of the Purchaser and shall be treated for such management and
reporting purposes in the same way as any employee of the Purchaser’s Group. Controlled Business Instructions may, accordingly, be given by the Instructing Personnel directly to any Delayed Employee engaged in a Controlled Delayed Business.

  

	3.9	To the extent that the implementation of any Controlled Business Instruction requires an action or actions of a person employed by the Seller’s Group who is not a
Delayed Employee engaged in a Controlled Delayed Business (whether because Applicable Law prevents such Controlled Business Instruction from being made directly to a Delayed Employee or for any other reason) (a “Seller Involvement
Instruction”), the Purchaser (or relevant member of the Purchaser’s Group) shall also provide the Controlled Business Instruction, in writing (which may include email) to that Seller’s Delayed Business Representative, specifying
(i) that it is a Seller Involvement Instruction; (ii) the actions that are required to be taken by such person; and (iii) a reasonable time within which such actions are required to be taken. 

 

	3.10	The Seller and the Purchaser each acknowledges that the Seller’s Delayed Employees shall continue to be bound by, and shall comply with, the employment policies
and procedures (including terms and conditions and disciplinary procedures) of the Seller’s Group that apply to employees of such Seller’s Group. 

 

	3.11	Subject to paragraph 3.10 of this Schedule 25, the Seller and the Purchaser acknowledge that the Seller’s Delayed Employees shall continue to be bound by, and
shall comply with the policies of the Seller’s Group provided that the Seller shall provide the Purchaser with copies of its operational and other policies that apply in relation to Controlled Delayed Businesses. In respect of such policies,
the Purchaser may give notice to the Seller that it wishes a particular policy of the Purchaser’s Group to apply in respect of a Controlled Delayed Business and/or the applicable Delayed Employees in addition to the Seller’s equivalent
policy. The Purchaser’s equivalent policy shall apply to the applicable Delayed Employees from the date on which such Delayed Employees are given notice of the relevant policy. If a policy of the Seller and a policy of the Purchaser apply at
the same time, if and to the extent there is any inconsistency or conflict between the two policies, the policy which requires behaviour that is least likely to expose the parties to legal, regulatory and/or compliance risk shall prevail.

  
 214

	3.12	The Purchaser hereby undertakes to the Seller (for itself and on behalf of each other member of such Seller’s Group) and their respective directors, officers,
employees and agents (excluding any Delayed Employees) (the “Delayed Indemnity Parties”) that, with effect from the Effective Time, the Purchaser will indemnify on demand and hold harmless each of the Delayed Indemnity Parties
against and in respect of any and all Liabilities, other than Liabilities in respect of Tax that are taken into account in calculating any amount pursuant to paragraph 4.2 of this Schedule 25, resulting directly or indirectly from any Controlled
Delayed Business and/or from any Controlled Business Instruction to the extent that (i) such Liabilities are not Assumed Liabilities and (ii) the Delayed Indemnity Parties concerned would not have incurred such Liabilities if the Controlled Delayed
Business in question had been transferred to the relevant member of the Purchaser’s Group at Closing (“Incremental Delay Liabilities”) but in any case excluding any such Liabilities to the extent that such Liabilities arise as
a result of a breach of paragraph 3.15 of this Schedule 25. 

  

	3.13	If a Seller is of the opinion that any Controlled Business Instruction may result in any Liability that would fall to be indemnified pursuant to paragraph 3.12 of this
Schedule 25, the Seller shall use its reasonable endeavours to inform (and procure that the members of the Seller’s Group shall inform) the Purchaser of that opinion and the reasons for it as soon as reasonably practicable after reaching that
opinion. The indemnity set out in paragraph 3.12 shall not be affected or limited in any way by any failure of any member of the Seller’s Group so to inform the Purchaser. 

 

	3.14	The Purchaser shall not be entitled to make any claim for damages against a Seller in respect of a breach of a provision of this Schedule 25 otherwise than pursuant to
a claim brought under paragraph 3.15 of this Schedule 25. 

  

	3.15	The Seller shall procure that: 

  

	 	3.15.1	for Controlled Business Instructions that are not Seller Involvement Instructions, neither it nor any of its Associated Persons shall act (or fail to act) fraudulently
or with Gross Negligence in connection with the implementation of any Controlled Delayed Business or Controlled Business Instruction. “Gross Negligence” for these purposes means any act or failure to act by the Seller (or any of its
Associated Persons that: (i) the Seller (or the relevant Associated Person) knew may create a risk of material harm to the relevant Controlled Delayed Business; (ii) was intended to cause such harm, or was done in reckless disregard of, or in wanton
indifference to, such risk of harm; and (iii) in all the circumstances (having regard to both the probability and seriousness of such harm) was an unreasonable risk for the Seller (or the relevant Associated Person) to take; and

  

	 	3.15.2	for Seller Involvement Instructions, neither it nor any of its Associated Persons shall act (or fail to act) fraudulently or negligently or in wilful default in
connection with the implementation of the Seller Involvement Instruction and shall take no step which is intended to prevent the implementation of a Seller Involvement Instruction, 

but it shall not be a breach of this paragraph 3.15 (and shall accordingly not be acting with Gross Negligence for the purposes of this
paragraph) to carry out any act, or fail to act, if to do so is: 
  

	 	(i)	required in connection with a Controlled Business Instruction; 

  

	 	(ii)	required to comply with Applicable Law; 

  
 215

	 	(iii)	required to implement or comply with the terms of this Agreement or any Ancillary Agreement; or 

 

	 	(iv)	taken to mitigate any other loss or damage to the Controlled Delayed Business which the Seller (or the relevant Associated Person) believes, acting reasonably and in
good faith, could be material in the context of that Controlled Delayed Business. 

 In any event, no claim shall
be made by the Purchaser (and the Purchaser shall ensure that no member of the Purchaser’s Group shall make any claim) for any breach of any other provisions of this Agreement (or the provisions of any Ancillary Agreement) by a Seller (or any
member of the Seller’s Group) that occurs in order to comply with any Controlled Business Instruction. 
  

	3.16	Prior to the making of any claim under this Schedule 25, the parties shall use reasonable endeavours to escalate such matter first for consideration to the Delayed
Business Representatives and then to the Purchaser’s and the Seller’s chief financial officers, for the purposes of seeking to resolve such matter within a period of 30 days following such escalation. 

 

	3.17	Subject to Applicable Law, the Seller shall, in the period between Closing and the relevant Delayed Closing Date, promptly upon request by the Purchaser provide (or
procure that any member of its Group shall provide) the Purchaser and its representatives with access to: 

  

	 	3.17.1	any books and records of the Seller’s Group to the extent relating to any Delayed Business of the Seller; and 

 

	 	3.17.2	any personnel of the Seller for the purposes of any requests for information from such personnel in relation to the Delayed Business. 

For the avoidance of doubt, the parties shall take all steps necessary to ensure that no information is provided to the Purchaser or any
person on behalf of the Purchaser which relates to any business of the Seller or any member of the Seller’s Group other than the Controlled Delayed Business. 
  

	3.18	For the purposes of the Warranties deemed repeated by the Seller (on behalf of the relevant Business Seller) immediately before Closing pursuant to Clause 9.1.5,
ownership of the Delayed Businesses shall be deemed to have transferred to the Purchaser at Closing. 

 Schedule
1Non-Controlled Delayed Businesses 
  

	3.19	From Closing until the relevant Delayed Closing Date: 

  

	 	3.19.1	the other provisions of paragraph 3 of this Schedule 25 shall not apply in respect of the Non-Controlled Delayed Businesses, with the exception of paragraphs 3.6, 3.7,
3.10, 3.17 and 3.18 which shall apply to the extent permitted by Applicable Law; and 

  

	 	3.19.2	to the extent permitted by Applicable Law, the provisions of Clause 5 and Schedule 19 will continue to apply to the Non-Controlled Delayed Businesses and the Seller
shall exercise such interests, rights and powers that the Seller has in respect of that Non-Controlled Business to the maximum extent that it is able in order to procure that the Non-Controlled Business is operated in accordance with Clause 5 and
Schedule 19. 

  
 216

 Schedule 2Saudi Business 

 

	3.20	The Seller and the Purchaser agree that the Saudi Business need not transfer to the Purchaser (or a member of the Purchaser’s Group) on a single date and the
Purchaser and the Seller agree to cooperate to ensure that the relevant Assets and Employees shall transfer to the Purchaser (or a member of the Purchaser’s Group or its designee) as soon as this is permitted by Applicable Law.

  

	4.	Economic transfer 

  

	4.1	The economic benefit and burden of the Delayed Business which shall be for the account of the Purchaser in respect of each Delayed Business for the period from the
Effective Time to the relevant Delayed Closing Date (the “Delay Period”), shall be calculated and paid in accordance with this paragraph 4. 

 

	4.2	The economic benefit or burden attributable to each Delayed Business during the Delay Period shall be calculated by the Seller on a monthly basis and shall be:

  

	 	4.2.1	the Profit derived from sales of the Products by the relevant Delayed Business in the relevant month; 

minus 
  

	 	4.2.2	the sum of the Provider Costs, the Delayed Employee Costs and the R&D Costs incurred by the relevant Delayed Business in the relevant month,

 provided that any cost which falls within more than one of the categories listed in sub-paragraph 4.2.2 shall
not be counted more than once. 
  

	4.3	The provisions of clause 4 of the Transitional Distribution Services Agreement shall apply for the relevant Delay Period in respect of each Delayed Business as if such
Delayed Business were subject to the provisions of clause 4 of that agreement from the Effective Time such that: 

  

	 	4.3.1	net sales received from the sale and distribution of the Products by each Delayed Business shall be calculated in accordance with clause 4.1(A) of the Transitional
Distribution Services Agreement and be included in the relevant “Sales Report” provided to the Purchaser pursuant to clause 4.3 of the Transitional Distribution Services Agreement; but 

 

	 	4.3.2	the amount payable under any “Invoice” pursuant to clause 4.6 of the Transitional Distribution Agreement in respect of each Delayed Business shall be
calculated in accordance with paragraph 4.2 above so as to include the relevant Provider Costs, Delayed Employee Costs and R&D Costs and shall be subject to paragraphs 4.4 to 4.6 (inclusive) below. 

 

	4.4	To the extent that the amount resulting from the calculation set out in paragraph 4.2 above results in a profit (an amount greater than zero) then, if the relevant
Delayed Business is a Controlled Delayed Business, such amount shall be added to the amount to be remitted to the Purchaser (or the relevant member of the Purchaser’s Group) in accordance with clause 4 of the Transitional Distribution Services
Agreement. 

  
 217

	4.5	To the extent that the amount resulting from the calculation set out in paragraph 4.2 above results in a loss (an amount less than zero) then, if the relevant Delayed
Business is a Controlled Delayed Business, such amount shall be deducted from the amount to be remitted to the Purchaser (or the relevant member of the Purchaser’s Group) in accordance with clause 4 of the Transitional Distribution Services
Agreement. 

  

	4.6	In respect of each Non-Controlled Delayed Business, the accrued profit or loss (as calculated in accordance with paragraph 4.2 above) made by such Non-Controlled
Delayed Business in the Delay Period, shall be added or deducted (as applicable) to the amount to be remitted to the Purchaser (or the relevant member of the Purchaser’s Group) on the first date following the Delayed Closing Date in respect of
such Non-Controlled Delayed Business on which any profit or loss would be remitted to the relevant member of the Purchaser’s Group under clause 4 of the Transitional Distribution Services Agreement. 

 

	4.7	Within 30 days after the end of the Delay Period in respect of a Delayed Business the Seller (or relevant Business Seller) shall provide to the Purchaser (or relevant
Business Purchaser) a statement setting out, in respect of the relevant Delayed Business: 

  

	 	4.7.1	the Contract Amount in respect of each Contract during the Delay Period; and 

 

	 	4.7.2	details of any other revenue, cost or expense of the relevant Delayed Business during the Delay Period which is not a Contract Amount, has not been taken into account
under paragraph 4.2 above, and which would need to be taken into account in order to put the Purchaser’s Group and the Seller’s Group in the same economic position they would have been in, taking into account any arrangements that would
have been in place in respect of the Delayed Business pursuant to any Ancillary Agreement, had the Delayed Business transferred to the Purchaser at Closing, 

 (the “Draft Economic Benefit Statement”) and which shall include details of the components of the revenues, costs and expenses incorporated in the Draft Economic Benefit Statement and
shall be accompanied by reasonable supporting information. 
  

	4.8	The Seller shall, and shall procure that the members of the Seller’s Group (and, if applicable, its external accountants) shall, provide to the Purchaser and its
Representatives, without charge, such access to their personnel, books and records, calculations and working papers as the Purchaser may reasonably request in connection with its review of the Draft Economic Benefit Statement (and the parties
acknowledge that local market information that is not contained on central consolidation systems will only be requested where material in the context of the Draft Economic Benefit Statement as a whole), subject (where applicable) to the Purchaser
providing such undertakings as the relevant external accountants may reasonably request, and provided that the Purchaser hereby undertakes to the Seller that it shall procure that each Representative of any member of the Purchaser’s Group who
has access to such information shall (i) keep any such information which is commercially sensitive (the “Protected Information”) confidential and shall only disclose such information to, and discuss such information with, other such
Representatives who are engaged in the review of the Draft Economic Benefit Statement; (ii) be expressly prohibited from communicating (in any form) any Protected Information to any other employee, agent, adviser or consultant of any member of the
Purchaser’s Group; and (iii) be subject to the above requirements whilst employed or engaged by any member of that Purchaser’s Group in any capacity. The provisions of Clause 13 of this Agreement shall apply mutatis mutandis to such
information including, for the avoidance of doubt, to allow (where permitted by that clause) disclosure of information otherwise prohibited to be communicated to any agent, adviser or consultant of the Purchaser’s Group.

  
 218

	4.9	The Seller and the Purchaser shall meet within 10 Business Days after the delivery of each Draft Economic Benefit Statement to discuss in good faith and use their
reasonable endeavours to agree within 20 Business Days of the commencement of such discussions (or such longer period as they may agree in writing) the contents of the Draft Economic Benefit Statement as soon as reasonably practicable and:

  

	 	4.9.1	any dispute or difference in relation to the Draft Economic Benefit Statement shall be referred to the Co-Chairs appointed by the Seller and Purchaser in accordance
with clause 12.1 of the Transitional Distribution Services Agreement, who shall be responsible for working within the protocols established between the Parties; and 

 

	 	4.9.2	if such dispute is not resolved by such Co-Chairs within 10 Business Days, it shall be referred to the Committee (established under clause 12.1 of the Transitional
Distribution Services Agreement) for determination; 

  

	 	4.9.3	if such Committee is unable to resolve the dispute within 10 Business Days the dispute shall be referred to the Chief Financial Officer of the Seller and the Chief
Financial Officer of the Purchaser for resolution and, if they are unable to resolve the matter within 10 Business Days, the dispute resolution process will be deemed to have been exhausted in respect of such dispute, and each Party shall be free to
pursue the rights granted to it by this Agreement in respect of such dispute without further reference to this dispute resolution process. 

 If the Purchaser and the Seller, or their representatives referred to in this paragraph 4.9 are able to agree the contents of the Draft Economic Benefit Statement, it shall be amended to reflect any
changes which have been so agreed and shall then constitute the “Economic Benefit Statement” in respect of that Delayed Business for the relevant Delay Period. 

 

	4.10	The Contract Amount and the aggregate revenues and the aggregate costs and expenses referred to in paragraph 4.7.2, in each case as set out in the Economic Benefit
Statement in respect of a Delayed Business, shall be added or deducted (as applicable) to the amount to be remitted to the Purchaser (or the relevant member of the Purchaser’s Group) on the first date on which any profit would be remitted to
the relevant member of the Purchaser’s Group under clause 4 of the Transitional Distribution Services Agreement after either the agreement of the Economic Benefit Statement for such Delayed Business or the exhaustion of the dispute resolution
process in accordance with paragraph 4.9 above in respect of the Draft Economic Benefit Statement or, if it is not practicable to make such an addition or deduction, the Seller and the Purchaser may agree that the Seller or the Purchaser (as
applicable) shall make the necessary payment as is required to settle the Economic Benefit Statement. 

  

	4.11	The Seller shall provide to the Purchaser with equivalent information and audit rights in respect of sales of the Products or the calculation of Profit as the Purchaser
would have received under the Transitional Distribution Services Agreement had the relevant Delayed Business transferred to the Purchaser on Closing. The parties agree that the information and audit rights set out in clause 27 of the
Transitional Distribution Services Agreement shall apply mutatis mutandis to the Delayed Employee Costs and the R&D Costs. 

  
 219

 Appendix 
 Delayed Businesses 
  

					
	 Jurisdiction
	  	 Delayed Business
	  	 Delay Milestone

			
	Bangladesh	  	GlaxoSmithKline Bangladesh Limited	  	The passing of a resolution of the board of Novartis (Bangladesh) Limited validly approving the acquisition of the Bangladesh Business by the Purchaser and the entry into of the
Bangladesh Transfer Documents.
			
	India	  	GlaxoSmithKline Pharmaceuticals Limited	  	The receipt by the parties of all necessary approvals, consents and filings from or with the Indian Foreign Investment Promotion Board in respect of the sale and transfer of the
India Business and the India Transfer Documents.
			
	Ukraine	  	GlaxoSmithKline Pharmaceuticals Ukraine LLC	  	The receipt by the parties of all necessary approvals, consents and filings from or with the Competition Commission of Ukraine in respect of the transfer of the Ukraine
Business.
			
	Saudi Arabia	  	Glaxo Saudi Arabia Ltd	  	As soon as reasonably practicable after Closing and by written agreement by the parties but no later than the Marketing Authorisation Transfer Date in respect of Saudi
Arabia.
			
	Thailand	  	GlaxoSmithKline (Thailand) Limited	  	The receipt by the relevant members of the Seller’s Group of a Foreign Business Licence in respect of transitional services and/or transitional distribution services to be
provided to the Purchaser in Thailand and, if required, the receipt by the relevant members of the Purchaser’s Group of a Foreign Business Licence in respect of transitional services to be provided by the Purchaser’s Group to the
Sellers’s Group.

  
 220

 Schedule 26 
 Assets related to China 
 [***] 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 221

 Schedule 27 
 Transitional Trademark Licence 
  

	1.	Transitional Trademark Use 

  

	1.1	Grant of Transitional Trademark Licence 

  

	 	1.1.1	Subject to the terms set out in this paragraph 1, the Seller hereby grants, and shall procure that each member of the Seller’s Group shall grant (as
applicable), to the Purchaser from Closing a non-exclusive, worldwide, royalty-free, non-assignable, licence without the right to sub-license (save with the prior written consent of the Seller which shall not be unreasonably withheld or delayed, or
as otherwise permitted under paragraph 1.1.7) to use the Seller Marks: 

  

	 	(i)	subject to paragraph 1.1.3, on any websites (or related digital assets) which exclusively relate to any Product solely in the manner and to the extent such websites (or
related digital assets) bear any Seller Marks as at the Closing Date, which licence shall, unless terminated earlier under paragraph 1.6, continue in force on a country by country basis for the longer of: (i) 6 months from the Marketing
Authorisation Transfer Date or Marketing Authorisation Re-registration Date, as applicable, in accordance with Schedule 6; or (ii) for such period following the Closing Date as is required by Applicable Laws, provided that in either case the
Purchaser shall, and shall procure that its sub-licensees shall, use all reasonable endeavours to cease such use of such Seller Marks as soon as reasonably practicable following the Closing Date (“GSK Branded Websites”);

  

	 	(ii)	on any Products intended to be sold by the Business as the result of the Manufacturing and Supply Agreements or the Transitional Distribution Services Agreement solely
in the manner and to the extent that those Products bear any Seller Marks as at the Closing Date or as is otherwise required by Applicable Law (“GSK Branded Products”); and 

 

	 	(iii)	on any stationery, sales literature, patient information leaflets or similar documentation used in the Business, solely in the manner and to the extent such materials:
(i) bear any Seller Marks as at the Closing Date; and (ii) relate to the GSK Branded Products (“GSK Branded Literature”) 

 (the “Transitional Trademark Licence”). 
  

	 	1.1.2	Subject to paragraphs 1.1.3, 1.1.4, 1.1.5 and 1.1.6, in each case in respect of paragraphs 1.1.1(ii) and 1.1.1(iii), such licence shall, unless terminated
earlier under paragraph 1.6, continue in force, on a country by country basis, in relation to each item of GSK Branded Product (or any GSK Branded Literature related to the same), as applicable, from the Closing Date for the longer of:

  

	 	(i)	the period required by the Manufacturing and Supply Agreements or the Transitional Distribution Services Agreement, where applicable; 

 

	 	(ii)	the period until the Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration, as applicable, in accordance with Schedule 6; or

  
 222

	 	(iii)	such period as is required by Applicable Law. 

  

	 	1.1.3	Subject always to paragraph 1.1.6, the parties shall co-operate in the consideration of an extension of any licences granted under this paragraph 1.1 in the
event that it is reasonably necessary for any such licences to continue beyond the period contemplated in paragraph 1.1 and the Seller shall not unreasonably withhold its agreement to any such extension. 

 

	 	1.1.4	The Purchaser shall, and shall procure that its sub-licensees shall: 

 

	 	(i)	use all reasonable endeavours to cease such use of the Seller Marks as soon as reasonably practicable following the Closing Date; and 

 

	 	(ii)	use the Seller Marks in accordance with Applicable Law only. 

  

	 	1.1.5	Neither the Purchaser nor its sub-licensees shall have any rights under the licences granted in paragraphs 1.1.1(ii) and 1.1.1(iii) to use any of the Seller
Marks in relation to any GSK Branded Products whose “sell-by date” or shelf life, as applicable, has passed or expired. 

  

	 	1.1.6	The licences granted under paragraphs 1.1.1(i) to 1.1.1(iii) shall expire after 24 months of the Closing Date (the “Long Stop Expiry Date”).

  

	 	1.1.7	The Purchaser shall be entitled to sub-license its rights under the Transitional Trademark Licence to: 

 

	 	(i)	any member of the Purchaser’s Group without the prior written consent of the Seller, provided that any act of the sub-licensee, which would if committed by the
Purchaser be a breach of any of the terms applying to the Transitional Trademark Licence, shall be treated as an equivalent breach by the Purchaser of the terms of the Transitional Trademark Licence; and 

 

	 	(ii)	if the Seller or the Purchaser determines that any sub-licensee under paragraph 1.1.7(i) is using any Seller Marks outside the scope of a permitted sub-licence under
this paragraph 1.1, the Purchaser promptly will cause the sub-licensee to cease such unpermitted use and will notify such sub-licensee that it is in material breach of its sub-licence agreement. If the breach continues unremedied for a period of
fifteen (15) calendar days after the Purchaser provides notice to such sub-licensee describing the nature of the breach, the Purchaser will, upon the Seller’s request, terminate the applicable sub-licence and will cooperate with the Seller to
enforce the Seller’s rights against such former sub-licensee as the Seller directs. 

  

	1.2	Reservation of Rights 

The Seller reserves all rights in and to the Seller Marks. The Purchaser acknowledges and agrees that as between the Seller (or the
relevant member of the Seller’s Group) and the Purchaser, the Seller (or the relevant member of the Seller’s Group) is the sole and exclusive owner of all right, title and interest in and to the Seller Marks, including all goodwill of the
business connected with the use of, or symbolised by, the Seller Marks. All goodwill generated from the use of the Seller Marks by the Purchaser or its sub-licensees shall inure solely to the benefit of the Seller (or the relevant member of the
Seller’s Group). Nothing in this paragraph 1 grants the Purchaser or its sub-licensees any ownership or other proprietary interest in any Seller Marks. 

  
 223

	1.3	Restrictions on Use 

  

	 	1.3.1	The Purchaser shall have no right pursuant to this paragraph 1 to use or permit any other person to use, any of the Seller Marks as part of a corporate or
trading name or to hold itself out or otherwise represent itself to be a member of, or to be associated or connected with, any member or business venture of the Seller’s Group, or permit any other person to do that same.

  

	 	1.3.2	Without limiting the generality of paragraph 1.2 above, the Purchaser will not, nor attempt to, nor permit, enable, or request any other person to:

  

	 	(i)	use any Seller Marks in any manner, or engage in any other act or omission, that would impair the right of the Seller (or the relevant member of the Seller’s
Group) in and to the Seller Marks, including any act or omission that would invalidate or cause the cancellation or abandonment of any Seller Marks; 

  

	 	(ii)	file, acquire or otherwise obtain any registration for or application to register any Trademark or domain name, or acquire, create or otherwise obtain any social media
account that consists of, incorporates, uses, or is confusingly similar to any Seller Marks; whether with any Governmental Entity, internet domain name registrar, social media platform or otherwise (each, a “Registration”);

  

	 	(iii)	adopt or use any variation, derivation or acronym of the Seller Marks or any word, symbol or Trademark that is confusingly similar to the Seller Marks (each, a
“Variation”); 

  

	 	(iv)	use any Seller Marks with any other word, symbol or Trademark (other than a Trademark assigned or otherwise expressly transferred to the Purchaser pursuant to this
Agreement) so as to form a composite Trademark (each, a “Composite”); 

  

	 	(v)	represent to any other person that it, any sub-licensee, or any other person (other than the Seller (or the relevant member of the Seller’s Group) or its or their
successors in interest to the Seller Marks) has or will have any ownership interest in any Seller Marks; or 

  

	 	(vi)	grant or attempt to grant a security interest in or lien on, record any security interest or lien against, or otherwise encumber, any Seller Marks.

  

	1.4	Transfer of Rights 

 If
the Purchaser or any of its sub-licensees has or acquires any rights in or to the Seller Marks, or any Registrations, Composites or Variations, the Purchaser hereby irrevocably assigns, and will cause its sub-licensees to assign irrevocably, all
such rights to the Seller. At the request of the Seller, the Purchaser will, and will procure that its sub-licensees will, execute any document, and perform any act reasonably necessary to obtain, or confirm the Seller’s or its designee’s
exclusive ownership interest in and to the Seller Marks and 

  
 224

 
Registrations, in each applicable jurisdiction, including executing and delivering applications, oaths, declarations, affidavits, waivers, assignments and other documents. 

 

	1.5	Quality Control 

  

	 	1.5.1	The Purchaser will use, and cause its sub-licensees to use, the Seller Marks under the terms of this paragraph 1 solely in a manner consistent with the operation
of the Business immediately prior to the Closing Date. 

  

	 	1.5.2	The Purchaser will comply, and will cause its sub-licensees to comply, with any specifications, standards and directions that the Seller may provide in writing
from time to time relating to the use of the Seller Marks under this paragraph 1. 

  

	 	1.5.3	Concerning any GSK Branded Products manufactured by the Seller or its Affiliates, or by any third party in privity of contract with the Seller or its Affiliates,
the Purchaser will not tamper, modify or otherwise take any action, and will procure that its sub-licensees will not tamper, modify or otherwise take any action, to affect the quality of such GSK Branded Products. 

 

	 	1.5.4	Concerning any GSK Branded Products manufactured by the Purchaser or its sub-licensees, or by any third party in privity of contract with the Purchaser or its
sub-licensees, the Purchaser will ensure that such GSK Branded Products at all times meet or exceed (i) the quality and manufacturing standards of similar products in the GSK Branded Products’ industry; (ii) the Good Manufacturing Practices
applicable to such GSK Branded Products, as updated from time to time; (iii) any other standards imposed by the applicable Governmental Entities; and (iv) any specifications and quality provisions set forth in any agreement entered into by the
Parties in connection with this Agreement. The Purchaser will notify the Seller in the event that any Product does not meet such standards. 

  

	 	1.5.5	 1.5.5 Except where GSK Branded Literature originate with the Seller or the Seller’s Affiliates, the Purchaser will, to the extent
physically practicable, include, and will procure that its sub-licensees will include on all GSK Branded Literature and GSK Branded Websites that bear the Seller Marks: (i) a statement that the Seller Marks used thereon is a Trademark of the Seller
and used under license (or any similar statement required by the Seller concerning the status of the Seller Marks), and (ii) the symbols “®,” “TM” or other notice required by the applicable Governmental Entity in proximity to each prominent use of the Seller Marks, all in line with the
current practices applied by the Seller or its Affiliates prior to the Closing Date. 

  

	1.6	Termination of the Transitional Trademark Licence 

  

	 	1.6.1	The Seller may terminate the Transitional Trademark Licence and the rights granted to the Purchaser under the same at any time by providing notice of termination
to the Purchaser if: 

  

	 	(i)	the Purchaser commits a material breach of this paragraph 1 and the breach continues un-remedied for two months after the Seller provides notice to the Purchaser
describing the nature of the material breach. 

  

	 	(ii)	the Purchaser contests, challenges or otherwise makes any claim or takes any action adverse to the Seller’s (or the relevant member of the Seller’s Group)
ownership of or interest in, or the validity of, the Seller Marks, including in any proceeding before any Governmental Entity. 

  
 225

 Schedule 28 
 Local Payments 
 Part 1 Local payments to be funded on Closing 

 

							
	 (1)

Jurisdiction
	  	 (2)

Relevant member of
Purchaser’s Group
	  	 (3)

Business Seller
	  	 (4)

Local Payment

Amount

	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]

 Part 2 Local payments to be funded post-Closing 

 

							
	 (1)

Jurisdiction
	  	 (2)

Relevant member of
Purchaser’s Group
	  	 (3)

Business Seller
	  	 (4)

Local Payment

Amount

	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 226

 Schedule 29 
 Excluded Employees 
 [***] 

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 227

 Schedule 30 
 China Product Trademarks 
  

													
	 Trademark
	  	 Country
	  	
    Application    
No.
	  	
    Application    
Date
	  	
    Registration    
No.
	  	
    Registration    
 Date
	  	 Owner

							
	 HYCAMTIN in simplified chinese (he mei xin)
	  	China (Peoples Republic)	  	950130759	  	19/Oct/1995	  	1014870	  	28/May/1997	  	SmithKline Beecham Limited
							
	 ZOFRAN
	  	China (Peoples Republic)	  	8940790	  	14/Nov/1989	  	533169	  	10/Nov/1990	  	Glaxo Group Limited
							
	 ZOFRAN IN CHINESE 3
	  	China (Peoples Republic)	  	8940793	  	14/Nov/1989	  	533171	  	10/Nov/1990	  	Glaxo Group Limited
							
	 ZOFRAN IN CHINESE 3
	  	China (Peoples Republic)	  	91018152	  	08/May/1991	  	590079	  	10/Apr/1992	  	Glaxo Group Limited
							
	 TYKERB and device
	  	China (Peoples Republic)	  	6421611	  	06/Dec/2007	  	6421611	  	28/Mar/2010	  	SmithKline Beecham (Cork) Limited
							
	 TYKERB and device (in colour) (purple/green)
	  	China (Peoples Republic)	  	6421610	  	06/Dec/2007	  	6421610	  	28/Mar/2010	  	SmithKline Beecham (Cork) Limited
							
	 TYKERB in simplified chinese (tai ke) (great, capability)
	  	China (Peoples Republic)	  	6184680	  	25/Jul/2007	  	6184680	  	28/Feb/2010	  	SmithKline Beecham (Cork) Limited
							
	 TYKERB in simplified chinese (tai ke) (great, science)
	  	China (Peoples Republic)	  	6184679	  	25/Jul/2007	  	6184679	  	28/Feb/2010	  	SmithKline Beecham (Cork) Limited
							
	 TYKERB in simplified chinese (tai li sha)
	  	China (Peoples Republic)	  	2000107409	  	20/Jul/2000	  	1620407	  	21/Aug/2001	  	SmithKline Beecham (Cork) Limited

  
 228

 Schedule 31 
 Anti-bribery and corruption 
  

	1.	Anti-bribery and corruption 

  

	1.1	Each of the Purchaser and the Seller requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which the
Purchaser’s Group or the Seller’s Group (as the case may be) (whether through a third party or otherwise) conducts business. 

  

	1.2	Each of the Purchaser and the Seller requires the members of the Purchaser’s Group or the Seller’s Group (as the case may be), their employees and any
third party acting for or on behalf of the party, its members or their employees to ensure that all dealings with third parties, both in the private and government sectors, are carried out in compliance with all Applicable Law and with the required
standards of integrity. Each party values integrity and transparency and does not tolerate corrupt activities of any kind, whether committed by its employees, officers, or third-parties acting for or on its behalf. 

 

	1.3	In performing this Agreement or any of the Ancillary Agreements, each of the Purchaser and the Seller shall (and shall procure that each member of the
Purchaser’s Group or the Seller’s Group (as the case may be) shall): 

  

	 	1.3.1	comply with all Applicable Law, including but not limited to applicable anti-corruption laws, of the territory in which the party or the relevant member of the
Purchaser’s Group or the Seller’s Group (as the case may be) conducts business with the other party or the relevant member of the Seller’s Group or the Purchaser’s Group (as the case may be); 

 

	 	1.3.2	covenant that it has not, and covenants that it will not, in connection with the performance of this Agreement or any of the Ancillary Agreements, directly or
indirectly, promise, authorise, ratify or offer to make or make any Payments of Anything of Value to any individual (or at the request of any individual) including a Government Official for the improper purpose of influencing or inducing or as a
reward for any act, omission or decision to secure an improper advantage or to improperly assist the Seller’s Group or the Purchaser’s Group in obtaining or retaining business; and 

 

	 	1.3.3	covenant that it has not, and covenants and that it will not, in connection with the performance of this Agreement or any of the Ancillary Agreements, directly
or indirectly, promise, authorise, ratify or offer to make or make any Facilitating Payments to any individual (or at the request of any individual) including a Government Official. 

In this Schedule: 

“Anything of Value” includes cash or cash equivalents, gifts, services, employment offers, loans, travel expenses,
entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value; 

  
 229

 “Facilitating Payments” (otherwise known as “greasing payments”)
means any payment to an individual to secure or expedite the performance of a routine government action by government officials. 

“Government Official” means: (i) any officer or employee of a government or any department, agency or instrument of a
government; (ii) any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (iii) any officer or employee of a company or business owned in whole or part by a government; (iv)
any officer or employee of a public international organisation such as the World Bank or United Nations; (v) any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or (vi) any
candidate for political office. 
 “Payments” includes any direct or indirect offers to pay, promises to pay,
authorisations of or payments of anything of value. 
 The terms defined in this Schedule should be construed broadly to give
effect to the letter and spirit of each party’s ethical standards. 

  
 230

 Schedule 32 
 Ukraine Business 
  

	 	1.	From Closing until the date on which the parties receive all necessary approvals, consents and filings from or with the Antimonopoly Committee of Ukraine in respect of
the concentration intended to be effected through the transfer of the Ukraine Business in accordance with this Agreement (such date, the “Ukraine Clearance Date”), the Purchaser and the Seller shall ensure, to the extent each is
legally able, that no competitively sensitive information in relation to the Ukraine Business shall be provided to anybody other than: (i) any Delayed Employees located in the Ukraine; and (ii) other employees of any member of the Seller’s
Group located outside of the Ukraine who strictly need access to such competitively sensitive information in order to operate the Ukraine Business. 

  

	 	2.	From Closing until the Ukraine Clearance Date, the Purchaser shall not, and shall have no right to, exercise any management control over or in relation to the Ukraine
Business or any part of the Ukraine Business, there shall be no transfer of any commercially sensitive information between the Sellers and the Purchaser in relation to the Ukraine Business and the Seller shall ensure that the Ukraine Business is in
no way held out to any person as being related to the Purchaser. 

  

	 	3.	The parties agree that from Closing until the Ukraine Clearance Date: 

  

	 	(i)	the Ukraine Business shall constitute a Delayed Business for the purposes of this Agreement; 

 

	 	(ii)	to the extent permitted by Applicable Law, the provisions of paragraphs 3.6, 3.7, 3.10, 3.18 and 3.19 of Schedule 25 shall apply in respect of the Ukraine Business;

  

	 	(iii)	the provisions of paragraph 4 of Schedule 25 shall not apply in respect of the Ukraine Business and, after the Ukraine Clearance Date such provisions shall apply with
respect to the entire period from the Effective Time until Delayed Closing in respect of the Ukraine Business; and 

  

	 	(iv)	if and to the extent permitted by Applicable Law, the provisions of Clause 5 and Schedule 19 will continue to apply to the Ukraine Business. 

For the avoidance of doubt, the parties agree that during the period from Closing until the Ukraine Clearance Date, the Seller shall not exercise any
control over, or derive any economic benefit from, any Intellectual Property Rights relating to the oncology business of the Purchaser’s Group in the Ukraine. 

  
 231

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]